drug_id	drug_name	drug_type	synonyms	ttd_id	drugmap_id	mw	mf	polararea	complexity	xlogp	heavycnt	hbonddonor	hbondacc	rotbonds	inchi	isosmiles	canonicalsmiles	inchikey	iupacname
ferrodrug0001	Formaldehyde	Small molecular drug	formaldehyde; formalin; methanal; Paraformaldehyde; 50-00-0; formol; Methylene oxide; Oxomethane; Formic aldehyde; Paraform; Oxymethylene; Methyl aldehyde; Superlysoform; Lysoform; Fannoform; Formalith; Formalina; Methaldehyde; Oxomethylene; Morbicid; Karsan; 30525-89-4; Formaldehyd; Formaline; FYDE; Formaldehyde, gas; Aldeide formica; Aldehyde formique; Oplossingen; Formalin 40; Dormol; Rcra waste number U122; Aldehyd mravenci; Formalin-loesungen; Formalaz; Caswell No. 465; NCI-C02799; CH2O; UN 2209 (formalin); Formaldehyde (gas); UN 1198; Formaline [German]; Formalina [Italian]; Oplossingen [Dutch]; HCHO; CCRIS 315; FORMYL GROUP; HSDB 164; Fordor; NSC 298885; CHEBI:16842; Aldehyd mravenci [Czech]; Aldeide formica [Italian]; AI3-26806; Aldehyde formique [French]; BFV; Formalin-loesungen [German]; Formaldehyd [Czech, Polish]; EPA Pesticide Chemical Code 043001; NSC-298885; Formaldehyde [USP]; Aldehyde formique [ISO-French]; DTXSID7020637; UNII-1HG84L3525; EINECS 200-001-8; UN1198; UN2209; RCRA waste no. U122; 1HG84L3525; EC 200-001-8; Formaldehyde-13C, d2 solution; Formaldehyde (USP); NSC298885; CARBON MONOXIDE (13C; 18O); DSSTox_CID_637; FORMALDEHYDE (IARC); FORMALDEHYDE [IARC]; DSSTox_RID_82549; Paraformic aldehyde; DSSTox_GSID_47796; Formaldehyd (CZECH, POLISH); Aldehyde formique (ISO-French); 63101-50-8; Formaldehido; Veracur; MFCD00003274; MFCD00133991; 35907-63-2; Methan 21; Formic aldehyde; formaidehyde; formaldeyde; formaldhyde; methanon; paraformaldehyd; paraformaldehye; Formadehyde; Formaldehye; Formalinum; Durine; paraformaidehyde; para formaldehyde; paraform-aldehyde; Para-formaldehyde; F-gen; Hyperband (TN); Formalin [JAN]; HCOH; 28 - Formaldehyde; Floguard 1015; Formalin (JP17); CARBON-MONOXIDE; Formaldehyde; Methanal; Hercules 37M6-8; H2CO; WLN: VHH; Formaldehyde [BSI:ISO]; FORMALDEHYDE [II]; FORMALDEHYDE [MI]; Paraformaldehyde (JP17); bmse000256; Epitope ID:116196; FORMALDEHYDE [INCI]; Formaldehyde, 4% in PBS; Formaldehyde, methanol-free; CHEMBL1255; FORMALDEHYDE [VANDF]; Pesticide Code: 043001; BIDD:ER0493; DTXCID30637; GTPL4196; AMY6741; CHEBI:188447; NSC28424; STR00013; Tox21_111160; Tox21_302438; FM 282; AKOS008967440; DB03843; NA 9202; UN 1016; UN 2209; NCGC00255116-01; 53026-80-5; 8013-13-6; BP-21234; E240; Formaldehyde (37per cent w/w aq. soln.); F0622; FT-0626522; FT-0689115; P0018; C00067; D00017; D01494; A827922; Q161210; SR-01000944454; SR-01000944454-1; Q27110014; formaldehyde;formaldehyde [bsi:iso];methanal;formaldehyde (act. 37%);formalin;formaldehyde formaldehyde [bsi:iso] methanal formaldehyde (act. 37%) formalin	D01KEE	DM7Q6M0	30.026	CH2O	17.1	2	1.2	2	0	1	0	InChI=1S/CH2O/c1-2/h1H2	C=O	C=O	WSFSSNUMVMOOMR-UHFFFAOYSA-N	formaldehyde
ferrodrug0002	Boric Acid	.	BORIC ACID; Orthoboric acid; 10043-35-3; Boracic acid; Borofax; Boron hydroxide; Boron trihydroxide; Three Elephant; Basilit B; Boric acid (BH3O3); 11113-50-1; Trihydroxyborane; Trihydroxyborone; Flea Prufe; Boric acid (H3BO3); Super Flea Eliminator; Orthoborsaeure; Borsaeure; Borsaure; Orthoboric acid (B(OH)3); Optibor; Acidum boricum; NCI-C56417; Dr.'s 1 Flea Terminator DT; component of Aci-Jel; Dr.'s 1 Flea Terminator DFPBO; Dr.'s 1 Flea Terminator DF; Boric acid (VAN); Bluboro; Boricum acidum; Caswell No. 109; Dr.'s 1 Flea Terminator DTPBO; trihydroxidoboron; B(OH)3; Collyrium Eye Wash; Niban Granular Bait; CCRIS 855; NSC 81726; HSDB 1432; Ant flip; Homberg's salt; Orthoboric acid (H3BO3); EINECS 233-139-2; UNII-R57ZHV85D4; MFCD00011337; NSC-81726; Boric acid (TN); EPA Pesticide Chemical Code 011001; INS NO.284; R57ZHV85D4; CHEBI:33118; AI3-02406; INS-284; (10B)Orthoboric acid; Boric acid (h(sub 3)bo(sub 3)); H3BO3; DTXSID1020194; E-284; EC 233-139-2; [B(OH)3]; NSC81726; NCGC00090745-02; BORIC ACID (II); BORIC ACID [II]; Orthboric Acid; BORIC ACID (MART.); BORIC ACID [MART.]; Borsaure [German]; DTXCID10194; BORIC ACID (EP IMPURITY); BORIC ACID [EP IMPURITY]; BORIC ACID (EP MONOGRAPH); BORIC ACID [EP MONOGRAPH]; (B(OH)3); Kjel-sorb; Kill-off; ortho-boric acid; Boric acid [USAN:JAN]; Boric acid flakes; hydrogen orthoborate; BO3; CAS-10043-35-3; Boric acid [JAN:NF]; BORIC ACID, ACS; acido borico; Orthoborc acd; Bluboro (Salt/Mix); Boric acid ACS grade; Boric acid, Puratronic?; WLN: QBQQ; BORIC ACID [MI]; Boric acid, ACS reagent; BORIC ACID [JAN]; Heptaoxotetra-Borate(2-); bmse000941; Boric acid (JP15/NF); Boric acid (JP17/NF); BORIC ACID [INCI]; Acidum boricum (Salt/Mix); BORIC ACID [VANDF]; Boric acid, NF/USP grade; BORIC ACID [USP-RS]; BORIC ACID [WHO-DD]; Boric acid, biochemical grade; BIDD:ER0252; BORICUM ACIDUM [HPUS]; CHEMBL42403; BORIC ACID (B(OH)3); Boric acid Electrophoresis grade; Collyrium Eye Wash (Salt/Mix); BDBM39817; KGBXLFKZBHKPEV-UHFFFAOYSA-; Boric acid, 99.9% metals basis; BCP21018; Boric acid, 99.99% metals basis; Boric acid, BioXtra, >=99.5%; EINECS 237-478-7; Tox21_111004; Tox21_202185; Tox21_301000; 1332-77-0 (di-potassium salt); STL445672; Boric acid, 99.998% metals basis; AKOS015833571; Boric acid, ACS reagent, >=99.5%; DB11326; USEPA/OPP Pesticide Code: 011001; 11113-50-1;Boric acid;Boracic acid; Boric acid, 99.97% trace metals basis; Boric acid, USP, 99.5-100.5%; NCGC00090745-01; NCGC00090745-03; NCGC00090745-04; NCGC00090745-05; NCGC00254902-01; NCGC00259734-01; Boric acid, ReagentPlus(R), >=99.5%; BP-13473; Boric acid, 99.999% trace metals basis; Boric acid, SAJ first grade, >=99.5%; Boric acid, for electrophoresis, >=99.5%; Boric acid, JIS special grade, >=99.5%; Boric acid, Vetec(TM) reagent grade, 98%; FT-0623166; FT-0623167; InChI=1/BH3O3/c2-1(3)4/h2-4H; Boric acid, tablet, 1 g boric acid per tablet; D01089; A800201; Q187045; J-000132; J-523836; Boric acid, >=99.5%, suitable for amino acid analysis; Boric acid, NIST(R) SRM(R) 951a, isotopic standard; Boric acid, NIST(R) SRM(R) 973, acidimetric standard; Boric acid, BioUltra, for molecular biology, >=99.5% (T); Boric acid, United States Pharmacopeia (USP) Reference Standard; Boric acid, cell culture tested, plant cell culture tested, >=99.5%; Boric acid, Biotechnology Performance Certified, >=99.5% (titration), Cell Culture Tested; Boric acid, p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.5-100.5%; Boric acid, BioReagent, for molecular biology, suitable for cell culture, suitable for plant cell culture, >=99.5%; Boric acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., buffer substance, >=99.8%; Boric acid, puriss., meets analytical specification of Ph. Eur., BP, NF, 99.5-100.5%, powder	.	.	61.84	BH3O3	60.7	8	.	4	3	3	0	InChI=1S/BH3O3/c2-1(3)4/h2-4H	B(O)(O)O	B(O)(O)O	KGBXLFKZBHKPEV-UHFFFAOYSA-N	boric acid
ferrodrug0003	Ascorbic Acid	Small molecular drug	l-ascorbic acid; ascorbic acid; vitamin C; 50-81-7; L(+)-Ascorbic acid; L-ascorbate; Ascoltin; ascorbate; Ascorbicap; Cevitamic acid; Hybrin; Laroscorbine; Testascorbic; Allercorb; Ascorbajen; Ascorbutina; Ascorteal; Ascorvit; Cantaxin; Cebicure; Cegiolan; Celaskon; Cenetone; Cenolate; Cescorbat; Cetemican; Cevatine; Cevitamin; Citriscorb; Colascor; Concemin; Lemascorb; Proscorbin; Roscorbic; Viforcit; Viscorin; Vitacimin; Vitamisin; Vitascorbol; Adenex; Ascorb; Ascorin; Cantan; Cebion; Cebione; Ceglion; Cemagyl; Cemill; Cereon; Cergona; Cetamid; Cevalin; Cevimin; Cevital; Cevitan; Cevitex; Ciamin; Redoxon; Ribena; Vicelat; Vitace; Vitacee; Vitacin; Cebid; Cecon; Celin; Cevex; Cipca; Hicee; Xitix; Davitamon C; Arco-cee; Planavit C; Catavin C; Ce lent; Liqui-Cee; Vicomin C; Cee-Vite; Cevi-Bid; Natrascorb; Scorbacid; Scorbu-C; Secorbate; Duoscorb; C-Level; C-Vimin; Cetane-Caps TD; Cewin; Antiscorbic vitamin; C-Long; C-Quin; C-Span; Meri-C; Cee-Caps TD; L-Lyxoascorbic acid; L-Xyloascorbic acid; 3-Oxo-L-gulofuranolactone; Antiscorbutic vitamin; Ce-Mi-Lin; Natrascorb injectable; 3-Keto-L-gulofuranolactone; IDO-C; L-(+)-Ascorbic Acid; Cetane-Caps TC; Acidum ascorbinicum; CE-VI-Sol; Acidum ascorbicum; Kyselina askorbova; Dora-C-500; Ferrous ascorbate; Ascor-B.I.D.; Ascorbicab; Acide ascorbique; (R)-5-((S)-1,2-dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; Cortalex; Ferancee; Stuartinic; Tolfrinic; Acido ascorbico; L-Threoascorbic acid; L-3-Ketothreohexuronic acid lactone; Caswell No. 061B; Antiscorbutic factor; FEMA No. 2109; Ascorbinsaeure; Chromagen; Cetebe; Kyselina askorbova [Czech]; Ascor; L-threo-Ascorbic acid; NCI-C54808; Ascorbicum acidum; L-threo-Hex-2-enonic acid, gamma-lactone; Acide ascorbique [INN-French]; Acido ascorbico [INN-Spanish]; Acidum ascorbicum [INN-Latin]; 3-Oxo-L-gulofuranolactone (enol form); Sodascorbate; Ascorbic acid, l-; Ascorbicin; CCRIS 57; (+)-Ascorbic acid; Chewcee; Citrovit; HSDB 818; Juvamine; Vasc; UNII-PQ6CK8PD0R; PQ6CK8PD0R; Rovimix C; Scorbu C; Hex-2-enonic acid gamma-lactone, L-threo-; EINECS 200-066-2; NSC 33832; Ascorbin; Vitamin c (as ascorbic acid); Ronotec 100; Ascorbyl radical; INS NO.300; DTXSID5020106; Rontex 100; CHEBI:29073; INS-300; E-300; L-threo-hex-2-enono-1,4-lactone; L-Ascorbic acid (GMP); MFCD00064328; NSC-33832; Iron(II) ascorbate; NSC-218455; component of E and C-Level; component of Endoglobin Forte; E300; DTXCID90106; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2,5-dihydrofuran-2-one; component of Cortalex; component of Ferancee; NSC 218455; 6730-29-6; cevibid; NCGC00164357-01; Xyloascorbic acid, L-; Ester-C; (2R)-2-[(1S)-1,2-dihydroxyethyl]-4,5-dihydroxyfuran-3-one; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one; ASCORBIC ACID (II); ASCORBIC ACID [II]; L-Ascorbic acid 1000 microg/mL in Acetonitrile; 2,3-DEHYDRO-L-THREO-HEXONO-1,4-LACTONE; Ascorbinsaure; Kangbingfeng; Ceklin; ASCORBIC ACID (MART.); ASCORBIC ACID [MART.]; Acido ascorbico (INN-Spanish); Acidum ascorbicum (INN-Latin); Parentrovite; Cell C; NSC33832; vitamin-c; Viscorin 100M; (2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one; ASCORBIC ACID (EP MONOGRAPH); ASCORBIC ACID [EP MONOGRAPH]; ASCORBIC ACID (USP MONOGRAPH); ASCORBIC ACID [USP MONOGRAPH]; Suncoat VC 40; Acid, Ascorbic; (5R)-5-((1S)-1,2-DIHYDROXYETHYL)-3,4-DIHYDROXYFURAN-2(5H)-ONE; L Ascorbic Acid; Ascorbicap (TN); Acid, L-Ascorbic; Ascoltin (TN); L-xylo-ascorbic acid; [14C]ascorbic acid; Ascorbic acid [BAN:INN:JAN]; [14C]-ascorbic acid; ascorbic acid (vit C); L-Ascorbic acid, meets USP testing specifications; DTXSID7048112; Ascorbinezuur; Cevitamate; Asorbicap; L-lyxoascorbate; L-xyloascorbate; .Ascorbinsaure; C Vitamin; 3eka; Ester C; (+)-ascorbate; L(+)-ascorbate; L-Ascorbic acid, free radical form; L-(+)-ascorbate; Ascorbic acid [USP:INN:BAN:JAN]; Vitamin C,(S); E 300; NEO-VALDRIN; Ascorbic Acid DC97SF; VIT C; Vitamin xyloascorbic acid; Prestwick3_000325; L-Ascorbic acid, 99%; ASCOR (TN); SCHEMBL785; hex-1-enofuranos-3-ulose; bmse000182; VITAMIN C [VANDF]; Vitamin C (Ascorbic acid); ASCORBIC ACID [MI]; SCHEMBL4430; ASCORBIC ACID [FCC]; ASCORBIC ACID [INN]; ASCORBIC ACID [JAN]; L-Ascorbic acid, FCC, FG; L-Ascorbic Acid, Free Acid; ASCORBIC ACID [FHFI]; ASCORBIC ACID [HSDB]; ASCORBIC ACID [INCI]; BSPBio_000329; (r)-5-(1,2-dihydroxy-ethyl)-3,4-dihydroxy-5h-furan-2-one; MLS002153776; ASCORBIC ACID [VANDF]; CHEMBL40274; L-Ascorbic acid, cell culture; L-(+)-ACSCORBIC ACID; BPBio1_000363; GTPL4532; GTPL4781; L-Ascorbic acid, reagent grade; ASCORBIC ACID [USP-RS]; ASCORBIC ACID [WHO-DD]; ASCORBIC ACID [WHO-IP]; L-Ascorbic acid, >=99.0%; CHEBI:22652; HY-B0166G; DTXCID50820452; DTXSID50986567; Ascorbic acid (JP17/USP/INN); CIWBSHSKHKDKBQ-JLAZNSOCSA-N; HMS2096A11; HMS2231N16; HMS3713A11; L-Ascorbic acid ACS reagent grade; (2R)-2-[(1S)-1,2-Dihydroxyethyl]-4,5-dihydroxy-furan-3-one; ASCORBIC ACID [ORANGE BOOK]; BCP27915; HY-B0166; L-Threoascorbic acid,Antiscorbutic factor,Vitamin C;(R)-5-((S)-1,2-Dihydroxyethyl)-3,4-dihydroxyfuran-2(5H)-one; Tox21_110315; Tox21_112104; Tox21_202127; Tox21_302958; gamma-lactone L-threo-Hex-2-enonate; HB1238; L-Ascorbic acid, analytical standard; L-Ascorbic acid, AR, >=99.5%; s3114; AKOS016843589; Tox21_112104_1; CCG-207946; DB00126; L-Ascorbic acid, mixt. with vitamin B; ACIDUM ASCORBICUM [WHO-IP LATIN]; gamma-lactone L-threo-Hex-2-enonic acid; L-Ascorbic acid, ACS reagent, >=99%; NCGC00091517-01; NCGC00091517-02; NCGC00091517-03; NCGC00091517-06; NCGC00188972-01; NCGC00256504-01; NCGC00259676-01; 53262-66-1; BP-12831; SMR001233160; L-Ascorbic acid, plant cell culture tested; L-Ascorbic acid, reagent grade, crystalline; A0537; AB00376923; Ascorbic Acid (L-Ascorbic Acid; Vitamin C); CS-0626121; SW198791-2; L-3-KETO-THREO-HEXURONIC ACID LACTONE; L-Ascorbic acid, BioUltra, >=99.5% (RT); L-Ascorbic acid, tested according to Ph.Eur.; C00072; D00018; E80759; EN300-708766; L-Ascorbic acid, p.a., ACS reagent, 99.0%; AB00376923_04; AB00376923_05; L-Ascorbic acid, JIS special grade, >=99.0%; L-Ascorbic acid, Vetec(TM) reagent grade, 99%; L-Ascorbic acid, BioXtra, >=99.0%, crystalline; Q199678; 2-(1,2-dihydroxyethyl)-4,5-dihydroxy-furan-3-one; L-Ascorbic acid, puriss. p.a., >=99.0% (RT); Q27101942; 47A605F0-4187-47A8-B0CE-F9E7DA1B0076; L-Ascorbic acid, p.a., ACS reagent, reag. ISO, 99.7%; L-Threo-2,3,4,5,6-pentahydroxy-1-hexenoicacid-4-lactone; Ascorbic acid, British Pharmacopoeia (BP) Reference Standard; Ascorbic acid, European Pharmacopoeia (EP) Reference Standard; L-Ascorbic acid, certified reference material, TraceCERT(R); L-Ascorbic acid, powder, cell culture tested, gamma-irradiated; Ascorbic acid, United States Pharmacopeia (USP) Reference Standard; 4-((E)-2-[(2-HYDROXYETHYL)SULFANYL]DIAZENYL)BENZENECARBOXYLICACID; (5R)-5-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxyfuran-2(5H)-one (non-preferred name); L-Ascorbic acid, anhydrous, free-flowing, Redi-Dri(TM), ACS reagent, >=99%; L-Ascorbic acid, suitable for cell culture, suitable for plant cell culture, >=98%; L-Ascorbic acid, puriss. p.a., ACS reagent, reag. ISO, reag. Ph. Eur., 99.7-100.5% (oxidimetric)	D07AHW	DMXJ7O8	176.12	C6H8O6	107	232	-1.6	12	4	6	2	InChI=1S/C6H8O6/c7-1-2(8)5-3(9)4(10)6(11)12-5/h2,5,7-10H,1H2/t2-,5+/m0/s1	C([C@@H]([C@@H]1C(=C(C(=O)O1)O)O)O)O	C(C(C1C(=C(C(=O)O1)O)O)O)O	CIWBSHSKHKDKBQ-JLAZNSOCSA-N	(2R)-2-[(1S)-1,2-dihydroxyethyl]-3,4-dihydroxy-2H-furan-5-one
ferrodrug0004	Hydrogen Peroxide	.	hydrogen peroxide; 7722-84-1; perhydrol; oxydol; Superoxol; Interox; Hydrogen dioxide; Inhibine; Peroxaan; Albone; Hioxyl; Kastone; Albone 35; Albone DS; Dihydrogen dioxide; hydroperoxide; T-Stuff; Elawox; Lensept; Perone; Albone 35CG; Albone 50; Albone 50CG; Albone 70; Albone 70CG; Perone 50; Peroxan; Peroxide; H2O2; Hydrogen peroxide, 30%; Hydrogen peroxide, 90%; Perone 30; Perone 35; Waterstofperoxyde; Hydrogen peroxide (H2O2); Wasserstoffperoxid; Hydrogen peroxide, 3%; Caswell No. 486AAA; dioxidane; Peroxyde d'hydrogene; Oxyfull; Perossido di idrogeno; Eskata; Hyrogen peroxide; CCRIS 1060; HSDB 547; Astri-UC; High Test Peroxide; Teat dip HP 5; Asepticper; Baquashock; Crystacide; Peroxclean; Pre milk HP 0.5; Pre milk HP 1.0; Dentasept; Hybrite; Metrokur; Mirasept; Oxigenal; Oxysept; Pegasyl; EPA Pesticide Chemical Code 000595; Hipox; Hydrogen peroxide, 8% to 20%; Select Bleach; Xtra White; Hydrogen peroxide (conc > 52%); Hydrogen peroxide, 20% to 60%; Oxysept I; Lensan A; Odosat D; UNII-BBX060AN9V; Adeka Super EL; dihydrogen peroxide; EINECS 231-765-0; BBX060AN9V; HTP [peroxide]; Crestal Whitestrips; NSC 19892; NSC-19892; Pre milk HP 0.5 10; UN2014; UN2015; UN2984; dihydrogen(peroxide); Anti-Keim 50; HOOH; UN 2015 (>52%); CHEBI:16240; UN 2984 (8%-20%); UN 2014 (20%-52%); Hydrogen peroxide (> 52% conc.); Hydrogen peroxide [USP]; MFCD00011333; bis(hydridooxygen)(O--O); DTXSID2020715; EC 231-765-0; HTP (peroxide); NSC19892; Hydrogen peroxide (USP); PEO; HYDROGEN PEROXIDE (II); HYDROGEN PEROXIDE [II]; (OH(OH)); [OH(OH)]; HYDROGEN PEROXIDE (IARC); HYDROGEN PEROXIDE [IARC]; HYDROGEN PEROXIDE (MART.); HYDROGEN PEROXIDE [MART.]; Puresept; hydrogenperoxide; Waterstofperoxyde [Dutch]; Wasserstoffperoxid [German]; HYDROGEN PEROXIDE (USP IMPURITY); HYDROGEN PEROXIDE [USP IMPURITY]; Peroxide, Hydrogen; CIX; Peroxyde d'hydrogene [French]; Perossido di idrogeno [Italian]; Hydrogen peroxide 35%; Whitespeed; a peroxide; Magic Bleaching; Clarigel Gold; Lase Peroxide; Quasar Brite; Opalescence Xtra; Whiteness HP; Deslime LP; Hydrogen peroxide (conc >52%); hydrogen per oxide; Oxyfull (TN); hydrogen hydroperoxide; Nite White Excel 2; Oxydol (JP17); Hydrogen peroxide 50%; HYDROGEN-PEROXIDE; OXYDOL [JAN]; Hydrogen peroxide (8CI); MolMap_000025; 8007-30-5; CHEMBL71595; DTXCID40715; Hydrogen peroxide 32 wt. %; HYDROGEN PEROXIDE [MI]; HYDROGEN PEROXIDE [FCC]; HYDROGEN PEROXIDE [HSDB]; HYDROGEN PEROXIDE [INCI]; CHEBI:25940; HYDROGEN PEROXIDE [VANDF]; MHAJPDPJQMAIIY-UHFFFAOYSA-N; HYDROGEN PEROXIDE [WHO-DD]; Hydrogen peroxide (H2O2) (9CI); OXTERIL? 350 SPRAY (Evonik); WLN: H2 O2 90%; AKOS015856794; HYDROGEN PEROXIDE [GREEN BOOK]; DB11091; HYDROGEN PEROXIDE [ORANGE BOOK]; QTL1_000041; FT-0627133; H1222; C00027; D00008; Q171877; Q1088474; Hydrogen peroxide 30%, meets the analytical specifications of Ph. Eur., stabilized	.	.	34.015	H2O2	40.5	0	-0.9	2	2	2	0	InChI=1S/H2O2/c1-2/h1-2H	OO	OO	MHAJPDPJQMAIIY-UHFFFAOYSA-N	hydrogen peroxide
ferrodrug0005	Acrolein	Small molecular drug	ACROLEIN; Acrylaldehyde; 2-Propenal; 107-02-8; Propenal; Acrylic aldehyde; prop-2-enal; Allyl aldehyde; Ethylene aldehyde; Aqualin; Magnacide H; Acraldehyde; Slimicide; 2-Propen-1-one; Aqualine; Crolean; Prop-2-en-1-al; Magnacide; Acquinite; Biocide; Acrylaldehyd; Acroleina; Acroleine; Akrolein; Akroleina; Papite; Aldeide acrilica; Aldehyde acrylique; Acraldehydeacroleina; NSC 8819; Rcra waste number P003; Propenaldehyde; trans-Acrolein; Caswell No. 009; Magnacide B; Aldehyde, Allyl; Aldehyde, Acrylic; Aldehyde, Ethylene; Magnacide H and B; CCRIS 3278; HSDB 177; UN 1092; CHEBI:15368; 2-Propenaldehyde; EINECS 203-453-4; UNII-7864XYD3JJ; EPA Pesticide Chemical Code 000701; Acrolein (stabilized with hydroquinone); 7864XYD3JJ; DTXSID5020023; AI3-24160; CH2=CHCHO; NSC-8819; 25068-14-8; CHEMBL721; DTXCID8023; EC 203-453-4; ACROLEIN (IARC); ACROLEIN [IARC]; ACROLEIN (MART.); ACROLEIN [MART.]; Akrolein [Czech]; Propenal [Czech]; Acrolein, analytical standard; Akroleina [Polish]; Acroleina [Italian]; Acrylaldehyd [German]; 2 Propenal; Acroleine [Dutch, French]; Aldeide acrilica [Italian]; Propadien-1-ol; Aldehyde acrylique [French]; Acrolein, inhibited; Propenal, inhibited; Acraldehydeacroleina [Italian]; UN1092; RCRA waste no. P003; Acrylic aldehyde, inhibited; allol; Acrylehyde; Allylaldehyde; Acrehyde; Acrylehyd; Aerolein; Acrolein Monomer; 2-propen-1-al; prop-2-en-1-one; 81788-96-7; ACROLEIN [HSDB]; ACROLEIN [INCI]; ACROLEIN [MI]; Epitope ID:143621; WLN: VH1U1; Acroleine(DUTCH, FRENCH); trans-Acrolein Formylethylene; GTPL2418; DTXSID50526220; NSC8819; Acrolein 5000 microg/mL in Water; BCP07056; STR00291; Acrolein 100 microg/mL in Acetone; Tox21_200984; BDBM50010912; Acrolein 1000 microg/mL in Methanol; Acrolein 5000 microg/mL in Methanol; AKOS000120766; Acrolein, 96%, stab with hydroquinone; NCGC00091484-01; NCGC00091484-02; NCGC00258537-01; BP-14004; CAS-107-02-8; Acrolein, inhibited [UN1092] [Poison]; A0137; C01471; InChI=1/C3H4O/c1-2-3-4/h2-3H,1H; A801558; Q342790; Acrolein 5000 microg/mL in Methanol, Second Source; Acrolein, contains hydroquinone as stabilizer, 90%; Acrolein, stabilized with 3 wt% water, 1000ppm hydroquinone, stored over Copper	D0I0AA	DMAMCSR	56.06	C3H4O	17.1	30.3	0	4	0	1	1	InChI=1S/C3H4O/c1-2-3-4/h2-3H,1H2	C=CC=O	C=CC=O	HGINCPLSRVDWNT-UHFFFAOYSA-N	prop-2-enal
ferrodrug0006	Cadmium	Small molecular drug	7440-43-9; Cadmium; Cd; Cadmium, elemental; Colloidal cadmium; Kadmium; Cadmium metal; Elemental cadmium; Cadmium114; C.I. 77180; 00BH33GNGH; MFCD00010914; Solder alloy, 50g Chips; Kadmium [German]; 72172-64-6; Cadmium alloy, O 40x15 mm; cadmio; Cadmium powder; Cadmium,sponge; Al/Zn/Mg/Cu alloy CRM, O50x20mm; CCRIS 112; HSDB 282; Cadmium, mass of 135; EINECS 231-152-8; Cadmium Standard: Cd @ 1000 microg/mL in 5% HNO3; UNII-00BH33GNGH; Cadmium Standard: Cd @ 10000 microg/mL in 5% HNO3; Cadmium AA Standard: Cd @ 1000 microg/mL in 5% HNO3; Cadmium pieces; C I 77180; Cadmium granules; CD135; Cadmium single crystal, 15mm (0.59in) dia, 50mm (2.0in) long, (111) orientation, +/-2 degrees; Cadmium, p.a.; Cadmium metal-sticks; Cadmium shot, 3N5; 10C - Metals; CADMIUM [HSDB]; CADMIUM [MI]; CADMIUM [MART.]; 785 - Metals in oil; Cadmium powder 325 mesh; CADMIUM [WHO-DD]; 48Cd; Cadmium, >=99.9%; EC 231-152-8; Cadmium powder - 100mesh; 747 - Meat based sample; 871 - Elements in herbs; 784 - Metals in Cereals; 742 - Fish Based Sample; Cadmium powder, -200 mesh; Cadmium powder, -325 mesh; Cadmium, thermovacuum aerosol; 01 - Metals 25mm filters; 69011-70-7; 719 - Cadmium in chocolate; 780 - Metals in tea matrix; 795 - Elements in mushrooms; Aerosol of thermovacuum cadmium; Cadmium - Cd @1000ug/mL; 01-C - Metals IOM capsules; 786 - Metals in dried fruit; Cadmium - Cd @ 10microg/mL; Cadmium shot, 5cm (2in) dia; 01-B - Metals 37mm filters; 741 - Shellfish Based Sample; DTXSID1023940; NIOSH/EV3380000; 01-A - Metals 37mm capsules; 34A - WFD A; CHEBI:22977; CHEBI:37249; CADMIUM METALLICUM [HPUS]; BDOSMKKIYDKNTQ-UHFFFAOYSA-N; 866 - Elements in ground pepper; Cadmium powder, 99.999%, 5N; AKOS015902734; Cadmium rod, 12.7mm (0.5in) dia; DB14085; 718 - Metals analysis in cocoa powder; 819 - Chemical analysis - Table salt; Cadmium shot, tear drop, -5+20 mesh; Cadmium shot, tear drop, 3mm (0.1in); 81271-94-5; CI 77180; Cadmium, granular, >=99%, 5-20 mesh; Cadmium, granular, 30-80 mesh, >=99%; Cadmium, purum p.a., for filling reductors; EV33800000; Q1091; C01413; Cadmium, rod, 25mm, diameter 40mm, 99.9%; Cadmium, rod, 50mm, diameter 40mm, 99.9%; H11246; 827 - Elements in infant fruit/vegetable puree; Cadmium, rod, 100mm, diameter 40mm, 99.9%; 874 - Lead and Cadmium in 4% aqueous acetic acid; Cadmium - Cd @ 1000 microg/g in Hydrocarbon Oil; Cadmium - Cd @ 5000 microg/g in Hydrocarbon Oil; Cadmium shot, 1-3mm (0.04-0.1in), Puratronic?; Cadmium Standard: Cd @ 10 microg/mL in 2% HNO3; Cadmium, rod, 50mm, diameter 10.0mm, 99.999%; Cadmium, shot, 3 mm, 99.999% trace metals basis; 05B - EQS Metals (Preserved in 0.5% Nitric Acid); Cadmium, rod, 100mm, diameter 10.0mm, 99.999%; Cadmium, rod, 200mm, diameter 10.0mm, 99.999%; Cadmium, foil, 4mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.01mm, 99.7+%; Cadmium, powder, -100 mesh, 99.5% trace metals basis; Cadmium Standard: Cd @ 1000 microg/g in Hydrocarbon Oil; Cadmium Standard: Cd @ 5000 microg/g in Hydrocarbon Oil; Cadmium, foil, 10mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 10mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 10mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 10mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.01mm, 99.7+%; Cadmium, foil, 15mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 4mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 4mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 4mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 6mm disks, thickness 0.025mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.005mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.015mm, 99.7+%; Cadmium, foil, 8mm disks, thickness 0.025mm, 99.7+%; Cadmium, rod, diam. 4.0 mm, 99.999% trace metals basis; Cadmium, wire reel, 1m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 1m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 1m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 2m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 2m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 5m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 5m, diameter 0.5mm, hard, 99.99+%; Cadmium wire, 0.5mm (0.02in) dia, 99.998% (metals basis); Cadmium wire, 1.0mm (0.04in) dia, 99.998% (metals basis); Cadmium wire, 2.0mm (0.08in) dia, 99.998% (metals basis); Cadmium, foil, 0.5m coil, thickness 0.5mm, as rolled, 100%; Cadmium, foil, 10mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 15mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 1m coil, thickness 0.5mm, as rolled, 100%; Cadmium, foil, 25mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 2m coil, thickness 0.5mm, as rolled, 100%; Cadmium, foil, 4mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 50mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 50x50mm, thickness 3.0mm, as rolled, 99.9%; Cadmium, foil, 6mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, foil, 8mm disks, thickness 1.0mm, as rolled, 100%; Cadmium, purum p.a., for metal reduction, 99.99%, granular; Cadmium, rod, 1000mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, rod, 100mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, rod, 150mm, diameter 10.0mm, as drawn, 99.99+%; Cadmium, rod, 200mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, rod, 300mm, diameter 10.0mm, as drawn, 99.99+%; Cadmium, rod, 500mm, diameter 5.0mm, as drawn, 99.99+%; Cadmium, wire reel, 0.1m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 0.1m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 0.1m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 0.1m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 0.1m, diameter 2.0mm, hard, 99.99+%; Cadmium, wire reel, 0.2m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 0.2m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 0.2m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 0.2m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 0.2m, diameter 2.0mm, hard, 99.99+%; Cadmium, wire reel, 0.5m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 0.5m, diameter 0.5mm, hard, 99.95+%; Cadmium, wire reel, 0.5m, diameter 0.5mm, hard, 99.99+%; Cadmium, wire reel, 0.5m, diameter 1.0mm, hard, 99.999%; Cadmium, wire reel, 0.5m, diameter 2.0mm, hard, 99.99+%; Cadmium, wire reel, 10m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 1m, diameter 0.125mm, as drawn, 99.9%; Cadmium, wire reel, 1m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire reel, 1m, diameter 1.2mm, as drawn, 99.99+%; Cadmium, wire reel, 2m, diameter 0.125mm, as drawn, 99.9%; Cadmium, wire reel, 2m, diameter 1.2mm, as drawn, 99.99+%; Cadmium, wire reel, 5m, diameter 0.125mm, as drawn, 99.9%; Cadmium, wire reel, 5m, diameter 0.25mm, hard, 99.99+%; Cadmium, wire, diam. 1.0 mm, 99.999% trace metals basis; Cadmium foil, 0.05mm (0.002in) thick, 99.999% (metals basis); Cadmium foil, 0.1mm (0.004in) thick, 99.9975% (metals basis); Cadmium foil, 0.25mm (0.01in) thick, 99.9975% (metals basis); Cadmium foil, 0.5mm (0.02in) thick, 99.9975% (metals basis); Cadmium foil, 1.0mm (0.04in) thick, 15x15cm (5.9x5.9in); Cadmium foil, 1.0mm (0.04in) thick, 99.998% (metals basis); Cadmium foil, 2.0mm (0.08in) thick, 99.998% (metals basis); Cadmium, foil, 100x100mm, thickness 0.25mm, as rolled, 99.99%; Cadmium, foil, 100x100mm, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 100x100mm, thickness 1.0mm, as rolled, 99.99%; Cadmium, foil, 100x100mm, thickness 2.0mm, as rolled, 99.99%; Cadmium, foil, 100x100mm, thickness 3.0mm, as rolled, 99.9%; Cadmium, foil, 10mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 10mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 10mm disks, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 10mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 10mm disks, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 10mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 10mm disks, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 150x150mm, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 150x150mm, thickness 0.5mm, as rolled, 99.99%; Cadmium, foil, 150x150mm, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 150x150mm, thickness 3.0mm, as rolled, 99.9%; Cadmium, foil, 15mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 15mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 15mm disks, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 15mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 15mm disks, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 15mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 15mm disks, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 195x200mm, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 200x200mm, thickness 0.5mm, as rolled, 99.99%; Cadmium, foil, 200x200mm, thickness 1.0mm, as rolled, 99.99%; Cadmium, foil, 25mm disks, thickness 0.05mm, as rolled, 99.99+%; Cadmium, foil, 25mm disks, thickness 0.125mm, as rolled, 99.95%; Cadmium, foil, 25mm disks, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 25mm disks, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 25mm disks, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 25mm disks, thickness 0.5mm, as rolled, 99.95%; Cadmium, foil, 25mm disks, thickness 1.0mm, as rolled, 99.95%; Cadmium, foil, 25x25mm, thickness 0.125mm, as rolled, 99.99+%; Cadmium, foil, 25x25mm, thickness 0.25mm, as rolled, 99.9%; Cadmium, foil, 25x25mm, thickness 0.25mm, as rolled, 99.99+%; Cadmium, foil, 25x25mm, thickness 0.5mm, as rolled, 99.999%; Cadmium, foil, 25x25mm, thickness 1.0mm, as rolled, 99.999%; Cadmium, foil, 300x1000mm, thickness 2.0mm, as rolled, 99.99%; Cadmium, foil, 300x300mm, thickness 0.25mm, as rolled, 99.95%; Cadmium, foil, 300x300mm, thickness 0.5mm, as rolled, 99.99%; Cadmium, foil, 300x300mm, thickness 2.0mm, as rolled, 99.99%; Cadmium, foil, 30x100mm, thickness 0.5mm, as rolled, 99.999%; Cadmium, foil, 30x150mm, thickness 0.5mm, as rolled, 99.999%; Cadmium, foil, 30x50mm, t	.	DG00364	112.41	Cd	0	0	.	1	0	0	0	InChI=1S/Cd	[Cd]	[Cd]	BDOSMKKIYDKNTQ-UHFFFAOYSA-N	cadmium
ferrodrug0007	Arsenic	.	7440-38-2; Arsenic; As; Agent SA; Arsenowodor; Arsen; Arsenic hydride (AsH3); ARSENIC METAL; V1I29R0RJQ; Arsenicals; CHEBI:27563; Arsenic-75; Gray arsenic; Colloidal arsenic; Arsenic, inorganic; Arsenicals; Arsenic, inorganic; Arsen; CCRIS 55; Arsenic 75; HSDB 509; HSDB 510; Arsenic - As @ 1000 microg/g in Hydrocarbon Oil; EINECS 231-148-6; EINECS 232-066-3; UN2188; Arsenic Standard: As @ 1000 microg/mL in 5% HNO3; UNII-V1I29R0RJQ; Arsenic Standard: As @ 10000 microg/mL in 5% HNO3; arsenico; arsenicum; Arsenic AA Standard: As @ 1000 microg/mL in 5% HNO3; Arsinidene; arsenic atom; Arsenic sponge; UNII-N712M78A8G; Arsenic, lump; Inorganic arsenic; ARSINO; 04 - Elements; 19 - Lipstick; 21 - Powder sample; 2B - Trace elements; ARSENIC, SOLID; ARSENIC, METALLIC; 20 - Lip gloss sample; ARSINE [MI]; ARSENIC, (SOLID); ARSENICUM METALLICUM; 33As; Cannabis Target Elements-A; EC 232-066-3; S36 - Organic Fertilizer; ARSENIC METAL: ARSENIA; Arsenic - As @1000ug/mL; 62 - Saline Water - Metals; DTXCID703886; 13 - Sewage Sludge Inorganics; CHEMBL1231052; DTXSID3023760; DTXSID4023886; CHEBI:35826; 104 - Saline Water - Metals; RQNWIZPPADIBDY-UHFFFAOYSA-N; DTXSID201080837; DTXSID501080836; N712M78A8G; 02 - Sample 2 Cane/Beet Sugar; Arsenic, >=99.999%, pieces; 14 - Agricultural Soil Inorganics; Arsine [UN2188] [Poison gas]; AKOS015902733; Arsenic, 99.999% trace metals basis; 2 - Minerals and elements in animal feed; FT-0696579; C06269; 14 - Elemental contamination in herbal supplement; 17 - Elemental contamination in Pollen supplement; Arsenic, powder, >=99.997% trace metals basis; 8 - Minerals and trace elements in premix materials; Arsenic Standard: As @ 10 microg/mL in 2% HNO3; ARSENIC AND INORGANIC ARSENIC COMPOUNDS (IARC); Q21060492; Arsenic Standard: As @ 1000 microg/g in Hydrocarbon Oil; Arizona Heavy Metal Mixture 4-12 microg/mL in 2%HNO3, 1%HCl; AQ-14-QC sample 14 - Agricultural Soil Inorganics and Specific Elements; California Heavy Metal Mixture 5-30 microg/mL in 2% HNO3, 1% HCl; Cannabis Target Elements Mixture A 1-5 microg/mL in 2% HNO3, 1% HCl; Colorado Heavy Metal Mixture 40-100 microg/mL in 2% HNO3, 1% HCl; New Hampshire Heavy Metal Mixture 3-9 microg/mL in 2% HNO3, 1% HCl; Pennsylvania Heavy Metal Mixture 3-15 microg/mL in 2% HNO3, 1% HCl; Vermont Heavy Metal Mixture 20-100 microg/mL in 2% HNO3, 1% HCl; Washington Heavy Metal Mixture 40-200 microg/mL in 2% HNO3, 1% HCl; Arsenic polycrystalline lump, 2-8mm (0.08-0.3in), 99.9999% (metals basis); Arsenic polycrystalline lump, 2-8mm (0.08-0.3in), 99.99999% (metals basis); Connecticut, Michigan, Nevada Heavy Metal Mixture 9-29 microg/mL in 2% HNO3, 1% HCl	.	.	74.921	As	0	0	.	1	0	0	0	InChI=1S/As	[As]	[As]	RQNWIZPPADIBDY-UHFFFAOYSA-N	arsenic
ferrodrug0008	Resveratrol	Small molecular drug	resveratrol; 501-36-0; trans-resveratrol; 3,4',5-Trihydroxystilbene; (E)-5-(4-Hydroxystyryl)benzene-1,3-diol; 3,5,4'-Trihydroxystilbene; (E)-resveratrol; Resvida; 3,4',5-Stilbenetriol; 5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; 3,4',5-Trihydroxy-trans-stilbene; Biofort; Cuspidatin; SRT 501; SRT-501; (E)-5-(p-Hydroxystyryl)resorcinol; Resveratrol p 5; SRT501; Resveratrol(e)-form; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 3,5,4'-Trihydroxy-trans-stilbene; Melinjo resveratrol 20; CHEBI:45713; Srt 501m; trans-3,4',5-trihydroxystilbene; 5-[(E)-2-(4-hydroxyphenyl)vinyl]benzene-1,3-diol; 3,4',5-trihydroxy-stilbene; NSC 327430; NSC-327430; trans-1,2-(3,4',5-Trihydroxydiphenyl)ethylene; CCRIS 8952; 5-[2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol; DTXSID4031980; UNII-Q369O8926L; HSDB 7571; 5-((1E)-2-(4-Hydroxyphenyl)ethenyl)-1,3-benzenediol; Ca 1201; C14H12O3; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)ethenyl)-, (E)-; 1,3-Benzenediol, 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-; BIA 6-512; BIA-6-512; NSC327430; CHEMBL165; Q369O8926L; (E)-5-[2-(4-hydroxyphenyl)ethenyl]-1,3-benzendiol; MLS000069735; DTXCID2011980; CHEBI:27881; trans-3,4',5 - trihydroxystilbene; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 133294-37-8; SMR000058206; RESVERATROL (MART.); RESVERATROL [MART.]; (E)-5-[2-(4-Hydroxyphenyl)ethenyl]-1,3-benzenediol; 1,3-Benzenediol, 5-((E)-2-(4-hydroxyphenyl)ethenyl)-; Resveratol; TRANS-RESVERATROL (USP-RS); TRANS-RESVERATROL [USP-RS]; 5-((E)-2-(4-HYDROXYPHENYL)-ETHENYL) BENZENE-1,3 DIOL; MFCD00133799; trans Resveratrol; 5-(2-(4-hydroxyphenyl)ethenyl)benzene-1,3-diol; SR-01000000163; 5-((E)-2-(4-hydroxyphenyl)vinyl)benzene-1,3-diol; 1,3-Benzenediol, 5-[(E)-2-(4-hydroxyphenyl)ethenyl]-; 3fts; 4jaz; 4qer; Resveratrol, E-; Resveratrol,(S); KUC104385N; Stilbene, 2f; TaxusChinensisiRehd; NCGC00015894-02; CAS-501-36-0; STL; Prestwick_619; Resveratrol, trans-; KSC-10-164; RM-1812; Opera_ID_586; RESVERATROL [MI]; Prestwick2_000508; Prestwick3_000508; Spectrum5_000552; RESVERATROL [HSDB]; RESVERATROL [INCI]; R 5010; RESVERATROL [VANDF]; 1,3-Benzenediol, 5-[(1Z)-2-(4-hydroxyphenyl)ethenyl]-; Lopac0_001111; REGID_for_CID_6240; SCHEMBL19425; BSPBio_000435; BSPBio_001114; BSPBio_003461; RESVERATROL [WHO-DD]; MLS001055357; MLS001076538; MLS001424228; MLS002207121; MLS002222231; SPECTRUM1502223; CU-01000001503-3; BPBio1_000479; cid_445154; GTPL8741; SGCUT00007; Resveratrol, analytical standard; REGID_for_CID_445154; BDBM23926; Resveratrol, >=99% (HPLC); AMY5760; 2l98; BCPP000091; HMS1362H15; HMS1569F17; HMS1792H15; HMS1921N04; HMS1990H15; HMS2052I09; HMS2096F17; HMS2232A18; HMS3263O04; HMS3403H15; HMS3412O14; HMS3649A20; HMS3676O14; BCP01416; to_000079; Tox21_110257; Tox21_201374; Tox21_303376; Tox21_501111; AC-727; BBL028252; CCG-38874; HB4055; LMPK13090005; s1396; STL146386; AKOS005720936; Tox21_110257_1; CS-1050; DB02709; KS-5047; LP01111; NC00349; SDCCGMLS-0002998.P003; SDCCGSBI-0051080.P003; IDI1_002152; NCGC00017352-05; NCGC00017352-06; NCGC00017352-07; NCGC00017352-08; NCGC00017352-09; NCGC00017352-10; NCGC00017352-11; NCGC00017352-12; NCGC00017352-13; NCGC00017352-14; NCGC00017352-15; NCGC00017352-16; NCGC00017352-17; NCGC00017352-18; NCGC00017352-19; NCGC00017352-24; NCGC00017352-31; NCGC00017352-39; NCGC00024003-00; NCGC00024003-04; NCGC00024003-05; NCGC00024003-06; NCGC00024003-07; NCGC00024003-08; NCGC00024003-09; NCGC00024003-10; NCGC00024003-11; NCGC00024003-12; NCGC00024003-13; NCGC00024003-14; NCGC00257465-01; NCGC00258925-01; NCGC00261796-01; AS-12413; HY-16561; EU-0101111; R0071; Resveratrol, Vetec(TM) reagent grade, 98%; SW196786-4; trans [2,5,4'-trihydroxydiphenyl] ethylene; C03582; N88795; 5-[2-(4-hydroxyphenyl)vinyl]-1,3-benzenediol; AB00052942-29; AB00052942_31; trans-Resveratrol 100 microg/mL in Acetonitrile; A827984; Q407329; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzoldiol; SR-01000000163-3; SR-01000000163-4; SR-01000000163-9; 5-[(E)-2-(4-Hydroxyphenyl)ethenyl]benzol-1,3-diol; 5-[(E)-2-(4-Hydroxyphenyl)vinyl]-1,3-benzenediol; 5[(E)-2-(4-Hydroxyphenyl)-vinyl]benzene 1,3-diol; BRD-K25591257-001-01-2; BRD-K80738081-001-06-2; BRD-K80738081-001-07-0; BRD-K80738081-001-09-6; BRD-K80738081-001-10-4; BRD-K80738081-001-23-7; SR-01000000163-10; SR-01000000163-11; SR-01000000163-16; (E)-1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; (E)1-(3,5-dihydroxyphenyl)-2-(4-hydroxyphenyl)ethene; 5-((1E)-2-(4-hydroxyphenyl)ethenyl)benzene-1,3-diol; 5-[(1E)-2-(4-Hydroxyphenyl)ethenyl]-1,3,benzenediol; Resveratrol, certified reference material, TraceCERT(R); Resveratrol, European Pharmacopoeia (EP) Reference Standard; 1,3-Benzenediol, 5-(2-(4-hydroxyphenyl)-ethenyl)-, (E)-; 533C1DA0-4104-42B5-9D32-9265F40857E4; trans-Resveratrol, United States Pharmacopeia (USP) Reference Standard; 3,4',5-Trihydroxy-trans-stilbene 5-[(1E)-2-(4-hydroxyphenyl)ethenyl]-1,3-benzenediol; (E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol(E)-5-(2-(4-hydroxyphenyl)ethenyl)-1,3-benzenediol; 31100-06-8; InChI=1/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1	D0U3EP	DM3RWXL	228.24	C14H12O3	60.7	246	3.1	17	3	3	2	InChI=1S/C14H12O3/c15-12-5-3-10(4-6-12)1-2-11-7-13(16)9-14(17)8-11/h1-9,15-17H/b2-1+	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O)O)O	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)O)O)O	LUKBXSAWLPMMSZ-OWOJBTEDSA-N	5-[(E)-2-(4-hydroxyphenyl)ethenyl]benzene-1,3-diol
ferrodrug0009	Quercetin	.	quercetin; 117-39-5; Meletin; Sophoretin; Quercetine; Xanthaurine; Quercetol; Quertine; Quercitin; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one; 3,3',4',5,7-Pentahydroxyflavone; Cyanidelonon 1522; Flavin meletin; 3,5,7,3',4'-Pentahydroxyflavone; Quertin; T-Gelb bzw. grun 1; C.I. Natural Yellow 10; Quercetin content; Kvercetin; C.I. 75670; C.I. Natural red 1; Cyanidenolon 1522; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-1-benzopyran-4-one; CI Natural Yellow 10; Korvitin; Lipoflavon; 3',4',5,7-Tetrahydroxyflavan-3-ol; C.I. Natural yellow 10 & 13; Flavone, 3,3',4',5,7-pentahydroxy-; NSC 9219; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one; CCRIS 1639; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-; HSDB 3529; NCI-C60106; 3'-hydroxykaempferol; Corvitin; CHEBI:16243; NSC9219; 3,5,7-Trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-on; AI3-26018; UNII-9IKM0I5T1E; NSC-9219; EINECS 204-187-1; 9IKM0I5T1E; Quercetin (GMP); 3',4',5,7-tetrahydroxyflavon-3-ol; BRN 0317313; CI 75670; DTXSID4021218; 3,3',4,5,7-Pentahydroxyflavone; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromen-4-one; CHEMBL50; Ci-75670; MFCD00006828; NSC-57655; LDN-0052529; Flavone, 3,4',5,5',7-pentahydroxy-; DTXCID001218; 2-(3,4-Dihydroxy-phenyl)-3,5,7-trihydroxy-chromen-4-one; 74893-81-5; 3,5,7-trihydroxy-2-(3,4-dihydroxyphenyl)-4H-chromen-4-one; Quercetin (constituent of ginkgo); 5-18-05-00494 (Beilstein Handbook Reference); 3,5,7,3',4'-Pentahydroxyflavon; Kvercetin [Czech]; Natural Yellow 10; QUERCETIN (IARC); QUERCETIN [IARC]; 7255-55-2; QUE; BRD9794; Dikvertin; BRD-9794; 2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-4H-BENZOPYRAN-4-ONE; CAS-117-39-5; 3',4',5,7-tetrahydroxyflavonol; 3,5,7,3',4'-pentahydroflavone; NSC57655; NSC58588; SR-01000076098; MixCom3_000183; Ritacetin; Quer; 4dfu; 4mra; Quercetin2H2O; Meletin;Sophoretin; KUC104418N; KUC107684N; LIM-5662; LNS-5662; TNP00070; TNP00089; CI Natural Red 1; KSC-23-76; Quercetin_sathishkumar; KSC-10-126; Quercetin (Sophoretin); Quercetin - Sophoretin; Spectrum_000124; Tocris-1125; 3cf8; QUERCETIN [DSC]; QUERCETIN [MI]; BiomolKI_000062; QUERCETIN [HSDB]; QUERCETIN [INCI]; Maybridge1_008992; Prestwick0_000507; Prestwick1_000507; Prestwick2_000507; Prestwick3_000507; Spectrum2_000059; Spectrum3_000642; Spectrum4_000807; Spectrum5_001389; Lopac-Q-0125; QUERCETIN [VANDF]; P0042; C.I. natural yellow 13; BiomolKI2_000068; Enicostemma Littorale Blume; UPCMLD-DP081; Q 0125; QUERCETIN [USP-RS]; QUERCETIN [WHO-DD]; NCIOpen2_007628; NCIOpen2_007882; BIDD:PXR0007; Lopac0_000999; SCHEMBL19723; BSPBio_000433; BSPBio_001068; BSPBio_002243; KBioGR_000408; KBioGR_001293; KBioSS_000408; KBioSS_000584; MLS006011766; BIDD:ER0315; DivK1c_000485; SCHEMBL219729; SPECTRUM1500672; T-GELB BZW, GRUN 1; CU-01000012502-3; SPBio_000217; SPBio_002354; BDBM7460; BPBio1_000477; GTPL5346; MEGxp0_000381; SGCUT00001; 3,4',5,7-Pentahydroxyflavone; CI Natural Yellow 10 & 13; NIOSH/LK8760000; UPCMLD-DP081:001; ACon1_000560; HMS501I07; KBio1_000485; KBio2_000408; KBio2_000584; KBio2_002976; KBio2_003152; KBio2_005544; KBio2_005720; KBio3_000775; KBio3_000776; KBio3_001463; 3,7,3',4'-Pentahydroxyflavone; NINDS_000485; 3',5,7-Tetrahydroxyflavan-3-ol; Bio1_000369; Bio1_000858; Bio1_001347; Bio2_000374; Bio2_000854; HMS1362F09; HMS1792F09; HMS1923O19; HMS1990F09; HMS3263G19; HMS3267M12; HMS3414J21; HMS3649D04; HMS3656C15; HMS3678J19; to_000078; 3,4',5,5',7-pentahydroxyflavone; Tox21_202308; Tox21_300285; Tox21_500999; BBL005513; CCG-40054; Flavone,3',4',5,7-pentahydroxy-; HB0542; HY-18085G; LMPK12110004; NSC 57655; NSC324608; NSC756660; s2391; STK365650; Quercetin, >=95% (HPLC), solid; 3,4',5,5',7-pentahydroxy-Flavone; AKOS000511724; Quercetin 1000 microg/mL in Acetone; CS-3981; DB04216; DS-3416; LP00999; NSC-756660; SDCCGSBI-0050972.P003; IDI1_000485; IDI1_002129; LDN 0052529; SMP1_000252; NCGC00015870-01; NCGC00015870-02; NCGC00015870-03; NCGC00015870-04; NCGC00015870-05; NCGC00015870-06; NCGC00015870-07; NCGC00015870-08; NCGC00015870-09; NCGC00015870-10; NCGC00015870-11; NCGC00015870-12; NCGC00015870-13; NCGC00015870-14; NCGC00015870-15; NCGC00015870-16; NCGC00015870-17; NCGC00015870-18; NCGC00015870-19; NCGC00015870-21; NCGC00015870-22; NCGC00015870-23; NCGC00015870-24; NCGC00015870-25; NCGC00015870-28; NCGC00015870-48; NCGC00015870-50; NCGC00025016-01; NCGC00025016-02; NCGC00025016-03; NCGC00025016-04; NCGC00025016-05; NCGC00025016-06; NCGC00025016-07; NCGC00025016-08; NCGC00168962-01; NCGC00168962-02; NCGC00168962-03; NCGC00168962-04; NCGC00254218-01; NCGC00259857-01; NCGC00261684-01; Quercetin 100 microg/mL in Acetonitrile; AC-19596; AC-29756; HY-18085; NCI60_042036; SMR000112559; SY057722; (+)-3,3',4',5,7-Pentahydroxyflavone; Quercetin, Sophoretin, Meletin, Quercetine; CS-0638666; EU-0100999; FT-0603318; FT-0655108; LK87600000; Q0025; SW148203-4; Quercetin; 3,3',4',5,7-Pentahydroxyflavone; C00389; EN300-199773; K00029; S00057; QUERCETIN (CONSTITUENT OF GINKGO) [DSC]; WLN: T66 BO EVJ CR CQ DQ & DQ GQ IQ; 2-(3,4-Dihydroxyphenyl)-4H-1-benzopyran-4-one; Flavone, 3,3',4',5,7-pentahydroxy-, (+)-; Q409478; Q-200333; SR-01000076098-1; SR-01000076098-3; SR-01000076098-7; SR-01000076098-8; BRD-K97399794-001-02-1; BRD-K97399794-001-07-0; BRD-K97399794-001-09-6; BRD-K97399794-001-11-2; BRD-K97399794-335-03-1; SR-01000076098-11; Z57176222; 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chromone;hydrate; QUERCETIN (CONSTITUENT OF HAWTHORN LEAF WITH FLOWER); 49643640-FD4C-4B93-BD28-0D7C2021CC52; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-4H-chromen-4-one #; (+)-4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-; 4H-1-Benzopyran-4-one,2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-,zirconium(2+)salt(1:1); 4H-1-Benzopyran-4-one,2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-, zirconium(2+) salt (1:1)	.	.	302.23	C15H10O7	127	488	1.5	22	5	7	1	InChI=1S/C15H10O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,16-19,21H	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O	C1=CC(=C(C=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O	REFJWTPEDVJJIY-UHFFFAOYSA-N	2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychromen-4-one
ferrodrug0010	Capsaicin	.	Capsaicin; 404-86-4; Zostrix; (E)-Capsaicin; Qutenza; CAPSAICINE; Axsain; Styptysat; Isodecenoic acid vanillylamide; Ausanil; trans-Capsaicin; E-CAPSAICIN; NGX-4010; trans-8-Methyl-N-vanillyl-6-nonenamide; Mioton; (E)-8-Methyl-N-vanillyl-6-nonenamide; FEMA No. 3404; Dolenon; Ovocap; Capzasin-hp; Caswell No. 158; Togarashi orenji; ALGRX 4975; C18H27NO3; Ratden pe 40; NCI-C56564; NSC 56353; Capsaicinoid; CCRIS 1588; CHEBI:3374; HSDB 954; Transacin; 8-Methyl-N-vanillyl-trans-6-nonenamide; 8-Methyl-N-Vanillyl-6-Nonenamide; Cntx-4975; NGX-1998; EINECS 206-969-8; 6-Nonenamide, 8-methyl-N-vanillyl-, (E)-; UNII-S07O44R1ZM; MFCD00017259; NSC-56353; trans-Capsaicin-d3; (e)-n-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; (6E)-N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; EPA Pesticide Chemical Code 070701; N-(4-Hydroxy-3-methoxybenzyl)-8-methylnon-trans-6-enamide; BRN 2816484; ALGRX-4975; S07O44R1ZM; DTXSID9020241; 8-Methyl-N-vanillyl-6-nonenamide, (E)-; Capsaicin (JAN/USP); NSC56353; ZOSTRIX (TN); 1217899-52-9; (6E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; (E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (E)-; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (6E)-; DTXCID30241; CHEMBL294199; (E)-N-((4-Hydroxy-3-methoxyphenyl)-methyl)-8-methyl-6-nonenamide; 6-Nonenamide, (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide, (E)-; Capsaicin [in oleoresin of capsicum]; N-(4-hydroxy-3-methoxybenzyl)-8-methylnon-6-enamide; NCGC00017337-02; 8-Methyl-N-vanillyl-(trans)-6-nonenamide; (E)-N-[(4-hydroxy-3-methoxy-phenyl)methyl]-8-methyl-non-6-enamide; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-, (E)-; 7553-53-9; CAPSAICIN (MART.); CAPSAICIN [MART.]; (E)-N-[(4-HYDROXY-3-METHOXYPHENYL)METHYL]-8-METHYL-6-NONENAMIDE; Capsaicin [USAN]; CAPSAICIN (USP MONOGRAPH); CAPSAICIN [USP MONOGRAPH]; Capsicine; Vanilloid; Zacin; 6-Nonenamide, N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methyl-; Capsaicin (in oleoresin of capsicum); (6E)-N-{[4-hydroxy-3-(methyloxy)phenyl]methyl}-8-methylnon-6-enamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-, (6E)-; NGX 4010; SR-05000001861; capsaicinum; neurotoxic; Capsaicina; Isodecenoate; Zucapsaicin;Civamide;cis-Capsaicin; N-[(4-Hydroxy-3-methoxyphenyl)methyl]-8-methyl-6-nonenamide; Adlea; TNP00277; (E)-N-((4-hydroxy-3-methoxy-phenyl)methyl)-8-methyl-non-6-enamide; (E)-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; (E)-N-[(4-Hydroxy-3-methoxyphenyl)-methyl]-8-methyl-6-nonenamide; epsilon-capsaicin; capsacin(E); Qutenza;Vanilloid; Zostrix HP; 8 Methyl N Vanillyl 6 Nonenamide; Capsaicin,(S); 4DY; CAS-404-86-4; Prestwick_204; Capsaicin (Natural); depletes Substance P; n-(4-hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide; starbld0019180; Capsaicin [USP:INN]; CAPSAICIN [INN]; CAPSAICIN [JAN]; CAPSAICIN [MI]; isoamyl4-methoxycinnamate; 6-Nonenamide, (E)-; CAPSAICIN [HSDB]; CAPSAICIN [INCI]; Prestwick2_000879; Prestwick3_000879; Spectrum5_000538; CAPSAICIN [VANDF]; CAPSAICIN, NATURAL; UPCMLD-DP092; CAPSAICIN [USP-RS]; CAPSAICIN [WHO-DD]; SCHEMBL8085; SCHEMBL8086; MR3H3; BSPBio_000957; BSPBio_001548; BSPBio_002917; CAPSAICIN [EMA EPAR]; MLS002154049; N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; Capsaicin, analytical standard; SPECTRUM1501128; BPBio1_001053; GTPL2486; MEGxp0_001448; CAPSAICIN [ORANGE BOOK]; Methyl-N-vanillyl-6-noneneamide; UPCMLD-DP092:001; UPCMLD-DP092:002; BDBM20461; BDBM86537; CHEBI:94524; HMS501B16; HMS1361N10; HMS1570P19; HMS1791N10; HMS1921H11; HMS1989N10; HMS2089N11; HMS2092D21; HMS2097P19; HMS2230O23; HMS3402N10; HMS3414F11; HMS3649N15; HMS3678F11; Pharmakon1600-01501128; 8-Methyl-N-vanillyl-6E-nonenamide; AMY25669; NGX-3781; NGX-7325; NSC_2548; Tox21_110817; Tox21_200315; BBL027836; CCG-39657; CCG-39908; EI-125; HB1179; HY-10448A; LMFA08020085; NSC757844; s1990; STL372889; (E)8-methyl-N-vanillyl-6-Nonenamide; AKOS007930159; (6E)-N-; CS-1518; DB06774; KS-5181; NSC-757844; SDCCGMLS-0066678.P001; TQ-1018; Capsaicin 10 microg/mL in Acetonitrile; Capsaicin, >=95%, from Capsicum sp.; IDI1_000354; IDI1_034018; SMP2_000337; USEPA/OPP Pesticide Code: 070701; NCGC00017337-03; NCGC00017337-04; NCGC00017337-05; NCGC00017337-06; NCGC00017337-07; NCGC00017337-08; NCGC00017337-09; NCGC00017337-10; NCGC00017337-11; NCGC00017337-12; NCGC00017337-13; NCGC00017337-17; NCGC00017337-18; NCGC00090853-01; NCGC00090853-02; NCGC00090853-03; NCGC00090853-04; NCGC00090853-06; NCGC00090853-07; NCGC00090853-08; NCGC00090853-09; NCGC00090853-10; NCGC00090853-11; NCGC00090853-12; NCGC00257869-01; AC-10114; CAS_404-86-4; HY-10448; SMR000718774; CAPSAICIN (CONSTITUENT OF CAPSICUM); SBI-0052593.P002; CS-0181240; M1149; (E)-8-Methyl-N-vanillyl-6-nonenamide(8cl); C-1700; C06866; D00250; AB00053098-11; AB00053098_12; Capsaicin, from Capsicum sp., >=50% (HPLC); EN300-7544118; 826 - Capsaicin and heat units in chilli powder; CAPSAICIN (CONSTITUENT OF CAPSICUM) [DSC]; Q273169; SR-05000001861-1; SR-05000001861-4; SR-05000001861-5; SR-05000001861-6; SR-05000001861-9; BRD-K37056290-001-01-1; BRD-K50590187-001-06-6; Capsaicin, certified reference material, TraceCERT(R); Flavor and Extract Manufacturers' Association No. 3404; Capsaicin, European Pharmacopoeia (EP) Reference Standard; N-(4-hydroxy-3-methoxyphenylmethyl)-8-Methyl-6-Nonenamide; (6E)-N-(4-Hydroxy-3-methoxybenzyl)-8-methyl-6-nonenamide #; Capsaicin, United States Pharmacopeia (USP) Reference Standard; Capsaicin; 8-Methyl-N-vanillyl-trans-6-nonenamide; NGX-4010; N-[(4-hydroxy-3-methoxyphenyl)methyl]-6E-8-methyl-nonenamide; 6-Nonenamide, N-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-(E)-; N-(4-HYDROXY-3-METHOXYBENZYL)-8-METHYL-6-NONENAMIDE [FHFI]; trans-N-((4-Hydroxy-3-methoxyphenyl)methyl)-8-methyl-6-nonenamide; 6-nonenamide,n-((4-hydroxy-3-methoxyphenyl)methyl)-8-methyl-,(6e)-; Capsaicin, Pharmaceutical Secondary Standard; Certified Reference Material	.	.	305.4	C18H27NO3	58.6	341	3.6	22	2	3	9	InChI=1S/C18H27NO3/c1-14(2)8-6-4-5-7-9-18(21)19-13-15-10-11-16(20)17(12-15)22-3/h6,8,10-12,14,20H,4-5,7,9,13H2,1-3H3,(H,19,21)/b8-6+	CC(C)/C=C/CCCCC(=O)NCC1=CC(=C(C=C1)O)OC	CC(C)C=CCCCCC(=O)NCC1=CC(=C(C=C1)O)OC	YKPUWZUDDOIDPM-SOFGYWHQSA-N	(E)-N-[(4-hydroxy-3-methoxyphenyl)methyl]-8-methylnon-6-enamide
ferrodrug0011	Curcumin	.	curcumin; 458-37-7; Diferuloylmethane; Natural yellow 3; Indian saffron; Kacha haldi; Curcuma; Gelbwurz; Haldar; Curcumin I; Souchet; Haidr; Halad; Halud; Yellow Ginger; Terra Merita; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; Safran d'Inde; Yo-Kin; C.I. Natural Yellow 3; Hydrastis; Yellow puccoon; Golden seal; Diferaloylmethane; Curcumine; Tumeric yellow; CI Natural Yellow 3; Kurkumin [Czech]; Kurkumin; C.I. 75300; 8024-37-1; Zlut prirodni 3; Jianghuangsu; Zlut prirodni 3 [Czech]; Cucurmin; Curcumin (synthetic); NanoCurc; E 100; Tumeric oleoresin; 94875-80-6; CI 75300; NSC32982; NSC 32982; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; CCRIS 3257; CHEBI:3962; Curcurmin; Lipocurc; Kurkum; HSDB 4334; 1,5-Di(vanillyliden)acetylaceton; NCI-C61325; 1,5-Divanillyliden-2,4-pentandion; EINECS 207-280-5; UNII-IT942ZTH98; MFCD00008365; NSC-32982; Curcumin e100; NSC 687842; trans,trans-Curcumin; BRN 2306965; IT942ZTH98; 1,9-Bis(4-hydroxy-3-methoxyphenyl)-2,7-nonadiene-4,6-dione; E 100 (Dye); MLS000069631; DTXSID8031077; 1,7-Bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (E,E)-; CHEMBL140; NSC-687842; (E,E)-1,7-bis(4-Hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; SMR000058237; 1,6-Heptadiene-3,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-, (1E,6E)-; DTXCID901421; INS NO. 100(I); INS-100(I); 4-08-00-03697 (Beilstein Handbook Reference); NSC687842; curouma; NCGC00017159-05; kachs haldi; 2,7-Nonadiene-4,6-dione, 1,9-bis(4-hydroxy-3-methoxyphenyl)-; safra d'inde; CURCUMIN (MART.); CURCUMIN [MART.]; (1E,6E)-1,7-bis(4-hydroxy-3-methoxy-phenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1,7-bis[4-hydroxy-3-(methyloxy)phenyl]hepta-1,6-diene-3,5-dione; Tumeric; Ukon; 1,7-BIS-(4-HYDROXY-3-METHOXYPHENYL)-HEPTA-1,6-DIENE-3,5-DIONE; CAS-458-37-7; Phytosome, Curcumin; Ukon (dye); FEMA No. 3085; FEMA No. 3086; CCRIS 5804; C Yellow 15; SR-01000000149; Curcuminoids; Curcumin,(S); (E/Z)-Curcumin; starbld0017234; CURCUMIN [HSDB]; CURCUMIN [INCI]; CURCUMIN [MI]; Opera_ID_1627; CURCUMIN [USP-RS]; CURCUMIN [WHO-DD]; SCHEMBL8440; SCHEMBL8441; Curcumin, analytical standard; MLS001148449; BIDD:ER0479; CU-01000001305-2; cid_969516; GTPL7000; SCHEMBL13521974; SCHEMBL23884885; SCHEMBL23884886; SCHEMBL23884892; SCHEMBL23884893; BDBM29532; cid_5281767; cMAP_000052; CI 75300 [INCI]; HMS2233K04; HMS3649K06; AMY33436; BCP04695; Tox21_110803; Tox21_111505; Tox21_201116; BBL027711; BDBM50067040; BDBM50140172; CCG-36020; CCG-36107; STL371943; AKOS001305497; BCP9000557; DB11672; NCGC00017159-04; NCGC00017159-06; NCGC00017159-07; NCGC00017159-09; NCGC00017159-10; NCGC00017159-11; NCGC00017159-12; NCGC00023332-03; NCGC00023332-04; NCGC00023332-05; NCGC00258668-01; AC-24238; AS-72202; BP-25396; CURCUMIN (CONSTITUENT OF TURMERIC); BCP0726000035; WLN: 1OR BQ E1U1V1V1U1R DQ CO1; C-230; C2302; CS-0149275; EN300-21494; F21478; K00009; Curcumin, Curcuma longa L. - CAS 458-37-7; A826902; Curcumin, primary pharmaceutical reference standard; Q312266; 1,5-dione, 1,7-bis(4-hydroxy-3-methoxyphenyl)-; SR-01000000149-2; SR-01000000149-5; BRD-K07572174-001-02-2; BRD-K07572174-001-19-6; BRD-K07572174-001-22-0; Z104500108; Curcumin, >=94% (curcuminoid content), >=80% (Curcumin); 1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadien-3,5-dione; 1,7-bis(4-hydroxy-3-methoxyphenyl)1,6-heptadiene-3,5-dione; Curcumin, matrix substance for MALDI-MS, >=99.5% (HPLC); Curcumin, United States Pharmacopeia (USP) Reference Standard; 1,7-BIS(4-HYDROXYMETHOXYPHENYL)-1,6-HEPTADIENE-3,5-DIONE; 1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; 1,7-bis-(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; '(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione'; ((E,E)-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione); (1E,6E)-1,7-bis(3-methoxy-4-oxidanyl-phenyl)hepta-1,6-diene-3,5-dione; (1E,6E)-1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione #; (1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione.; (1E,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; (1Z,6E)-1,7-Bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,6-diene-3,5-dione; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione, (E,E)-; 5-hydroxy-1,7-bis(4-hydroxy-3-methoxyphenyl)-1,4,6-heptatrien-3-one; 5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one; Curcumin; 1,7-Bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione; (1E,4Z,6E)-5-Hydroxy-1,7-bis-(4-hydroxy-3-methoxy-phenyl)-hepta-1,4,6-trien-3-one	.	.	368.4	C21H20O6	93.1	507	3.2	27	2	6	8	InChI=1S/C21H20O6/c1-26-20-11-14(5-9-18(20)24)3-7-16(22)13-17(23)8-4-15-6-10-19(25)21(12-15)27-2/h3-12,24-25H,13H2,1-2H3/b7-3+,8-4+	COC1=C(C=CC(=C1)/C=C/C(=O)CC(=O)/C=C/C2=CC(=C(C=C2)O)OC)O	COC1=C(C=CC(=C1)C=CC(=O)CC(=O)C=CC2=CC(=C(C=C2)O)OC)O	VFLDPWHFBUODDF-FCXRPNKRSA-N	(1E,6E)-1,7-bis(4-hydroxy-3-methoxyphenyl)hepta-1,6-diene-3,5-dione
ferrodrug0012	Palmitic acid	Small molecular drug	palmitic acid; Hexadecanoic acid; 57-10-3; Cetylic acid; palmitate; n-Hexadecanoic acid; Hexadecylic acid; Hydrofol; n-Hexadecoic acid; 1-Pentadecanecarboxylic acid; Palmitinic acid; hexaectylic acid; Pentadecanecarboxylic acid; hexadecoic acid; 1-Hexyldecanoic Acid; Industrene 4516; Emersol 140; Emersol 143; Hystrene 8016; Hystrene 9016; Palmitinsaeure; Palmitic acid, pure; Palmitic acid 95%; Kortacid 1698; FEMA No. 2832; Loxiol EP 278; Palmitic acid (natural); Hydrofol Acid 1690; Cetyl acid; Prifac 2960; C16:0; HSDB 5001; Pristerene 4934; Pristerene-4934; Edenor C16; NSC 5030; AI3-01594; Lunac P 95KC; Lunac P 95; Lunac P 98; CCRIS 5443; Prifac-2960; CHEBI:15756; NSC5030; NSC-5030; EINECS 200-312-9; UNII-2V16EO95H1; FA 16:0; BRN 0607489; Palmitic acid (NF); DTXSID2021602; Glycon P-45; IMEX C 1498; 2V16EO95H1; Hexadecanoic acid (9CI); MFCD00002747; Palmitic acid (7CI,8CI); CHEMBL82293; DTXCID101602; CH3-[CH2]14-COOH; EC 200-312-9; 4-02-00-01157 (Beilstein Handbook Reference); n-hexadecoate; LMFA01010001; PA 900; EDENOR C 16-98-100; 67701-02-4; FA 1695; SURFAXIN COMPONENT PALMITIC ACID; 1-hexyldecanoate; NCGC00164358-01; LUCINACTANT COMPONENT PALMITIC ACID; pentadecanecarboxylate; Hexadecanoic acid 10 microg/mL in Acetonitrile; HEXADECANOIC-11,11,12,12-D4 ACID; PALMITIC ACID (II); PALMITIC ACID [II]; PALMITIC ACID (MART.); PALMITIC ACID [MART.]; CH3-(CH2)14-COOH; Palmitic acid; Hexadecanoic acid; PLM; palmic acid; Hexadecanoate (n-C16:0); PALMITIC ACID (EP MONOGRAPH); PALMITIC ACID [EP MONOGRAPH]; Acid, Palmitic; CAS-57-10-3; Acid, Hexadecanoic; SR-01000944716; Palmitic acid [USAN:NF]; palmitoate; Hexadecoate; Palmitinate; Palmitinsaure; palmitic-acid; palmitoic acid; Hexadecanoicacid; Aethalic acid; Hexadecanoic acid Palmitic acid; 2hmb; 2hnx; Palmitic acid_jeyam; n-Hexadecyclic Acid; fatty acid 16:0; Palmitic Acid, FCC; Kortacid 1695; Palmitic acid_RaGuSa; Univol U332; 1219802-61-5; Prifrac 2960; Hexadecanoic acid anion; Hexadecanoic--d5 Acid; 3v2q; Palmitic acid, >=99%; bmse000590; Epitope ID:141181; CETYL ACID [VANDF]; PALMITIC ACID [MI]; SCHEMBL6177; PALMITIC ACID [DSC]; PALMITIC ACID [FCC]; PALMITIC ACID [FHFI]; PALMITIC ACID [HSDB]; PALMITIC ACID [INCI]; PALMITIC ACID [USAN]; FAT; WLN: QV15; P5585_SIGMA; PALMITIC ACID [VANDF]; GTPL1055; QSPL 166; PALMITIC ACID [USP-RS]; PALMITIC ACID [WHO-DD]; (1(1)(3)C)hexadecanoic acid; 1b56; HMS3649N08; Palmitic acid, analytical standard; Palmitic acid, BioXtra, >=99%; Palmitic acid, Grade II, ~95%; HY-N0830; Palmitic acid, natural, 98%, FG; Tox21_112105; Tox21_201671; Tox21_302966; AC9381; BBL011563; BDBM50152850; s3794; STL146733; Palmitic acid, >=95%, FCC, FG; AKOS005720983; Tox21_112105_1; CCG-267027; CR-0047; DB03796; Palmitic acid, for synthesis, 98.0%; NCGC00164358-02; NCGC00164358-03; NCGC00256424-01; NCGC00259220-01; BP-27917; Palmitic acid, purum, >=98.0% (GC); SY006518; CS-0009861; FT-0626965; FT-0772579; P0002; P1145; Palmitic acid, SAJ first grade, >=95.0%; EN300-19603; A14813; C00249; D05341; Palmitic acid, Vetec(TM) reagent grade, 98%; PALMITIC ACID (CONSTITUENT OF SPIRULINA); Palmitic acid, >=98% palmitic acid basis (GC); A831313; Q209727; PALMITIC ACID (CONSTITUENT OF FLAX SEED OIL); PALMITIC ACID (CONSTITUENT OF SAW PALMETTO); SR-01000944716-1; SR-01000944716-2; BA71C79B-C9B1-451A-A5BE-B480B5CC7D0C; PALMITIC ACID (CONSTITUENT OF BORAGE SEED OIL); PALMITIC ACID (CONSTITUENT OF SPIRULINA) [DSC]; F0001-1488; Z104474418; PALMITIC ACID (CONSTITUENT OF EVENING PRIMROSE OIL); PALMITIC ACID (CONSTITUENT OF SAW PALMETTO) [DSC]; Palmitic acid, certified reference material, TraceCERT(R); Palmitic acid, European Pharmacopoeia (EP) Reference Standard; Palmitic acid, United States Pharmacopeia (USP) Reference Standard; Palmitic acid, Pharmaceutical Secondary Standard; Certified Reference Material; Sodium Palmitate, Palmitic acid sodium salt, Sodium hexadecanoate, Sodium pentadecanecarboxylate, HSDB 759	D02TVS	DMWUXDZ	256.42	C16H32O2	37.3	178	6.4	18	1	2	14	InChI=1S/C16H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16(17)18/h2-15H2,1H3,(H,17,18)	CCCCCCCCCCCCCCCC(=O)O	CCCCCCCCCCCCCCCC(=O)O	IPCSVZSSVZVIGE-UHFFFAOYSA-N	hexadecanoic acid
ferrodrug0013	Gallic acid	Small molecular drug	Gallic acid; 3,4,5-Trihydroxybenzoic acid; 149-91-7; gallate; Benzoic acid, 3,4,5-trihydroxy-; Gallic acid, tech.; Kyselina gallova; Pyrogallol-5-carboxylic acid; GALOP; HSDB 2117; CCRIS 5523; 3,4,5-Trihydroxybenzoate; MFCD00002510; NSC 674319; CHEBI:30778; Kyselina 3,4,5-trihydroxybenzoova; AI3-16412; EINECS 205-749-9; NSC 20103; NSC-20103; NSC-674319; UNII-632XD903SP; BRN 2050274; DTXSID0020650; 632XD903SP; NSC20103; DTXCID60650; CHEMBL288114; 3,4,5-trihydroxy-Benzoic acid; 3-10-00-02070 (Beilstein Handbook Reference); NSC674319; NCGC00091125-01; GALLIC ACID ANHYDROUS; Kyselina gallova [Czech]; Acid, Gallic; CAS-149-91-7; Gallic acid [NF]; SR-05000001537; gallic-acid; Kyselina 3,4,5-trihydroxybenzoova [Czech]; Gallic acid tech.; Gallic Acid, F; GDE; Spectrum_000342; 3,4,5-Trihydroxybenzoic acid, anhydrous; SpecPlus_000307; 5-Trihydroxybenzoic acid; Spectrum2_000399; Spectrum3_000254; Spectrum4_001544; Spectrum5_000108; GALLIC ACID [MI]; bmse000389; 3,5-Trihydroxybenzoic acid; GALLIC ACID [HSDB]; GALLIC ACID [INCI]; 3,4,5-hydroxybenzoic acid; WLN: QVR CQ DQ EQ; 3,4,5-trihydroxy-Benzoate; Oprea1_087792; SCHEMBL15012; 3,4,5-Trihydroxybenzoicacid; BSPBio_001668; KBioGR_002008; KBioSS_000822; SPECTRUM210369; BIDD:ER0374; DivK1c_006403; GALLIC ACID [WHO-DD]; SPBio_000617; 3,4,5-Trihydroxybenzoate, X; Benzoic acid,4,5-trihydroxy-; GTPL5549; 3,4,5-Trihydroxybenzoic acid;; KBio1_001347; KBio2_000822; KBio2_003390; KBio2_005958; KBio3_001168; CPD-183; Gallic acid, puriss., 98.0%; HMS1923K07; HMS2091A07; Pharmakon1600-00210369; BCP18127; HY-N0523; NSC36997; Tox21_111089; Tox21_202515; BBL009937; BDBM50085536; CCG-38670; NSC-36997; NSC755825; s4603; STK298718; AKOS000119625; Tox21_111089_1; AC-1206; CS-8191; NSC-755825; PS-8710; SDCCGMLS-0066503.P001; NCGC00091125-02; NCGC00091125-03; NCGC00091125-04; NCGC00091125-05; NCGC00091125-07; NCGC00260064-01; SY038078; SBI-0052184.P002; Gallic acid, 97.5-102.5% (titration); FT-0626592; G0011; EN300-21542; C01424; D85056; 3,4,5-trihydroxybenzoic acid (ACD/Name 4.0); AB00052697_03; Q375837; Q-201146; SR-05000001537-1; SR-05000001537-2; SR-05000001537-3; BRD-K77345217-001-01-9; F1908-0156; Gallic acid, certified reference material, TraceCERT(R); Z104501122; 78563C7D-0E2D-4766-A8EA-670A03C78FCF; GALLIC ACID (CONSTITUENT OF GRAPE SEEDS OLIGOMERIC PROANTHOCYANIDINS); InChI=1/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12; 137657-43-3	D0Y3TZ	DM6Y3A0	170.12	C7H6O5	98	169	0.7	12	4	5	1	InChI=1S/C7H6O5/c8-4-1-3(7(11)12)2-5(9)6(4)10/h1-2,8-10H,(H,11,12)	C1=C(C=C(C(=C1O)O)O)C(=O)O	C1=C(C=C(C(=C1O)O)O)C(=O)O	LNTHITQWFMADLM-UHFFFAOYSA-N	3,4,5-trihydroxybenzoic acid
ferrodrug0014	Acetaminophen	.	acetaminophen; Paracetamol; 4-Acetamidophenol; 103-90-2; Tylenol; N-(4-Hydroxyphenyl)acetamide; APAP; Panadol; N-Acetyl-p-aminophenol; 4'-Hydroxyacetanilide; Acetaminofen; Datril; p-Hydroxyacetanilide; Algotropyl; Lonarid; Naprinol; p-Acetamidophenol; Doliprane; Injectapap; Acamol; Acenol; Anelix; Multin; p-Acetaminophenol; Abensanil; Acetagesic; Acetalgin; Biocetamol; Clixodyne; Febridol; Febrilix; Febrolin; Gelocatil; Homoolan; Liquagesic; Pyrinazine; Servigesic; Tabalgin; Tussapap; Valgesic; Vermidon; Acephen; Alpiny; Alvedon; Amadil; Anaflon; Anhiba; Apamide; Calpol; Dymadon; Eneril; Fendon; Finimal; Lestemp; Lyteca; Neopap; Pacemo; Panets; Paracet; Parmol; Tempra; Tralgon; Valadol; Dirox; Hedex; Tapar; Paracetamolo; Dafalgan; Disprol; Dolprone; Momentum; Ortensan; Paldesic; Salzone; Captin; Enelfa; Exdol; p-Acetylaminophenol; Febro-Gesic; Acetamide, N-(4-hydroxyphenyl)-; Paracetamolum; Dolgesic; Febrectal; Tempanal; Abenol; Apacet; Apadon; Banesin; Cetadol; Fensum; Janupap; Minoset; Napafen; Neodol; Nobedon; Pacemol; Panodil; Parapan; Pedric; Phendon; Rounox; Suppap; Korum; Pinex; Temlo; 4-(Acetylamino)phenol; NEBS; Acetamol; Acetofen; Aferadol; Algesidal; Apitrelal; Atralidon; Bacetamol; Ben-u-ron; Calmanticold; Causalon; Codabrol; Codalgin; Codapane; Codoliprane; Cosutone; Custodial; Deminofen; Demogripal; Desfebre; Dial-A-Gesic; Dolegrippin; Dolofugin; Doloreduct; Dolorfug; Dolorstop; Dorocoff; Dristancito; Duracetamol; Ecosetol; Elixodyne; Excipain; Fanalgic; Farmadol; Febranine; Febrectol; Febricet; Fluparmol; Geluprane; Grippostad; Gynospasmine; Infadrops; Kataprin; Magnidol; Malidens; Medocodene; Miralgin; Neodolito; Neuridon; Oxycocet; Paedialgon; Panacete; Panadeine; Panadiene; Panasorbe; Pantalgin; Paracemol; Paracenol; Paracetanol; Paracetol; Paracodol; Paradrops; Parakapton; Paralief; Paralink; Paralyoc; Paramolan; Parasedol; Paraspen; Parcetol; Pediapirin; Pediatrix; Perfalgan; Phenipirin; Phogoglandin; Pirinasol; Polmofen; Predimol; Predualito; Prontina; Pulmofen; Pyrigesic; Rubophen; Sanicopyrine; Scentalgyl; Schmerzex; Sedalito; Semolacin; Seskamol; Sinaspril; Stanback; Sunetheton; Tachiprina; Termacet; Termalgin; Termalgine; Termofren; Titralgan; Treuphadol; Tricoton; Veralgina; Abrolet; Acertol; Acetaco; Afebrin; Afebryl; Algina; Algomol; Alpinyl; Analter; Antidol; Asetam; Asomal; Asplin; Babikan; Benmyo; Cadafen; Calapol; Cefalex; Codicet; Codisal; Cofamol; Cuponol; Curadon; Curpol; Darocet; Daygrip; Democyl; Dhamol; Dolcor; Dolefin; Dolotec; Dresan; Durapan; Febrex; Febrin; Fepanil; Finiweh; Ildamol; Inalgex; Labamol; Lekadol; Lemgrip; Lemsip; Lupocet; Malgis; Maxadol; Mexalen; Minafen; Nodolex; Ofirmev; Oralgan; Paceco; Pacimol; Paedol; Panamax; Panofen; Paracin; Paracod; Parador; Parake; Paralen; Paramol; Paranox; Parasin; Parogal; Paroma; Plicet; Prodol; Puernol; Pyromed; Remedol; Rupemol; Sanicet; Scanol; Setakop; Setamol; Sifenol; Sinedol; Sinmol; Stopain; Supofen; Tazamol; Upsanol; Utragin; Verpol; Viruflu; Vivimed; Volpan; Zatinol; Zolben; Abrol; Anacin-3; Andox; Dolko; Eu-Med; Oltyl; Pacet; Pamol; Panex; Reliv; Setol; Tiffy; Tylex; Tylol; Tymol; NeoCitran; NilnOcen; Nina; RubieMol; Vips; Supadol mono; Treupel mon; Bickie-mol; Fortalidon P; Lonarid Mono; Panadeine Co; Gattaphen T; Gripin Bebe; Influbene N; Dymadon Co; Toximer P; Treupel N; 4-Acetaminophenol; Helon N; Malex N; Spalt N; Tylex CD; Paracetamole; Dimindol; Dularin; Febrinol; Nealgyl; Neotrend; Panaleve; Piramin; Rivalgyl; SK-Apap; Anapap; Aspac; Atasol; Duaneo; Duorol; Dypap; Painex; Freka-cetamol; N-Acetyl-4-aminophenol; A-Per; Junior Disprol; Kinder Finimal; Mono Praecimed; Codisal Forte; Croix Blanche; Dolorol Forte; Dymadon Forte; Kratofin simplex; Liquigesic Co; Percocet-Demi; Perdolan Mono; Rockamol Plus; Viclor Richet; Geralgine-P; Neo-Fepramol; Paracetamol AL; Paracetamol BC; Paracetamol PB; Pyregesic-C; Anti-Algos; Claradol Codeine; Melabon Infantil; Migraleve Yellow; Para-Suppo; Paracetamol Saar; Supramol-M; Fever All; No-Febril; Panado-Co; Para-Tabs; Accu-Tap; Dol-Stop; Paracetamol Hexal; Paracetamol Raffo; Paracetamol Rosch; Paracetamol Stada; Percocet-5; Acetanilide, 4'-hydroxy-; Anadin dla dzieci; Cod-Acamol Forte; Contra-Schmerz P; Medinol Paediatric; Paracetamol Basics; p-Hydroxyphenolacetamide; Panado-Co Caplets; Paracetamol von ct; Paracetamol Fecofar; Paracetamol Harkley; Paracetamol Heumann; Paracetamol Nycomed; Pe-Tam; Acetominophen; Codral Pain Relief; Aminofen; Conacetol; Darvocet; Empracet; Panasorb; Paracetamol Hanseler; Paracetamol Winthrop; Resfenol; Parelan; Phenaphen W/Codeine; Prompt; 4-Hydroxyacetanilide; Fevor; Spalt fur die nacht; A.F. Anacin; Paracetamol Genericon; Actifed Plus; Paracetamol DC; Paracetamol Ratiopharm; Dafalgan Codeine; Pasolind N; Paracetamol Italfarmaco; Paracetamol Antipanin P; St Joseph Aspirin-Free; New Cortal for Children; INFANTS' FEVERALL; p-hydroxy-acetanilid; acetaminophene; Actamin; Demilets; Efferalgan; Endecon; Flexsure; Intensin; Naldegesic; Paracetamol Dr. Schmidgall; Pasolind; Redutemp; Robigesic; Tycolet; Valorin; Allay; Norco; Acetamide, N-(p-hydroxyphenyl)-; Children's Tylenol Chewable; p-(Acetylamino)phenol; Coricidin Sinus; NCI-C55801; PCM Paracetamol Lichtenstein; Sudafed Sinus; Aceta Elixir; Quiet World; Acenol (pharmaceutical); Paracetamol SmithKline Beecham; Scherzatabletten Rezeptur 534; Co-Gesic; Tylenol (caplet); Tylenol (geltab); 4-Hydroxyanilid kyseliny octove; N-(4-Hydroxyphenyl)acetanilide; Tylenol 8-Hour; CCRIS 3; St. Joseph Fever Reducer; Midol Teen Formula; Aspirin-Free Anacin; Propacet 100; Dolene AP-65; Tylenol Allergy Sinus; St Joseph Aspirin-Free for Children; Phenol, p-acetamido-; Rhinex D-Lay Tablets; Midol Regular Strength; Children's Acetaminophen Elixir Drops; Percogesic with Codeine; Excedrin; Bayer Select Head Cold; DTXSID2020006; CHEBI:46195; HSDB 3001; p-Acetoaminophen; N-acetyl-para-aminophenol; 4-(N-Acetylamino)phenol; n-acetyl-4-hydroxyaniline; Bayer Select Allergy-Sinus; Bayer Select Headache Pain; Dristan Cold No Drowsiness; NSC-3991; EINECS 203-157-5; Prestwick_13; UNII-362O9ITL9D; 222 AF; 4-acetylaminophenol; MFCD00002328; Midol PM Night Time Formula; Tavist Allergy/Sinus/Headache; Triaminic Sore Throat Formula; N-(4-hydroxyphenyl)ethanamide; NSC 109028; NSC-109028; N-(4-hydroxyphenyl)-acetamide; 362O9ITL9D; Bayer Select Sinus Pain Relief; Sine-Off Sinus Medicine Caplets; Roxicet 5/500; Tocris-1706; Acetaminophen (4-hydroxyacetanilide); Bayer Select Menstrual Multi-Symptom; St. Joseph Cold Tablets for Children; CHEMBL112; DTXCID606; N-(4-Hydroxyphenyl)acetamide (Tylenol); Acetaminophen-13C2,15N1; NSC3991; EC 203-157-5; 4-13-00-01091 (Beilstein Handbook Reference); ALLAY COMPONENT ACETAMINOPHEN; BUCET COMPONENT ACETAMINOPHEN; component of Dialog; component of Dilone; ESGIC COMPONENT ACETAMINOPHEN; NORCO COMPONENT ACETAMINOPHEN; TRIAD COMPONENT ACETAMINOPHEN; TYLOX COMPONENT ACETAMINOPHEN; Paracetamol (INN); BANCAP COMPONENT ACETAMINOPHEN; CODRIX COMPONENT ACETAMINOPHEN; component of Endecon; FEMCET COMPONENT ACETAMINOPHEN; LORTAB COMPONENT ACETAMINOPHEN; NORCET COMPONENT ACETAMINOPHEN; OXYCET COMPONENT ACETAMINOPHEN; TENCON COMPONENT ACETAMINOPHEN; TREZIX COMPONENT ACETAMINOPHEN; ZYDONE COMPONENT ACETAMINOPHEN; NSC109028; ANEXSIA COMPONENT ACETAMINOPHEN; ANOQUAN COMPONENT ACETAMINOPHEN; BUTAPAP COMPONENT ACETAMINOPHEN; component of Percocet; HY-PHEN COMPONENT ACETAMINOPHEN; ROXICET COMPONENT ACETAMINOPHEN; ROXILOX COMPONENT ACETAMINOPHEN; SEDAPAP COMPONENT ACETAMINOPHEN; TALACEN COMPONENT ACETAMINOPHEN; TYCOLET COMPONENT ACETAMINOPHEN; VICODIN COMPONENT ACETAMINOPHEN; WYGESIC COMPONENT ACETAMINOPHEN; DARVOCET COMPONENT ACETAMINOPHEN; EXCEDRIN COMPONENT ACETAMINOPHEN; FIORICET COMPONENT ACETAMINOPHEN; PERCOCET COMPONENT ACETAMINOPHEN; TRIAPRIN COMPONENT ACETAMINOPHEN; ULTRACET COMPONENT ACETAMINOPHEN; XARTEMIS COMPONENT ACETAMINOPHEN; ACETAMINOPHEN COMPONENT OF ALLAY; ACETAMINOPHEN COMPONENT OF BUCET; ACETAMINOPHEN COMPONENT OF ESGIC; ACETAMINOPHEN COMPONENT OF NORCO; ACETAMINOPHEN COMPONENT OF TRIAD; ACETAMINOPHEN COMPONENT OF TYLOX; CO-GESIC COMPONENT ACETAMINOPHEN; component of Phenaphen; DHC PLUS COMPONENT ACETAMINOPHEN; TYL; ACETAMINOPHEN COMPONENT OF BANCAP; ACETAMINOPHEN COMPONENT OF CODRIX; ACETAMINOPHEN COMPONENT OF FEMCET; ACETAMINOPHEN COMPONENT OF LORTAB; ACETAMINOPHEN COMPONENT OF NORCET; ACETAMINOPHEN COMPONENT OF OXYCET; ACETAMINOPHEN COMPONENT OF TENCON; ACETAMINOPHEN COMPONENT OF ZYDONE; BANCAP HC COMPONENT ACETAMINOPHEN; LORCET-HD COMPONENT ACETAMINOPHEN; PHRENILIN COMPONENT ACETAMINOPHEN; component of Percogesic; NCGC00016361-07; ACETAMINOPHEN COMPONENT OF ANEXSIA; ACETAMINOPHEN COMPONENT OF ANOQUAN; ACETAMINOPHEN COMPONENT OF BUTAPAP; ACETAMINOPHEN COMPONENT OF HY-PHEN; ACETAMINOPHEN COMPONENT OF ROXICET; ACETAMINOPHEN COMPONENT OF ROXILOX; ACETAMINOPHEN COMPONENT OF SEDAPAP; ACETAMINOPHEN COMPONENT OF TALACEN; ACETAMINOPHEN COMPONENT OF TYCOLET; ACETAMINOPHEN COMPONENT OF VICODIN; ACETAMINOPHEN COMPONENT OF WYGESIC; CAS-103-90-2; ACETAMINOPHEN COMPONENT OF CO-GESIC; ACETAMINOPHEN COMPONENT OF DARVOCET; ACETAMINOPHEN COMPONENT OF DHC PLUS; ACETAMINOPHEN COMPONENT OF EXCEDRIN; ACETAMINOPHEN COMPONENT OF FIORICET; ACETAMINOPHEN COMPONENT OF PERCOCET; ACETAMINOPHEN COMPONENT OF TRIAPRIN; ACETAMINOPHEN COMPONENT OF ULTRACET; ACETAMINOPHEN COMPONENT OF XARTEMIS; ACETAMINOPHEN COMPONENT OF BANCAP HC; ACETAMINOPHEN COMPONENT OF LORCET-HD; ACETAMINOPHEN COMPONENT OF PHRENILIN; DURADYNE DHC COMPONENT ACETAMINOPHEN; DOLENE AP-65 COMPONENT ACETAMINOPHEN; DRIXORAL PLUS COMPONENT ACETAMINOPHEN; SYNALGOS-DC-A COMPONENT ACETAMINOPHEN; PARACETAMOL [INN]; MEDIGESIC PLUS COMPONENT ACETAMINOPHEN; ACETAMINOPHEN COMPONENT OF DURADYNE DHC; PARACETAMOL (IARC); PARACETAMOL [IARC]; Jin Gang; WLN: QR DMV1; ACETAMINOPHEN COMPONENT OF DOLENE AP-65; ACETAMINOPHEN COMPONENT OF DRIXORAL PLUS; ACETAMINOPHEN COMPONENT OF MEDIGESIC PLUS; ACETAMINOPHEN COMPONENT OF SYNALGOS-DC-A; PARACETAMOL (MART.); PARACETAMOL [MART.]; 8055-08-1; component of Hycomine Compound; Acetavance; Paracetamolo [Italian]; Actimol; Calonal; Genapap; Tapanol; Genebs; n-(4-hydroxyphenyl-2,3,5,6-d4)acetamide-2,2,2-d3; Drixoral Sinus; Aceta Tablets; Paracetamol [INN:BAN]; Valorin Extra; Bayer Select; Snaplets-FR; Oraphen-PD; Phenaphen Caplets; Paracetamolum [INN-Latin]; SMR000112065; Dapa X-S; Drixoral Cold & Flu; SR-01000597517; Acetaminophen [USP:JAN]; acetominophene; 4-Hydroxyanilid kyseliny octove [Czech]; Claratal; Daphalgan; Resprin; Apacet Capsules; Atasol Caplets; Atasol Tablets; Tempra Caplets; Tylenol Caplets; Tylenol Elixir; Tylenol Gelcaps; Tylenol Tablets; Actamin Extra; Actamin Super; Aminofen M	.	.	151.16	C8H9NO2	49.3	139	0.5	11	2	2	1	InChI=1S/C8H9NO2/c1-6(10)9-7-2-4-8(11)5-3-7/h2-5,11H,1H3,(H,9,10)	CC(=O)NC1=CC=C(C=C1)O	CC(=O)NC1=CC=C(C=C1)O	RZVAJINKPMORJF-UHFFFAOYSA-N	N-(4-hydroxyphenyl)acetamide
ferrodrug0015	Rotenone	Small molecular drug	rotenone; 83-79-4; Dactinol; Paraderil; Barbasco; Tubatoxin; (-)-Rotenone; (-)-cis-Rotenone; Rotocide; Derrin; Derris; Rotenon; Nicouline; Ronone; Canex; Deril; Liquid Derris; Cube-Pulver; Dri-Kil; Rotessenol; Noxfire; Rotefive; Rotefour; Rotenox; Cubor; Haiari; Mexide; Chem-Mite; Cenol garden dust; Curex flea duster; Tubotoxin; Gerane; Prentox; Ro-Ko; Synpren; Derris (insecticide); Pb-nox; Rotenox 5EC; 5'-beta-Rotenone; Green Cross Warble Powder; Caswell No. 725; Extrax; Rotenone, dehydro; Foliafume E.C.; ENT 133; Rotenone, commercial; CCRIS 895; HSDB 1762; NCI-C55210; 5'beta-Rotenone; EPA Pesticide Chemical Code 071003; AI3-00133; C23H22O6; NSC26258; Rotenona; Derris resins; MLS000738056; CHEMBL429023; 1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-(1)benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one; DTXSID6021248; CHEBI:28201; 03L9OT429T; Rotacide E.C.; CUBE; NSC-26258; (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-alpha-isopropenyl-8,9-dimethoxy-; (12aS,6aS,2R)-8,9-dimethoxy-2-(1-methylvinyl)-1,2-dihydrochromano[3,4-b]furano [2,3-h]chroman-6-one; (2R,6aS,12aS)-8,9-dimethoxy-2-(prop-1-en-2-yl)-1,2,12,12a-tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one; (2R-(2alpha,6aalpha,12aalpha))-1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)(1)benzopyrano(3,4-b)furo(2,3-h)benzopyran-6(6aH)-one; 1,2,12,12aalpha-Tetrahydro-2a-isopropenyl-8,9-dimethoxy(1)benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one; NCGC00017358-05; Nekoe; (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R-(2alpha,6aalpha,12aalpha))-; (1S,6R,13S)-16,17-dimethoxy-6-prop-1-en-2-yl-2,7,20-trioxapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-3(11),4(8),9,14,16,18-hexaen-12-one; (2R,6aS,12aS)-1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-[1]benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one; (2R,6aS,12aS)-1,2,6,6a,12,12a-hexahydro-2-isopropenyl-8,9-dimethoxychromeno(3,4-b)furo(2,3-h)chromen-6-one; [2R-(2alpha,6aalpha,12aalpha)]-1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)[1]benzopyrano[3,4-b]furo[2,3-H][1]benzopyran-6(6aH)-one; Rotenona [Spanish]; DTXCID901248; Rotenone [BSI:ISO]; Protax; 5'.beta.-Rotenone; CAS-83-79-4; (1)Benzopyrano(3,4-b)furo(2,3-h)(1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R,6aS,12aS)-; (2R,6aS,12aS)-1,2,6,6a,12,12a- hexahydro-2-isopropenyl-8,9- dimethoxychromeno[3,4-b] furo(2,3-h)chromen-6-one; (2R,6aS,12aS)-1,2,6,6a,12,12a-hexahydro-2-isopropenyl-8,9-dimethoxychromeno[3,4-b]furo[2,3-h]chromen-6-one; (2R,6aS,12aS)-2-isopropenyl-8,9-dimethoxy-1,2,12,12a-tetrahydrochromeno[3,4-b]furo[2,3-h]chromen-6(6aH)-one; (2R,6aS,12aS)-8,9-Dimethoxy-2-(prop-1-en-2-yl)-1,2,12,12a-tetrahydrofuro[2',3':7,8][1]benzopyrano[2,3-c][1]benzopyran-6(6aH)-one; [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R,6aS,12aS)-; SR-01000076110; EINECS 201-501-9; NSC 26258; Rotenoid; Roteonone; UNII-03L9OT429T; WLN: T G5 D6 B666 CV HO MO POT&TT&J IY1&U1 SO1 TO1; 5''beta-rotenone; 5'b-Rotenone; Rotocide E.C.; (1)Benzopyrano[3,3-h](1)benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-.alpha.-iospropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,3-h][1]benzopyran-6(6a.alpha.H)-one, 1,2,12,12a.alpha.-tetrahydro-2.alpha.-isopropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, [2R-(2.alpha.,6a.alpha.,12a.alpha.)]-; [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, [2R-(2alpha,6aalpha,12aalpha)]-; Derris, JMAF; Prestwick_542; Rotenone (7CI); Rotenone, >=95%; Spectrum_000065; ROTENONE [HSDB]; ROTENONE [ISO]; ROTENONE [MI]; Spectrum2_000457; Spectrum3_000158; Spectrum4_001638; Spectrum5_000455; ROTENONE [MART.]; Lopac0_001112; SCHEMBL42253; BSPBio_001896; isopropenyl(dimethoxy)[?]one; KBioGR_002075; KBioSS_000465; SPECTRUM200013; (2R-(6aalpha,12aalpha)-1,2-Dihydro-2-isopropenyl-8,9-dimethoxychromano(3,4-b)furo(2,3-h)chroman-6-on; DivK1c_000947; ROTENONE [GREEN BOOK]; SPBio_000534; HMS502P09; KBio1_000947; KBio2_000465; KBio2_003033; KBio2_005601; KBio3_001116; inhibits NADH2 oxidation to NAD; NSC8505; JUVIOZPCNVVQFO-HBGVWJBISA-N; NINDS_000947; HMS3263O06; BCP07278; HY-B1756; NSC-8505; TNP00301; Tox21_110819; Tox21_201904; Tox21_300695; Tox21_501112; BDBM50135527; CCG-39886; HB5398; LMPK12060007; AKOS004910398; Tox21_110819_1; CS-6067; DB11457; LP01112; SDCCGMLS-0066415.P001; SDCCGSBI-0051081.P003; IDI1_000947; Rotenone 100 microg/mL in Acetonitrile; NCGC00017358-01; NCGC00017358-02; NCGC00017358-03; NCGC00017358-04; NCGC00017358-06; NCGC00017358-07; NCGC00017358-08; NCGC00017358-09; NCGC00017358-10; NCGC00017358-11; NCGC00017358-14; NCGC00017358-15; NCGC00017358-22; NCGC00094382-01; NCGC00094382-02; NCGC00094382-03; NCGC00094382-04; NCGC00094382-05; NCGC00254603-01; NCGC00259453-01; NCGC00261797-01; AC-31290; AS-10183; NCI60_002093; SMR000393729; EU-0101112; R0090; Rotenone, PESTANAL(R), analytical standard; C07593; R 8875; Q412388; SR-01000076110-2; SR-01000076110-5; SR-01000076110-6; W-104134; BRD-K08316444-001-01-9; BRD-K08316444-001-05-0; (2R,6AS,12AS)-1,2,12,12A-TETRAHYDRO-8,9-DIMETHOXY-2-(1-METHYLETHENYL)(1)BENZOPYRANO(3,4-B)FURO(2,3-H)(1)BENZOPYRAN-6(6AH)-ONE; (2R-(6aalpha,12aalpha)-1,2-Dihydro-2-isopropenyl-8,9-dimethoxychromano(3,4-b)furo(2,3-h)chroman-6-one; [1]Benzopyrano[3,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-.alpha.-isopropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-2-isopropenyl-8,9-dimethoxy-; [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aalphaH)-one, 1,2,12,12aalpha-tetrahydro-2alpha-isopropenyl-8,9-dimethoxy- (8CI); [1]Benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 1,2,12,12a-tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-, (2R,6aS,12aS)- (9CI); 1,2,12,12a-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-[1]benzopyrano[3,4-b]furo[2,3-h][1]benzopyran-6(6aH)-one, 9CI; Tubatoxin 1,2,12,12a,-Tetrahydro-8,9-dimethoxy-2-(1-methylethenyl)-[1]benzopyrano[3,4-b]furo[2,3-h][1]-benzopyran-6(6aH)-one	.	DG01789	394.4	C23H22O6	63.2	664	4.1	29	0	6	3	InChI=1S/C23H22O6/c1-11(2)16-8-14-15(28-16)6-5-12-22(24)21-13-7-18(25-3)19(26-4)9-17(13)27-10-20(21)29-23(12)14/h5-7,9,16,20-21H,1,8,10H2,2-4H3/t16-,20-,21+/m1/s1	CC(=C)[C@H]1CC2=C(O1)C=CC3=C2O[C@@H]4COC5=CC(=C(C=C5[C@@H]4C3=O)OC)OC	CC(=C)C1CC2=C(O1)C=CC3=C2OC4COC5=CC(=C(C=C5C4C3=O)OC)OC	JUVIOZPCNVVQFO-HBGVWJBISA-N	(1S,6R,13S)-16,17-dimethoxy-6-prop-1-en-2-yl-2,7,20-trioxapentacyclo[11.8.0.03,11.04,8.014,19]henicosa-3(11),4(8),9,14,16,18-hexaen-12-one
ferrodrug0016	Disulfiram	.	disulfiram; Tetraethylthiuram disulfide; 97-77-8; Antabuse; Bis(diethylthiocarbamoyl) disulfide; Antabus; TETD; Alcophobin; Anticol; Esperal; Teturam; Dicupral; Exhorran; Hoca; Ethyldithiurame; Abstensil; Antaethyl; Antietanol; Antivitium; Contralin; Tetradine; Tetraetil; Teturamin; Abstinil; Abstinyl; Antadix; Antalcol; Antetan; Antetil; Antietil; Antikol; Aversan; Averzan; Cronetal; Krotenal; Refusal; Etabus; Ethyl tuads; Ethyl Thiram; Ethyl Thiurad; Ethyl Tuex; Antaenyl; Antaetil; Antiaethan; Contrapot; Disulfan; Disulfuram; Ephorran; Stopetyl; Thiuranide; Anteyl; Bonibal; Disetil; Nocbin; Tenurid; Tenutex; Tetidis; Ekagom TEDS; Ekagom TETDS; Ethyldithiourame; Noxal; Anti-ethyl; Alk-aubs; Tetraethylthiuram disulphide; Thiuram E; TATD; Soxinol TET; Tetraethylthiram disulfide; Ekagom DTET; Accel TET; Espenal; Exhoran; Sanceler TET-G; Ro-sulfiram; Tetraethylthiuram; Tuads, ethyl; Usaf B-33; Sanceler TET; Tetraethylthioperoxydicarbonic diamide; Stopaethyl; Thireranide; Antaethan; Antethyl; Tetradin; Tillram; Accel TET-R; Ethyl Thiudad; Dupon 4472; Tetraethylthiuran disulfide; Nocceler TET; Nocceler TET-G; Anthethyl; Disulphuram; Stopethyl; Dupont fungicide 4472; Hocakrotenalnci-C02959; Tetraethylthiram disulphide; Bis(diethylthiocarbamyl) disulfide; Stopety; THIOCID; Ancazide ET; Etyl Tuex; Tetraethylthiuram sulfide; Thiuram disulfide, tetraethyl-; Akrochem TETD; Perkacit TETD; Ekaland TETD; Perkait TETD; N,N,N',N'-Tetraethylthiuram disulfide; Antabuse (TN); Bis(N,N-diethylthiocarbamoyl) disulfide; Ethyl Tuads Rodform; C10H20N2S4; 1,1'-Dithiobis(N,N-diethylthioformamide); Disulfide, bis(diethylthiocarbamoyl); ENT 27,340; NSC 190940; Thioperoxydicarbonic diamide, tetraethyl-; Bis(diethylthiocarbamoyl)disulphide; NCI-C02959; diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate; NSC-25953; N,N-diethyl[(diethylcarbamothioyl)disulfanyl]carbothioamide; Bis(N,N-diethylthiocarbamoyl)disulphide; N,N,N',N'-Tetraethylthiuram disulphide; Bis((diethylamino)thioxomethyl)disulphide; Bis((diethylamino)thioxomethyl) disulfide; Tetraethylthiuram disulfide;TETD; TTS; Disulfiram (Antabuse); TR3MLJ1UAI; Thioperoxydicarbonic diamide ([(H2N)C(S)]2S2), tetraethyl-; CHEMBL964; MLS000069818; CHEBI:4659; ORA102; DTXSID1021322; ORA-102; Bis(diethylthiocarbamyoyl)disulfide; NSC25953; Esperal [France]; CAS-97-77-8; NCGC00016000-08; NCGC00016000-13; SMR000059171; Thioperoxydicarbonic diamide (((H2N)C(S))2S2), tetraethyl-; 1,1',1'',1'''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane; DTXCID101322; Gababentin; Disulfram; Disulfiramum [INN-Latin]; Disulfiramo [INN-Spanish]; Bis[(diethylamino)thioxomethyl] disulfide; CCRIS 582; 1,1'-Dithiobis[N,N-diethylthioformamide]; TTS x; HSDB 3317; SR-01000076145; UNII-TR3MLJ1UAI; EINECS 202-607-8; MFCD00009048; NSC 25953; AI3-27340; Formamide, 1,1'-dithiobis(N,N-diethylthio-; Thioperoxydicarbonic diamide (((H2N)C(S))2S2), N,N,N',N'-tetraethyl-; Thioperoxydicarbonic diamide ([(H2N)C(S)]2S2), N,N,N',N'-tetraethyl-; Disulfiram [USP:INN:BAN:JAN]; Prestwick_182; Spectrum_001010; CPD000059171; DISULFIRAM [MI]; Opera_ID_224; DISULFIRAM [INN]; DISULFIRAM [JAN]; Prestwick0_000097; Prestwick1_000097; Prestwick2_000097; Prestwick3_000097; Spectrum2_001176; Spectrum3_000405; Spectrum4_000228; Spectrum5_001590; DISULFIRAM [HSDB]; DISULFIRAM [IARC]; Lopac-T-1132; 1,N-diethylthioformamide]; DISULFIRAM [VANDF]; Formamide, 1,1'-dithiobis(N,N-diethylthio)-; UPCMLD-DP090; EC 202-607-8; T 1132; tetraethyl thiuram disulfide; DISULFIRAM [MART.]; Tetraethyldithiuram disulfide; DISULFIRAM [WHO-DD]; Lopac0_001164; SCHEMBL27213; BSPBio_000054; BSPBio_001930; KBioGR_000895; KBioSS_001490; MLS000758264; MLS001076475; MLS001423963; SPECTRUM1500262; SPBio_001191; SPBio_001993; BPBio1_000060; Disulfiram (JP17/USP/INN); GTPL7168; DISULFIRAM [EP IMPURITY]; DISULFIRAM [ORANGE BOOK]; UPCMLD-DP090:001; KBio2_001490; KBio2_004058; KBio2_006626; KBio3_001150; DISULFIRAM [EP MONOGRAPH]; Thioperoxydicarbonic diamide ((H2N)C(S))2S2, tetraethyl-; DISULFIRAM [USP MONOGRAPH]; HMS1568C16; HMS1920I16; HMS2051M17; HMS2090C18; HMS2091O22; HMS2095C16; HMS2230K06; HMS3263J09; HMS3371B21; HMS3393M17; HMS3655I19; HMS3712C16; HMS3867H13; Pharmakon1600-01500262; BCP07331; HY-B0240; bis-(diethyl-thiocarbamyl)-disulfide; Tox21_110280; Tox21_300403; Tox21_400072; Tox21_501164; BDBM50058655; CCG-39549; DL-379; HB1119; N,N',N'-Tetraethylthiuram disulfide; NSC756748; NSC800739; s1680; STL069539; 1,1',1'',1'''-{disulfanediylbis[(thioxomethylene)-nitrilo]}tetraethane; AKOS000120201; Tox21_110280_1; AT13284; DB00822; HS-0057; LP01164; NC00063; NSC-756748; NSC-800739; SDCCGSBI-0051131.P005; WLN: 2N2 & YUS & S 2; NCGC00016000-01; NCGC00016000-02; NCGC00016000-03; NCGC00016000-04; NCGC00016000-05; NCGC00016000-06; NCGC00016000-07; NCGC00016000-09; NCGC00016000-10; NCGC00016000-11; NCGC00016000-12; NCGC00016000-14; NCGC00016000-15; NCGC00016000-18; NCGC00016000-29; NCGC00094423-01; NCGC00094423-02; NCGC00094423-03; NCGC00094423-05; NCGC00094423-06; NCGC00094423-07; NCGC00254447-01; NCGC00261849-01; N,N,N'',N''-tetraethylthiuram disulfide; BIS(DIETHYLTHIOCARBAMOYL) DISULPHIDE; Formamide,1'-dithiobis(N,N-diethylthio)-; SBI-0051131.P004; 1,1''-dithiobis(N,N-diethylthioformamide); AB00051976; B0479; EU-0101164; FT-0631502; FT-0667720; SW196492-4; Tetraethylthiuram disulfide, >=97.0% (S); EN300-19458; C01692; D00131; S00294; AB00051976-20; AB00051976-21; AB00051976-23; AB00051976_22; AB00051976_25; A845750; Q409665; Q-201812; SR-01000076145-1; SR-01000076145-5; SR-01000076145-8; BRD-K32744045-001-05-6; BRD-K32744045-001-17-1; Z104473910; Disulfiram, British Pharmacopoeia (BP) Reference Standard; Disulfiram, European Pharmacopoeia (EP) Reference Standard; Disulfiram, United States Pharmacopeia (USP) Reference Standard; 1,1'',1'''',1''''''-[disulfanediylbis(carbonothioylnitrilo)]tetraethane; Disulfiram, Pharmaceutical Secondary Standard; Certified Reference Material; N,N-diethylcarbamodithioic acid [[diethylamino(sulfanylidene)methyl]thio] ester; THIOPEROXYDICARBONIC DIAMIDE ((H2N)C(S))(SUB 2) S(SUB 2), TETRAETHYL-; InChI=1/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H; TETRAETHYLTHIOPEROXYDICARBONIC DIAMIDE ((((C(SUB 2)H(SUB 5))(SUB 2)N)C(S))(SUB 2)S(SUB 2))	.	.	296.5	C10H20N2S4	121	201	3.9	16	0	4	7	InChI=1S/C10H20N2S4/c1-5-11(6-2)9(13)15-16-10(14)12(7-3)8-4/h5-8H2,1-4H3	CCN(CC)C(=S)SSC(=S)N(CC)CC	CCN(CC)C(=S)SSC(=S)N(CC)CC	AUZONCFQVSMFAP-UHFFFAOYSA-N	diethylcarbamothioylsulfanyl N,N-diethylcarbamodithioate
ferrodrug0017	Benzophenone	.	BENZOPHENONE; 119-61-9; diphenylmethanone; Diphenyl ketone; Benzoylbenzene; Phenyl ketone; Methanone, diphenyl-; Ketone, diphenyl; alpha-Oxoditane; Benzene, benzoyl-; alpha-Oxodiphenylmethane; Diphenylketone; diphenyl-methanone; Kayacure bp; .alpha.-Oxoditane; Adjutan 6016; FEMA No. 2134; .alpha.-Oxodiphenylmethane; Diphenyl-methanon; 1dzp; NSC 8077; DTXSID0021961; MFCD00003076; CHEMBL90039; 701M4TTV9O; CHEBI:41308; NSC-8077; NCGC00090787-05; DTXCID101961; Diphenylmethanone (Benzophenone); Caswell No. 081G; CAS-119-61-9; CCRIS 629; HSDB 6809; WLN: RVR; EINECS 204-337-6; EPA Pesticide Chemical Code 000315; BENZOPHENONE (8CI); phenylketone; UNII-701M4TTV9O; Benzopheneone; Benzophenon; benzophenone-; benzoyl-benzene; a-Oxoditane; AI3-00754; meta-benzophenone; alpha -oxoditane; FEMA 2134; di(phenyl)methanone; a-Oxodiphenylmethane; METHANONE, DIPHENYL- (9CI); Ph2CO; SPEEDCURE BP; DAROCUR BP; Diphenylmethanone, 9CI; alpha -oxodiphenylmethane; Dimenhydrinate Impurity J; BENZOPHENONE [MI]; BENZOPHENONE [FCC]; UPCMLD-DP071; BENZOPHENONE [FHFI]; BENZOPHENONE [HSDB]; BENZOPHENONE [IARC]; BENZOPHENONE [INCI]; EC 204-337-6; BIDD:PXR0008; SCHEMBL17745; MLS001055400; ADK STAB 1413; BENZOPHENONE [USP-RS]; BENZOPHENONE [WHO-DD]; BIDD:ER0022; Benzophenone (diphenyl-ketone); Benzophenone (Diphenylmethanone); UPCMLD-DP071:001; BDBM22726; Benzophenone, analytical standard; DIPHENHYDRAMINE IMPURITY E; AMY7704; NSC8077; HMS2268A24; BENZOPHENONE [USP IMPURITY]; Benzophenone, >=99%, FCC, FG; HY-Y0546; Tox21_113465; Tox21_202425; Tox21_300058; Benzophenone, ReagentPlus(R), 99%; s4438; STL363250; Benzophenone, for synthesis, 98.0%; AKOS000119029; Tox21_113465_1; BENZOPHENONE (DIPHENYL-KETONE); DB01878; Benzophenone, purum, >=99.0% (GC); Benzophenone, ReagentPlus(R), >=99%; NCGC00090787-01; NCGC00090787-03; NCGC00090787-04; NCGC00090787-06; NCGC00090787-07; NCGC00090787-08; NCGC00254183-01; NCGC00259974-01; BP-21212; SMR000112143; PHENYTOIN IMPURITY A [EP IMPURITY]; Benzophenone, SAJ first grade, >=99.0%; B0083; CS-0015323; FT-0622720; FT-0693251; Benzophenone, purified by sublimation, >=99%; Benzophenone, Vetec(TM) reagent grade, 98%; EN300-19181; C06354; D72506; DIMENHYDRINATE IMPURITY J [EP IMPURITY]; PHENYTOIN SODIUM IMPURITY A [EP IMPURITY]; Q409482; Melting point standard 47-49C, analytical standard; Q-200691; PHENYTOIN IMPURITY BENZOPHENONE [USP IMPURITY]; F0001-0309; Z104473064; Benzophenone, European Pharmacopoeia (EP) Reference Standard; DIPHENHYDRAMINE HYDROCHLORIDE IMPURITY E [EP IMPURITY]; Mettler-Toledo Calibration substance ME 18870, Benzophenone; PHENYTOIN SODIUM IMPURITY BENZOPHENONE [USP IMPURITY]; Benzophenone, United States Pharmacopeia (USP) Reference Standard; HYDROCODONE HYDROGEN TARTRATE 2.5-HYDRATE IMPURITY H [EP IMPURITY]; YQ/T 31-2013 Photoinitiators Mixture 525 100 microg/mL in Acetonitrile; Benzophenone, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C13H10O/c14-13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10; Mettler-Toledo Calibration substance ME 18870, Benzophenone, for the calibration of the thermosystem 900, traceable to primary standards (LGC)	.	.	182.22	C13H10O	17.1	165	3.4	14	0	1	2	InChI=1S/C13H10O/c14-13(11-7-3-1-4-8-11)12-9-5-2-6-10-12/h1-10H	C1=CC=C(C=C1)C(=O)C2=CC=CC=C2	C1=CC=C(C=C1)C(=O)C2=CC=CC=C2	RWCCWEUUXYIKHB-UHFFFAOYSA-N	diphenylmethanone
ferrodrug0018	Ferulic acid	Small molecular drug	ferulic acid; trans-Ferulic Acid; 1135-24-6; 537-98-4; 4-Hydroxy-3-methoxycinnamic acid; trans-4-Hydroxy-3-methoxycinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; (E)-Ferulic acid; Coniferic acid; ferulate; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-; Ferulic acid, trans-; 3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; (2E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; Cinnamic acid, 4-hydroxy-3-methoxy-; 3-methoxy-4-hydroxycinnamic acid; Fumalic acid; Cinnamic acid, 4-hydroxy-3-methoxy-, (E)-; (E)-4-Hydroxy-3-methoxycinnamic acid; UNII-AVM951ZWST; (E)-4'-Hydroxy-3'-methoxycinnamic acid; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (2E)-; AVM951ZWST; 4-Hydroxy-3-methoxy cinnamic acid; EINECS 208-679-7; Cinnamic acid, 4-hydroxy-3-methoxy-, trans-; MFCD00004400; 2-Propenoic acid, 3-(4-hydroxy-3-methoxyphenyl)-, (E)-; (E)-3-(4-hydroxy-3-methoxyphenyl)acrylic acid; CCRIS 3256; CCRIS 7127; CIS-FERULICACID; CHEBI:17620; HSDB 7663; NSC 2821; NSC-2821; EINECS 214-490-0; NSC 51986; NSC-51986; (2E)-3-(4-Hydroxy-3-methoxyphenyl)acrylic acid; NSC 674320; (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; Fumalic acid (Ferulic acid); 4-Hydroxy-3-methoxycinnamate; (2E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoic acid; (E)-3-(4-hydroxy-3-methoxy-phenyl)prop-2-enoic acid; CHEMBL32749; 3-(4-Hydroxy-3-methoxyphenyl)propenoic acid; NSC2821; 3-Methoxy-4-hydroxy-trans-cinnamate; NSC-674320; 97274-61-8; 3-methoxy-4-hydroxy-trans-cinnamic acid; (E)-Ferulate; trans-Ferulic Acid (purified by sublimation); Trans-3-(4-hydroxy-3-methoxyphenyl)acrylic acid; 4-HYDROXY-3-METHOXY-D3-CINNAMIC ACID; FERULIC ACID (USP-RS); FERULIC ACID [USP-RS]; CINNAMIC ACID,4-HYDROXY,3-METHOXY FERULIC ACID; caffeic acid 3-methyl ether; ferulic acid, (E)-isomer; SMR000112202; 3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid; DTXSID5040673; ferulasaure; Ferulicacid; trans-Ferulate; (E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoate; CCRIS 7575; trans-FerulicAcid; Ferulic acid, E-; (E)-Coniferic acid; trans-4-Hydroxy-3-methoxycinnamicacid; Ferulic acid (M5); Ferulic Acid ,(S); FERULIC-ACID; Spectrum5_000554; bmse000459; bmse000587; bmse010211; FERULIC ACID [MI]; trans-Ferulic acid, 99%; FERULIC ACID [HSDB]; FERULIC ACID [INCI]; SCHEMBL15673; BSPBio_003168; MLS001066385; MLS001332483; MLS001332484; MLS002207079; MLS006011435; SPECTRUM1501017; trans-Ferulic acid, >=99%; FERULIC ACID [WHO-DD]; DTXCID3020673; DTXSID70892035; HMS1921D05; HMS2269P04; (E)-4-Hydroxy-3-methoxycinnamate; trans-4-Hydroxy-3-methoxycinnamate; BCP21231; BCP21789; HY-N0060; NSC51986; STR00961; (E)-4-hydroxy-3-methoxy-Cinnamate; TRANS-FERULIC ACID [WHO-DD]; (E)4-hydroxy-3-methoxycinnamic acid; AC7905; BBL010345; BDBM50214744; CCG-38860; s2300; STK801551; AKOS000263735; AC-7965; BCP9000163; DB07767; PS-3435; SDCCGMLS-0066667.P001; trans-3-methoxy-4-hydroxycinnamic acid; (E)-4-hydroxy-3-methoxy-Cinnamic acid; 3-(4-Hydroxy-3-methoxyphenyl)propenoate; 4-Hydroxy-3-methoxycinnamic acid, trans; NCGC00094889-01; NCGC00094889-02; NCGC00094889-03; NCGC00094889-04; AC-10321; BS-17543; SMR004703246; AM20060784; CS-0007108; F1257; H0267; SW219616-1; EN300-16798; C01494; A829775; FERULIC ACID (CONSTITUENT OF BLACK COHOSH); Q417362; SR-01000765539; (2E)-3-(4-Hydroxy-3-methoxyphenyl)-2-propenoate; (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoicacid; J-002980; SR-01000765539-3; Z56782558; (E)-3-(3-methoxy-4-oxidanyl-phenyl)prop-2-enoic acid; FERULIC ACID (CONSTITUENT OF BLACK COHOSH) [DSC]; 055E203F-B305-4B7F-8CE7-F9C0C03AB609; 3986A1BE-A670-4B06-833B-E17253079FD8; Ferulic acid, European Pharmacopoeia (EP) Reference Standard; trans-Ferulic acid, certified reference material, TraceCERT(R); Diethyl2-(acetamido)-2-(2-(bromomethyl)-5-nitrobenzyl)malonate; Ferulic acid, United States Pharmacopeia (USP) Reference Standard; trans-Ferulic acid, matrix substance for MALDI-MS, >=99.0% (HPLC); Ferulic Acid, Pharmaceutical Secondary Standard; Certified Reference Material; 831-85-6; InChI=1/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13	D03SLR	DMJC7NF	194.18	C10H10O4	66.8	224	1.5	14	2	4	3	InChI=1S/C10H10O4/c1-14-9-6-7(2-4-8(9)11)3-5-10(12)13/h2-6,11H,1H3,(H,12,13)/b5-3+	COC1=C(C=CC(=C1)/C=C/C(=O)O)O	COC1=C(C=CC(=C1)C=CC(=O)O)O	KSEBMYQBYZTDHS-HWKANZROSA-N	(E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoic acid
ferrodrug0019	Testosterone	Small molecular drug	testosterone; 58-22-0; Androderm; Testim; Testosteron; Mertestate; Testoderm; Virosterone; Sustanon; Homosterone; Androlin; Testiculosterone; AndroGel; Synandrol F; Testosteroid; Andronaq; Andropatch; Andrusol; Homosteron; Orquisteron; Perandren; Primotest; Primoteston; Sustanone; Testandrone; Testobase; Testogel; Testopropon; Testrone; Oreton; Relibra; Teslen; Testryl; Cristerona T; Testoviron T; Neotestis; Malerone; trans-Testosterone; Cristerone T; Testoviron Schering; Geno-cristaux gremy; Testostosterone; Testolin; Testoviron; LibiGel; 17beta-Hydroxyandrost-4-en-3-one; Sustason 250; Percutacrine androgenique; Neo-Hombreol F; Oreton-F; Testosteronum; Intrinsa; Testosterona; Striant; Testoject-50; Testoderm Tts; Testosterone hydrate; Neo-testis; Testro AQ; Malestrone (amps); Andro 100; Virormone; beta testosterone; Malogen, aquaspension injection; Vogelxo; Testosteronum [INN-Latin]; Testosterona [INN-Spanish]; Androst-4-en-17beta-ol-3-one; CDB 111C; Livensa; Nasobol; Natesto; Axiron; Tefina; CompleoTRT; Testopel Pellets; 17beta-Hydroxy-4-androsten-3-one; 7-beta-Hydroxyandrost-4-en-3-one; COL 1621; delta4-Androsten-17beta-ol-3-one; Testosterone ciii; 17beta-Hydroxyandrost-4-ene-3-one; 17-beta-Hydroxyandrost-4-en-3-one; 4-Androsten-17beta-ol-3-one; Androgel 1%; CP 601B; CCRIS 574; 17-Hydroxy-(17beta)-androst-4-en-3-one; Androgel 1.62%; 17beta-Hydroxy-delta(sup4)-androsten-3-one; delta(sup 4)-Androsten-17(beta)-ol-3-one; 17-Hydroxy-(17-beta)-androst-4-en-3-one; 17-beta-Hydroxy-delta(sup 4)-androsten-3-one; AA 2500; Androst-4-en-3-one, 17beta-hydroxy-; CHEBI:17347; HSDB 3398; Androst-4-en-3-one, 17-beta-hydroxy-; NSC 9700; EINECS 200-370-5; (+)-testosterone; UNII-3XMK78S47O; ANDROLAN; Androst-4-en-3-one, 17-hydroxy-, (17beta)-; 3XMK78S47O; DTXSID8022371; (17beta)-17-Hydroxyandrost-4-en-3-one; Oreton F; ANDROID-T; LPCN 1021; NSC-9700; Androst-4-en-3-one, 17-hydroxy-, (17-beta)-; DTXCID302371; (8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one; Androst-4-en-3-one, 17-hydroxy-, (17b)-; EC 200-370-5; TESTOSTERONE (MART.); TESTOSTERONE [MART.]; Halotensin; Androsorb; Fortesta; Testaqua; Testopel; TESTOSTERONE (EP IMPURITY); TESTOSTERONE [EP IMPURITY]; TESTOSTERONE (EP MONOGRAPH); TESTOSTERONE [EP MONOGRAPH]; Androst-4-en-3-one, 17-hydroxy-, (17.beta.)-; TESTOSTERONE (USP MONOGRAPH); TESTOSTERONE [USP MONOGRAPH]; T-Cypionate; (8alpha,10alpha,13alpha,14beta,17alpha)-17-hydroxyandrost-4-en-3-one; Virilon IM; Testrin-P.A; Androderm (TN); 17.beta.-Testosterone; Androgel (TN); SMR000058344; Andronate 100; Andronate 200; Andropository 200; Striant (TN); Testamone 100; Bio-T-Gel; Testim (TN); Everone 200; Andryl 200; Scheinpharm Testone-Cyp; Testred Cypionate 200; Testosterone (JAN/USP); Androst-4-en-3-on-17B-ol; CHEMBL386630; component of Duogen (Salt/Mix); component of Tostrex (Salt/Mix); component of Di-Met (Salt/Mix); NSC9700; component of Intrinsa (Salt/Mix); Epitestosteron; Lumitestosteron; 4-Androsten-17.beta.-ol-3-one; 4-Androsten-3-one-17.beta.-ol; Tostrelle; Tostrex; Viatrel; component of Di-Genik (Salt/Mix); 4-Androsten-3-one, 17b-hydroxy-; Testosterone [USP:INN:BAN]; 9b-testosterone; component of Mal-O-Fem (Salt/Mix); Testostroval-PA; 4-androstene-17beta-ol-3-one; 17b-hydroxy-4-androsten-3-one; delta4-androsten-17b-ol-3-one; Testosterone, 1; 3kdm; 17b-Testosterone; 17-.beta.-Hydroxyandrost-4-en-3-one; NCGC00091018-01; 8-iso-testosterone; 17 beta Hydroxy 4 Androsten 3 one; 17-beta-Hydroxy-4-Androsten-3-one; (+-)-testosterone; Axiron (TN); CMC_13449; 13-iso-testosterone; mpp10; TESTSTERONE; 9b,10a-testosterone; 17.beta.-Hydroxy-.DELTA.4-androsten-3-one; 17-Hydroxyandrost-4-en-3-one, (17.beta.)-; Therapeutic Testosterone; (+-)-retrotestosterone; Testosterone, >=98%; TESTOSTERONE [MI]; TESTOSTERONE [INN]; TESTOSTERONE [JAN]; Epitope ID:135865; TESTOSTERONE [HSDB]; TESTOSTERONE [INCI]; Testosterone EP Impurity C; (+-)-8-iso-testosterone; SCHEMBL8452; TESTOSTERONE [VANDF]; 4-Androsten-3-one-17b-ol; MLS000563091; MLS001032098; MLS001306401; MLS001424262; MLS002174283; BIDD:ER0555; TESTOSTERONE [WHO-DD]; D4-Androsten-17b-ol-3-one; Androst-4-en-17b-ol-3-one; BDBM8885; GTPL2858; Androst-4-ene-17b-ol-3-one; TESTOSTERONE [EMA EPAR]; 17-hydroxy-D4-androsten-3-one; 17-hydroxy-androst-4-en-3-one; 17beta-hydroxy-4-androsten-3one; TESTOSTERONE [GREEN BOOK]; Testosterone, cell culture tested; 17b-Hydroxy-androst-4-en-3-on; 17b-Hydroxy-D4-androsten-3-one; 17b-Hydroxyandrost-4-ene-3-one; 1i37; Testosterone, 1mg/ml in Methanol; 17a-hydroxy-androst-4-en-3-one; 17b-hydroxy-androst-4-en-3-one; HMS2052N11; HMS2272B03; HMS2272P03; TESTOSTERONE [ORANGE BOOK]; (8R,9S,10R,13S,14S,17S)-17-Hydroxy-10,13-dimethyl-6,7,8,9,10,11,12,13,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3(2H)-one; 17-Hydroxy-10,13-dimethyl-1,2,6,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-cyclopenta[a]phenanthren-3-one; Tox21_200689; HY-15554A; LMST02020002; RB3046; 17b-hydroxy-8a-androst-4-en-3-one; rac-17b-hydroxy-androst-4-en-3-one; AKOS015894897; 17a-hydroxy-13a-androst-4-en-3-one; 17a-hydroxy-14b-androst-4-en-3-one; 17b-hydroxy-13a-androst-4-en-3-one; CCG-101189; CS-1415; DB00624; Human Serum - Testosterone, low level; NC00439; CAS-58-22-0; Human Serum - Testosterone, high level; Testosterone 1.0 mg/ml in Acetonitrile; (17?)-17-Hydroxyandrost-4-en-3-one; 17b-hydroxy-(8a)-androst-4-en-3-one; 17b-hydroxy-(9b)-androst-4-en-3-one; NCGC00258243-01; (17b)-17-hydroxy-androst-4-en-3-one; 17a-hydroxy-(13a)-androst-4-en-3-one; 17b-hydroxy-(10a)-androst-4-en-3-one; 17b-hydroxy-(13a)-androst-4-en-3-one; AC-14899; CPD000058344; SMR001261453; Testosterone, purum, >=99.0% (HPLC); Testosterone 100 microg/mL in Acetonitrile; rac-17b-hydroxy-(13a)androst-4-en-3-one; rac-17b-hydroxy-(8a)-androst-4-en-3-one; T0027; 17b-hydroxy-(8a,10a)-androst-4-en-3-one; 17b-hydroxy-(9b,10a)-androst-4-en-3-one; BIM-0061761.0001; C00535; D00075; rac-17b-hydroxy-(9b,10a)androst-4-en-3-one; S00309; AB00973630-03; Testosterone, VETRANAL(TM), analytical standard; Androst-4-en-3-one, 17-hydroxy, (17.beta.)-; Q-101251; Q1318776; B5DEE83F-632B-48A1-A0ED-A51E7F13DF2E; TESTOSTERONE ENANTATE IMPURITY D [EP IMPURITY]; TESTOSTERONE PROPIONATE IMPURITY C [EP IMPURITY]; Testosterone, European Pharmacopoeia (EP) Reference Standard; Testosterone; 4-Androsten-17?-ol-3-one; 17?-Hydroxy-4-androsten-3-one; Testosterone for impurity D identification, European Pharmacopoeia (EP) Reference Standard; Testosterone for system suitability, European Pharmacopoeia (EP) Reference Standard; (1S,2R,10R,11S,14S,15S)-14-hydroxy-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-6-en-5-one; 1050678-68-6; 17?-hydroxyandrost-4-en-3-one; epitestosterone; 17-epi-Testosterone; 17?-cis-Testosterone; 4-Androstene-17?-ol-3-one; Isotestosterone	D06XMU	DM7HUNW	288.4	C19H28O2	37.3	508	3.3	21	1	2	0	InChI=1S/C19H28O2/c1-18-9-7-13(20)11-12(18)3-4-14-15-5-6-17(21)19(15,2)10-8-16(14)18/h11,14-17,21H,3-10H2,1-2H3/t14-,15-,16-,17-,18-,19-/m0/s1	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C	CC12CCC3C(C1CCC2O)CCC4=CC(=O)CCC34C	MUMGGOZAMZWBJJ-DYKIIFRCSA-N	(8R,9S,10R,13S,14S,17S)-17-hydroxy-10,13-dimethyl-1,2,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-3-one
ferrodrug0020	Ethoxyquin	.	ethoxyquin; 91-53-2; 6-Ethoxy-2,2,4-trimethyl-1,2-dihydroquinoline; Ethoxyquine; Santoquin; Santoquine; Niflex; Antioxidant EC; Santoflex A; Santoflex AW; Stop-Scald; Dawe's nutrigard; Nix-Scald; Nocrack AW; Quinol ED; (-)-Normetazocine; Permanax 103; Aries Antox; Amea 100; Niflex D; Antage AW; Nocrac AW; Alterungsschutzmittel EC; Ethoxyquin [ISO]; Ethoxychin; Quinoline, 6-ethoxy-1,2-dihydro-2,2,4-trimethyl-; Usaf B-24; Santoquine (VAN); 1,2-Dihydro-6-ethoxy-2,2,4-trimethylquinoline; 6-Ethoxy-1,2-dihydro-2,2,4-trimethylquinoline; Santoflex; 6-ethoxy-2,2,4-trimethyl-1H-quinoline; NSC-6795; 1,2-Dihydro-2,2,4-trimethyl-6-ethoxyquinoline; 2,2,4-Trimethyl-6-ethoxy-1,2-dihydroquinoline; EMQ; EQ; 63301-91-7; DTXSID9020582; CHEBI:77323; 9T1410R4OR; 6-(ethyloxy)-2,2,4-trimethyl-1,2-dihydroquinoline; CAS-91-53-2; NCGC00016348-02; E324; DTXCID70582; Ethoxychin [Czech]; Ethyl 2,2,4-trimethyl-1,2-dihydro-6-quinolinyl ether; Caswell No. 427D; CCRIS 2513; HSDB 400; EINECS 202-075-7; 6-ETMDQ; EPA Pesticide Chemical Code 055501; SantoquinEQ; UNII-9T1410R4OR; AI3-17715; Prestwick_1064; Spectrum_001214; ETHOXYQUIN [MI]; ETHOXYQUIN [FCC]; Prestwick0_000765; Prestwick1_000765; Prestwick2_000765; Prestwick3_000765; Spectrum2_001384; Spectrum3_001423; Spectrum4_000404; Spectrum5_001530; ETHOXYQUIN [HSDB]; ETHOXYQUIN [MART.]; SCHEMBL21601; BSPBio_000810; BSPBio_003126; KBioGR_000668; KBioSS_001694; MLS001055488; BIDD:GT0822; DivK1c_000183; SPECTRUM1500998; SPBio_001368; SPBio_002749; BPBio1_000892; CHEMBL172064; HMS500J05; KBio1_000183; KBio2_001694; KBio2_004262; KBio2_006830; KBio3_002346; NSC6795; NINDS_000183; HMS1570I12; HMS1923K03; HMS2097I12; HMS3714I12; 1,2,4-trimethyl-6-ethoxyquinoline; HY-B1425; NSC 6795; 6-Ethoxy-1,2,4-trimethylquinoline; Tox21_110388; Tox21_201336; Tox21_300328; CCG-39002; Ethoxyquin, >=75% (capillary GC); MFCD00023883; s5369; STK772149; AKOS000121441; CS-8200; IDI1_000183; NCGC00016348-01; NCGC00016348-03; NCGC00016348-04; NCGC00016348-05; NCGC00016348-06; NCGC00016348-07; NCGC00016348-08; NCGC00016348-09; NCGC00016348-15; NCGC00090792-01; NCGC00090792-02; NCGC00090792-03; NCGC00090792-04; NCGC00090792-05; NCGC00254395-01; NCGC00258888-01; AC-11742; AS-14741; SMR000686069; Ethoxyquin, Vetec(TM) reagent grade, 75%; WLN: T66 BM CHJ C1 C1 E1 HO2; E 324; E0237; FT-0621107; FT-0673108; 2,4-Trimethyl-6-ethoxy-1,2-dihydroquinoline; 6-Ethoxy-2,4-trimethyl-1,2-dihydroquinoline; EN300-21213; Ethoxyquin, PESTANAL(R), analytical standard; F85585; 2,2, 4-Trimethyl-6-ethoxy-1,2-dihydroquinoline; 6-Ethoxy-1, 2-dihydro-2,2,4-trimethylquinoline; 6-Ethoxy-1,2-dihydro-2,2,4-trimethyl-Quinoline; 6-Ethoxy-2,2,4-trimethyl-1, 2-dihydroquinoline; A843964; SR-01000854319; J-010251; Q1657816; SR-01000854319-2; W-100306; BRD-K56792340-001-05-8; Z104494382; 6-Ethoxy-1,2-dihydro-2,2,4-trimethylquinoline, 9CI, 8CI; A10AE280-05F4-4846-ACAE-D565B0D263A2; Ethyl 2,2,4-trimethyl-1,2-dihydro-6-quinolinyl ether #; 1,2-DIHYDRO-2,2,4-TRIMETHYLQUINOLIN-6-YL ETHYL ETHER	.	.	217.31	C14H19NO	21.3	283	3.1	16	1	2	2	InChI=1S/C14H19NO/c1-5-16-11-6-7-13-12(8-11)10(2)9-14(3,4)15-13/h6-9,15H,5H2,1-4H3	CCOC1=CC2=C(C=C1)NC(C=C2C)(C)C	CCOC1=CC2=C(C=C1)NC(C=C2C)(C)C	DECIPOUIJURFOJ-UHFFFAOYSA-N	6-ethoxy-2,2,4-trimethyl-1H-quinoline
ferrodrug0021	Estradiol	.	estradiol; beta-Estradiol; 17beta-Estradiol; 50-28-2; Oestradiol; Dihydrofolliculin; Estrace; Vivelle; Ovocyclin; progynon; Dihydrotheelin; Dihydroxyestrin; Diogynets; Gynoestryl; Aquadiol; Climara; Diogyn; Gynergon; Vagifem; Dimenformon; Follicyclin; Oestroglandol; Aerodiol; Bardiol; Corpagen; Divigel; Estraderm; Estrovite; Femestral; Ginosedol; Lamdiol; Macrodiol; Oestergon; Ovasterol; Ovastevol; Perlatanol; Primofol; Profoliol; Syndiol; Altrad; Evorel; Dihydromenformon; Estraldine; Estroclim; Estrogel; Menorest; Nordicol; Ovahormon; Femogen; Systen; Zumenon; estradiol-17beta; cis-Estradiol; D-Oestradiol; D-Estradiol; Estraderm TTS; Progynon DH; Climaderm; Compudose; Dermestril; Ovocycline; Trocosone; Estring; Innofem; Oesclim; Alora; Encore; Dihydroxyoestrin; 17beta-Oestradiol; Progynon-DH; Estrasorb; Fempatch; Gynestrel; Gynodiol; Microdiol; Oestrogynal; Ovociclina; Ovocylin; Tradelia; Esclim; Macrol; Menest; Zerella; Estroclim 50; Oestradiol R; SK-Estrogens; Estring vaginal ring; Elestrin; Estrifam; Extrasorb; Ginedisc; Estreva; Evamist; Femtran; Trial SAT; Theelin, dihydro-; GynPolar; Compudose 200; Compudose 365; Sandrena Gel; Sisare Gel; Estrofem 2; Estradot; Menostar; Oestrogel; Zesteem; 17 beta-Estradiol; Climara Forte; Profoliol B; Estraderm TTS 50; Oestradiol Berco; Estraderm MX; 17b-Oestradiol; VIVELLE-DOT; NSC-9895; Estrapak 50; Estradiol-17-beta; Estradiolum; Estrodiolum; Gelestra; 3,17-Epidihydroxyestratriene; Dihydroxyesterin; cis-Oestradiol; Estrogens, esterified; 17.beta.-Estradiol; B-Estradiol; Epiestriol 50; 17beta oestradiol; Estra-1,3,5(10)-triene-3,17beta-diol; Estradiol Anhydrous; E(sub 2); 17-beta-estradiol; Estradiol-17 beta; Elestrim; Femanest; Femestrol; Minivelle; Yuvvexy; 3,17-Epidihydroxyoestratriene; Sandrena 1; 17b-Estradiol; Estraderm (TN); [3H]-estradiol; 17; A-estradiol; 17; A-Oestradiol; Estrogel (TN); Climara (TN); Divigel (TN); Estrace (TN); Estring (TN); Innofem (TN); Vagifem (TN); Vivelle (TN); (17beta)-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Oestradiol; CCRIS 280; CHEBI:16469; HSDB 3589; 3,17.beta.-Estradiol; .beta.-Estradiol; (8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; EINECS 200-023-8; .beta.-Oestradiol; [3H]]estradiol; NSC-20293; Estradiol 17-beta; 17-beta-oestradiol; UNII-4TI98Z838E; IMVEXXY; TX-004HR; Estradiol, .beta.-; Estradiol-17.beta.; Estra-1,3,5(10)-triene-3,17-diol (17beta)-; Oestradiol-17.beta.; 17-.beta.-oestradiol; 4TI98Z838E; ESTRADIOL HEMIHYDRATE; Oestra-1,3,5(10)-triene-3,17beta-diol; Estrasorb (TN); 17.beta.-OH-estradiol; 17.beta.-OH-oestradiol; 17beta estradiol (E2); 17beta-Estra-1,3,5(10)-triene-3,17-diol; WC3011; C18H24O2; CHEMBL135; (17beta)-estra-1(10),2,4-triene-3,17-diol; D-3,17.beta.-Estradiol; WC-3011; D-3,17.beta.-Oestradiol; Estra-1,3,5(10)-triene-3,17-diol, (17beta)-; MLS000069494; 3,17b-Dihydroxyestra-1,3,5(10)-triene; (+)-3,17.beta.-Estradiol; 141290-02-0; Oestradiolum; DTXSID0020573; Estradiol valerate metabolite e2; BIJUVA COMPONENT ESTRADIOL; NSC9895; ANGELIQ COMPONENT ESTRADIOL; EC 200-023-8; ORIAHNN COMPONENT ESTRADIOL; PREFEST COMPONENT ESTRADIOL; ACTIVELLA COMPONENT ESTRADIOL; ESTRADIOL COMPONENT OF BIJUVA; COMBIPATCH COMPONENT ESTRADIOL; [3H]E2; ESTRADIOL COMPONENT OF ANGELIQ; ESTRADIOL COMPONENT OF ORIAHNN; ESTRADIOL COMPONENT OF PREFEST; CLIMARA PRO COMPONENT ESTRADIOL; Oestradiol-17beta; (8R,9S,13S,14S,17S)-13-Methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-diol; E2; ESTRADIOL COMPONENT OF ACTIVELLA; ESTRADIOL COMPONENT OF COMBIPATCH; Estradiolum [INN]; Estradiolo [DCIT]; NCGC00091544-04; Oestradiol-17-beta; ESTRADIOL COMPONENT OF CLIMARA PRO; Estradiolo; SMR000059126; Estradiol-3,17beta; 17-beta-OH-estradiol; 3,17-beta-Estradiol; 3,17beta-Dihydroxyestra-1,3,5(10)-triene; 3,17-beta-Oestradiol; D-3,17beta-Estradiol; 3,17.beta.-Dihydroxyestra-1,3,5(10)-triene; Methyl 1-cyclopropyl-6,7-difluoro-8-methoxy-4-oxo-1,4-dihydroquinoline-3-carboxylate.; Benzogynestry; Estropause; Estasorb; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2(7),3,5-triene-5,14-diol; [2,4,6,7-3H]-E2; E 2; DTXCID80573; ESTRADIOL (USP MONOGRAPH); ESTRADIOL [USP MONOGRAPH]; Destradiol; ESTRADIOL IMPURITY A (IP); ESTRADIOL IMPURITY A [IP]; Zesteen; .alpha.-Estradiol; 17-beta-OH-oestradiol; 17?-Estradiol; D-3,17beta-Oestradiol; D-3,17-beta-Estradiol; Estrodiolum [INN-Latin]; Estra-1,3,5(10)-triene-3,17-diol (17.beta.)-; D-3,17-beta-Oestradiol; Activella (Salt/Mix); Combipatch (Salt/Mix); component of Menrium; Estradiol-17 alpha; Climara Pro (Salt/Mix); 3,17beta-Estradiol; 3,17-.beta.-Oestradiol; Estraderm TTS 100; ETHINYLESTRADIOL IMPURITY D (EP IMPURITY); ETHINYLESTRADIOL IMPURITY D [EP IMPURITY]; 3,3,5(10)-triene; SR-01000075866; 17-.BETA.-Estradiol; 1,3,5-Estratriene-3,17-beta-diol; oestrodiol; Estradiol [USP:INN:BAN]; 3,17beta-Dihydroxyestra-1,3,5-triene; Estradurin; 3,17beta-Dihydroxyoestra-1,3,5-triene; delta-Estradiol; dihydro-Theelin; 3,17-beta-Dihydroxyoestra-1,3,5-triene; NSC20293; beta -estradiol; delta-Oestradiol; Estra-1,3,5(10)-triene-3,17-beta-diol; Estrogel HBF; Oestra-1,3,5(10)-triene-3,17-beta-diol; 1jgl; 1lhu; 1qkt; 1qku; 3,17-beta-Dihydroxyestra-1,3,5(10)-triene; [3H]estradiol; 1,3,5-Estratriene-3,17.beta.-diol; 3,17-beta-Dihydroxy-1,3,5(10)-oestratriene; CAS-50-28-2; 17-beta-Estra-1,3,5(10)-triene-3,17-diol; 17beta-Oestra-1,3,5(10)-triene-3,17-diol; .alpha.-Oestradiol; 17-beta-Oestra-1,3,5(10)-triene-3,17-diol; Estra-1,3,5(10)-triene-3,17-diol; Prestwick_207; 3,17b-Estradiol; Bio-E-Gel; Fem7; [3H]-Estrogen; 17 ?-Estradiol; 3,17.beta.-Dihydroxyestra-1,3,5-triene; 3,17.beta.-Dihydroxyoestra-1,3,5-triene; CMC_11154; Therapeutic Estradiol; 1,3,5,(10)-Estratrien-3,17.beta.-diol; SL-1100; Estra-1,3,5(10)-triene-3,17.beta.-diol; Oestra-1,3,5(10)-triene-3,17.beta.-diol; 2j7x; 3,17.beta.-Dihydroxy-1,3,5(10)-estratriene; 3,17.beta.-Dihydroxy-1,3,5(10)-oestratriene; 3,3,5-triene; [3H]17beta-estradiol; ESTRADIOL [INN]; ESTRADIOL [JAN]; (17?)-Estra-1,3,5(10)-triene-3,17-diol; 17.beta.-Estra-1,3,5(10)-triene-3,17-diol; ESTRADIOL [MI]; ESTRADIOL [HSDB]; ESTRADIOL [INCI]; 17.beta.-Oestra-1,3,5(10)-triene-3,17-diol; Opera_ID_1688; Prestwick0_000441; Prestwick1_000441; Prestwick2_000441; Prestwick3_000441; Spectrum5_002055; 17beta-estradiol (E2); ESTRADIOL [VANDF]; 3,17beta-Dihydroxy-1,3,5(10)-estratriene; alpha-estradiol (obsolete); beta-Estradiol, >=98%; bmse000642; Epitope ID:136018; (+)-3,17b-Estradiol; E 8875; ESTRADIOL [USP-RS]; ESTRADIOL [WHO-DD]; SCHEMBL8049; (+)-3,17beta-Estradiol; Estradiol (JAN/USP/INN); Tritiated estradiol-17-beta; BIDD:PXR0065; Lopac0_000503; S-21400; BSPBio_000482; BSPBio_001065; KBioGR_000405; KBioGR_002269; KBioSS_000405; KBioSS_002270; MLS000758312; MLS001076331; MLS001424022; BIDD:ER0125; SPBio_002421; ESTRADIOL [GREEN BOOK]; BPBio1_000532; GTPL1012; GTPL1013; ESTRADIOL [ORANGE BOOK]; NIOSH/KG7030000; BDBM17292; KBio2_000405; KBio2_002269; KBio2_002973; KBio2_004837; KBio2_005541; KBio2_007405; KBio3_000769; KBio3_000770; KBio3_002749; 1a52; 1g50; 2d06; cMAP_000005; Bio1_000403; Bio1_000892; Bio1_001381; Bio2_000363; Bio2_000843; HMS1362E07; HMS1569I04; HMS1792E07; HMS1990E07; HMS2051C17; HMS2090E18; HMS2096I04; HMS2236H04; HMS3261F07; HMS3403E07; HMS3713I04; HMS3884A08; beta-Estradiol, analytical standard; (8S,9S,13S,14S,17S)-13-Methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol; BCP08579; ESTRADIOL 17-BETA [VANDF]; HY-B0141; Tox21_111148; Tox21_202057; Tox21_300288; Tox21_500503; 1,5-Estratriene-3,17.beta.-diol; HB2494; LMST02010001; s1709; Estradiol-17-beta-6,7-(sup 3)H; [2,4,6,7-3H]-17beta-estradiol; AKOS015896570; CCG-100808; CS-1938; DB00783; LP00503; NC00058; SDCCGSBI-0050487.P002; IDI1_002118; SMP1_000121; NCGC00091544-00; NCGC00091544-01; NCGC00091544-02; NCGC00091544-05; NCGC00091544-06; NCGC00091544-07; NCGC00091544-09; NCGC00091544-10; NCGC00091544-11; NCGC00091544-12; NCGC00091544-13; NCGC00091544-14; NCGC00091544-15; NCGC00091544-16; NCGC00091544-18; NCGC00091544-27; NCGC00179321-01; NCGC00179321-02; NCGC00254177-01; NCGC00259606-01; NCGC00261188-01; 17-E; AC-22346; AS-13729; CPD000059126; Estra-1,3,5(10)-triene-3,17b-diol; Oestra-1,3,5(10)-triene-3,17b-diol; WLN: L E5 B666TTT&J E1 FQ OQ; 17 beta-Estradiol, 1mg/ml in Acetonitrile; Estra-1,5(10)-triene-3,17.beta.-diol; Estradiol, meets USP testing specifications; 3,17beta-dihydroxyestra-1,3,5(10)-trien; EU-0100503; KG70300000; Oestra-1,5(10)-triene-3,17.beta.-diol; C00951; D00105; EN300-119518; (17b)-Estra-1,3,5(10)-triene-3,17-diol; 13b-Methyl-1,3,5(10)-gonatriene-3,17b-ol; 17.beta.-Estra-1,5(10)-triene-3,17-diol; 17.beta.-Oestra-1,5(10)-triene-3,17-diol; 17-beta-Estradiol 100 microg/mL in Acetonitrile; Q422416; SR-01000721892; 13beta-Methyl-1,3,5(10)-gonatriene-3,17beta-ol; Estra-1,5(10)-triene-3,17-diol (17.beta.)-; ESTRADIOL BENZOATE IMPURITY A [EP IMPURITY]; ESTRADIOL VALERATE IMPURITY A [EP IMPURITY]; Q-201503; SR-01000075866-1; SR-01000075866-4; SR-01000721892-3; BRD-K18910433-001-04-4; BRD-K18910433-001-43-2; estra-1(10),2,4-triene-3,17-diol, (17beta)-; Estra-1,5(10)-triene-3,17-diol, (17.beta.)-; Z1521553843; B8B5AEF5-4957-49EB-A14F-444A8212C482; beta-Estradiol, BioReagent, powder, suitable for cell culture; Estradiol, United States Pharmacopeia (USP) Reference Standard; 13.BETA.-METHYL-1,3,5(10)-GONATRIENE-3,17.BETA.-OL; beta-Estradiol, powder, gamma-irradiated, suitable for cell culture; Estra-1,3,5(10)-triene-3,17-diol, (6,7-(sup 3)H,17-beta)-; (9beta,13alpha,14beta,17alpha)-estra-1,3,5(10)-triene-3,17-diol; Estradiol, Pharmaceutical Secondary Standard; Certified Reference Material; (13S,17S)-13-methyl-7,8,9,11,12,13,14,15,16,17-decahydro-6H-cyclopenta[a]phenanthrene-3,17-beta-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadeca-2,4,6-triene-5,14-diol; (1S,10R,11S,14S,15S)-15-methyltetracyclo[8.7.0.0^{2,7}.0^{11,15}]heptadeca-2,4,6-triene-5,14-diol	.	.	272.4	C18H24O2	40.5	382	4	20	2	2	0	InChI=1S/C18H24O2/c1-18-9-8-14-13-5-3-12(19)10-11(13)2-4-15(14)16(18)6-7-17(18)20/h3,5,10,14-17,19-20H,2,4,6-9H2,1H3/t14-,15-,16+,17+,18+/m1/s1	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O	CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)O	VOXZDWNPVJITMN-ZBRFXRBCSA-N	(8R,9S,13S,14S,17S)-13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol
ferrodrug0022	Bisphenol A	Small molecular drug	Bisphenol A; 80-05-7; 2,2-Bis(4-hydroxyphenyl)propane; 4,4'-Isopropylidenediphenol; Diphenylolpropane; 4,4'-Bisphenol A; Bisphenol; Diano; Bisphenol-A; 4,4'-(propane-2,2-diyl)diphenol; Biphenol A; Parabis A; 2,2-Bis(p-hydroxyphenyl)propane; DIAN; p,p'-Isopropylidenebisphenol; Rikabanol; p,p'-Bisphenol A; Bisferol A; 2,2-Di(4-phenylol)propane; Ipognox 88; Pluracol 245; p,p'-Dihydroxydiphenylpropane; Phenol, 4,4'-(1-methylethylidene)bis-; 4,4'-Dihydroxydiphenylpropane; Ucar bisphenol A; 4-[2-(4-hydroxyphenyl)propan-2-yl]phenol; Dimethylmethylene-p,p'-diphenol; p,p'-Isopropylidenediphenol; BPA; Bis(4-hydroxyphenyl)propane; Ucar bisphenol HP; 4,4'-(1-Methylethylidene)bisphenol; 2,2-Di(4-hydroxyphenyl)propane; 4,4'-Isopropylidene diphenol; 2,2-Bis(hydroxyphenyl)propane; p,p'-Dihydroxydiphenyldimethylmethane; 4,4'-Isopropylidenebisphenol; Bis(4-hydroxyphenyl)dimethylmethane; Isopropylidenebis(4-hydroxybenzene); Bis(4-hydroxyphenyl) dimethylmethane; 4,4'-Dihydroxydiphenyldimethylmethane; 2,2-Bis-4'-hydroxyfenylpropan; 4,4'-Dihydroxy-2,2-diphenylpropane; Phenol, 4,4'-isopropylidenedi-; 2,2-(4,4'-Dihydroxydiphenyl)propane; 4,4'-propane-2,2-diyldiphenol; Phenol, (1-methylethylidene)bis-; 4,4' Isopropylidinediphenol; NCI-C50635; Dimethylbis(p-hydroxyphenyl)methane; 2,2-Bis(4'-hydroxyphenyl)propane; beta-di-p-hydroxyphenylpropane; Dimethyl bis(p-hydroxyphenyl)methane; Bisphenol A.; 4,4'-Dihydroxydiphenyl-2,2-propane; Bis(p-hydroxyphenyl)propane; CCRIS 95; Phenol, 4,4'-dimethylmethylenedi-; 2,2-Bis (4-hydroxyphenol) propane; Propane, 2,2-bis(p-hydroxyphenyl)-; 4,4'-Dimethylmethylenediphenol; HSDB 513; 4-[1-(4-hydroxyphenyl)-1-methylethyl]phenol; beta,beta'-Bis(p-hydroxyphenyl)propane; DTXSID7020182; 4,4-ISOPROPYLIDENEDIPHENOL; NSC 1767; EINECS 201-245-8; 4,4[-Isopropylidenediphenol; 4,4'-Dihydroxdiphenylpropane; UNII-MLT3645I99; BRN 1107700; 4,4'-Isopropylidenebis[phenol]; Bisphenol A (BPA); CHEBI:33216; 4,4'-(1-Methylethane-1,1-diyl)diphenol; AI3-04009; 2,2-bis[4-Hydroxyphenyl]propane; MLT3645I99; 2, 2-Bis(4-hydroxyphenyl)propane; 2,2-bis(4-hydroxyphenyl) propane; NSC-1767; MFCD00002366; 2,2-(4,4-Dihydroxydiphenyl)propane; 25766-59-0; beta,beta-di-(p-hydroxyphenyl)propane; DTXCID30182; BPA 157; EC 201-245-8; di-2,2-(4-Hydroxyphenyl)propane; 2,2'-Bis(4-hydroxyphenyl)propane; 4,4'-ISOPROPYLIDENEDIPHENOL (BISPHENOL A); 4-06-00-06717 (Beilstein Handbook Reference); 4,2-propane; 2,2-di-(4'-Hydroxyphenyl)-propane; 4,2-diphenylpropane; 2,2-Bis(4,4'-hydroxyphenyl)propane; NCGC00090952-07; BISPHENOL-A-2,2',6,6'-D4; .beta.,.beta.'-Bis(p-hydroxyphenyl)propane; BISPHENOL-A-3,3',5,5'-D4; Phenol,4'-isopropylidenedi-; 27100-33-0; Bisphenol-A-2,2',3,3',5,5',6,6'-D8; BISPHENOL A (USP-RS); BISPHENOL A [USP-RS]; Phenol,4'-dimethylmethylenedi-; 2,4'-Dihydroxydiphenyl)propane; Bisferol A [Czech]; WLN: QR DX1&1&R DQ; Propane,2-bis(p-hydroxyphenyl)-; .beta.-Di-(p-hydroxyphenyl)propane; Phenol,4'-(1-methylethylidene)bis-; 4,4'-ISOPROPYLIDENEBIS(PHENOL); CAS-80-05-7; 347841-41-2; 102438-62-0; bisphenol A, sodium salt; bisphenol A, disodium salt; 2,2-Bis-4'-hydroxyfenylpropan [Czech]; bis-phenol-a; bis-phenol A; Bis Phenol A; Millad HBPA; 2OH; 4,4'-ISOPROPYLIDENE-DIPHENOL; bis(4-hyd roxyphenyl) dimethylmethane; 4,4'-bisphenol-A; Bisphenol A, 97%; 2e2r; 2p7g; 4, 4'-Bisphenol A; BISPHENOL A [MI]; Bisphenol A, >=99%; 4,4'-isopropylidendiphenol; BISPHENOL A [HSDB]; Bisphenol a(ring 13c12); HIDORIN F 285; BIDD:PXR0120; Oprea1_215541; p, p'-Isopropylidenediphenol; SCHEMBL15062; bis(4-hydroxyphenyl)-propane; MLS001055461; BIDD:ER0208; 4,4'-Isopropylidenedi-Phenol; p, p'-Dihydroxydiphenylpropane; (1-methylethylidene)bis-Phenol; 2, 2-Di(4-phenylol)propane; 4,4'-Isopropylidenediphenol B; CHEMBL418971; GTPL7865; 4, 4'-Dihydroxydiphenylpropane; 2, 2-Bis(hydroxyphenyl)propane; .beta.-di-p-hydroxyphenylpropane; 4,4'-Dimethylmethylenedi-Phenol; 4,4'-Isopropylidendiphenol dust; BDBM29608; beta-Di-(p-hydroxyphenyl)propane; BPA 154; NSC1767; 2,2-bis(p-hydroxyphenyl)-propane; HMS2866B07; HMS3749E11; KUC105370N; 2,2-di(p-hydroxy-phenyl-)propane; 4,4'-Isopropylidenediphenol, 8CI; 2,2-bis-(p-hydroxyphenyl)-propane; CS-B1737; NSC17959; 2,2-bis-(4-hydroxy phenyl)propane; 2,2-bis-(4-hydroxyphenyl) propane; 2,2-bis-(4-hydroxyphenyl)-propane; Tox21_202992; Tox21_400088; 4,4?-(1-Methylethylidene)bisphenol; BBL010647; dimethyl bis(p-hydroxyphenyl)methane; KSC-7-199; NSC-17959; s6007; STK801675; 2,2-bis-(4- hydroxyphenyl)-propane; p, p'-Dihydroxydiphenyldimethylmethane; 4,4'-(1-methylethylidene)bis-phenol; 4,4'-dihydroxy diphenyl-2,2-propane; AKOS000119022; 4, 4'-Dihydroxydiphenyl-2,2-propane; 4, 4'-Dihydroxydiphenyldimethylmethane; CCG-214370; DB06973; beta, beta'-Bis(p-hydroxyphenyl)propane; UPCMLD0ENAT5883875:001; NCGC00090952-01; NCGC00090952-02; NCGC00090952-03; NCGC00090952-04; NCGC00090952-05; NCGC00090952-06; NCGC00090952-08; NCGC00090952-09; NCGC00260537-01; HY-18260; SMR000315090; VS-02603; 4,4'-(1-Methylethylidene)bisphenol, 9CI; 4,4'-ISOPROPYLIDENEDIPHENOL [INCI]; Bisphenol A 100 microg/mL in Acetonitrile; 1,1'-(1-Methylethylidene)bisphenylol, 9CI; B0494; FT-0609178; FT-0663365; FT-0663366; FT-0663367; 872 - Bisphenols in 3% aqueous acetic acid; EN300-19430; Bisphenol A 2,2-Bis(4-hydroxyphenyl) propane; D77313; 4,4'-Isopropylidenediphenol, analytical standard; 4,4'-ISOPROPYLIDENEDIPHENOL; BISPHENOL A; Bisphenol A-d14 100 Amicrog/mL in Acetonitrile; A839823; AE-848/01247026; Q271980; SR-01000596928; SR-01000596928-1; 4,4'-Isopropylidenediphenol C12-15 alcohol phosphite; BRD-K41494493-001-04-7; Bisphenol A, certified reference material, TraceCERT(R); F1284-0895; Z104473824; Bisphenol A, United States Pharmacopeia (USP) Reference Standard; 96152-48-6; InChI=1/C15H16O2/c1-15(2,11-3-7-13(16)8-4-11)12-5-9-14(17)10-6-12/h3-10,16-17H,1-2H	D02RQP	DM2ZLD7	228.29	C15H16O2	40.5	209	3.3	17	2	2	2	InChI=1S/C15H16O2/c1-15(2,11-3-7-13(16)8-4-11)12-5-9-14(17)10-6-12/h3-10,16-17H,1-2H3	CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O	CC(C)(C1=CC=C(C=C1)O)C2=CC=C(C=C2)O	IISBACLAFKSPIT-UHFFFAOYSA-N	4-[2-(4-hydroxyphenyl)propan-2-yl]phenol
ferrodrug0023	Carvacrol	Small molecular drug	CARVACROL; 5-Isopropyl-2-methylphenol; 499-75-2; Antioxine; Isopropyl-o-cresol; 2-p-Cymenol; o-Thymol; Karvakrol; 5-Isopropyl-o-cresol; Isothymol; 2-Hydroxy-p-cymene; p-Cymen-2-ol; Phenol, 2-methyl-5-(1-methylethyl)-; 2-Methyl-5-isopropylphenol; 3-Isopropyl-6-methylphenol; p-Cymene, 2-hydroxy-; 5-Isopropyl-2-methyl-phenol; o-Cresol, 5-isopropyl-; 2-Methyl-5-(1-methylethyl)phenol; 2-Methyl-5-(Propan-2-Yl)Phenol; 6-Methyl-3-isopropylphenol; 1-Hydroxy-2-methyl-5-isopropylbenzene; FEMA No. 2245; 2-methyl-5-propan-2-ylphenol; Phenol, 5-isopropyl-2-methyl-; Cymene-2-ol, p-; Caswell No. 511; Phenol, 3-isopropyl-6-methyl-; 1-Methyl-2-hydroxy-4-isopropylbenzene; CYMOPHENOL; DENTOL; NSC 6188; CCRIS 7450; HSDB 906; Oxycymol; 2-Hydroxycymene; NSC-6188; EINECS 207-889-6; EPA Pesticide Chemical Code 022104; UNII-9B1J4V995Q; BRN 1860514; CHEBI:3440; AI3-03438; 9B1J4V995Q; CHEMBL281202; DTXSID6042074; 2-methyl-5-propan-2-yl-phenol; 4-06-00-03331 (Beilstein Handbook Reference); 2-Methyl-5-(1-methylethyl)-Phenol; Cymenol; Hydroxy-p-cymene; Carvacrol,(S); p-Cymene-2-ol; Carvacrol, 98%; MFCD00002236; CARVACROL [FCC]; CARVACROL [MI]; CARVACROL [FHFI]; CARVACROL [HSDB]; CARVACROL [INCI]; CARVACROL [WHO-DD]; SCHEMBL24734; 3-Isopropyl-6-methyl phenol; 3-Isopropyl-6-methyl-Phenol; BIDD:ER0492; Carvacrol, analytical standard; O-CRESOL, 5-ISOPROPYL; GTPL2497; Carvacrol, natural, 99%, FG; DTXCID4022074; Methyl-5-(1-methylethyl)phenol; p-Mentha-1,3,5-trien-2-ol; WLN: QR B1 EY1&1; FEMA 2245; NSC6188; Carvacrol, >=98%, FCC, FG; HY-N0711; Tox21_301378; BDBM50240433; s3788; STL453136; AKOS000120828; AC-2688; CCG-266210; FS-4199; LMPR0102090017; MB00118; NCGC00256001-01; CAS-499-75-2; Isothymol (=2-Isopropyl-4-methyl phenol); Carvacrol Cymenol 5-Isopropyl-2-methylphenol; CS-0009729; FT-0627526; 2-HYDROXY-4-ISOPROPYL-1-METHYLBENZENE; EN300-21426; C09840; F17722; A827907; Q225543; Carvacrol, primary pharmaceutical reference standard; W-105999; BENZENE,2-HYDROXY,4-ISOPROPYL,1-METHYL CARVACROL; F8889-1978; Z104496566; BENZENE,2-HYDROXY,4-ISOPROPYL,1-METHYL CARVACROL; InChI=1/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H; S5V	D07JDC	DMINM2D	150.22	C10H14O	20.2	120	3.1	11	1	1	1	InChI=1S/C10H14O/c1-7(2)9-5-4-8(3)10(11)6-9/h4-7,11H,1-3H3	CC1=C(C=C(C=C1)C(C)C)O	CC1=C(C=C(C=C1)C(C)C)O	RECUKUPTGUEGMW-UHFFFAOYSA-N	2-methyl-5-propan-2-ylphenol
ferrodrug0024	Tert-Butylhydroquinone	.	tert-Butylhydroquinone; 1948-33-0; TBHQ; 2-tert-Butylhydroquinone; 2-tert-butylbenzene-1,4-diol; T-BUTYLHYDROQUINONE; MTBHQ; t-Butyl hydroquinone; 2-t-Butylhydroquinone; Mono-tert-butylhydroquinone; Sustane; 2-tert-Butyl-1,4-benzenediol; Mono-tertiarybutylhydroquinone; tert-Butyl-1,4-benzenediol; Tenox TBHQ; tertiary-Butylhydroquinone; Banox 20BA; Hydroquinone, tert-butyl-; 2-(1,1-Dimethylethyl)-1,4-benzenediol; 1,4-Benzenediol, 2-(1,1-dimethylethyl)-; 2-tert-Butyl(1,4)hydroquinone; 2-tertiary-butylhydroquinone; Tertiary butylhydroquinone; tert-Butylhydrochinone; t-BHQ; 2-(tert-butyl)benzene-1,4-diol; 2-t-Butyl-1,4-benzenediol; Hydroquinone, t-butyl-; Butylhydroquinone, tert-; NSC 4972; Tenox 20; monotertiary butyl hydroquinone; CCRIS 1447; HSDB 838; CHEBI:78886; 1,4-Benzenediol (1,1-dimethylethyl)-; NSC4972; Eastman MTBHQ; NSC-4972; EINECS 217-752-2; MFCD00002344; BRN 0637923; DTXSID6020220; AI3-61039; tert-butyl-hydroquinone; UNII-C12674942B; 2-(1,1-dimethylethyl)benzene-1,4-diol; DTXCID60220; BUTYLHYDROQUINONE,TERT-; INS NO.319; C12674942B; INS-319; EC 217-752-2; HYDROQUINONE,TERTIARY BUTYL; 2-tert-butyl-1,4-dihydroxybenzene; NCGC00013051-05; E319; E-319; TERT-BUTYLHYDROQUINONE (II); TERT-BUTYLHYDROQUINONE [II]; 2-(tert-Butyl)benzene-1,4-diol(may occur to produce black solid); EYK; TERTIARY BUTYLHYDROQUINONE (MART.); TERTIARY BUTYLHYDROQUINONE [MART.]; CAS-1948-33-0; Butylhydroquinone, t-; tert-butyl hydroquinone; 2-(tert-Butyl)-p-hydroquinone; Sustane TBHQ; Tenox TBHO; Tenox TBHQTBHQ; t-butyl-hydroquinone; THBQ; 2-t-butyl hydroquinone; tert.-butyl hydroquinone; 2-tert-butyl-hydroquinone; TBHQ [INCI]; TBHQ [FCC]; NCIStruc1_000241; NCIStruc2_000017; SCHEMBL26745; tert-Butylhydroquinone, 97%; MLS002222348; CHEMBL242080; NCI4972; WLN: QR DQ BX1&1&1; KUC109743N; T-BUTYLHYDROQUINONE [HSDB]; 1,4-dihydroxy-2-tert-butylbenzene; Tox21_110006; Tox21_110007; Tox21_202309; Tox21_300081; BDBM50065387; CCG-37948; NCGC00013051; s4990; STK372011; AKOS003627061; CS-5774; DB07726; 2-TERT-BUTYL-1,4-HYDROQUINONE; NCGC00013051-01; NCGC00013051-02; NCGC00013051-03; NCGC00013051-04; NCGC00013051-06; NCGC00013051-07; NCGC00013051-08; NCGC00013051-09; NCGC00013051-10; NCGC00090788-01; NCGC00090788-02; NCGC00090788-03; NCGC00090788-04; NCGC00254178-01; NCGC00259858-01; AC-10579; BS-15862; NCI60_004196; SMR001253806; SY001798; 2-(1,1-DIMETHYLETHYL)HYDROQUINONE; HYDROQUINONE,TERTIARY BUTYL [VANDF]; KSC-241-078-1; tert-Butylhydroquinone, analytical standard; HY-100489; B0833; FT-0652102; 2-(1,1-Dimethylethyl)-1,4-benzenediol, 9CI; D70420; EN300-120878; Q662443; W-107698; BRD-K36452089-001-01-8; BRD-K36452089-001-02-6; F0001-0696; Z1255402624	.	.	166.22	C10H14O2	40.5	148	2.8	12	2	2	1	InChI=1S/C10H14O2/c1-10(2,3)8-6-7(11)4-5-9(8)12/h4-6,11-12H,1-3H3	CC(C)(C)C1=C(C=CC(=C1)O)O	CC(C)(C)C1=C(C=CC(=C1)O)O	BGNXCDMCOKJUMV-UHFFFAOYSA-N	2-tert-butylbenzene-1,4-diol
ferrodrug0025	Glycyrrhizin	Small molecular drug	Glycyrrhizic acid; glycyrrhizin; 1405-86-3; Glycyrrhizinic acid; Glycyron; Glycyrrhetinic acid glycoside; potenlini; Glizigen; glycyrrhizate; glyzyrrhizin; 18-beta-Glycyrrhizic acid; beta-Glycyrrhizin; 18beta-Glycyrrhizic acid; Glycyrrizin; Rizinsan K2 A2 (free acid); HSDB 496; CHEBI:15939; EINECS 215-785-7; Glycyrrhizin [JAN]; .beta.-glycyrrhizin; NSC 167409; NSC 234419; NSC-167409; NSC-234419; UNII-6FO62043WK; BRN 0077922; CCRIS 8444; DTXSID8047006; 6FO62043WK; C42H62O16; 18.beta.-glycyrrhizic acid; Glycyrrhizinate; CHEMBL441687; NSC 2800; DTXCID6027006; 4-18-00-05156 (Beilstein Handbook Reference); (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; 20beta-Carboxy-11-oxo-30-norolean-12-en-3beta-yl-2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; 30-hydroxy-11,30-dioxoolean-12-en-3beta-yl (2-O-beta-D-glucopyranosyluronic acid)-alpha-D-glucopyranosiduronic acid; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl-2-O-beta-D-glucopyranuron osyl-; GLYCYRRHIZIN (II); GLYCYRRHIZIN [II]; Glycyrrhitin; Dermacrin; (3beta,20beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; GLYCYRRHIZIC ACID (MART.); GLYCYRRHIZIC ACID [MART.]; GLYCYRRHIZIC ACID (USP-RS); GLYCYRRHIZIC ACID [USP-RS]; NSC167409; Glycyram; Neo-Umor; Acid, Glycyrrhizic; (2S,3S,4S,5R,6S)-6-{[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,14,14a,14b-icosahydropicen-3-yl]oxy}-5-{[(2R,3R,4S,5S,6S)-6-carboxy-3,4,5-trihydroxyoxan-2-yl]oxy}-3,4-dihydroxyoxane-2-carboxylic acid; CAS-1405-86-3; Acid, Glycyrrhizinic; MFCD00065194; NSC234419; NCGC00183128-01; (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxy-tetrahydropyran-3-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; ammonium-glycyrrhizinate; Glycyrrhizic acid, 2K; beta-Glycyrrhizinic acid; GLYCYRRHIZIN [HSDB]; SCHEMBL17684; alpha-D-glucopyranosiduronic acid, (3 beta,20 beta)-20-carboxy-11-oxo-30-norolean-12-en-3-yl 2-O-beta-D-glucopyranuronosyl-; BIDD:ER0363; GLYCYRRHIZIC ACID [MI]; GTPL4688; GLYCYRRHIZIC ACID [INCI]; Glycyrrhizin (Glycyrrhizic Acid); LPLVUJXQOOQHMX-QWBHMCJMSA-N; GLYCYRRHIZIC ACID [WHO-DD]; HY-N0184; Tox21_111520; Tox21_113426; Tox21_303493; BDBM50185127; HMDB:0029843; s2302; AKOS015893086; AKOS015969345; CCG-270511; CS-7695; DB13751; GM-1292; NCGC00257455-01; NCGC00386162-01; NCGC00386162-02; (3beta,20beta)-20-Carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-beta-1- 7-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-beta-1- 7-glucopyranuronosyl-; AS-13001; E958; G0150; AB01566834_01; EN300-25023649; Q418705; Q-201172; BRD-K83486494-318-01-5; GLYCYRRHIZIC ACID (GLYCYRRHIZIN) (CONSTITUENT OF LICORICE); GLYCYRRHIZIC ACID (GLYCYRRHIZIN) (CONSTITUENT OF LICORICE) [DSC]; Glycyrrhizic acid, United States Pharmacopeia (USP) Reference Standard; Glycyrrhizic Acid, Pharmaceutical Secondary Standard; Certified Reference Material; (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid; (2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylicacid; (3.beta.,20.beta.)-20-Carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-.beta.-1- 7-glucopyranuronosyl-.alpha.-D-glucopyranosiduronic acid; (3.BETA.,20.BETA.)-20-CARBOXY-11-OXO-30-NOROLEAN-12-EN-3-YL 2-O-.BETA.-D-GLUCOPYRANURONOSYL-.ALPHA.-D-GLUCOPYRANOSIDURONIC ACID; (3beta,20beta)-20-Carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-beta-1-7-glucopyranuronosyl-alpha-D-glucopyranosiduronic acid; 20BETA-CARBOXY-11-OXO-30-NOROLEAN-12-EN-3BETA-YL-2-O-BE TA-D-GLUCOPYRANURONOSYL-ALPHA-D-GLUCOPYRANOSIDURONIC ACID; alpha-D-Glucopyranosiduronic acid, (3beta,20beta)-20-carboxy-11-oxo-30-norlean-12-en-3-yl-2-O-beta-1-7-glucopyranuronosyl-	D0T8QB	DM8M2N3	822.9	C42H62O16	267	1730	3.7	58	8	16	7	InChI=1S/C42H62O16/c1-37(2)21-8-11-42(7)31(20(43)16-18-19-17-39(4,36(53)54)13-12-38(19,3)14-15-41(18,42)6)40(21,5)10-9-22(37)55-35-30(26(47)25(46)29(57-35)33(51)52)58-34-27(48)23(44)24(45)28(56-34)32(49)50/h16,19,21-31,34-35,44-48H,8-15,17H2,1-7H3,(H,49,50)(H,51,52)(H,53,54)/t19-,21-,22-,23-,24-,25-,26-,27+,28-,29-,30+,31+,34-,35-,38+,39-,40-,41+,42+/m0/s1	C[C@]12CC[C@](C[C@H]1C3=CC(=O)[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O[C@@H]6[C@@H]([C@H]([C@@H]([C@H](O6)C(=O)O)O)O)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)C(=O)O)O)O)O)C)(C)C(=O)O	CC1(C2CCC3(C(C2(CCC1OC4C(C(C(C(O4)C(=O)O)O)O)OC5C(C(C(C(O5)C(=O)O)O)O)O)C)C(=O)C=C6C3(CCC7(C6CC(CC7)(C)C(=O)O)C)C)C)C	LPLVUJXQOOQHMX-QWBHMCJMSA-N	(2S,3S,4S,5R,6R)-6-[(2S,3R,4S,5S,6S)-2-[[(3S,4aR,6aR,6bS,8aS,11S,12aR,14aR,14bS)-11-carboxy-4,4,6a,6b,8a,11,14b-heptamethyl-14-oxo-2,3,4a,5,6,7,8,9,10,12,12a,14a-dodecahydro-1H-picen-3-yl]oxy]-6-carboxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
ferrodrug0026	Diallyl trisulfide	.	Diallyl trisulfide; 2050-87-5; ALLYL TRISULFIDE; Allitridin; Trisulfide, di-2-propenyl; Diallyltrisulfide; Diallyl trisulphide; allitridum; Di-2-propenyl trisulfide; diallyltrisulfane; 8008-99-9; Trisulfide, di-2-propen-1-yl; FEMA No. 3265; 3-(prop-2-enyltrisulfanyl)prop-1-ene; 1,3-Diallyltrisulfane; NSC651936; 0ZO1U5A3XX; CHEMBL123040; bis(prop-2-en-1-yl)trisulfane; DTXSID9045972; CHEBI:78492; NSC-651936; Prop-2-enyl prop-2-enylthio disulfide; NCGC00095290-01; Dasuansu; CCRIS 3251; C6H10S3; EINECS 218-107-8; UNII-0ZO1U5A3XX; NSC 651936; BRN 1745734; AI3-35127; 3-(allyltrisulfanyl)prop-1-ene; ALLITRIDE; Allyl trisulfide, 8CI; Trisulfide di-2-propenyl; 1,3-Diallyltrisulfane #; Diprop-2-en-1-yltrisulfane; (CH2=CHCH2S)2S; 0-01-00-00441 (Beilstein Handbook Reference); SCHEMBL562845; SPECTRUM1505014; DIALLYL TRISULFIDE [MI]; DTXCID7025972; FEMA 3265; 4,5,6-Trithia-1,8-nonadiene; Diallyl Trisulfide (80per cent); DIALLYL TRISULFIDE [FHFI]; UBAXRAHSPKWNCX-UHFFFAOYSA-N; Trisulfide, di-2-propenyl (9CI); DIALLYL TRISULFIDE [WHO-DD]; Tox21_111500; BDBM50318454; Diallyl trisulfide, >=97% (HPLC); Diallyl trisulfide, >=98% (HPLC); AKOS006282485; 3-(prop-2-enyltrisulfanyl)-1-propene; CCG-230978; NCGC00095290-02; AS-75640; CAS-2050-87-5; HY-117235; CS-0064491; FT-0624607; FT-0626632; A814621; Q-100252; Q17148332	.	.	178.3	C6H10S3	75.9	70.4	2.6	9	0	3	6	InChI=1S/C6H10S3/c1-3-5-7-9-8-6-4-2/h3-4H,1-2,5-6H2	C=CCSSSCC=C	C=CCSSSCC=C	UBAXRAHSPKWNCX-UHFFFAOYSA-N	3-(prop-2-enyltrisulfanyl)prop-1-ene
ferrodrug0027	Salinomycin	Small molecular drug	salinomycin; Procoxacin; 53003-10-4; Coxistac; Bio-cox; CHEBI:80025; 62UXS86T64; Salinomycin (INN); SALINOMYCIN [INN]; Salinomicina; Salinomycine; Salinomycinum; Salinomycin [INN:BAN]; Salinomycine [INN-French]; Salinomycinum [INN-Latin]; Salinomicina [INN-Spanish]; UNII-62UXS86T64; K 364; HSDB 7032; Procoxacin (TN); AHR 3096; EINECS 258-290-1; SALINOMYCIN [MI]; SALINOMYCIN [JAN]; SALINOMYCIN [HSDB]; SCHEMBL36890; CHEMBL1208572; DTXSID4048486; GTPL11088; KQXDHUJYNAXLNZ-XQSDOZFQSA-N; BDBM430647; NSC757437; s2352; s8129; Salinomycin (from Streptomyces albus); CCG-208535; CS-1299; DB11544; NSC-757437; BS-17023; E716; HY-15597; D08502; A829344; Q411909; J-524236; SR-05000002207-3; Salinomycin, from Streptomyces albus, >=98% (HPLC); (2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(2S,5S,7R,9S,10S,12R,15R)-2-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.5?.3?]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid; (2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(3S,5S,7R,9S,10S,12R,15R)-3-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid; (R)-2-((2R,5S,6R)-6-((2S,3S,4S,6R)-6-((2S,5S,7R,9S,10S,12R,15R)-2-((2R,5R,6S)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl)-3-hydroxy-4-methyl-5-oxooctan-2-yl)-5-methyltetrahydro-2H-pyran-2-yl)butanoic acid; (R)-2-((2R,5S,6R)-6-((2S,3S,4S,6R)-6-((2S,5S,7R,9S,10S,12R,15R)-2-((2R,5R,6S)-5-ethyl-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)-15-hydroxy-2,10,12-trimethyl-1,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl)-3-hydroxy-4-methyl-5-oxooctan-2-yl)-5-methyltetrahydro-2H-pyran-2-yl)butanoicacid; sodium 2-[6-[5-[3-(5-ethyl-5-hydroxy-6-methyl-tetrahydropyran-2-yl)-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.5^{7}.3^{5}]pentadec-13-en-9-yl]-2-hydroxy-1,3-dimethyl-4-oxo-heptyl]-5-methyl-tetrahydropyran-2-yl]butanoate	.	DG61186	751	C42H70O11	161	1320	5.7	53	4	11	12	InChI=1S/C42H70O11/c1-11-29(38(46)47)31-15-14-23(4)36(50-31)27(8)34(44)26(7)35(45)30(12-2)37-24(5)22-25(6)41(51-37)19-16-32(43)42(53-41)21-20-39(10,52-42)33-17-18-40(48,13-3)28(9)49-33/h16,19,23-34,36-37,43-44,48H,11-15,17-18,20-22H2,1-10H3,(H,46,47)/t23-,24-,25+,26-,27-,28-,29+,30-,31+,32+,33+,34+,36+,37-,39-,40+,41-,42-/m0/s1	CC[C@H]([C@H]1CC[C@@H]([C@@H](O1)[C@@H](C)[C@@H]([C@H](C)C(=O)[C@H](CC)[C@@H]2[C@H](C[C@H]([C@]3(O2)C=C[C@H]([C@@]4(O3)CC[C@@](O4)(C)[C@H]5CC[C@@]([C@@H](O5)C)(CC)O)O)C)C)O)C)C(=O)O	CCC(C1CCC(C(O1)C(C)C(C(C)C(=O)C(CC)C2C(CC(C3(O2)C=CC(C4(O3)CCC(O4)(C)C5CCC(C(O5)C)(CC)O)O)C)C)O)C)C(=O)O	KQXDHUJYNAXLNZ-XQSDOZFQSA-N	(2R)-2-[(2R,5S,6R)-6-[(2S,3S,4S,6R)-6-[(3S,5S,7R,9S,10S,12R,15R)-3-[(2R,5R,6S)-5-ethyl-5-hydroxy-6-methyloxan-2-yl]-15-hydroxy-3,10,12-trimethyl-4,6,8-trioxadispiro[4.1.57.35]pentadec-13-en-9-yl]-3-hydroxy-4-methyl-5-oxooctan-2-yl]-5-methyloxan-2-yl]butanoic acid
ferrodrug0028	Brucine	Small molecular drug	BRUCINE; 357-57-3; 10,11-Dimethoxystrychnine; Brucinum; 2,3-Dimethoxystrychnine; (-)-Brucine; l-Brucine; 2,3-Dimethoxystrychnidin-10-one; Strychnidin-10-one, 2,3-dimethoxy-; 10,11-Dimethystrychnine; Brucine, Anhydrous; Brucina; Brucin; 6NG17YCK6H; Brucine alkaloid; CHEBI:3193; DTXSID2024662; Dimethoxy strychnine; Brucine hydrate; NSC-757797; Bruzin; 2,3-Dimethoxy-strychnine; RCRA waste number P018; Strychnine, 2,3-dimethoxy-; DTXCID204662; 145428-94-0; Brucin [German]; Brucina [Italian]; CAS-357-57-3; SMR000112281; 63428-84-2; 5892-11-5; UNII-6NG17YCK6H; 10,11-dimethoxy strychnine; CCRIS 4754; HSDB 307; anhydrous brucine; Bisdesmethylbrucin; UN 1570; NCGC00094861-01; EINECS 206-614-7; UN1570; BRUCINE [VANDF]; BRUCINUM [HPUS]; BRUCINE [HSDB]; BRUCINE [MI]; RCRA waste no. P018; Brucine, anhydrous, 98%; BRUCINE [NFLIS-DRUG]; GTPL342; MLS000515808; MLS001424166; SCHEMBL113229; CHEMBL501756; MEGxp0_001865; ACon1_001990; Brucine [UN1570] [Poison]; RRKTZKIUPZVBMF-IBTVXLQLSA-N; HMS2052O03; HMS2268L16; Tox21_111349; Tox21_302174; BDBM50401037; AKOS015955678; AKOS024282466; CCG-101078; NC00328; NSC 757797; NCGC00255253-01; NCGC00263445-02; NCGC00384497-01; B0670; B0946; C09084; Q411022; SR-01000712407; Q-100426; SR-01000712407-5; BRD-K68077509-001-01-6; Brucine, European Pharmacopoeia (EP) Reference Standard; (1R,11S,18S,20R,21R,22S)-4,5-dimethoxy-12-oxa-8,17-diazaheptacyclo[15.5.2.0^{1,18}.0^{2,7}.0^{8,22}.0^{11,21}.0^{15,20}]tetracosa-2(7),3,5,14-tetraen-9-one	D0H2UT	DM50RUD	394.5	C23H26N2O4	51.2	785	1	29	0	5	2	InChI=1S/C23H26N2O4/c1-27-16-8-14-15(9-17(16)28-2)25-20(26)10-18-21-13-7-19-23(14,22(21)25)4-5-24(19)11-12(13)3-6-29-18/h3,8-9,13,18-19,21-22H,4-7,10-11H2,1-2H3/t13-,18-,19-,21-,22-,23+/m0/s1	COC1=C(C=C2C(=C1)[C@]34CCN5[C@H]3C[C@@H]6[C@@H]7[C@@H]4N2C(=O)C[C@@H]7OCC=C6C5)OC	COC1=C(C=C2C(=C1)C34CCN5C3CC6C7C4N2C(=O)CC7OCC=C6C5)OC	RRKTZKIUPZVBMF-IBTVXLQLSA-N	(4aR,5aS,8aR,13aS,15aS,15bR)-10,11-dimethoxy-4a,5,5a,7,8,13a,15,15a,15b,16-decahydro-2H-4,6-methanoindolo[3,2,1-ij]oxepino[2,3,4-de]pyrrolo[2,3-h]quinolin-14-one
ferrodrug0029	Hydrogen Sulfide	Small molecular drug	hydrogen sulfide; sulfane; Hydrosulfuric acid; Dihydrogen monosulfide; Stink DAMP; Hydrogen sulphide; Dihydrogen sulfide; Sulfureted hydrogen; Sewer gas; 7783-06-4; Hydrogene sulfure; Acide sulfhydrique; Schwefelwasserstoff; Netzschwefel; Zwavelwaterstof; Kolospray; Liquamat; Micowetsulf; Microflotox; Siarkowodor; Colsul; Crystex; Elosal; Hexasul; Kolofog; Kumulus; Sastid; Cosan; Hydrogen sulfide (H2S); Polsulkol Extra; Hydrogen-sulfide; Idrogeno solforato; Corosul D and S; RC-Schwefel Extra; Kolloidschwefel 95; Sulfuretted hydrogen; Cosan 80; Hepatic acid; Hydrogene sulphure; Kolo 100; Acide sulphhydrique; RCRA waste number U135; Hydrogen sulfuric acid; dihydridosulfur; FEMA No. 3779; UN 1053; YY9FVM7NSN; CHEBI:16136; Hepatic gas; Hydrogen sulfure; H2S; dihydrogen(sulfide); sulfure d'hydrogene; Sulfur-32S; HSDB 576; CHEBI:26833; UNII-YY9FVM7NSN; EINECS 231-977-3; NSC-403664; SULPHUR HYDROGENISATUM; DIHYDROGEN MONOSULPHIDE; 37331-50-3; DTXSID4024149; Collokit; Kristex; Microthiol; Shreesul; 13981-57-2; Kumulus FL; Sulfur-(32-S); EC 231-977-3; Magnetic 6; Caswell No. 812; HYDROGEN SULFIDE (MART.); HYDROGEN SULFIDE [MART.]; mercaptans; thiols; (SH2); [SH2]; Proactiv; Transact; Schwefel, feinverteilter; Thiol; Sulfide, Hydrogen; Siarkowodor [Polish]; Hydrogen sulfide H2S; Magnetic 70, 90, and 95; HSDB 5166; Sulfur Standard: S @ 10000 microg/mL in H2O; Sulfur Standard: S BLK (0 wt%) in Crude Oil; Zwavelwaterstof [Dutch]; EINECS 231-722-6; NA1350; NA2448; UN1350; UN2448; Hydrogen sulfure [French]; RCRA waste no. U135; EPA Pesticide Chemical Code 077501; Hydrogene sulfure [French]; NSC 403664; Acide sulfhydrique [French]; monosulfane; Schwefelwasserstoff [German]; Hydrosulfurate; Idrogeno solforato [Italian]; Acnaveen; Cuticura; Hepatate; Merkaptan; Acnil; Meted; Sulfur,sublimed; a thiol; Sulfur Standard: S @ 1000 microg/g (0.100 wt%) in Crude Oil; Sulfur Standard: S @ 10000 microg/g (1.00 wt%) in Crude Oil; Sulfur Standard: S @ 20000 microg/g (2.00 wt%) in Crude Oil; Sulfur Standard: S @ 2500 microg/g (0.250 wt%) in Crude Oil; Sulfur Standard: S @ 30000 microg/g (3.00 wt%) in Crude Oil; Sulfur Standard: S @ 40000 microg/g (4.00 wt%) in Crude Oil; Sulfur Standard: S @ 5000 microg/g (0.500 wt%) in Crude Oil; Sulfur Standard: S @ 50000 microg/g (5.00 wt%) in Crude Oil; Sulfur,colloidal; Sour gas; Sulfur, molten; Colloidal sulphur; Dome-Acne; intracellular S0; Sulfur Standard: S @ 7500 microg/g (0.750 wt%) in 20 cSt Mineral Oil; Sulfur (Powder); Sulfur, colloidal; Bensulfoid (TN); Dihydrogen sulphide; Sulfur,precipitated; RSH; Sastid (TN); UN1053; component of Bensulfoid; SULFUR DIHYDRIDE; Sour gas (Salt/Mix); Magnetic 70, and 95; EC 231-722-6; SULPHURETTED HYDROGEN; HYDROGEN SULFIDE [MI]; SULFUR HYDRIDE (SH2); DTXCID404149; Hydrogen sulfide, >=99.5%; HYDROGEN SULFIDE [FHFI]; HYDROGEN SULFIDE [HSDB]; CHEMBL1200739; CHEMBL2105487; NIOSH/MX1229000; CHEBI:29256; Sulfur Blank (0%) in Isooctane; NINIDFKCEFEMDL-UHFFFAOYSA-N; HYDROGEN SULFIDE, LIQUEFIED; HYDROGEN SULPHIDE, LIQUEFIED; Sulfur Blank (0 wt%) in Kerosene; Sulfur [NA1350] [Class 9]; BDBM50147625; BDBM50498447; NSC403664; Sulfur Blank (0 wt%) in Isooctane; SULPHUR HYDROGENISATUM [HPUS]; Hydrogen sulfide, purum, >=99.0%; AKOS015833648; AKOS015950634; Sulfur - S @15microg/g, 500 mL; Sulphur in Diesel, Low (7.2 mg/kg); Sulfur [UN1350] [Flammable solid]; Sulfur Blank (0%) in Synthetic Diesel; BP-21056; Q682; Sulfur Blank (0%) in Heavy Mineral Oil; Sulfur Blank (0%) in Light Mineral Oil; Sulfur Blank (0%) in Odourless Kerosene; Sulfur, molten [NA2448] [Class 9]; Hydrogen sulfide [UN1053] [Poison gas]; Sulfur - S @ 0ug/g in Heavy Mineral Oil; Sulfur @ 0.0005% (5ppm) in Isooctane; Sulfur @ 0.001% (10ppm) in Isooctane; Sulfur @ 0.005% (50ppm) in Isooctane; Sulfur @ 0.01% (100ppm) in Isooctane; Sulfur @ 0.03% (300ppm) in Isooctane; Sulfur @ 0.05% (500ppm) in Isooctane; Sulfur @ 0.07% (700ppm) in Isooctane; Sulfur @ 0.1% (1000ppm) in Isooctane; Sulfur @ 0.3% (3000ppm) in Isooctane; Sulfur Blank (0 wt%) in #2 Diesel Fuel; FT-0698736; MX12290000; PTP Sample for Sulfur in Isooctane Analysis; Sulfur @ 0.0025% (25ppm) in Isooctane; Sulfur @ 0.025% (250ppm) in Isooctane; Sulfur @ 0.075% (750ppm) in Isooctane; Sulfur @ 0.25% (2500ppm) in Isooctane; Sulfur @ 10 microg/g, from Polysulfide Oil; U0149; Sulfur - S @ 500ug/g in Heavy Mineral Oil; Sulfur, powder, 99.998% trace metals basis; C00087; C00283; D00024; F21255; Sulfur - S @ 0ug/g in Light Mineral, 1 gal; Sulfur - S @ 1.00wt% in Heavy Mineral Oil; Sulfur - S @ 400microg/g in #2 Diesel fuel; Sulfur @ 1% (10000ppm) in Synthetic Diesel; Sulfur @ 2% (20000ppm) in Synthetic Diesel; Sulfur @ 3% (30000ppm) in Synthetic Diesel; Sulfur @ 4% (40000ppm) in Synthetic Diesel; Sulfur @ 5% (50000ppm) in Synthetic Diesel; Sulfur Blank (0 wt%) in 20 cSt Mineral Oil; Sulfur Blank (0 wt%) in 75 cSt Mineral Oil; Sulfur, molten [UN2448] [Flammable solid]; di-n-butyl sulfide, S @ 22% nominally, 100g; Sulfur - S @ 400ug/g in #2 Diesel Fuel, L; Sulfur @ 0.0005% (5ppm) in Synthetic Diesel; Sulfur @ 0.001% (10ppm) in Synthetic Diesel; Sulfur @ 0.005% (50ppm) in Synthetic Diesel; Sulfur @ 0.01% (100ppm) in Synthetic Diesel; Sulfur @ 0.03% (300ppm) in Synthetic Diesel; Sulfur @ 0.05% (500ppm) in Synthetic Diesel; Sulfur @ 0.07% (700ppm) in Synthetic Diesel; Sulfur @ 0.1% (1000ppm) in Synthetic Diesel; Sulfur @ 0.3% (3000ppm) in Synthetic Diesel; Sulfur @ 0.5% (5000ppm) in Synthetic Diesel; Sulfur @ 1% (10000ppm) in Odourless Kerosene; Sulfur @ 2% (20000ppm) in Odourless Kerosene; Sulfur @ 3% (30000ppm) in Odourless Kerosene; Sulfur @ 4% (40000ppm) in Odourless Kerosene; Sulfur @ 5% (50000ppm) in Odourless Kerosene; Sulfur Standard: S @ 250microg/g in Isooctane; A857440; PTP Sample for Sulfur in #2 Diesel Fuel Analysis; PTP Sample for Sulfur in B100 Biodiesel Analysis; Q170591; Sulfur - S @ 0ug/g in #2 Diesel Fuel, 500mL; Sulfur - S @ 2wt% in #2 Diesel Fuel, 1 Liter; Sulfur - S @ 3.00wt% in #2 Diesel, 500mL; Sulfur - S @ 4000microg/g in Heavy Mineral Oil; Sulfur - S @ 5ug/g in #2 Diesel Fuel, 1 Gal; Sulfur - S @ 5ug/g in #2 Diesel Fuel, 500mL; Sulfur @ 0.0005% (5ppm) in Heavy Mineral Oil; Sulfur @ 0.0005% (5ppm) in Light Mineral Oil; Sulfur @ 0.0005% (5ppm) in Odourless Kerosene; Sulfur @ 0.001% (10ppm) in Heavy Mineral Oil; Sulfur @ 0.001% (10ppm) in Light Mineral Oil; Sulfur @ 0.001% (10ppm) in Odourless Kerosene; Sulfur @ 0.0025% (25ppm) in Synthetic Diesel; Sulfur @ 0.005% (50ppm) in Heavy Mineral Oil; Sulfur @ 0.005% (50ppm) in Light Mineral Oil; Sulfur @ 0.005% (50ppm) in Odourless Kerosene; Sulfur @ 0.01% (100ppm) in Heavy Mineral Oil; Sulfur @ 0.01% (100ppm) in Light Mineral Oil; Sulfur @ 0.01% (100ppm) in Odourless Kerosene; Sulfur @ 0.025% (250ppm) in Synthetic Diesel; Sulfur @ 0.03% (300ppm) in Heavy Mineral Oil; Sulfur @ 0.03% (300ppm) in Light Mineral Oil; Sulfur @ 0.03% (300ppm) in Odourless Kerosene; Sulfur @ 0.05% (500ppm) in Heavy Mineral Oil; Sulfur @ 0.05% (500ppm) in Light Mineral Oil; Sulfur @ 0.05% (500ppm) in Odourless Kerosene; Sulfur @ 0.07% (700ppm) in Heavy Mineral Oil; Sulfur @ 0.07% (700ppm) in Light Mineral Oil; Sulfur @ 0.07% (700ppm) in Odourless Kerosene; Sulfur @ 0.075% (750ppm) in Synthetic Diesel; Sulfur @ 0.1% (1000ppm) in Heavy Mineral Oil; Sulfur @ 0.1% (1000ppm) in Light Mineral Oil; Sulfur @ 0.1% (1000ppm) in Odourless Kerosene; Sulfur @ 0.25% (2500ppm) in Synthetic Diesel; Sulfur @ 0.3% (3000ppm) in Heavy Mineral Oil; Sulfur @ 0.3% (3000ppm) in Light Mineral Oil; Sulfur @ 0.3% (3000ppm) in Odourless Kerosene; Sulfur @ 0.5% (5000ppm) in Heavy Mineral Oil; Sulfur @ 0.5% (5000ppm) in Light Mineral Oil; Sulfur @ 0.5% (5000ppm) in Odourless Kerosene; Sulfur @ 1% (10000ppm) in Heavy Mineral Oil; Sulfur @ 1% (10000ppm) in Light Mineral Oil; Sulfur @ 1.5% (15000ppm) in Synthetic Diesel; Sulfur @ 2% (20000ppm) in Heavy Mineral Oil; Sulfur @ 2% (20000ppm) in Light Mineral Oil; Sulfur @ 3% (30000ppm) in Heavy Mineral Oil; Sulfur @ 3% (30000ppm) in Light Mineral Oil; Sulfur @ 4% (40000ppm) in Heavy Mineral Oil; Sulfur @ 4% (40000ppm) in Light Mineral Oil; Sulfur @ 5% (50000ppm) in Heavy Mineral Oil; Sulfur @ 5% (50000ppm) in Light Mineral Oil; Sulfur Standard: S @ 250 microg/g in Isooctane; Q7636182; Sulfur - S @ 0ug/g in #2 Diesel Fuel, 1 gallon; Sulfur - S @ 0ug/g in Heavy Mineral Oil, 500mL; Sulfur - S @ 0ug/g in Light Mineral Oil, 500mL; Sulfur - S @ 10ug/g in #2 Diesel Fuel, 1 Gal; Sulfur - S @ 10ug/g in #2 Diesel Fuel, 500mL; Sulfur - S @ 15ug/g in #2 Diesel Fuel, 1 Gal; Sulfur - S @ 15ug/g in #2 Diesel Fuel, 500mL; Sulfur - S @ 2.00wt% in Heavy Mineral, 500mL; Sulfur - S @ 20ug/g in #2 Diesel Fuel, 500mL; Sulfur - S @ 25ug/g in #2 Diesel Fuel, 1 Gal; Sulfur - S @ 25ug/g in #2 Diesel Fuel, 500mL; Sulfur - S @ 300ug/g in #2 Diesel Fuel, 50mL; Sulfur - S @ 500ug/g in #2 Diesel Fuel, 50mL; Sulfur - S @ 50ug/g in #2 Diesel Fuel, 500mL; Sulfur - S @ 5ug/g in Light Mineral Oil, 500mL; Sulfur - S @ 75ug/g in #2 Diesel Fuel, 500mL; Sulfur @ 0.0025% (25ppm) in Heavy Mineral Oil; Sulfur @ 0.0025% (25ppm) in Light Mineral Oil; Sulfur @ 0.0025% (25ppm) in Odourless Kerosene; Sulfur @ 0.025% (250ppm) in Heavy Mineral Oil; Sulfur @ 0.025% (250ppm) in Light Mineral Oil; Sulfur @ 0.025% (250ppm) in Odourless Kerosene; Sulfur @ 0.075% (750ppm) in Heavy Mineral Oil; Sulfur @ 0.075% (750ppm) in Light Mineral Oil; Sulfur @ 0.075% (750ppm) in Odourless Kerosene; Sulfur @ 0.25% (2500ppm) in Heavy Mineral Oil; Sulfur @ 0.25% (2500ppm) in Light Mineral Oil; Sulfur @ 0.25% (2500ppm) in Odourless Kerosene; Sulfur @ 1.5% (15000ppm) in Heavy Mineral Oil; Sulfur @ 1.5% (15000ppm) in Light Mineral Oil; Sulfur @ 1.5% (15000ppm) in Odourless Kerosene; ASTM D5453 Curve 1, S @ 0.5-10ppm in p-xylene; ASTM D5453 Curve 2, S @ 5-100 ppm in isooctane; ASTM D5453 Curve 2, S @ 5-100 ppm in p-xylene; PTP Sample for Sulfur in 20 cSt Mineral Oil Analysis; Q60998679; Sulfur - S @ 400ug/g in #2 Diesel Fuel, 250mL; Sulfur - S @ 1.00wt% in #2 Diesel Fuel, 1 Gal; Sulfur - S @ 1.00wt% in #2 Diesel Fuel, 1 Liter; Sulfur - S @ 1.00wt% in #2 Diesel Fuel, 500mL; Sulfur - S @ 1.0wt% in Light Mineral Oil, 500mL; Sulfur - S @ 100ug/g in #2 Diesel Fuel, 500mL; Sulfur - S @ 100ug/g in Light Mineral Oil, 500mL; Sulfur - S @ 10ug/g in #2 Diesel Fuel, 1 Liter; Sulfur - S @ 10ug/g in Heavy Mineral Oil, 50	.	DG01769	34.08	H2S	1	0	0.5	1	1	1	0	InChI=1S/H2S/h1H2	S	S	RWSOTUBLDIXVET-UHFFFAOYSA-N	sulfane
ferrodrug0030	Sodium Chlorate	.	SODIUM CHLORATE; 7775-09-9; Chloric acid, sodium salt; Asex; Atlacide; Agrosan; Desolet; Oxycil; Sodakem; Travex; Evau-super; Kusa-tohru; B-Herbatox; Granex O; Shed-A-leaf; Chlorate de sodium; Chlorsaure; Kusatol; Rasikal; Tumbleaf; Tumbleleaf; Dervan; Defol; Fall; Drexel defol; Harvest-aid; Soda chlorate; VAL-DROP; Weed Killer; Chlorate salt of sodium; Drop-Leaf; Hibar C; Leafex 2; Leafex 3; Sodium chlorate (NaClO3); Caswell No. 753; Ortho-C-1-Defoliant; Natriumchloraat; Natriumchlorat; Sodium chlorate [ISO]; Natrium chlorat; Natrium chloraat; Grain sorghum harvest-aid; T95DR77GMR; Shed-A-Leaf L; Sodium(chlorate de); Sodio (clorato di); CCRIS 9185; HSDB 732; DTXSID7026025; Sodium (chlorate de); CHEBI:65242; United Chemical Defoliant No. 1; NACLO3; Ortho C-1 defoliant & weed killer; EINECS 231-887-4; UNII-T95DR77GMR; EPA Pesticide Chemical Code 073301; DTXCID206025; Chloric acid, sodium salt (1:1); 9011-70-5; EC 231-887-4; SODIUM CHLORATE (II); SODIUM CHLORATE [II]; SODIUM CHLORATE (MART.); SODIUM CHLORATE [MART.]; MFCD00003479; Chlorsaure [German]; Natriumchloraat [Dutch]; Natriumchlorat [German]; Natrium chloraat [Dutch]; Natrium chlorat [German]; Dropleaf; sodium;chlorate; Sodium(chlorate de) [French]; Sodio (clorato di) [Italian]; Sodium (chlorate de) [French]; Chlorate de sodium [ISO-French]; UN1495; UN2428; Sodium chlorate [UN1495] [Oxidizer]; CHLORATE OF SODA; SHED-A-LEAF'L'; SODIUM CHLORATE [MI]; Pesticide Code: 073301.; SODIUM CHLORATE [HSDB]; SODIUM CHLORATE [INCI]; CHEMBL1559268; SODIUM CHLORATE [WHO-DD]; YZHUMGUJCQRKBT-UHFFFAOYSA-M; NSC41881; Tox21_202133; NSC-41881; AKOS015843818; SODA CHLORIC ACID, SODIUM SALT; UNITED CHEMICAL DEFOLIANT NO 1; NCGC00091465-01; NCGC00259682-01; CAS-7775-09-9; Sodium chlorate, ACS reagent, >=99.0%; Sodium chlorate, ReagentPlus(R), >=99%; Sodium chlorate, p.a., ACS reagent, 99%; 3-(4-ISOBUTYL-PHENYL)-PROPIONICACID; FT-0694099; Sodium chlorate, SAJ first grade, >=98.0%; C18765; Q407446; Sodium chlorate, puriss. p.a., >=99.0% (T); Sodium chlorate - metastable high temperature (255C) phase III	.	.	106.44	ClNaO3	57.2	49.8	.	5	0	3	0	InChI=1S/ClHO3.Na/c2-1(3)4;/h(H,2,3,4);/q;+1/p-1	[O-]Cl(=O)=O.[Na+]	[O-]Cl(=O)=O.[Na+]	YZHUMGUJCQRKBT-UHFFFAOYSA-M	sodium;chlorate
ferrodrug0031	Alpha-Tocopherol	.	alpha-Tocopherol; VITAMIN E; D-alpha-Tocopherol; 59-02-9; 5,7,8-Trimethyltocol; (+)-alpha-Tocopherol; Phytogermine; TOCOPHEROL; 2074-53-5; Aquasol E; (R,R,R)-alpha-Tocopherol; Syntopherol; Viteolin; Eprolin; Esorb; a-Tocopherol; (2R,4'R,8'R)-alpha-Tocopherol; Tocopherol alpha; dl-a-Tocopherol; alpha Tocopherol; Profecundin; Denamone; Epsilan; Tokopharm; Vascuals; Viprimol; Etavit; alpha-Tokoferol; Evion; alpha-Tocopherol, D-; d-a-tocopherol; alpha-Vitamin E; Vitamin E alpha; Eprolin S; Viterra E; E Prolin; E-Vimin; D-alpha tocopherol; Lan-E; Med-E; Antisterility vitamin; alpha-Tocopherol acid; Tenox GT 1; Vi-E; Rhenogran Ronotec 50; (2R)-2,5,7,8-TETRAMETHYL-2-[(4R,8R)-4,8,12-TRIMETHYLTRIDECYL]CHROMAN-6-OL; Covitol F 1000; E 307 (tocopherol); (R)-2,5,7,8-Tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)chroman-6-ol; Vitamin Ea; a-D-Tocopherol; Tocopherol (R,S); (+)-a-Tocopherol; CCRIS 3588; 1406-18-4; CHEBI:18145; Vitamin-E; 2,5,7,8-Tetramethyl-2-(4',8',12'-trimethyltridecyl)-6-chromanol; HSDB 2556; EINECS 200-412-2; NSC 20812; Evitaminum; Waynecomycin; Almefrol; E307; Emipherol; Etamican; Vitayonon; Ilitia; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-chromen-6-ol; H4N855PNZ1; BPBio1_000362; 18920-62-2; Vitaplex E; DTXSID0026339; E 307; Spavit E; EC 200-412-2; ido-E; Endo E; N9PR3490H9; Vita E; a-Vitamin E; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-, (2R)-; (+/-)-alpha-Tocopherol; rel-alpha-Vitamin E; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-, (2R)-rel-; DTXCID706339; MFCD00072045; RRR-alpha-tocopherol; CAS-59-02-9; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-, (2R)-; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, (2R-(2R*(4R*,8R*)))-; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, [2R-[2R*(4R*,8R*)]]-; SMR000471844; VIV; 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopyran-6-ol; (all-R)-alpha-Tocopherol; DTXSID8021355; Phytogermin; Palmvtee; alpha-Tocoferol; (+-)-Med-E; UNII-N9PR3490H9; Vitamin Ealpha; NSC-20812; Alpha-tocopherols; .ALPHA.-TOCOPHEROL, D-; Pheryl-E; DL--Tocopherol; Vita plus E; rel--Vitamin E; -Vitamin E; Vitamin e d-alpha; NCGC00016688-02; Prestwick_653; EINECS 215-798-8; EINECS 218-197-9; .alpha.-Vitamin E; Envirose 100; NSC 82623; COVIREL; RRR-alpha-tocopheryl; Vitamin E [USP]; ()-alpha-Tocopherol; delta-alpha-tocopherol; alpha-delta-Tocopherol; Tocopherol, d-alpha-; CONTROX VP; EPROLIN-S; Vitamin E (D-form); TENOX GT; CHEMBL47; (R,R,R)-a-Tocopherol; Prestwick3_000404; (+)- alpha -Tocopherol; (+)-.alpha.-Tocopherol; bmse000600; R,r,r-.alpha.-tocopherol; alpha-TOCOPHEROL (II); SCHEMBL3097; COVI-OX T 30P; RIKKI N 70; UNII-H4N855PNZ1; BIDD:PXR0174; COVI-OX T 50; BSPBio_000328; E-MIX 40A; MLS001066396; MLS001335981; MLS001335982; BIDD:ER0562; INS NO.307A; T1539_SIGMA; DTXCID201355; INS-307A; (+)-ALPHA-TOCOPHEROL-; ALPHA-TOCOPHEROL [HSDB]; Vitamin e (as alpha tocopherol); (2R,4'R,8'R)-a-Tocopherol; .ALPHA.-TOCOPHEROL [MI]; ALPHA TOCOPHEROL (USP-RS); (+)--Tocopherol; D--Tocopherol; HMS2096A10; HMS2231G08; C29H50O2 (D-alpha-tocopherol); D-ALPHA TOCOPHEROL [MART.]; HY-N0683; Tox21_110563; Tox21_113208; Tox21_202081; BDBM50458513; E-307A; LMPR02020001; AKOS004910417; CS-8161; DB00163; (2R)-2-((4R,8R)-4,8,12-trimethyltridecyl)-2,5,7,8-tetramethylchroman-6-ol; NCGC00142625-01; NCGC00142625-04; NCGC00142625-05; NCGC00142625-06; NCGC00142625-07; NCGC00142625-10; NCGC00259630-01; (2R*(4R*,8R*))-(1)-3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-benzopyran-6-ol; ALPHA-TOCOPHEROL, UNSPECIFIED FORM; AS-13990; J24.260H; rel-(+)--Tocopherol; rel-D--Tocopherol; J203.513H; E-307; T2309; C02477; F82497; EN300-7417123; Q158348; Q-201932; W-107596; W-109164; Z2235811339; 07AA93F0-3339-4EEC-B50B-ADB70F657087; (2R,4'R,8'R)-2,5,7,8-Tetramethyl-2-(4',8',12'-trimethyltridecyl)-6-chromanol; 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1- -benzopyran-6-ol; 3,4-Dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-2H-1--benzopyran-6-ol; (2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydro-2H-1-benzopyran-6-ol; (2R)-3,4-Dihydro-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-2H-1-benzopyran-6-ol; (R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-3,4-dihydro-2H-chromen-6-ol; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, 2R- 2R*(4R*,8R*) -; 2H-1-Benzopyran-6-ol, 3,4-dihydro-2,5,7,8-tetramethyl-2-(4,8,12-trimethyltridecyl)-, (2R*(4R*,8R*))-(+-)-; rel-(2R)-2,5,7,8-tetramethyl-2-((4R,8R)-4,8,12-trimethyltridecyl)-3,4-dihydro-2H-chromen-6-ol	.	.	430.7	C29H50O2	29.5	503	10.7	31	1	2	12	InChI=1S/C29H50O2/c1-20(2)12-9-13-21(3)14-10-15-22(4)16-11-18-29(8)19-17-26-25(7)27(30)23(5)24(6)28(26)31-29/h20-22,30H,9-19H2,1-8H3/t21-,22-,29-/m1/s1	CC1=C(C2=C(CC[C@@](O2)(C)CCC[C@H](C)CCC[C@H](C)CCCC(C)C)C(=C1O)C)C	CC1=C(C2=C(CCC(O2)(C)CCCC(C)CCCC(C)CCCC(C)C)C(=C1O)C)C	GVJHHUAWPYXKBD-IEOSBIPESA-N	(2R)-2,5,7,8-tetramethyl-2-[(4R,8R)-4,8,12-trimethyltridecyl]-3,4-dihydrochromen-6-ol
ferrodrug0032	Paclitaxel	.	33069-62-4; P88XT4IS4D; Paclitaxel; Taxol; Taxol A; Yewtaxan; Genaxol; Plaxicel; Onxol; Paxene; Abraxane; Ebetaxel; Genetaxyl; Capxol; Cyclopax; Genexol; Intaxel; Mitotax; Pacliex; TaxAlbin; OncoGel; Paxceed; EmPAC; Onxal; Zisu; Taxus stent; Taxus Liberte; ABI-007; Padexol; EndoTAG 1; LipoPac; NSC-125973; Tocosol Paclitaxel; (-)-Paclitaxel; Nanoxel; Paclitaxol; Sindaxel; Coroflex Please; Cypher select; Taxus Express; LEP-ETU; Genexol-PM; (NAB)-Paclitaxel; MBT 0206; BMS 181339-01; Infinnium; NSC 125973; Taxus; HSDB 6839; ABI 007; DHP 107; DHP-107; Abraxane I.V. Suspension; BMS-181339-01; UNII-P88XT4IS4D; DRG-0190; Paclitaxel (Taxol); NK 105; NSC125973; Paclitaxel (taxus canadensis); QW 8184; CCRIS 8143; Liposome-entrapped paclitaxel easy-to-use; DTXSID9023413; CHEBI:45863; ABI-007 COMPONENT PACLITAXEL; IG 001; NK-105; 5beta,20-Epoxy-1,2-alpha,4,7beta,10beta,13alpha-hexahydroxytax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; QW-8184; CHEMBL428647; DTXCID603413; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b-diyl diacetate; nab-paclitaxel; 7-epi-Paclitaxel; ORAXOL COMPONENT PACLITAXEL; Abraxane (albumin-bound suspension); ABRAXANE COMPONENT PACLITAXEL; MBT-0206; ABI 007 COMPONENT PACLITAXEL; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; NCGC00164367-01; NAB-PACLITAXEL COMPONENT PACLITAXEL; MFCD00869953; PACLITAXEL (MART.); PACLITAXEL [MART.]; PACLITAXEL (USP-RS); PACLITAXEL [USP-RS]; (1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-bis(acetyloxy)-1,9-dihydroxy-15-{[(2R,3S)-2-hydroxy-3-phenyl-3-(phenylformamido)propanoyl]oxy}-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.0^{3,10}.0^{4,7}]heptadec-13-en-2-yl benzoate; PACLITAXEL (EP MONOGRAPH); PACLITAXEL (USP IMPURITY); PACLITAXEL [EP MONOGRAPH]; PACLITAXEL [USP IMPURITY]; Anzatax; Cynviloq; PACLITAXEL (USP MONOGRAPH); PACLITAXEL [USP MONOGRAPH]; Xorane; Bris Taxol; Taxol, Bris; 7,11-Methano-1H-cyclodeca[3,4]benz[1,2-b]oxete, benzenepropanoic acid deriv.; SMR000857385; EndoTAG-1; SR-01000075350; paclitaxelum; Nanotaxel; Paclical; Pacligel; Paxoral; Paclitaxel,(S); Paclitaxel [USAN:USP:INN:BAN]; Abraxane (TN); (2alpha,5beta,7beta,10beta,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; [diacetoxy-[(2R,3S)-3-benzamido-2-hydroxy-3-phenyl-propanoyl]oxy-dihydroxy-tetramethyl-oxo-[?]yl] benzoate; 4alpha,10beta-bis(acetyloxy)-13alpha-((2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy)-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; 4alpha,10beta-bis(acetyloxy)-13alpha-[(2S,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyloxy]-1,7beta-dihydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; Paclitaxel; 5beta,20-Epoxy-1,7beta-dihydroxy-9-oxotax-11-ene-2alpha,4,10beta,13alpha-tetrayl 4,10-diacetate 2-benzoate 13-[(2R,3S)-3-(benzoylamino)-2-hydroxy-3-phenylpropanoate]; Taxol; Docetaxel Anhydrous Impurity F; Docetaxel Impurity F; CAS-33069-62-4; PACITAXEL; BMS-181339; Paclitaxel-SSMM-VIP; P-SSMM-VIP; PACLITAXEL [MI]; PACLITAXEL [INN]; PACLITAXEL [JAN]; Prestwick3_000155; PACLITAXEL [HSDB]; PACLITAXEL [USAN]; TAXOL (TN); PACLITAXEL [VANDF]; SCHEMBL3976; 3PPC5TL76P; Nova-12005; PACLITAXEL [WHO-DD]; Paclitaxel, Taxus brevifolia; BIDD:PXR0046; BSPBio_000290; KBioGR_002509; KBioSS_002517; Paclitaxel (JAN/USP/INN); MLS002154218; MLS002695976; OAS-PAC-100; PACLITAXEL [EMA EPAR]; BPBio1_000320; GTPL2770; MEGxp0_001940; Taxol (TN) (Bristol Meyers); PACLITAXEL [GREEN BOOK]; PACLITAXEL [ORANGE BOOK]; ACon1_002231; KBio2_002509; KBio2_005077; KBio2_007645; KBio3_002987; ANX-513; DHP-208; DTS-301; L01CD01; SDP-013; cMAP_000068; RCINICONZNJXQF-MZXODVADSA-N; HMS2090D07; HMS2095O12; HMS2231A16; HMS3712O12; HY-B0015; MPI-5018; Tox21_112107; BDBM50001839; NSC745099; AKOS007930675; AKOS015969673; AKOS025312303; CCG-220155; CS-1145; DB01229; GS-6554; NSC-745099; NCGC00164367-02; NCGC00164367-03; NCGC00164367-04; NCGC00164367-05; NCGC00164367-10; Paclitaxel, From Taxus brevifolia, 95%; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro-4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano-5H-cyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate, 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; NCI60_000601; Paclitaxel, from Taxus yannanensis, powder; PACLITAXEL IMPURITY L [EP IMPURITY]; AB00513812; D00491; EN300-117275; M02242; N88686; AB00513812-02; AB00513812-03; Paclitaxel, Antibiotic for Culture Media Use Only; Q423762; 7,4]benz[1,2-b]oxete,benzenepropanoic acid deriv.; Q-201533; SR-01000075350-1; SR-01000075350-3; SR-01000075350-6; SR-01000075350-7; SR-01000075350-9; BRD-K62008436-001-03-1; BRD-K62008436-001-05-6; BRD-K62008436-001-22-1; Paclitaxel, from semisynthetic (from Taxus sp.), >=97%; Paclitaxel, European Pharmacopoeia (EP) Reference Standard; Paclitaxel, from Taxus brevifolia, >=95% (HPLC), powder; Paclitaxel, United States Pharmacopeia (USP) Reference Standard; 12-benzoate, 9-ester with (2R,3S)-N-benzoyl-3-phenylisoserine; Paclitaxel, Pharmaceutical Secondary Standard; Certified Reference Material; Paclitaxel natural for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,2S,3R,4S,5R,7S,8S,10R,13S)-4,10-Diacetoxy-2-benzoyloxy-5,20-epoxy-1,7-dihydroxy-9-oxotax-11-en-13-yl (2R,3S)-3-benzoylamino-2-hydroxy-3-phenylpropionate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-1,2a,3,4,4a,6,9,10,11,12,12a,12b-Dodecahydro 4,6,9,11,12,12b-hexahydroxy-4a,8,13,13-tetramethyl-7,11-methano 5Hcyclodeca(3,4)benz(1,2-b)oxet-5-one 6,12b-diacetate,; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-Tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (alphaR,betaS)-beta-(benzoylamino)-alpha-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl (aR,bS)-b-(benzoylamino)-a-hydroxybenzenepropanoate; (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-9-(((2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl)oxy)-12-(benzoyloxy)-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-3,4,4a,5,6,9,10,11,12,12a-decahydro-1H-7,11-methanocyclodeca[3,4]benzo[1,2-b]oxete-6,12b(2aH)-diyl diacetate; (2aR-(2aalpha,4beta,4abeta,6beta,9alpha(alpha R*,betaS*),11alpha,12alpha,12balpha))-beta-(Benzoylamino)-alpha-hydroxybenzenepropanoic acid 6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12; (2beta,5beta,7alpha,8alpha,10alpha,13alpha)-4,10-bis(acetyloxy)-1,7-dihydroxy-13-({(2R,3S)-2-hydroxy-3-phenyl-3-[(phenylcarbonyl)amino]propanoyl}oxy)-9-oxo-5,20-epoxytax-11-en-2-yl benzoate; ,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxet-9-yl ester; ,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)- (9CI); -cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR-[2aalpha,4beta,4abeta,6beta,9alpha(aR*,betaS*),11alpha,12alpha,12aalpha,12balpha]]-; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate; [(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl]benzoate; 1203669-79-7; 4,7beta,10beta-tris(acetyloxy)-13alpha-[[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy]-1-hydroxy-9-oxo-5beta,20-epoxytax-11-en-2alpha-yl benzoate; 5-BETA,20-EPOXY-1,2-ALPHA,4,7-BETA,10-BETA,13-ALPHA-HEXAHYDROXY-TAX-11-EN-9-ONE 4,10-DIACETATE 2-BENZOATE 13-ESTER WITH (2R,3S)-N-BENZOYL-3-PHENYL-ISOSERINE; 5beta,20-Epoxy-1,2 alpha, 4,7beta, 10beta, 13alpha-hexahydroxy tax-11-en-9-one 4,10-diacetate 2-benzoate 13-ester with (2R, 3S)-N-benzoyl-3-phenylisoserine; BENZENEPROPANOIC ACID, .BETA.-(BENZOYLAMINO)-.ALPHA.-HYDROXY-, (2AR,4S,4AS,6R,9S,11S,12S,12AR,12BS)-6,12B-BIS(ACETYLOXY)-12-(BENZOYLOXY)-2A,3,4,4A,5,6,9,10,11,12,12A,12B-DODECAHYDRO-4,11-DIHYDROXY-4A,8,13,13-TETRAMETHYL-5-OXO-7,11-METHANO-1H-CYCLODECA(3,4)BENZ(1,2-B)OXET-9-YL ESTER, (.ALPHA.R,.BETA.S)-; Benzenepropanoic acid, 6,12b-bis(acetyl oxy)-12-(benzoyloxy)- 2a,3,4,4a,5,6,9,10,11,12,12a,12b,- dodecahydro-4,11- dihydroxy-4a,8,13,13-tetramethyl-5-oxo- 7,11-methano- 1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, [2aR- [2a.alpha.,4.beta.,4a.beta.,6.beta.,9.alpha.(alpha. R*,.beta.S*),11.alpha.,12.alpha.,12a.alpha.,12b.alpha.]]-; Benzenepropanoic acid, b-(benzoylamino)-.alpha.-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (aR,bS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-4,6,12b-tris(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-11-hydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca[3,4]benz[1,2-b]oxet-9-yl ester, (alphaR,betaS)-; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13; Benzenepropanoic acid, beta-(benzoylamino)-alpha-hydroxy-, (2aR,4S,4aS,6R,9S,11S,12S,12aR,12bS)-6,12b-bis(acetyloxy)-12-(benzoyloxy)-2a,3,4,4a,5,6,9,10,11,12,12a,12b-dodecahydro-4,11-dihydroxy-4a,8,13,13-tetramethyl-5-oxo-7,11-methano-1H-cyclodeca(3,4)benz(1,2-b)oxe	.	.	853.9	C47H51NO14	221	1790	2.5	62	4	14	14	InChI=1S/C47H51NO14/c1-25-31(60-43(56)36(52)35(28-16-10-7-11-17-28)48-41(54)29-18-12-8-13-19-29)23-47(57)40(61-42(55)30-20-14-9-15-21-30)38-45(6,32(51)22-33-46(38,24-58-33)62-27(3)50)39(53)37(59-26(2)49)34(25)44(47,4)5/h7-21,31-33,35-38,40,51-52,57H,22-24H2,1-6H3,(H,48,54)/t31-,32-,33+,35-,36+,37+,38-,40-,45+,46-,47+/m0/s1	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	CC1=C2C(C(=O)C3(C(CC4C(C3C(C(C2(C)C)(CC1OC(=O)C(C(C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	RCINICONZNJXQF-MZXODVADSA-N	[(1S,2S,3R,4S,7R,9S,10S,12R,15S)-4,12-diacetyloxy-15-[(2R,3S)-3-benzamido-2-hydroxy-3-phenylpropanoyl]oxy-1,9-dihydroxy-10,14,17,17-tetramethyl-11-oxo-6-oxatetracyclo[11.3.1.03,10.04,7]heptadec-13-en-2-yl] benzoate
ferrodrug0033	Vitamin K1	Small molecular drug	Phylloquinone; Vitamin K1; phytonadione; 84-80-0; Phytomenadione; Phytylmenadione; 3-Phytylmenadione; Aquamephyton; Konakion; Phyllochinon; Mephyton; Monodion; Synthex P; Kinadion; Kephton; 2-Methyl-3-phytyl-1,4-naphthoquinone; Mono-Kay; Combinal K1; Kativ N; alpha-Phylloquinone; Fitomenadiona; K-Ject; Phyllochinonum; Phytomenadionum; Phytonadionum; trans-Phylloquinone; Aqua mephyton; VitaminK1; Antihemorrhagic vitamin; Fitomenadione; Vitamin K 1; 79083-00-4; 2',3'-trans-Vitamin K1; 2-Methyl-3-phytyl-1,4-naphthochinon; 11104-38-4; CHEBI:18067; Vitamin K1(20); UNII-S5Z3U87QHF; NSC 270681; Phylloquinone e-form; Aqua-Mephytin; Phythyl-menadion; VITAMIN K; 1,4-Naphthoquinone, 2-methyl-3-phytyl-; DTXSID8023472; HSDB 3162; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; 2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]naphthalene-1,4-dione; EINECS 201-564-2; NSC-270681; S5Z3U87QHF; 2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione; DTXCID003472; MLF3D1712D; Phytonadione, (E)-(+/-)-; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, (R-(R*,R*-(E)))-; 1,4-Naphthalenedione,2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl]-; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-; 2-Methyl-3-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; Orakay; 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone; 2-Methyl-3-phythyl-1,4-naphthochinon; 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecenyl)-; CAS-84-80-0; rel-2-Methyl-3-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; Phytonadione, K1; 1,4-Naphthalenedione, 2-methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-, [R-[R*,R*-(E)]]-; 2-methyl-3-[(2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl]-1,4-dihydronaphthalene-1,4-dione; Vitamin K-1; Phytonadione [USP:JAN]; Kanavit; Neokay; a-Phylloquinone; Konakion mm; NSC270681; vitaminum k1; 2-Methyl-3-((2E)-3,7,11,15-tetramethyl-2-hexadecenyl)naphthoquinone; Konakion mm paed; (E)-phytonadione; 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl)naphthalene-1,4-dione; 2-methyl-3-((7R,11R,E)-3,7,11,15-tetramethylhexadec-2-enyl)naphthalene-1,4-dione; NCGC00159423-02; EINECS 234-330-3; EINECS 279-052-3; MFCD00214063; vitamin K1, 11; Vitamin K1 ,(S); VEDA-K1; VETA-K1; PHYTONADIONE [JAN]; phylloquinone;2-METHYL-3-PHYTYL-1,4-NAPHTHOQUINONE; Phylloquinone;Phytomenadione; SCHEMBL3882; 2',3'-trans-phylloquinone; Phythyl-menadion (GERMAN); Vitamin K1 (Phylloquinone); Vitamin K1, viscous liquid; CHEMBL1550; UNII-MLF3D1712D; PHYTONADIONE, (E)-; PHYLLOQUINONE, (E)-; MLS001074732; BIDD:GT0793; PHYTOMENADIONE, (E)-; PHYTONADIONE (USP-RS); SCHEMBL351365; 2', 3'-trans-Vitamin K1; PHYTOMENADIONE (MART.); 2-Methyl-3-[(2E)-3,7,11,15-tetramethyl-2-hexadecenyl]naphthoquinone #; -2-enyl)naphthalene-1,4-dione; BDBM24782; B02BA01; [r-[r*,R*-(E)]]-2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-napthalenedione; [r-[r*,R*-(E)]]-2-Methyl-3-(3-7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalenedione; PHYLLOQUINONE E-FORM [MI]; HMS2094G09; HMS2270J10; Pharmakon1600-01505485; HY-N0684; PHYTOMENADIONE (EP IMPURITY); PHYTONADIONE (USP MONOGRAPH); Tox21_111655; BDBM50553259; LMPR02030028; NSC760373; s4698; 2-Methyl-3-phytyl-1,4-napthoquinone; AKOS015841892; Tox21_111655_1; A034SE7857; CCG-213568; CS-6376; DB01022; NSC-760373; (R*,R*-(E))-(1)-2-Methyl-3-(3,7,11,15-tetramethylhexadec-2-enyl)-1,4-naphthoquinone; NCGC00159423-03; Phylloquinone (K1), analytical standard; AC-34846; AS-13734; SMR000112043; SBI-0206926.P001; trans-Phytomenadione 100 microg/mL in Ethanol; AB00698065_04; A840928; EN300-22411510; Q186093; SR-05000001941; C31H46O2 (2-methyl-3-phytyl-1,4-naphthoquinone); Q-201934; SR-05000001941-1; W-108488; Z2568644345; 2-methyl-3-((7R,11R,E)-3,7,11,15-tetramethylhexadec; 84C51B31-3CE2-476B-BE66-A84BDD46A513; VITAMIN K1; 2-METHYL-3-PHYTYL-1,4-NAPHTHOQUINONE; Phytomenadione, European Pharmacopoeia (EP) Reference Standard; Phytonadione, United States Pharmacopeia (USP) Reference Standard; 2-Methyl-3-(3,7,11,15-tetramethyl-2-hexadecenyl)-1,4-naphthalened- ione; Vitamin K1, BioXtra, >=99.0% (sum of isomers, HPLC), mixtur of isomers; 1,4-Naphthalenedione, 2-methyl-3-((2E,7R,11R)-3,7,11,15-tetramethyl-2-hexadecen-1-yl)-; 2-Methyl-3-((2E,7R,11R)-3,7,11,15-tetramethylhexadec-2-en-1-yl)-1,4-naphthoquinone; Phytonadione, Pharmaceutical Secondary Standard; Certified Reference Material; 1,4-NAPHTHALENEDIONE, 2-METHYL-3-((2E,7R,11R)-3,7,11,15-TETRAMETHYL-2-HEXADECEN-1-YL)-, REL-; 2-METHYL-3-((2E,7R,11R)-3,7,11,15-TETRAMETHYL-2-HEXADECENYL)-1,4-NAPHTHALENEDIONE; 2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione;Vitamin K1; MIXTURE OF THE TRANS (E) AND CIS (Z) ISOMERS CONTAINING NOT LESS THAN 75% OF TRANS-PHYTOMENADIONE	D00FSV	DM8HDOL	450.7	C31H46O2	34.1	696	10.9	33	0	2	14	InChI=1S/C31H46O2/c1-22(2)12-9-13-23(3)14-10-15-24(4)16-11-17-25(5)20-21-27-26(6)30(32)28-18-7-8-19-29(28)31(27)33/h7-8,18-20,22-24H,9-17,21H2,1-6H3/b25-20+/t23-,24-/m1/s1	CC1=C(C(=O)C2=CC=CC=C2C1=O)C/C=C(\C)/CCC[C@H](C)CCC[C@H](C)CCCC(C)C	CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C	MBWXNTAXLNYFJB-NKFFZRIASA-N	2-methyl-3-[(E,7R,11R)-3,7,11,15-tetramethylhexadec-2-enyl]naphthalene-1,4-dione
ferrodrug0034	Apigenin	.	apigenin; 520-36-5; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Versulin; Apigenol; 4',5,7-Trihydroxyflavone; Chamomile; Spigenin; Apigenine; C.I. Natural Yellow 1; Pelargidenon 1449; 5,7,4'-Trihydroxyflavone; 5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; NSC 83244; 2-(p-Hydroxyphenyl)-5,7-dihydroxychromone; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-; UCCF 031; CCRIS 3789; FLAVONE, 4',5,7-TRIHYDROXY-; CHEBI:18388; EINECS 208-292-3; MFCD00006831; NSC-83244; UNII-7V515PI7F6; APEGENIN; BRN 0262620; 8002-66-2; Chamomile oil, german; DTXSID6022391; HSDB 7573; 7V515PI7F6; CHEMBL28; PELARGIDENON-1449; CI NATURAL YELLOW 1; DTXCID902391; UCCF-031; 5-18-04-00574 (Beilstein Handbook Reference); NSC83244; CAS-520-36-5; LY-080400; 4',5,7-Trihydroxyflavone;Apigenol;C.I. Natural Yellow 1; SMR000326850; 4?5,7-Trihydroxyflavone; SR-01000075663; Pelargidenone; 4der; 4dgm; 4hkk; Naringenin, 18; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4',5,7-Trihydroxyflavone; Pelargidenon 1449;; Prestwick_719; Apigenin, 13; Tocris-1227; 3cf9; ST056301; APIGENIN [HSDB]; APIGENIN [INCI]; 4',7-Trihydroxyflavone; APIGENIN [MI]; BiomolKI_000078; Prestwick0_000414; Prestwick1_000414; Prestwick2_000414; Prestwick3_000414; Spectrum2_000428; Spectrum3_001882; Spectrum4_001999; Lopac-A-3145; APIGENIN [USP-RS]; APIGENIN [WHO-DD]; BiomolKI2_000082; 4,5, 7-Trihydroxyflavone; Lopac0_000065; Oprea1_622293; SCHEMBL19428; 4',5,7-trihydroxy-Flavone; Apigenin, analytical standard; BSPBio_000368; BSPBio_003384; KBioGR_002565; SPECTRUM200846; MLS000697626; MLS000859991; MLS001074874; MLS006011839; BIDD:ER0135; DivK1c_000798; SCHEMBL222227; SPBio_000416; SPBio_002307; ghl.PD_Mitscher_leg0.1194; BDBM7458; BPBio1_000406; GTPL4136; MEGxp0_000176; ACon1_002450; cid_5280443; HMS502H20; KBio1_000798; KBio3_002887; NINDS_000798; Bio1_000376; Bio1_000865; Bio1_001354; HMS1569C10; HMS1922P22; HMS2096C10; HMS2230D17; HMS3260M11; HMS3267D21; HMS3373B18; HMS3412A08; HMS3561P09; HMS3655D18; HMS3676A08; HMS3866D03; Apigenin, >=95.0% (HPLC); BCP28288; HY-N1201; Tox21_201542; Tox21_302884; Tox21_500065; Apigenin; 4',5,7-Trihydroxyflavone; BBL010499; CCG-40061; HB0117; HSCI1_000221; LMPK12110005; NSC815095; s2262; STK801630; ZB1873; AKOS002140699; AC-8011; CS-5432; DB07352; LP00065; ND-9076; NSC-815095; SDCCGMLS-0066379.P001; SDCCGSBI-0050053.P003; IDI1_000798; SMP2_000338; Apigenin, >=97% (TLC), from citrus; NCGC00015049-01; NCGC00015049-02; NCGC00015049-03; NCGC00015049-04; NCGC00015049-05; NCGC00015049-06; NCGC00015049-07; NCGC00015049-08; NCGC00015049-09; NCGC00015049-10; NCGC00015049-11; NCGC00015049-12; NCGC00015049-13; NCGC00015049-14; NCGC00015049-15; NCGC00015049-16; NCGC00015049-18; NCGC00015049-28; NCGC00025057-01; NCGC00025057-02; NCGC00025057-03; NCGC00025057-04; NCGC00025057-05; NCGC00025057-06; NCGC00025057-07; NCGC00025057-08; NCGC00025057-09; NCGC00169835-01; NCGC00169835-02; NCGC00169835-03; NCGC00256419-01; NCGC00259092-01; NCGC00260750-01; LY080400; NCI60_041830; SY005957; TS-00897; APIGENIN (CONSTITUENT OF CHAMOMILE); LY 080400; EU-0100065; FT-0622445; FT-0623582; FT-0662251; SW196866-2; A 3145; C01477; K00045; M01289; O11338; Apigenin 100 microg/mL in Acetonitrile:Methanol; Apigenin, >=97% (TLC), from parsley, powder; Biochem Biophys Res Comm 212: 767 (1997); EN300-7382221; 5,7-dihydroxy-2-(4-hydroxyphenyl)-chromen-4-one; A828903; APIGENIN (CONSTITUENT OF CHAMOMILE) [DSC]; Apigenin, primary pharmaceutical reference standard; Q424567; 2-(P-HYDROXYPHENYL)-5,7-DIHYDROXY-CHROMONE; 4 inverted exclamation mark ,5,7-trihydroxyflavone; Q-100586; Q-200822; SR-01000075663-1; SR-01000075663-3; SR-01000075663-7; SR-01000075663-8; BRD-K01493881-001-10-4; BRD-K01493881-001-17-9; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one #; Z1741982550; 4H-1-Benzopyran-4-one,7-dihydroxy-2-(4-hydroxyphenyl)-; D50A2D8A-6D8B-4708-B21E-2DE9580D033F; Apigenin, United States Pharmacopeia (USP) Reference Standard; 4H-1BENZOPYRAN-4-ONE,5,7-DIHYDROXY-2-(4-HYDROXY-PHENYL)-	.	.	270.24	C15H10O5	87	411	1.7	20	3	5	1	InChI=1S/C15H10O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-7,16-18H	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O	C1=CC(=CC=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O	KZNIFHPLKGYRTM-UHFFFAOYSA-N	5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
ferrodrug0035	Melatonin	.	Melatonin; 73-31-4; Melatonine; N-Acetyl-5-methoxytryptamine; Circadin; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl]acetamide; 5-Methoxy-N-acetyltryptamine; Melatol; N-(2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; Melovine; Melatonex; Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-; N-[2-(5-methoxyindol-3-yl)ethyl]acetamide; 8041-44-9; N-acetyl-5-methoxy-tryptamine; N-(2-(5-Methoxyindol-3-yl)ethyl)acetamide; CCRIS 3472; NSC 113928; Acetamide, N-(2-(5-methoxyindol-3-yl)ethyl)-; UNII-JL5DK93RCL; JL5DK93RCL; Acetamide, N-(2-(5-methoxy-1H-indol-3-yl)ethyl)-; EINECS 200-797-7; NSC-56423; 5-methoxy n-acetyl-tryptamine; NSC-113928; BRN 0205542; DTXSID1022421; CHEBI:16796; HSDB 7509; BCI-049; CHEMBL45; MFCD00005655; NSC113928; J5.258B; 3-(n-acetyl-2-aminoethyl)-5-methoxyindole; DTXCID002421; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]-; Melatonin (JAN); 5-22-12-00042 (Beilstein Handbook Reference); NSC56423; N-[2-(5-Methoxy-1H-indol-3-yl)-ethyl]-acetamide; MT6; CAS-73-31-4; NCGC00015680-11; MELATONIN [JAN]; MELATONIN (MART.); MELATONIN [MART.]; MELATONIN (USP-RS); MELATONIN [USP-RS]; Melatonina; Melapure; Posidorm; Vivitas; Primex; Sleep Right; WLN: T56 BMJ D2MV1 GO1; Night Rest; Rx Balance; Revital Melatonin; Nature'S Harmony; [3H]melatonin; Melatonin, Powder; Melatonina (TN); Mela-T; [3H]-melatonin; ML1; SMR000326666; N-(2-(5-methoxyindol-3-yl)ethyl)-Acetamide; N-[2-(5-methoxyindol-3-yl)ethyl]-Acetamide; N-[2-(5-Methoxy-1H-indol-3-yl)ethyl)acetamide; SR-01000075559; [3H]MLT; Melatobel; Melaxen; Melatonine;; Guna-dermo; Melatobel (TN); TNP00300; Prestwick_312; IN1244; Therapeutic Melatonin; Spectrum_000185; NMR/14327425; MELATONIN [DSC]; Guna-dermo (Salt/Mix); MELATONIN [MI]; MELATONIN [HSDB]; MELATONIN [INCI]; Prestwick0_000458; Prestwick1_000458; Prestwick2_000458; Prestwick3_000458; Spectrum2_001344; Spectrum3_001393; Spectrum4_000066; Spectrum5_001745; Lopac-M-5250; MELATONIN [VANDF]; M1105; ChemDiv2_003916; M 5250; Melatonin, >=99.5%; MELATONIN [WHO-DD]; Lopac0_000787; Oprea1_104553; Oprea1_814234; SCHEMBL19018; BSPBio_000536; BSPBio_003006; GTPL224; KBioGR_000591; KBioSS_000665; MELATONIN [EMA EPAR]; Acetamide, {N-[2-(5-methoxyindol-3-yl)ethyl]-}; MLS000859594; MLS001055382; MLS001240204; BIDD:ER0618; DivK1c_000353; SPECTRUM1500690; SPBio_001527; SPBio_002475; Melatonin (synth.) ultra-pure; MELATONIN [GREEN BOOK]; BDBM9019; BPBio1_000590; GTPL1357; Acetamide, {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-}; HMS501B15; KBio1_000353; KBio2_000665; KBio2_003233; KBio2_005801; KBio3_002226; Melatonin 1.0 mg/ml in Methanol; NINDS_000353; 3-N-Acetyl-5-methoxyl tryptamine; GLXC-25215; HMS1380B22; HMS1569K18; HMS1921E04; HMS2089F09; HMS2096K18; HMS2233D23; HMS3262M16; HMS3370J20; HMS3413P14; HMS3654A22; HMS3677P14; HMS3713K18; HMS3884M05; Melatonin (synth.) standard-grade; AMY33320; BCP28154; HY-B0075; Tox21_110195; Tox21_201527; Tox21_302926; Tox21_500787; 4-ACETAMIDO-4'-ISOTHIO-CYANATOSTILBENE-2,2'-DISULFONIC ACID; CCG-38837; HSCI1_000400; Melatonin, powder, >=98% (TLC); STK386880; AKOS000276269; Tox21_110195_1; CS-1769; DB01065; KS-1454; LP00787; SDCCGMLS-0065812.P001; SDCCGMLS-0065812.P002; SDCCGSBI-0050765.P003; IDI1_000353; IDI1_002631; SMP2_000309; N-acetyl-5-methoxy-tryptamine Melatonine; NCGC00015680-01; NCGC00015680-02; NCGC00015680-03; NCGC00015680-04; NCGC00015680-05; NCGC00015680-06; NCGC00015680-07; NCGC00015680-08; NCGC00015680-09; NCGC00015680-10; NCGC00015680-12; NCGC00015680-13; NCGC00015680-14; NCGC00015680-15; NCGC00015680-16; NCGC00015680-18; NCGC00015680-35; NCGC00090727-01; NCGC00090727-02; NCGC00090727-03; NCGC00090727-04; NCGC00090727-05; NCGC00090727-06; NCGC00090727-07; NCGC00090727-08; NCGC00090727-09; NCGC00256404-01; NCGC00259077-01; NCGC00261472-01; AC-10019; BA164660; NCI60_004378; SY051401; AB00053279; EU-0100787; FT-0628191; FT-0658928; FT-0670984; S1204; SW196607-4; C01598; D08170; M02088; AB00053279-10; AB00053279_12; EN300-6486827; {N-[2-(5-methoxyindol-3-yl)ethyl]-} Acetamide; A929721; L001261; N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-Acetamide; Q180912; SR-01000075559-1; SR-01000075559-6; SR-01000075559-7; SR-01000075559-8; {N-[2-(5-methoxy-1H-indol-3-yl)ethyl]-} Acetamide; BRD-K97530723-001-07-6; BRD-K97530723-001-11-8; F1929-1777; Melatonin, British Pharmacopoeia (BP) Reference Standard; Z1191880499; 0E2B08C1-B325-45B1-8939-6F9081EFDFA4; Acetamide, N-[2-(5-methoxyindol-3-yl)ethyl]- (6CI,8CI); Acetamide, N-[2-(5-methoxy-1H-indol-3-yl)ethyl]- (9CI); Melatonin, United States Pharmacopeia (USP) Reference Standard; Melatonin, Pharmaceutical Secondary Standard; Certified Reference Material	.	.	232.28	C13H16N2O2	54.1	270	0.8	17	2	2	4	InChI=1S/C13H16N2O2/c1-9(16)14-6-5-10-8-15-13-4-3-11(17-2)7-12(10)13/h3-4,7-8,15H,5-6H2,1-2H3,(H,14,16)	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC	CC(=O)NCCC1=CNC2=C1C=C(C=C2)OC	DRLFMBDRBRZALE-UHFFFAOYSA-N	N-[2-(5-methoxy-1H-indol-3-yl)ethyl]acetamide
ferrodrug0036	Ibuprofen	Small molecular drug	ibuprofen; 15687-27-1; 2-(4-Isobutylphenyl)propanoic acid; Motrin; Brufen; Advil; Nurofen; Nuprin; Dolgit; Liptan; Medipren; Anflagen; Buburone; Butylenin; Ibumetin; Ibuprocin; Lamidon; Ebufac; Rufen; Mynosedin; Roidenin; Andran; Apsifen; Bluton; Epobron; Haltran; Nobfen; Nobgen; Trendar; Adran; PediaProfen; 2-[4-(2-methylpropyl)phenyl]propanoic acid; Brufort; Ibuprohm; Inabrin; Nobfelon; Pantrop; Rebugen; Suspren; Tabalon; Burana; Anco; Urem; (RS)-Ibuprofen; Ibu-slo; Brufanic; Napacetin; Ibufen; Ibuprin; Profen; Ibren; Midol; 4-Isobutylhydratropic acid; Cap-Profen; Tab-Profen; Ibu-Tab; Novoprofen; Proartinal; Amersol; Dibufen; Dolocyl; Lidifen; Optifen; Ostofen; p-Isobutylhydratropic acid; Panafen; Paxofen; Proflex; Quadrax; Uprofen; Carol; Rafen; Cobo; Ifen; (+-)-Ibuprofen; (+/-)-Ibuprofen; Artril 300; duralbuprofen; Balkaprofen; Betaprofen; Butacortelone; Daiprophen; Ibuprofeno; Ibuprofenum; Jenaprofen; Algofen; Amelior; Amibufen; Antagil; Antalfene; Antarene; Antiflam; Artofen; Bruflam; Bufigen; Bukrefen; Buracaps; Citalgan; Combiflam; Dansida; Dentigoa; Dignoflex; Dolgirid; Dolmaral; Dolofen; Dolofin; Dolofort; Dologel; Dolomax; Doloren; Doltibil; Dorival; Duobrus; Dysdolen; Easifon; Exneural; Femadon; Femafen; Femapirin; Femidol; Fenspan; Fibraflex; Gelufene; Gynofug; Ibubest; Ibubeta; Ibucasen; Ibudolor; Ibuflamar; Ibugesic; Ibuhexal; Ibulagic; Ibuleve; Ibulgan; Ibumerck; Ibupirac; Junifen; Kratalgin; Lebrufen; Librofem; Malafene; Manypren; Mensoton; Neobrufen; Nerofen; Noalgil; Nobafon; Noritis; Novadol; Novogent; Nuprilan; Opturem; Oralfene; Ostarin; Paduden; Perofen; Ranofen; Relcofen; Rhinadvil; Sadefen; Salivia; Seclodin; Sednafen; Seklodin; Seskafen; Siyafen; Solpaflex; Sugafen; Suprafen; Syntofene; Tatanal; Unipron; Alaxan; Anafen; Artril; Bloom; Brofen; Bufeno; Bupron; Cesra; Cunil; Dalsy; Dolibu; Dolven; Duafen; Emflam; Eputex; Ergix; Faspic; Fenbid; Fendol; Gofen; Grefen; Ibudol; Ibufug; Ibugel; Ibugen; Ibular; Ibulav; Ibumed; Ibusal; Ibutid; Inflam; Inoven; Ipren; Irfen; Isodol; Kesan; Lopane; Melfen; Midol 200; Moment; Narfen; Ozonol; Provon; Rofen; Rufin; Rupan; Stelar; Tempil; Tofen; Tonal; Upfen; Zofen; Drin; Ibol; Pediatric Advil; 4-Isobutyl-alpha-methylphenylacetic acid; Apo-Ibuprofen; Brufen Retard; Deep Relief; Dolo-Dolgit; Ibu-Attritin; Neo-Helvagit; Novo-Profen; Ibu-slow; Neo-Mindol; Dolofen-F; Donjust B; Nagifen-D; Dura-Ibu; Children's Advil; alpha-(4-Isobutylphenyl)propionic acid; Motrin IB; Children's Motrin; Togal N; ACHES-N-PAIN; Dularbuprofen; Caldolor; Ibu-Tab 200; Ibuprofene; Ibuprophen; Pedea; Children's Ibuprofen; IP-82; Kontagripp Mono; Tabalon 400; Novo Dioxadol; Schmerz-Dolgit; Junior Strength Advil; Brufen 400; Emflam-200; DOLO PUREN; Hemagene Tailleur; Junior Strength Motrin; Act-3; Ak+C2278tren; Advil Liqui-Gels; Adex 200; Codral Period Pain; Hydratropic acid, p-isobutyl-; Junior Strength Ibuprofen; (+-)-Ibuprophen; Children's Elixsure; RD 13621; Am-Fam 400; (4-Isobutylphenyl)-alpha-methylacetic acid; 58560-75-1; IB-100; Alivium; (+-)-p-Isobutylhydratropic acid; Advil migraine; p-Isobutyl-2-phenylpropionic acid; U-18,573; Perrigo ibuprofen; (+-)-2-(p-Isobutylphenyl)propionic acid; alpha-(p-isobutylphenyl)propionic acid; VUFB 9649; MOTRIN MIGRAINE PAIN; alpha-p-Isobutylphenylpropionic acid; UCB 79171; CCRIS 3223; CHEBI:5855; (+-)-alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid; CHILDREN'S ADVIL-FLAVORED; HSDB 3099; UNII-WK2XYI10QM; alpha-Methyl-4-(2-methylpropyl)benzeneacetic acid; Advil Migraine Liqui-Gels; WK2XYI10QM; (+/-)-p-Isobutylhydratropic acid; 2-(p-Isobutylphenyl)propionic acid; EINECS 239-784-6; Midol Liquid Gels; Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl)-; NSC 256857; NSC-256857; BRN 2049713; U 18573; U-18573; DTXSID5020732; Ibu; 2-(4-ISOBUTYLPHENYL)PROPIONIC ACID; M01AE01; MFCD00010393; NSC256857; CHEMBL521; 2-(4-Isobutyl-phenyl)-propionic acid; Acide (isobutyl-4-phenyl)-2 propionique; Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl)-; DTXCID90732; alpha-Methyl-4-(isobutyl)phenylacetic acid; (+/-)-2-(p-isobutylphenyl)propionic acid; MLS000069733; Esprenit; R.D. 13621; Zafen; EC 239-784-6; alpha-(4-Isobutylphenyl)propionate; COMBUNOX COMPONENT IBUPROFEN; REPREXAIN COMPONENT IBUPROFEN; (.+-.)-p-Isobutylhydratropic acid; VICOPROFEN COMPONENT IBUPROFEN; IBUPROFEN COMPONENT OF COMBUNOX; SINE-AID IB COMPONENT IBUPROFEN; IBUPROFEN COMPONENT OF REPREXAIN; IBUPROFEN COMPONENT OF VICOPROFEN; .alpha.-(p-isobutylphenyl)propionic acid; NCGC00015529-09; .alpha.-(4-Isobutylphenyl)propionic acid; Acide (isobutyl-4 phenyl)-2 propionique; SMR000058184; IBUPROFEN COMPONENT OF SINE-AID IB; 4-Isobutyl-.alpha.-methylphenylacetic acid; ADVIL ALLERGY SINUS COMPONENT IBUPROFEN; IBUPROFEN (MART.); IBUPROFEN [MART.]; CHILDREN'S ADVIL COLD COMPONENT IBUPROFEN; ADVIL CONGESTION RELIEF COMPONENT IBUPROFEN; CHILDREN'S MOTRIN COLD COMPONENT IBUPROFEN; IBUPROFEN COMPONENT OF ADVIL ALLERGY SINUS; Advil, Children's; .alpha.-Methyl-4-(2-methylpropyl)benzeneacetic acid; IBUPROFEN COMPONENT OF ADVIL CONGESTION RELIEF; IBUPROFEN COMPONENT OF CHILDREN'S ADVIL COLD; IBUPROFEN COMPONENT OF CHILDREN'S MOTRIN COLD; IBUPROFEN (EP MONOGRAPH); IBUPROFEN (USP IMPURITY); IBUPROFEN [EP MONOGRAPH]; IBUPROFEN [USP IMPURITY]; IBUPROFEN (USP MONOGRAPH); IBUPROFEN [USP MONOGRAPH]; Actiprofen; Midol IB Cramp Relief; Benzeneacetic acid, a-methyl-4-(2-methylpropyl)-, (A+/-)-; Genpril; Codral; Bayer Select Pain Relief; Pedia-Profen; Ibuprofene [INN-French]; Ibuprofenum [INN-Latin]; Novogent N; Apsifen-F; Racemic ibuprofen; Ibuprofeno [INN-Spanish]; 2-(4-isobutylphenyl)propanoate; Motrin IB Gelcaps; CAS-15687-27-1; Motrin (TN); 2-(4-(2-methylpropyl)phenyl)propanoic acid; Advil (TN); (4-isobutylphenyl)-alpha-methylacetate; Children's Elixsure IB; SR-01000000214; alpha-methyl-4-(2-methylpropyl)benzeneacetate; Ibupril; Ibuprox; Aktren; Ibux; rac Ibuprofen; (+/-)-2-(4-Isobutylphenyl)Propanoic Acid; CDT-ibuprofen; MFCD00069289; Nurofen Meltlets; (y)-Ibuprofen; Ibuprofen,(S); (+) ibuprofen; Ibuprofen (Advil); Acide (isobutyl-4-phenyl)-2 propionique [French]; (?)-Ibuprofen; Ibuprofen [USAN]; EPROBRON; p-Isobutylhydratropate; Ibuprofen [USAN:USP:INN:BAN:JAN]; Combunox (Salt/Mix); (A+/-)-Ibuprofen; INFANT'S ADVIL; Spectrum_000849; IBUPROFEN [INN]; IBUPROFEN [JAN]; Opera_ID_554; IBUPROFEN [MI]; IBUPROFEN [HSDB]; IBUPROFEN [INCI]; Spectrum2_000129; Spectrum3_000465; Spectrum4_000015; Spectrum5_000862; IBUPROFEN [VANDF]; WLN: QVY&R DIY; CBMicro_005634; Epitope ID:139973; p-isobutyl-hydratropic acid; I 4883; Cambridge id 5152402; IBUPROFEN [USP-RS]; IBUPROFEN [WHO-DD]; IBUPROFEN [WHO-IP]; SCHEMBL3001; Lopac0_000691; BSPBio_002170; Ibuprofen - Adooq Bioscience; IBUPROFEN [EMA EPAR]; KBioGR_000389; KBioSS_001329; MLS001146965; p-Isobutyl-2-phenylpropionate; BIDD:GT0050; DivK1c_000887; SPECTRUM1500347; Ibuprofen, >=98% (GC); SPBio_000178; Ibuprofen (JP17/USP/INN); Ibuprofen, 1mg/ml in Methanol; alpha-p-Isobutylphenylpropionate; GTPL2713; Motrin IB Gelcaps (Salt/Mix); IBUPROFEN [ORANGE BOOK]; 2-p-isobutylphenylpropionic acid; HEFNNWSXXWATRW-UHFFFAOYSA-; HMS502M09; KBio1_000887; KBio2_001329; KBio2_003897; KBio2_006465; KBio3_001390; Advil Cold & Sinus (Salt/Mix); C01CB16; G02CC01; M02AA13; R02AX02; Ibuprofen 1.0 mg/ml in Methanol; NINDS_000887; Sine-Aid IB Caplets (Salt/Mix); Benzeneacetic acid, alpha-methyl-4-(2-methylpropyl), (+-)-; HMS1920F15; HMS2089P05; HMS2091N03; HMS2230N04; HMS3259G05; HMS3262K03; HMS3372M09; HMS3649M11; HMS3651A15; HMS3884I04; Pharmakon1600-01500347; IBUPROFENUM [WHO-IP LATIN]; BCP10423; BCP20325; BCP25225; ZAG-1701; ( inverted question mark)-Ibuprofen; Children's Elixsure IB (Salt/Mix); Tox21_110170; Tox21_201384; Tox21_302829; Tox21_500691; 1189866-35-0 (unlabeled); 2-(4'-isobutylphenyl)propionic acid; 2-(4-isobutylphenyl) propanoic acid; 2-(4-isobutylphenyl) propionic acid; 2-(4-isobutylphenyl)-propionic acid; BBL010660; BDBM50009859; CCG-38947; COMBOGESIC COMPONENT IBUPROFEN; NSC757073; s1638; STK177358; (.+/-.)-p-Isobutylhydratropic acid; 2-(4-isobutylphenyl)-propionoic acid; 2-(4'-isobutylphenyl)-propionic acid; AKOS003237488; AKOS016340658; Propanoic acid, 2-(4-isobutylphenyl); Tox21_110170_1; ( inverted exclamation markA)-Ibuprofe; CS-1931; DB01050; KS-5029; LP00691; NC00458; NSC-757073; SB19113; SDCCGSBI-0050669.P005; ST-1482; alpha-(4-isobutylphenyl)-propionic acid; alpha-(p-isobutylphenyl)-propionic acid; IBUPROFEN COMPONENT OF COMBOGESIC; IDI1_000887; 2-(4-Isobutylphenyl)propionic Acid-d3;; NCGC00015529-04; NCGC00015529-05; NCGC00015529-06; NCGC00015529-07; NCGC00015529-08; NCGC00015529-10; NCGC00015529-12; NCGC00015529-13; NCGC00015529-14; NCGC00015529-15; NCGC00015529-18; NCGC00015529-32; NCGC00089819-02; NCGC00089819-03; NCGC00089819-04; NCGC00089819-05; NCGC00089819-06; NCGC00089819-07; NCGC00256416-01; NCGC00258935-01; NCGC00261376-01; AC-11312; BI166241; HY-78131; NCI60_002065; SY046826; Ibuprofen, Vetec(TM) reagent grade, 97%; SBI-0050669.P004; .alpha.-2-(p-Isobutylphenyl)propionic acid; Ibuprofen, meets USP testing specifications; (.+-.)-2-(p-Isobutylphenyl)propionic acid; 4-Isobutylphenyl)-.alpha.-methylacetic acid; AM20060782; BB 0258487; EU-0100691; FT-0601629; FT-0642971; FT-0655194; FT-0670257; FT-0670258; I0415; SW203738-2; (.+/-.)-2-(p-Isobutylphenyl)propionic acid; Ibuprofen, VETRANAL(TM), analytical standard; (r/s)-alpha-methyl-4-isobutylphenylacetic acid; C01588; D00126; EN300-120638; AB00052020-16; AB00052020-17; AB00052020_18; AB00052020_19; A831926; Q186969; (2RS)-2-(4-(2-Methylpropyl)phenyl)propanoic acid; J-009349; SR-01000000214-2; SR-01000000214-4; BRD-A17655518-001-02-0; BRD-A17655518-001-12-9; SR-01000000214-13; F2173-0233; Ibuprofen, British Pharmacopoeia (BP) Reference Standard; Pharmaceuticals Mixture 327 200 microg/mL in Methanol; Z1695709473; (+/-)-alpha-methyl-4-(2-methylpropyl)benzeneacetic acid; Ibuprofen, European Pharmacopoeia (EP) Reference Standard; Ibuprofen, United States Pharmacopeia (USP) Reference Standard; Benzeneacetic acid, .alpha.-methyl-4-(2-methylpropyl), (.+/-.)-; BENZENEACETIC ACID, .ALPHA.-METHYL-4-(2-METHYLPROPYL), (+/-)-; Dexibuprofen;(S)-Ibuprofen; L 669455; L-669,455, MK 233; MK-233; Ibuprofen, Pharmaceutical Secondary Standard; Certified Reference Material; Ibuprofen for peak identification, European Pharmacopoeia (EP) Reference Standard; 139466-08-3; InChI=1/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)	D0R1QE	DM8VCBE	206.28	C13H18O2	37.3	203	3.5	15	1	2	4	InChI=1S/C13H18O2/c1-9(2)8-11-4-6-12(7-5-11)10(3)13(14)15/h4-7,9-10H,8H2,1-3H3,(H,14,15)	CC(C)CC1=CC=C(C=C1)C(C)C(=O)O	CC(C)CC1=CC=C(C=C1)C(C)C(=O)O	HEFNNWSXXWATRW-UHFFFAOYSA-N	2-[4-(2-methylpropyl)phenyl]propanoic acid
ferrodrug0037	Simvastatin	.	simvastatin; 79902-63-9; Zocor; Synvinolin; Sinvacor; Denan; Lipex; MK-733; Sivastin; Lodales; Cholestat; Simvastatine; Colemin; Medipo; Pantok; Simovil; Labistatin; Simvastatina; Simvastatinum; Velostatin; Coledis; Corolin; Nivelipol; Rendapid; Vasotenal; Zorced; Rechol; Zocord; Simvastatin (Zocor); Simvastatin lactone; MK-0733; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Lipovas; Simcard; Simvacor; Simvoget; Simlup; Zosta; Simvastatinum [Latin]; DRG-0320; CCRIS 7558; MK 0733; HSDB 7208; UNII-AGG2FN16EV; AGG2FN16EV; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-(2-((1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl)ethyl)tetrahydro-4-hydroxy-2H-pyran-2-one; MK 733; NSC-758706; L 644128-000U; Simvastatine [French]; BRN 4768037; CHEBI:9150; Simvastatina [Spanish]; DTXSID0023581; C10AA01; Statin; DTXCID103581; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxotetrahydro-2H-pyran-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; SIMCOR COMPONENT SIMVASTATIN; VYTORIN COMPONENT SIMVASTATIN; Simcor; NSC633782; SIMVASTATIN COMPONENT OF SIMCOR; NSC 758706; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; Butanoic acid, 2,2-dimethyl-, (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-((2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester; SIMVASTATIN COMPONENT OF VYTORIN; Simvastatinum (Latin); SIMVASTATIN (MART.); SIMVASTATIN [MART.]; SIMVASTATIN (USP-RS); SIMVASTATIN [USP-RS]; Butanoic acid, 2,2-dimethyl-, 1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl ester, (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-; SIMVASTATIN (EP MONOGRAPH); SIMVASTATIN [EP MONOGRAPH]; SIMVASTATIN (USP MONOGRAPH); SIMVASTATIN [USP MONOGRAPH]; Simvast CR; (1S,3R,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; [(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxo-tetrahydropyran-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate; SMR000718785; Zocor (TN); Simvastatin & Primycin; MK733; SR-05000001894; Kolestevan; Lipinorm; Modutrol; Simvotin; Sinvascor; Valemia; Eucor; Nor-Vastina; Simvastatin,(S); simvastatin predrug; (+)-Simvastatin; NCGC00016940-01; inactive simvastatin; 2,2-Dimethylbutyric acid, 8-ester with (4R,6R)-6-[2-[(1S,2S,6R,8S,8aR)-1,2,6,7,8,8a-hexahydro-8-hydroxy-2,6-dimethyl-1-naphthyl]ethyl]tetrahydro-4-hydroxy-2H-pyran-2-one; Simvastatin [USAN:USP:INN:BAN]; TNP00259; Prestwick_171; Simvastatin- Bio-X; CAS-79902-63-9; FLOLIPID; KS-1113; Spectrum_001717; SpecPlus_000895; SIMVASTATIN [MI]; Prestwick0_000865; Prestwick1_000865; Prestwick2_000865; Prestwick3_000865; Spectrum2_001671; Spectrum3_000669; Spectrum4_000632; Spectrum5_001428; SIMVASTATIN [INN]; SIMVASTATIN [JAN]; SIMVASTATIN [HSDB]; SIMVASTATIN [USAN]; SIMVASTATIN [VANDF]; SCHEMBL2471; CHEMBL1064; BSPBio_000909; BSPBio_002337; KBioGR_001244; KBioSS_002197; SIMVASTATIN [WHO-DD]; MLS001304029; MLS001333077; MLS001333078; MLS002154038; MLS006011866; BIDD:GT0769; DivK1c_006991; SPECTRUM1504236; SPBio_001881; SPBio_002830; BPBio1_001001; GTPL2955; Simvastatin (JP17/USP/INN); Simvastatin, analytical standard; BCBcMAP01_000007; KBio1_001935; KBio2_002197; KBio2_004765; KBio2_007333; KBio3_001557; RYMZZMVNJRMUDD-HGQWONQESA-; SIMVASTATIN [ORANGE BOOK]; HMS1570N11; HMS1922H13; HMS2089D12; HMS2093E06; HMS2097N11; HMS2231N22; HMS3259B12; HMS3412P08; HMS3676P08; HMS3714N11; HMS3884G10; Pharmakon1600-01504236; BUTANOIC ACID, 2,2-DIMETHYL-, 1,2,3,7,8,8A-HEXAHYDRO-3,7-DIMETHYL-8-(2-(TETRAHYDRO-4-HYDROXY-6-OXO-2H-PYRAN-2-YL)ETHYL)-1-NAPHTHALENYL ESTER, (1S-(1.ALPHA.,3.ALPHA.,7.BETA.,8.BETA.(2S*,4S*),8A.BETA.))-; Tox21_110696; Tox21_300400; BBL024390; BDBM50139181; CCG-39069; NSC758706; s1792; STK801938; AKOS005111006; AKOS015842733; Simvastatin, >=97% (HPLC), solid; Tox21_110696_1; AC-1530; DB00641; NC00719; NSC-633782; MRF-0000729; NCGC00017324-01; NCGC00017324-02; NCGC00017324-03; NCGC00017324-04; NCGC00017324-05; NCGC00017324-07; NCGC00017324-08; NCGC00017324-09; NCGC00254418-01; 2,2-Dimethylbutanoic acid (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyl ester; BS164407; HY-17502; SBI-0206773.P001; Simvastatin 100 microg/mL in Acetonitrile; S0509; EN300-52503; D00434; AB00053395-07; AB00053395-08; AB00053395-10; AB00053395_11; AB00053395_13; A839783; Q670131; SR-05000001894-1; SR-05000001894-2; BRD-K22134346-001-05-8; BRD-K22134346-001-11-6; BRD-K22134346-001-15-7; Z754918914; Simvastatin, British Pharmacopoeia (BP) Reference Standard; Simvastatin, European Pharmacopoeia (EP) Reference Standard; Simvastatin, United States Pharmacopeia (USP) Reference Standard; Simvastatin, Pharmaceutical Secondary Standard; Certified Reference Material; Simvastatin for peak identification, European Pharmacopoeia (EP) Reference Standard; (1S,3R,7S,8S,8aR)-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-[2-[(2R,4R)-tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl]ethyl]-1-naphthalenyly-2,2-dimethyl butanoate; (1S,3R,7S,8S,8aR)-8-(2-((2R,4R)-4-Hydroxy-6-oxotetrahydro-2H-pyran-2-yl)ethyl)-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbu; (1S,7S,8S,8aR)-8-{2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl}-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl 2,2-dimethylbutanoate; (1S-(1alpha,3alpha,7beta,8beta(2S*,4S*),8abeta))-1,2,3,7,8,8a-Hexahydro-3,7-dimethyl-8-(2-(tetrahydro-4-hydroxy-6-oxo-2H-pyran-2-yl)ethyl)-1-naphthalenyl 2,2-dimethylbutanoate; InChI=1/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1	.	.	418.6	C25H38O5	72.8	706	4.7	30	1	5	7	InChI=1S/C25H38O5/c1-6-25(4,5)24(28)30-21-12-15(2)11-17-8-7-16(3)20(23(17)21)10-9-19-13-18(26)14-22(27)29-19/h7-8,11,15-16,18-21,23,26H,6,9-10,12-14H2,1-5H3/t15-,16-,18+,19+,20-,21-,23-/m0/s1	CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C	CCC(C)(C)C(=O)OC1CC(C=C2C1C(C(C=C2)C)CCC3CC(CC(=O)O3)O)C	RYMZZMVNJRMUDD-HGQWONQESA-N	[(1S,3R,7S,8S,8aR)-8-[2-[(2R,4R)-4-hydroxy-6-oxooxan-2-yl]ethyl]-3,7-dimethyl-1,2,3,7,8,8a-hexahydronaphthalen-1-yl] 2,2-dimethylbutanoate
ferrodrug0038	Sorafenib	.	Sorafenib; 284461-73-0; Nexavar; BAY 43-9006; sorafenibum; 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N-METHYLPICOLINAMIDE; 4-[4-({[4-chloro-3-(trifluoromethyl)phenyl]carbamoyl}amino)phenoxy]-N-methylpyridine-2-carboxamide; Sorafenib free base; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide; UNII-9ZOQ3TZI87; N-(4-Chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl)urea; 100012-18-8; 9ZOQ3TZI87; BAY-43-9006; 4-(4-((((4-Chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-2-pyridinecarboxamide; DTXSID7041128; CHEBI:50924; HSDB 8173; 284461-73-0 (free base); MFCD06411450; BAY43-9006; CHEMBL1336; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-pyridine-2-carboxamide; 2-Pyridinecarboxamide, 4-(4-((((4-chloro-3-(trifluoromethyl)phenyl)amino)carbonyl)amino)phenoxy)-N-methyl-; 4-{4-[({[4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL]AMINO}CARBONYL)AMINO]PHENOXY}-N-METHYLPYRIDINE-2-CARBOXAMIDE; EC 608-209-4; BAY-439006; Sorafenib [INN]; 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; Sorafenib (Nexavar); SORAFENIB (MART.); SORAFENIB [MART.]; 4-(4-{3-(4-Chloro-3-(trifluoromethyl)phenyl)ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; Donafenib (Sorafenib D3); 2-Pyridinecarboxamide, 4-[4-[[[[4-chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-; 4-(4-(3-(4-CHLORO-3-(TRIFLUOROMETHYL)PHENYL)UREIDO)PHENOXY)-N(SUP 2)-METHYLPYRIDINE-2-CARBOXAMIDE; BAX; NSC-724772; NCGC00167488-01; Sorafenib [USAN:INN:BAN]; SR-00000000529; 1uwh; 3gcs; 3heg; 4asd; Hit compound, 8; Sorafenib, 4; 4-(4-(((4-chloro-3-(trifluoromethyl)phenyl)carbamoyl)amino)phenoxy)-N-methylpyridine-2-carboxamide; 4-[4-[[[[4-Chloro-3-(trifluoromethyl)phenyl]amino]carbonyl]amino]phenoxy]-N-methyl-2-pyridinecarboxamide; BAY 43-9006; N-[4-Chloro-3-(trifluoromethyl)phenyl]-N'-[4-[2-(N-methylcarbamoyl)-4-pyridyloxy]phenyl]urea; Nevaxar; Sorafenib; Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-kappaN21,kappaN22,kappaN23,kappaN24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-; BAY 439006; 4-(4-(3-(4-chloro-3-trifluoromethylphenyl)ureido)phenoxy)pyridine-2-carboxyllic acid methyamide-4-methylbenzenesulfonate; Kinome_766; SORAFENIB BASE; SORAFENIB [MI]; Sorafenib (USAN/INN); SORAFENIB [USAN]; Nexavar (TN) (Bayer); sorafenib tosilate hydrate; SORAFENIB [VANDF]; SCHEMBL8218; SORAFENIB [WHO-DD]; SORAFENIB [EMA EPAR]; BAY 43-9006; Sorafenib; cid_216239; GTPL5711; DTXCID5021128; BDBM16673; L01XE05; BCPP000064; HMS2043A18; HMS3244A15; HMS3244A16; HMS3244B15; HMS3656N20; K00597a; BCP01767; BCP34023; EX-A2894; BAY439006; NSC747971; NSC800934; s7397; STK627350; AKOS005560229; AC-1674; CCG-269400; CS-1590; DB00398; NSC-747971; NSC-800934; PB14443; SB19942; SF-0529; BAY-43-0006; Sorafenib free base (BAY-43-9006); NCGC00167488-02; NCGC00167488-03; NCGC00167488-04; NCGC00167488-05; NCGC00167488-07; NCGC00167488-14; 4(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N(sup 2)-methylpyridine-2-carboxamide; BS164413; HY-10201; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcar bamoyl)-4-pyridyloxy)phenyl)urea; SY009239; PA-216239; AM20090614; FT-0650736; FT-0674632; SW202562-4; BA4 43 9006; D08524; EN300-120647; AB00933189-05; AB00933189-06; AB00933189_08; A819449; Q421136; Q-201728; SR-00000000529-1; BRD-K23984367-001-01-8; Z89277543; BAY 439006; BAY439006; BAY-439006; Sorafenib (D3); CM-4307; CM 4307; CM4307;Bay 43-9006 (D3); 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido) phenoxy)-N-methylpicolinamide; 4-(4-(3-(4-chloro-3-(trifluoromethyl)phenyl) ureido)phenoxy)-N-methylpicolinamide; N-(3-trifluoromethyl-4-chlorophenyl)-N'-(4-(2-methylcarbamoyl pyridin-4-yl)oxyphenyl)urea; 4-(4-{3-[4-chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)- N-methylpyridine-2-carboxamide; 4-(4-{3-[4-Chloro-3-(trifluoromethyl)phenyl]ureido}phenoxy)-N2-methylpyridine-2-carboxamide; 4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methyl-picolinamide;tosylic acid; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)-amino]phenoxy}-N-methylpyridine-2-carboxamide; 4-{4-[({[4-chloro-3-(trifluoromethyl)phenyl]amino}carbonyl)amino]phenoxy}-N-methyl-pyridine-2-carboxamide; Manganese(4+), chloro[[4,4',4'',4'''-(21H,23H-porphine-5,10,15,20-tetrayl-N21,N22,N23,N24)tetrakis[1-methylpyridiniumato]](2-)]-, chloride (1:4), (SP-5-12)-; N-(4-chloro-3-(trifluoromethyl)phenyl)-N'-(4-(2-(N-methylcarbamoyl)-4-pyridyloxy)phenyl) urea	.	.	464.8	C21H16ClF3N4O3	92.4	646	4.1	32	3	7	5	InChI=1S/C21H16ClF3N4O3/c1-26-19(30)18-11-15(8-9-27-18)32-14-5-2-12(3-6-14)28-20(31)29-13-4-7-17(22)16(10-13)21(23,24)25/h2-11H,1H3,(H,26,30)(H2,28,29,31)	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	MLDQJTXFUGDVEO-UHFFFAOYSA-N	4-[4-[[4-chloro-3-(trifluoromethyl)phenyl]carbamoylamino]phenoxy]-N-methylpyridine-2-carboxamide
ferrodrug0039	Orlistat	Small molecular drug	orlistat; 96829-58-2; Tetrahydrolipstatin; Xenical; Alli; Orlipastat; (-)-Tetrahydrolipstatin; Orlipastatum [INN-Latin]; Ro-18-0647; C29H53NO5; Ro 18-0647/002; Orlistat (Alli, Xenical); (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl (2S)-2-formamido-4-methylpentanoate; [(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate; N-Formyl-L-leucine (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; MLS002207022; N-Formyl-L-leucine, ester with (3S,4S)-3-hexyl-4-((2S)-2-hydroxytridecyl)-2-oxetanone; CHEMBL175247; DTXSID8023395; 95M8R751W8; NSC-758881; Orlipastatum; SMR000466339; THLP; Ro-180647002; Ro-180647-002; Ro-18-0647/002; (S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl formyl-L-leucinate; tetrahydrolipastatin; DTXCID40820067; MFCD05662360; (S)-((S)-1-((2S,3S)-3-hexyl-4-oxooxetan-2-yl)tridecan-2-yl) 2-formamido-4-methylpentanoate; Xenical (TN); CAS-96829-58-2; L-Leucine, N-formyl-, (1S)-1-(((2S,3S)-3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester; SR-01000759417; orlistatum; Orlistat [USAN:INN:BAN]; UNII-95M8R751W8; HSDB 7556; N-formyl-L-leucine (1S)-1-{[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl}dodecyl ester; L-Leucine, N-formyl-, (1S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; NCGC00095128-01; (-)-Tetrahydrolipstatin; Orlistat; Ro 18-0647/002; Tetrahydrolipstatin; Xenical; L-Leucine, N-formyl-, 1-[(3-hexyl-4-oxo-2-oxetanyl)methyl]dodecyl ester, [2S-[2alpha(R*),3beta]]-; THL; KS-1183; Lipase Inhibitor, THL; ORLISTAT [HSDB]; ORLISTAT [USAN]; ORLISTAT [INN]; ORLISTAT [JAN]; ORLISTAT [MI]; (-)-tetrahydrolipostatin; ORLISTAT [VANDF]; R-212; ORLISTAT [MART.]; ORLISTAT [USP-RS]; ORLISTAT [WHO-DD]; Orlistat (JAN/USP/INN); ORLISTAT [EMA EPAR]; Orlistat, >=98%, solid; SCHEMBL16408; L-Leucine, N-formyl-, 1-((3-hexyl-4-oxo-2-oxetanyl)methyl)dodecyl ester, (2S-(2alpha(R*),3beta))-; MLS000759448; MLS001423955; BIDD:GT0853; ORLISTAT [ORANGE BOOK]; GTPL5277; ORLISTAT [USP MONOGRAPH]; BDBM24567; CHEBI:94686; AHLBNYSZXLDEJQ-FWEHEUNISA-N; Tetrahydrolipstatin;Ro-18-0647; HMS2051I08; HMS3413P06; HMS3677P06; HY-B0218; Tox21_111437; HB4009; s1629; AKOS015894875; Tox21_111437_1; BCP9001031; CCG-100851; DB01083; NC00101; NSC 758881; Ro18-0647; NCGC00165856-01; NCGC00165856-02; NCGC00165856-03; NCGC00165856-15; [(1S)-1-[[(2S,3S)-3-hexyl-4-oxo-oxetan-2-yl]methyl]dodecyl] (2S)-2-formamido-4-methyl-pentanoate; BO164179; R212; BCP0726000044; O0381; SW197481-2; D04028; EN300-268136; AB00639987-09; AB00639987_10; Q424163; Q-201519; SR-01000759417-5; SR-01000759417-7; Z2379810072; Orlistat, United States Pharmacopeia (USP) Reference Standard; Orlistat, Pharmaceutical Secondary Standard; Certified Reference Material; (2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl N-formyl-L-leucinate; 2-formamido-3-[(3-hexyl-4-oxo-oxetan-2-yl)methyl]-2-isobutyl-tetradecanoate; N-formyl-L-leucine (S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]dodecyl ester; N-formyl-L-leucine-(S)-1-[[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]methyl]-dodecyl ester; (2S)-2-formamido-4-methylpentanoic acid [(2S)-1-[(2S,3S)-3-hexyl-4-oxo-2-oxetanyl]tridecan-2-yl] ester; [(2S)-1-[(2R,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2R)-2-formamido-4-methylpentanoate; 104872-04-0; L-LEUCINE, N-FORMYL-, 1-((3-HEXYL-4-OXO-2-OXETANYL)METHYL)DODECYL ESTER, (2S-(2.ALPHA.(R*),3.BETA.))-	D0T9TJ	DMRJSP8	495.7	C29H53NO5	81.7	579	10	35	1	5	23	InChI=1S/C29H53NO5/c1-5-7-9-11-12-13-14-15-16-18-24(34-29(33)26(30-22-31)20-23(3)4)21-27-25(28(32)35-27)19-17-10-8-6-2/h22-27H,5-21H2,1-4H3,(H,30,31)/t24-,25-,26-,27-/m0/s1	CCCCCCCCCCC[C@@H](C[C@H]1[C@@H](C(=O)O1)CCCCCC)OC(=O)[C@H](CC(C)C)NC=O	CCCCCCCCCCCC(CC1C(C(=O)O1)CCCCCC)OC(=O)C(CC(C)C)NC=O	AHLBNYSZXLDEJQ-FWEHEUNISA-N	[(2S)-1-[(2S,3S)-3-hexyl-4-oxooxetan-2-yl]tridecan-2-yl] (2S)-2-formamido-4-methylpentanoate
ferrodrug0040	5-Azacitidine	.	5-azacytidine; Azacitidine; 320-67-2; Ladakamycin; Azacytidine; Vidaza; Mylosar; 5-azacitidine; Azacitidinum; Azacitidina; Azacitidinum [INN-Latin]; 5-AZAC; Azacitidina [INN-Spanish]; C8H12N4O5; NSC-102816; U-18496; Onureg; 4-Amino-1-beta-D-ribofuranosyl-s-triazin-2(1H)-one; NSC102816; 5AzaC; 4-Amino-1-beta-d-ribofuranosyl-1,3,5-triazin-2(1H)-one; Antibiotic U 18496; 5-AZCR; 4-amino-1-((2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; 5 AZC; 5-AC; NSC 102816; CHEBI:2038; M801H13NRU; DTXSID9020116; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; U-18,496; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; WR-183027; NCGC00090851-04; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-triazine-2(1H)-one; U 18496; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; DTXCID10116; 1,3,5-Triazin-2(1H)-one, 4-amino-1-.beta.-D-ribofuranosyl-; MFCD00006539; CCRIS 60; SMR000857239; Vidaza (TN); HSDB 6879; 5-aza-CR; SR-01000075662; EINECS 206-280-2; Azacitidine;5-AzaC;Ladakamycin; BRN 0620461; UNII-M801H13NRU; Azacitidine (JAN/USAN/INN); Azacitidine [USAN:INN:BAN]; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-traizin-2(1H)-one; NS-17; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; CAS-320-67-2; Azacitidine (Vidaza); 2-(beta-D-Ribofuranosyl)-4-amino-1,3,5-triazin-2-one; Antibiotic U18496; U18496; Spectrum_001262; AZACITIDINE [MI]; Spectrum2_000786; Spectrum3_001509; Spectrum4_000922; Spectrum5_001166; AZACITIDINE [INN]; AZACITIDINE [JAN]; AZACITIDINE [HSDB]; AZACITIDINE [IARC]; AZACITIDINE [USAN]; MolMap_000062; 4-Amino-1-.beta.-D-ribofuranosyl-s-triazin-2(1H)-one; A 2385; AZACITIDINE [VANDF]; SCHEMBL3741; AZACITIDINE [MART.]; CHEMBL1489; Azacitidine (5-Azacytidine); Lopac0_000035; AZACITIDINE [USP-RS]; AZACITIDINE [WHO-DD]; BSPBio_003157; KBioGR_001444; KBioGR_002556; KBioSS_001742; KBioSS_002565; MLS001333121; MLS001333122; MLS002153249; MLS002548894; DivK1c_000125; SPECTRUM1502111; SPBio_000892; AZACITIDINE [EMA EPAR]; GTPL6796; s-Triazin-2(1H)-one, 4-amino-1-beta-D-ribofuranosyl-; BCBcMAP01_000083; HMS500G07; KBio1_000125; KBio2_001742; KBio2_002556; KBio2_004310; KBio2_005124; KBio2_006878; KBio2_007692; KBio3_002657; KBio3_003034; NMUSYJAQQFHJEW-KVTDHHQDSA-; AZACITIDINE [ORANGE BOOK]; pyrimidine antimetabolite: inhibits nucleic acid replication; cMAP_000082; NINDS_000125; NMUSYJAQQFHJEW-KVTDHHQDSA-N; HMS1921J22; HMS2092D08; HMS2231F15; HMS3259D19; HMS3260G11; Pharmakon1600-01502111; 5-Azacytidine, >=98% (HPLC); Tox21_111032; Tox21_302985; Tox21_500035; BDBM50424715; CCG-39046; HB1374; NSC758186; s1782; Onureg (CC-486; oral azacitidine); AKOS015896938; Tox21_111032_1; AM83944; CS-1287; DB00928; LP00035; NC00672; NSC-758186; NSC103-627; 4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triaz; IDI1_000125; NCGC00090851-01; NCGC00090851-02; NCGC00090851-03; NCGC00090851-05; NCGC00090851-06; NCGC00090851-07; NCGC00090851-08; NCGC00090851-10; NCGC00090851-14; NCGC00090851-22; NCGC00178234-01; NCGC00256541-01; NCGC00260720-01; AS-13697; HY-10586; SRI-10756_10; SRI-10756_12; WR183027; SL-000003; EU-0100035; D03021; EN300-118700; F10504; A821115; Q416451; J-700085; SR-01000075662-1; SR-01000075662-3; SR-01000075662-7; BRD-K03406345-001-02-1; BRD-K03406345-001-27-8; 4-Amino-1-?-D-ribofuranosyl-1,3,5-triazin-2(1H)-one; Z1515383340; 4-Amino-1-(bet.-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-Amino-1-beta-D-ribofuranosyl-1,3,5-tr iazin-2(1H)-one; Azacitidine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-1-(beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; Ladakamycin; Azacitidine, Pharmaceutical Secondary Standard; Certified Reference Material; 1401238-97-8; 5-Azacytidine, Hybri-Max(TM), gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; 5AE; 6-amino-3-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1H-1,3,5-triazin-3-ium-2-one; InChI=1/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1	.	.	244.2	C8H12N4O5	141	384	-2.2	17	4	5	2	InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1	C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N	C1=NC(=NC(=O)N1C2C(C(C(O2)CO)O)O)N	NMUSYJAQQFHJEW-KVTDHHQDSA-N	4-amino-1-[(2R,3R,4S,5R)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
ferrodrug0041	Pioglitazone	.	Pioglitazone; 111025-46-8; Actos; Glustin; 105355-27-9; Zactos; Pioglitazona; Pioglitazonum; Pioglitazonum [INN-Latin]; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)thiazolidine-2,4-dione; Pioglitazona [INN-Spanish]; AD-4833; U 72107; Pioglitazone [BAN:INN]; Pioglitazone (Actos); 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-2,4-thiazolidinedione; pioglitazone (INN); 105390-47-4; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione; CHEBI:8228; C19H20N2O3S; U-72107; 5-[4-[2-(5-Ethyl-2-pyridyl)ethoxy]benzyl]thiazolidine-2,4-dione; Actos (TN); 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-1,3-thiazolidine-2,4-dione; 2,4-thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-; X4OV71U42S; 5-[4-[2-(5-ETHYL-2-PYRIDYL)ETHOXY]BENZYL]-2,4-THIAZOLIDINEDIONE; 5-({4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl}methyl)-1,3-thiazolidine-2,4-dione; MFCD00865504; PIOGLITAZONE [INN]; 5-((4-(2-(5-Ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; Pioglitazone [INN:BAN]; Piozone; Actost; Pioglu; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-; HSDB 7322; UNII-X4OV71U42S; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4-thiazolidinedione; SR-01000763737; 5-(4-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]-, (+/-)-; [( inverted exclamation markA)-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; 2,4-THIAZOLIDINEDIONE, 5-((4-(2-(5-ETHYL-2-PYRIDINYL)ETHOXY)PHENYL)METHYL)-, (+/-)-; Pioglitazone-[d4]; Pioglitazone- Bio-X; HS-0047; Spectrum_001623; Spectrum2_001679; Spectrum3_001002; Spectrum4_001130; Spectrum5_001480; Spectrum5_002067; PIOGLITAZONE [MI]; PIOGLITAZONE [HSDB]; PIOGLITAZONE [IARC]; SCHEMBL4121; PIOGLITAZONE [VANDF]; BSPBio_002723; KBioGR_001619; KBioSS_002103; MLS006011848; PIOGLITAZONE [WHO-DD]; SPBio_001897; GTPL2694; PIOGLITAZONE [EMA EPAR]; DTXSID3037129; KBio2_002103; KBio2_004671; KBio2_007239; KBio3_001943; HYAFETHFCAUJAY-UHFFFAOYSA-N; HMS2089H14; HMS3651D09; HMS3712E16; HMS3884L10; Pharmakon1600-01504401; BCP26474; BBL029068; BDBM50103521; HB4139; NSC758876; s2590; STL309607; STL373406; (+/-)-5-[p-[2-(ethyl-2-pyridyl)ethoxy]benzyl]-2,4-thiazolidinedione; 5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione; AKOS015894953; AKOS022109420; AC-1021; CCG-220107; CS-1700; DB01132; SB17323; (+/-)-5-[[4-[2-(5-Ethyl-2-pyridinyl)-ethoxy]phenyl]methyl]-2,4-thiazolidinedione; 2,4-Thiazolidinedione, 5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-, (+-)-; NCGC00163128-01; NCGC00163128-02; NCGC00163128-03; NCGC00163128-04; NCGC00163128-05; NCGC00163128-06; NCGC00163128-07; BP164273; HY-13956; SMR002204015; SY017473; SBI-0206791.P001; FT-0601906; FT-0645030; SW197561-3; C07675; D08378; EN300-117258; AB00698454-10; AB00698454_11; AB00698454_12; AB00698454_13; A802277; Q417765; J-002506; J-516181; SR-01000763737-5; BRD-A48430263-003-02-4; BRD-A48430263-003-06-5; Z1501480426; 5-[4-[2-(5-ethyl-2-pyridyl) ethoxy]benzyl]-2,4-thiazolidinedione; 5-[4-[2-(5-ethyl-2-pyridyl)eth-oxy]benzyl]-2,4-thiazolidinedione; 5-{4-[2-(5-ethyl-2-pyridyl)ethoxy]benzyl}-2,4thiazolidinedione; 5-(4-(2-(5-ethylpyridin-2-yl)ethoxy)benzyl)-thiazolidine-2,4-dione; 5-[[4-[2-(5-Ethyl-2-pyridinyl)ethoxy]phenyl]methyl-2,4-thiazolidinedione; 5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy] phenyl]methyl]-2,4-thiazolidinedione; (+/-)-5-((4-(2-(5-ethyl-2-pyridinyl)ethoxy)phenyl)methyl)-2,4-thiazolidinedione; (+/-)-5-(P-(2-(5-ETHYL-2-PYRIDYL)ETHOXY)BENZYL)-2,4-THIAZOLIDINEDIONE; (5S)-5-[[4-[2-(5-ethyl-2-pyridyl)ethoxy]phenyl]methyl]thiazolidine-2,4-dione;Pioglitazone; (RS)-5-(4-(2-(5-ETHYLPYRIDIN-2-YL)ETHOXY)BENZYL)THIAZOLIDINE-2,4-DIONE; 2,4-Thiazolidinedione, 5-[[4-[2-(5-ethyl-2-pyridinyl)ethoxy]phenyl]methyl]- (9CI); 5-[[4-[2-[(5-ethyl-2-pyridyl)]ethoxy]phenyl]methyl]thiazolidine- 2,4-dione; 5-{4-[2-(5-ethylpyridin-2-yl)ethoxy]benzyl}-4-hydroxy-1,3-thiazol-2(5H)-one; [()-5-[[4-[2-(5-ethyl-2-pyridinyl) ethoxy] phenyl] methyl]-2,4-] thiazolidinedione monohydrochlorid; 198077-89-3	.	.	356.4	C19H20N2O3S	93.6	466	3.8	25	1	5	7	InChI=1S/C19H20N2O3S/c1-2-13-3-6-15(20-12-13)9-10-24-16-7-4-14(5-8-16)11-17-18(22)21-19(23)25-17/h3-8,12,17H,2,9-11H2,1H3,(H,21,22,23)	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3	HYAFETHFCAUJAY-UHFFFAOYSA-N	5-[[4-[2-(5-ethylpyridin-2-yl)ethoxy]phenyl]methyl]-1,3-thiazolidine-2,4-dione
ferrodrug0042	Chrysophanol	.	Chrysophanol; 481-74-3; CHRYSOPHANIC ACID; 3-Methylchrysazin; 1,8-Dihydroxy-3-methylanthraquinone; Turkey rhubarb; 1,8-dihydroxy-3-methylanthracene-9,10-dione; C.I. Natural Yellow 23; NSC 37132; 1,8-Dihydroxy-3-methyl-9,10-anthracenedione; NSC 646567; 4,5-Dihydroxy-2-methylanthraquinone; Crysophanic acid; Crysophanol; 2-Methyl-4,5-dihydroxyanthraquinone; 3-Methyl-1,8-dihydroxyanthraquinone; C.I. 75400; 1,8-Dihydroxy-3-Methyl-Anthraquinone; CCRIS 3525; CHEBI:3687; Chrysophansaeure; UNII-N1ST8V8RR2; EINECS 207-572-2; N1ST8V8RR2; NSC-37132; NSC-646567; Anthraquinone, 1,8-dihydroxy-3-methyl-; DTXSID6024832; 1,8-dihydroxy-3-methyl-9,10-anthraquinone; 9,10-Anthracenedione, 1,8-dihydroxy-3-methyl-; Chrysophanic acid (1,8-dihydroxy-3-methylanthraquinone); DTXCID704832; 1,8-Dihydroxy-3-methylanthra-9,10-quinone; HSDB 8483; NSC646567; Archinin; Rumicin; MFCD00001208; TURKEY-RHUBARB; RHENIC ACID; Spectrum_000792; Chrysophanic Acid,(S); SpecPlus_000321; Spectrum2_000043; Spectrum3_001183; Spectrum4_001477; Spectrum5_000153; 1,8-dihydroxy-3-methyl-anthracene-9,10-dione; BSPBio_002825; KBioGR_002053; KBioSS_001272; SPECTRUM300545; MLS000574888; CHEMBL41092; DivK1c_006417; SCHEMBL308131; SPBio_000165; CHRYSOPHANIC ACID [MI]; 9, 1,8-dihydroxy-3-methyl-; Chrysophanic acid (Chrysophanol); Chrysophanic acid - Chrysophanol; Chrysophanol, analytical standard; KBio1_001361; KBio2_001272; KBio2_003840; KBio2_006408; KBio3_002325; HMS3656G17; CHRYSOPHANIC ACID [WHO-DD]; BCP23439; EX-A6777; NSC37132; Tox21_202499; Anthraquinone,8-dihydroxy-3-methyl-; BDBM50455992; CCG-38348; LMPK13040006; s2406; STL564344; 3-Methyl-1, 8-dihydroxyanthraquinone; 4, 5-Dihydroxy-2-methylanthraquinone; AKOS015905000; AC-7980; BCP9000004; DS-9706; SDCCGMLS-0066504.P001; NCGC00091823-01; NCGC00091823-02; NCGC00091823-03; NCGC00091823-04; NCGC00091823-05; NCGC00260048-01; CAS-481-74-3; HY-13595; SMR000156239; 1,8-Dihydroxy-3-methylanthraquinone, 98%; 8,9-dihydroxy-6-methyl-1,10-anthraquinone; C2505; FT-0623813; SW219732-1; 1,8-Dihydroxy-3-methylanthra-9,10-quinone #; EN300-7401332; A827496; N-(diaminomethylene)formamide;3-METHYLCHRYSAZIN; SR-01000712223; 1,8-Dihydroxy-3-methyl-9,10-anthracenedione, 9CI; Q-100527; SR-01000712223-2; BRD-K59284035-001-02-0; BRD-K59284035-001-03-8; Q15410875; 9,10-Anthracenedione, 1,8-dihydroxy-3-methyl- (9CI); 1,8-DIHYDROXY-3-METHYL-9,10-DIHYDROANTHRACENE-9,10-DIONE	.	.	254.24	C15H10O4	74.6	405	3.5	19	2	4	0	InChI=1S/C15H10O4/c1-7-5-9-13(11(17)6-7)15(19)12-8(14(9)18)3-2-4-10(12)16/h2-6,16-17H,1H3	CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O	CC1=CC2=C(C(=C1)O)C(=O)C3=C(C2=O)C=CC=C3O	LQGUBLBATBMXHT-UHFFFAOYSA-N	1,8-dihydroxy-3-methylanthracene-9,10-dione
ferrodrug0043	Etoposide	.	etoposide; 33419-42-0; VePesid; Toposar; trans-Etoposide; Lastet; (-)-Etoposide; Zuyeyidal; Etoposidum; VP-16; Etoposido; Etoposidum [INN-Latin]; VP-16-213; Etoposide (VP16); VP 16-213; Vepesid J; Sintopozid; 4-Demethylepipodophyllotoxin beta-D-ethylideneglucoside; NSC-141540; DTXSID5023035; Etoposide (VP-16); VP 16 (pharmaceutical); 4'-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); VP 16; 6PLQ3CP4P3; Epipodophyllotoxin VP-16213; CHEMBL44657; CHEBI:4911; NK 171; Demethylepipodophyllotoxin-beta-D-ethylideneglucoside; NSC 141540; 4'-Demethylepipodophyllotoxin 9-(4,6-O-ethylidene-beta-D-glucopyranoside); Etosid; Etoposido [INN-Spanish]; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; Etopophos (phosphate salt); DTXCID601473876; Etopol; VP 16213; NSC141540; (10R,11R,15R,16S)-16-{[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-hexahydro-2H-pyrano[3,2-d][1,3]dioxin-6-yl]oxy}-10-(4-hydroxy-3,5-dimethoxyphenyl)-4,6,13-trioxatetracyclo[7.7.0.0^{3,7}.0^{11,15}]hexadeca-1(9),2,7-trien-12-one; (5R,5aR,8aR,9S)-9-(((4aR,6R,7R,8R,8aS)-7,8-Dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3',4'':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; SMR000112002; CCRIS 2392; Demethyl-epiodophyllotoxin ethylidene glucoside; HSDB 6517; VePESID (TN); EINECS 251-509-1; UNII-6PLQ3CP4P3; 4'-Demethylepipodophyllotoxin ethylidene-.beta.-D-glucoside; Etoposide,(S); NCGC00016821-01; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; EVP; Furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one, 9-[[4,6-O-(1R)-ethylidene-.beta.-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; 4'-O-Demethyl-1-O-(4,6-O-ethylidene-beta-D-glucopyranosyl)epipodophyllotoxin; Epipodophyllotoxin, 4'-demethyl-, 9-(4,6-O-ethylidene-beta-D-glucopyranoside); CAS-33419-42-0; Etoposide [USAN:USP:INN:BAN:JAN]; Etoposide; VP-16; CPD000112002; Epipodophyllotoxin-beta-D-ethyliden-glucoside, 4'-demethyl-; ETOPOSIDE [INN]; ETOPOSIDE [JAN]; ETOPOSIDE [MI]; ETOPOSIDE [HSDB]; ETOPOSIDE [IARC]; ETOPOSIDE [USAN]; Prestwick3_000396; ETOPOSIDE [VANDF]; ETOPOSIDE [MART.]; Epipodophyllotoxin, 4'-demethyl-, 4,6-O-ethylidene-beta-D-glucopyranoside; ETOPOSIDE [USP-RS]; ETOPOSIDE [WHO-DD]; ETOPOSIDE [WHO-IP]; SCHEMBL4259; BSPBio_000611; 9-((4,6-O-Ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4- hydroxy-3,4-dimethyloxyphenyl)furo (3',4'':6,7) naptho-(2,3-d)-1,3-dioxol-6 (5aH)-one; MLS000049957; MLS001074951; MLS001424283; MLS002153463; MLS002207239; MLS002222184; Etoposide (JP17/USP/INN); BPBio1_000673; GTPL6815; ETOPOSIDE [EP IMPURITY]; ETOPOSIDE [ORANGE BOOK]; ETOPOSIDE [EP MONOGRAPH]; ETOPOSIDE [USP IMPURITY]; ETOPOSIDE [USP MONOGRAPH]; ETOPOSIDUM [WHO-IP LATIN]; VJJPUSNTGOMMGY-MRVIYFEKSA-N; etoposide4-o-b-d-galactopyranoside; HMS2052N05; HMS2089F14; HMS2096O13; HMS2232L03; HMS3713O13; EX-A1207; Tox21_110630; Tox21_302201; BDBM50127140; s1225; Etoposide - CAS 33419-42-0; AKOS007930275; BCP9000669; CCG-101165; CS-1774; DB00773; Etoposide, synthetic, >=98%, powder; NC00415; SDCCGSBI-0050405.P002; 4'-Demethyl-epipodophyllotoxin 9-[4,6-O-(R)-ethylidene-beta-D-glucopyranoside; NCGC00179504-02; NCGC00255126-01; AS-35312; BE164434; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one, 9-((4,6-O-(1R)-ethylidene-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)-, (5R,5aR,8aR,9S)-; Furo(3',4':6,7)naphtho(2,3-d)-1,3-dioxol-6(5aH)-one-, 9-((4,6-O-ethylidene-beta-D-glucopyranosyl)oxy)5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl), (5R-(5alpha,5abeta,8aalpha,9beta(R*)))-; HY-13629; SBI-0051910.P002; AB00438905; EN300-97099; C01576; D00125; AB00438905-17; AB00438905-18; AB00438905_19; Q418817; SR-01000763196; SR-01000763196-3; BRD-K37798499-001-02-5; BRD-K37798499-001-05-8; BRD-K37798499-001-10-8; BRD-K37798499-001-14-0; BRD-K37798499-001-27-2; -5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; Etoposide, British Pharmacopoeia (BP) Reference Standard; Z1304065033; Etoposide, European Pharmacopoeia (EP) Reference Standard; Etoposide, United States Pharmacopeia (USP) Reference Standard; 4''-Demethylepipodophyllotoxin 9-(4,6-O-(R)-ethylidene-beta-D-glucopyranoside); 4'-DEMETHYLEPIPODOPHYLLOTOXIN 9-(4,6-O-(R)-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSIDE); Etoposide for system suitability, European Pharmacopoeia (EP) Reference Standard; (5R,5AR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahy; (5R,5aR,8aR,9S)-9-(((2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methylhexahydropyrano[3,2-d][1,3]dioxin-6-yl)oxy)-5-(4-hydroxy-3,5-dimethoxyphenyl)-5,5a,8a,9-tetrahydrofuro[3',4':6,7]naphtho[2,3-d][1,3]dioxol-6(8H)-one; (5R,5AR,8AR,9S)-9-((4,6-O-((1R)-ETHANE-1,1-DIYL)-.ALPHA.-D-GLUCOPYRANOSYL)OXY)-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL)-5,8,8A,9-TETRAHYDRO(2)BENZOFURO(5,6-F)(1,3)BENZODIOXOL-6(5AH)-ONE; (5R,5aR,8aR,9S)-9-[[4,6-O-(1R)-Ethylidene-beta-D-glucopyranosyl]oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6(5aH)-one; (5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxy-phenyl)-5a,6,8a,9-tetrahydro-5H-isobenzofuro[5,6-f][1,3]benzodioxol-8-one; (5S,5aR,8aR,9R)-9-(4-hydroxy-3,5-dimethoxyphenyl)-8-oxo-5,5a,6,8,8a,9-hexahydrofuro[3'',4'':6,7]naphtho[2,3-d][1,3]dioxol-5-yl 4,6-O-[(1R)-ethylidene]-beta-D-glucopyranoside; [5R-[5?,5a?,8a?,9?(R*)]]-9-[(4,6-?-Ethylidene-?-D-glucopyranosyl)oxy]-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,5-dimethoxyphenyl)furo[3',4':6,7]naphtho[2,3-d]-1,3-dioxol-6-(5aH)-one; 121471-01-0; 9-((4,6-O-Ethylidine-beta-D-glucopyranosyl)oxy)-5,8,8a,9-tetrahydro-5-(4-hydroxy-3,4-dimethyloxyphenyl)furo(3'',4'''':6,7)naptho-(2,3-d)-1,3-dioxol-6(5aH)-one; FURO(3',4':6,7)NAPHTHO(2,3-D)-1,3-DIOXOL-6(5AH)-ONE-, 9-((4,6-O-ETHYLIDENE-.BETA.-D-GLUCOPYRANOSYL)OXY)5,8,8A,9-TETRAHYDRO-5-(4-HYDROXY-3,5-DIMETHOXYPHENYL), (5R-(5.ALPHA.,5A.BETA.,8A.ALPHA.,9.BETA.(R*)))-	.	.	588.6	C29H32O13	161	969	0.6	42	3	13	5	InChI=1S/C29H32O13/c1-11-36-9-20-27(40-11)24(31)25(32)29(41-20)42-26-14-7-17-16(38-10-39-17)6-13(14)21(22-15(26)8-37-28(22)33)12-4-18(34-2)23(30)19(5-12)35-3/h4-7,11,15,20-22,24-27,29-32H,8-10H2,1-3H3/t11-,15+,20-,21-,22+,24-,25-,26-,27-,29+/m1/s1	C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O	CC1OCC2C(O1)C(C(C(O2)OC3C4COC(=O)C4C(C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O	VJJPUSNTGOMMGY-MRVIYFEKSA-N	(5S,5aR,8aR,9R)-5-[[(2R,4aR,6R,7R,8R,8aS)-7,8-dihydroxy-2-methyl-4,4a,6,7,8,8a-hexahydropyrano[3,2-d][1,3]dioxin-6-yl]oxy]-9-(4-hydroxy-3,5-dimethoxyphenyl)-5a,6,8a,9-tetrahydro-5H-[2]benzofuro[6,5-f][1,3]benzodioxol-8-one
ferrodrug0044	Lidocaine	.	lidocaine; 137-58-6; Lignocaine; Xylocaine; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide; Lidoderm; Alphacaine; Duncaine; Esracaine; Xylestesin; Cappicaine; Gravocain; Leostesin; Maricaine; Isicaina; Solcain; Xylocain; L-Caine; Isicaine; Xylocitin; Rucaina; Xilina; Xycaine; Cito optadren; Anestacon; Lida-Mantle; Dentipatch; Xylotox; 2-(Diethylamino)-2',6'-acetoxylidide; Lidocainum; Lignocainum; Cuivasil; Jetocaine; Octocaine; Remicaine; Xilocaina; Xyloneural (free base); Dalcaine; 2-Diethylamino-N-(2,6-dimethylphenyl)acetamide; Lidocaina; ELA-Max; Acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-; ZTlido; Diethylaminoaceto-2,6-xylidide; 2',6'-Acetoxylidide, 2-(diethylamino)-; alpha-Diethylamino-2,6-dimethylacetanilide; Dilocaine; Versatis; Ztilido; CHEBI:6456; alfa-Dietilamino-2,6-dimetilacetanilide; HSDB 3350; EINECS 205-302-8; NSC 40030; NSC-40030; Lidocaton; Xylocard; Zingo; BRN 2215784; ALGRX 3268; ALGRX-3268; DTXSID1045166; Xylocaine Viscous; UNII-98PI200987; Xylocaine (TN); CHEMBL79; LIDOPEN; N-(2,6-dimethylphenyl)-N(2),N(2)-diethylglycinamide; Diethylaminoacet-2,6-xylidide; MLS000069724; EMLA COMPONENT LIDOCAINE; 98PI200987; DTXCID9025166; ORAQIX COMPONENT LIDOCAINE; SYNERA COMPONENT LIDOCAINE; Xllina; FORTACIN COMPONENT LIDOCAINE; LIDOCAINE COMPONENT OF EMLA; 4-12-00-02538 (Beilstein Handbook Reference); NSC40030; LIDOCAINE COMPONENT OF ORAQIX; LIDOCAINE COMPONENT OF SYNERA; 2-diethylamino-2',6'-acetoxylidide; LANABIOTIC COMPONENT LIDOCAINE; LIDOCAIN COMPONENT OF FORTACINE; N-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine (VAN); ROCEPHIN KIT COMPONENT LIDOCAINE; .alpha.-Diethylaminoaceto-2,6-xylidide; LIDOCAINE COMPONENT OF LANABIOTIC; NCGC00015611-10; Xilocaina [Italian]; Lanabiotic; SMR000058189; .alpha.-(Diethylamino)-2,6-acetoxylidide; LIDOCAINE COMPONENT OF ROCEPHIN KIT; DIETHYLAMINO-2,6-DIMETHYLACETANILIDE; Rocephin Kit; .alpha.-Diethylamino-2,6-dimethylacetanilide; .omega.-Diethylamino-2,6-dimethylacetanilide; LIDOCAINE (MART.); LIDOCAINE [MART.]; Lidocainum [INN-Latin]; Lidocaina [INN-Spanish]; N-(2,6-Dimethylphenyl)-N2,N2-diethylglycinamide; 2-(Diethylamino)-N-(2,6-Dimethylphenyl)ethanamide; EMBOLEX; LIDOCAINE (EP MONOGRAPH); LIDOCAINE [EP MONOGRAPH]; LIDOCAINE (USP MONOGRAPH); LIDOCAINE [USP MONOGRAPH]; DermaFlex; Anestacon Jelly; Xylocaine-Mpf; Zilactin-L; 2-(Diethylamino)-N-(2,6-dimethylphenyl)-acetamide; After Burn Gel; Lidoject-1; Lidoject-2; After Burn Spray; Dentipatch (TN); Octocaine-50; 91484-71-8; CAS-137-58-6; LQZ; Octocaine-100; Xylocaine Test Dose; Xylocaine Endotracheal; Norwood Sunburn Spray; Xylocaine 5% Spinal; 2-2EtN-2MePhAcN; Xylocaine Dental Ointment; MFCD00026733; Xylocaine-Mpf with Glucose; alfa-Dietilamino-2,6-dimetilacetanilide [Italian]; Lidocain; Qualigens; Xyline; Lignocaine base; After Burn Double Strength Gel; LidocaineHClH2O; After Burn Double Strength Spray; Lidocaine [USP:INN:BAN:JAN]; Lidocaine, powder; N1-(2,6-dimethylphenyl)-N2,N2-diethylglycinamide; Zingo (Salt/Mix); CDS1_000283; Lidocaine (Alphacaine); Spectrum_001118; Lidothesin (Salt/Mix); Xyloneural (Salt/Mix); LIDOCAINE [INN]; LIDOCAINE [JAN]; Opera_ID_385; LIDOCAINE [MI]; LIDOCAINE [HSDB]; LIDOCAINE [INCI]; Maybridge1_002571; Prestwick0_000050; Prestwick1_000050; Prestwick2_000050; Prestwick3_000050; Spectrum2_001343; Spectrum3_001392; Spectrum4_000070; Spectrum5_001549; LIDOCAINE [VANDF]; Lopac-L-5647; Lidaform HC (Salt/Mix); Epitope ID:116205; Lidamantle HC (Salt/Mix); 2', 2-(diethylamino)-; LIDOCAINE [USP-RS]; LIDOCAINE [WHO-DD]; LIDOCAINE [WHO-IP]; Neosporin Plus (Salt/Mix); Lopac0_000669; SCHEMBL15689; BSPBio_000179; BSPBio_001359; BSPBio_003004; KBioGR_000079; KBioGR_000599; KBioSS_000079; KBioSS_001598; 2-Diethylamino-N-(2,6-dimethyl-phenyl)-acetamide; MLS000758263; MLS001074177; MLS001423964; BIDD:GT0342; DivK1c_000174; DivK1c_001323; Lidocaine, analytical standard; SPBio_001525; SPBio_002100; Lidocaine (JP17/USP/INN); LIDOCAINE [GREEN BOOK]; Lidocaine, 1mg/ml in Methanol; BPBio1_000197; GTPL2623; LIDOCAINE [ORANGE BOOK]; SCHEMBL17967359; HMS548M19; KBio1_000174; KBio2_000079; KBio2_001598; KBio2_002647; KBio2_004166; KBio2_005215; KBio2_006734; KBio3_000157; KBio3_000158; KBio3_002224; C01BB01; C05AD01; D04AB01; N01BB02; R02AD02; S01HA07; S02DA01; Lidocaine 1.0 mg/ml in Methanol; LIDOCAINUM [WHO-IP LATIN]; NINDS_000174; Bio1_000379; Bio1_000868; Bio1_001357; Bio2_000079; Bio2_000559; HMS1791D21; HMS1989D21; HMS2051C21; HMS2089E15; HMS2235O14; HMS3371J04; HMS3393C21; HMS3428O07; HMS3651G09; AMY25560; BCP09081; HY-B0185; Tox21_110183; BDBM50017662; NSC789222; s1357; STK552033; AKOS001026768; Tox21_110183_1; CCG-100824; CS-2070; DB00281; NC00074; NSC-789222; SB19118; SDCCGSBI-0050648.P005; WLN: 2N2 & 1VMR B1 F1; .alpha.-Diethylamino-2,6-acetoxylidide; CAS-73-78-9; IDI1_000174; IDI1_033829; NCGC00015611-01; NCGC00015611-02; NCGC00015611-03; NCGC00015611-04; NCGC00015611-05; NCGC00015611-06; NCGC00015611-07; NCGC00015611-08; NCGC00015611-09; NCGC00015611-11; NCGC00015611-12; NCGC00015611-13; NCGC00015611-14; NCGC00015611-15; NCGC00015611-16; NCGC00015611-18; NCGC00015611-31; NCGC00022176-05; NCGC00022176-06; NCGC00022176-07; NCGC00022176-08; NCGC00022176-09; AC-10282; AS-13718; SY052029; 2-(Diethylamino)-2'',6''-acetoxylidide; SBI-0050648.P004; AB00053581; L0156; SW196598-4; A18187; C07073; D00358; M06299; AB00053581-27; AB00053581-28; AB00053581_29; AB00053581_30; EN300-6472705; A833036; Q216935; W-108233; 2-(Diethylamino)-N-(2,6-dimethylphenyl)acetamide #; BRD-K52662033-001-02-6; BRD-K52662033-003-05-5; BRD-K52662033-003-14-7; Z55135799; Lidocaine, British Pharmacopoeia (BP) Reference Standard; Lidocaine, European Pharmacopoeia (EP) Reference Standard; N~1~-(2,6-dimethylphenyl)-N~2~,N~2~-diethylglycinamide; Lidocaine, United States Pharmacopeia (USP) Reference Standard; 2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide hydrate hydrochloride; Lidocaine, Pharmaceutical Secondary Standard; Certified Reference Material	.	.	234.34	C14H22N2O	32.299	228	2.3	17	1	2	5	InChI=1S/C14H22N2O/c1-5-16(6-2)10-13(17)15-14-11(3)8-7-9-12(14)4/h7-9H,5-6,10H2,1-4H3,(H,15,17)	CCN(CC)CC(=O)NC1=C(C=CC=C1C)C	CCN(CC)CC(=O)NC1=C(C=CC=C1C)C	NNJVILVZKWQKPM-UHFFFAOYSA-N	2-(diethylamino)-N-(2,6-dimethylphenyl)acetamide
ferrodrug0045	Atorvastatin	.	atorvastatin; 134523-00-5; Cardyl; Tozalip; Xavator; Lipitor; ATORVASTATIN CALCIUM; Torvast; Sotis; 110862-48-1; atorvastatina; atorvastatine; Atofast; Atorcor; Atorlip; Lipilou; Lipinon; Atorin; Ator; atorvastatinum; CCRIS 7159; (3R,5R)-7-(2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; HSDB 7039; rel-Atorvastatin; UNII-A0JWA85V8F; A0JWA85V8F; Liprimar; Tulip; Atorvastatin (INN); DTXSID8029868; CHEBI:39548; CI-981; Lipitor (TN); (R-(R*,R*))-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic acid; CHEMBL1487; DTXCID509868; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrole-1-heptanoic acid; Xarator; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (R-(R*,R*))-; ATORVASTATIN [INN]; 134523-03-8; Atorvastatin [INN:BAN]; 1H-Pyrrole-1-heptanoic acid, 2-(4-fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-, (betaR,deltaR)-; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]- 3,5-DIHYDROXY-HEPTANOIC ACID; Atorvastatin calcium salt; atrovastin; Lipotropic; Atorpic; Faboxim; Torvacard; Vastina; Xanator; Zurinel; Atogal; Lowden; Sincol; Lipovastatinklonal; Lipitor(TM); (3R,5R)-7-[2-(4-fluorophenyl)-5-(1-methylethyl)-3-phenyl-4-(phenylcarbamoyl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-2-isopropyl-4-phenyl-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 7-[2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; Sortis (TN); C33H35FN2O5; NCGC00159458-03; (3R,5R)-7-(3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl)-3,5-dihydroxyheptanoic acid; (3R,5R)-7-[3-(anilinocarbonyl)-5-(4-fluorophenyl)-4-phenyl-2-(propan-2-yl)-1H-pyrrol-1-yl]-3,5-dihydroxyheptanoic acid; 7-(2-(4-FLUORO-PHENYL)-5-ISOPROPYL-3-PHENYL-4-PHENYLCARBAMOYL-PYRROL-1-YL)-3,5-DIHYDROXY-HEPTANOIC ACID; Atorvastatin & Primycin; ATORVASTATIN [MI]; ATORVASTATIN [HSDB]; SCHEMBL3831; ATORVASTATIN [VANDF]; ATORVASTATIN [WHO-DD]; BIDD:GT0336; Atorvastatin (Relative Stereo); GTPL2949; BDBM22164; C10AA05; DTXSID60274003; XUKUURHRXDUEBC-KAYWLYCHSA-N; HMS3715L05; HMS3886C20; Lipilou; Tozalip; Torvast; Cardyl; (3S,5S)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; HY-B0589; Tox21_302417; MFCD00899261; s5715; AKOS000281127; AC-9386; CCG-221172; DB01076; MRF-0000761; NCGC00159458-02; NCGC00159458-20; NCGC00255181-01; AS-35260; CAS-134523-00-5; C06834; D07474; A802259; A806791; A806793; EN300-18527331; Q668093; SR-01000872702; SR-01000872702-1; BRD-K69726342-001-02-6; Atorvastatin is known as an HMG-CoA reductase inhibitor.; (.BETA.R,.DELTA.R)-2-(P-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-ISOPROPYL-3-PHENYL-4-(PHENYLCARBAMOYL)PYRROLE-1-HEPTANOIC ACID; (3R,5R)-7-[2-(4-FLUOROPHENYL)-3-PHENYL-4-(PHENYLCARBAMOYL)-5-PROPAN-2-YL-PYRROL-1-YL]-3,5-DIHYDROXY-HEPTANOIC ACID; (3R,5R)-7-[2-(4-fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoyl-pyrrol-1-yl]-3,5-dihydroxy-heptanoic acid; (3R,5R)-7-[2-(4-Fluorophenyl)-5-isopropyl-3-phenyl-4-phenylcarbamoylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid; (betaR,deltaR)-2-(4-Fluorophenyl)-beta,delta-dihydroxy-5-(1-methylethyl)-3-phenyl-4-((phenylamino)carbonyl)-1H-pyrrole-1-heptanoic Acid; (betaR,deltaR)-2-(p-Fluorophenyl)-beta,delta-dihydroxy-5-isopropyl-3-phenyl-4-(phenylcarbamoyl)-pyrrole-1-heptanoic Acid; 1H-PYRROLE-1-HEPTANOIC ACID, 2-(4-FLUOROPHENYL)-.BETA.,.DELTA.-DIHYDROXY-5-(1-METHYLETHYL)-3-PHENYL-4-((PHENYLAMINO)CARBONYL)-, (R-(R*,R*))-; sodium 7-[5-(4-fluorophenyl)-2-isopropyl-4-phenyl-3-(phenylcarbamoyl)-2,3-dihydropyrrol-1-yl]-3,5-dihydroxy-heptanoate	.	.	558.6	C33H35FN2O5	112	822	5	41	4	6	12	InChI=1S/C33H35FN2O5/c1-21(2)31-30(33(41)35-25-11-7-4-8-12-25)29(22-9-5-3-6-10-22)32(23-13-15-24(34)16-14-23)36(31)18-17-26(37)19-27(38)20-28(39)40/h3-16,21,26-27,37-38H,17-20H2,1-2H3,(H,35,41)(H,39,40)/t26-,27-/m1/s1	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4	CC(C)C1=C(C(=C(N1CCC(CC(CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4	XUKUURHRXDUEBC-KAYWLYCHSA-N	(3R,5R)-7-[2-(4-fluorophenyl)-3-phenyl-4-(phenylcarbamoyl)-5-propan-2-ylpyrrol-1-yl]-3,5-dihydroxyheptanoic acid
ferrodrug0046	Dimethyl fumarate	Small molecular drug	Dimethyl fumarate; 624-49-7; Tecfidera; Methyl fumarate; Fumaderm; (E)-Dimethyl fumarate; Fumaric acid, dimethyl ester; Fumaric acid dimethyl ester; BG-12; Dimethyl (E)-but-2-enedioate; Boletic acid dimethyl ester; BG 12 compound; Panaclar; Dimethylfumarate; Dimethyl trans-ethylenedicarboxylate; trans-Butenedioic acid dimethyl ester; Allomaleic acid dimethyl ester; dimethyl (2E)-but-2-enedioate; BG00012; trans-1,2-Ethylenedicarboxylic acid dimethyl ester; 23055-10-9; 2-Butenedioic acid (E)-, dimethyl ester; BG 00012; BG-00012; Dimethyl 2-butenedioate; FAG-201; AZL O 211089; AZL-O-211089; NSC-25942; Dimethylester kyseliny fumarove; NSC-167432; Dimethyl fumar; CHEBI:76004; (E)-but-2-enedioic acid dimethyl ester; FAG 201; BG 12; FP187; Dimethyl fumarate [USAN]; 2-Butenedioic acid (2E)-, dimethyl ester; LAS41008; EINECS 210-849-0; UNII-FO2303MNI2; FP-187; LAS-41008; NSC 25942; TL 353; NSC 167432; AZL-0211089; BRN 0774590; FO2303MNI2; 1,2-bis(methoxycarbonyl)-trans-ethylene; AI3-07872; HSDB 7725; BG 12 [Fumarate]; BG-12 [Fumarate]; Ethylene, 1,2-bis(methoxycarbonyl)-, trans-; Fumaric acid-dimethyl ester; 2-BUTENEDIOIC ACID, DIMETHYL ESTER, (E)-; Dimethyl (2e)-2-butenedioate; 2-butenedioic acid, (2E)-, dimethyl ester; 2-Butenedioic acid, dimethyl ester; dimethyl (~{E})-but-2-enedioate; 4-02-00-02205 (Beilstein Handbook Reference); But-2-enedioic acid, dimethyl ester; BG 12 (Fumarate); BG-12 (Fumarate); AZL 0 211089; Dimethyl fumarate (USAN); 2-Butenedioic acid (2E)-, 1,4-dimethyl ester; WLN: 1OV1U1VO1 -T; Fumaric acid-dimethyl ester 1000 microg/mL in Acetonitrile; BIS-METHYL ESTER; MFCD00064438; Fumarate, Dimethyl; Ethylene,2-bis(methoxycarbonyl)-, trans-; FAG201; Dimethylester kyseliny fumarove [Czech]; 1,4-dimethyl but-2-enedioate; dimethyl-fumarate; FUMARIC ACID DIMETHYL ESTER (1,1,1,8,8,8-D6); Tecfidera (TN); Dimethyl fumarate, 97%; (E/Z)-Dimethyl fumarate; dimethyl trans-butenedioate; Dimethyl (E)-Butenedioate; Dimethyl (E)-butenedionate; SCHEMBL41835; SCHEMBL41836; DIMETHYL FUMARATE [MI]; Dimethyl fumarate (JAN/USAN); GTPL7045; DIMETHYL FUMARATE [JAN]; CHEMBL2107333; DIMETHYL FUMARATE [HSDB]; DTXSID4060787; DIMETHYL FUMARATE [VANDF]; 2-Butenedioic acid, dimethylester; But-2-enedioic aciddimethyl ester; HMS3264D14; Pharmakon1600-01506154; DIMETHYL FUMARATE [WHO-DD]; NSC25942; BDBM50504654; Fumaric acid, dimethyl ester (8CI); NSC167432; NSC760139; s2586; STK039379; Dimethyl ester(E)-2-Butenedioic acid; (E)-CH3OC(O)CH=CHC(O)OCH3; 1,4-dimethyl (2E)-but-2-enedioate; AKOS000121333; CCG-213618; CS-0909; DB08908; Dimethyl ester(2E)-2-Butenedioic acid; DIMETHYL FUMARATE [ORANGE BOOK]; NSC-760139; (E)-2-Butenedioic Acid, Dimethyl Ester; HY-17363; 2(E)-Butenedioic acid 1,4-dimethyl ester; 2-Butenedioic acid, dimethyl ester, (2E)-; CS-0369103; F0069; SW219154-1; EN300-16090; D03846; EN300-305306; H11241; AB00172980_03; AB00172980_04; Dimethyl fumarate, Vetec(TM) reagent grade, 97%; Q418123; SR-01000944222; SR-01000944222-1; trans-1, 2-Ethylenedicarboxylic acid dimethyl ester; BRD-K31111078-001-01-8; Z49500377; F0001-1675; Dimethyl fumarate, certified reference material, TraceCERT(R); 12287-98-8; EOU	D0A7MY	DM2OVDT	144.12	C6H8O4	52.6	141	0.7	10	0	4	4	InChI=1S/C6H8O4/c1-9-5(7)3-4-6(8)10-2/h3-4H,1-2H3/b4-3+	COC(=O)/C=C/C(=O)OC	COC(=O)C=CC(=O)OC	LDCRTTXIJACKKU-ONEGZZNKSA-N	dimethyl (E)-but-2-enedioate
ferrodrug0047	Aspirin	.	aspirin; ACETYLSALICYLIC ACID; 50-78-2; 2-Acetoxybenzoic acid; 2-(Acetyloxy)benzoic acid; O-Acetylsalicylic acid; Acetylsalicylate; o-Acetoxybenzoic acid; Acylpyrin; Easprin; Ecotrin; Salicylic acid acetate; Acenterine; Acetophen; Acetosal; Colfarit; Polopiryna; Acetosalin; Aspirdrops; Enterosarein; Pharmacin; Premaspin; Salcetogen; Aceticyl; Acetonyl; Acetylin; Acidum acetylsalicylicum; Benaspir; Empirin; Endydol; Measurin; Rhodine; Saletin; Temperal; Ecolen; Rheumintabletten; Solprin acid; o-Carboxyphenyl acetate; Enterosarine; Acetisal; Acetylsal; Aspirine; Bialpirina; Bialpirinia; Claradin; Clariprin; Entericin; Enterophen; Globentyl; Micristin; Neuronika; Salacetin; Solpyron; Acesal; Acisal; Asagran; Asteric; Cemirit; Decaten; Duramax; Extren; Globoid; Helicon; Idragin; Levius; Pirseal; Rhonal; Solfrin; Adiro; Aspec; Aspro; Novid; Yasta; Acetosalic acid; Benzoic acid, 2-(acetyloxy)-; 2-acetyloxybenzoic acid; Spira-Dine; Bi-prin; Acimetten; Delgesic; Entrophen; Acetilum acidulatum; Acetilsalicilico; 2-Carboxyphenyl acetate; Dolean pH 8; Triple-sal; ZORprin; Contrheuma retard; XAXA; Acido acetilsalicilico; Acide acetylsalicylique; Endosprin; Persistin; A.S.A. empirin; ASA; 8-hour Bayer; Acetysal; Kapsazal; Asatard; Durlaza; Solprin; Bayer; Ronal; Acetylsalicylsaure; Rheumin tabletten; 2-Acetoxybenzenecarboxylic acid; Acetylsalycilic acid; Triaminicin; Asaphen; Crystar; Tasprin; acetyl salicylate; Aspir-Mox; Nu-seals aspirin; Salicylic acid, acetate; Acido O-acetil-benzoico; aspirin (acetylsalicylic acid); Kyselina acetylsalicylova; Durlaza ER; Acetylsalicylsaeure; Azetylsalizylsaeure; SP 189; St. Joseph Aspirin for Adults; A.S.A.; St. Joseph; Kyselina 2-acetoxybenzoova; AC 5230; Acetylsalicyclic acid; S-211; Acetylsalicylicum acidum; Aspropharm; Cardioaspirin; Acetard; CCRIS 3243; HSDB 652; CHEBI:15365; o-(Acetyloxy)benzoic acid; Acetylsalicylsaure [German]; ECM; EINECS 200-064-1; UNII-R16CO5Y76E; Bay E4465; NSC 27223; NSC-27223; acide 2-(acetyloxy)benzoique; Bayer Extra Strength Aspirin for Migraine Pain; NSC-406186; BRN 0779271; R16CO5Y76E; DTXSID5020108; Acide acetylsalicylique [French]; 2-(acetyloxy)benzoate; AI3-02956; benzoic acid, 2-acetoxy-; BAY1019036; DTXCID50108; Acetylsalicylic acid (who-ip); AXOTAL COMPONENT ASPIRIN; AZDONE COMPONENT ASPIRIN; CODOXY COMPONENT ASPIRIN; AGGRENOX COMPONENT ASPIRIN; Aspirin form II; DUOCOVER COMPONENT ASPIRIN; EXCEDRIN COMPONENT ASPIRIN; FIORINAL COMPONENT ASPIRIN; NORGESIC COMPONENT ASPIRIN; PERCODAN COMPONENT ASPIRIN; Q-GESIC COMPONENT ASPIRIN; ROXIPRIN COMPONENT ASPIRIN; VICOPRIN COMPONENT ASPIRIN; YOSPRALA COMPONENT ASPIRIN; DUOPLAVIN COMPONENT ASPIRIN; EC 200-064-1; EQUAGESIC COMPONENT ASPIRIN; INVAGESIC COMPONENT ASPIRIN; LANORINAL COMPONENT ASPIRIN; MICRAININ COMPONENT ASPIRIN; ROBAXISAL COMPONENT ASPIRIN; component of Midol; ASPIRIN COMPONENT OF AXOTAL; ASPIRIN COMPONENT OF AZDONE; ASPIRIN COMPONENT OF CODOXY; 4-10-00-00138 (Beilstein Handbook Reference); NSC27223; ORPHENGESIC COMPONENT ASPIRIN; ASPIRIN COMPONENT OF AGGRENOX; ASPIRIN COMPONENT OF DUOCOVER; ASPIRIN COMPONENT OF EXCEDRIN; ASPIRIN COMPONENT OF FIORINAL; ASPIRIN COMPONENT OF NORGESIC; ASPIRIN COMPONENT OF PERCODAN; ASPIRIN COMPONENT OF Q-GESIC; ASPIRIN COMPONENT OF ROXIPRIN; ASPIRIN COMPONENT OF VICOPRIN; ASPIRIN COMPONENT OF YOSPRALA; SYNALGOS-DC COMPONENT ASPIRIN; component of Synirin; ASPIRIN COMPONENT OF DUOPLAVIN; ASPIRIN COMPONENT OF EQUAGESIC; ASPIRIN COMPONENT OF INVAGESIC; ASPIRIN COMPONENT OF LANORINAL; ASPIRIN COMPONENT OF MICRAININ; ASPIRIN COMPONENT OF ROBAXISAL; NSC406186; component of Zactirin; MEPRO-ASPIRIN COMPONENT ASPIRIN; PERCODAN-DEMI COMPONENT ASPIRIN; PRAVIGARD PAC COMPONENT ASPIRIN; SOMA COMPOUND COMPONENT ASPIRIN; ASPIRIN COMPONENT OF ORPHENGESIC; component of Coricidin; component of Persistin; component of Robaxisal; o-Acetoxybenzoate; ASPIRIN COMPONENT OF SYNALGOS-DC; DARVON COMPOUND COMPONENT ASPIRIN; INVAGESIC FORTE COMPONENT ASPIRIN; TALWIN COMPOUND COMPONENT ASPIRIN; NCGC00015067-04; ACIDUM ACETYLSALICYLICUM (WHO-IP); ASPIRIN COMPONENT OF MEPRO-ASPIRIN; ASPIRIN COMPONENT OF PERCODAN-DEMI; ASPIRIN COMPONENT OF PRAVIGARD PAC; ASPIRIN COMPONENT OF SOMA COMPOUND; Istopirin; Magnecyl; Medisyl; Polopirin; ORPHENGESIC FORTE COMPONENT ASPIRIN; ASPIRIN COMPONENT OF DARVON COMPOUND; ASPIRIN COMPONENT OF INVAGESIC FORTE; ASPIRIN COMPONENT OF TALWIN COMPOUND; ASPIRIN (MART.); ASPIRIN [MART.]; Bayer Buffered; ASPIRIN COMPONENT OF ORPHENGESIC FORTE; Aspro Clear; component of Ascodeen-30; Bayer Plus; WLN: QVR BOV1; CARISOPRODOL COMPOUND COMPONENT ASPIRIN; AcetylsalicylicAcid; Acetylsalicylsaure (GERMAN); ASPIRIN COMPONENT OF CARISOPRODOL COMPOUND; Aspirina 03; acetyl salicylic acid; CLOPIDOGREL/ACETYLSALICYLIC ACID COMPONENT ASPIRIN; component of Darvon with A.S.A; Bayer Aspirin 8 Hour; Acide acetylsalicylique (FRENCH); Aspalon; ASPIRIN COMPONENT OF CLOPIDOGREL/ACETYLSALICYLIC ACID; Asprin; Bayer Children's Aspirin; Nu-seals; component of St. Joseph Cold Tablets; CAS-50-78-2; Acetoxybenzoic acid; Acetysalicylic acid; AIN; SMR000059138; Ascoden-30; Acid, Acetylsalicylic; Acido acetilsalicilico [Italian]; Kyselina acetylsalicylova [Czech]; Acido O-acetil-benzoico [Italian]; SR-01000075668; Kyselina 2-acetoxybenzoova [Czech]; Aspirin [USP:BAN:JAN]; Bayer Enteric 325 mg Regular Strength; Bayer Enteric 81 mg Adult Low Strength; Cardioaspirina; Acetyonyl; Angettes; Asacard; Ascolong; Aspirina; Bayer Enteric 500 mg Arthritis Strength; Cardiprin; Claragine; Colsprin; Encaprin; Miniasal; Salospir; Acesan; Toldex; Azetylsalizylsaure; ASA Empirin; 1oxr; 2-Acetoxybenzoate; Aspirin,(S); Aspalon (JAN); Durlaza (TN); Easprin (TN); MFCD00002430; acetyl-salicylic acid; VAZALORE; acetyl salicyclic acid; o-(Acetyloxy)benzoate; Percodan (Salt/Mix); Ascriptin (Salt/Mix); Micrainin (Salt/Mix); 2-acetoxy benzoic acid; RHODINE NC RP; Spectrum_001245; 2-Acetylsalicyclic acid; Acide acetyl salicylique; ASPIRIN [VANDF]; ASPIRIN [HSDB]; Salicylic acid, acetyl-; ASPIRIN [JAN]; ASPIRIN [MI]; CHEMBL25; Spectrum2_001899; Spectrum3_001295; Spectrum4_000099; Spectrum5_000740; Aspirin (JP17/USP); Lopac-A-5376; Salycylacetylsalicylic acid; ASPIRIN [USP-RS]; Epitope ID:114151; Percodan Demi (Salt/Mix); Soma Compound (Salt/Mix); Acetylsalicylic acid, 99%; cid_2244; Pravigard PAC (Salt/Mix); SCHEMBL1353; 2-(Acetyloxy)-benzoic acid; Bay-e-4465; Lopac0_000038; KBioGR_000398; KBioGR_002271; KBioSS_001725; KBioSS_002272; MLS001055329; MLS001066332; MLS001336045; MLS001336046; ASPIRIN [ORANGE BOOK]; BIDD:GT0118; DivK1c_000555; SPECTRUM1500130; SPBio_001838; Acetylsalicylic acid, >=99%; GTPL4139; ASPIRIN [USP MONOGRAPH]; O-Acetylsalicylic acid; Aspirin; BDBM22360; HMS501L17; KBio1_000555; KBio2_001725; KBio2_002271; KBio2_004293; KBio2_004839; KBio2_006861; KBio2_007407; KBio3_002149; KBio3_002751; Empirin with Codeine (Salt/Mix); Acetylsalicylic acid, >=99.0%; cMAP_000006; component of Zactirin (Salt/Mix); NINDS_000555; HMS1920E13; HMS2090G03; HMS2091K13; HMS2233L18; HMS3260G17; HMS3372N15; HMS3656N14; HMS3715P19; HMS3866L03; HMS3885G03; Pharmakon1600-01500130; ACETYLSALICYLIC ACID [INCI]; BCP21790; STR01551; ACETYLSALICYLIC ACID; ASPIRIN; Tox21_110076; Tox21_202117; Tox21_300146; Tox21_500038; CCG-39490; NSC755899; s3017; STL137674; ACETYLSALICYLIC ACID [WHO-DD]; AKOS000118884; component of Ascodeen-30 (Salt/Mix); Tox21_110076_1; ACETYLSALICYLIC ACID [EMA EPAR]; ACETYLSALICYLICUM ACIDUM [HPUS]; CS-2001; DB00945; LP00038; NSC-755899; PL-2200; SDCCGSBI-0050027.P005; BAY-1019036; IDI1_000555; ACETYLSALICYLIC ACID [GREEN BOOK]; Acetylsalicylic acid, analytical standard; NCGC00015067-01; NCGC00015067-02; NCGC00015067-03; NCGC00015067-05; NCGC00015067-06; NCGC00015067-07; NCGC00015067-08; NCGC00015067-09; NCGC00015067-10; NCGC00015067-11; NCGC00015067-12; NCGC00015067-13; NCGC00015067-14; NCGC00015067-24; NCGC00015067-26; NCGC00090977-01; NCGC00090977-02; NCGC00090977-03; NCGC00090977-04; NCGC00090977-05; NCGC00090977-06; NCGC00090977-07; NCGC00254034-01; NCGC00259666-01; NCGC00260723-01; Aspirin, meets USP testing specifications; HY-14654; NCI60_002222; ACETYLSALICYLIC ACID [EP MONOGRAPH]; SBI-0050027.P004; UNM-0000306102; component of Darvon with A.S.A (Salt/Mix); EU-0100038; FT-0655181; FT-0661360; SW199665-2; EN300-19606; A 5376; Acetylsalicylic Acid 1.0 mg/ml in Acetonitrile; C01405; D00109; E80792; Q18216; AB00051918-08; AB00051918_09; AB00051918_10; Arthritis Pain Formula Maximum Strength (Salt/Mix); SR-01000075668-1; SR-01000075668-4; SR-01000075668-6; Acetylsalicylic acid, Vetec(TM) reagent grade, >=99%; Aspirin, British Pharmacopoeia (BP) Reference Standard; F2191-0068; Z104474430; Aspirin, United States Pharmacopeia (USP) Reference Standard; D41527A7-A9EB-472D-A7FC-312821130549; Acetylsalicylic acid, European Pharmacopoeia (EP) Reference Standard; Acetylsalicylic acid, BioReagent, plant cell culture tested, >=99.0%; Acetylsalicylic acid for peak identification, European Pharmacopoeia (EP) Reference Standard; InChI=1/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12; 11126-35-5; Aspirin (Acetyl Salicylic Acid), Pharmaceutical Secondary Standard; Certified Reference Material	.	.	180.16	C9H8O4	63.6	212	1.2	13	1	4	3	InChI=1S/C9H8O4/c1-6(10)13-8-5-3-2-4-7(8)9(11)12/h2-5H,1H3,(H,11,12)	CC(=O)OC1=CC=CC=C1C(=O)O	CC(=O)OC1=CC=CC=C1C(=O)O	BSYNRYMUTXBXSQ-UHFFFAOYSA-N	2-acetyloxybenzoic acid
ferrodrug0048	Calcitriol	.	calcitriol; Rocaltrol; Calcijex; 32222-06-3; Topitriol; 1alpha,25-Dihydroxyvitamin D3; Silkis; 1alpha,25-Dihydroxycholecalciferol; Soltriol; Vectical; 1,25-DHCC; 1,25-DIHYDROXYCHOLECALCIFEROL; 1,25-Dihydroxyvitamin D3; 1,25-Dihydroxyvitamin D; Calcitriolum; 1alpha,25(OH)2D3; Ro 21-5535; Dihydroxyvitamin D3; 1-alpha,25-Dihydroxyvitamin D3; DN-101; CHEMBL846; (1S,3R,5Z,7E)-9,10-secocholesta-5,7,10-triene-1,3,25-triol; 1a,25-Dihydroxyvitamin D3; FXC9231JVH; Ro-21-5535; 1,25-dihydroxy vitamin D3; 1a,25-Dihydroxycholecalciferol; CHEBI:17823; 1-alpha-25-dihydroxyvitamin D3; vit D; (1R,3S,Z)-5-((E)-2-((1R,3aS,7aR)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methylhexahydro-1H-inden-4(2H)-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol; Ro-215535; DN 101; (5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol; (1alpha,3beta,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol; (5Z,7E)-(1S,3R)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1a,3b,5Z,7E)-; Ro 215535; 1,25-(OH)2D3; Toptriol; 1000873-74-4; 1alpha,25-Dihydroxyvitamin D; Decostriol; (1S,3R,5Z,7E)-9,10-secocholesta-5,7,10(19)-triene-1,3,25-triol; (5Z,7E)-(1S,3R)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol; Calcitriolum [INN-Latin]; 1alpha,25-dihydroxyvitamin D3 / 1alpha,25-dihydroxycholecalciferol / calcitriol; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol; 1,25-Dihydroxycholecaliferol; SMR000466393; 1,25 (OH)2 D3; CCRIS 5522; dihydroxy-vitamin D3; HSDB 3482; EINECS 250-963-8; UNII-FXC9231JVH; DTXSID5022722; Asentar; Panbonis; 1,25 Dihydroxycholecalciferol; 1,25-(OH)2-D3; 1.alpha.,25-dihydroxycholecalciferol; Calcitriol; (5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1alpha,3beta,25-triol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta.,5Z,7E)-; 1alpha 25-dihydroxycholecalciferol; Rocaltrol (TN); NCGC00161327-04; (1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(1R)-5-hydroxy-1,5-dimethyl-hexyl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylene-cyclohexane-1,3-diol; 5-{2-[1-(5-HYDROXY-1,5-DIMETHYL-HEXYL)-7A-METHYL-OCTAHYDRO-INDEN-4-YLIDENE]-ETHYLIDENE}-4-METHYLENE-CYCLOHEXANE-1,3-DIOL; U 49562; MFCD00867079; Calcitriol [USAN:USP:INN:BAN:JAN]; Cholecalciferol, 1-alpha,25-dihydroxy-; 1db1; starbld0021993; CALCITRIOL [MI]; CALCITRIOL [INN]; CALCITRIOL [JAN]; Spectrum5_002061; CALCITRIOL [HSDB]; CALCITRIOL [USAN]; 9,10-Seco(5Z,7E)-5,7,10(19)-cholestatriene-1alpha,3beta,25-triol; CALCITRIOL [VANDF]; 25-dihydroxycholecalciferol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1alpha,3beta,5Z,7E)-; CALCITRIOL [MART.]; SCHEMBL3245; CALCITRIOL [USP-RS]; CALCITRIOL [WHO-DD]; 1alpha,25(OH)2-D3; BSPBio_001287; Calcitriol (JAN/USP/INN); MLS000759536; MLS001424122; BML2-E03; GTPL2779; (1S,3R,5Z,7E)-9,10-seco-5,7,10(19)-cholestatriene-1,3,25-triol; CALCITRIOL [ORANGE BOOK]; BCBcMAP01_000160; CHEBI:93988; CALCITRIOL [EP MONOGRAPH]; Cas Number 32222-06-3; GMRQFYUYWCNGIN-NKMMMXOESA-N; BCPP000304; CALCITRIOL [USP MONOGRAPH]; HMS1361A09; HMS1791A09; HMS1989A09; HMS2051F06; HMS2089N03; HMS2232D18; HMS3402A09; 1 alpha ,25-Dihydroxyvitamin D3; EX-A4435; 1a,25-(OH)2D3; BDBM50200182; LMST03020258; NSC749776; s1466; 1-alpha,-1,25-Dihydroxyvitamin D3; AKOS015961898; AC-1859; BCP9000474; CCG-101001; CD-2027; CS-0388; DB00136; NC00251; NSC-749776; '1,25 DIHYDROXY VITAMIN D3'; 1,25(OH2)D3; IDI1_033757; 1,25(OH)2D3 & CD4; Calcitrol 100 microg/mL in Acetonitrile; NCGC00161327-01; (1R,3S,Z)-5-(2-((1R,3aS,7aR,E)-1-((R)-6-hydroxy-6-methylheptan-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)-4-methylenecyclohexane-1,3-diol; 1.alpha.,25-Dihydroxyvitamin D(sub 3); CPD000466393; HY-10002; RO215535; C3078; Vitamin D3-1alpha,25-dihydroxy (Calcitriol); 1,25D3; C01673; D00129; AB00639957-06; AB00639957_07; 1,25-DIHYDROXYCHOLECALCIFEROL, (1ALPHA)-; 1alpha,25-Dihydroxyvitamin D3, >=99% (HPLC); EN300-22411582; Q139195; SR-01000759361; SR-01000946978; 1alpha,25-Dihydroxyvitamin D3, >=97.0% (HPLC); SR-01000759361-4; SR-01000946978-1; 1.Alpha.,25-Dihydroxy-26,27-hexadeuterovitamin D3; BRD-K27316855-001-06-7; BRD-K27316855-001-19-0; (3b,5Z,7E)-9,10-Secocholesta-5,7,10(19)-trienetriol; Calcitriol, European Pharmacopoeia (EP) Reference Standard; (1?,3?,5Z,7E)-9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol; (5Z,10-secocholesta-5,7,10(19)-triene-1.alpha.,3.beta.,25-triol; (1S,3R,5Z,7E,14beta,17alpha)-9,10-secocholesta-5,7,10-triene-1,3,25-triol; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)-; 9,10-Secocholesta-5,7,10(19)-triene-1,3,25-triol, (1.alpha.,3.beta,.5Z,7E)- & CD4; (1R,3S)-5-{2-[(1R,3aS,7aR)-1-((R)-5-Hydroxy-1,5-dimethyl-hexyl)-7a-methyl-octahydro-inden-4-ylidene]-ethylidene}-4-methylene-cyclohexane-1,3-diol; (1R,3S,5Z)-5-{2-[(1R,3aS,4E,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-octahydro-1H-inden-4-ylidene]ethylidene}-4-methylidenecyclohexane-1,3-diol; 1,3-Cyclohexanediol, 4-methylene-5-[2-[(1R,3aS,7aR)-octahydro-1-[(1R)-5-hydroxy-1,5-dimethylhexyl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3S)-	.	.	416.6	C27H44O3	60.7	688	5.1	30	3	3	6	InChI=1S/C27H44O3/c1-18(8-6-14-26(3,4)30)23-12-13-24-20(9-7-15-27(23,24)5)10-11-21-16-22(28)17-25(29)19(21)2/h10-11,18,22-25,28-30H,2,6-9,12-17H2,1,3-5H3/b20-10+,21-11-/t18-,22-,23-,24+,25+,27-/m1/s1	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C	CC(CCCC(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3=C)O)O)C	GMRQFYUYWCNGIN-NKMMMXOESA-N	(1R,3S,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(2R)-6-hydroxy-6-methylheptan-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]-4-methylidenecyclohexane-1,3-diol
ferrodrug0049	Metformin	.	metformin; 657-24-9; 1,1-Dimethylbiguanide; N,N-dimethylimidodicarbonimidic diamide; Fluamine; Metiguanide; Dimethylbiguanide; Flumamine; Gliguanid; Haurymelin; Metformine; Melbin; Imidodicarbonimidic diamide, N,N-dimethyl-; N,N-Dimethylbiguanide; Islotin; Dimethyldiguanide; N1,N1-Dimethylbiguanide; DMGG; NNDG; N,N-Dimethyldiguanide; Diabetosan; Metformina; Metforminum; Glumetza; Glifage; Siofor; LA-6023; BIGUANIDE, 1,1-DIMETHYL-; 3-(diaminomethylidene)-1,1-dimethylguanidine; Dimethylbiguanid; 1,1-Dimethyl biguanide; C4H11N5; Metformin extended release; EINECS 211-517-8; CCRIS 9321; CHEBI:6801; DTXSID2023270; UNII-9100L32L2N; 9100L32L2N; CHEMBL1431; DTXCID803270; Imidodicarbonimidic diamide-, N,N-dimethyl-; Metformina [DCIT]; Metformina [Spanish]; Dimethylguanylguanidine; Metformine [INN-French]; Metforminum [INN-Latin]; Metformin [USAN:INN:BAN]; Gen-Metformin; MLS000028493; Nu-Metformin; [14C]metformin; [14C]-metformin; Metformin (USAN/INN); NCGC00016564-01; SMR000058277; CAS-1115-70-4; N,N-dimethylguanylguanidine; Dianben; Obimet; N-dimethylbiguanide; Metforminum (Latin); DMBG; Glucophage (Salt/Mix); METFORMIN [INN]; n',n'-dimethylbiguanide; METFORMIN [MI]; METFORMIN [USAN]; Prestwick0_000004; Prestwick1_000004; Prestwick2_000004; Prestwick3_000004; METFORMIN [VANDF]; N,N-Dimethylguanylguanidin; METFORMIN [WHO-DD]; SCHEMBL8944; BSPBio_000007; BSPBio_002314; KBioGR_002310; KBioSS_002312; cid_14219; LA 6023 (Salt/Mix); BIDD:GT0697; SPBio_001928; N(1),N(1)-dimethylbiguanide; BPBio1_000009; GTPL4503; GTPL4779; SCHEMBL9913821; SCHEMBL10276396; BDBM57047; KBio2_002310; KBio2_004878; KBio2_007446; KBio3_002790; A10BA02; cMAP_000016; HMS2089D19; HY-B0627; Tox21_302370; BBL012337; BDBM50229665; HSCI1_000295; MFCD00242652; NSC813213; s5958; STK011633; STL483693; STL484070; N,N-Dimethyltriimidodicarbonic diamide; AKOS000121065; AKOS005206848; AKOS015966566; CCG-102605; DB00331; N,N-Diethyl-Imidodicarbonimidic diamide; NSC-813213; 3-carbamimidoyl-1,1-dimethyl-guanidine; NCGC00016564-02; NCGC00016564-03; NCGC00016564-05; NCGC00016564-07; NCGC00188959-01; NCGC00255255-01; AC-32484; AS-65365; CAS-657-24-9; SBI-0206876.P001; 1-carbamimidamido-N,N-dimethylmethanimidamide; CS-0009563; FT-0628266; EN300-23696; A19551; C07151; D04966; D72476; EN300-746417; Q19484; (E)-3-[Amino(dimethylamino)methylidene]guanidine; 1-[(E)-amino(dimethylamino)methylidene]guanidine; W-109589; {[amino(dimethylamino)methylidene]amino}methanimidamide; BRD-K79602928-003-04-1; BRD-K79602928-003-08-2; 3-(diaminomethylene)-1,1-dimethyl-guanidine;hydrochloride; [(E)-[AMINO(DIMETHYLAMINO)METHYLIDENE]AMINO]METHANIMIDAMIDE; 3-[bis(azanyl)methylidene]-1,1-dimethyl-guanidine;hydrochloride; MF8	.	.	129.16	C4H11N5	91.5	132	-1.3	9	3	1	2	InChI=1S/C4H11N5/c1-9(2)4(7)8-3(5)6/h1-2H3,(H5,5,6,7,8)	CN(C)C(=N)N=C(N)N	CN(C)C(=N)N=C(N)N	XZWYZXLIPXDOLR-UHFFFAOYSA-N	3-(diaminomethylidene)-1,1-dimethylguanidine
ferrodrug0050	Pyridoxine	Small molecular drug	pyridoxine; 65-23-6; vitamin B6; Pyridoxol; Pyridoxin; Gravidox; 3-hydroxy-4,5-bis(hydroxymethyl)-2-methylpyridine; Adermine; Hydoxin; Pyridoxolum; 3,4-Pyridinedimethanol, 5-hydroxy-6-methyl-; 4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol; 5-Hydroxy-6-methyl-3,4-pyridinedimethanol; Pyridoxinum; Piridossina; Piridoxina; Piridossina [DCIT]; 3-Hydroxy-4,5-dimethylol-alpha-picoline; Pyridoxinum [INN-Latin]; Piridoxina [INN-Spanish]; Hexabione; (5-Hydroxy-6-methylpyridine-3,4-diyl)dimethanol; 12001-77-3; 2-Picoline-4,5-dimethanol, 3-hydroxy-; Pyridoxine [INN:BAN]; 2-Methyl-3-hydroxy-4,5-di(hydroxymethyl)pyridine; Vitamin V6; 2-Methyl-3-hydroxy-4,5-bis(hydroxymethyl)pyridine; 2-Methyl-4,5-bis(hydroxymethyl)-3-hydroxypyridine; CHEBI:16709; Aderoxine; Hexa-Betalin; EINECS 200-603-0; 4,5-bis(hydroxymethyl)-2-methyl-pyridin-3-ol; UNII-KV2JZ1BI6Z; KV2JZ1BI6Z; VitaminB6; Pyridoxin hydrochloride; vitamin B-6; 2-methyl-3-hydroxy-4,5-dihydroxymethylpyridine; Adermin hydrochloride; NSC-759148; DTXSID4023541; Pyridoxine free base; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin [German]; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol; Prestwick0_000623; Prestwick1_000623; Prestwick2_000623; Prestwick3_000623; 2-Methyl-3-hydroxy-4,5-dihydroxymethyl-pyridin; TimTec1_000657; Oprea1_061614; BSPBio_000586; CBDivE_015627; SPBio_002805; DTXCID903541; BPBio1_000646; Pyridoxine hydrogen chloride; Pyridoxine (INN); M.V.I.-12; STK177324; 65-23-6 (FREE BASE); 2-methyl-3-hydroxy-4,5-bis(hydroxy-methyl) pyridine; 3-hydroxy-2-Picoline-4,5-dimethanol; NSC 759148; DB00165; CAS-58-56-0; SMP2_000230; NCGC00016261-01; NCGC00016261-03; PYRIDOXINE [INN]; C00314; Tex Six T.R.; AC-907/25014218; PN; Adermin; Bezatin; Pirivitol; CAS-65-23-6; NSC36225; Pyridoxine (Vit B6); SR-05000001644; NCGC00164317-01; pyridoxina; Hexermine; Nestrex; Pridoxine; vitaminum b6; Rodex TD; Beesix (Salt/Mix); nchembio.93-comp1; Becilan (Salt/Mix); Benadon (Salt/Mix); Hexobion (Salt/Mix); Vitamin B6 (TN); Pyridoxol; Vitamin B6; Pyridoxine, >=98%; Hexabetalin (Salt/Mix); PYRIDOXINE [MI]; Vitamin b6,hydrochloride; LS-134393; PYRIDOXINE [INCI]; PYRIDOXINE [VANDF]; bmse000288; SCHEMBL3506; CHEMBL1364; PYRIDOXINE [WHO-DD]; BIDD:PXR0180; VITAMIN B6 [VANDF]; P5669_SIGMA; PYRIDOXINE [ORANGE BOOK]; A11HA02; NSC36225 (HCL); Pyridoxol, Vitamin B6, Gravidox; AIDS006784; HMS2093L07; KUC106691N; Pharmakon1600-01505453; AIDS-006784; BCP27975; HY-B1328; Tox21_113644; Tox21_300365; BBL005552; BDBM50103505; c1302; MFCD00006335; NSC759148; s3980; ZINC00049154; AKOS005410791; Tox21_113644_1; CCG-213453; CS-W019950; 2-methyl-4,5-dimethylol-pyridin-3-ol; Vitamin B6 100 microg/mL in Methanol; NCGC00016261-02; NCGC00016261-04; NCGC00016261-05; NCGC00016261-08; NCGC00164317-02; NCGC00254340-01; AC-14512; DS-11013; 58-56-0 (HCL); KSC-11-207-23; SBI-0206844.P001; 3-Hydroxy-4,5-dimethylol-.alpha.-picoline; AM20070169; FT-0631288; FT-0674200; EN300-39851; 4,5-bis(hydroxymethyl)-2-methylpyridine-3-ol; D08454; O10129; 4,5-Bis(hydroxymethyl)-2-methyl-3-pyridinol #; A835033; Q423746; Q-201646; SR-05000001644-1; SR-05000001644-3; 2B3E07D2-E4CC-4CC5-B085-6070BA01F9F0; Z382721012; 2-methyl-3-hydroxy-4-hydroxymethyl-5-hydroxymethyl pyridine; InChI=1/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H	D07MUN	DMDBZMV	169.18	C8H11NO3	73.6	142	-0.8	12	3	4	2	InChI=1S/C8H11NO3/c1-5-8(12)7(4-11)6(3-10)2-9-5/h2,10-12H,3-4H2,1H3	CC1=NC=C(C(=C1O)CO)CO	CC1=NC=C(C(=C1O)CO)CO	LXNHXLLTXMVWPM-UHFFFAOYSA-N	4,5-bis(hydroxymethyl)-2-methylpyridin-3-ol
ferrodrug0051	Doxorubicin	.	doxorubicin; Adriamycin; 23214-92-8; Adriablastin; Doxil; Doxorubicine; Doxorubicinum; Adriblastina; 14-Hydroxydaunomycin; Hydroxydaunorubicin; Doxorubicina; 14-Hydroxydaunorubicine; Adriamycin semiquinone; Doxorubicine [INN-French]; Doxorubicinum [INN-Latin]; Doxorubicina [INN-Spanish]; Caelyx; Doxorubicin HCl; CCRIS 739; Adriblastin; HSDB 3070; NCI-C01514; NDC 38242-874; EINECS 245-495-6; FI 106; Resmycin; CHEBI:28748; UNII-80168379AG; NSC-759155; CHEMBL53463; Caelyx (liposomal doxorubicin); (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 80168379AG; DTXSID8021480; (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-(3-amino-2,3,6-tridesoxy-alpha-L-lyxo-hexopyranosid); (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S,10S)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-8-glycoloyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 1,2,3,4,6,11-Hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6,11-dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-L-lyxohexopyranoside; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S-cis)-; DM2; ADM; NSC-123127; DOXORUBICIN (MART.); DOXORUBICIN [MART.]; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (8S,10S)-10-{[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione; (8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; Doxorubicin [USAN:INN:BAN]; ThermoDox; hydroxydaunomycin; MLS000028393; Doxorubicin-hLL1; RDF Rubex; (1S,3S)-3,5,12-trihydroxy-3-(hydroxyacetyl)-10-(methyloxy)-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, (8S,10S)-; Adriblastina (TN); Doxorubicin-P4/D10; Doxorubicin (USAN/INN); VALRUBICIN IMPURITY, DOXORUBICIN (USP IMPURITY); VALRUBICIN IMPURITY, DOXORUBICIN [USP IMPURITY]; Doxorubicin-hLL1 conjugate; doxorrubicina; Doxorubicin-P4/D10 conjugate; ADR; Hydroxyldaunorubicin; Hydroxyl Daunorubicin; NSC123127; DOXORUBICIN [MI]; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; Prestwick0_000438; Prestwick1_000438; Prestwick2_000438; Prestwick3_000438; DOXORUBICIN [INN]; DOXORUBICIN [HSDB]; DOXORUBICIN [USAN]; Probes1_000151; Probes2_000129; DOXORUBICIN [VANDF]; SCHEMBL3243; BSPBio_000456; BSPBio_001031; DOXORUBICIN [WHO-DD]; 10-((3-Amino-2,3,6-trideoxy-D-lyxohexopyranosyl)oxy)-8-glycolcyl-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; SPBio_002395; (8S-cis)-10-; BPBio1_000502; cid_443939; DTXCID301480; GTPL7069; Valrubicin impurity, doxorubicin; BDBM22984; BDBM32022; L01DB01; AOJJSUZBOXZQNB-TZSSRYMLSA-N; HMS2089H06; (8S,10S)-10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-8-GLYCOLOYL-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-1-METHOXY-5,12-NAPHTHACENEDIONE; 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-LYXO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, (8S-CIS)-; GR-319; HY-15142A; LMPK13050001; AKOS015951330; Conjugate of doxorubicin with humanized monoclonal antibody LL1 against CD74; Conjugate of doxorubicin with monoclonal antibody P4/D10 against GP120; DB00997; SMP1_000106; NCGC00024415-35; NCGC00024415-37; NCGC00024415-38; NCGC00024415-40; NCGC00024415-41; NCGC00024415-42; NCGC00024415-61; BP-23114; (8S,10S)-10; (8S,10S)-10-; A14403; C01661; D03899; EN300-120698; Epirubicin hydrochloride impurity, doxorubicin-; H11954; Q18936; A816625; BRD-K92093830-003-04-3; BRD-K92093830-003-25-8; EPIRUBICIN HYDROCHLORIDE IMPURITY C [EP IMPURITY]; DAUNORUBICIN HYDROCHLORIDE IMPURITY D [EP IMPURITY]; EPIRUBICIN HYDROCHLORIDE IMPURITY, DOXORUBICIN- [USP IMPURITY]; (7S,9R)-7-[(2S,4S,5S,6S)-4-Amino-5-hydroxy-6-methyl-oxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-9-glycoloyl-6,9,11-trihydroxy-4-methoxy-8,10-dihydro-7H-tetracene-5,12-quinone;hydrochloride; (7S,9S)-7-[(2R,4S,5S,6S)-4-azanyl-6-methyl-5-oxidanyl-oxan-2-yl]oxy-4-methoxy-6,9,11-tris(oxidanyl)-9-(2-oxidanylethanoyl)-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (7S,9S)-7-[[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyl-2-oxanyl]oxy]-6,9,11-trihydroxy-9-(2-hydroxy-1-oxoethyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride; (8S,10S)-10-(((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione;(7S,9S)-7-[(4S,5S,6S)-4-amino-5-hydroxy-6-methyl-tetrahydropyran-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione; (8S,10S)-10-((2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione; (8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroacetyl)-1-methoxy-5,12-naphthacenedione; (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-.alpha.-L-lyxo-hexopyranosyl]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione; 1,2,3,4,6,11-hexahydro-4beta,5,12-trihydroxy-4-(hydroxyacetyl)-10-methoxy-6, 11-Dioxonaphthacen-1beta-yl-3-amino-2,3,6-trideoxy-alpha-l-lyxohexopyranoside; 1392315-46-6; 5,12-naphthacenedione, 10-((3-Amino-2,3,6-trideoxy-alpha-l-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-1-methoxy-5,12-naphthacenedione; 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, (8S,10S)-	.	.	543.5	C27H29NO11	206	977	1.3	39	6	12	5	InChI=1S/C27H29NO11/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3/t10-,13-,15-,17-,22+,27-/m0/s1	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	CC1C(C(CC(O1)OC2CC(CC3=C2C(=C4C(=C3O)C(=O)C5=C(C4=O)C(=CC=C5)OC)O)(C(=O)CO)O)N)O	AOJJSUZBOXZQNB-TZSSRYMLSA-N	(7S,9S)-7-[(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione
ferrodrug0052	Tetrachlorobenzoquinone	Small molecular drug	Chloranil; 118-75-2; p-Chloranil; Tetrachloro-p-benzoquinone; Tetrachloro-1,4-benzoquinone; 2,3,5,6-tetrachlorocyclohexa-2,5-diene-1,4-dione; Spergon; Tetrachlorobenzoquinone; Vulklor; Coversan; Reranil; Tetrachloroquinone; 2,3,5,6-TETRACHLORO-1,4-BENZOQUINONE; Khloranil; Psorisan; Tetrachloro-p-quinone; Tetrachloroparabenzoquinone; Spergon technical; Spergon I; Chloranile; Quinone tetrachloride; 2,3,5,6-Tetrachloro-p-benzoquinone; Geigy-444E; 2,3,5,6-Tetrachlorobenzo-1,4-quinone; 2,3,5,6-Tetrachloro-2,5-cyclohexadiene-1,4-dione; Dow Seed Disinfectant No. 5; 2,5-Cyclohexadiene-1,4-dione, 2,3,5,6-tetrachloro-; 2,3,5,6-Tetrachloroquinone; ENT 3,797; G-444E; alpha-Chloranil; p-Benzoquinone, 2,3,5,6-tetrachloro-; 2,3,5,6-Tetrachlorobenzoquinone; NSC 8432; .alpha.-Chloranil; G-25804; 1,4-Benzoquinone, 2,3,5,6-tetrachloro-; tetrachlorocyclohexa-2,5-diene-1,4-dione; 01W5X7N5XV; DTXSID2020266; CHEBI:36703; NSC-8432; 2,3,5,6-Tetrachlor-1,4-benzochinon; 2,3,5,6-tetrachloro-[1,4]benzoquinone; DTXCID20266; Caswell No. 171; CAS-118-75-2; CCRIS 7155; HSDB 1533; EINECS 204-274-4; EPA Pesticide Chemical Code 079301; UNII-01W5X7N5XV; para-chloranil; AI3-03797; Tetrachlorquinone; tetrachloro-1; 4-Chloranil; MFCD00001594; P-CHLORONIL; Spectrum_001590; SpecPlus_000850; CHLORANIL [MI]; CHLORANIL [HSDB]; Spectrum2_000024; Spectrum3_001660; Spectrum4_000794; Spectrum5_001386; 2,5,6-Tetrachloroquinone; EC 204-274-4; CHLORANIL [WHO-DD]; SCHEMBL24049; BSPBio_003419; KBioGR_001268; KBioSS_002070; Chloranil, analytical standard; DivK1c_006946; SPECTRUM1504212; SPBio_000087; 2,5,6-Tetrachlorobenzoquinone; CHEMBL192627; BDBM22782; KBio1_001890; KBio2_002070; KBio2_004638; KBio2_007206; KBio3_002639; NSC8432; 2,5,6-Tetrachloro-p-benzoquinone; AMY12556; ENT 3797; WLN: L6V DVJ BG CG EG FG; p-Benzoquinone,3,5,6-tetrachloro-; Tox21_201656; Tox21_303021; CCG-39987; STK396683; Tetrachloro-1,4-benzoquinone, 99%; 2,5,6-Tetrachloro-1,4-benzoquinone; AKOS001569085; Chloranil, purum, >=97.0% (AT); 2,4-dione, 2,3,5,6-tetrachloro-; NCGC00091254-01; NCGC00091254-02; NCGC00091254-03; NCGC00091254-04; NCGC00091254-05; NCGC00256410-01; NCGC00259205-01; AC-11776; AS-14117; BP-30129; 2,3,5,6-Tetrachlorobenzo-1,4-quinone #; C1770; CS-0013526; FT-0609408; T0061; Chloranil, PESTANAL(R), analytical standard; EN300-18125; C18933; D72499; 2,5,6-Tetrachloro-2,5-cyclohexadiene-1,4-dione; A804087; Q629632; Z57188200; InChI=1/C6Cl4O2/c7-1-2(8)6(12)4(10)3(9)5(1)1	D0D0BI	DMCHGF1	245.9	C6Cl4O2	34.1	278	3.4	12	0	2	0	InChI=1S/C6Cl4O2/c7-1-2(8)6(12)4(10)3(9)5(1)11	C1(=C(C(=O)C(=C(C1=O)Cl)Cl)Cl)Cl	C1(=C(C(=O)C(=C(C1=O)Cl)Cl)Cl)Cl	UGNWTBMOAKPKBL-UHFFFAOYSA-N	2,3,5,6-tetrachlorocyclohexa-2,5-diene-1,4-dione
ferrodrug0053	Artemether	.	Artemether; 71963-77-4; beta-Artemether; Dihydroartemisinin methyl ether; Artemetherum; Artenam; Artemisininelactol methyl ether; Methyl-dihydroartemisinine; Artemetero; Artemos; Artesaph; Falcidol; Gvither; Malartem; Paluther; beta-Dihydroartemisinin methyl ether; SM 224; Artemetheri; Dihydroqinghaosu methyl ether; CHEBI:195280; Larither; DTXSID7040651; CPD000469218; (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecane; .beta.-Artemether; SM-224; Artemetero [INN-Spanish]; Artemetherum [INN-Latin]; methoxy(trimethyl)[?]; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-10-methoxy-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin; 10-methoxy-1,5,9-trimethyl-(1R,4S,5R,8S,9R,10S,12R,13R)-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; Dihydroquinghaosu methyl ether; HSDB 7456; C7D6T3H22J; NSC 665970; UNII-C7D6T3H22J; Artimist; Qinghao; SM224; beta artemether; Artemether [USAN:INN:BAN]; CGP 56696; NSC665970; NSC-665970; NSC-759820; NCGC00164591-01; (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane; Dihydroartemisinin impurity g; MLS001424249; Artemether (JAN/USAN/INN); CHEMBL566534; GTPL9955; SCHEMBL1650501; Artemether, >=98% (HPLC); DTXCID30819889; SXYIRMFQILZOAM-HVNFFKDJSA-N; HMS2052L09; HMS2232J21; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-; AMY25769; HY-N0402; Tox21_112217; BDBM50248200; AKOS026750084; CCG-101180; DB06697; NC00430; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin, decahydro-10-methoxy-3,6,9-trimethyl-, (3-alpha,5a-beta,6-beta,8a-beta,9-alpha,12-beta,12aR)-, (+)-; Artemether 100 microg/mL in Acetonitrile; SMR000469218; CAS-71963-77-4; D02483; EN300-122380; AB00698368-05; AB00698368_06; Q416199; 2-Chloro-3,5-dimethyl-4-methoxypyridinehydrochloride; Z1541759910; Artemether, United States Pharmacopeia (USP) Reference Standard; (1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0;{4,13}.0;{8,13}]hexadecane; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepine; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-10-methoxy-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromene; (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-10methoxy-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j]-1,2benzodioxepin; D8Z	.	.	298.37	C16H26O5	46.2	429	3.1	21	0	5	1	InChI=1S/C16H26O5/c1-9-5-6-12-10(2)13(17-4)18-14-16(12)11(9)7-8-15(3,19-14)20-21-16/h9-14H,5-8H2,1-4H3/t9-,10-,11+,12+,13+,14-,15-,16-/m1/s1	C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC)C	CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC)C	SXYIRMFQILZOAM-HVNFFKDJSA-N	(1R,4S,5R,8S,9R,10S,12R,13R)-10-methoxy-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecane
ferrodrug0054	Astaxanthin	.	Astaxanthin; 472-61-7; Ovoester; all-trans-Astaxanthin; AstaREAL; 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione; Astaxanthine; BioAstin; (3S,3'S)-Astaxanthin; trans-Astaxanthin; Astaxanthin, (3S,3'S)-; (3S,3'S)-all-trans-Astaxanthin; 8XPW32PR7I; 3,3'-Dihydroxy-beta-carotene-4,4'-dione; (3S,3'S)-3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione; CHEBI:40968; NSC-635689; (6S,6'S)-3,3'-((1E,3E,5E,7E,9E,11E,13E,15E,17E)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaene-1,18-diyl)bis(6-hydroxy-2,4,4-trimethylcyclohex-2-enone); .beta.,.beta.-Carotene-4,4'-dione, 3,3'-dihydroxy-, (3S,3'S)-; Algae Haematococcus pluvialis; (6S)-6-hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one; Natupink; AstaXin; Carophyll Pink; Lucantin Pink; BioAstin oleoresin; (6S)-6-Hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-hydroxy-2,6,6-trimethyl-3-oxo-1-cyclohexenyl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethyl-1-cyclohex-2-enone; Astaxanthin (6CI); Astaxanthin, all-trans-; UNII-8XPW32PR7I; astaxantin; CCRIS 7118; HSDB 7468; EINECS 207-451-4; NSC 635689; 3S,3'S-Astaxanthin; Astaxanthin, all-trans-, (3S,3'S)-; Astaxanthin, 5% active; ASTAXANTHIN [MI]; b-Carotene-4,4'-dione; ASTAXANTHIN [HSDB]; ASTAXANTHIN [INCI]; ASTAXANTHIN [VANDF]; beta-Carotene-4,4'-dione; ASTAXANTHIN [MART.]; SCHEMBL20047; ASTAXANTHIN [USP-RS]; ASTAXANTHIN [WHO-DD]; E161j; CHEMBL1255871; Astaxanthin, >=98% (HPLC); E 161j; DTXSID00893777; all-trans-(3S,3'S)-astaxanthin; 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione, (3S,3'S)-; HMS3885C08; BCP05821; HY-B2163; LMPR01070263; MFCD00672621; s3834; AKOS015841055; AKOS015895756; AC-8760; BCP9000329; CCG-270185; DB06543; all-trans-Astaxanthin, analytical standard; AS-14095; CS-0020413; C08580; M01303; 3,3'-dihydroxy-4,4'-diketo-beta,beta-carotene; A827177; Q413740; Q-200655; 3,3'-DIHYDROXY-4,4'-DIKETO-.BETA.-CAROTENE; all-trans-3,3'-dihydroxy-b-Carotene-4,4'-dione (8CI); .beta.-Carotene-4,4'-dione, 3,3'-dihydroxy-, all-trans-; 3-(4,6-Dimethyl-2-oxo-2H-pyrimidin-1-yl)-propionicacid; all-trans-3,3'-dihydroxy-beta-Carotene-4,4'-dione (8CI); 3,3'-Dihydroxy-.beta.,.beta.-carotene-4,4'-dione, (3S,3'S)-; (3S,3'S)-3,3'-DIHYDROXY-.BETA.,.BETA.-CAROTENE-4,4'-DIONE; 3,3'-Dihydroxy-beta,beta-carotene-4,4'-dione;(S)-6-hydroxy-3-((1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-((S)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohex-1-enyl)-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl)-2,4,4-trimethylcyclohex-2-enone;	.	.	596.8	C40H52O4	74.6	1340	10.3	44	2	4	10	InChI=1S/C40H52O4/c1-27(17-13-19-29(3)21-23-33-31(5)37(43)35(41)25-39(33,7)8)15-11-12-16-28(2)18-14-20-30(4)22-24-34-32(6)38(44)36(42)26-40(34,9)10/h11-24,35-36,41-42H,25-26H2,1-10H3/b12-11+,17-13+,18-14+,23-21+,24-22+,27-15+,28-16+,29-19+,30-20+/t35-,36-/m0/s1	CC1=C(C(C[C@@H](C1=O)O)(C)C)/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C2=C(C(=O)[C@H](CC2(C)C)O)C)\C)\C)/C)/C	CC1=C(C(CC(C1=O)O)(C)C)C=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC2=C(C(=O)C(CC2(C)C)O)C)C)C	MQZIGYBFDRPAKN-UWFIBFSHSA-N	(6S)-6-hydroxy-3-[(1E,3E,5E,7E,9E,11E,13E,15E,17E)-18-[(4S)-4-hydroxy-2,6,6-trimethyl-3-oxocyclohexen-1-yl]-3,7,12,16-tetramethyloctadeca-1,3,5,7,9,11,13,15,17-nonaenyl]-2,4,4-trimethylcyclohex-2-en-1-one
ferrodrug0055	Zalcitabine	.	zalcitabine; Dideoxycytidine; 7481-89-2; 2',3'-DIDEOXYCYTIDINE; ddCyd; HIVID; Cytidine, 2',3'-dideoxy-; ddC; 4-Amino-1-((2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl)pyrimidin-2(1H)-one; Zalcitibine; NSC 606170; Ro 24-2027/000; Ro-24-2027/000; NSC-606170; CHEMBL853; 6L3XT8CB3I; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2(1H)-one; DTXSID0023747; CHEBI:10101; 1-(2,3-Dideoxy-beta-D-ribofuranosyl)cytosine; NCGC00090705-08; Ro-242027000; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one; Ro-24-2027000; 4-AMINO-1-[(2R,5S)-5-(HYDROXYMETHYL)OXOLAN-2-YL]-1,2-DIHYDROPYRIMIDIN-2-ONE; 2,3-dideoxycytidine; DTXCID703747; NSC606170; 4-amino-1-[(2R,5S)-5-(hydroxymethyl)tetrahydrofuran-2-yl]pyrimidin-2-one; SMR000058253; CCRIS 692; Hivid(TM); Hivid (TN); HSDB 7156; Interferon AD + ddC; ddC & GM-CSF; ddC & sCD4; PC-SOD & ddC; DDC (DDC); UNII-6L3XT8CB3I; BRN 0654956; Zalcitabine (JAN/USP/INN); DS-4152 & ddC; ddC & NP (from PHCA or HSA); SRI-7707; Zalcitabine [USAN:USP:INN:BAN]; 2',3'-Dideoxycytidine;ddC;Dideoxycytidine; CAS-7481-89-2; Zalcitabine- Bio-X; MFCD00012188; KS-1130; ddC & IFN.alpha.; .beta.-D-DDC; dideoxycytidine (DDC); ZALCITABINE [MI]; Prestwick0_001037; Prestwick1_001037; Prestwick2_001037; Prestwick3_001037; ddC & Interferon.alpha.; ZALCITABINE [INN]; ZALCITABINE [JAN]; 2', 3'-dideoxycytidine; ZALCITABINE [HSDB]; ZALCITABINE [IARC]; ZALCITABINE [USAN]; bmse000712; UPCMLD-DP115; D 5782; ZALCITABINE [VANDF]; SCHEMBL3598; TimTec1_004969; ZALCITABINE [MART.]; Lopac0_000360; BSPBio_001253; ZALCITABINE [USP-RS]; ZALCITABINE [WHO-DD]; 3'-Azido-3'-deoxythymidine/2',3'-Dideoxycytidine; 5-25-14-00313 (Beilstein Handbook Reference); MLS000069636; MLS000759540; MLS001055363; MLS001424210; MLS006011951; SPBio_003104; BPBio1_001378; GTPL4828; UPCMLD-DP115:001; 2',3'-Dideoxycytidine & sCD4(soluble recombinant protein); Zalcitabine (dideoxycytidine,ddc); ZALCITABINE [ORANGE BOOK]; HMS1548B19; HMS1571O15; HMS2051H18; HMS2090C12; HMS2098O15; HMS2236N08; HMS3261G21; HMS3715O15; Pharmakon1600-01502360; ZALCITABINE [USP IMPURITY]; .beta.-D-2',3'-Dideoxycytidine; Zalcitabine, 2'3'-Dideoxycytidine; BCP13878; Tox21_113491; Tox21_201655; Tox21_303169; Tox21_500360; AC-824; BDBM50145605; Lecithinized superoxide dismutase & .beta.-D-2',3'-Dideoxycytidine; NSC759655; s1719; AKOS015854844; AKOS015894505; Tox21_113491_1; CCG-101050; CS-1110; DB00943; LP00360; NC00300; NSC-759655; SDCCGSBI-0050348.P002; SRI-7707-13; SRI-7707-14; SRI-7707_15; SRI-7707_17; NCGC00090705-01; NCGC00090705-02; NCGC00090705-03; NCGC00090705-05; NCGC00090705-06; NCGC00090705-07; NCGC00090705-09; NCGC00090705-10; NCGC00090705-11; NCGC00090705-13; NCGC00090705-15; NCGC00090705-24; NCGC00090705-25; NCGC00179242-01; NCGC00257202-01; NCGC00259204-01; NCGC00261045-01; BD164564; BP-58631; HY-17392; ddC;Dideoxycytidine;2',3'-Dideoxycytidine; 2',3'-Dideoxycytidine & Interferon.alpha.; 2',3'-Dideoxycytidine, >=98% (HPLC); D3581; EU-0100360; SW197364-4; 2',3'-Dideoxycytidine, >=99.0% (HPLC); C07207; C76390; D00412; EN300-120633; Cytidine, 2',3'-dideoxy- & Interferon.alpha.; A838234; SR-01000075822; SR-01000736919; ZALCITABINE (DIDEOXYCYTIDINE,DDC) [VANDF]; J-700276; Q-201941; Q2344582; SR-01000075822-1; SR-01000736919-5; Cytidine, 2',3'-dideoxy- & Colony-stimulating factor; Ro-242027000/Ro-24-2027-000; Z1550648753; Zalcitabine, United States Pharmacopeia (USP) Reference Standard; 4-Amino-1-(5-hydroxymethyl-tetrahydro-furan-2-yl)-1H-pyrimidin-2-one; .beta.-D-2',3'-Dideoxycytidine & Granulocyte-macrophage colony-stimulating factor	.	.	211.22	C9H13N3O3	88.2	327	-1.3	15	2	3	2	InChI=1S/C9H13N3O3/c10-7-3-4-12(9(14)11-7)8-2-1-6(5-13)15-8/h3-4,6,8,13H,1-2,5H2,(H2,10,11,14)/t6-,8+/m0/s1	C1C[C@@H](O[C@@H]1CO)N2C=CC(=NC2=O)N	C1CC(OC1CO)N2C=CC(=NC2=O)N	WREGKURFCTUGRC-POYBYMJQSA-N	4-amino-1-[(2R,5S)-5-(hydroxymethyl)oxolan-2-yl]pyrimidin-2-one
ferrodrug0056	N-acetylcysteine	Small molecular drug	N-Acetyl-L-cysteine; acetylcysteine; 616-91-1; N-Acetylcysteine; mercapturic acid; Acetadote; Broncholysin; Mucomyst; L-Acetylcysteine; Fluimucetin; Fluimucil; Parvolex; N-Acetyl-cysteine; Fluprowit; Respaire; Acetein; Airbron; Fabrol; Mucosil; Flumucetin; Mucosolvin; Brunac; L-Cysteine, N-acetyl-; Fluimicil Infantil; N-Acetyl cysteine; Acetilcisteina; Acetylcysteinum; Syntemucol; Lysomucil; Mucofilin; acetyl cysteine; Exomuc; Inspir; Tixair; Mucolyticum Lappe; Mucolytikum Lappe; N-Acetyl-3-mercaptoalanine; (R)-2-Acetamido-3-mercaptopropanoic acid; Mucolyticum; Cetylev; Neo-fluimucil; Ac-Cys-OH; Cysteine, N-acetyl-, L-; Mucolyticum-Lappe; N-Acetyl-L-(+)-cysteine; NAC-TB; Acetyl-L-cysteine; component of Naxid; Mercapturic acid, (R)-; Fluatox; Fluimicil; Mucolator; Flumil; Mucret; (R)-mercapturic acid; Muco sanigen; Oristar nalc; (2R)-2-acetamido-3-sulfanylpropanoic acid; MUCOSIL-10; MUCOSIL-20; N-acetyi-l-cysteine; cysteine, N-acetyl-; L-alpha-Acetamido-beta-mercaptopropionic acid; CCRIS 3764; Mucocedyl; N-acetyl-(R)-cysteine; NSC 111180; UNII-WYQ7N0BPYC; WYQ7N0BPYC; HSDB 3003; EINECS 210-498-3; (2R)-2-Acetamido-3-sulfanyl-propanoic acid; Ilube (eye drops); N-A-C Sustain; NSC-111180; (r)-n-acetylcysteine; DTXSID5020021; CHEBI:28939; N-Acetyl-L-cysteine hydrochloride; RK-0202; DTXCID4021; MLS000028419; (R)-2-acetylamino-3-mercaptopropanoic acid; (2R)-2-acetylamino-3-sulfanylpropanoic acid; NSC111180; NCGC00022304-05; LNAC; SMR000058377; MFCD00004880; ACETYLCYSTEINE (II); ACETYLCYSTEINE [II]; ACETYLCYSTEINE (MART.); ACETYLCYSTEINE [MART.]; Ilube; N-acetylcystein; ACETYLCYSTEINE (EP MONOGRAPH); ACETYLCYSTEINE [EP MONOGRAPH]; N Acetylcysteine; ACETYLCYSTEINE (USP MONOGRAPH); ACETYLCYSTEINE [USP MONOGRAPH]; Acid, Mercapturic; Acetylcysteinum [INN-Latin]; CAS-616-91-1; Acetilcisteina [INN-Spanish]; N Acetyl L cysteine; N-Acetyl-N-Cysteine; SR-01000075439; DTXSID8048105; AcCys; N-acetyl-l-cys; Sodium 2-acetamido-3-mercaptopropionate; SC2; N-acetyl-L-cystein; Naxid (Salt/Mix); N-Acety-L-Cysteine; Acetyl Cysteine,(S); Acetylcysteine [USAN:USP:INN:BAN:JAN]; Opera_ID_452; MUCOMYST (TN); Acetylcysteine Ph. Eur.; Spectrum2_000086; Spectrum3_000287; Spectrum4_000137; Spectrum5_000764; CHEMBL600; NAC & TNF; ACETYLCYSTEINE [MI]; SCHEMBL5292; ACETYLCYSTEINE [INN]; ACETYLCYSTEINE [JAN]; Lopac0_000081; ACETYLCYSTEINE [HSDB]; ACETYLCYSTEINE [USAN]; BSPBio_001794; KBioGR_000554; MLS001076125; MLS006011563; ACETYLCYSTEINE [VANDF]; SPECTRUM1500105; SPBio_000012; ACETYL CYSTEINE [INCI]; ACETYLCYSTEINE [USP-RS]; ACETYLCYSTEINE [WHO-DD]; Acetylcysteine(N-acetylcysteine); BRONCHOLYSIN (MUCOLYTIC); DTXCID6028076; CHEBI:22198; GTPL10945; KBio3_001294; N-Acetyl-L-cysteine, USP grade; R05CB01; S01XA08; V03AB23; Acetylcysteine (JP17/USP/INN); HMS1920A11; HMS2091G11; HMS2234J22; HMS3260A04; HMS3655G11; HMS3715D03; HMS3884E04; HY-B0215; 2-Acetylamino-3-mercapto-propionate; ACETYLCYSTEINE [ORANGE BOOK]; Tox21_110877; Tox21_201078; Tox21_500081; acetylcysteine (n-acetyl-l-cysteine); BDBM50420190; CCG-38902; s1623; AKOS015841009; Tox21_110877_1; CCG-204176; DB06151; GS-3121; LP00081; SDCCGSBI-0050069.P002; (R)-2-Acetamido-3-mercaptopropanoicacid; NCGC00015086-04; NCGC00022304-03; NCGC00022304-04; NCGC00022304-06; NCGC00022304-07; NCGC00022304-08; NCGC00022304-17; NCGC00022304-23; NCGC00258631-01; NCGC00260766-01; AC-16071; AC-24117; BP-12854; SBI-0051272.P003; A0905; AM20100502; EU-0100081; SW199597-2; (2R)-2-acetylamino-3-mercapto-propionic acid; EN300-72028; A 7250; A-1100; C06809; D00221; L-Cysteine, N-acetyl- & Tumor necrosis factor; N-Acetyl-L-cysteine, BioXtra, >=99% (TLC); AB00051908_02; AB00382974-12; AB00382974_13; L-.alpha.-Acetamido-.beta.-mercaptopropionic acid; Q375613; J-507685; N-Acetyl-L-cysteine & Tumor necrosis factor (TNF); N-Acetyl-L-cysteine 100 microg/mL in Acetonitrile; SR-01000075439-1; SR-01000075439-3; SR-01000075439-5; BRD-K59058747-001-20-9; N-Acetyl-L-cysteine, cell culture tested, BioReagent; N-Acetyl-L-cysteine, Vetec(TM) reagent grade, 98%; F1905-7178; Z1143441555; CABC898A-E48B-4E13-9F72-98D0609A1854; N-Acetyl-L-cysteine, SAJ special grade, 98.0-102.0%; N-Acetyl-L-cysteine, Sigma Grade, >=99% (TLC), powder; Acetylcysteine, British Pharmacopoeia (BP) Reference Standard; Acetylcysteine, European Pharmacopoeia (EP) Reference Standard; Acetylcysteine, United States Pharmacopeia (USP) Reference Standard; N-Acetyl-L-cysteine, Pharmaceutical Secondary Standard; Certified Reference Material	.	DG00869	163.2	C5H9NO3S	67.4	148	0.4	10	3	4	3	InChI=1S/C5H9NO3S/c1-3(7)6-4(2-10)5(8)9/h4,10H,2H2,1H3,(H,6,7)(H,8,9)/t4-/m0/s1	CC(=O)N[C@@H](CS)C(=O)O	CC(=O)NC(CS)C(=O)O	PWKSKIMOESPYIA-BYPYZUCNSA-N	(2R)-2-acetamido-3-sulfanylpropanoic acid
ferrodrug0057	Thioguanine	.	thioguanine; 6-Thioguanine; 154-42-7; Tioguanine; 2-Amino-6-mercaptopurine; 6-Mercaptoguanine; Tabloid; 2-Amino-6-purinethiol; Tioguanin; Lanvis; 2-Amino 6MP; 2-Aminopurin-6-thiol; 2-Aminopurine-6-thiol; 2-Aminopurine-6(1H)-thione; 2-Amino-9H-purine-6-thiol; Wellcome U3B; 6-Mercapto-2-aminopurine; 6-TG; 2-Amino-6-merkaptopurin; Tioguaninum; Guanine, thio-; 2-amino-1H-purine-6(7H)-thione; Tioguanina; 6H-Purine-6-thione, 2-amino-1,7-dihydro-; 2-Amino-1,7-dihydro-6H-purine-6-thione; 2-amino-3,7-dihydropurine-6-thione; Thioguanine Anhydrous; NSC-752; BW 5071; Purine-6-thiol, 2-amino-; Purine-6(1H)-thione, 2-amino-; 2-Amino-1,9-Dihydro-6h-Purine-6-Thione; TG; C5H5N5S; Thioguanine, anhydrous; THG; NSC 752; 2-Amino-1,7-dihydro-6H-purin-6-thion; X 27; 2-amino-6,7-dihydro-3H-purine-6-thione; 6-TG/Thioguanine; Tioguanine (INN); Tioguanine [INN]; 2-amino-3,7-dihydro-6H-purine-6-thione; 2-amino-1,9-dihydropurine-6-thione; CHEMBL727; WIX31ZPX66; CHEBI:9555; NSC752; DTXSID6023652; Thioguanine2-Amino-6-purinethiol; 2-Thioguanine; 2-amino-1H-purine-6(9H)-thione; NSC-76504; NCGC00094792-01; 2-Amino-6-MP; Tioguanine hemihydrate; Tioguaninum [INN-Latin]; DTXCID803652; 2-Aminopurin-6-thiol [Czech]; Guanine, thio- (VAN); 2-Amino-6-merkaptopurin [Czech]; 6-Tioguanine; Tioguanina [INN-Spanish]; CAS-154-42-7; DX4; SMR000857244; Lanvis (TN); CCRIS 8997; HSDB 2504; SR-05000002077; EINECS 205-827-2; Thioguanine [USAN:USP]; 2-Amino-1,7-dihydro-6H-purin-6-thion [Czech]; UNII-WIX31ZPX66; Thioquanine; AI3-26078; 6-thioguano-sine; MFCD00233553; 1330266-29-9; Spectrum_000235; THIOGUANINE [MI]; Spectrum2_000695; Spectrum3_000577; Spectrum4_000926; Spectrum5_001455; purine antimetabolite: antimetabolite: inhibits nucleic acid replication; THIOGUANINE [HSDB]; 2-Amino-6-mercapto-purin; 6-Thioguanine, >=98%; SCHEMBL3701; SCHEMBL5898; NCIOpen2_004153; TIOGUANINE [WHO-DD]; BSPBio_001994; KBioGR_001452; KBioGR_002476; KBioSS_000715; KBioSS_002483; MLS001333131; MLS001333132; MLS006010896; DivK1c_000428; SPECTRUM1500573; SPBio_000849; 154-42-7; 6-Thioguanine; 2-amino-6-mercapto-9H-purine; GTPL6845; Thioguanine (TN) (GlaxoSmith); HMS501F10; KBio1_000428; KBio2_000715; KBio2_002476; KBio2_003283; KBio2_005044; KBio2_005851; KBio2_007612; KBio3_001494; KBio3_002954; cMAP_000061; NINDS_000428; BCPE000001; HMS1921E09; HMS2092M11; HMS2235F05; HMS3865G13; Pharmakon1600-01500573; BCP27718; Tox21_111035; Tox21_113184; Tox21_202401; Tox21_300275; BDBM50200099; CCG-39890; HB1379; NSC757348; s1774; AKOS003389499; AKOS015901298; Tox21_111035_1; 2-Amino-1,7-dihydro-purine-6-thione; 2-Amino-1,9-dihydro-purine-6-thione; AC-8421; BCP9000197; CCG-213953; CCG-266338; CS-1497; DB00352; NSC-757348; PS-5007; WLN: T56 BNM FYM INJ FUS HZ; IDI1_000428; SMP2_000326; NCGC00094792-02; NCGC00094792-03; NCGC00094792-05; NCGC00094792-06; NCGC00094792-17; NCGC00188976-01; NCGC00188976-02; NCGC00254082-01; NCGC00259950-01; NCGC00263442-01; NCGC00263442-02; NCGC00263442-05; 157646-93-0; AC-23020; BT166463; HY-13765; NCI60_041643; SMR004701808; SBI-0051533.P003; FT-0611217; T0212; 2-Amino-1,7-dihydro-6H-purine-6-thione #; C07648; D08603; EN300-119530; T71841; AB00174074_06; AB00918694_06; AB01273926-01; AB01273926-02; AB01273926_03; A809532; Q385347; SR-05000002077-1; SR-05000002077-5; W-108030; W-205813; Z2299468139; 6-Thioguanine;6-TG;2-Amino-6-mercaptopurine;2-Amino-6-purinethiol; Thioguanine, United States Pharmacopeia (USP) Reference Standard; Thioguanine;6-TG; 2-Amino-6-mercaptopurine; 2-Amino-6-purinethiol; 6-Thioguanine, Hybri-Max(TM), 50 x, gamma-irradiated, lyophilized powder, BioXtra, suitable for hybridoma; 611-67-6	.	.	167.19	C5H5N5S	111	225	-0.1	11	3	2	0	InChI=1S/C5H5N5S/c6-5-9-3-2(4(11)10-5)7-1-8-3/h1H,(H4,6,7,8,9,10,11)	C1=NC2=C(N1)C(=S)N=C(N2)N	C1=NC2=C(N1)C(=S)N=C(N2)N	WYWHKKSPHMUBEB-UHFFFAOYSA-N	2-amino-3,7-dihydropurine-6-thione
ferrodrug0058	Stigmasterol	.	STIGMASTEROL; 83-48-7; Stigmasterin; beta-Stigmasterol; Stigmasta-5,22-dien-3beta-ol; Stigmasta-5,22-dien-3-ol, (3b,22E)-; (24S)-5,22-Stigmastadien-3beta-ol; Stigmasta-5,22-dien-3-beta-ol; UNII-99WUK5D0Y8; Stigmasta-5,22-dien-3-ol, (3beta,22E)-; Delta5-Stigmasterol; .beta.-Stigmasterol; STIMASTEROL; 99WUK5D0Y8; CCRIS 7476; CHEBI:28824; HSDB 7683; (3beta,22E)-Stigmasta-5,22-dien-3-ol; NSC 8095; NSC-8095; EINECS 201-482-7; Wulzen anti-stiffness factor; Stigmasta-5,22-dien-3-ol, (3beta)-; Stigmasta-5,22E-dien-3beta-ol; DTXSID801015733; Delta5,22-Stigmastadien-3beta-ol; 5,22-Cholestadien-24-ethyl-3beta-ol; GUINEA-PIG-ANTI-STIFFNESS FACTOR; (22E)-stigmasta-5,22-dien-3beta-ol; .delta.5,22-Stigmastadien-3.beta.-ol; (3.beta.,22E)-Stigmasta-5,22-dien-3-ol; Stigmasta-5,22-dien-3-ol; MFCD00003630; (3S,8S,9S,10R,13R,14S,17R)-17-[(E,1R,4S)-4-ethyl-1,5-dimethyl-hex-2-enyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 3beta-Hydroxy-24-ethyl-5,22-cholestadiene; Serposterol; b-stigmasterol; Stigmasta-5,22-dien-3.beta.-ol; D5-Stigmasterol; Stigmasterol, ~95%; STIGMASTEROL [MI]; STIGMASTEROL [HSDB]; SCHEMBL23999; .DELTA.5-STIGMASTEROL; STIGMASTEROL [WHO-DD]; stigmasta-5,22t-dien-3b-ol; CHEMBL400247; stigmasta-5,22-dien-3-b-ol; HCXVJBMSMIARIN-PHZDYDNGSA-N; DTXCID601473919; GLXC-13540; HY-N0131; (24S)-5,22-stigmastadien-3b-ol; BDBM50376364; HB4095; LMST01040123; s2361; STL570256; 24aFH-stigmasta-5,22t-dien-3b-ol; AKOS022168193; CS-7746; (24S)-Stigmast-5,22-dien-3beta-ol; (24xH)-stigmasta-5,22t-dien-3b-ol; 24-Ethyl-5,22-cholestadien-3beta-ol; (24aFH)-stigmasta-5,22t-dien-3b-ol; (24x)-ethylcholesta-5,22-dien-3b-ol; NCGC00142599-03; (3b,22E)-stigmasta-5,22-dien-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-((2R,5S,E)-5-ethyl-6-methylhept-3-en-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; 14-((2E)(4S,1R)-4-ethyl-1,5-dimethylhex-2-enyl)(1S,5S,10S,11S,2R,14R,15R)-2,15 -dimethyltetracyclo[8.7.0.0<2,7>.0<11,15>]heptadec-7-en-5-ol; 24x-24-ethylcholest-5,22-dien-3b-ol; AS-15473; 24-Ethyl-5,22-cholestadien-3.beta.-ol; 5,22-Cholestadien-24beta-ethyl-3beta-ol; rac-(24xH)-stigmasta-5,22t-dien-3b-ol; STIGMASTEROL (CONSTITUENT OF PYGEUM); (24S)-24-Ethylcholesta-5,22-dien-3beta-ol; C05442; Q425004; STIGMASTEROL (CONSTITUENT OF PYGEUM) [DSC]; STIGMASTEROL (CONSTITUENT OF SAW PALMETTO); Q-201746; STIGMASTEROL (CONSTITUENT OF SAW PALMETTO) [DSC]; 3beta-HYDROXY-24-ETHYL-delta(SUP 5,22)-CHOLESTADIENE; 3.BETA.-HYDROXY-24-ETHYL-.DELTA.(SUP 5,22)-CHOLESTADIENE; Stigmasterol, certified reference material, 10 mg/mL in chloroform; 17-(4-ethyl-1,5-dimethyl-hex-2-enyl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol	.	.	412.7	C29H48O	20.2	674	8.6	30	1	1	5	InChI=1S/C29H48O/c1-7-21(19(2)3)9-8-20(4)25-12-13-26-24-11-10-22-18-23(30)14-16-28(22,5)27(24)15-17-29(25,26)6/h8-10,19-21,23-27,30H,7,11-18H2,1-6H3/b9-8+/t20-,21-,23+,24+,25-,26+,27+,28+,29-/m1/s1	CC[C@H](/C=C/[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)C(C)C	CCC(C=CC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)C(C)C	HCXVJBMSMIARIN-PHZDYDNGSA-N	(3S,8S,9S,10R,13R,14S,17R)-17-[(E,2R,5S)-5-ethyl-6-methylhept-3-en-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
ferrodrug0059	Itraconazole	.	itraconazole; Sporanox; 84625-61-6; Oriconazole; Itraconazol; Sporonox; Itrizole (TN); Itraconazolum; Sporal; Itrizole; Sporanox (TN); ITCZ; Orungal; Itraconazol [Spanish]; Fungitraxx; Itraconazolo; 873066-43-4; Candistat; Canditral; Hyphanox; Itralek; Sempera; Sporamelt; Traconal; Triasporin; Itrac; Cladosal 100; C35H38Cl2N8O4; Spherazole CR; Spherazole IR; DTXSID3023180; Itraconazole (Sporanox); R-51211; NSC-759239; Itraconazolum [Latin]; cis-Itraconazole; 304NUG5GF4; CHEBI:6076; DTXCID903180; 2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one; ITZ; R51211; SUBA Itraconazole; ITRACONAZOLE (EMA EPAR: VETERINARY); SUBA-ITRACONAZOLE COMPONENT ITRACONAZOLE; UNII-304NUG5GF4; ITRACONAZOLE COMPONENT OF SUBA-ITRACONAZOLE; ITRACONAZOLE (MART.); ITRACONAZOLE [MART.]; 3H-1,2,4-Triazol-3-one, 4-(4-(4-(4-((2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl)methoxy)phenyl)-1-piperazinyl)phenyl)-2,4-dihydro-2-(1-methylpropyl)-; Onmel; ITRACONAZOLE (USP-RS); ITRACONAZOLE [USP-RS]; HSDB 7839; ITRACONAZOLE (EP IMPURITY); ITRACONAZOLE [EP IMPURITY]; ITRACONAZOLE (EP MONOGRAPH); ITRACONAZOLE [EP MONOGRAPH]; R 51211; EINECS 283-347-2; ITRACONAZOLE (USP MONOGRAPH); ITRACONAZOLE [USP MONOGRAPH]; Itraconazolum (Latin); BRN 6042047; 2-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-2,4-dihydro-3H-1,2,4-triazol-3-one; 4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-2-sec-butyl-1,2,4-triazol-3-one; CAS-84625-61-6; R 51,211; Intraconazole; Lozanoc; Sporanos; Triasporn; NSC 759239; Sporanox(TM); NCGC00018268-03; 4-(4-{4-[4-({[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methyl}oxy)phenyl]piperazin-1-yl}phenyl)-2-(1-methylpropyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; DRG-0044; TOLSURA; Itraconazole & Nyotran; MFCD00941396; ITRACONAZOLE [MI]; ITRACONAZOLE [INN]; ITRACONAZOLE [JAN]; ITRACONAZOLE [INCI]; ITRACONAZOLE [USAN]; Itraconazole (JP17/USP); ITRACONAZOLE [VANDF]; SCHEMBL23934; 84604-65-9; MLS006011958; CHEMBL22587; ITRACONAZOLE [WHO-DD]; AMY922; GTPL11426; ITRACONAZOLE [GREEN BOOK]; J02AC02; ITRACONAZOLE [ORANGE BOOK]; Pharmakon1600-01505756; 4-(4-(4-(4-((2-((1H-1,2,4-Triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; Tox21_110854; AC-542; BDBM50127138; NSC759239; s2476; 3H-1,2,4-Triazol-3-one, 4-; AKOS015842738; AKOS015961385; Tox21_110854_1; CCG-270391; DB01167; KS-1268; NCGC00274068-01; NCGC00274068-02; NCGC00274068-07; 1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 4-(4-(4-(4-(((2R,4S)-2-((1H-1,2,4-triazol-1-yl)methyl)-2-(2,4-dichlorophenyl)-1,3-dioxolan-4-yl)methoxy)phenyl)piperazin-1-yl)phenyl)-2-(sec-butyl)-2,4-dihydro-3H-1,2,4-triazol-3-one; HY-17514; SMR001827898; Itraconazole & Nyotran(Liposomal Nystatin); SBI-0206914.P001; SW219756-1; Itraconazole 2.0 mg/ml in Dimethyl Sulfoxide; D00350; EN300-122640; AB01274818-01; AB01274818_02; AB01274818_03; A933954; Q411229; BRD-A23067620-001-01-7; Z1544404944; (+/-)-1-SEC-BUTYL-4-(P-(4-(P-(((2R*,4S*)-2-(2,4-DICHLOROPHENYL)-2-(1H-1,2,4-TRIAZOL-1-YLMETHYL)-1,3-DIOXOLAN-4-YL)METHOXY)PHENYL)-1-PIPERAZINYL)PHENYL)-.DELTA.(SUP 2)-1,2,4-TRIAZOLIN-5-ONE; 1-(butan-2-yl)-4-{4-[4-(4-{[(2R,4S)-2-(2,4-dichlorophenyl)-2-[(1H-1,2,4-triazol-1-yl)methyl]-1,3-dioxolan-4-yl]methoxy}phenyl)piperazin-1-yl]phenyl}-4,5-dihydro-1H-1,2,4-triazol-5-one; 3H-1,2,4-Triazol-3-one, 4-[4-[4-[4-[[2-(2,4-dichlorophenyl)-2-(1H-1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]-1-pipera-zinyl]phenyl]-2,4-dihydro-2-(1-methylpropyl)	.	.	705.6	C35H38Cl2N8O4	101	1120	5.7	49	0	9	11	InChI=1S/C35H38Cl2N8O4/c1-3-25(2)45-34(46)44(24-40-45)29-7-5-27(6-8-29)41-14-16-42(17-15-41)28-9-11-30(12-10-28)47-19-31-20-48-35(49-31,21-43-23-38-22-39-43)32-13-4-26(36)18-33(32)37/h4-13,18,22-25,31H,3,14-17,19-21H2,1-2H3/t25?,31-,35-/m0/s1	CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl	CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5COC(O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl	VHVPQPYKVGDNFY-ZPGVKDDISA-N	2-butan-2-yl-4-[4-[4-[4-[[(2R,4S)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one
ferrodrug0060	Dihydroquercetin	Small molecular drug	TAXIFOLIN; (+)-Taxifolin; 480-18-2; dihydroquercetin; Distylin; Taxifoliol; (+)-Dihydroquercetin; (2R,3R)-Dihydroquercetin; 24198-97-8; Lavitol; Diquertin; Lariksin; 2,3-Dihydroquercetin; Flamena D; (+/-)-Taxifolin; TAXIFOLIN-(+); 17654-26-1; (2R,3R)-3,3',4',5,7-Pentahydroxyflavanone; trans-Dihydroquercetin; (2R,3R)-(+)-Taxifolin; 3,5,7,3',4'-Pentahydroxyflavanone; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxychroman-4-one; taxifolin (dihydroquercetin); (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one; UNII-9SOB9E3987; FLAMENA; CCRIS 9292; (2R,3R)-2-(3,4-DIHYDROXYPHENYL)-3,5,7-TRIHYDROXY-2,3-DIHYDRO-4H-CHROMEN-4-ONE; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R,3R)-; CHEBI:17948; Flavanone, 3,3',4',5,7-pentahydroxy-; (+)-(2R,3R)-dihydroquercetin; (+/-)-dihydroquercetin; 9SOB9E3987; (2R-trans)-2-(3,4-Dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-4-benzopyrone; Taxifolin, (+/-)-; EINECS 207-543-4; EAS93SC1VS; BRN 0093548; Dihydroquercetin, (+/-)-; DTXSID8022450; 5-18-05-00451 (Beilstein Handbook Reference); 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-; Flavone, 2,3-dihydro-3,3',4',5,7-pentahydroxy-; DIHYDROQUERCETIN, (+)-(2R,3R)-; trans dihydroquercetin; (2R,3R)-2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, (2R-trans)-; (?)-Taxifolin; (2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-chroman-4-one; rel-(2R,3R)-2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxychroman-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-, trans-(+/-)-; DQH; SMR000466389; (+)-trans-Taxifolin; a cis or trans dihydroquercetin; (+/-)-Taxifolin hydrate; (+)-Dihydroquercetin; (+)-Taxifolin; Taxifolin (Tax); ()-Taxifolin; MFCD00006845; (+)-trans Taxifolin; UNII-EAS93SC1VS; SCHEMBL39786; MLS000759539; MLS001066341; MLS001074712; MLS001424044; MLS002153142; BIDD:ER0483; Taxifolin, analytical standard; DIHYDROQUERCETIN [INCI]; DTXCID502450; MEGxp0_000741; ACon1_000239; DIHYDROQUERCETIN [WHO-DD]; rel-(2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-chromen-4-one; BDBM212435; DTXSID301017215; HMS2051M22; HMS2234L14; HY-N0136; AC-935; s2366; AKOS015965399; CCG-100909; CS-3365; DB02224; KS-1312; NC00159; NCGC00016024-08; NCGC00180750-01; 20254-28-8; AS-17723; '(2R,3R)-TRANS-DIHYDROQUERCETIN'; SW197539-2; T3666; C01617; (2R,3R)-3,5,7,3',4'-Pentahydroxyflavanone; Q412191; SR-01000759385; (+)-TAXIFOLIN (CONSTITUENT OF MILK THISTLE); Flavanone, 3,3',4',5,7-pentahydroxy-, (R,R)-; J-011205; SR-01000759385-6; Taxifolin, primary pharmaceutical reference standard; (+)-TAXIFOLIN (CONSTITUENT OF MARITIME PINE); F40AB773-26FA-4112-A46D-DC970AF64BC1; Flavanone, 3,3',4',5,7-pentahydroxy-, (2R)-trans-; Flavanone, 3,3',4',5,7-pentahydroxy-, trans-(+)-; (+)-TAXIFOLIN (CONSTITUENT OF MARITIME PINE) [DSC]; (+)-TAXIFOLIN (CONSTITUENT OF MILK THISTLE) [DSC]; Flavanone, 3,3',4',5,7-pentahydroxy-, (2R,3R)-(+)-; 2-(3,4-Dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydro-4H-chromen-4-one, (2R-trans)-; 4H-1-Benzopyran-4-one,2-(3,4-dihydroxyphenyl)-2,3-dihydro-3,5,7-trihydroxy-,(2R,3R)-rel-	.	DMQJSF9	304.25	C15H12O7	127	428	1.5	22	5	7	1	InChI=1S/C15H12O7/c16-7-4-10(19)12-11(5-7)22-15(14(21)13(12)20)6-1-2-8(17)9(18)3-6/h1-5,14-19,21H/t14-,15+/m0/s1	C1=CC(=C(C=C1[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O	C1=CC(=C(C=C1C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O)O	CXQWRCVTCMQVQX-LSDHHAIUSA-N	(2R,3R)-2-(3,4-dihydroxyphenyl)-3,5,7-trihydroxy-2,3-dihydrochromen-4-one
ferrodrug0061	Hesperidin	Small molecular drug	hesperidin; Cirantin; 520-26-3; Hesperidoside; Hesper bitabs; Hesperetin 7-rhamnoglucoside; Hesperetin 7-rutinoside; Hesperetin-rutinosid; Hesperidine; Ciratin; (S)-(-)-Hesperidin; Hesperetin 7-O-rutinoside; NSC 44184; CCRIS 3940; EINECS 208-288-1; (2S)-Hesperidin; UNII-E750O06Y6O; BRN 0075140; DIOSVEIN; Hesperetin-7-O-rhamnoglucoside; Hesperidin, (2S)-; DTXSID9044328; Hesperetin-7-rutinoside; CHEBI:28775; E750O06Y6O; USAF CF-3; Hesperitin-7-rhamnoglucoside; Hesperidin, (S)-(-)-; 3',5'-Dihydroxy-4'-methoxy-7-rutinosyloxyflavan-4-on; MLS001304066; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one; DTXCID7024328; EC 208-288-1; 5-18-05-00218 (Beilstein Handbook Reference); Hesperidin (JAN); Hesperetin, 7-(6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside); C28H34O15; NSC-44184; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-oxo-3,4-dihydro-2H-chromen-7-yl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-({[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-3,4-dihydro-2H-1-benzopyran-4-one; (S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)chroman-4-one; 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydo-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-; 5-Hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((6-O-alpha-L-rhamnopyranosyl-beta-D-glucopyranosyl)oxy)-4-chromanon; 7-((6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one, (S)-; 7-(6-O-Desoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyloxy)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4-chromanon; SMR000718775; HESPERIDIN [JAN]; MFCD00075663; HESPERIDIN (MART.); HESPERIDIN [MART.]; HESPERIDIN (USP-RS); HESPERIDIN [USP-RS]; (s)-7-[[6-o-(6-deoxy-alpha-l-mannopyranosyl)-beta-d-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4h-1-benzopyran-4-one; Aurantiamarin (Methyl Hesperidin); 3',5'-DIHYDROXY-4'-METHOXY-7-RUTINOSYLOXYFLAVAN-4-ONE; hesperetin 7-(6-O-alpha-L-rhamnopyranosyl)-beta-D-glucopyranoside; NSC44184; Hesperidin 2S; 2S, Hesperidin; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxy-phenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-2-yl]oxy-chroman-4-one; Hesperitin-7-rutinoside; Hesperetin 7 Rutinoside; SR-01000799145; Hesperetin 7 Rhamnoglucoside; Hesperidina; 7-Rhamnoglucoside, Hesperetin; Hesperidin,(S); NCGC00016481-01; (2S)-7-[[6-O-(6-Deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl]oxy]-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-2,3-dihydro-4H-1-benzopyran-4-one (Hesperidin); (S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-2H-pyran-2-yloxy)chroman-4-one; CAS-520-26-3; Hesperetin Glycoside; Hesperidin, >=80%; HESPERIDIN [MI]; DIOSMIN [NDI]; Prestwick3_000400; HESPERIDIN [INCI]; HESPERIDIN [VANDF]; Glucopyranoside, hesperetin-7 6-O-(6-deoxy-alpha-L-mannopyranosyl)-, beta-D-; HESPERIDIN [WHO-DD]; SCHEMBL94586; BSPBio_000619; 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (S)-; cid_10621; Hesperidin, analytical standard; BPBio1_000681; CHEMBL449317; NDI 590 [FDMS]; BCBcMAP01_000136; BDBM61776; NDI 590; 2H-pyran-2-yloxy)chroman-4-one; QUQPHWDTPGMPEX-QJBIFVCTSA-N; HMS2096O21; HMS2233I03; HMS3713O21; Tox21_110448; s2309; AKOS015895450; CCG-208580; CS-5631; DB04703; KS-5308; SMP1_000149; NCGC00179501-01; 4H-1-Benzopyran-4-one, 7-((6-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranosyl)oxy)-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-, (2S)-; HY-15337; AB00513829; H0049; C09755; D01038; (S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-; EN300-7419024; Q385937; Hesperidin, primary pharmaceutical reference standard; methyltetrahydro-2H-pyran-2-yloxy)methyl)tetrahydro-; SR-01000799145-4; SR-01000799145-5; SR-01000799145-7; 7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-; BRD-K38903228-001-02-8; BRD-K38903228-001-13-5; Hesperidin, European Pharmacopoeia (EP) Reference Standard; Hesperidin, Pharmaceutical Secondary Standard; Certified Reference Material; Flavanone, 3',5,7-trihydroxy-4'-methoxy-, 7-(6-O-alpha-L-rhamnosyl-D-glucoside); (2S)-2-(4-methoxy-3-oxidanyl-phenyl)-7-[(2S,3R,4S,5S,6R)-6-[[(2R,3R,4R,5R,6S)-6-methyl-3,4,5-tris(oxidanyl)oxan-2-yl]oxymethyl]-3,4,5-tris(oxidanyl)oxan-2-yl]oxy-5-oxidanyl-2,3-dihydrochromen-4-one; (2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-2-oxanyl]oxymethyl]-2-oxanyl]oxy]-3,4-dihydro-2H-1-benzopyran-4-one; (2S)-7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDRO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; (2S)-7-((6-O-(6-DEOXY-alpha-L-MANNOPYRANOSYL)-beta-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDRO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-4H-1-BENZOPYRAN-4-ONE; (S)-7-[[6-O-(6-Deoxy-.alpha.-L-mannopyranosyl)-.beta.-D-glucopyranosyl]oxy]-2,3-dihydro-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-BENZOPYRAN-4-ONE, 7-((6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-2,3-DIHYDO-5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-, (S)-; 5-HYDROXY-2-(3-HYDROXY-4-METHOXYPHENYL)-7-((6-O-.ALPHA.-L-RHAMNOPYRANOSYL-.BETA.-D-GLUCOPYRANOSYL)OXY)-4-CHROMANON	D0I9HF	DMI5DW1	610.6	C28H34O15	234	940	-1.1	43	8	15	7	InChI=1S/C28H34O15/c1-10-21(32)23(34)25(36)27(40-10)39-9-19-22(33)24(35)26(37)28(43-19)41-12-6-14(30)20-15(31)8-17(42-18(20)7-12)11-3-4-16(38-2)13(29)5-11/h3-7,10,17,19,21-30,32-37H,8-9H2,1-2H3/t10-,17-,19+,21-,22+,23+,24-,25+,26+,27+,28+/m0/s1	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=CC(=C4C(=O)C[C@H](OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=CC(=C4C(=O)CC(OC4=C3)C5=CC(=C(C=C5)OC)O)O)O)O)O)O)O)O	QUQPHWDTPGMPEX-QJBIFVCTSA-N	(2S)-5-hydroxy-2-(3-hydroxy-4-methoxyphenyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,3-dihydrochromen-4-one
ferrodrug0062	Triiodothyronine	Small molecular drug	liothyronine; triiodothyronine; 3,3',5-Triiodo-L-thyronine; 6893-02-3; Tresitope; Liothyronin; 3,5,3'-triiodothyronine; L-Liothyronine; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine; T3; 3,5,3'-Triiodo-L-thyronine; triothyrone; Liothyroninum; Lyothyronine; Liotironina; L-T3; 3,3',5-Triiodothyronine; 3,5,3'TRIIODOTHYRONINE; Cyronine; L-3,5,3'-Triiodothyronine; L-3,3',5-TriioDOThyronine; (2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid; (S)-2-amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoic acid; Triiodo-L-thyronine; L-Tyrosine, O-(4-hydroxy-3-iodophenyl)-3,5-diiodo-; Liothyronine (GMP); Liothyronine (INN); Rathyronine, (s)-; CHEBI:18258; Thyronine, 3,3',5-triiodo-, L-; CHEMBL1544; 4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenylalanine; 06LU7C9H1V; 4-(4-hydroxy-3-iodophenoxy)-3,5-diiodo-L-phenylalanine; 3,5,3'-triiodothyronine, l-; DTXSID8023216; NSC-80203; L-triiodothyronine; Alanine, 3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)-, L-; LIOTHYRONINE [INN]; O-(4-Hydroxy-3-iodophenyl-3,5-diiodo-L-tyrosine; T3 (amino acid); DTXCID403216; T3 liothyronine; Liothyronine [INN:BAN]; Euthroid-1; Euthroid-2; Euthroid-3; Thyrolar-1; Thyrolar-2; Thyrolar-3; (+)-Triiodothyronine; Liotironina [INN-Spanish]; CAS-6893-02-3; Euthroid-0.5; Thyrolar-0.5; T3 (VAN); Thyrolar-0.25; Triiodothyronine, l-; 3,5,3'-Tri-iodo-L-thyronine; Triiodothyronine (T3); SR-05000000455; 5714-08-9; T-3; 3,3',5-Triiodo-D-thyronine; Liothyroninum [INN-Latin]; NSC-46046; 3,3',5-Triiodothyronine, L-; HSDB 3110; 1xzx; (2S)-2-AMINO-3-(4-(4-HYDROXY-3-IODOPHENOXY)-3,5-DIIODOPHENYL)PROPANOIC ACID; Prestwick_135; EINECS 229-999-3; MFCD00002593; NSC 80203; 4-(3-Iodo-4-hydroxyphenoxy)-3,5-diiodophenylalanine; BRN 2710227; Spectrum_001445; L-3-(4-(4-Hydroxy-3-iodophenoxy)-3,5-diiodophenyl)alanine; Triiodothyronine;3,3',5-Triiodo-L-thyronine;T3; Prestwick0_000853; Prestwick1_000853; Prestwick2_000853; Prestwick3_000853; Spectrum2_001984; Spectrum3_001887; Spectrum4_000326; Spectrum5_001793; LIOTHYRONINE [MI]; Epitope ID:131324; LIOTHYRONINE [HSDB]; SCHEMBL8300; NCIStruc1_000449; LIOTHYRONINE [VANDF]; UNII-06LU7C9H1V; REGID_for_CID_5920; BSPBio_000865; BSPBio_003394; KBioGR_000671; KBioGR_002568; KBioSS_001925; KBioSS_002577; MLS000028458; 3,5,3'-triodo-L-thyronine; LIOTHYRONINE [USP-RS]; LIOTHYRONINE [WHO-DD]; SPBio_002167; SPBio_002786; BPBio1_000953; GTPL2634; HY-A0070AG; L-3,3',5-triiodo-Thyronine; BCBcMAP01_000192; BDBM18860; HY-A0070A; KBio2_001925; KBio2_002568; KBio2_004493; KBio2_005136; KBio2_007061; KBio2_007704; KBio3_002897; KBio3_003046; cMAP_000088; HMS1570L07; HMS2097L07; HMS2235A22; HMS3714L07; LIOTHYRONINE [USP IMPURITY]; TRIIODOTHYRONINE (T3 OR LIOTHYRONINE, ACTIVE) (6-11%); Tox21_110029; Tox21_301943; HB7470; NCGC00013556; s5726; 3,5,3'-triiodo-L-thyronine (T3); (S)-2-Amino-3-(4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl)propanoicacid; AKOS016003266; 3,3',5-Triiodo-L-thyronine, 95%; AM83597; CCG-220853; CS-4141; DB00279; L-3,3',5-Triiodothyronine, free acid; SMP1_000179; NCGC00013556-01; NCGC00013556-02; NCGC00013556-03; NCGC00013556-04; NCGC00013556-05; NCGC00013556-15; NCGC00096669-01; NCGC00096669-02; NCGC00255336-01; [125I]T3; AC-31935; AS-17446; SMR000058402; SBI-0206718.P001; CS-0622788; T0453; C02465; D08128; EN300-123970; A836290; Q327362; SR-01000003143; SR-01000003143-4; SR-05000000455-2; SR-05000000455-3; 3,3 inverted exclamation mark ,5-Triiodo-L-thyronine; BRD-K89152108-001-03-3; LEVOTHYROXINE SODIUM IMPURITY A [EP IMPURITY]; 3,3',5-Triiodo-L-thyronine, >=95% (HPLC), powder; Z1557400301; D-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]alanine; L-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]-Alanine; Liothyronine, United States Pharmacopeia (USP) Reference Standard; 3,3',5 Triiodothyronine (T3), IRMM(R) certified Reference Material; O-(4-Hydroxy-3-iodophenyl)-3,5-diiodo-L-tyrosine,labeled with(125i)iodine; Liothyronine, Pharmaceutical Secondary Standard; Certified Reference Material; 57164-27-9	D0S6JG	DM6IR3P	650.97	C15H12I3NO4	92.8	402	1.7	23	3	5	5	InChI=1S/C15H12I3NO4/c16-9-6-8(1-2-13(9)20)23-14-10(17)3-7(4-11(14)18)5-12(19)15(21)22/h1-4,6,12,20H,5,19H2,(H,21,22)/t12-/m0/s1	C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O	C1=CC(=C(C=C1OC2=C(C=C(C=C2I)CC(C(=O)O)N)I)I)O	AUYYCJSJGJYCDS-LBPRGKRZSA-N	(2S)-2-amino-3-[4-(4-hydroxy-3-iodophenoxy)-3,5-diiodophenyl]propanoic acid
ferrodrug0063	Microcystin-LR	.	Microcystin-LR; 101043-37-2; Microcystin LR; Cyanoginosin LR; Toxin-LR; Cyanoginosin-LR; MCYST-LR; Toxin I (Microcystis aeruginosa); Microcystis aeruginosa toxin; CHEBI:6925; Cyanoginosin LA, 5-L-arginine-; CHEMBL444092; C49H74N10O12; EQ8332842Y; NSC-733608; C05371; (5R,8S,11R,12S,15S,18S,19S,22R)-15-[3-(diaminomethylideneamino)propyl]-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylidene-8-(2-methylpropyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic acid; Akerstox; toxin I, cyanobacterium; Microcystin-a; 1,7-anhydro[D-alanyl-L-leucyl-(3S)-3-methyl-D-beta-aspartyl-L-arginyl-(2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl-D-gamma-glutamyl-2,3-didehydro-N-methylalanine]; cyclo[2,3-didehydro-N-methylalanyl-D-alanyl-L-leucyl-erythro-3-methyl-D-beta-aspartyl-L-arginyl-(2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl-D-gamma-glutamyl]; cyclo[D-alanyl-L-leucyl-(3S)-3-methyl-D-beta-aspartyl-L-arginyl-(2S,3S,4E,6E,8S,9S)-3-amino-4,5,6,7-tetradehydro-9-methoxy-2,6,8-trimethyl-10-phenyldecanoyl-D-gamma-glutamyl-2,3-didehydro-N-methylalanyl]; MCLR; 5-L-Argininecyanoginosin LA; 5-L-Arginine-microcystin LA; cyclo(Ala-Leu-MAsp-Arg-Adda-isoGlu-Mdha); microcystin-la, 5-l-arginine-; UNII-EQ8332842Y; HSDB 7751; toxin t-17 (Microcystis aeruginosa); Toxin T 17 (Microcystis aeruginosa); BRN 4779759; Toxin, blue green alga, Microcystis aeruginosa; Cyanoginosin-LR;MC-LR;Toxin T 17 (Microcystis aeruginosa); MICROCYSTIN-LR [HSDB]; MICROCYSTIN-LR [IARC]; GTPL4735; DTXSID3031654; SCHEMBL21245230; HY-P0072; BDBM50061067; NSC733608; CS-5404; NSC 733608; Q6839436; 1,7-ANHYDRO(D-ALANYL-L-LEUCYL-(3S)-3-METHYL-D-.BETA.-ASPARTYL-L-ARGINYL-(2S,3S,4E,6E,8S,9S)-3-AMINO-4,5,6,7-TETRADEHYDRO-9-METHOXY-2,6,8-TRIMETHYL-10-PHENYLDECANOYL-D-.GAMMA.-GLUTAMYL-2,3-DIDEHYDRO-N-METHYLALANINE); 15-(3-Guanidino-propyl)-8-isobutyl-18-((1E,3E)-6-methoxy-3,5-dimethyl-7-phenyl-hepta-1,3-dienyl)-1,5,12,19-tetramethyl-2-methylene-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21heptaaza-cyclopentacosane-11,22-dicarboxylic acid; 15-(3-Guanidino-propyl)-8-isobutyl-18-(6-methoxy-3,5-dimethyl-7-phenyl-hepta-1,3-dienyl)-1,5,12,19-tetramethyl-2-methylene-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21heptaaza-cyclopentacosane-11,22-dicarboxylic acid; 8-[3-amino(imino)methylaminopropyl]-15-isobutyl-5-[6-methoxy-3,5-dimethyl-7-phenyl-(1E,3E)-1,3-heptadienyl]-4,11,18,22-tetramethyl-21-methylene-3,7,10,14,17,20,23-heptaoxo-2,6,9,13,16,19,22-heptaazacyclopentacosane-1,12-dicarboxylic acid; CYCLO(2,3-DIDEHYDRO-N-METHYLALANYL-D-ALANYL-L-LEUCYL-(3S)-3-METHYL-D-.BETA.-ASPARTYL-L-ARGINYL-(2S,3S,4E,6E,8S,9S)-3-AMINO-9-METHOXY-2,6,8-TRIMETHYL-10-PHENYL-4,6-DECADIENOYL-D-.GAMMA.-GLUTAMYL); CYCLO(2,3-DIDEHYDRO-N-METHYLALANYL-D-ALANYL-L-LEUCYL-ERYTHRO-3-METHYL-D-.BETA.-ASPARTYL-L-ARGINYL-(2S,3S,4E,6E,8S,9S)-4,5,6,7-TETRADEHYDRO-9-METHOXY-2,6,8-TRIMETHYL-10-PHENYL-3-AMINODECANOYL-D-.GAMMA.-GLUTAMYL)	.	.	995.2	C49H74N10O12	343	2000	2.3	71	10	13	15	InChI=1S/C49H74N10O12/c1-26(2)23-37-46(66)58-40(48(69)70)30(6)42(62)55-35(17-14-22-52-49(50)51)45(65)54-34(19-18-27(3)24-28(4)38(71-10)25-33-15-12-11-13-16-33)29(5)41(61)56-36(47(67)68)20-21-39(60)59(9)32(8)44(64)53-31(7)43(63)57-37/h11-13,15-16,18-19,24,26,28-31,34-38,40H,8,14,17,20-23,25H2,1-7,9-10H3,(H,53,64)(H,54,65)(H,55,62)(H,56,61)(H,57,63)(H,58,66)(H,67,68)(H,69,70)(H4,50,51,52)/b19-18+,27-24+/t28-,29-,30-,31+,34-,35-,36+,37-,38-,40+/m0/s1	C[C@H]1[C@@H](NC(=O)[C@@H](NC(=O)[C@H]([C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)C(=C)N(C(=O)CC[C@@H](NC1=O)C(=O)O)C)C)CC(C)C)C(=O)O)C)CCCN=C(N)N)/C=C/C(=C/[C@H](C)[C@H](CC2=CC=CC=C2)OC)/C	CC1C(NC(=O)C(NC(=O)C(C(NC(=O)C(NC(=O)C(NC(=O)C(=C)N(C(=O)CCC(NC1=O)C(=O)O)C)C)CC(C)C)C(=O)O)C)CCCN=C(N)N)C=CC(=CC(C)C(CC2=CC=CC=C2)OC)C	ZYZCGGRZINLQBL-GWRQVWKTSA-N	(5R,8S,11R,12S,15S,18S,19S,22R)-15-[3-(diaminomethylideneamino)propyl]-18-[(1E,3E,5S,6S)-6-methoxy-3,5-dimethyl-7-phenylhepta-1,3-dienyl]-1,5,12,19-tetramethyl-2-methylidene-8-(2-methylpropyl)-3,6,9,13,16,20,25-heptaoxo-1,4,7,10,14,17,21-heptazacyclopentacosane-11,22-dicarboxylic acid
ferrodrug0064	Vincristine	.	vincristine; 22-Oxovincaleukoblastine; Leurocristine; Vinkristin; Vincrystine; 57-22-7; Vincristina [DCIT]; leucristine; vincristin; Vincristinum [INN-Latin]; Tecnocris; Vincrstine; Oncovine; Vincasar; Oncotcs; rel-Vincristine; Vincaleukoblastine, 22-oxo-; Onco TCS; Onkocristin; Vincristina; Vincristinum; Citomid; Farmistin; Marqibo; oncovin (brand name); DTXSID1032278; CHEBI:28445; NSC-67574; 22-oxo-vincaleukoblastine; DTXCID9012278; Vincristine (INN); CCRIS 5763; VIN; HSDB 3199; NCGC00163700-01; NCI-C04864; EINECS 200-318-1; UNII-5J49Q6B70F; (+)-Vincristine; LCR; VCR; CAS-57-22-7; Tecnocris (TN); 22-Oxovincaleukoblastin; 1217704-92-1; Vincasar (1:1 sulfate salt); C46H56N4O10; Vincristine Sulfate PFS; Oncovin (1:1 sulfate salt); Vincrex (1:1 sulfate salt); Leurocristine;NSC-67574;22-Oxovincaleukoblastine; SCHEMBL3709; CHEMBL90555; GTPL6785; L01CA02; OGWKCGZFUXNPDA-XQKSVPLYSA-N; HMS2090E19; Tox21_112067; BDBM50139772; Lilly 37231 (1:1 sulfate salt); Tox21_112067_1; NCGC00163700-02; NCGC00163700-04; NCGC00263543-01; NCI60_026703; SRI-10749-04; SRI-10749-05; C07204; D08679; Q408977; Vincaleukoblastine, 22-oxo- 22-Oxovincaleukoblastine; methyl (1R,9R,10S,11R,12R,19R)-11-(acetyloxy)-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-(methoxycarbonyl)-1,11-diazatetracyclo[13.3.1.0^{4,12}.0^{5,10}]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.0^{1,9}.0^{2,7}.0^{16,19}]nonadeca-2(7),3,5,13-tetraene-10-carboxylate; methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate	.	.	825	C46H56N4O10	171	1750	2.8	60	3	12	10	InChI=1S/C46H56N4O10/c1-7-42(55)22-28-23-45(40(53)58-5,36-30(14-18-48(24-28)25-42)29-12-9-10-13-33(29)47-36)32-20-31-34(21-35(32)57-4)50(26-51)38-44(31)16-19-49-17-11-15-43(8-2,37(44)49)39(60-27(3)52)46(38,56)41(54)59-6/h9-13,15,20-21,26,28,37-39,47,55-56H,7-8,14,16-19,22-25H2,1-6H3/t28-,37+,38-,39-,42+,43-,44-,45+,46+/m1/s1	CC[C@@]1(C[C@@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	CCC1(CC2CC(C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)C78CCN9C7C(C=CC9)(C(C(C8N6C=O)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	OGWKCGZFUXNPDA-XQKSVPLYSA-N	methyl (1R,9R,10S,11R,12R,19R)-11-acetyloxy-12-ethyl-4-[(13S,15S,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10-hydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate
ferrodrug0065	Phenethyl isothiocyanate	.	2-Phenylethyl isothiocyanate; Phenethyl isothiocyanate; 2257-09-2; Phenylethyl isothiocyanate; (2-Isothiocyanatoethyl)benzene; Benzene, (2-isothiocyanatoethyl)-; PEITC; Phenylaethylsenfoel; 2-isothiocyanatoethylbenzene; ISOTHIOCYANIC ACID, PHENETHYL ESTER; PHENETHYLISOTHIOCYANATE; phenethyl-isothiocyanate; beta-Phenylethyl isothiocyanate; .beta.-Phenylethyl isothiocyanate; CHEBI:351346; NSC 87868; 2-phenylethylisothiocyanate; 6U7TFK75KV; beta-Phenethyl isothiocyanate; CHEMBL151649; .beta.-Phenethyl isothiocyanate; 1-Isothiocyanato-2-phenylethane; DTXSID5021120; NSC-87868; Isothiocyanic Acid 2-Phenylethyl Ester; JC-5411; MFCD00004821; Phenylaethylsenfoel [German]; 1-ISOTHIOCYANATO-2-PHENYLETHANE (1,1,2,2-D4); CCRIS 3146; EINECS 218-855-5; BRN 2084162; WLN: SCN2R; ss-Phenethyl isothiocyanate; Epitope ID:138724; UNII-6U7TFK75KV; 2-phenyl ethyl isothiocyanate; SCHEMBL156960; Phenethyl isothiocyanate, 99%; DTXCID901120; FEMA NO. 4014; IZJDOKYDEWTZSO-UHFFFAOYSA-; (2-Isothiocyanato-ethyl)-benzene; (2-Isothiocyanatoethyl)benzene #; 1-(2-isothiocyanatoethyl)benzene; 2-Phenylethyl isothiocyanate, FG; HMS1783C17; HMS3870G13; NSC87868; Tox21_200100; (2-Isothiocyanatoethyl)benzene, 9CI; BBL009999; BDBM50240850; JC5411; PHENETHYL ISOTHIOCYANATE [MI]; STK397325; AKOS000119469; DB12695; JC 5411; JC 5411JC-5411; NCGC00248526-01; NCGC00257654-01; PHENYLETHYL ISOTHIOCYANATE [FHFI]; AC-12769; AS-17373; BP-12941; HY-23155; NCI60_041942; CAS-2257-09-2; Isothiocyanic acid .beta.-phenylethyl ester; FT-0604634; P0986; Phenethyl isothiocyanate, analytical standard; EN300-17386; D92051; 4-12-00-02476 (Beilstein Handbook Reference); A816267; J-802164; Q7181339; W-107466; BRD-K56700933-001-02-1; Z56924472; F0001-0795; InChI=1/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2	.	.	163.24	C9H9NS	44.4	144	3.5	11	0	2	3	InChI=1S/C9H9NS/c11-8-10-7-6-9-4-2-1-3-5-9/h1-5H,6-7H2	C1=CC=C(C=C1)CCN=C=S	C1=CC=C(C=C1)CCN=C=S	IZJDOKYDEWTZSO-UHFFFAOYSA-N	2-isothiocyanatoethylbenzene
ferrodrug0066	Paraquat	Small molecular drug	PARAQUAT; 4685-14-7; Paraquat ion; Paraquat dication; 1,1'-Dimethyl-4,4'-bipyridinium; Dimethyl viologen; 4,4'-Bipyridinium, 1,1'-dimethyl-; Methyl viologen (2+); Starfire; Weedol; Spraytop-graze; Dextrone X; Gramoxone; Methyl viologen ion(2+); N,N'-Dimethyl-4,4'-bipyridinium; 1,1'-Dimethyl-4,4'-bipyridyldiylium; CCRIS 7731; 1-methyl-4-(1-methylpyridin-1-ium-4-yl)pyridin-1-ium; HSDB 1668; PRIGLONE; 1,1'-Dimethyl-4,4'-bipyridinium salt; 1,1'-Dimethyl-4,4'-bipyridinium cation; Gramoxone S; PARAQUAT CATION; CHEBI:34905; N,N'-Dimethyl-4,4'-bipyridinium dication; PLG39H7695; DTXSID3034799; 1,1'-dimethyl-4,4'-bipyridium; 1,1'-dimethyl-4,4'-bipyridin-1-ium; PARAQUAT (MART.); PARAQUAT [MART.]; BIPYRIDINIUM, 1,1'-DIMETHYL-4,4'-; MLS001332595; Viologen, Methyl; Paraquat [ANSI:BSI:ISO]; 1,1'-dimethyl-(4,4'-bipyridin)-1,1'-diium; 1,1'-dimethyl-[4,4'-bipyridin]-1,1'-diium; SMR000875209; EINECS 225-141-7; N,N'-Dimethyl-gamma,gamma'-dipyridylium; UNII-PLG39H7695; KHJ; PARAQUAT [HSDB]; PARAQUAT [ISO]; PARAQUAT [MI]; 3240-78-6; ChemDiv3_000231; NCIMech_000502; NCIOpen2_005422; SCHEMBL21652; MLS001304933; BIDD:ER0480; CHEMBL74469; 1,1'-Dimethyl-4,4'-bipyridyldiylium ion (8CI)(9CI); DTXCID1014799; BDBM96275; cid_5351279; 1,1'-Dimethyl,4,4'-bipyridyl; INFDPOAKFNIJBF-UHFFFAOYSA-N; HMS1473K11; 1,1 '-dimethyl-4,4'-bipyridinium; CCG-35984; STK387391; AKOS001483177; IDI1_019549; 1,1'-DIMETHYL-4,4'-BIPYRIDYL; NCGC00166161-02; NCI60_002105; SMR000752910; 1,1'-Dimethyl-4,4'-bipyridyldiylium ion; FT-0606133; FT-0652363; 1,1'-Dimethyl-4,4'-bipyridium bromide (1:2); AC-907/25005209; W-106083; Q26841324; 1,1'-DIMETHYL-[4,4'-BIPYRIDINE]-1,1'-DIIUM; 1-methyl-4-(1-methyl-4-pyridin-1-iumyl)pyridin-1-ium;chloride; 1-methyl-4-(1-methylpyridin-1-ium-4-yl)pyridin-1-ium;chloride	D00CAF	DMR8O3X	186.25	C12H14N2+2	7.8	145	1.7	14	0	0	1	InChI=1S/C12H14N2/c1-13-7-3-11(4-8-13)12-5-9-14(2)10-6-12/h3-10H,1-2H3/q+2	C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C	C[N+]1=CC=C(C=C1)C2=CC=[N+](C=C2)C	INFDPOAKFNIJBF-UHFFFAOYSA-N	1-methyl-4-(1-methylpyridin-1-ium-4-yl)pyridin-1-ium
ferrodrug0067	Rifampicin	.	Rifampicin; rifampin; Rifadin; Rimactan; Rimactane; Rifamycin AMP; 13292-46-1; Rifaldazine; Rifaprodin; Rifoldin; Rifa; Rifampicinum; Riforal; Tubocin; L-5103 Lepetit; R/AMP; Archidyn; Rifadine; Rifaldin; Rifoldine; Rimactizid; Abrifam; Eremfat; Rifagen; Rimazid; Rifampicin SV; Arficin; Benemicin; Doloresum; Fenampicin; Rifaldazin; Rifamor; Rifobac; Sinerdol; Arzide; Rifcin; Rifam; Dione 21-acetate; Rifinah; Rimactazid; Ba 41166/E; Rifampicine [French]; Rifampicina; Rifapiam; Rifampicinum [INN-Latin]; Rifampicina [INN-Spanish]; BA-41166E; 3-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; CCRIS 551; Rifadin I.V.; NSC-113926; HSDB 3181; Rifamycin, 3-(((4-methyl-1-piperazinyl)imino)methyl)-; L-5103; NSC113926; VJT6J7R4TR; Rifampicine; L-5103-LEPETIT; RFP; CHEBI:28077; 3-(4-Methylpiperazinyliminomethyl)-rifamycin SV; 8-(4-Methylpiperazinyliminomethyl) rifamycin SV; NIH-10782; 8-(((4-Methyl-1-piperazinyl)imino)methyl)rifamycin SV; Rifamycin, 3-[[(4-methyl-1-piperazinyl)imino]methyl]-; Rifomycin SV, 8-(N-(4-methyl-1-piperazinyl)formidoyl)-; Rifampin [USAN:USP]; C43H58N4O12; UNII-VJT6J7R4TR; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; [(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate; Famcin; NSC 113926; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.1(4,7).0(5,28)]triaconta-1(28),1(29),2,4,9,19,21,25,27-nonaen-13-yl acetate; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione 21-acetate; Rifampin [USAN]; 3-(4-Methylpiperazinyliminomethyl)rifamycin SV; 3-([(4-Methyl-1-piperazinyl)imino]methyl)rifamycin SV; 8-[[(4-Methyl-1-piperazinyl)imino]methyl]rifamycin sv; DTXSID6021244; rifamcin; 3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN; Rifomycin sv, 8-[N-(4-Methyl-1-piperazinyl)formidoyl]-; Rifamsolin; Rifampicin [INN:BAN:JAN]; DRG-0109; Rimactane (TN); AZT + Rifampin; Rifampin (USP); (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acet; (2S,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-Pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl acetate; [pentahydroxy-methoxy-heptamethyl-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-dioxo-[?]yl] acetate; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate; Rifampicin & EEP; Prestwick_833; EINECS 236-312-0; R-Cin; Rifadin (TN); Piperine & Rifampicin; Rifampicin & Propolis; Reserpine & Rifampicin; RIFAMPIN [HSDB]; RIFAMPIN [MI]; RIFAMPICIN [INN]; RIFAMPICIN [JAN]; RIFAMPIN [VANDF]; Prestwick2_000525; Prestwick3_000525; Spectrum5_002018; RIFAMPICIN [IARC]; 3-[[(4-Methyl-1-piperazinyl)imino]-methyl]rifamycin; Rifampicin (JP17/INN); RIFAMPICIN [MART.]; RIFAMYCIN AMP [MI]; RIFAMPICIN [WHO-DD]; RIFAMPICIN [WHO-IP]; SCHEMBL23490; BSPBio_000509; RIFAMPIN [ORANGE BOOK]; 8CI); BPBio1_000561; CHEMBL374478; RIFAMPICIN [EP IMPURITY]; RIFAMPIN [USP MONOGRAPH]; RIFATER COMPONENT RIFAMPIN; RIFAMPICIN [EP MONOGRAPH]; RIFAMATE COMPONENT RIFAMPIN; HMS1569J11; HMS2089F12; HMS2096J11; HMS3713J11; Rifampicin, >=97.0% (HPLC); RIFAMPICINUM [WHO-IP LATIN]; Rifampicin, powder, gamma-irradiated; RIFAMPIN COMPONENT OF RIFATER; Ba 41166; BDBM50370232; GR-306; RIFAMPIN COMPONENT OF RIFAMATE; AKOS015951372; Rifampicin - CAS 13292-46-1; Rifampicin, >=97% (HPLC), powder; BA 411661E; BA-41166/E; CCG-208267; DB01045; NCGC00022678-03; NCGC00022678-04; NCGC00022678-05; NCGC00022678-06; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate; C06688; D00211; Rifampicin, VETRANAL(TM), analytical standard; AB00383022_07; SR-05000002118; 8-[[(4-Methyl-1-piperazinyl)imino[methyl]rifamycin; 8-[[(4-Methylpiperazinyl)imino]methyl]rifamycin sv; SR-05000002118-3; WLN: V1 WQ A&1 E&1 E1UN- AT6N DNTJ D1; 3-[(4-Methyl-1-piperazinyl)iminomethyl]rifamycin SV; Rifampicin, European Pharmacopoeia (EP) Reference Standard; Rifampin, United States Pharmacopeia (USP) Reference Standard; Rifampin, Pharmaceutical Secondary Standard; Certified Reference Material; Rifampicin, plant cell culture tested, BioReagent, >=97% (HPLC), crystalline; yl]-, (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-; (2S,12Z,14E,16S,17S,18R,19R,20R,21S,22R,23S,24E)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-{(E)-[(4-methylpiperazin-1-yl)imino]methyl}-1,11-dioxo-1,2-dihydro-2,7-(epoxypentadeca[1,11,13]trienoimino)naphtho[2,1-b]furan-21-yl ac; (7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11- methoxy-3,7,12,14,16,18,22-heptamethyl-26-{(E)-[(4-methylpiperazin-1-yl)imino] methyl}-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1 (28),2,4,9,19,21,25(29),26-octaen-13-yl acetate; 2,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; 2,7-(epoxy[1,11,13]pentadecatrienoimino)naphtho[2,1-b]furan-1,11(2H)-dione, 21-(acetyloxy)-5,6,9,17,19-pentahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[(E)-[(4-methyl-1-piperazinyl)imino]meth; 2,7-(Epoxypentadeca(1,11,13)trienimino)naphtho(2,1-b)furan-1,11(2H)-dione, 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-, 21-acetate (; 5,6,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-(N-(4-methyl-1-piperazinyl)formimidoyl)-2,7-(epoxypentadeca(1,11,13)trienimino)naphtho(2,1-beta)furan-1,11(2H)-dione 21-acetate; 5,6,9,17,19,21-hexahydroxy-23-methoxy-2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-, 21-acetate; Rifampicin in combination with actinonin, BB-3497, hydroxylamine hydrochloride, and 1,10-phenanthroline; Stereoisomer of 5,9,17,19,21-Hexahydroxy-23-methoxy-2,4,12,16,18,20,22-he@ptamethyl-8-[N-(4-methyl-1-piperazinyl)formimidoyl]-2,7-(epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan-1,11(2H)-dione 21-acetate	.	.	822.9	C43H58N4O12	220	1620	4.9	59	6	15	5	InChI=1S/C43H58N4O12/c1-21-12-11-13-22(2)42(55)45-33-28(20-44-47-17-15-46(9)16-18-47)37(52)30-31(38(33)53)36(51)26(6)40-32(30)41(54)43(8,59-40)57-19-14-29(56-10)23(3)39(58-27(7)48)25(5)35(50)24(4)34(21)49/h11-14,19-21,23-25,29,34-35,39,49-53H,15-18H2,1-10H3,(H,45,55)/b12-11+,19-14+,22-13-,44-20+/t21-,23+,24+,25+,29-,34-,35+,39+,43-/m0/s1	C[C@H]1/C=C/C=C(\C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C=N/N5CCN(CC5)C)/C	CC1C=CC=C(C(=O)NC2=C(C(=C3C(=C2O)C(=C(C4=C3C(=O)C(O4)(OC=CC(C(C(C(C(C(C1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)C=NN5CCN(CC5)C)C	JQXXHWHPUNPDRT-WLSIYKJHSA-N	[(7S,9E,11S,12R,13S,14R,15R,16R,17S,18S,19E,21Z)-2,15,17,27,29-pentahydroxy-11-methoxy-3,7,12,14,16,18,22-heptamethyl-26-[(E)-(4-methylpiperazin-1-yl)iminomethyl]-6,23-dioxo-8,30-dioxa-24-azatetracyclo[23.3.1.14,7.05,28]triaconta-1(29),2,4,9,19,21,25,27-octaen-13-yl] acetate
ferrodrug0068	Borneol	.	(+)-Borneol; 464-43-7; Borneol; Camphol; d-Borneol; Hechenglongnao; Bingpian; Malayan camphor; Baros camphor; endo-Borneol; Bhimsaim camphor; Isoborneol; 2-Hydroxybornane; 2-Camphanol; 507-70-0; 2-borneol; 2-Hydroxycamphane; FEMA No. 2157; DL-Isoborneol; Borneol, dl-; Dryobalanops camphor; (1R,2S,4R)-Borneol; Borneolum syntheticum; 2-Bornanol, endo-; 2-endo-Bornyl alcohol; Camphane, 2-hydroxy-; Borneol, (+)-; (1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol; (1R,2S,4R)-rel-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-ol; UNII-M89NIB437X; Bornyl alcohol; CCRIS 7300; HSDB 946; M89NIB437X; EINECS 208-080-0; NSC-60223; Bicyclo[2.2.1]heptan-2-ol, 1,7,7-trimethyl-, (1R,2S,4R)-; 8D24LWT4FK; Borneocamphor; Borneo camphor; endo-(1R)-1,7,7-Trimethylbicyclo[2.2.1]heptan-2-ol; Sumatra camphor; AI3-00116; 2-Hydroxy-1,7,7-trimethylnorbornane, endo-; BORNEOL, (+/-)-; BICYCLO(2.2.1)HEPTAN-2-OL, 1,7,7-TRIMETHYL-, endo-; CHEBI:15393; DL-Borneol; Bicyclo[2.2.1]heptan-2-ol, 1,7,7-trimethyl-, (1R,2S,4R)-rel-; NSC 60223; 1,7,7-Trimethyl-bicyclo(2.2.1)heptan-2-ol, endo-; 124-76-5; BORNEOL (MART.); BORNEOL [MART.]; (1R-endo)-1,7,7-Trimethylbicyclo(2.2.1)heptan-2-ol; Endo-2-camphanol; trans-Borneol; Endo-2-hydroxycamphane; (+-)-borneol; BORNEOL, D-; UNII-8D24LWT4FK; (1R-endo)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol; Bicyclo(2.2.1)heptan-2-ol, 1,7,7-trimethyl-, (1R,2S,4R)-rel-; CCRIS 6550; Borneol (contains ca. 20% Isoborneol); (+)-Borneol 100 microg/mL in Methanol; EINECS 207-352-6; endo-2-Hydroxy-1,7,7-trimethylnorbornane; UN1312; (-) Borneol; D-CAMPHANOL; BRN 2038056; BORNEOL D-FORM; BORNEOL [FHFI]; BORNEOL [HSDB]; BORNEOL [INCI]; BORNEOL [FCC]; BORNEOL [MI]; BORNEOL [WHO-DD]; (+)-Borneol, 97%; D-BORNEOL [WHO-DD]; SCHEMBL56713; BORNEOL D-FORM [MI]; 4-06-00-00281 (Beilstein Handbook Reference); endo-1,7,7-Trimethylbicyclo; CHEMBL486208; GTPL6413; DTXSID2058700; DTXSID3052143; REL-(1S,2R,4S)-1,7,7-TRIMETHYLBICYCLO(2.2.1)HEPTAN-2-OL; BDBM36265; HY-N1368A; (+)-Borneol, analytical standard; BORNEOLUM SYNTHETICUM [CHP]; ENDO-(+-)-BORNAN-2-OL; Bicyclo(2.2.1)heptan-2-ol, 1,7,7-trimethyl-, (1R-endo)-; CCG-36088; MFCD00066427; AKOS016004136; CS-7758; Borneol [UN1312] [Flammable solid]; BS-42578; FEMA NO. 2157, (+)-; BORNEOL (CONSTITUENT OF BLACK PEPPER); EN300-84951; A14485; D96054; Q412435; BORNEOL (CONSTITUENT OF BLACK PEPPER) [DSC]; Q-100570; F0001-1255; Z1255372631; (1R,3S,4R)-4,7,7-trimethylbicyclo[2.2.1]heptan-3-ol; (1R,4R,6S)-1,7,7-trimethylbicyclo[2.2.1]heptan-6-ol; Flavor and Extract Manufacturers' Association Number 2157	.	.	154.25	C10H18O	20.2	185	2.7	11	1	1	0	InChI=1S/C10H18O/c1-9(2)7-4-5-10(9,3)8(11)6-7/h7-8,11H,4-6H2,1-3H3/t7-,8+,10+/m1/s1	C[C@@]12CC[C@@H](C1(C)C)C[C@@H]2O	CC1(C2CCC1(C(C2)O)C)C	DTGKSKDOIYIVQL-WEDXCCLWSA-N	(1R,2S,4R)-1,7,7-trimethylbicyclo[2.2.1]heptan-2-ol
ferrodrug0069	Methamphetamine	.	METHAMPHETAMINE; Metamfetamine; d-Deoxyephedrine; d-Desoxyephedrine; d-Methamphetamine; Methylamphetamine; d-N-Methylamphetamine; Metamphetamine; d-Methylamphetamine; N-Methylamphetamine; d-Phenylisopropylmethylamine; (S)-Methamphetamine; D-1-Phenyl-2-methylaminopropane; Norodin; (S)-Methylamphetamine; (+)-Methylamphetamine; d-(S)-Methamphetamine; Metamfetamina; Metamfetaminum; Methyl-beta-phenylisopropylamine; Desyphed; (+)-N-Methylamphetamine; 537-46-2; (+)-(S)-Deoxyephedrine; (S)-(+)-Deoxyephedrine; L-Methamphetamine; 1-Phenyl-2-methylaminopropane; Metanfetamina; Stimulex; Speed; Meth; S-(+)-Methamphetamine; (2S)-N-methyl-1-phenylpropan-2-amine; (+)-methamphetamine; (S)-N,alpha-Dimethylbenzeneethanamine; D-N,alpha-dimethylphenethylamine; Crank; Methamphetaminum; Crystal Meth; Metamfetamine [INN]; (+)-2-(N-Methylamino)-1-phenylpropane; Metamfetaminum [INN-Latin]; Metamfetamina [INN-Spanish]; Metanfetamina [INN-Spanish]; Methamphetaminum [INN-Latin]; (+)-N,alpha-Dimethylphenethylamine; dextromethamphetamine; D-1-Phenyl-2-methylaminopropan; (+)-N,alpha-Dimethyl-beta-phenylethylamine; Meth (Street Name); N-Methyl-beta-phenylisopropylamine; 1-Phenyl-2-methylamino-propan [German]; (+)-(S)-N-alpha-Dimethylphenethylamine; Metamfetaminum [Latin]; d-1-Phenyl-2-methylaminopropan [German]; 2S-(+)-Methamphetamine; (S)-(+)-Methamphetamine; (alphaS)-N,alpha-dimethylbenzeneethanamine; ICE [Street Name]; N-Methyl-beta-phenylisopropylamin [German]; Crank [Street Name]; Speed [Street Name]; NSC 25115; CHEBI:6809; HSDB 3359; (s)-phenylmethylaminopropane; EINECS 208-668-7; Crystal Meth [Street Name]; NSC-25115; (S)-N,alpha-Dimethylbenzeneethanoamine; UNII-44RAL3456C; (S)-(+)-N,alpha,dimethylphenethylamine; Metamfetamine (INN); Phenethylamine, N,alpha-dimethyl-, (+)-; N-Methyl-1-phenyl-2-propanamine; 44RAL3456C; Benzeneethanamine, N,alpha-dimethyl-, (S)-; Methyl-.beta.-phenylisopropylamine; d-N,.alpha.-Dimethylphenethylamine; Benzeneethanamine, N,alpha-dimethyl-, (alphaS)-; J6.362B; DTXSID8037128; Desoxyephedrine hydrochloride; 1-Phenyl-2-methylamino-propan; Crank (Street Name); ICE (Street Name); Speed (Street Name); N-Methyl-beta-phenylisopropylamin; Metamfetaminum (Latin); Methamphetaminum [JP]; Metanfetamina [Spanish]; Crystal Meth (Street Name); Desyphed hydrochloride; desohyephedrine; Metamfetamine-m; N Methylamphetamine; (+ )-Methylamphetamine; Benzeneethanamine, N,alpha-dimethyl-, (+)-; DEA No. 1105; B40; metamfetamine racemate; Benzeneethanamine, N,.alpha.-dimethyl-, (S)-; Phenethylamine, N,.alpha.-dimethyl-, (S)-(+)-; Epitope ID:178090; intra-venous methamphetamine; Phenethylamine, N,alpha-dimethyl-, (S)-(+)-; Benzeneethanamine,.alpha.-dimethyl-, (S)-; d-N,a-dimethylphenethylamine; METHAMPHETAMINE [MI]; SCHEMBL42615; Phenethylamine,.alpha.-dimethyl-, (S)-(+)-; METHAMPHETAMINE [HSDB]; METAMFETAMINE [WHO-DD]; METHAMPHETAMINE [VANDF]; CHEMBL1201201; DTXCID6017128; WLN: 1MY1&1R -D; N06BA03; N,I+/--Dimethyl-phenethyl amine; Desyphed hydrochloride (Salt/Mix); NSC25115; N-Methyl-1-phenyl-2-propanamine #; BDBM50359499; PDSP1_001404; PDSP1_001405; PDSP2_001388; PDSP2_001389; (+)-N,.alpha.-Dimethylphenethylamine; (S)-N-methyl-1-phenylpropan-2-amine; DB01577; Desoxyephedrine hydrochloride (Salt/Mix); methyl[(2S)-1-phenylpropan-2-yl]amine; Phenethylamine,.alpha.-dimethyl-, (+)-; (+)-(S)-N-.alpha.-Dimethylphenethylamine; Benzeneethanamine,.alpha.-dimethyl-, (+)-; Phenethylamine, N,.alpha.-dimethyl-, (+)-; Benzeneethanamine, N,.alpha.-dimethyl-, (+)-; C07164; D08187; (+)-N,.alpha.-Dimethyl-.beta.-phenylethylamine; Q191924; Phenethylamine, N,alpha-dimethyl-, (S)-(+)- (8CI); Benzeneethanamine, N,alpha-dimethyl-, (alphaS)- (9CI); (+)-N,.alpha.-Dimethylphenethylamine hydrochloride (Salt/Mix)	.	.	149.23	C10H15N	12	95	2.1	11	1	1	3	InChI=1S/C10H15N/c1-9(11-2)8-10-6-4-3-5-7-10/h3-7,9,11H,8H2,1-2H3/t9-/m0/s1	C[C@@H](CC1=CC=CC=C1)NC	CC(CC1=CC=CC=C1)NC	MYWUZJCMWCOHBA-VIFPVBQESA-N	(2S)-N-methyl-1-phenylpropan-2-amine
ferrodrug0070	Caryophyllene	Small molecular drug	BETA-CARYOPHYLLENE; Caryophyllene; trans-Caryophyllene; (-)-trans-Caryophyllene; 87-44-5; (-)-beta-caryophyllene; L-Caryophyllene; (-)-(E)-Caryophyllene; (E)-Caryophyllene; .beta.-Caryophyllene; b-caryophyllene; FEMA No. 2252; (E)-beta-caryophyllene; trans-beta-caryophyllene; CHEBI:10357; Beta-Caryophylene; trans-.beta.-Caryophyllene; (-)-Caryophyllene; .beta.-Caryophyllen; DTXSID8024739; (E)-beta-caryophylene; NSC 11906; NSC-11906; .beta.-(E)-Caryophyllene; BHW853AU9H; Cannabinoid; E-Caryophyllene; DTXCID304739; beta-Caryophyllen; (-)-E-Caryophyllene; 8-Methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene; UNII-BHW853AU9H; (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene; Bicyclo(7.2.0)undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; g-Caryophyllene; CCRIS 8094; EINECS 201-746-1; (1R,4E,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; trans-(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; (1R,4E,9S)-4,11,11-TRIMETHYL-8-METHYLENEBICYCLO(7.2.0)UNDEC-4-ENE; E-.beta.-caryophyllene; AI3-36121; .beta.-Caryophyllene, (-); CHEBI:63191; 2-Methylene-6,10,10-trimethylbicyclo(7.2.0)undec-5-ene; cariofileno; Tincturoid; Copaiba; 8-Methylene-4,11,11-(trimethyl)bicyclo[7.2.0]undec-4-ene; clove terpenes; NSC11906; Caryophyllene B; Caryophyllene hg; beta-cariofillene; cb2 receptor; (1R,4E,9S)-4,11,11-trimethyl-8-methylene-bicyclo[7.2.0]undec-4-ene; (1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo(7.2.0)undec-4-ene; trans-(1R,9S)-4,11,11-trimethyl-8-methylenebicyclo(7.2.0)undec-4-ene; beta-caryophillene; BICYCLO(7.2.0)UNDEC-4-ENE, 4,11,11-TRIMETHYL-8-METHYLENE-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, (E)-(1R,9S)-(-)-; Bicyclo[7.2.0]undec-4-ene, 8-methylene-4,11,11-trimethyl-, (E)-(1R,9S)-(-)-; 4,11,11-Trimethyl-8-methylenebicyclo(7.2.0)undec-4-ene, (1R-(1R*,4E,9S))-; Bicyclo(7.2.0)undec-4-ene, 4,11,11-trimethyl-8-methylene-, (1R-(1R*,4E,9S*))-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R-(1R*,4E,9S*)]-; trans caryophyllene; caryophyllene 917; E-beta-caryophyllene; MFCD00075925; Caryophyllene, (E); 02 - Terpenes; (?)-b-caryophyllene; 1-CARYOPHYLLENE; beta-(e)-caryophyllene; beta-trans-caryophyllene; clove terpene derivative; (?)-trans-Caryophyllene; caryophyllene beta natural; CARYOPHYLLENE [MI]; .beta.-trans-Caryophyllene; (-)-I(2)-caryophyllene; 12 - Analysis of terpenes; Bicyclo(7.2.0)undec-4-ene, 4,11,11-trimethyl-8-methylene-; CHEMBL445740; BETA-CARYOPHYLLENE [FCC]; BETA-CARYOPHYLLENE [INCI]; Bicyclo(7.2.0)undec-4-ene, 4,11,11-trimethyl-8-methylene-, (1R,4E,9S)-; HY-N1415; .BETA.-CARYOPHYLLENE [FHFI]; Tox21_301497; (1S,9R)-6,10,10-trimethyl-2-methylenebicyclo[7.2.0]undec-5-ene; 11CAR7501; BDBM50529607; s6058; AKOS024283988; LMPR0103120001; beta-Caryophyllene, >=80%, FCC, FG; CAS-87-44-5; NCGC00142620-01; NCGC00255159-01; (-)-trans-Caryophyllene, analytical standard; CS-0016839; C09629; beta-Caryophyllene 2000 microg/mL in Acetonitrile; P198906; Q421614; W-109317; (-)-trans-Caryophyllene, >=98.5% (sum of enantiomers, GC); 8-Methylene-4,11,11-(trimethyl)bicyclo(7.2.0)undec-4-ene, (1R,4E,9S)-; BICYCLO(7.2.0)UNDEC-4-ENE, 4,11,11-TRIMETHYL-8-METHYLENE-, (1R-(1R*,4E,9S*)-; Bicyclo[7.2.0]undec-4-ene, 4,11,11-trimethyl-8-methylene-, [1R- (1R*,4E,9S*)]-	D53QMP	DM7583A	204.35	C15H24	0	293	4.4	15	0	0	0	InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6+/t13-,14-/m1/s1	C/C/1=C\CCC(=C)[C@H]2CC([C@@H]2CC1)(C)C	CC1=CCCC(=C)C2CC(C2CC1)(C)C	NPNUFJAVOOONJE-GFUGXAQUSA-N	(1R,4E,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene
ferrodrug0071	Cumene hydroperoxide	.	CUMENE HYDROPEROXIDE; Cumyl hydroperoxide; 80-15-9; Cumenyl hydroperoxide; Cumolhydroperoxid; Cumolhydroperoxide; 7-Cumyl hydroperoxide; Hydroperoxide, 1-methyl-1-phenylethyl; alpha,alpha-Dimethylbenzyl hydroperoxide; Cument hydroperoxide; 2-hydroperoxypropan-2-ylbenzene; Hydroperoxyde de cumene; Hydroperoxyde de cumyle; Cumeenhydroperoxyde; Kumenylhydroperoxid; Isopropylbenzene hydroperoxide; 7-Hydroperoxykumen; RCRA waste number U096; Hydroperoxide de cumene; Idroperossido di cumene; Idroperossido di cumolo; Percumyl H; 1-Methyl-1-phenylethyl hydroperoxide; CCRIS 3801; HSDB 254; Hyperiz; DTXSID3024869; UNII-PG7JD54X4I; EINECS 201-254-7; PG7JD54X4I; alpha,alpha-Dimethylbenzylhydroperoxide; Trigonox K 80; BRN 1908117; Hydroperoxide, 1-methyl-1-phenylethyl-; CHEBI:78673; Hydroperoxide, alpha,alpha-dimethylbenzyl-; PH 80; alpha-Cumyl hydroperoxide; alpha-Cumene hydroperoxide; LUPEROX CU 80; TRIGONOX K 90; 2-Phenylpropane-2-peroxol; Hydroperoxide, alpha,alpha-dimethylbenzyl; DTXCID404869; EC 201-254-7; 4-06-00-03221 (Beilstein Handbook Reference); .alpha.,.alpha.-Dimethylbenzyl hydroperoxide; cumylhydroperoxide; Hydroperoxide, .alpha.,.alpha.-dimethylbenzyl; Cumene Hydroperoxide (80per cent, Technical grade); Cumolhydroperoxid [German]; Cumeenhydroperoxyde [Dutch]; Kumenylhydroperoxid [Czech]; 7-Hydroperoxykumen [Czech]; Hydroperoxyde de cumene [French]; Hydroperoxyde de cumyle [French]; Idroperossido di cumene [Italian]; Idroperossido di cumolo [Italian]; RCRA waste no. U096; r 239a; isopropyl benzene hydroperoxide; cumyl-hydroperoxide; Trigonox K-95; Trigonox R 239A; KAYACUMENE H; dimethylbenzyl hydroperoxide; TRIGONOX R 239R; .alpha.-Cumyl hydroperoxide; CHP-5; .alpha.-Cumene hydroperoxide; SCHEMBL15251; CHEMBL1518369; SCHEMBL11210695; CHP-158; 2-phenylpropan-2-yl hydroperoxide; CUMENE HYDROPEROXIDE [HSDB]; Tox21_300283; MFCD00002129; STL453641; AKOS015841738; CCG-207896; UN 2116; 2-PHENYL-2-PROPYL HYDROPEROXIDE; CAS-80-15-9; alpha, alpha-dimethylbenzyl hydroperoxide; NCGC00091748-01; NCGC00091748-02; NCGC00091748-03; NCGC00254045-01; Cumene hydroperoxide, technical grade, 80%; C2223; ALPHA,ALPHA-DIMETHYLBENZENE HYDROPEROXIDE; Cumene hydroperoxide, technical, ~80% in cumene; Q414439	.	.	152.19	C9H12O2	29.5	115	1.7	11	1	2	2	InChI=1S/C9H12O2/c1-9(2,11-10)8-6-4-3-5-7-8/h3-7,10H,1-2H3	CC(C)(C1=CC=CC=C1)OO	CC(C)(C1=CC=CC=C1)OO	YQHLDYVWEZKEOX-UHFFFAOYSA-N	2-hydroperoxypropan-2-ylbenzene
ferrodrug0072	Sodium arsenite	.	SODIUM ARSENITE; 7784-46-5; Sodium metaarsenite; Sodium dioxoarsenate; sodium;oxoarsinite; sodium meta-arsenite; Sodium (meta)arsenite; Arsenite, sodium; NaAsO2; Arsenious acid, sodium salt; Arsenious acid, monosodium salt; 48OVY2OC72; CHEBI:29678; Arsenenous acid, sodium salt (1:1); Prodalumnol; Sodanit; Penite; Kill-All; Prodalumnol double; Rat Death Liquid; Chem Pels C; Chem-Sen 56; Caswell No. 744; MFCD00003472; Sodium arsenenite; Atlas A; Arsenite de sodium; Arsenenous acid, sodium salt; Arsenite de sodium [French]; CCRIS 5554; HSDB 693; EINECS 232-070-5; EPA Pesticide Chemical Code 013603; UNII-48OVY2OC72; (NaAsO2)n; SODIUM META ARSENITE; SODIUM ARSENITE [MI]; SODIUM ARSENITE [HSDB]; 7784-46-5 (anhydrous); CHEMBL1909078; DTXSID5020104; Sodium (meta)arsenite, >=90%; SODIUM ARSENITE [WHO-DD]; AKOS025295751; Na(+)n-(-As(O(-))O-)-n; Sodium (meta)arsenite, p.a., 98.0%; Q419586	.	.	129.91	AsNaO2	40.1	13.5	.	4	0	2	0	InChI=1S/AsHO2.Na/c2-1-3;/h(H,2,3);/q;+1/p-1	[O-][As]=O.[Na+]	[O-][As]=O.[Na+]	PTLRDCMBXHILCL-UHFFFAOYSA-M	sodium;oxoarsinite
ferrodrug0073	Rapamycin	.	(-)-Rapamycin; 53123-88-9; AY 22989; AY-22989; I 2190A; I-2190A; I2190A; NSC 226080; RAPA; Rapammune; Rapamune; Rapamycin; SIIA 9268A; Sirolimus; Wy 090217; rapalimus; Supralimus; WY-090217; Rapamycin (Sirolimus); HYFTOR; sirolimusum; Cypher; Antibiotic AY 22989; Rapamycin (GMP); FYARRO; CCRIS 9024; CHEBI:9168; SILA 9268A; W36ZG6FT64; HSDB 7284; L04AA10; Npc-12g; SM-88 COMPONENT SIROLIMUS; DE-109; NSC-226080; UNII-W36ZG6FT64; DTXSID5023582; NAB-RAPAMYCIN COMPONENT RAPAMYCIN; SIROLIMUS (MART.); SIROLIMUS [MART.]; EC 610-965-5; SIROLIMUS (USP-RS); SIROLIMUS [USP-RS]; C51H79NO13; NSC226080; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; RAP; EVEROLIMUS IMPURITY A (EP IMPURITY); EVEROLIMUS IMPURITY A [EP IMPURITY]; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; DTXCID503582; Perceiva; 1fkb; 1pbk; NCGC00021305-05; Rapamycin from Streptomyces hygroscopicus; Rapamycin/Sirolimus; LCP-Siro; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-((2S)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-((2R)-1-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)propan-2-yl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido(2,1-c)(1,4)oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-(methyloxy)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-10,21-bis(methyloxy)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone; RPM; MFCD00867594; S1039; SIROLIMUS [INN]; SIROLIMUS [JAN]; RAPAMYCIN [MI]; Human Blood - Sirolimus; SIROLIMUS [HSDB]; SIROLIMUS [USAN]; SIROLIMUS [VANDF]; BiomolKI2_000084; SCHEMBL3463; SIROLIMUS [WHO-DD]; Rapamycin,Sirolimus,Rapamune; BIDD:PXR0165; SIROLIMUS [EMA EPAR]; 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine; MLS006010168; Sirolimus [USAN:INN:BAN]; GTPL6031; SIROLIMUS [ORANGE BOOK]; BDBM36609; MS-R001; S01XA23; QFJCIRLUMZQUOT-HPLJOQBZSA-N; HMS2089A21; HMS3403F11; HMS3884C03; EX-A1044; AC-722; BDBM50064359; HY-10219G; STL570275; AKOS015850976; AKOS015961618; CCG-100684; CS-0063; DB00877; NSC-2260804; NCGC00021305-06; NCGC00021305-07; AS-11687; HY-10219; SMR004701276; Fyarro (sirolimus albumin-bound particles); UNM-0000358684; A-275; CS-0626126; R0097; Rapamycin, VETRANAL(TM), analytical standard; M02444; Q32089; Q-201659; BRD-K84937637-001-04-0; BRD-K84937637-001-06-5; BRD-K89626439-001-01-0; Z2568665260; 24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypy; Rapamycin from Streptomyces hygroscopicus, >=95% (HPLC), powder; Rapamycin from Streptomyces hygroscopicus, Vetec(TM) reagent grade, >=95%; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-{(2S)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; (3 S,6 R,7 E,9 R,10 R,12 R,14 S,15 E,17 E, 19 E,21 S,23 S,26 R,27 R,34a S)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34, 34a-hexadecahydro-9,27-dihydroxy-3-; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34 aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hex adecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3R,4R)-4-hydro xy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy- 6,8,12,14,20,26-hexamethyl-23,27-ep; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-4,9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-heptadecahydro-9,27-dihydroxy-3-[(1R)-2-[(1S,3,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl]-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-223,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine-1,5,11,28,29(6H,31H)-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-(methyloxy)cyclohexyl]-1-methylethyl}-6,8,12,14,20,26-hexamethyl-10,21-bis(methyloxy)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(1R)-2-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]-1-methylethyl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,; 1,18-Dihydroxy-12-[2-(4-hydroxy-3-methoxy-cyclohexyl)-1-methyl-ethyl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-aza-tricyclo[30.3.1.0*4,9*]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone (Rapamycin); 9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,2	.	.	914.2	C51H79NO13	195	1760	6	65	3	13	6	InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)O)C)C)O)OC)C)C)C)OC	QFJCIRLUMZQUOT-HPLJOQBZSA-N	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
ferrodrug0074	Selenium	Small molecular drug	7782-49-2; Se; Selenium; Selenium hydride; SELENIUM ATOM; Elemental selenium; Selenium elemental; Selenium, elemental; Selen; Selenium dihydride; Selenium metallicum; SELENIUM POWDER; CI 77805; Dihydrogen monoselenide; C.I. 77805; SELENIUM78; MFCD00134090; Hydrogen selenide, anhydrous; H6241UJ22B; Vandex; Gray selenium; Selenium base; Selenium dust; Colloidal selenium; Selen [Polish]; elenium, elemental; Vandex;; Selenium, metallic; Selenium, colloidal; Caswell No. 732; selenio; Selenium anhydride; Electronic E-2; CCRIS 4250; HSDB 4493; EINECS 231-957-4; UN2658; Hydrogen selenide (H2Se); EPA Pesticide Chemical Code 072001; Selenium Standard: Se @ 1000 microg/mL in 5% HNO3; Selenium Standard: Se @ 10000 microg/mL in 5% HNO3; Selenium AA Standard: Se @ 1000 microg/mL in 5% HNO3; Selenium metal; UNII-H6241UJ22B; HSDB 548; Non-Metals Standard: As, B, P, S, Se, Si, Te @ 100 microg/mL in 5% HCl, tr. HF; Selenium (Powder); EINECS 231-978-9; Selenium shot, 4N; selenium (hexagonal); UN2202; UN3283; selenium (iv) hydride; HYDROGEN SELENID; B-TRAXIM SE; SELENIUM [MI]; SELENIUM [VANDF]; Selenium hydride (SeH2); SELENIUM [MART.]; 34Se; SELENIUM [WHO-DD]; UNII-V91P54KPAM; EC 231-957-4; Selenium, powder, 99+%; Selenium compound, n.o.s.; Selenium powder, -200 mesh; Selenium powder, -325 mesh; SELSAF 2000; HYDROGEN SELENIDE [MI]; Selenium, p.a., 99.5%; Selenium - Se @1000ug/mL; CHEMBL1235891; DTXSID9021261; CHEBI:27568; HSDB 6909; Selenium Nanopowder in aq. media; BUGBHKTXTAQXES-UHFFFAOYSA-N; SELENIUM METALLICUM [HPUS]; SELENIUM, ELEMENTAL [HSDB]; DB11135; NSC-605850; NSC-605851; NSC-605852; N725; Q876; Selenium, pellets, < 5mm, >=99.999%; E1457; FT-0701285; Selenium ingot/button, ~38mm (1.5in) dia; C01529; Selenium - Se @ 1000 microg/g in Hydrocarbon Oil; Selenium powder [UN2658] [Keep away from food]; Selenium shot, amorphous, 1-5mm (0.04-0.20in); Selenium Standard: Se @ 10 microg/mL in 2% HNO3; Selenium, foil, 25x25mm, thickness 3mm, 99.95%; Hydrogen selenide, anhydrous [UN2202] [Poison gas]; S008000000; Selenium, shots, 99.99999% (7N), diameter 2-4 mm; Selenium Standard: Se @ 1000 microg/g in Hydrocarbon Oil; Selenium, pellets, <5 mm, >=99.99% trace metals basis; Selenium, powder, -100 mesh, >=99.5% trace metals basis; Selenium, powder, -100 mesh, 99.99% trace metals basis; Selenium compound, n.o.s. [UN3283] [Poison, Keep away from food]; Selenium, lump, 3 mm max. lump size, weight 100 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 20 g, high purity 99.999%; Selenium, lump, 3 mm max. lump size, weight 50 g, high purity 99.999%; Selenium, pellets, <5 mm particle size, >=99.999% trace metals basis; Sulfur-Free Selenium Standard: Se @ 1000 microg/g in Hydrocarbon Oil; Selenium shot, amorphous, 2-6mm (0.08-0.2in), Puratronic(R), 99.999% (metals basis); Selenium, powder, 250 max. part. size (micron), purity 99.95%, weight 100 g; Selenium, powder, 250 max. part. size (micron), weight 50 g, purity 99.95%; Selenium, powder, max. particle size 250 micron, weight 200 g, purity 99.95%; Selenium, rod, 99.9999% (6N), diameter 20 mm, length 55 mm, approx. 74g; Selenium, rod, 99.99999% (7N), diameter 20 mm, length 55 mm, approx. 74 g; Se0	.	DM25CGV	78.97	Se	0	0	.	1	0	0	0	InChI=1S/Se	[Se]	[Se]	BUGBHKTXTAQXES-UHFFFAOYSA-N	selenium
ferrodrug0075	Kaempferol	Small molecular drug	kaempferol; 520-18-3; Robigenin; Kaempherol; Kempferol; Populnetin; Rhamnolutein; Trifolitin; Swartziol; Pelargidenolon; Rhamnolutin; 3,4',5,7-Tetrahydroxyflavone; Indigo Yellow; Kampherol; Campherol; Kampferol; Nimbecetin; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; Kaemferol; 5,7,4'-Trihydroxyflavonol; Pelargidenolon 1497; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; C.I. 75640; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one; Pelargidenon; Kampcetin; CCRIS 41; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-; Flavone, 3,4',5,7-tetrahydroxy-; NSC 407289; NSC 656277; EINECS 208-287-6; Kempferol;Robigenin; NSC-407289; NSC-656277; UNII-731P2LE49E; BRN 0304401; 3,5,7,4'-Tetrahydroxyflavone; DTXSID7020768; CHEBI:28499; AI3-36096; HSDB 7703; 731P2LE49E; 3'-DEOXYQUERCETIN; MFCD00016938; CHEMBL150; DTXCID30768; 5-18-05-00251 (Beilstein Handbook Reference); NSC656277; CAS-520-18-3; CI 75640; KAEMPFEROL (IARC); KAEMPFEROL [IARC]; SMR000112585; 4det; Kaempferol,(S); KAEMPFEROL [MI]; 5,4'-Trihydroxyflavonol; Prestwick0_001098; Prestwick1_001098; Prestwick2_001098; Prestwick3_001098; KAEMPFEROL [HSDB]; KAEMPFEROL [INCI]; 3,5,7-Tetrahydroxyflavone; KAEMPFEROL [USP-RS]; BIDD:PXR0073; Oprea1_650954; SCHEMBL18817; BSPBio_001176; MLS000697730; MLS001055391; MLS001074884; MLS006010737; BIDD:ER0134; SPBio_003058; Kaempferol, analytical standard; BDBM7462; BPBio1_001294; MEGxp0_001283; Flavone,4',5,7-tetrahydroxy-; ACon1_001867; cid_5280863; GTPL11052; CHEBI: 28499; HMS1571K18; HMS2098K18; HMS2267I09; HMS3414C03; HMS3656M03; HMS3678C03; HMS3884B13; 4H-1-Benzopyran-4-one,3,5,7-trihydroxy-2-(4-hydroxyphenyl)-; Kaempferol, >=97.0% (HPLC); TNP00039; Tox21_201165; Tox21_303363; AC-544; HSCI1_000027; LMPK12110003; NSC407289; s2314; AKOS015895240; Kaempferol, >=90% (HPLC), powder; CCG-202823; CS-1273; DB01852; GS-3570; NCGC00016480-01; NCGC00016480-02; NCGC00016480-03; NCGC00016480-04; NCGC00016480-05; NCGC00016480-06; NCGC00016480-07; NCGC00016480-08; NCGC00016480-09; NCGC00091036-01; NCGC00091036-02; NCGC00164322-01; NCGC00179275-01; NCGC00179275-02; NCGC00257464-01; NCGC00258717-01; BP-25390; HY-14590; KAEMPFEROL (CONSTITUENT OF GINKGO); Kaempferol 100 microg/mL in Acetonitrile; SY023424; AB00514046; FT-0614420; K0018; SW197199-2; 3,4',5,7-tetrahydroxy-Flavone (7CI,8CI); C05903; EN300-205764; H10428; S00111; Flavone, 3,4',5,7-tetrahydroxy- (7CI,8CI); KAEMPFEROL (CONSTITUENT OF GINKGO) [DSC]; A828886; Q393336; SR-01000765646; Kaempferol, primary pharmaceutical reference standard; Q-100584; SR-01000765646-3; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-chromen-4-one; BRD-K12807006-001-05-2; BRD-K12807006-001-10-2; Z57183373; 2-(4-hydroxyphenyl)-3,5,7-tris(oxidanyl)chromen-4-one; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one??; A91A6666-86C8-4B33-B3EF-F74CD3CD7F47; 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-1-benzopyran-4-one; 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one #; 4H-1-Benzopyran-4-one,5,7-trihydroxy-2-(4-hydroxyphenyl)-; Kaempferol, United States Pharmacopeia (USP) Reference Standard; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)- (9CI); 3,4',5,7-Tetrahydroxyflavone, 3,5,7-Trihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-hydroxyphenyl)-5,7,4'-Trihydroxyflavonol	D0G3TK	DMHEMUB	286.24	C15H10O6	107	451	1.9	21	4	6	1	InChI=1S/C15H10O6/c16-8-3-1-7(2-4-8)15-14(20)13(19)12-10(18)5-9(17)6-11(12)21-15/h1-6,16-18,20H	C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O	C1=CC(=CC=C1C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O)O	IYRMWMYZSQPJKC-UHFFFAOYSA-N	3,5,7-trihydroxy-2-(4-hydroxyphenyl)chromen-4-one
ferrodrug0076	Sulfasalazine	.	sulfasalazine; 599-79-1; Salicylazosulfapyridine; Azulfidine; Salazosulfapyridine; Sulphasalazine; Salazopyrin; Asulfidine; Benzosulfa; Salazopyridin; Accucol; Azopyrin; Sulcolon; Colo-Pleon; Salazopiridazin; Azopyrine; Reupirin; Salisulf; Salazosulfapyridin; Sulfasalazinum; w-t Sasp oral; Azulfidine EN; Sulfasalazin; Sulfasalazina; Sulfazalazine; Azulfidine EN-tabs; Salazosulfapiridina; Salazosulfapyridinum; Sas-500; SASP; 5-(p-(2-Pyridylsulfamyl)phenylazo)salicylic acid; NSC 667219; S.A.S.-500; 5-(4-(2-Pyridylsulfamoyl)phenylazo)-2-hydroxybenzoic acid; 4-(Pyridyl-2-amidosulfonyl)-3'-carboxy-4'-hydroxyazobenzene; 5-((p-(2-Pyridylsulfamoyl)phenyl)azo)salicylic acid; 2-Hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)benzoic acid; 5-[4-(2-Pyridylsulfamoyl)phenylazo]salicylic Acid; CHEBI:9334; NSC 203730; S.A.S. 500; C18H14N4O5S; (E)-2-hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; Sulfasalazopyridine; MFCD00057363; Benzoic acid, 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]-; 3XC8GUZ6CB; Sulfasalazine (Azulfidine); NSC-203730; NSC-667219; Benzoic acid, 2-hydroxy-5-((4-((2-pyridinylamino)sulfonyl)phenyl)azo)-; S.A.S.; 737754-28-8; Azosulfidin; DTXSID0021256; 2-hydroxy-5-{[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 5-[p-(2-Pyridylsulfamoyl)phenylazo]salicylic acid; 2-HYDROXY-(5-([4-(2-PYRIDINYLAMINO)SULFONYL]PHENYL)AZO)BENZOIC ACID; 5-(p-(2-Pyridinylsulfamoyl)Phenylazo)Salicylic Acid; NSC203730; NSC667219; Salicylic acid, 5-((p-(2-pyridylsulfamoyl)phenyl)azo)-; SSZ; NCGC00090903-01; Salazo-sulfapyridinum; CAS-599-79-1; 2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid; 2-Hydroxy-5-[[4-[(2-pyridinylamino)sulfonyl]phenyl]azo]benzoic acid; 2-hydroxy-5-[(E)-{4-[(pyridin-2-ylamino)sulfonyl]phenyl}diazenyl]benzoic acid; 5-[p-(2-Pyridylsulfamyl)phenylazo]salicylic acid; (3Z)-6-Oxo-3-[[4-(pyridin-2-ylsulfamoyl)phenyl]hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 5-(p-(2-Pyridylsulfamoyl)phenylazo)salicylic acid; Salazopyrin EN-Tabs; DTXCID401256; Sulfasalazinum [INN-Latin]; Sulfasalazina [INN-Spanish]; Salicylic acid, 5-[[p-(2-pyridylsulfamoyl)phenyl]azo]-; 2-Hydroxy-5-[4-(pyridin-2-ylsulfamoyl)-phenylazo]-benzoic acid; Salazosulfapyridinum [INN-Latin]; Salazosulfapiridina [INN-Spanish]; SI-88; 2-Hydroxy-5-((4-(N-(pyridin-2-yl)sulfamoyl)phenyl)diazenyl)benzoic acid; Alti-Sulfasalazine; PMS-Sulfasalazine; 2-hydroxy-5-[(E)-2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl]benzoic acid; Azulfidine (TN); SMR000059146; Azlufidine EN-Tabs; Sulphasalazine, N-; CCRIS 4713; HSDB 3395; 13gs; Pms-Sulfasalazine E.C.; SR-05000001721; EINECS 209-974-3; UNII-3XC8GUZ6CB; 5-[[p-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; Sulfasalazine (USP/INN); S.A.S. Enteric-500; BRN 0356241; Iwata; Prestwick_848; Sulfasalazine [USAN:USP:INN:BAN]; Spectrum_000998; Prestwick0_000520; Prestwick1_000520; Prestwick2_000520; Prestwick3_000520; Spectrum2_001216; Spectrum3_001364; Spectrum4_000347; Spectrum5_001443; SULFASALAZINE [MI]; CHEMBL421; Epitope ID:122672; SULFASALAZINE [INN]; SCHEMBL4514; SCHEMBL4515; Salazosulfapyridine (JP17); SULFASALAZINE [HSDB]; SULFASALAZINE [IARC]; SULFASALAZINE [USAN]; SCHEMBL18490; BSPBio_000479; BSPBio_002888; KBioGR_000753; KBioGR_002314; KBioSS_001478; KBioSS_002316; SULFASALAZINE [VANDF]; 5-22-08-00433 (Beilstein Handbook Reference); MLS000759399; MLS001424109; MLS006011702; BIDD:GT0161; DivK1c_000860; SPECTRUM1500552; SULFASALAZINE [MART.]; SPBio_001032; SPBio_002400; SULFASALAZINE [USP-RS]; SULFASALAZINE [WHO-DD]; SULFASALAZINE [WHO-IP]; 5-[4-(2-Pyridylsulfamoyl)-phenylazo]-salicylic acid; BPBio1_000527; CHEMBL100848; CHEMBL242373; GTPL4840; SCHEMBL1079598; SCHEMBL1229516; CHEMBL1206016; SCHEMBL10289061; CHEBI:94500; HMS502K22; KBio1_000860; KBio2_001478; KBio2_002314; KBio2_004046; KBio2_004882; KBio2_006614; KBio2_007450; KBio3_002108; KBio3_002794; SALAZOSULFAPYRIDINE [JAN]; cMAP_000018; NCEXYHBECQHGNR-QZQOTICOSA-N; NCEXYHBECQHGNR-UHFFFAOYSA-N; NINDS_000860; OQANPHBRHBJGNZ-BKUYFWCQSA-N; OQANPHBRHBJGNZ-UHFFFAOYSA-N; HMS1569H21; HMS1921C05; HMS2051J21; HMS2090P13; HMS2092K07; HMS2096H21; HMS2232H07; HMS3370D16; HMS3393J21; HMS3655G07; HMS3713H21; HMS3871J13; HMS3884E21; Pharmakon1600-01500552; SULFASALAZINE [ORANGE BOOK]; BCP13311; SULFASALAZINE [EP MONOGRAPH]; Tox21_111037; Tox21_201239; Tox21_300541; BDBM50097125; BDBM50103596; CCG-39145; DL-510; NSC757330; s1576; SULFASALAZINE [USP MONOGRAPH]; SULFASALAZINUM [WHO-IP LATIN]; 2-hydroxy-5-(2-{4-[(pyridin-2-yl)sulfamoyl]phenyl}diazen-1-yl)benzoic acid; AKOS002311709; AKOS025116975; AKOS026749974; AKOS037515748; Tox21_111037_1; WLN: T6NJ BSWMR DNUNR DQ CVQ; CCG-100987; DB00795; HS-0062; NC00237; NSC-757330; IDI1_000860; SMP2_000059; NCGC00016518-01; NCGC00090903-02; NCGC00090903-03; NCGC00090903-04; NCGC00090903-05; NCGC00090903-06; NCGC00090903-07; NCGC00090903-08; NCGC00090903-09; NCGC00090903-11; NCGC00186644-01; NCGC00254313-01; NCGC00258791-01; AC-20497; HY-14655; PD087097; SMR004703430; SY052318; SBI-0051526.P003; FT-0603483; FT-0674746; S0580; SW196979-4; C07316; D00448; EN300-119546; H10652; AB00052101-04; AB00052101-06; AB00052101_07; AB00052101_08; A832559; Q420035; Q-201769; SR-05000001721-1; SR-05000001721-2; SR-05000001721-3; Sulfasalazine, analytical standard, >=98% (HPLC); 5-[[4-(2-Pyridylsulfamoyl)phenyl]azo]salicylic acid; BRD-K10670311-001-06-4; BRD-K10670311-001-08-0; Q27166356; Q63398427; Sulphasalazine, Antibiotic for Culture Media Use Only; F2173-1125; Z1521554012; 4-(Pyridyl-2-amidosulfonyl)-3''-carboxy-4''-hydroxyazobenzene; Sulfasalazine, European Pharmacopoeia (EP) Reference Standard; 2-hydroxy-5-[(E)-[4-(2-pyridylsulfamoyl)phenyl]azo]benzoic acid; 5-{4-[(2-pyridylideneamino)sulfonyl]phenyldiazenyl}salicylic acid; Sulfasalazine, United States Pharmacopeia (USP) Reference Standard; (E)-2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-hydroxy-5-((4-(N-pyridin-2-ylsulfamoyl)phenyl)diazenyl)benzoic acid; 2-Hydroxy-5-((4-[(2-pyridinylamino)sulfonyl]phenyl)diazenyl)benzoic acid #; 2-hydroxy-5-{(E)-[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl}benzoic acid; 2-HYDROXY-5-((4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)AZO)BENZOIC ACID [WHO-IP]; 6-oxo-3-(2-[4-(n-pyridin-2-ylsulfamoyl)phenyl]hydrazono)cyclohexa-1,4-dienecarboxylic acid; BENZOIC ACID, 2-HYDROXY-5-(2-(4-((2-PYRIDINYLAMINO)SULFONYL)PHENYL)DIAZENYL)-; 6-oxo-3-((4-(pyridin-2-ylsulfamoyl)phenyl) hydrazinylidene]cyclohexa-1,4-diene-1-carboxylic acid; 6-oxo-3-[[4-(2-pyridinylsulfamoyl)phenyl]hydrazinylidene]-1-cyclohexa-1,4-dienecarboxylic acid	.	.	398.4	C18H14N4O5S	150	657	-0.7	28	3	9	6	InChI=1S/C18H14N4O5S/c23-16-9-6-13(11-15(16)18(24)25)21-20-12-4-7-14(8-5-12)28(26,27)22-17-3-1-2-10-19-17/h1-11,23H,(H,19,22)(H,24,25)	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N=NC3=CC(=C(C=C3)O)C(=O)O	NCEXYHBECQHGNR-UHFFFAOYSA-N	2-hydroxy-5-[[4-(pyridin-2-ylsulfamoyl)phenyl]diazenyl]benzoic acid
ferrodrug0077	Temozolomide	.	temozolomide; 85622-93-1; Methazolastone; Temodar; Temodal; Temozolamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; Sch 52365; CCRG-81045; Temozolomidum [Latin]; Temozolodida [Spanish]; Temozolomidum; CCRG 81045; NSC 362856; Sch-52365; M&B 39831; M&B-39831; NSC-362856; C6H6N6O2; CCRIS 8996; MB 39831; 8-Carbamoyl-3-methylimidazo(5,1-d)-1,2,3,5-tetrazin-4(3H)-one; M & B 39831; BRN 5547136; M-39831; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-1,2,3,5-tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide; NSC362856; CHEMBL810; 3,4-Dihydro-3-methyl-4-oxoimidazo(5,1-d)-as-tetrazine-8-carboxamide; MLS002701861; YF1K15M17Y; DTXSID5043714; CHEBI:72564; 3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; Mk-7365; 3-methyl-4-oxo-3H,4H-imidazo[4,3-d][1,2,3,5]tetrazine-8-carboxamide; TMZ; NCGC00167429-01; Temozolodida; 8-CARBAMOYL-3-METHYLIMIDAZO[5,1-D]-1,2,3,5-TETRAZIN-4(3H)-ONE; DTXCID3023714; 3,4-dihydro-3-methyl-4-oxoimidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide; 3-methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide.; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide; SMR000466338; Temodal (TN); Temodar (TN); CAS-85622-93-1; Temozolomide, VETRANAL(TM), analytical standard; SR-01000759347; temozolomida; UNII-YF1K15M17Y; Temozolomide (JAN/USAN/INN); Temozolomide [USAN:INN:BAN]; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d]-as-tetrazine-8-carboxamide; MFCD00866492; Temozolomide- Bio-X; TEMOZOLOMIDE [MI]; TEMOZOLOMIDE [INN]; TEMOZOLOMIDE [JAN]; Temodar (TN) (Schering); TEMOZOLOMIDE [USAN]; SCHEMBL3739; 4-methyl-5-oxo-2,3,4,6,8-pentazabicyclo[4.3.0]nona-2,7,9-triene-9-carboxamide; TEMOZOLOMIDE [VANDF]; TEMOZOLOMIDE [MART.]; MLS000759447; MLS001424028; BIDD:GT0204; TEMOZOLOMIDE [USP-RS]; TEMOZOLOMIDE [WHO-DD]; GTPL7301; TEMOZOLOMIDE [EMA EPAR]; Temozolomide, >=98% (HPLC); BPEGJWRSRHCHSN-UHFFFAOYSA-N; HMS2051O12; HMS2090B08; HMS2232N13; HMS3264I14; HMS3269P05; HMS3372K13; HMS3393O12; HMS3413D06; HMS3654N05; HMS3677D06; HMS3713H16; Pharmakon1600-01502289; TEMOZOLOMIDE [ORANGE BOOK]; TEMOZOLOMIDE [EP MONOGRAPH]; 3-methyl-4-oxo-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; BCP03692; TEMOZOLOMIDE [USP MONOGRAPH]; Tox21_112433; AC-758; BDBM50034562; DL-190; NSC759883; s1237; STK623541; 3,4-Dihydro-3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo-[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-4-oxo-3,4-dihydroimidazo[5,1-d][1,2,3,5]tetraazine-8-carboxamide; AKOS005557098; Tox21_112433_1; CCG-100870; CS-0943; DB00853; KS-1216; NC00120; NSC-759883; Imidazo(5,1-d)(1,2,3,5)tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; NCGC00167429-02; NCGC00167429-04; NCGC00167429-05; BP-25388; BT164447; HY-17364; NCI60_003316; BCP0726000154; Temozolomide 100 microg/mL in Acetonitrile; AM20110227; FT-0630936; FT-0674845; SW197500-4; T2744; D06067; EN300-122324; AB00639915-06; AB00639915-08; AB00639915-09; AB00639915_10; AB00639915_11; A841386; Q425088; Q-201786; SR-01000759347-4; SR-01000759347-5; BRD-K32107296-001-04-5; Z1201620684; 3-methyl-4-oxo-8-imidazo[5,1-d][1,2,3,5]tetrazinecarboxamide; Temozolomide, United States Pharmacopeia (USP) Reference Standard; 3-methyl-4-oxidanylidene-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide; 3-Methyl-8-aminocarbonyl-imidazo[5,1-d]-1,2,3,5-tetrazin-4(3H)-one; Imidazo[5,2,3,5-tetrazine-8-carboxamide, 3,4-dihydro-3-methyl-4-oxo-; {Imidazo[5,1-d]-1,2,3,5-tetrazine-8-carboxamide,} 3, 4-dihydro-3-methyl-4-oxo-; Temozolomide, Pharmaceutical Secondary Standard; Certified Reference Material; 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide (Temozolomide); 3-Methyl-4-oxo-3,4-dihydro-imidazo[5,1-d][1,2,3,5]tetrazine-8-carboxylic acid amide(Temozolomide)	.	.	194.15	C6H6N6O2	106	315	-1.1	14	1	5	1	InChI=1S/C6H6N6O2/c1-11-6(14)12-2-8-3(4(7)13)5(12)9-10-11/h2H,1H3,(H2,7,13)	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N	BPEGJWRSRHCHSN-UHFFFAOYSA-N	3-methyl-4-oxoimidazo[5,1-d][1,2,3,5]tetrazine-8-carboxamide
ferrodrug0078	Luteolin	.	luteolin; 491-70-3; Digitoflavone; Luteolol; 3',4',5,7-Tetrahydroxyflavone; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one; Flacitran; Luteoline; Salifazide; Weld Lake; Yama kariyasu; Cyanidenon 1470; 5,7,3',4'-Tetrahydroxyflavone; C.I. Natural Yellow 2; Bismite; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one; Cyanidenon-1470; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-; Daphneflavonol; Flavopurpol; CCRIS 3790; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-benzopyrone; BRN 0292084; UNII-KUX1ZNC9J2; KUX1ZNC9J2; EINECS 207-741-0; CHEBI:15864; C.I. 75590; FLAVONE, 3',4',5,7-TETRAHYDROXY-; MFCD00017309; CHEMBL151; DTXSID4074988; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4H-1-benzopyran-4-one; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4-chromenone; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromen-4-one; 1318-21-4; SMR000326896; 7-Tetrahydroxyflavone; SR-01000779333; Argemexitin; Lutl; 4dew; 4dgn; 4hkn; Luteolin,(S); 3',4',5,7-Tetrahydroxy-Flavone; LU2; Prestwick_122; LUTEOLIN [INCI]; LUTEOLIN [MI]; Prestwick0_000870; Prestwick1_000870; Prestwick2_000870; Prestwick3_000870; LUTEOLIN [WHO-DD]; BIDD:PXR0059; Lopac0_000660; Oprea1_849964; SCHEMBL20426; BSPBio_000919; Luteolin, analytical standard; MLS000697655; MLS000860038; MLS002154043; MLS006011917; BIDD:ER0122; SPBio_002840; BDBM7459; BPBio1_001011; GTPL5215; MEGxp0_000143; DTXCID6040668; ACon1_000223; cid_5280445; HMS1570N21; HMS2097N21; HMS2220C06; HMS3356L02; HMS3561N09; HMS3649N21; HMS3656A05; HMS3714N21; Luteolin, >=99.0% (TLC); BCP03511; HY-N0162; TNP00073; Luteolin, >=98% (TLC), powder; BBL027837; LMPK12110006; s2320; STK801923; AKOS002140588; AC-1125; BCP9000865; CCG-208309; CS-4611; DB15584; KS-5202; Luteolin 100 microg/mL in Acetonitrile; SMP2_000042; NCGC00016467-01; NCGC00016467-02; NCGC00016467-03; NCGC00016467-04; NCGC00016467-05; NCGC00016467-06; NCGC00016467-07; NCGC00016467-08; NCGC00016467-21; NCGC00142375-01; NCGC00142375-02; NCGC00142375-03; NCGC00179375-01; NCGC00179375-02; CAS-491-70-3; SY030155; BCP0726000198; FT-0600053; SW196433-3; T2682; C01514; L 9283; S00110; EN300-1659559; A827664; Luteolin, primary pharmaceutical reference standard; Q415011; Q-100551; SR-01000779333-4; SR-01000779333-5; SR-01000779333-7; BRD-K05236810-001-05-9; 23A002A4-B47B-46CD-848C-65042EACF3FF; NCGC00142375-01,NCGC00142375-02; Z1741977179; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-benzopyrone-4-one; 2-(3,4-Dihydroxyphenyl)-5,7-dihydroxy-4H-chromen-4-one #; 4H-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-	.	.	286.24	C15H10O6	107	447	1.4	21	4	6	1	InChI=1S/C15H10O6/c16-8-4-11(19)15-12(20)6-13(21-14(15)5-8)7-1-2-9(17)10(18)3-7/h1-6,16-19H	C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O	C1=CC(=C(C=C1C2=CC(=O)C3=C(C=C(C=C3O2)O)O)O)O	IQPNAANSBPBGFQ-UHFFFAOYSA-N	2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromen-4-one
ferrodrug0079	Omeprazole	Small molecular drug	omeprazole; 73590-58-6; Losec; Prilosec; Esomeprazole; Antra; Audazol; Omeprazon; Mopral; Omapren; Parizac; Miol; Ceprandal; Dizprazol; Emeproton; Epirazole; Gastrimut; Gastroloc; Inhibitron; Logastric; Peptilcer; Sanamidol; Secrepina; Ulcometion; Belmazol; Dudencer; Gibancer; Indurgan; Inhipump; Miracid; Omepral; Omeprol; Ompanyt; Pepticum; Prazidec; Ramezol; Ulceral; Ulcesep; Ulcozol; Zegerid; Desec; Elgam; Lomac; Mepral; Omezol; Omisec; Omizac; Ozoken; Prysma; Ulsen; Ultop; Zefxon; Zimor; Zoltum; Ocid; Omed; Omid; Demeprazol; Nopramin; OMEP; Omezolan; Paprazol; Pepticus; Prazentol; Prazolit; Procelac; Regulacid; Danlox; Erbolin; Lensor; Morecon; Nilsec; Olexin; Omegast; Omesek; Ortanol; Proclor; Result; Ulcsep; Victrix; Zepral; Exter; Gasec; Ulzol; Tedec Ulceral; Omebeta 20; AULCER; Omeprazol; Osiren; Antra MUPS; Omez; Omeprazolum; Omerprazole; 119141-88-7; Gastrogard; Omepradex; H 168/68; Nexium IV; Omeprazol [INN-Spanish]; Omeprazolum [INN-Latin]; Esomperazole; Nuclosina; Omesec; Omeprazole magnesium; Omeprazole delayed-release; (+-)-Omeprazole; CCRIS 7099; HSDB 3575; H-168/68; OMZ; MFCD00083192; Prestwick_808; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridyl)methyl)sulfinyl)benzimidazole; NSC-751450; NSC-759192; UNII-KG60484QX9; 1H-Benzimidazole, 5-methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-; 6-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; DTXSID6021080; C17H19N3O3S; CHEBI:77260; Omeprazole 13CD3; KG60484QX9; 6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole; Aisi'aomeilazuona Esomeprazole Sodium; CHEMBL1503; 2-(((3,5-Dimethyl-4-methoxy-2-pyridyl)methyl)sulfinyl)-5-methoxy-1H-benzimidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methanesulfinyl]-1H-1,3-benzodiazole; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole; MLS000069373; DTXCID501080; 326602-80-6; ZEGERID COMPONENT OMEPRAZOLE; 73590-58-6 (free form); YOSPRALA COMPONENT OMEPRAZOLE; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-3H-benzoimidazole; 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methane]sulfinyl}-1H-1,3-benzodiazole; OMEPRAZOLE COMPONENT OF ZEGERID; NSC 751450; NSC 759192; OMEPRAZOLE COMPONENT OF YOSPRALA; NCGC00016925-06; SMR000058847; Emilok; CAS-73590-58-6; Esomeprazole Sodium; 5-Methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]benzimidazole; 5-Methoxy-2[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; OMEPRAZOLE (MART.); OMEPRAZOLE [MART.]; 2-({[3,5-dimethyl-4-(methyloxy)pyridin-2-yl]methyl}sulfinyl)-5-(methyloxy)-1H-benzimidazole; ( -)-Omeprazole; (R)-5-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; OMEPRAZOLE (USP IMPURITY); OMEPRAZOLE [USP IMPURITY]; Omeprazone; Omebeta; Omeprazen; OMEPRAZOLE (USP MONOGRAPH); OMEPRAZOLE [USP MONOGRAPH]; Olit; Omeprazole Pellets; 5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzo[d]imidazole; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methylsulfinyl]-1H-benzimidazole; Prilosec (TN); 5-METHOXY-2-(((4-METHOXY-3,5,-DIMETHYL-2-PYRIDINYL)-METHYL)SULPHINYL)-1H-BENZIMIDAZOLE; Esomeprazole sodium salt; SR-01000003003; omeprazolo; SAN-15; 161796-78-7; Omeprazole, solid; 5-Methoxy-2-(((4-methoxy-3,5-dimethyl-2-pyridinyl)methyl)sulfinyl)-1H-benzimidazole; AGI-010; Omeprazole,(S); Omeprazole-[d3]; (RS)-6-METHOXY-2-((4-METHOXY-3,5-DIMETHYLPYRIDIN-2-YL) METHYLSULFINYL)-1H-BENZO(D)IMIDAZOLE; (RS)-6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl) methylsulfinyl)-1H-benzo[d]imidazole; Omeprazole - Bio-X; DM-3458; Omeprazole [USAN:USP:INN:BAN:JAN]; 5-Methoxy-2-; Omeprazole (Prilosec); OMEPRAZOLE [MI]; OMEPRAZOLE [INN]; OMEPRAZOLE [JAN]; Maybridge4_002645; Opera_ID_1863; Prestwick0_000493; Prestwick1_000493; Prestwick2_000493; Prestwick3_000493; (.+/-.)-Omeprazole; OMEPRAZOLE [HSDB]; OMEPRAZOLE [USAN]; O0359; OMEPRAZOLE [VANDF]; UPCMLD-DP075; cid_4594; SCHEMBL1191; OMEPRAZOLE [USP-RS]; OMEPRAZOLE [WHO-DD]; H 16868; H168/68; BSPBio_000385; MLS001076112; MLS001424148; MLS006010400; MLS006011759; BIDD:GT0189; SPBio_002306; BPBio1_000425; CHEBI:7772; GTPL4279; Omeprazole (JP17/USP/INN); OMEPRAZOLE [GREEN BOOK]; OMEPRAZOLE [ORANGE BOOK]; SCHEMBL11995456; UPCMLD-DP075:001; CHEBI:91766; A02BC01; HMS1528I05; HMS1569D07; HMS2052G17; HMS2090E16; HMS2090F11; HMS2096D07; HMS2232B21; HMS3269D17; HMS3394G17; HMS3413J07; HMS3651A11; HMS3677J07; HMS3713D07; Pharmakon1600-01505693; AMY30573; BCP05852; BCP13592; BCP21299; HY-B0113; 2,3,5-Trimethylpyridine/Omeprazole; Tox21_110686; Tox21_200509; AC-401; BBL028172; BDBM50103597; BDBM50241343; DL-462; MFCD23135254; NSC751450; NSC759192; s1389; STK623746; AKOS005066653; AKOS015895343; Tox21_110686_1; AC-4676; CCG-101130; CCG-213517; CS-1868; DB00338; HS-0055; NC00380; (S)-5-Methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-3H-benzoimidazole; IDI1_032523; NCGC00016925-01; NCGC00016925-02; NCGC00016925-03; NCGC00016925-04; NCGC00016925-05; NCGC00016925-07; NCGC00016925-08; NCGC00016925-10; NCGC00016925-11; NCGC00021522-03; NCGC00021522-04; NCGC00021522-05; NCGC00258063-01; Omeprazole, analytical reference material; BO164173; SY009746; SY077145; SBI-0206896.P001; FT-0601585; FT-0652860; FT-0653294; FT-0673283; FT-0689771; H 199; SW196942-4; A19447; C07324; D00455; EN300-117238; A837865; A892647; A937349; Q422210; SR-01000003003-4; SR-01000003003-7; SR-01000003003-8; 5-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl); BRD-A55962179-001-04-9; BRD-A55962179-001-08-0; BRD-A55962179-001-20-5; BRD-A88691025-001-07-4; F0001-2386; Z1501475006; Omeprazole, British Pharmacopoeia (BP) Reference Standard; Omeprazole, European Pharmacopoeia (EP) Reference Standard; Omeprazole, United States Pharmacopeia (USP) Reference Standard; 2-(3-methoxy-2,4-dimethylbenzylsulfinyl)-6-methoxy-1H-benzo[d]imidazole; 5-Methoxy-2-((S)-((4-methoxy-3,5-dimethyl-2- pyridinyl)methyl)sulfinyl)-; Omeprazole, Pharmaceutical Secondary Standard; Certified Reference Material; (+)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (-)-5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]-sulfinyl]-1h-benzimidazole; (RS)-5-Methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzimidazole; (RS)-5-Methoxy-2-(4-methoxy-3,5-dimethyl-2-pyridylmethylsulphinyl)benzimidazole; 1H-Benzimidazole,5-methoxy-2-[(R)-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyrdinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1 H-benzimidazole; 5-methoxy 2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-(2-(4-methoxy-3,5-dimethylpyridin-2-yl)ethylsulfinyl)-1H-benzo[d]imidazole; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl- 1H-benzimidazole; 5-methoxy-2-[[(3,5-dimethyl-4-methoxy-2-pyridyl)methyl]sulfinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulphinyl]-1H-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridyl)methyl]sulfinyl]-benzimidazole; 5-methoxy-2-[[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulphinyl]1H-benzimidazole; 6-methoxy-2-(((4-methoxy-3,5-dimethyl pyridin-2-yl)methyl)sulfinyl)-1h-benzo[d]imidazole; 6-methoxy-2-((4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl)-1H-benzo[d]imidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[(4-methoxy-3,5-dimethyl-pyridin-2-yl)methylsulfinyl]-1H-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5-dimethyl-2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy-3,5dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4-methoxy3,5-dimethyl-2-pyridinyl)-methyl]sulfinyl]-1h-benzimidazole; 6-methoxy-2-[[(4methoxy-3,5-dimethyl2-pyridinyl)methyl]sulfinyl]-1h-benzimidazole; Omeprazole for peak identification, European Pharmacopoeia (EP) Reference Standard; rac-5-methoxy-2-(((4-methoxy-3,5-dimethylpyridin-2-yl)methyl)sulfinyl)-1H-benzimidazole; (omeprazole)5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole; 1H-BENZIMIDAZOLE,6-METHOXY-2-[(R)-[(4-METHOXY-3,5-DIMETHYL-2-PYRIDINYL)METHYL]SULFINYL]-; 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole (omeprazole); 5-Methoxy-2-(4-methoxy-3,5-dimethyl-pyridin-2-ylmethanesulfinyl)-1H-benzoimidazole(Omeprazole)	D01XNB	DM471KJ	345.4	C17H19N3O3S	96.3	453	2.2	24	1	6	5	InChI=1S/C17H19N3O3S/c1-10-8-18-15(11(2)16(10)23-4)9-24(21)17-19-13-6-5-12(22-3)7-14(13)20-17/h5-8H,9H2,1-4H3,(H,19,20)	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC	SUBDBMMJDZJVOS-UHFFFAOYSA-N	6-methoxy-2-[(4-methoxy-3,5-dimethylpyridin-2-yl)methylsulfinyl]-1H-benzimidazole
ferrodrug0080	Olanzapine	.	olanzapine; 132539-06-1; Zyprexa; Olansek; Zalasta; Zyprexa Zydis; Zyprexa Velotab; Zyprexa Intramuscular; Olanzapine Mylan; LY-170053; olanzapina; Zolafren; Zypadhera; Olazax; Olanzapine Teva; Olazax Disperzi; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; Olanzapine Glenmark; olanzapinum; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine; LY 170053; Olzapin; Lanzac; Oferta; Olanzapine cipla; Olanzapine apotex; C17H20N4S; Olanzapine Neopharma; LY170053; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; Olanzapin; Olanzapine Glenmark Europe; UNII-N7U69T4SZR; N7U69T4SZR; CHEBI:7735; DTXSID9023388; HSDB 8155; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno(2,3-b)(1,5)benzodiazepine; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[3,2-c][1,5]benzodiazepine; 10H-thieno[2,3-b][1,5]benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; CHEMBL715; DTXCID503388; LYBALVI COMPONENT OLANZAPINE; SYMBYAX COMPONENT OLANZAPINE; 10H-Thieno(2,3-b)(1,5)benzodiazepine, 2-methyl-4-(4-methyl-1-piperazinyl)-; OLANZAPINE COMPONENT OF LYBALVI; OLANZAPINE COMPONENT OF SYMBYAX; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0^{3,7}]tetradeca-1(10),3(7),5,8,11,13-hexaene; NCGC00096077-03; OLANZAPINE (MART.); OLANZAPINE [MART.]; OLANZAPINE (USP-RS); OLANZAPINE [USP-RS]; OLANZAPINE (EP MONOGRAPH); OLANZAPINE [EP MONOGRAPH]; OLANZAPINE (USP MONOGRAPH); OLANZAPINE [USP MONOGRAPH]; Midax; Zydis; 2-methyl-4-(4-methyl-1-piperazinyl)-5H-thieno[3,2-c][1,5]benzodiazepine; Olanzapine Teva; SMR000466345; CAS-132539-06-1; SR-01000759343; ALKS-7921; 2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno(2,3-b)(1,5)benzodiazepine; Olanzapine [USAN:USP:INN:BAN]; Olanzapine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine; LY 170053; Lanzac; Zyprexa; Olanzapine- Bio-X; MFCD00866702; Olanzapine (Zyprexa); KS-1090; PS15 - Olanzapine; OLANZAPINE [MI]; OLANZAPINE [INN]; OLANZAPINE [JAN]; OLANZAPINE [USAN]; OLANZAPINE [VANDF]; GTPL47; 2-Methyl-4-(4-methyl-1-piperazinyl)- 10H-thieno[2,3-b][1,5]benzodiazepine; OLANZAPINE [WHO-DD]; BIDD:PXR0138; SCHEMBL28763; Olanzapine (JAN/USP/INN); US8802672, Olanzapine; MLS000759457; MLS001165781; MLS001195646; MLS001424057; BIDD:GT0332; OLANZAPINE [EMA EPAR]; SCHEMBL117695; SPECTRUM1505024; Olanzapine (LY-170053); OLANZAPINE [ORANGE BOOK]; Olanzapine, >=98% (HPLC); BDBM35254; BDBM82479; CHEBI:94534; AMY7709; N05AH03; HMS2051H05; HMS2089M04; HMS2093I04; HMS2233F24; HMS3374L02; HMS3393H05; HMS3657I15; HMS3714J03; HMS3743A09; HMS3884J21; BCP04917; NSC_4585; Olanzapine, 1mg/ml in Acetonitrile; Tox21_111556; AC-665; HB1786; NSC754829; NSC801187; s2493; STK634338; STL388024; 2-methyl-4-(4-methylpiperazin-1-yl)-5H-thieno[2,3-b][1,5]benzodiazepine; AKOS000282888; AKOS005566122; Olanzapine 1.0 mg/ml in Acetonitrile; Tox21_111556_1; BCP9001021; CCG-100922; CS-1114; DB00334; NC00172; NSC-754829; NSC-801187; NCGC00096077-01; NCGC00096077-04; NCGC00096077-05; NCGC00096077-06; NCGC00096077-18; NCGC00389791-02; BO164166; HY-14541; SBI-0206786.P001; CAS_132539-06-1; FT-0673219; O0393; SW220248-1; C07322; D00454; EN300-119499; AB00639907-06; AB00639907-07; AB00639907_08; AB00639907_09; A806453; L000455; L005958; Q201872; J-006186; SR-01000759343-4; SR-01000759343-6; Z1521553472; Olanzapine, European Pharmacopoeia (EP) Reference Standard; Olanzapine, United States Pharmacopeia (USP) Reference Standard; Olanzapine, Pharmaceutical Secondary Standard; Certified Reference Material; (E)-2-methyl-4-(4-methylpiperazin-1-yl)-10H-benzo[b]thieno[2,3-e][1,4]diazepine; 2-Methyl-10-(4-methyl-piperazin-1-yl)-4H-3-thia-4,9-diaza-benzo[f]azulene; 2-methyl-4-(4-methyl-1-piperazinyl) -10h-thieno[2,3-b][1,5]benzodiazepine; 2-methyl-4-(4-methyl-1-piperazinyl)-10H-thieno-[2,3-b][1,5]benzodiazepine; 2-Methyl-4-(4-methyl-1-piperazinyl)-10H-thieno[2,3-b][1,5]benzodiazepine #; 2-Methyl-4-(4-methylpiperazin-1-yl)-10H- thieno[2,3-b][1,5]benzodiazepin; Olanzapine for system suitability, European Pharmacopoeia (EP) Reference Standard; Olanzapine-d8, 100 mug/mL in acetonitrile, ampule of 1 mL, certified reference material; 5-methyl-8-(4-methylpiperazin-1-yl)-4-thia-2,9-diazatricyclo[8.4.0.0,3,7]tetradeca-1(10),3(7),5,8,11,13-hexaene	.	.	312.4	C17H20N4S	59.1	432	2.9	22	1	4	1	InChI=1S/C17H20N4S/c1-12-11-13-16(21-9-7-20(2)8-10-21)18-14-5-3-4-6-15(14)19-17(13)22-12/h3-6,11,19H,7-10H2,1-2H3	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C	CC1=CC2=C(S1)NC3=CC=CC=C3N=C2N4CCN(CC4)C	KVWDHTXUZHCGIO-UHFFFAOYSA-N	2-methyl-4-(4-methylpiperazin-1-yl)-10H-thieno[2,3-b][1,5]benzodiazepine
ferrodrug0081	Gefitinib	.	Gefitinib; 184475-35-2; Iressa; ZD1839; N-(3-Chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; Irressat; gefitinib (zd1839); ZD 1839; ZD-1839; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(morpholin-4-yl)propoxy]quinazolin-4-amine; C22H24ClFN4O3; Gefitinib (GMP); N-(3-Chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; 4-(3'-Chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)quinazoline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine; MFCD04307832; CHEMBL939; NSC-759856; S65743JHBS; DTXSID8041034; CHEBI:49668; 3-Chloro-4-Fluoro-N-[(4z)-7-Methoxy-6-(3-Morpholin-4-Ylpropoxy)quinazolin-4(1h)-Ylidene]aniline; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-4-quinazolinamine; Gefitinib [USAN]; NCGC00159455-02; N-(3-chloro-4-fluoro-phenyl)-7-methoxy-6-(3-morpholinopropoxy)quinazolin-4-amine; DTXCID6021034; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-; Iressa(TM); IRE; Iressa (TN); CCRIS 9011; CAS-184475-35-2; SR-00000000262; gefitinibum; UNII-S65743JHBS; Gefitinib (JAN/USAN/INN); Gefitinib [USAN:INN:BAN]; Gefitini; Iressa; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-[3-(4-morpholinyl)propoxy]-; N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-(4-morpholinyl)propoxy)-4-quinazolinamine; gefitinib (iressa); Gefitinib - Iressa; Iressa (AstraZeneca); nchembio866-comp14; Kinome_3321; Kinome_3322; GEFITINIB [INN]; GEFITINIB [JAN]; GEFITINIB [MI]; GEFITINIB [VANDF]; GEFITINIB [MART.]; GEFITINIB [WHO-DD]; SCHEMBL7866; Gefitinib,ZD-1839,Iressa; GEFITINIB [EMA EPAR]; KBioSS_002241; MLS003899193; CU-00000000396-1; BDBM5447; cid_123631; GTPL4941; GEFITINIB [ORANGE BOOK]; GEFITINIB [EP MONOGRAPH]; Gefitinib, >=98% (HPLC); BCPP000221; HMS2089B19; HMS3244M21; HMS3244M22; HMS3244N21; HMS3295A21; HMS3413H08; HMS3654A07; HMS3677H08; HMS3714A05; HMS3748E17; Pharmakon1600-01502274; BCP01365; Tox21_111683; HY-50895G; NSC715055; NSC759856; NSC800105; s1025; STK621310; AKOS000280752; Tox21_111683_1; AB20814; AC-1556; BCP9000718; CCG-220642; CS-0124; DB00317; KS-1204; NSC 759856; NSC-715055; NSC-800105; 4-[(3-Chloro-4-fluorophenyl)amino]-7-methoxy-6-(3-morpholinopropoxy)quinazoline; 4-Quinazolinamine, N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-4-morpholin)propoxy)-; 6-(3-morpholinopropoxy)-N-(3-chloro-4-fluorophenyl)-7-methoxyquinazolin-4-amine; NCGC00159455-03; NCGC00159455-04; NCGC00159455-05; NCGC00159455-06; NCGC00159455-08; NCGC00159455-09; NCGC00159455-14; BCB03_000781; BG164498; HY-50895; SMR002204119; SY002154; AM20090619; CS-0622782; FT-0602325; G0546; SW199108-4; EC-000.2409; D01977; EN300-123024; G-4408; K00240; AB01273954-01; AB01273954-02; AB01273954-03; AB01273954_04; A812870; Q417824; Q-201149; SR-00000000262-2; SR-00000000262-3; Gefitinib, EuropePharmacopoeia (EP) Reference Standard; Z1546610485; 4-(3'-chloro-4'-fluoroanilino)-7-methoxy-6-(3-morpholinopropoxy)-quinazoline; Gefitinib for system suitability, EuropePharmacopoeia (EP) Reference Standard; (3-CHLORO-4-FLUORO-PHENYL)-[7-METHOXY-6-(3-MORPHOLIN-4-YL-PROPOXY)-QUINAZOLIN-4-YL]-AMINE	.	.	446.9	C22H24ClFN4O3	68.7	545	4.1	31	1	8	8	InChI=1S/C22H24ClFN4O3/c1-29-20-13-19-16(12-21(20)31-8-2-5-28-6-9-30-10-7-28)22(26-14-25-19)27-15-3-4-18(24)17(23)11-15/h3-4,11-14H,2,5-10H2,1H3,(H,25,26,27)	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	XGALLCVXEZPNRQ-UHFFFAOYSA-N	N-(3-chloro-4-fluorophenyl)-7-methoxy-6-(3-morpholin-4-ylpropoxy)quinazolin-4-amine
ferrodrug0082	Busulfan	Small molecular drug	busulfan; 55-98-1; Myleran; Busulphan; Sulphabutin; Leucosulfan; Busulfex; Myelosan; Myeloleukon; Citosulfan; Mielucin; Misulban; Mitostan; Mylecytan; Sulfabutin; Mablin; Mielevcin; Mielosan; Milecitan; Mileran; 1,4-Dimesyloxybutane; butane-1,4-diyl dimethanesulfonate; 1,4-BUTANEDIOL DIMETHANESULFONATE; Buzulfan; Myeleukon; Busulfanum; Myelosanum; 1,4-Dimethanesulfonoxybutane; Tetramethylene dimethane sulfonate; Busilvex; Busulfano; 1,4-Butanediol, dimethanesulfonate; 1,4-Dimethylsulfonyloxybutane; 1,4-Dimethanesulfonyloxybutane; NCI-C01592; 1,4-Dimethylsulfonoxybutane; 1,4-Bis(methanesulfonoxy)butane; 1,4-Butanediol dimethylsulfonate; Busulphane; Mitosan; 1,4-Bis(methanesulfonyloxy)butane; GT 41; NSC-750; 1,4-Butanediol dimethanesulphonate; CB 2041; Tetramethylene bis(methanesulfonate); AN 33501; Methanesulfonic acid, tetramethylene ester; 1,4-Dimethanesulphonyloxybutane; NSC 750; 4-methylsulfonyloxybutyl methanesulfonate; 1,4-Dimethanesulfonoxylbutane; Tetramethylenester kyseliny methansulfonove; C.B. 2041; X 149; GT 2041; 1,4-Butanediyl dimethanesulfonate; 1,4-Dimethane sulfonyl oxybutane; 1,4-Butanediol, dimethanesulphonate; CCRIS 418; Bisulfex; NSC750; CHEBI:28901; Busulfex IV; Butanedioldimethanesulfonate; Tetramethylene bis[methanesulfonate]; 2041 C. B.; EINECS 200-250-2; UNII-G1LN9045DK; BRN 1791786; G1LN9045DK; DTXSID3020910; 1,4-Bis[methanesulfonoxy]butane; AI3-25012; HSDB 7605; G.T. 41; DTXCID10910; BUSULFAN FRESENIUS KABI; 2041 C.B.; 4-(methanesulfonyloxy)butyl methanesulfonate; NCGC00090905-06; BUSULFAN (IARC); BUSULFAN [IARC]; TETRAMETHYLENE DI(METHANESULFONATE); BUSULFAN (MART.); BUSULFAN [MART.]; Busulfanum [INN-Latin]; Busulfano [INN-Spanish]; BUSULFAN (EP IMPURITY); BUSULFAN [EP IMPURITY]; BUSULFAN (EP MONOGRAPH); BUSULFAN [EP MONOGRAPH]; BUSULFAN (USP MONOGRAPH); BUSULFAN [USP MONOGRAPH]; Methanesulfonic; Myleran tablets; CAS-55-98-1; SR-01000765405; Bussulfam; Joacamine; Misulfan; Busulfan;; Busulfan/Myleran; Busulfan [USP:INN:BAN:JAN]; Tetramethylenester kyseliny methansulfonove [Czech]; Prestwick_989; (1,4-Bis(methanesulfonyloxy)butane); MFCD00007562; Tetramethylene {bis[methanesulfonate]}; Spectrum_000092; BUSULFAN [HSDB]; BUSULFAN [INN]; BUSULFAN [JAN]; BUSULFAN [MI]; BUSULFAN [VANDF]; Spectrum2_000067; Spectrum3_000320; Spectrum4_000259; Spectrum5_000928; BUSULFAN [WHO-DD]; BUSULFAN [WHO-IP]; CHEMBL820; NCIMech_000192; SCHEMBL4373; BUSULFAN [EMA EPAR]; MYELOSANUM [WHO-IP]; WLN: WS1&O4OSW1; BSPBio_001920; KBioGR_000698; KBioSS_000512; 1,4-Dimethanesulphonoxybutane; MLS001076666; 1,4-Dimethylsulphonoxy-butane; Busulfan (Myleran, Busulfex); DivK1c_000847; SPECTRUM1500152; Busulfan (JP17/USP/INN); SPBio_000253; Tetramethylenedimethanesulfonate; BUSULFAN [ORANGE BOOK]; GTPL7136; 1,4-di(methylsulfonyloxy)butane; COVZYZSDYWQREU-UHFFFAOYSA-; HMS502K09; KBio1_000847; KBio2_000512; KBio2_003080; KBio2_005648; KBio3_001420; 1,4-Bis(methanesulphonoxy)butane; 1,4-di(methanesulfonyloxy)butane; butane-1,4-diyldimethanesulfonate; L01AB01; 1, 4-Bis(methanesulfonoxy)butane; 1,4-BUTANEDIOL DIMESYLATE; BUSULFANUM [WHO-IP LATIN]; NINDS_000847; GT-41; HMS1920I07; HMS2091O09; HMS2233H04; HMS3259G15; HMS3370E11; HMS3655A21; HMS3712A20; Pharmakon1600-01500152; AMY33355; HY-B0245; Tetramethylene bis(methanesulphonate); Tox21_111038; Tox21_201848; Tox21_300318; 1, {4-Bis[methanesulfonoxy]butane}; 2041CB; AC-198; BDBM50237623; CCG-35458; NSC755916; s1692; AKOS003614975; Tox21_111038_1; CB-2041; DB01008; KS-5212; NC00498; NSC-755916; IDI1_000847; methanesulfonic acid tetramethylene ester; 1,4-Bitanediol Dimethanesulfonate Esters; NCGC00090905-01; NCGC00090905-02; NCGC00090905-03; NCGC00090905-04; NCGC00090905-05; NCGC00090905-07; NCGC00090905-08; NCGC00090905-09; NCGC00090905-10; NCGC00090905-11; NCGC00090905-12; NCGC00254038-01; NCGC00259397-01; NCI60_041640; SMR000058613; WR-19508; Methanesulphonic acid, tetramethylene ester; SBI-0051300.P003; B1022; FT-0623291; FT-0663910; SW198555-3; C06862; D00248; D88731; EN300-118686; 4-[(Methylsulfonyl)oxy]butyl methanesulfonate #; AB00051929-10; AB00051929-11; AB00051929_12; AB00051929_14; Busulfan, analytical standard, for drug analysis; Busulfan; Butane-1,4-diyl di(methanesulfonate); Q348922; SR-01000765405-2; SR-01000765405-3; SR-01000765405-7; Busulfan, European Pharmacopoeia (EP) Reference Standard; Z276508890; InChI=1/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3; 129316-96-7; BUS	D07SUG	DMXYJ9C	246.3	C6H14O6S2	104	294	-0.5	14	0	6	7	InChI=1S/C6H14O6S2/c1-13(7,8)11-5-3-4-6-12-14(2,9)10/h3-6H2,1-2H3	CS(=O)(=O)OCCCCOS(=O)(=O)C	CS(=O)(=O)OCCCCOS(=O)(=O)C	COVZYZSDYWQREU-UHFFFAOYSA-N	4-methylsulfonyloxybutyl methanesulfonate
ferrodrug0083	Haloperidol	.	haloperidol; 52-86-8; Haldol; Serenace; Aloperidin; Eukystol; Aloperidol; Brotopon; Serenase; Serenelfi; Linton; Dozic; Einalon S; Aloperidolo; Galoperidol; Halopoidol; Halojust; Halopal; Keselan; Mixidol; Ulcolind; Uliolind; Pernox; Sernas; Sernel; Aldo; Bioperidolo; Lealgin compositum; Sigaperidol; Peluces; Haldol Solutab; Aloperidon; Haloperidolum; Fortunan; Halosten; McN-JR-1625; 4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one; Halol; Halidol; Halopidol; Neurodol; Pekuces; C21H23ClFNO2; R-1625; 4-(4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl)-1-(4-fluorophenyl)butan-1-one; 177716-59-5; NSC 170973; R 1625; CCRIS 1630; 1-(3-p-Fluorobenzoylpropyl)-4-p-chlorophenyl-4-hydroxypiperidine; HSDB 3093; EINECS 200-155-6; 4'-Fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidinyl)butyrophenone; 4'-Fluoro-4-(4-hydroxy-4-(4'-chlorophenyl)piperidino)butyrophenone; NSC 615296; NSC-170973; NSC-615296; UNII-J6292F8L3D; BRN 0331267; CHEBI:5613; Haloperidol (Haldol); DTXSID4034150; 4-(4-Hydroxy-4'-chloro-4-phenylpiperidino)-4'-fluorobutyrophenone; J6292F8L3D; 1-Butanone, 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-; 4-(4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl)-1-(4-fluorophenyl)-1-butanone; CHEMBL54; NSC170973; Haldol (TN); 4-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; Butyrophenone, 4'-fluoro-4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-; 4-[4-(4-Chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-1-butanone; MLS000028450; DTXCID2014150; 4'-Fluoro-4-(4-hydroxy-4-p-chlorophenylpiperidino)butyrophenone; 4-(4-(para-Chlorophenyl)-4-hydroxypiperidino)-4'-fluorobutyrophenone; 4-[4-(p-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorbutyrophenone; gamma-(4-(p-Chlorophenyl)-4-hydroxypiperidino)-p-fluorobutyrophenone; 5-21-02-00377 (Beilstein Handbook Reference); Butyrophenone, 4-(4-(p-chlorophenyl)-4-hydroxypiperidino)-4'-fluoro-; 1-Butanone, 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidinyl]-1-(4-fluorophenyl)-; VESALIUM COMPONENT HALOPERIDOL; NSC615296; CAS-52-86-8; HALOPERIDOL COMPONENT OF VESALIUM; NCGC00015500-10; Aloperidolo [DCIT]; SMR000058303; Aloperidolo [Italian]; gamma-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)-butan-1-one; HALOPERIDOL (MART.); HALOPERIDOL [MART.]; HALOPERIDOL (USP-RS); HALOPERIDOL [USP-RS]; Haloperidolum [INN-Latin]; Haloperido; HALOPERIDOL (EP MONOGRAPH); HALOPERIDOL (USP IMPURITY); HALOPERIDOL [EP MONOGRAPH]; HALOPERIDOL [USP IMPURITY]; Peridol; Dozix; HALOPERIDOL (USP MONOGRAPH); HALOPERIDOL [USP MONOGRAPH]; Apo-Haloperidol; Pms Haloperidol; Novo-Peridol; Butyrophenone, 4-[4-(p-chlorophenyl)-4-hydroxypiperidino]-4'-fluoro-; Haldol La; SR-01000003076; Duraperidol; Epoxy resins; 4'-Fluoro-4-[4-hydroxy-4-(4'-chlorophenyl)piperidino]butyrophenone; gamma-[4-(p-chlorophenyl)-4-hydroxypiperidino]-p-fluorobutyrophenone; 4-[4-(para-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; Picroside-III; Haloperidol, 1; 4-(4-(4-chlorophenyl)-4-hydroxy-1-piperidyl)-1-(4-fluorophenyl)-butan-1-one; Haloperidol, powder; Prestwick_250; Haloperidol [USAN:USP:INN:BAN:JAN]; PS14 - Haloperidol; Spectrum_000861; Tocris-0931; starbld0018801; Opera_ID_446; HALOPERIDOL [MI]; 4-[4-(4-Chloro-phenyl)-4-hydroxy-piperidin-1-yl]-1-(4-fluoro-phenyl)-butan-1-one;propionate(HCl); 4-[4-(4-Chlorophenyl)-4-hydroxypiperidino]-4'-fluorobutyrophenone; Prestwick0_000115; Prestwick1_000115; Prestwick2_000115; Prestwick3_000115; Spectrum2_001268; Spectrum3_000448; Spectrum4_000570; Spectrum5_000788; HALOPERIDOL [INN]; HALOPERIDOL [JAN]; Lopac-H-1512; HALOPERIDOL [HSDB]; HALOPERIDOL [USAN]; Biomol-NT_000035; GTPL86; Probes1_000255; Probes2_000296; H 1512; HALOPERIDOL [VANDF]; SCHEMBL8264; Lopac0_000583; Oprea1_509923; BSPBio_000130; BSPBio_002096; HALOPERIDOL [WHO-DD]; HALOPERIDOL [WHO-IP]; KBioGR_000980; KBioGR_002390; KBioSS_001341; KBioSS_002395; MLS001146904; BIDD:GT0128; DivK1c_000654; SPECTRUM1500325; SPBio_001236; SPBio_002069; McM-JR-1625; BPBio1_000144; BPBio1_001231; Haloperidol (JP17/USP/INN); BDBM21398; Haloperidol, 1mg/ml in Methanol; HMS502A16; KBio1_000654; KBio2_001341; KBio2_002390; KBio2_003909; KBio2_004958; KBio2_006477; KBio2_007526; KBio3_001316; KBio3_002869; LNEPOXFFQSENCJ-UHFFFAOYSA-; HALOPERIDOL [ORANGE BOOK]; N05AD01; cMAP_000037; Haloperidol for system suitability; NINDS_000654; AC250; Haloperidol for peak identification; HMS1568G12; HMS1920D03; HMS2089M15; HMS2091J09; HMS2095G12; HMS2234P08; HMS3261F08; HMS3370H11; HMS3657I13; HMS3712G12; Pharmakon1600-01500325; BCP33202; CHA71659; Haloperidol 1.0 mg/ml in Methanol; STR04750; Tox21_110162; Tox21_300475; Tox21_500583; CCG-36042; CCG-39111; HALOPERIDOLUM [WHO-IP LATIN]; NSC757054; STL417208; 4-[4-(4-chlorophenyl)-4-hydroxy-1-piperidyl]-1-(4-fluorophenyl)butan-1-one; AKOS000280660; Tox21_110162_1; AT13670; CS-1971; DB00502; LP00583; NSC-757054; SDCCGSBI-0050565.P005; IDI1_000654; MRF-0000027; QTL1_000042; WLN: T6NTJ A3VR DF& DQ DR DG; NCGC00015500-01; NCGC00015500-02; NCGC00015500-03; NCGC00015500-04; NCGC00015500-05; NCGC00015500-06; NCGC00015500-07; NCGC00015500-08; NCGC00015500-09; NCGC00015500-11; NCGC00015500-12; NCGC00015500-13; NCGC00015500-14; NCGC00015500-15; NCGC00015500-16; NCGC00015500-17; NCGC00015500-19; NCGC00015500-24; NCGC00015500-32; NCGC00016234-01; NCGC00023875-02; NCGC00023875-04; NCGC00023875-05; NCGC00023875-06; NCGC00023875-07; NCGC00023875-08; NCGC00023875-09; NCGC00254503-01; NCGC00261268-01; AC-19691; BH166165; HY-14538; SBI-0050565.P004; Haloperidol decanoate impurity, haloperidol-; SC 170973; AB00052008; EU-0100583; FT-0669100; FT-0669101; FT-0697842; H0912; S1920; SW196557-4; C01814; D00136; VU0239704-10; AB00052008-21; AB00052008-22; AB00052008_23; AB00052008_24; A899749; L000288; Q251347; SR-01000003076-2; SR-01000003076-8; W-105791; BRD-K67783091-001-04-8; BRD-K67783091-001-05-5; BRD-K67783091-003-03-6; HALOPERIDOL DECANOATE IMPURITY G [EP IMPURITY]; SR-01000003076-11; Z1590789254; Haloperidol, European Pharmacopoeia (EP) Reference Standard; .gamma.-[4-(p-Chlorphenyl)-4-hydroxpiperidino]-p-fluorbutyrophenone; HALOPERIDOL DECANOATE IMPURITY, HALOPERIDOL- [USP IMPURITY]; Haloperidol, United States Pharmacopeia (USP) Reference Standard; .gamma.-(4-(p-Chlorophenyl)-4-hydroxpiperidino)-p-fluorbutyrophenone; 4-(4-HYDROXY-4'-CHLORO-4-PHENYLPIPERIDINO)-4'-FLUORBUTYROPHENONE; Haloperidol, Pharmaceutical Secondary Standard; Certified Reference Material; Haloperidol for peak identification, European Pharmacopoeia (EP) Reference Standard; Haloperidol for system suitability, European Pharmacopoeia (EP) Reference Standard; InChI=1/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2	.	.	375.9	C21H23ClFNO2	40.5	451	3.2	26	1	4	6	InChI=1S/C21H23ClFNO2/c22-18-7-5-17(6-8-18)21(26)11-14-24(15-12-21)13-1-2-20(25)16-3-9-19(23)10-4-16/h3-10,26H,1-2,11-15H2	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F	LNEPOXFFQSENCJ-UHFFFAOYSA-N	4-[4-(4-chlorophenyl)-4-hydroxypiperidin-1-yl]-1-(4-fluorophenyl)butan-1-one
ferrodrug0084	Lapatinib	.	Lapatinib; 231277-92-2; Tykerb; GW572016; GW 572016; Lapatinib [INN]; Lapatinib base; Tyverb; 388082-78-8; Lapatinib (INN); Lapatinib free base; N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine; N-{3-chloro-4-[(3-fluorophenyl)methoxy]phenyl}-6-(5-{[(2-methanesulfonylethyl)amino]methyl}furan-2-yl)quinazolin-4-amine; Lapatinib (free base); 231277-92-2 (free base); GSK572016; FMM; N-{3-CHLORO-4-[(3-FLUOROBENZYL)OXY]PHENYL}-6-[5-({[2-(METHYLSULFONYL)ETHYL]AMINO}METHYL)-2-FURYL]-4-QUINAZOLINAMINE; CHEMBL554; GW-572016; DTXSID7046675; CHEBI:49603; 0VUA21238F; NSC745750; GSK-572016; GW-572016X; 1210608-87-9; NCGC00167507-01; N-[3-Chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl]quinazolin-4-amine; DTXCID5026675; 4-Quinazolinamine, N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-; 4-Quinazolinamine, N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-; N-(3-chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)-2-furanyl)-4-quinazolinamine; N-(3-Chloro-4-((3-fluorophenyl)methoxy)phenyl)-6-(5-((2-methylsulfonylethylamino)methyl)-2-furyl)quinazolin-4-amine; n-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[[[2-(methylsulfonyl)ethyl]amino]methyl]-2-furanyl]-4-quinazolinamine; N-{3-chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; GSK 572016; CAS-231277-92-2; GW-2016; Lapatinib [INN:BAN]; MFCD09264194; GW 282974X; C29H26ClFN4O4S; UNII-0VUA21238F; HSDB 8209; 1xkk; Lapatinib, Tykerb, GW572016; N-[3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl]-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methanesulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; Lapatinib, Free base; nchembio866-comp20; Kinome_3684; Kinome_3685; Lapatinib base- Bio-X; LAPATINIB [MI]; LAPATINIB [VANDF]; LAPATINIB [WHO-DD]; SCHEMBL8100; Lapatinib (GW572016); LAPATINIB [EMA EPAR]; BDBM5445; cid_208908; GTPL5692; EX-A402; BCFGMOOMADDAQU-UHFFFAOYSA-N; BCPP000188; BCPP000189; HMS2089H10; HMS3244N06; HMS3244N10; HMS3244N14; HMS3744K11; Tykerb (TN) (Glaxo Smith Kline); BCP01874; Tox21_112505; NSC800780; AKOS005145766; Tox21_112505_1; AC-1314; BCP9000837; BCP9000838; CCG-270133; DB01259; NSC-745750; NSC-800780; SB16918; NCGC00167507-02; NCGC00167507-03; NCGC00167507-04; NCGC00167507-09; 913989-15-8; AS-14065; BC164610; HY-50898; N-(3-chloro-4-(3-fluorobenzyloxy)phenyl)-6-(5-((2-(methylsulfonyl)ethylamino)methyl)furan-2-yl)quinazolin-4-amine; N-(3-Chloro-4-{[(3-fluorophenyl)methyl]oxy}phenyl)-6-[5-({[2-(methylsulfonyl)ethyl]amino}methyl)-2-furanyl]-4-quinazolinamine; AM20090641; FT-0659650; L0360; SW199101-5; A25184; D08108; EN300-117254; AB01273965-01; AB01273965-02; AB01273965-03; AB01273965_04; AB01273965_05; Q420323; Q-101353; SR-05000001472-1; BRD-K19687926-001-01-7; BRD-K19687926-379-02-5; 1092929-10-6; GW-2016;N-(3-chloro-4-((3-fluorobenzyl)oxy)phenyl)-6-(5-(((2-(methylsulfonyl)ethyl)amino)methyl)furan-2-yl)quinazolin-4-amine;4-[[3-Chloro-4-(3-fluorobenzyloxy)phenyl]amino]-6-[5-[[(2-methanesulfonylethyl)amino]methyl]furan-2-yl]quinazoline; N-[3-chloro-4-(3-fluorobenzyloxy)phenyl]-6-[5-({[2-(methanesulfonyl)ethyl]amino}methyl)furan-2-yl]quinazolin-4-amine; N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]-2-furyl] quinazolin-4-amine; N-{3-chloro-4-[(3-fluoro-benzyl)oxy]phenyl}-6-[5-({2-(methylsulfonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N-{3-Chloro-4[(3-fluorobenzyl)oxy]phenyl}-6-[5-({[2-(methane sulphonyl)ethyl]amino}methyl)-2-furyl]-4-quinazolinamine; N3-Chloro-4-(3-fluorophenyl)methoxyphenyl-6-5-(2-methylsulfonylethylamino)methyl-2-furylquinazolin-4-amine	.	.	581.1	C29H26ClFN4O4S	115	898	5.1	40	2	9	11	InChI=1S/C29H26ClFN4O4S/c1-40(36,37)12-11-32-16-23-7-10-27(39-23)20-5-8-26-24(14-20)29(34-18-33-26)35-22-6-9-28(25(30)15-22)38-17-19-3-2-4-21(31)13-19/h2-10,13-15,18,32H,11-12,16-17H2,1H3,(H,33,34,35)	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	CS(=O)(=O)CCNCC1=CC=C(O1)C2=CC3=C(C=C2)N=CN=C3NC4=CC(=C(C=C4)OCC5=CC(=CC=C5)F)Cl	BCFGMOOMADDAQU-UHFFFAOYSA-N	N-[3-chloro-4-[(3-fluorophenyl)methoxy]phenyl]-6-[5-[(2-methylsulfonylethylamino)methyl]furan-2-yl]quinazolin-4-amine
ferrodrug0085	Carvedilol	.	carvedilol; 72956-09-3; Coreg; Dilatrend; Eucardic; Kredex; Carvedilolum [Latin]; Carvedilolum; Querto; BM 14190; 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; BM-14190; Dimitone; Artist; SKF 105517; 1-((9H-Carbazol-4-yl)oxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)propan-2-ol; Coronis; Korvasan; Talliton; DQ 2466; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol; DQ-2466; (+-)-1-(Carbazol-4-yloxy)-3-((2-(o-methoxyphenoxy)ethyl)amino)-2-propanol; (+/-)-Carvedilol-d4; CHEMBL723; NSC-758694; SK&F-105517; [3-(9H-carbazol-4-yloxy)-2-hydroxypropyl][2-(2-methoxyphenoxy)ethyl]amine; BM 14.190; BM-14-190; BM-14.190; CHEBI:3441; C07AG02; 0K47UL67F2; SKF-105517; Carvedilol-methyl-d3; 1-(9H-carbazol-4-yloxy)-3-{[2-(2-methoxyphenoxy)ethyl]amino}propan-2-ol; Coropress; Dibloc; 1-(9H-carbazol-4-yloxy)-3-[(2-{[2-(methyloxy)phenyl]oxy}ethyl)amino]propan-2-ol; SMR000449280; Artist (TN); Coreg (TN); HSDB 7044; SR-01000759289; UNII-0K47UL67F2; MFCD00869663; 1-(9H-Carbazol-4-yloxy)-3-(2-(2-methoxyphenoxy)ethylamino)propan-2-ol; EG-P042; (R)-BM 14190; MFCD00864692; Carvedilol - Bio-X; BM14190; Carvedilol [USAN:USP:INN:BAN:JAN]; Spectrum_001665; CARVEDILOL [MI]; CARVEDILOL [INN]; CARVEDILOL [JAN]; Spectrum2_001673; Spectrum3_001182; Spectrum4_000636; Spectrum5_001436; CARVEDILOL [HSDB]; CARVEDILOL [USAN]; CARVEDILOL [VANDF]; CARVEDILOL [MART.]; CARVEDILOL [USP-RS]; CARVEDILOL [WHO-DD]; SCHEMBL22293; GTPL551; KBioGR_001252; KBioSS_002145; MLS000758299; MLS000759508; MLS001424092; MLS006011886; SPBio_001885; Carvedilol (JP17/USP/INN); CARVEDILOL [ORANGE BOOK]; DTXSID8022747; SCHEMBL10082334; SCHEMBL13287211; BDBM25759; KBio2_002145; KBio2_004713; KBio2_007281; KBio3_002323; CARVEDILOL [EP MONOGRAPH]; (R)-1-[(4-Carbazolyl)oxy]-3-[[2-(2-methoxyphenoxy)ethyl]amino]-2-propanol; OGHNVEJMJSYVRP-UHFFFAOYSA-N; CARVEDILOL [USP MONOGRAPH]; HMS2051N03; HMS2089B09; HMS2093E12; HMS3261E15; HMS3269N11; HMS3393N03; HMS3413B14; HMS3655O14; HMS3677B14; HMS3715D15; HMS3750I15; HMS3884E12; Pharmakon1600-01504257; Carvedilol 1.0 mg/ml in Methanol; AMY40801; BCP23386; EX-A5746; HY-B0006; Tox21_500347; BBL029064; MFCD00869664; NSC758694; s1831; STK621453; AKOS005554967; Carvedilol, >=98% (HPLC), solid; AC-1641; BCP9000493; CCG-100917; CCG-207952; CS-1194; DB01136; KS-1037; LP00347; NC00167; NSC 758694; SB17441; SDCCGSBI-0206771.P002; 2-Propanol, 1-(9H-carbazol-4-yloxy)-3-((2-(2-methoxyphenoxy)ethyl)amino)-, (+-)-; NCGC00167832-01; NCGC00167832-02; NCGC00167832-03; NCGC00167832-04; NCGC00167832-19; NCGC00261032-01; BC164291; SY129821; SY283162; BCP0726000253; SBI-0206771.P001; C2260; FT-0603055; FT-0603057; FT-0652640; FT-0664397; SW197547-3; C06875; D00255; F19969; AB00639903-07; AB00639903-09; AB00639903_10; AB00639903_11; AB00639903_12; L001243; Q412534; Q-200801; SR-01000759289-5; SR-01000759289-6; SR-01000759289-9; BRD-A10977446-001-04-8; BRD-A10977446-001-05-5; BRD-A10977446-045-01-1; Z1515383337; Carvedilol, European Pharmacopoeia (EP) Reference Standard; Ethyl 2-(9-(pyridin-4-ylmethyl)-9H-fluoren-9-yl)acetate; Carvedilol, United States Pharmacopeia (USP) Reference Standard; 1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxy-phenoxy)-ethylamino]-propan-2-ol; Carvedilol, Pharmaceutical Secondary Standard; Certified Reference Material; (+/-)-1-CARBAZOL-4-YLOXY)-3-((2-(O-METHOXYPHENOXY)ETHYL)AMINO)-2-PROPANOL; 1-(CARBAZOL-4-YLOXY)-3-((2-(O-METHOXY-PHENOXY)ETHYL)AMINO)-2-PROPANOL; Carvedilol for system suitability, European Pharmacopoeia (EP) Reference Standard; 107741-96-8; 2-PROPANOL, 1-(9H-CARBAZOL-4-YLOXY)-3-((2-(2-METHOXYPHENOXY)ETHYL)AMINO)-, (+/-)-	.	.	406.5	C24H26N2O4	75.7	508	4.2	30	3	5	10	InChI=1S/C24H26N2O4/c1-28-21-10-4-5-11-22(21)29-14-13-25-15-17(27)16-30-23-12-6-9-20-24(23)18-7-2-3-8-19(18)26-20/h2-12,17,25-27H,13-16H2,1H3	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O	OGHNVEJMJSYVRP-UHFFFAOYSA-N	1-(9H-carbazol-4-yloxy)-3-[2-(2-methoxyphenoxy)ethylamino]propan-2-ol
ferrodrug0086	Vorinostat	.	Vorinostat; 149647-78-9; SAHA; suberoylanilide hydroxamic acid; Zolinza; N-hydroxy-N'-phenyloctanediamide; N1-hydroxy-N8-phenyloctanediamide; Suberanilohydroxamic acid; MK-0683; MK0683; Octanediamide, N-hydroxy-N'-phenyl-; Vorinostat (SAHA, MK0683); N'-hydroxy-N-phenyloctanediamide; OCTANEDIOIC ACID HYDROXYAMIDE PHENYLAMIDE; Vorinostat (SAHA); CCRIS 8456; N-Hyrdroxy-N'-phenyloctanediamide; NSC-701852; SHH; C14H20N2O3; CHEMBL98; MFCD00945317; NSC-748799; NSC-759852; 58IFB293JI; DTXSID6041133; CHEBI:45716; N1-hydroxy-N8-phenyl-octanediamide; WIN64652; NSC701852; SAHA cpd; NCGC00168085-01; NCGC00168085-02; Vorinostat [USAN]; Zolinza (TN) (Merck); N-hydroxy-N'-phenyl-octane-1,8-diotic acid diamide; DTXCID4021133; Vorinostat MSD; SMR000486344; Zolinza (TN); CAS-149647-78-9; SR-05000000373; Vorinostat (JAN/USAN); Vorinostat [USAN:INN]; MK 0683; vorinostatum; UNII-58IFB293JI; SKI390; HSDB 7930; 4lxz; Vorinostat(SAHA); Zolinza; SAHA; Vorinostat - SAHA; SAHA, Suberoylanilide hydroxamic acid; 1zz1; VORINOSTAT [MI]; SW-064652; VORINOSTAT [INN]; VORINOSTAT [JAN]; 8-(hydroxyamino)-8-oxo-N-phenyl-octanamide; VORINOSTAT [VANDF]; cid_5311; SCHEMBL9018; VORINOSTAT [MART.]; VORINOSTAT [WHO-DD]; Suberoylanilidehydroxamic Acid; MLS001065855; MLS006011941; n-hydroxy-n-phenyloctanediamide; GTPL6852; VORINOSTAT [ORANGE BOOK]; BDBM19149; Vorinostat (SAHA; MK0683); SUBERANILOHYDROXAMINIC ACID; 1t69; N-hydroxy-N''-phenyloctanediamide; BCPP000018; HMS2219L20; HMS3264D20; HMS3327C12; HMS3426G03; HMS3650D09; HMS3654G11; HMS3715E22; HMS3745M03; Pharmakon1600-01502267; BCP01858; EX-A2745; SAHA, >=98% (HPLC); Vorinostat,SAHA,Zolinza,MK-0683; Tox21_112605; Tox21_113623; Vorinostat,CAS:149647-78-9; HB1396; NSC748799; NSC759852; Octanediamide, N1-hydroxy-N8-phenyl; s1047; SK1390; AKOS015966648; Octanediamide, N1-hydroxy-N8-phenyl-; Tox21_112605_1; AC-1923; CCG-208659; CS-0589; DB02546; DG-0025; NSC 701852; NSC 748799; NSC 759852; SB17319; Suberoylanilide hydroxamic acid (SAHA); NCGC00168085-03; NCGC00168085-04; NCGC00168085-05; NCGC00168085-13; BP-25652; BP-30216; BV164560; HY-10221; SY009383; AM20030018; FT-0650593; H1388; SW199536-4; EC-000.2057; D06320; EN300-120641; AB00375377-07; AB00375377-08; AB00375377-09; AB01644613_25; A808935; Q905901; Vorinostat, SAHA, suberoylanilide hydroxamic acid; SR-05000000373-2; SR-05000000373-6; SR-05000000373-8; W-201327; BRD-K81418486-001-01-2; BRD-K81418486-001-10-3; BRD-K81418486-001-12-9; BRD-K81418486-001-13-7; BRD-K81418486-001-17-8; BRD-K81418486-001-18-6; Z1530532755; N-Hydroxy-N inverted exclamation mark -phenyloctanediamide; 1227736-21-1	.	.	264.32	C14H20N2O3	78.4	276	1.9	19	3	3	8	InChI=1S/C14H20N2O3/c17-13(15-12-8-4-3-5-9-12)10-6-1-2-7-11-14(18)16-19/h3-5,8-9,19H,1-2,6-7,10-11H2,(H,15,17)(H,16,18)	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO	WAEXFXRVDQXREF-UHFFFAOYSA-N	N'-hydroxy-N-phenyloctanediamide
ferrodrug0087	Bilirubin	Small molecular drug	bilirubin; 635-65-4; Hematoidin; Hemetoidin; Bilirubin IX-alpha; Cholerythrin; Bilibubin; Bilirubin IX.alpha.; 3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid; Bilirubin IXalpha; RFM9X3LJ49; 21H-Biline-8,12-dipropanoic acid, 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-; (4z,15z)-bilirubin ix.alpha.; CHEBI:16990; 93891-87-3; Disodium bilirubinate IXalpha; NSC-26685; PHEOPHYTIN; Biline-8,12-dipropionic acid, 1,10,19,22,23,24-hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-; 1,10,19,22,23,24-hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinylbiline-8,12-dipropionic acid; 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-biline-8,12-dipropanoic acid; 3-(2-((3-(2-carboxyethyl)-4-methyl-5-((Z)-(3-methyl-5-oxo-4-vinyl-1H-pyrrol-2(5H)-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((Z)-(4-methyl-5-oxo-3-vinyl-1H-pyrrol-2(5H)-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; Calcium bilirubinate; Basinite; EINECS 211-239-7; Bilirubin IX alpha; MFCD00005499; NSC 26685; UNII-RFM9X3LJ49; BRN 0074376; Bilirubin test; AI3-23078; CCRIS 9347; bilirubin-IXalpha; bilirubin(Z,Z); Bilirubin,(S); 3-[5-[(Z)-(4-Ethenyl-3-Methyl-5-Oxidanylidene-Pyrrol-2-Ylidene)methyl]-2-[[5-[(Z)-(3-Ethenyl-4-Methyl-5-Oxidanylidene-Pyrrol-2-Ylidene)methyl]-3-(3-Hydroxy-3-Oxopropyl)-4-Methyl-1h-Pyrrol-2-Yl]methyl]-4-Methyl-1h-Pyrrol-3-Yl]propanoic Acid; EINECS 299-468-9; Bilirubin, 98%; (Z,Z)-Bilirubin IXa; BILIRUBIN [MI]; Spectrum5_000410; bmse000627; BILIRUBIN [WHO-DD]; SCHEMBL19065; (4Z,15Z)-Bilirubin IXa; BSPBio_002531; 5-26-15-00523 (Beilstein Handbook Reference); SPECTRUM1500857; BILIRUBIN TEST [VANDF]; CHEMBL501680; GTPL4577; SCHEMBL5086205; DTXSID8060905; S00334a; BCP13520; HY-N0323; BDBM50442897; CCG-38548; HSCI1_000394; s5116; STL564421; AKOS015895627; Bilirubin, purum, >=95.0% (UV); SDCCGMLS-0066651.P001; NCGC00095645-01; 18422-02-1; 3-{2-({3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl}methyl)-4-methyl-5-[(Z)-(4-methyl-5-ox; AC-20194; AC-34137; Disodium 1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-2,17-divinyl-21H-biline-8,12-dipropionate; CS-0008888; -ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-; -(3-methyl-5-oxo-4-vinyl-1H-pyrrol-2(5H); B-2500; B-2501; C00486; methyl-5-((Z)-(4-methyl-5-oxo-3-vinyl-1H-; 3-(2-((3-(2-carboxyethyl)-4-methyl-5-((Z); Bilirubin, >=98% (EmM/453 = 60), powder; Q104219; SR-05000002757; SR-05000002757-1; pyrrol-2(5H)-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; 1,3,6,7-TETRAMETHYL-4,5-DICARBOXYETHYL-2,8-DIVINYL-(B-13)-DIHYDROBILENONE; 1,10,19,22,23,24-hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionate; 1,10,19,22,23,24-hexahydro-2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-Biline-8,12-dipropionic acid; 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-21H-Biline-8,12-dipropanoate; 2,7,13,17-tetramethyl-1,19-dioxo-3,18-divinyl-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid; 21H-Biline-8,12-dipropanoic acid, 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-, calcium salt; 21H-Biline-8,12-dipropanoic acid, 2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-, disodium salt; 21H-Biline-8,12-dipropanoic acid,2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-; 3,18-diethenyl-2,7,13,17-tetramethyl-1,19-dioxo-1,10,19,22,23,24-hexahydro-21H-biline-8,12-dipropanoic acid; 3-(2-((3-(2-carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoate; 3-(2-((3-(2-carboxyethyl)-4-methyl-5-((3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl)-1H-pyrrol-3-yl)propanoic acid; 3-(2-((3-(2-carboxyethyl)-4-methyl-5-((Z)-(3-methyl-5-oxo-4-vinyl-1H-pyrrol-2(5H)-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((Z)-(4-methyl-5-oxo-3-vinyl-1H-pyrrol-2(5H)-ylidene)methyl)-1H-pyrr; 3-(2-((3-(2-carboxyethyl)-4-methyl-5-((Z)-(3-methyl-5-oxo-4-vinyl-1H-pyrrol-2(5H)-ylidene)methyl)-1H-pyrrol-2-yl)methyl)-4-methyl-5-((Z)-(4-methyl-5-oxo-3-vinyl-1H-pyrrol-2(5H)-ylidene)methyl)-1H-pyrrol-3-yl)propanoicacid; 3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene; 3-(2-((3-(2-Carboxyethyl)-4-methyl-5-[(Z)-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene)methyl]-1H-pyrrol-2-yl)methyl)-4-methyl-5-[(Z)-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-2H-pyrrol-2-ylidene #; 3-(2-{[3-(2-carboxyethyl)-5-{[(2Z)-3-ethenyl-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-4-methyl-1H-pyrrol-2-yl]methyl}-5-{[(2Z)-4-ethenyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-4-methyl-1H-pyrrol-3-yl)propanoic acid; 3-(2-{[3-(2-carboxyethyl)-5-{[(2Z)-4-ethenyl-3-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-4-methyl-1H-pyrrol-2-yl]methyl}-5-{[(2Z)-3-ethenyl-4-methyl-5-oxo-2,5-dihydro-1H-pyrrol-2-ylidene]methyl}-4-methyl-1H-pyrrol-3-yl)propanoic acid; 3-[2-[[3-(2-carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate; 3-[2-[[3-(2-carboxyethyl)-5-[(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid; 3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoate; 3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxo-pyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid; 3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoicacid; 3-[2-[3-(2-Carboxy-ethyl)-4-methyl-5-(3-methyl-5-oxo-4-vinyl-1,5-dihydro-pyrrol-2-ylidenemethyl)-1H-pyrrol-2-ylmethyl]-4-methyl-5-(4-methyl-5-oxo-3-vinyl-1,5-dihydro-pyrrol-2-ylidenemethyl)-1H-pyrrol-; 3Q9; 8,12-bis(2-carboxyethyl)-2,7,13,17-tetramethyl-3,18-divinylbiladiene-ac-1,19(21H,24H)-dione; Bilirubin: 21H-Biline-8,12-dipropanoicacid,2,17-diethenyl-1,10,19,22,23,24-hexahydro-3,7,13,18-tetramethyl-1,19-dioxo-,	D0O8ZV	DMI0V4O	584.7	C33H36N4O6	164	1340	2.9	43	6	6	12	InChI=1S/C33H36N4O6/c1-7-20-19(6)32(42)37-27(20)14-25-18(5)23(10-12-31(40)41)29(35-25)15-28-22(9-11-30(38)39)17(4)24(34-28)13-26-16(3)21(8-2)33(43)36-26/h7-8,13-14,34-35H,1-2,9-12,15H2,3-6H3,(H,36,43)(H,37,42)(H,38,39)(H,40,41)/b26-13-,27-14-	CC1=C(NC(=C1CCC(=O)O)CC2=C(C(=C(N2)/C=C\3/C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)/C=C\4/C(=C(C(=O)N4)C=C)C	CC1=C(NC(=C1CCC(=O)O)CC2=C(C(=C(N2)C=C3C(=C(C(=O)N3)C)C=C)C)CCC(=O)O)C=C4C(=C(C(=O)N4)C=C)C	BPYKTIZUTYGOLE-IFADSCNNSA-N	3-[2-[[3-(2-carboxyethyl)-5-[(Z)-(3-ethenyl-4-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-2-yl]methyl]-5-[(Z)-(4-ethenyl-3-methyl-5-oxopyrrol-2-ylidene)methyl]-4-methyl-1H-pyrrol-3-yl]propanoic acid
ferrodrug0088	Zileuton	Small molecular drug	ZILEUTON; 111406-87-2; Zyflo; Leutrol; 1-(1-(Benzo[b]thiophen-2-yl)ethyl)-1-hydroxyurea; Zyflo CR; Zileutonum; Abbott 64077; Zileutonum [INN-Latin]; 1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea; A-64077; N-(1-Benzo(b)thien-2-ylethyl)-N-hydroxyurea; A 64077; Zyflo (TN); ABBOTT-64077; Urea, N-(1-benzo[b]thien-2-ylethyl)-N-hydroxy-; CHEMBL93; 1-[1-(1-benzothien-2-yl)ethyl]-1-hydroxyurea; NSC-730712; NSC-759277; N-[1-(benzo[b]thiophen-2-yl)ethyl]-N-hydroxyurea; V1L22WVE2S; (+-)-1-(1-Benzo(b)thien-2-ylethyl)-1-hydroxyurea; (+/-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; DTXSID9023752; CHEBI:10112; n-(1-benzo[b]thien-2-ylethyl)-n-hydroxyurea; (+-)-1-(1-Benzo[b]thien-2-ylethyl)-1-hydroxyurea; N-(1-BENZO(B)THIEN-2-YL-ETHYL)-N-HYDROXYUREA; NCGC00159453-02; Urea, N-(1-benzo(b)thien-2-ylethyl)-N-hydroxy-; DTXCID003752; Ziluton; Zyflo Filmtab; SMR000466377; CAS-111406-87-2; Zileuton (USP/INN); SR-01000759349; (+/-)-1-(1-benzo(b)thien-2-ylethyl)-1-hydroxyurea; UNII-V1L22WVE2S; CTI-02; ( inverted exclamation markA)-1(1-Benzo[b]thien-2-ylethyl)-1-hydroxyure; ABT-077; Zileuton [USAN:USP:INN:BAN]; Zileuton- Bio-X; MFCD00866097; starbld0016861; ZILEUTON [USAN]; ZILEUTON [INN]; ZILEUTON [MI]; ZILEUTON [VANDF]; Prestwick0_001090; ZILEUTON [MART.]; ZILEUTON [USP-RS]; ZILEUTON [WHO-DD]; SCHEMBL4209; MLS000759510; MLS001424079; MLS006011971; ZILEUTON [ORANGE BOOK]; GTPL5297; Zileuton, >=98% (HPLC); SCHEMBL18251470; ZILEUTON [USP MONOGRAPH]; Urea, N-(1-benzo(b)thien-2-ylethyl)-N-hydroxy-, (+-)-; MWLSOWXNZPKENC-UHFFFAOYSA-N; HMS2051M20; HMS2089J12; HMS2093H06; HMS2235O04; HMS3369I17; HMS3393M20; HMS3654J08; HMS3714E07; HMS3872F13; Pharmakon1600-01505906; AMY12540; BCP16199; Tox21_111680; Tox21_301148; BBL029070; BDBM50000541; NSC730712; NSC759277; s1443; STL373010; AKOS000280127; AKOS016340558; Tox21_111680_1; CCG-100901; CCG-213571; CS-1563; DB00744; KS-1195; NC00151; NSC 730712; NSC 759277; SB19083; MRF-0000030; NCGC00159453-03; NCGC00159453-04; NCGC00159453-05; NCGC00159453-06; NCGC00255046-01; AC-13198; AC-31490; BZ164573; HY-14164; SBI-0206869.P001; BB 0261152; FT-0601582; FT-0675903; SW197531-3; D00414; EN300-123022; N-(1-benzo[b]thien-2-ylethyl)-N-hydroxy-urea; ()-1(1-Benzo[b]thien-2-ylethyl)-1-hydroxyure; AB00639921-06; AB00639921-08; AB00639921-09; AB00639921_10; AB00639921_11; A802357; Q202998; J-002574; J-525169; SR-01000759349-4; SR-01000759349-5; SR-01000759349-6; Zileuton, commercially available as 600 mg tablets; BRD-A56359832-001-04-6; Z1546610483; Zileuton, United States Pharmacopeia (USP) Reference Standard; UREA, N-(1-BENZO(B)THIEN-2-YLETHYL)-N-HYDROXY-, (+/-)-	D09JUG	DMVRIC2	236.29	C11H12N2O2S	94.8	275	1.6	16	2	3	2	InChI=1S/C11H12N2O2S/c1-7(13(15)11(12)14)10-6-8-4-2-3-5-9(8)16-10/h2-7,15H,1H3,(H2,12,14)	CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O	CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O	MWLSOWXNZPKENC-UHFFFAOYSA-N	1-[1-(1-benzothiophen-2-yl)ethyl]-1-hydroxyurea
ferrodrug0089	Zoledronic acid	.	Zoledronic acid; 118072-93-8; Zoledronate; Zometa; Reclast; Aclasta; (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonic acid; CGP 42446; (1-Hydroxy-2-imidazol-1-ylethylidene)diphosphonic acid; Zoledronic Acid Anhydrous; C5H10N2O7P2; Anhydrous Zoledronic Acid; (1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid; Phosphonic acid, [1-hydroxy-2-(1H-imidazol-1-yl)ethylidene]bis-; ZOL; Zoledronic-d3 Acid; Orazol; ZOL 446; [1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl]bis(phosphonic acid); Zoledronic acid (INN); CGP-42446; Reclast (TN); Zometa (TN); CHEMBL924; Zoledronic Acid Teva; Zoledronic Acid, Anhydrous; NSC-721517; Zoledronic Acid Medac; 2-(imidazol-1-yl)-1-hydroxyethane-1,1-diphosphonic acid; DTXSID0042668; CHEBI:46557; [1-hydroxy-2-(1H-imidazol-1-yl)-1-phosphonoethyl]phosphonic acid; 70HZ18PH24; NCGC00159521-02; (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bisphosphonic acid; CGP-42446A; Zoledronate hydrate; Zoledronic acid [USAN:INN:BAN]; Phosphonic acid, (1-hydroxy-2-(1H-imidazol-1-yl)ethylidene)bis-; Zoladrona acid mylan; ZOLEDRONIC; Zoledronic acid accord; ZOLEDRONIC ACID [INN]; Zomera; 1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyldiphosphonic acid; Bisphosphonate 3; Zometa (Novartis); Aclasta and Reclast; [1-Hydroxy-2-(1H-imidazol-1-yl)ethylidene]bisphosphonic acid; zoledronic-acid; UNII-70HZ18PH24; BPH 91; (1-hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)bis(phosphonic acid); [1-HYDROXY-2-(1H-IMIDAZOL-1-YL)-ETHYLIDENE]BISPHOSPHONIC ACID; Zoledronic acid, Zoledronate; BIDD:PXR0134; SCHEMBL19054; ZOLEDRONIC ACID [MI]; BIDD:GT0292; Zoledronic Acid (Zoledronate); GTPL3177; JMC515594 Compound 55; DTXCID8022668; BDBM12578; CGP42446A; ZOLEDRONIC ACID [WHO-DD]; XRASPMIURGNCCH-UHFFFAOYSA-N; HMS2089O09; BCP22750; CGP-4244; Tox21_111739; HB0674; MFCD00867791; NSC721517; s1314; STL452893; AKOS005145739; AB07564; AC-1092; CS-1829; DB00399; HS-0091; NSC 721517; NCGC00159521-03; NCGC00159521-04; NCGC00159521-05; NCGC00159521-09; NCGC00159521-18; HY-13777; CAS-118072-93-8; FT-0601384; Z0031; D08689; EN300-117269; H11422; S00092; AB01273947-01; AB01273947-02; AB01273947-03; AB01273947_04; A803876; Q218507; SR-05000001436; Q-201946; SR-05000001436-1; 1-Hydroxy-2-(1-imidazolyl)ethane-1,1-diphosphonic Acid; Z1501485360; (1-Hydroxy-2-(1H-imidazol-1-yl)ethane-1,1-diyl)diphosphonicacid	.	.	272.09	C5H10N2O7P2	153	327	-4.3	16	5	8	4	InChI=1S/C5H10N2O7P2/c8-5(15(9,10)11,16(12,13)14)3-7-2-1-6-4-7/h1-2,4,8H,3H2,(H2,9,10,11)(H2,12,13,14)	C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O	C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O	XRASPMIURGNCCH-UHFFFAOYSA-N	(1-hydroxy-2-imidazol-1-yl-1-phosphonoethyl)phosphonic acid
ferrodrug0090	Clioquinol	.	clioquinol; 130-26-7; 5-Chloro-7-iodoquinolin-8-ol; Iodochlorhydroxyquin; Chinoform; Chloroiodoquin; 5-Chloro-7-iodo-8-quinolinol; Chloroiodoquine; 5-Chloro-8-hydroxy-7-iodoquinoline; Vioform; Iodochloroxyquinoline; Cliquinol; Iodochlorohydroxyquinoline; Chlorojodochin; Enteroquinol; Iodochloroquine; Iodochloroxine; Iodoenterol; 7-Iodo-5-chloroxine; Entero-Vioform; Iodochlorhydroxyquinoline; 5-Chloro-7-iodo-8-hydroxyquinoline; Iodoxyquinoline; Alchloquin; Barquinol; Budoform; Cifoform; Dermaform; Dioquinol; Domeform; Eczecidin; Enteroseptol; Enterozol; Enterseptol; Entrokin; Iodenterol; Lekosept; Mycoquin; Quinambicide; Quinoform; Rheaform; Amebil; Amoenol; Bactol; Emaform; Nioform; Rometin; Entero-Bioform; Iodochlorohydroxyquin; Hi-Enterol; Iodochlorhydroxyquinol; Hydriodide-enterol; Quin-O-Creme; Chinoformum; Cliochinolum; Entero-Septol; Enterum locorten; 5-Chloro-7-iodo-quinolin-8-ol; Domeform-HC; 8-Quinolinol, 5-chloro-7-iodo-; 7-Iodo-5-chloro-8-hydroxyquinoline; Clioquinolum; Enterovalodon; Alioform; Chloro-8-hydroxyiodoquinoline; Enteritan; Jodchloroxychinolinum; Corque; Cortin; Oralcer; Iodo; Iodochloroxychinolinum; Cremo-quin; Entero-bio form; Entero-Vioformio; Ala-Quin; Quinoform (antiseptic); UAD Lotion; Vioform n.n.r.; Cliochinolo; Cliochinolo [DCIT]; Caswell No. 193; Formtone-HC; Clioquinolum [INN-Latin]; Quinoline, chloro-8-hydroxyiodo-; 5-Chlor-7-jod-8-hydroxy-chinolin; Rheaform boluses; iodochlorhydroxyquinolone; 5-Chlor-7-jod-8-hydroxy-chinolin [German]; NSC-3531; 7BHQ856EJ5; DTXSID7022837; CHEBI:74460; NSC-74938; NCGC00016391-05; CAS-130-26-7; TG2-36-2; C9H5ClINO; PBT-1; Quinoform (VAN); DTXCID502837; loquinol; Vioformio; Hi-eneterol; Iodochlorhydroxyquin Cream; Vioform-Hydrocortisone Mild; 22112-03-4; SMR000058282; Rheaform Boluses (Veterinary); CCRIS 6050; HSDB 6843; SR-01000002987; NSC 3531; EINECS 204-984-4; EPA Pesticide Chemical Code 024001; BRN 0153637; UNII-7BHQ856EJ5; Linolasept; Clioquinol [USP:INN:BAN]; Cloquinol; AI3-16451; Clioquinol (CQ); component of Hyquin; MFCD00006787; NSC 74938; Nystaform (Salt/Mix); Clioquinol (USP/INN); CLIOQUINOL [INN]; component of Formtone-HC; component of Heb-Cort V; Prestwick0_000886; Prestwick1_000886; Prestwick2_000886; Prestwick3_000886; CLIOQUINOL [HSDB]; Formtone-HC (Salt/Mix); CLIOQUINOL [VANDF]; CHEMBL497; EC 204-984-4; cid_2788; CLIOQUINOL [MART.]; SCHEMBL3967; CLIOQUINOL [USP-RS]; CLIOQUINOL [WHO-DD]; NCIOpen2_009062; Oprea1_438281; BSPBio_000672; BSPBio_002466; 5-21-03-00294 (Beilstein Handbook Reference); ksc-8-192; MLS000069389; MLS002454410; SPECTRUM1505114; SPBio_002891; BPBio1_000740; CLIOQUINOL [ORANGE BOOK]; component of Hyquin (Salt/Mix); BDBM32188; IODOCHLORHYDROXYQUIN [MI]; CLIOQUINOL [EP MONOGRAPH]; NSC3531; WLN: T66 BNJ GG II JQ; CLIOQUINOL [USP MONOGRAPH]; HMS1570B14; HMS1648J07; HMS2093I12; HMS2097B14; HMS2230I20; HMS3372J20; HMS3714B14; KUC105859N; Pharmakon1600-01505114; component of Cort-Quin (Salt/Mix); Tox21_110416; Tox21_200291; NSC759822; NYSTAFORM COMPONENT CLIOQUINOL; s4601; STK399761; 5-chloro-8-hydroxy-7-iodo-quinoline; component of Heb-Cort V (Salt/Mix); AKOS000120779; Tox21_110416_1; AC-6792; CCG-213339; DB04815; FD10468; NSC-759822; CLIOQUINOL COMPONENT OF NYSTAFORM; SMP1_000073; IODOCHLORHYDROXYQUIN [GREEN BOOK]; NCGC00016391-01; NCGC00016391-02; NCGC00016391-03; NCGC00016391-04; NCGC00016391-06; NCGC00016391-07; NCGC00016391-08; NCGC00016391-09; NCGC00016391-10; NCGC00016391-13; NCGC00021665-03; NCGC00021665-04; NCGC00021665-05; NCGC00257845-01; S4601 5-Chloro-8-hydroxy-7-iodoquin; AS-14597; BC167259; HY-14603; SBI-0206782.P001; AB00384254; FT-0603209; 4-stearylamino-phenyl-trimethylam. metilsulf.; EN300-20836; A16461; Clioquinol, VETRANAL(TM), analytical standard; component of Vioform-Hydrocortisone (Salt/Mix); D03538; AB00384254_17; 5-Chloro-7-iodo-8-quinolinol, >=95.0% (HPLC); CU-01000000767-2; Q-200875; Q5134338; SR-01000002987-2; SR-01000002987-3; SR-01000002987-4; BRD-K09255212-001-04-2; Z104483432; Clioquinol, British Pharmacopoeia (BP) Reference Standard; Clioquinol, European Pharmacopoeia (EP) Reference Standard; Clindamycin phosphate, Antibiotic for Culture Media Use Only; Clioquinol, United States Pharmacopeia (USP) Reference Standard; InChI=1/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13; CQL	.	.	305.5	C9H5ClINO	33.1	193	3.5	13	1	2	0	InChI=1S/C9H5ClINO/c10-6-4-7(11)9(13)8-5(6)2-1-3-12-8/h1-4,13H	C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1	C1=CC2=C(C(=C(C=C2Cl)I)O)N=C1	QCDFBFJGMNKBDO-UHFFFAOYSA-N	5-chloro-7-iodoquinolin-8-ol
ferrodrug0091	Arachidonic acid	Small molecular drug	arachidonic acid; 506-32-1; arachidonate; Immunocytophyte; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid; (all-Z)-5,8,11,14-Eicosatetraenoic acid; cis-5,8,11,14-Eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid, (all-Z)-; all-cis-5,8,11,14-eicosatetraenoic acid; Arachidonsaeure; 5Z,8Z,11Z,14Z-eicosatetraenoic acid; (5Z,8Z,11Z,14Z)-5,8,11,14-Eicosatetraenoic Acid; UNII-27YG812J1I; CCRIS 6312; CHEBI:15843; 27YG812J1I; EINECS 208-033-4; CHEMBL15594; AI3-09613; DTXSID4040420; (5Z,8Z,11Z,14Z)-5,8,11,14-Eikosatetraensaeure; 5Z,8Z,11Z,14Z-icosatetraenoic acid; FA 20:4; ARACHIDONIC ACID (20:4, n-6); (5Z,8Z,11Z,14Z)-Icosatetraenoic acid; 5,8,11,14-Eicosatetraenoic acid; C20:4; cis-Delta(5,8,11,14)-eicosatetraenoic acid; [1-14C]Arachidonic acid; (5Z,8Z,11Z,14Z)-5,8,11,14-Icosatetraenoic acid; ARACHIDONIC ACID (MART.); ARACHIDONIC ACID [MART.]; (14C)Arachidonic acid; Arachidonic Acid, 99%; Immunocytophyt; Vevodar; 5,8,11,14-Icosatetraenoic Acid; arachidonic-acid; 1adl; 1gnj; 1vyg; MFCD00004417; (14C)-arachidonic acid; Spectrum5_001910; Arachidonic Acid, >97%; D0HD9P; Fatty Acid 20:4 n-6; SCHEMBL16162; BSPBio_001539; MLS001361328; ARACHIDONIC ACID [MI]; AA-[d8]; BML3-B03; GTPL2391; ARACHIDONIC ACID [INCI]; 5,8,11,14-Eicosatetraenoate; DTXCID2020420; BDBM22319; ARACHIDONIC ACID [WHO-DD]; CHEBI:137828; HMS1361M21; HMS1791M21; HMS1989M21; HMS3402M21; HMS3649B05; 5Z,8Z,11Z,14Z-Eicosatetraenoate; Arachidonic acid, >95.0% (GC); 5,8,11,14-Eicosatetraenoic acid, labeled with carbon-14, (all-Z)-; Arachidonic acid, analytical standard; cis-D5,8,11,14-Eicosatetraenoate; LMFA01030001; s6185; AKOS015950830; CCG-214838; DB04557; FS-5880; 5,8,11,14-all-cis-Eicosatetraenoate; all-cis-5,8,11,14-Eicosatetraenoate; ARACHIDONIC ACID (20:4 n-6); IDI1_034009; cis-D5,8,11,14-Eicosatetraenoic acid; NCGC00094608-01; NCGC00094608-02; NCGC00094608-03; NCGC00094608-04; NCGC00094608-05; NCGC00094608-06; (all-Z)-5,8,11,14-Eicosatetraenoate; 93444-49-6; AC-14348; AC-33769; BP-29803; SMR000857374; 5,8,11,14-all-cis-Eicosatetraenoic acid; All-cis-icosa-5,8,11,14-tetraenoic acid; HY-109590; A0781; all-cis-eicosa-5,8,11,14-tetraenoic acid; CS-0032762; 5-cis,8-cis,11-cis,14-cis-Eicosatetraenoate; Arachidonic acid (in Tocrisolvetrade mark100); C00219; W15452; FA(20:4(5Z,8Z,11Z,14Z)); 5-cis,8-cis,11-cis,14-cis-Eicosatetraenoic acid; A929392; Q407699; SR-01000838311; SR-01000838311-2; BRD-K03070961-001-02-8; BRD-K03070961-001-04-4; (5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoicacid; (5Z,8Z,11Z,14Z)-5,8,11,14-Icosatetraenoic acid #; Arachidonic acid, from non-animal source, >=98.5% (GC); Arachidonic acid, from porcine liver, >=99% (GC), liquid; D18DBC10-379C-4E78-9A50-8B791A2F4E68; Arachidonic acid, from porcine liver, >=85% (capillary GC), liquid; Arachidonic acid, 1.0 mg/mL in ethanol, certified reference material; Arachidonic acid, from porcine liver, BioReagent, suitable for cell culture, >=99% (GC)	D0HD9P	DMUOQZD	304.5	C20H32O2	37.3	362	6.3	22	1	2	14	InChI=1S/C20H32O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18-19-20(21)22/h6-7,9-10,12-13,15-16H,2-5,8,11,14,17-19H2,1H3,(H,21,22)/b7-6-,10-9-,13-12-,16-15-	CCCCC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O	CCCCCC=CCC=CCC=CCC=CCCCC(=O)O	YZXBAPSDXZZRGB-DOFZRALJSA-N	(5Z,8Z,11Z,14Z)-icosa-5,8,11,14-tetraenoic acid
ferrodrug0092	Ursolic Acid	.	Ursolic acid; 77-52-1; Prunol; Malol; Urson; 3beta-Hydroxyurs-12-en-28-oic acid; Micromerol; (3beta)-3-Hydroxyurs-12-en-28-oic acid; (+)-Ursolic acid; NSC-4060; CCRIS 7123; CHEBI:9908; NSC 167406; ursolic-acid; EINECS 201-034-0; NSC-167406; UNII-P3M2575F3F; AI3-03109; HSDB 7685; P3M2575F3F; CHEMBL169; Urs-12-en-28-oic acid, 3beta-hydroxy-; NSC 4060; .beta.-Ursolic acid; (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid; Bungeolic acid; URSOLIC ACID (USP-RS); URSOLIC ACID [USP-RS]; 3beta-Hydroxy-12-ursen-28-ic acid; NSC4060; Prunol;Urson;Malol; MFCD00009621; SMR000445681; SR-01000779684; Urs-12-en-28-oic acid, 3-hydroxy-, (3.beta.)-; TNP00103; (3 beta)-3-hydroxyurs-12-en-28-oic acid; 6Q5; Urs-12-en-28-oic acid, 3-hydroxy-, (3beta)-; 3beta-hydroxy-Urs-12-en-28-oic acid; 3B-HYDROXYURS-12-EN-28-OIC ACID; Prestwick3_000089; Ursolic acid, >=90%; URSOLIC ACID [MI]; URSOLIC ACID [HSDB]; URSOLIC ACID [INCI]; SCHEMBL70205; BSPBio_000018; MLS000728569; MLS002154196; MLS002207073; URSOLIC ACID [WHO-DD]; BPBio1_000020; N-Ethylhydroxylaminehydrochloride; DTXSID70883221; Ursolic acid, analytical standard; WCGUUGGRBIKTOS-GPOJBZKASA-N; 3beta-Hydroxyurs-12-en-28-oate; HMS2095A20; HMS2231P19; (1S,2R,4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid; 3beta-hydroxy-Urs-12-en-28-oate; HY-N0140; BDBM50148911; 3beta-Hydroxy-12-ursen-28-oic Acid; AKOS005228010; AKOS016023773; 3.beta.-hydroxy-Urs-12-en-28-oate; CCG-208282; CS-3799; DB15588; LMPR0106180007; (3beta)-3-Hydroxyurs-12-en-28-oate; (3beta)-3-hydroxy-Urs-12-en-28-oate; AS-35119; 3.beta.-hydroxy-Urs-12-en-28-oic acid; (3beta)-3-hydroxy-Urs-12-en-28-oic acid; AB00513802; U0065; C08988; A839123; Q416260; Q-201916; SR-01000779684-4; SR-01000779684-5; (3.BETA.)-3-HYDROXYURS-12-EN-28-OIC ACID; BRD-K68185022-001-02-3; BRD-K68185022-001-14-8; URSOLIC ACID (CONSTITUENT OF HOLY BASIL LEAF); Ursolic acid, primary pharmaceutical reference standard; AF479D19-631E-48F1-8ABA-FB2A806046FA; URSOLIC ACID (CONSTITUENT OF HOLY BASIL LEAF) [DSC]; (3beta,5beta,18alpha,20beta)-3-hydroxyurs-12-en-28-oic acid; Ursolic acid, European Pharmacopoeia (EP) Reference Standard; '(3beta,5beta,18alpha,20beta)-3-hydroxyurs-12-en-28-oic acid'; Ursolic acid, United States Pharmacopeia (USP) Reference Standard; (1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylicacid	.	.	456.7	C30H48O3	57.5	874	7.3	33	2	3	1	InChI=1S/C30H48O3/c1-18-10-15-30(25(32)33)17-16-28(6)20(24(30)19(18)2)8-9-22-27(5)13-12-23(31)26(3,4)21(27)11-14-29(22,28)7/h8,18-19,21-24,31H,9-17H2,1-7H3,(H,32,33)/t18-,19+,21+,22-,23+,24+,27+,28-,29-,30+/m1/s1	C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)O)C)C)[C@@H]2[C@H]1C)C)C(=O)O	CC1CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1C)C)C(=O)O	WCGUUGGRBIKTOS-GPOJBZKASA-N	(1S,2R,4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-1,2,6a,6b,9,9,12a-heptamethyl-2,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydro-1H-picene-4a-carboxylic acid
ferrodrug0093	Berberine	.	berberine; 2086-83-1; Umbellatine; Berberin; Berbericine; Majarine; Thalsine; Umbellatin; Berberone; 0I8Y3P32UF; CHEBI:16118; EINECS 218-229-1; BRN 3570374; UNII-0I8Y3P32UF; Benzo(g)-1,3-benzodioxolo(5,6-a)quinolizinium, 5,6-dihydro-9,10-dimethoxy-; DTXSID9043857; 9,10-Dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetrahydroberbinium; Berberal; 9,10-dimethoxy-5,6-dihydro[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ium; 16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene; BERBERINE (MART.); BERBERINE [MART.]; Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy-; BERBINIUM, 7,8,13,13a-TETRAHYDRO-9,10-DIMETHOXY-2,3-(METHYLENEDIOXY)-; Berberine hydrogen sulfate; CHEMBL12089; 5,6-Dihydro-9,10-dimethoxybenzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium; 9,10-dimethoxy-2,3-(methylenedioxy)-7,8,13,13a-tetradehydroberbinium; 5,6-DIHYDRO-9,10-DIMETHOXY-1,3-BENZODIOXOLO(5,6-A)BENZO(G)QUINOLIZINIUM; 5,6-DIHYDRO-9,10-DIMETHOXYBENZO(G)-1,3-BENZODIOXOLO(5,6-A)QUINOLIZINIUM; 9,10-DIMETHOXY-5,6-DIHYDRO(1,3)DIOXOLO(4,5-G)ISOQUINO(3,2-A)ISOQUINOLIN-7-IUM; GNF-PF-4545; BER; NSC646666; NCGC00016526-02; NCGC00016526-07; CAS-633-65-8; Berbinium; berberine dimer; Coptis rhizome; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenebis(oxy))berbinium; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-[methylenebis(oxy)]berbinium; C20H18NO4; Umbellatine (6CI); Spectrum_001110; ST055798; Berbinium, 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)-, chloride; BERBERINE [MI]; Prestwick0_000586; Prestwick1_000586; Prestwick2_000586; Prestwick3_000586; Spectrum2_000894; Spectrum3_000618; Spectrum4_000785; Spectrum5_001458; BERBERINE [VANDF]; UPCMLD-DP032; NCIMech_000354; BERBERINE [WHO-DD]; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium; SCHEMBL25632; BSPBio_000432; BSPBio_002156; KBioGR_001230; KBioSS_001590; cid_12456; DivK1c_000265; inverted exclamation markY97%; SPBio_000708; SPBio_002651; BPBio1_000476; CHEMBL295124; MEGxp0_001923; DTXCID7023857; UPCMLD-DP032:001; ACon1_001957; BCBcMAP01_000112; GTPL11353; KBio1_000265; KBio2_001590; KBio2_004158; KBio2_006726; KBio3_001656; NINDS_000265; YBHILYKTIRIUTE-UHFFFAOYSA-N; 34MD1011DM; HMS3561D13; HY-N0716; AC-117; BBL029198; BDBM50203126; CCG-35898; s9046; STK870320; 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)berbinium; AKOS002141363; DB04115; SDCCGMLS-0066718.P001; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo-[4,5-g]isoquinolino[3,2-a]isoquinolin-7-ium; IDI1_000265; SMP1_000298; NCGC00016526-01; NCGC00016526-03; NCGC00016526-04; NCGC00016526-05; NCGC00016526-06; NCGC00016526-08; NCGC00016526-11; NCGC00091896-03; NCI60_001050; NCI60_001224; NCI60_004319; SBI-0051613.P002; BERBERINE (CONSTITUENT OF GOLDENSEAL); CS-0009734; FT-0603587; C00757; A904183; Q176525; BERBERINE (CONSTITUENT OF GOLDENSEAL) [DSC]; Q-200701; Q-200702; SR-01000711827-5; BRD-K14796088-003-06-0; BRD-K14796088-003-17-7; Benzylpenicillin benzathine, Antibiotic for Culture Media Use Only; 5,6-dihydro-9,10-dimethoxy-benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium; Berbinium, 7,8,13,13a-tetradehydro-9,10-dimethoxy-2,3-(methylenedioxy)-; 3,4-dimethoxy-6,7-dihydro-[1,3]dioxolo[4,5-g]pyrido[2,1-a]isoquinolin-5-ylium; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ylium; 9,10-Dimethoxy-5,6-dihydro-7lambda~5~-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinoline; Benzo[g]-1,3-benzodioxolo[5,6-a]quinolizinium, 5,6-dihydro-9,10-dimethoxy- (9CI); 16,17-dimethoxy-5,7-dioxa-13$l^{5}-azapentacyclo[11.8.0.0^{2,10}.0^{4,8}.0^{15,20}]henicosa-1(13),2,4(8),9,14,16,18,20-octaen-13-ylium; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ylium chloride; 9,10-Dimethoxy-5,6-dihydro-[1,3]dioxolo[4,5-g]isoquino[3,2-a]isoquinolin-7-ylium; chloride; InChI=1/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+	.	.	336.4	C20H18NO4+	40.8	488	3.6	25	0	4	2	InChI=1S/C20H18NO4/c1-22-17-4-3-12-7-16-14-9-19-18(24-11-25-19)8-13(14)5-6-21(16)10-15(12)20(17)23-2/h3-4,7-10H,5-6,11H2,1-2H3/q+1	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC	COC1=C(C2=C[N+]3=C(C=C2C=C1)C4=CC5=C(C=C4CC3)OCO5)OC	YBHILYKTIRIUTE-UHFFFAOYSA-N	16,17-dimethoxy-5,7-dioxa-13-azoniapentacyclo[11.8.0.02,10.04,8.015,20]henicosa-1(13),2,4(8),9,14,16,18,20-octaene
ferrodrug0094	Deferiprone	Small molecular drug	deferiprone; 30652-11-0; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone; Ferriprox; 3-hydroxy-1,2-dimethylpyridin-4(1H)-one; CP20; 1,2-dimethyl-3-hydroxy-4-pyridone; 1,2-Dimethyl-3-hydroxypyrid-4-one; APO-66; 3-hydroxy-1,2-dimethylpyridin-4-one; 1,2-Dimethyl-3-hydroxypyridine-4-one; 4(1H)-Pyridinone, 3-hydroxy-1,2-dimethyl-; APO-066; DN-180-01-AF; Deferipron; MFCD00134497; Deferiprone (INN); PL-1; L1; CHEBI:68554; 1,2-Dimethyl-3-hydroxy-4(1H)-pyridinone; CP-20; DN-18001AF; NSC-758880; 2BTY8KH53L; MLS000069481; HK-1; PL1; DTXSID6040666; 4(1H)-Pyridinone, 1,2-dimethyl-3-hydroxy-; SMR000059136; DEFERIPRONE [INN]; L-1; CP20 (Chelating agent); Ferriprox (TN); UNII-2BTY8KH53L; BRN 1447108; Deferidone; Deferiprona; Deferum; Deferiprone [USAN:INN:BAN]; CCRIS 8318; 1,2-dimethyl-3-hydroxy-4-pyridinone; 3-Hydroxy-1,2-dimethyl-4-pyridinone; Opera_ID_366; 3-hydroxy-1,2-dimethyl-4(1H)-pyridinone; DEFERIPRONE [MI]; 4(1H)-Pyridone, 3-hydroxy-1,2-dimethyl-; Deferiprone (USAN/INN); DEFERIPRONE [USAN]; DEFERIPRONE [VANDF]; DEFERIPRONE [MART.]; SCHEMBL94474; DEFERIPRONE [WHO-DD]; MLS000758227; MLS001424029; MLS006011689; CHEMBL70927; DEFERIPRONE [EMA EPAR]; CRMD-001; GTPL7456; DTXCID4020666; HSDB 8335; TZXKOCQBRNJULO-UHFFFAOYSA-; DEFERIPRONE [ORANGE BOOK]; EX-A972; TZXKOCQBRNJULO-UHFFFAOYSA-N; CP020; DEFERIPRONE [EP MONOGRAPH]; HMS2051C05; HMS2232E24; HMS3264P17; HMS3393C05; HMS3873L13; Pharmakon1600-01504512; BCP09606; HY-B0568; 3-hydroxy-1,2-dimethylpyrid-4-one; Tox21_112429; BBL036482; BDBM50525976; CGP-37391; NSC758880; s4067; STL559018; 1,2-dimetyl-3-hydroxy-4-pyridinone; AKOS015902286; CCG-100760; CS-5240; DB08826; DS-5493; NC00010; NSC 758880; 3-hydroxy-1,2-dimethyl-4- pyridinone; 3-hydroxy-1,2-dimethyl-pyridin-4-one; NCGC00090548-01; NCGC00090548-02; NCGC00090548-04; NCGC00090548-05; AC-33026; BP-12415; SY052576; SBI-0207041.P001; CAS-30652-11-0; FT-0606424; H0944; D07416; 3-Hydroxy-1,2-dimethyl-4(1H)-pyridone, 98%; AB00572605_11; AB00572605_12; EN300-1718313; 3-hydroxy-1,2-dimethyl-1,4-dihydropyridin-4-one; A820470; Q749664; SR-01000721891; Deferiprone 1,2-DIMETHYL-3-HYDROXY-4-PYRIDONE; SR-01000721891-4; Z1255390865; InChI=1/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3	D0N0OU	DMS2M7O	139.15	C7H9NO2	40.5	228	0.5	10	1	3	0	InChI=1S/C7H9NO2/c1-5-7(10)6(9)3-4-8(5)2/h3-4,10H,1-2H3	CC1=C(C(=O)C=CN1C)O	CC1=C(C(=O)C=CN1C)O	TZXKOCQBRNJULO-UHFFFAOYSA-N	3-hydroxy-1,2-dimethylpyridin-4-one
ferrodrug0095	Edaravone	Small molecular drug	edaravone; 89-25-8; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE; Radicut; Norphenazone; 1-Phenyl-3-methyl-5-pyrazolone; MCI-186; Developer Z; Methylphenylpyrazolone; C.I. Developer 1; Norantipyrine; Phenyl methyl pyrazolone; Phenylmethylpyrazolone; Radicava; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one; 3-Methyl-1-phenyl-1H-pyrazol-5(4H)-one; 1-Phenyl-3-methyl-5-oxo-2-pyrazoline; 3H-Pyrazol-3-one, 2,4-dihydro-5-methyl-2-phenyl-; 1-Phenyl-3-methylpyrazolone; 5-methyl-2-phenyl-4H-pyrazol-3-one; 1-Phenyl-3-methylpyrazolone-5; Edaravone (MCI-186); 3-Methyl-1-phenylpyrazol-5-one; 3-Methyl-1-phenyl-2-pyrazoline-5-one; NCI-C03952; 2-Pyrazolin-5-one, 3-methyl-1-phenyl-; 5-Pyrazolone, 3-methyl-1-phenyl-; 2,4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; Colorex pmp; Jarocol pmp; NSC-2629; 1-Fenyl-3-methyl-2-pyrazolin-5-on; NSC-26139; CHEBI:31530; 3-methyl-1-phenyl-4,5-dihydro-1H-pyrazol-5-one; S798V6YJRP; MLS000069602; 3-METHYL-1-PHENYL-2-PYRAZOLIN-5-ONE (MCI-186); DTXSID9021130; CI Developer 1; NCGC00164015-01; SMR000059020; edaravone(jan); Edaravone [INN]; DTXCID201130; Monopyrazolone; WLN: T5NMV DHJ BR& E1; CAS-89-25-8; CCRIS 512; Radicut (TN); HSDB 4102; 3H-Pyrazol-3-one,4-dihydro-5-methyl-2-phenyl-; SR-01000000135; 1-Fenyl-3-methyl-2-pyrazolin-5-on [Czech]; EINECS 201-891-0; MFCD00003138; UNII-S798V6YJRP; BRN 0609575; AI3-03557; MCI186; (Edaravone); Radicava (TN); (MCI-186); IN1263; CDS1_000986; Spectrum_000267; Tocris-0786; EDARAVONE [JAN]; MCI-186; Edaravone; Edaravone [USAN:INN]; EDARAVONE [HSDB]; EDARAVONE [USAN]; Maybridge1_005738; Opera_ID_1057; Spectrum2_001574; Spectrum3_000971; Spectrum4_001091; Spectrum5_001217; NORPHENAZONE [MI]; M0687; EDARAVONE [MART.]; EC 201-891-0; EDARAVONE [WHO-DD]; SCHEMBL4704; BSPBio_001235; BSPBio_002601; KBioGR_000575; KBioGR_001502; KBioSS_000575; KBioSS_000747; AE-641/00371017; MLS001146878; MLS002415675; MLS006011753; DivK1c_001018; DivK1c_002026; SPECTRUM1503635; SPBio_001508; CHEMBL290916; Edaravone (USAN/JP17/INN); EDARAVONE [ORANGE BOOK]; BCBcMAP01_000127; GTPL11994; HMS503K17; HMS557M18; KBio1_001018; KBio2_000575; KBio2_000747; KBio2_003143; KBio2_003315; KBio2_005711; KBio2_005883; KBio3_001029; KBio3_001030; KBio3_001821; NSC2629; NINDS_001018; BCPP000246; Bio1_000438; Bio1_000927; Bio1_001416; Bio2_000448; Bio2_000928; HMS1362M17; HMS1792M17; HMS1990M17; HMS2234M19; HMS3266F04; HMS3403M17; HMS3411L05; HMS3654L15; HMS3675L05; HMS3884A11; Pharmakon1600-01503635; BCP26336; HY-B0099; NSC26139; Tox21_112077; Tox21_201747; Tox21_302819; BDBM50200541; CCG-39352; NSC758622; s1326; STK201315; 3-methyl-1-phenyl-2-pyrazolin-5one; AKOS000313817; Tox21_112077_1; AC-4745; BCP9000635; CS-1832; DB12243; NSC-758622; PHENYL METHYL PYRAZOLONE [INCI]; SB19128; IDI1_001018; IDI1_002203; NCGC00018218-01; NCGC00018218-02; NCGC00018218-03; NCGC00018218-04; NCGC00018218-05; NCGC00018218-06; NCGC00018218-07; NCGC00018218-08; NCGC00018218-10; NCGC00018218-17; NCGC00022665-02; NCGC00022665-04; NCGC00022665-05; NCGC00022665-06; NCGC00256515-01; NCGC00259296-01; PHENAZONE IMPURITY A [EP IMPURITY]; SBI-0051836.P002; AM20060748; FT-0608243; SW148216-2; 5-methyl-2-phenyl-2,4-dihydro-3-pyrazolone; EN300-16234; 3-Methyl-1-phenyl-2-pyrazoline-5-one, 99%; 4E-901; 5-methyl-2-phenyl-2,4-dihydro-pyrazol-3-one; D01552; D86209; 3-?Methyl-?1-?phenyl-?2-?pyrazolin-?5-?one; AB00375776_14; AB00375776_15; 2 4-Dihydro-5-methyl-2-phenyl-3H-pyrazol-3-one; 2,4-dihydro-2-phenyl-5-methyl-3H-pyrazol-3-one; A843105; Q335099; Q-200386; SR-01000000135-2; SR-01000000135-3; SR-01000000135-5; 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one #; BRD-K35458079-001-04-2; BRD-K35458079-001-12-5; BRD-K35458079-001-23-2; Z50145861; F0391-0021; 3-Methyl-1-phenyl-2-pyrazoline-5-one, SAJ special grade; 3-Methyl-1-phenyl-2-pyrazoline-5-one, purum, >=98.0% (NT); 5-Methyl-2-phenyl-2,4-dihydro-3H-pyrazol-3-one (Edaravone); Phenazone impurity A, European Pharmacopoeia (EP) Reference Standard; 5-Methyl-2-phenyl-1,2-dihydropyrazol-3-one;3-Methyl-1-phenyl-2-pyrazolin-5-one; InChI=1/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H	D06DLI	DM8ZHP1	174.2	C10H10N2O	32.7	241	1.3	13	0	2	1	InChI=1S/C10H10N2O/c1-8-7-10(13)12(11-8)9-5-3-2-4-6-9/h2-6H,7H2,1H3	CC1=NN(C(=O)C1)C2=CC=CC=C2	CC1=NN(C(=O)C1)C2=CC=CC=C2	QELUYTUMUWHWMC-UHFFFAOYSA-N	5-methyl-2-phenyl-4H-pyrazol-3-one
ferrodrug0096	Lupeol	Small molecular drug	Lupeol; 545-47-1; Fagarasterol; Clerodol; Monogynol B; farganasterol; Fagarsterol; Lupenol; Triterpene lupeol; beta-Viscol; Lup-20(29)-en-3b-ol; .beta.-Viscol; UNII-O268W13H3O; Lup-20(29)-en-3beta-ol; CHEBI:6570; Lup-20(29)-en-3-ol, (3b)-; (+)-Lupeol; Lup-20(29)-en-3-ol, (3-beta)-; HSDB 7687; O268W13H3O; EINECS 208-889-9; NSC 90487; NSC-90487; (3-beta)-Lup-20(29)-en-3-ol; LUPEOL, (+)-; Lup-20(29)-en-3-beta-ol; NSC90487; (3beta)-lup-20(29)-en-3-ol; (1R,3aR,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol; Lup-20(29)-en-3-ol, (3.beta.)-; Lup-20(29)-en-3-ol; Lup-20(29)-en-3.beta.-ol; 20(29)-Lupen-3beta-ol; MFCD00017351; Lup-20(29)-en-3-ol, (3beta)-; LUPEOL [HSDB]; LUPEOL [INCI]; LUPEOL [MI]; Lupeol, >=94%; Lupeol, analytical standard; SCHEMBL148518; CHEMBL289191; 3beta-lup-20(29)-en-3-ol; DTXSID901025006; HY-N0790; BDBM50377927; s3614; 3beta-HYDROXYLUP-20(29)-ENE; AKOS016008524; CCG-268968; CS-7563; DB12622; DS-3391; LMPR0106130001; NCI60_042005; 3.BETA.-HYDROXYLUP-20(29)-ENE; LUP-20(29)-EN-3-.BETA.-OL; (3b,13; I)-Lup-20(29)-en-3-ol; L0321; C08628; (3-.BETA.)-LUP-20(29)-EN-3-OL; Q409366; LUP-20(29)-EN-3-OL, (3-.BETA.)-; Q-100615; (1R,3aR,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-1-isopropenyl-3a,5a,5b,8,8,11a-hexamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol	D0RA6H	DM4ZLUH	426.7	C30H50O	20.2	766	9.9	31	1	1	1	InChI=1S/C30H50O/c1-19(2)20-11-14-27(5)17-18-29(7)21(25(20)27)9-10-23-28(6)15-13-24(31)26(3,4)22(28)12-16-30(23,29)8/h20-25,31H,1,9-18H2,2-8H3/t20-,21+,22-,23+,24-,25+,27+,28-,29+,30+/m0/s1	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)C	CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)C	MQYXUWHLBZFQQO-QGTGJCAVSA-N	(1R,3aR,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a,5a,5b,8,8,11a-hexamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol
ferrodrug0097	Entacapone	Small molecular drug	ENTACAPONE; 130929-57-6; Comtan; Comtess; Entacaponum; OR-611; Entacapona; Entacaponum [INN-Latin]; Entacapona [INN-Spanish]; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylacrylamide; 116314-67-1; Entacapone teva; Entacapone orion; (E)-alpha-Cyano-N,N-diethyl-3,4-dihydroxy-5-nitrocinnamamide; 2-Cyano-N,N-diethyl-3-(3,4-dihydroxy-5-nitrophenyl)propenamide; (2E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; (E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide; CHEMBL953; 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-; (E)-2-cyano-3-(3,4-dihydroxy-5-nitro-phenyl)-N,N-diethyl-prop-2-enamide; CHEBI:4798; DTXSID5046439; N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl) acrylamide; 4975G9NM6T; (2E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; NCGC00164555-01; Entacom; 2-Propenamide, 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-, (2E)-; Entacapone [USAN:INN]; DTXCID3026439; OR 611; (E)-Entacapone; (~{E})-2-cyano-~{N},~{N}-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide; Comtan (TN); CAS-130929-57-6; SR-05000001452; UNII-4975G9NM6T; COM-998; Entacapone [USAN:USP:INN:BAN]; ENTACAPONE [MI]; ENTACAPONE [INN]; ENTACAPONE [JAN]; ENTACAPONE [USAN]; (E)-2-Cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-2-propenamide; ENTACAPONE [VANDF]; ENTACAPONE [MART.]; ENTACAPONE [USP-RS]; ENTACAPONE [WHO-DD]; SCHEMBL34504; SCHEMBL34505; BIDD:GT0026; ENTACAPONE [EMA EPAR]; 2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-n,n-diethyl-2-propenamide; Entacapone (JP17/USP/INN); GTPL6647; ENTACAPONE [ORANGE BOOK]; SCHEMBL13596593; HSDB 8251; ENTACAPONE [EP MONOGRAPH]; JRURYQJSLYLRLN-BJMVGYQFSA-N; ENTACAPONE [USP MONOGRAPH]; HMS2089O16; HMS3713B20; HMS3885K09; OR611; STALEVO COMPONENT ENTACAPONE; CORBILTA COMPONENT ENTACAPONE; EX-A1130; Tox21_112184; AC-393; BDBM50108879; MFCD00866580; s3147; AKOS015907685; AKOS015965009; ENTACAPONE COMPONENT OF STALEVO; Tox21_112184_1; BCP9000645; CCG-213064; CS-1266; DB00494; ENTACAPONE COMPONENT OF CORBILTA; NCGC00164555-02; NCGC00164555-03; NCGC00164555-10; HY-14280; E0961; SW199035-2; C07943; D00781; AB01275450-01; AB01275450_02; AB01275450_03; A806167; A922031; Q416444; J-005902; J-008069; SR-05000001452-1; SR-05000001452-2; SR-05000001452-3; BRD-K83636919-001-01-4; LEVODOPA/CARBIDOPA/ENTACAPONE ORION COMPONENT ENTACAPONE; (E)-N,N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide; ENTACAPONE COMPONENT OF LEVODOPA/CARBIDOPA/ENTACAPONE ORION; (E)-.ALPHA.-CYANO-N,N-DIETHYL-3,4-DIHYDROXY-5-NITROCINNAMAMIDE; (E)-N, N-diethyl-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)acrylamide; (E)-2-cyano-N,N-diethyl-3-[3-nitro-4,5-bis(oxidanyl)phenyl]prop-2-enamide; 2-Propenamide,2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethyl-,(2E)-; PD9	D0J1VY	DMLBVKQ	305.29	C14H15N3O5	130	500	2.1	22	2	6	4	InChI=1S/C14H15N3O5/c1-3-16(4-2)14(20)10(8-15)5-9-6-11(17(21)22)13(19)12(18)7-9/h5-7,18-19H,3-4H2,1-2H3/b10-5+	CCN(CC)C(=O)/C(=C/C1=CC(=C(C(=C1)O)O)[N+](=O)[O-])/C#N	CCN(CC)C(=O)C(=CC1=CC(=C(C(=C1)O)O)[N+](=O)[O-])C#N	JRURYQJSLYLRLN-BJMVGYQFSA-N	(E)-2-cyano-3-(3,4-dihydroxy-5-nitrophenyl)-N,N-diethylprop-2-enamide
ferrodrug0098	Promethazine	.	promethazine; Proazamine; Diphergan; 60-87-7; Protazine; Promethazin; Prometazin; Prothazin; Vallergine; Dimapp; Fargan; Procit; Promazinamide; Promezathine; Phenargan; Phensedyl; Diprazine; Histargan; Phargan; Tanidil; Thiergan; Isophenergan; Pyrethiazine; Diprozin; Fenetazina; Provigan; Avomine; Fenazil; Hiberna; Prorex; Lilly 1516; Prometazina; Antiallersin; Fenetazine; Phenerzine; Pipolphene; Proazaimine; Prometasin; Promethazinum; Promethiazine; Camergan; Iergigan; Metaryl; Pelpica; Pilothia; Pilpophen; Promacot; Promergan; Promesan; PromethazineHcl; Promethacon; Promethegan; Lilly 01516; Phenoject-50; Lercigan; Valergine; Pyrethia; N-(2'-Dimethylamino-2'-methyl)ethylphenothiazine; SKF 1498; Pro-50; Prometh; (2-Dimethylamino-2-methyl)ethyl-N-dibenzoparathiazine; Prometazine; WY 509; Prothazine; Dimethylamino-isopropyl-phenthiazin; RP 3277; 10-(2-Dimethylaminopropyl)phenothiazine; 10-[2-(Dimethylamino)propyl]phenothiazine; N,N,alpha-Trimethyl-10H-phenothiazine-10-ethanamine; Lergigan; Romergan; N-Dimethylamino-2-methylethyl thiodiphenylamine; NCI-C60673; A-91033; 10-(2-(Dimethylamino)-2-methylethyl)phenothiazine; CCRIS 7056; Sominex; 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-; 3277 RP; HSDB 3173; 10-(2-(Dimethylamino)propyl)phenothiazine; Phenothiazine, 10-(2-dimethylaminopropyl)-; EINECS 200-489-2; UNII-FF28EJQ494; NSC 30321; NSC-30321; BRN 0088554; CHEBI:8461; FF28EJQ494; DTXSID7023518; N,N-dimethyl-1-(10H-phenothiazin-10-yl)propan-2-amine; CHEMBL643; N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine; RP-3277; 60-87-7 (free base); dimethyl[1-(10H-phenothiazin-10-yl)propan-2-yl]amine; 10H-Phenothiazine-10-ethanamine, N,N,.alpha.-trimethyl-; DTXCID803518; 38878-40-9; Phenothiazine, 10-[2-(dimethylamino)propyl]-; 4-27-00-01253 (Beilstein Handbook Reference); NSC30321; 73745-50-3; (+/-)-promethazine; NCGC00015817-05; Promethazine [INN:BAN]; PROMETHAZINE (MART.); PROMETHAZINE [MART.]; Prometazina [INN-Spanish]; Promethazinum [INN-Latin]; PHENOTHIAZINE, 10-(2-(DIMETHYLAMINO)PROPYL)-; 10-(2-DIMETHYLAMINO-2-METHYLETHYL)PHENOTHIAZINE; (+/-)-10-(2-(DIMETHYLAMINO)PROPYL)PHENOTHIAZINE; Promethaine; CAS-60-87-7; N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine hydrochloride; Dimethylamino-isopropyl-phenthiazin [German]; Promethazine (JAN/INN); Phenergan base; SR-01000002993; ()-Promethazine; Remsed (Salt/Mix); 3389 R.p.; Pyrethia (Salt/Mix); Pipolphen (Salt/Mix); Spectrum_000868; camsilate de promAthazine; Prestwick0_000888; Prestwick1_000888; Prestwick2_000888; Prestwick3_000888; Spectrum2_000840; Spectrum3_001019; Spectrum4_001149; Spectrum5_000977; PROMETHAZINE [MI]; (.+/-.)-Promethazine; 10H-Phenothiazine-10-ethanamine, N,N,alpha-trimethyl-, radical ion(1+); PROMETHAZINE [INN]; PROMETHAZINE [JAN]; PROMETHAZINE [HSDB]; SCHEMBL4700; PROMETHAZINE [VANDF]; Lopac0_000899; Oprea1_758749; BSPBio_000676; BSPBio_002777; KBioGR_001697; KBioSS_001348; DivK1c_000005; PROMETHAZINE [WHO-DD]; SPBio_000799; SPBio_002895; (Dimethylamino-2-propyl-10-phenothiazine hydrochloride; BPBio1_000744; GTPL7282; KBio1_000005; KBio2_001348; KBio2_003916; KBio2_006484; KBio3_001997; PWWVAXIEGOYWEE-UHFFFAOYSA-; D04AA10; EX-A891; N,N-DIMETHYL-1-PHENOTHIAZIN-10-YL-PROPAN-2-AMINE; R06AD02; NINDS_000005; HMS2089E08; Tox21_110227; BDBM50017696; AKOS015962127; Tox21_110227_1; 3389 RP; 4182 R.p.; 4182 RP; CCG-109848; DB01069; SDCCGSBI-0050874.P005; IDI1_000005; NCGC00015817-03; NCGC00015817-04; NCGC00015817-06; NCGC00015817-08; NCGC00015817-09; NCGC00015817-10; NCGC00015817-11; NCGC00015817-12; NCGC00015817-14; NCGC00015817-17; NCGC00015817-24; NCGC00089735-02; NCGC00089735-03; AC-15939; NCI60_001878; SBI-0050874.P004; AB00053535; FT-0700342; S5196; WLN: T C666 BN ISJ B1Y1&N1&1; C07404; D00494; EN300-708776; F17386; AB00053535-12; AB00053535_13; L000495; Q422970; J-690333; 10H-Phenothiazine-10-ethanamine,N,.alpha.-trimethyl-; N,N,-alpha-Trimethyl-10H-phenothiazine-10-ethanamine; SR-01000002993-10; N,N-Dimethyl-1-(10H-phenothiazin-10-yl)-2-propanamine; N-(2'-DIMETHYLAMINO-2-METHYL)ETHYLPHENOTHIAZINE; N,N-Dimethyl-1-(10H-phenothiazin-10-yl)-2-propanamine #; N,N,.ALPHA.-TRIMETHYL-10H-PHENOTHIAZINE-10-ETHANAMINE; 10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,.ALPHA.-TRIMETHYL-, (+/-)-; 10H-PHENOTHIAZINE-10-ETHANAMINE, N,N,alpha-TRIMETHYL-, (+/-)-; InChI=1/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3	.	.	284.4	C17H20N2S	31.8	298	4.8	20	0	3	3	InChI=1S/C17H20N2S/c1-13(18(2)3)12-19-14-8-4-6-10-16(14)20-17-11-7-5-9-15(17)19/h4-11,13H,12H2,1-3H3	CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C	CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C	PWWVAXIEGOYWEE-UHFFFAOYSA-N	N,N-dimethyl-1-phenothiazin-10-ylpropan-2-amine
ferrodrug0099	Lycopene	.	LYCOPENE; 502-65-8; all-trans-Lycopene; Psi,psi-carotene; trans-Lycopene; Lycopene 7; lycored; Redivivo; Mexoryl SAQ; Tomat-O-Red; (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; (all-trans)-lycopene; Lycopene, all-trans-; TOMATO LYCOPENE; Aec lycopene; (all-e)-lycopene; CI 75125; Solanorubin; Ateronon; CCRIS 7925; NSC 407322; UNII-SB0N2N0WV6; Blakeslea trispora; C.I. 75125; EINECS 207-949-1; SB0N2N0WV6; INS-160D(III); INS NO.160D(III); Lycopene from blakeslea trispora; DTXSID2046593; FEMA NO. 4110; CHEBI:15948; E-160D(III); NSC-407322; LYC-O-MATO; DTXCID0026593; NSC407322; (all-E)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene; NCGC00166291-01; .psi.,.psi.-Carotene; LYCOPENE (MART.); LYCOPENE [MART.]; Lycopene (VAN); cis-Lycopene; LYCOPENE PREPARATION (USP-RS); LYCOPENE PREPARATION [USP-RS]; MFCD00017350; All trans Lycopene; psi, psi-Carotene; LYC; LyocpenePowder; psi-psi-carotene; y,y-Carotene; Lyco Vit; Lycopene preparation; Lycopene all-trans-; LYCOPENE [INCI]; LYCOPENE [MI]; LYCOPENE [VANDF]; LYCOPENE [WHO-DD]; BSPBio_003389; Lycopene, analytical standard; E160d; TOMATO LYCOPENE [FHFI]; CHEMBL501174; Lycopene, >=90%, from tomato; CI 75125 [INCI]; HY-N0287; Tox21_112395; LMPR01070257; s3943; AKOS015961276; CS-6378; DB11231; FD10111; NCGC00166291-02; NCGC00166291-03; NCGC00166291-04; 2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene; AC-13571; AC-33932; CAS-502-65-8; LS-15428; Lycopene, >=98% (HPLC), from tomato; L0257; LYCOPENE FROM BLAKESLEA TRISPORA [FCC]; C05432; Q208130; Q-100561; Lycopene, United States Pharmacopeia (USP) Reference Standard; Lycopene, Pharmaceutical Secondary Standard; Certified Reference Material; (ALL-E)-LYCOPENE (CONSTITUENT OF LYCOPENE AND TOMATO EXTRACT CONTAINING LYCOPENE); (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-Octamethyl-2,6,8,10,12,14,16,18,20,22,24,26,30-dotriacontatridecaene; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-octamethyl-, (6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-; 2,6,8,10,12,14,16,18,20,22,24,26,30-Dotriacontatridecaene, 2,6,10,14,19,23,27,31-Octamethyl-, (all-E)-	.	.	536.9	C40H56	0	1050	15.6	40	0	0	16	InChI=1S/C40H56/c1-33(2)19-13-23-37(7)27-17-31-39(9)29-15-25-35(5)21-11-12-22-36(6)26-16-30-40(10)32-18-28-38(8)24-14-20-34(3)4/h11-12,15-22,25-32H,13-14,23-24H2,1-10H3/b12-11+,25-15+,26-16+,31-17+,32-18+,35-21+,36-22+,37-27+,38-28+,39-29+,40-30+	CC(=CCC/C(=C/C=C/C(=C/C=C/C(=C/C=C/C=C(/C=C/C=C(/C=C/C=C(/CCC=C(C)C)\C)\C)\C)/C)/C)/C)C	CC(=CCCC(=CC=CC(=CC=CC(=CC=CC=C(C)C=CC=C(C)C=CC=C(C)CCC=C(C)C)C)C)C)C	OAIJSZIZWZSQBC-GYZMGTAESA-N	(6E,8E,10E,12E,14E,16E,18E,20E,22E,24E,26E)-2,6,10,14,19,23,27,31-octamethyldotriaconta-2,6,8,10,12,14,16,18,20,22,24,26,30-tridecaene
ferrodrug0100	Sevoflurane	Small molecular drug	sevoflurane; 28523-86-6; 1,1,1,3,3,3-Hexafluoro-2-(fluoromethoxy)propane; Ultane; Sevofluran; Sevorane; Sojourn; MR6S4; sevoflo; Sevofluranum; Sevoflurano; Sevofluranum [INN-Latin]; Sevoflurano [INN-Spanish]; Fluoromethyl 1,1,1,3,3,3-Hexafluoroisopropyl Ether; Sevocalm; Propane, 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-; MR-6S4; Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether; NSC-760367; 38LVP0K73A; CHEBI:9130; DTXSID8046614; NCGC00167421-01; Sevofrane; Bax 3084; 1173021-96-9; Petrem; fluoromethyl hexafluoroisopropyl ether; Sevoflurane-d3, Fluoromethyl 1,1,1,3,3,3-hexafluoro-2-propyl ether-d3, Fluoromethyl 2,2,2-trifluoro-1-(trifluoromethyl)ethyl ether-d3; Ultane (TN); BRN 2041023; UNII-38LVP0K73A; HSDB 8059; MFCD00153189; Propane,1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)-; Sevoflurane [USAN:USP:INN:BAN:JAN]; SEVOFLURANE [MI]; SEVOFLURANE [INN]; SEVOFLURANE [JAN]; F0691; SEVOFLURANE [USAN]; SEVOFLURANE [VANDF]; (CF3)2CHOCH2F; SEVOFLURANE [MART.]; SCHEMBL61918; SEVOFLURANE [USP-RS]; SEVOFLURANE [WHO-DD]; GTPL7296; CHEMBL1200694; DTXCID6026614; SEVOFLURANE [GREEN BOOK]; Sevoflurane (JP17/USAN/INN); SEVOFLURANE [EP IMPURITY]; SEVOFLURANE [ORANGE BOOK]; HMS3264N21; Pharmakon1600-01503680; SEVOFLURANE [EP MONOGRAPH]; SEVOFLURANE [USP IMPURITY]; SEVOFLURANE [USP MONOGRAPH]; Tox21_112425; ETHER, FLUOROMETHYL 2,2,2-TRIFLUORO-1-(TRIFLUOROMETHYL)ETHYL-; Fluoromethyl 1,1,1,3,3,3-hexafluoroisopropyl ether (Sevoflurane); NSC760367; AKOS007930500; CCG-213707; DB01236; NSC 760367; NCGC00167421-02; SEVOFLURANE [EMA EPAR VETERINARY]; AC-15484; AS-13261; Fluoromethyl 2H-hexafluoroprop-2-yl ether; CAS-28523-86-6; FT-0605909; S2464; 6-CHLOROBENZIMIDAZOLE-4-CARBOXYLICACID; C07520; D00547; D78401; EN300-123016; AB01563174_01; A819479; Q419394; SR-01000944968; J-524240; SR-01000944968-1; Z1269113624; 1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane;Sevoflurane	D0W6ZF	DMC9O43	200.05	C4H3F7O	9.2	121	2.8	12	0	8	2	InChI=1S/C4H3F7O/c5-1-12-2(3(6,7)8)4(9,10)11/h2H,1H2	C(OC(C(F)(F)F)C(F)(F)F)F	C(OC(C(F)(F)F)C(F)(F)F)F	DFEYYRMXOJXZRJ-UHFFFAOYSA-N	1,1,1,3,3,3-hexafluoro-2-(fluoromethoxy)propane
ferrodrug0101	Sodium butyrate	.	SODIUM BUTYRATE; 156-54-7; Sodium butanoate; Butyric acid sodium salt; Butanoic acid, sodium salt; Butyric acid, sodium salt; Butyrate sodium; sodium;butanoate; Sodium n-butyrate; Sodium propanecarboxylate; Butanoic acid sodium salt; Butyric Acid, Na; C4H7NaO2; Sodium butyrate (USP); Sodium butyrate [USP]; TPA/BA; Butanoic acid, sodium salt (1:1); 8RAS91C36W; DTXSID3037672; CHEBI:64103; NSC-174280; CHEMBL62381; CCRIS 7068; NSC174280; HSDB 5655; SODIUM BUTYRATE-3,3,4,4,4-D5; NCGC00167555-01; EINECS 205-857-6; MFCD00002816; NSC 174280; sodiumbutyrate; UNII-8RAS91C36W; 204244-79-1; Sodium butyrate, 98%; Tetradecanoyl phorbol acetate/ sodium butyrate; SCHEMBL30148; SODIUM BUTYRATE [HSDB]; DTXCID1017672; HY-B0350A; SODIUM BUTYRATE [USP-RS]; SODIUM BUTYRATE [WHO-DD]; tetradecanoyl phorbol acetate (TPA)/ sodium butyrate (BA); MFBOGIVSZKQAPD-UHFFFAOYSA-M; HMS3650B09; BCP31813; Butanoicacidsodiumsalt butyratesodium; Tox21_112550; HB1399; s1999; Sodium butyrate, >=98.5% (GC); Sodium butyrate, >=99.0% (GC); AKOS003051490; AKOS015899795; CCG-266046; CS-3924; SODIUM BUTYRATE [USP MONOGRAPH]; AS-13929; CAS-156-54-7; FT-0660356; FT-0694101; D08998; AB01274751-01; Sodium butyrate, Vetec(TM) reagent grade, 99%; A921858; Q305004; Sodium butyrate, certified reference material, TraceCERT(R); Sodium butyrate, United States Pharmacopeia (USP) Reference Standard	.	.	110.09	C4H7NaO2	40.1	53.7	.	7	0	2	2	InChI=1S/C4H8O2.Na/c1-2-3-4(5)6;/h2-3H2,1H3,(H,5,6);/q;+1/p-1	CCCC(=O)[O-].[Na+]	CCCC(=O)[O-].[Na+]	MFBOGIVSZKQAPD-UHFFFAOYSA-M	sodium;butanoate
ferrodrug0102	Oleanolic acid	Small molecular drug	OLEANOLIC ACID; 508-02-1; Oleanic acid; Caryophyllin; Astrantiagenin C; Giganteumgenin C; Virgaureagenin B; Oleanol; 3beta-Hydroxyolean-12-en-28-oic acid; oleonolic acid; CCRIS 6493; NSC-114945; UNII-6SMK8R7TGJ; 6SMK8R7TGJ; Gledigenin 1; EINECS 208-081-6; (3-beta)-3-Hydroxyolean-12-en-28-oic acid; (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid; CHEBI:37659; NSC114945; 3-beta-Hydroxyolean-12-en-28-oic acid; Olean-12-en-28-oic acid, 3-hydroxy-, (3beta)-; Olean-12-en-28-oic acid, 3beta-hydroxy-; Olean-12-en-28-oic acid, 3-beta-hydroxy-; DTXSID50858790; NSC 114945; Olean-12-en-28-oic acid, 3-hydroxy-, (3-beta)-; (4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydropicene-4a(2H)-carboxylic acid; OleanolicAcid; OLEANOLIC ACID (USP-RS); OLEANOLIC ACID [USP-RS]; MFCD00064914; (4aS,5S,6aS,6bR,8R,8aR,10S,12aR,12bR,14bS)-10-Hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-octadecahydro-2H-picene-4a-carboxylic acid; SMR000445561; OLEANOLIC_ACID; CHEMBL168; (3.beta.)-3-Hydroxyolean-12-en-28-oic acid; Olean-12-en-28-oic acid, 3-hydroxy-, (3.beta.)-; oleanolic-acid; OleanolsA currencyure; Oleanoic Acid Hydrate; Olean-12-en-28-oic acid, 3.beta.-hydroxy-; Oleanolic acid, >=97%; OLEANOLIC ACID [MI]; SCHEMBL71070; MLS000697656; MLS002207133; OLEANOLIC ACID [INCI]; GTPL3306; OLEANOLIC ACID [WHO-DD]; MIJYXULNPSFWEK-GTOFXWBISA-N; DTXCID701474453; HMS2232D15; Oleanolic acid (OA)(Compound 1); Oleanolic acid, analytical standard; (4aS,6aS,6bR,8aR,10S,12aR,12bR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,2,3,4,4a,5,6,6a,6b,7,8,8a,9,10,11,12,12a,12b,13,14b-icosahydropicene-4a-carboxylic acid; EX-A1991; HY-N0156; BDBM50346601; 3-beta-Hydroxyolean-12-en-28-oate; 3beta-hydroxy-Olean-12-en-28-oate; AKOS015951416; AC-8026; CCG-208530; CS-3800; LMPR0106150004; 3.beta.-hydroxy-Olean-12-en-28-oate; 3beta-hydroxy-Olean-12-en-28-oic acid; NCGC00017222-10; (2S,5S,10S,18S,1R,14R,15R,20R)-18-hydroxy-1,2,8,8,15,19,19-heptamethylpentacyc lo[12.8.0.0<2,11>.0<5,10>.0<15,20>]docos-11-ene-5-carboxylic acid; AS-35338; BP-25410; (3-beta)-3-Hydroxyolean-12-en-28-oate; (3?)-3-Hydroxyolean-12-en-28-oic acid; 3.beta.-hydroxy-Olean-12-en-28-oic acid; (3beta)-3-hydroxyolean-12-en-28-oic acid; (3.beta.)-3-hydroxy-Olean-12-en-28-oate; C17148; EN300-342251; (3.beta.)-3-hydroxy-Olean-12-en-28-oic acid; (3.beta.)-3-beta-hydroxy-Olean-12-en-28-oate; 3.BETA.-HYDROXYOLEAN-12-EN-28-OIC ACID; Olean-12-en-28-oic acid, 3-hydroxy-, (3b)-; Q418628; OLEANOLIC ACID (CONSTITUENT OF BANABA LEAF); Q-100572; (3.beta.)-3-beta-hydroxy-Olean-12-en-28-oic acid; OLEANOLIC ACID (CONSTITUENT OF HOLY BASIL LEAF); Oleanolic acid, primary pharmaceutical reference standard; C7EE6ACC-7175-4947-B524-FF8479525DA1; OLEANOLIC ACID (CONSTITUENT OF BANABA LEAF) [DSC]; OLEANOLIC ACID (CONSTITUENT OF HOLY BASIL LEAF) [DSC]; Oleanolic acid, European Pharmacopoeia (EP) Reference Standard; Oleanolic acid, United States Pharmacopeia (USP) Reference Standard; (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylicacid	D0SJ2Q	DMWDMJ3	456.7	C30H48O3	57.5	885	7.5	33	2	3	1	InChI=1S/C30H48O3/c1-25(2)14-16-30(24(32)33)17-15-28(6)19(20(30)18-25)8-9-22-27(5)12-11-23(31)26(3,4)21(27)10-13-29(22,28)7/h8,20-23,31H,9-18H2,1-7H3,(H,32,33)/t20-,21-,22+,23-,27-,28+,29+,30-/m0/s1	C[C@]12CC[C@@H](C([C@@H]1CC[C@@]3([C@@H]2CC=C4[C@]3(CC[C@@]5([C@H]4CC(CC5)(C)C)C(=O)O)C)C)(C)C)O	CC1(CCC2(CCC3(C(=CCC4C3(CCC5C4(CCC(C5(C)C)O)C)C)C2C1)C)C(=O)O)C	MIJYXULNPSFWEK-GTOFXWBISA-N	(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-hydroxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
ferrodrug0103	Deferoxamine	.	deferoxamine; Desferrioxamine B; 70-51-9; DESFERRIOXAMINE; Deferoxamine B; Deferrioxamine B; Deferrioxamine; Deferoxamin; Deferoxaminum; Desferin; Desferan; Desferex; Desferral; Desferrin; DFOM; N-Benzoylferrioxamine B; Desferal; DF B; DFOA; Deferoxamide B; NSC-527604; Deferoxamina; Ferrioxamine B, N-benzoyl-; Desferoxamine b; N1-(5-Aminopentyl)-N1-hydroxy-N4-(5-(N-hydroxy-4-((5-(N-hydroxyacetamido)pentyl)amino)-4-oxobutanamido)pentyl)succinamide; Dfo-b; J06Y7MXW4D; CHEBI:4356; Butanediamide, N'-(5-((4-((5-(acetylhydroxyamino)pentyl)amino)-1,4-dioxobutyl)hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxy-; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide; Ba 33112; Ba-33112; NSC527604; 3,9,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,14,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Deferoxamine (USAN); DEFEROXAMINE [USAN]; N-(5-(3-((5-Aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)propionohydroxamic acid; N-(5-aminopentyl)-N-hydroxy-N'-[5-(N-hydroxy-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propanamido)pentyl]butanediamide; Propionohydroxamic acid, N-(5-(3-((5-aminopentyl)hydroxycarbamoyl)propionamido)pentyl)-3-((5-(N-hydroxyacetamido)pentyl)carbamoyl)-; Deferoxamine B; Deferriferrioxamine B; Deferrioxamine; Desferriferrioxamin B; MLS002702118; Deferoxamine [USAN:INN]; Deferoxaminum [INN-Latin]; Deferoxamina [INN-Spanish]; Butanediamide, N'-[5-[[4-[[5-(acetylhydroxyamino)pentyl]amino]-1,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; Ba 29837; NSC268993; NSC644468; HSDB 3311; SMR000058548; EINECS 200-738-5; UNII-J06Y7MXW4D; BRN 2514118; Cordaneurin; Desferrioxamin; Perineurin; Desferioxamine B; desferrioxamine-B; C25H48N6O8; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N-hydroxybutanediamide; N-[5-(3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido)pentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)propionohydroxamic acid; N-[5-{3-[(5-Aminopentyl)hydroxycarbamoyl]propionamido}pentyl]-3-{[5-(N-hydroxyacetamido)pentyl]carbamoyl}propionohydroxamic acid; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[[5-(N-hydroxyacetamido)pentyl]carbamoyl]-; deferoxamine-mesylate; Desferal (Salt/Mix); Spectrum_000892; 1950-39-6; Prestwick0_000725; Prestwick1_000725; Prestwick2_000725; Prestwick3_000725; Spectrum2_001155; Spectrum3_000376; Spectrum4_000311; Spectrum5_000827; DEFEROXAMINE [MI]; DEFEROXAMINE [INN]; CHEMBL556; DEFEROXAMINE [HSDB]; EC 200-738-5; DEFEROXAMINE [VANDF]; SCHEMBL34571; BSPBio_000650; BSPBio_002131; KBioGR_000922; KBioGR_002429; KBioSS_001372; KBioSS_002435; 1-Amino-6,17-dihydroxy-7,10,18,21-tetraoxo-27-(N-acetyl hydroxylamino)-6,11,17,22-tetraazaheptaeicosane; cid_62881; N'-(5-((4-((5-(Acetylhydroxamino)pentyl)amino)-1,4-dioxobutyl) hydroxyamino)pentyl)-N-(5-aminopentyl)-N-hydroxybutanediamide; DEFEROXAMINE [WHO-DD]; DivK1c_000082; Ba 29837 (Salt/Mix); SPBio_001109; SPBio_002589; BPBio1_000716; CGH-749B; ICL-749B; DTXSID7022887; BDBM47715; KBio1_000082; KBio2_001372; KBio2_002429; KBio2_003940; KBio2_004997; KBio2_006508; KBio2_007565; KBio3_001351; KBio3_002908; cMAP_000047; NINDS_000082; HMS3604E17; BCP16524; HY-B1625; LMFA08020169; WLN: Z5NQV/2VM5NQV/ 21; DEFEROXAMINE, Deferoxamine Mesylate; AKOS016004824; DB00746; IDI1_000082; SMP2_000121; NCGC00178802-01; NCGC00178802-02; NCGC00178802-03; MS-30181; NCI60_002181; SMR001550278; SBI-0051332.P003; AB00053447; CS-0013559; C06940; D03670; F11488; AB00053447_14; EN300-19748908; Q419618; Q-200933; BRD-K09821361-066-05-0; BRD-K09821361-066-06-8; BRD-K09821361-066-08-4; BRD-K09821361-066-13-4; BRD-K09821361-066-15-9; BRD-K09821361-066-16-7; 3,14,20,25-Pentaazatriacontane-2,10,13,21,24-pentone, 30-amino-3,14,25-trihydroxy-; 30-Amino-3,25-trihydroxy-3,9,14,20,25-pentaazatriacontane-2,10,13,21,24-pentaone; Butanediamide,4-dioxobutyl]hydroxyamino]pentyl]-N-(5-aminopentyl)-N-hydroxy-; N''''-(5-azanylpentyl)-N-[5-[[4-[5-[ethanoyl(oxidanyl)amino]pentylamino]-4-oxidanylidene-butanoyl]-oxidanyl-amino]pentyl]-N''''-oxidanyl-butanediamide;methanesulfonic acid; N'-[5-(acetyl-hydroxy-amino)pentyl]-N-[5-[3-(5-aminopentyl-hydroxy-carbamoyl)propanoylamino]pentyl]-N-hydroxy-butane diamide; N'-{5-[acetyl(hydroxy)amino]pentyl}-N-(5-{4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanamido}pentyl)-N-hydroxybutanediamide; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-1,4-dioxobutyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-keto-butanoyl]-hydroxy-amino]pentyl]-N''-(5-aminopentyl)-N''-hydroxy-succinamide;mesylic acid; N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N''''-(5-aminopentyl)-N''''-hydroxybutanediamide;methanesulfonic acid; N~1~-(5-(Acetyl(hydroxy)amino)pentyl)-N~4~-(5-((4-((5-aminopentyl)(hydroxy)amino)-4-oxobutanoyl)amino)pentyl)-N~4~-hydroxysuccinamide; N~4~-{5-[acetyl(hydroxy)amino]pentyl}-N~1~-[5-({4-[(5-aminopentyl)(hydroxy)amino]-4-oxobutanoyl}amino)pentyl]-N~1~-hydroxybutanediamide; Propionohydroxamic acid, N-[5-(3-[(5-aminopentyl)hydroxycarbamoyl]propionamido)phentyl]-3-([5-(N-hydroxyacetamido)pentyl]carbamoyl)-; Propionohydroxamic acid, N-[5-[3-[(5-aminopentyl)hydroxycarbamoyl]propionamido]pentyl]-3-[(5-N-hydroxyacetamido)pentyl]carbamoyl]-	.	.	560.7	C25H48N6O8	206	739	-2.1	39	6	9	23	InChI=1S/C25H48N6O8/c1-21(32)29(37)18-9-3-6-16-27-22(33)12-14-25(36)31(39)20-10-4-7-17-28-23(34)11-13-24(35)30(38)19-8-2-5-15-26/h37-39H,2-20,26H2,1H3,(H,27,33)(H,28,34)	CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O	CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O	UBQYURCVBFRUQT-UHFFFAOYSA-N	N-[5-[[4-[5-[acetyl(hydroxy)amino]pentylamino]-4-oxobutanoyl]-hydroxyamino]pentyl]-N'-(5-aminopentyl)-N'-hydroxybutanediamide
ferrodrug0104	Paeonol	.	PAEONOL; 552-41-0; 2'-Hydroxy-4'-methoxyacetophenone; 1-(2-Hydroxy-4-methoxyphenyl)ethanone; Peonol; 2-Hydroxy-4-methoxyacetophenone; Ethanone, 1-(2-hydroxy-4-methoxyphenyl)-; 1-(2-hydroxy-4-methoxyphenyl)ethan-1-one; 4-O-Methylresacetophenone; Resacetophenone-4-methyl ether; 4'-Methoxy-2'-hydroxyacetophenone; MFCD00008730; Paeonal; Acetophenone, 2'-hydroxy-4'-methoxy-; 2-acetyl-5-methoxyphenol; Resacetophenone, 4-O-methyl ester; EINECS 209-012-2; NSC 401442; UNII-3R834EPI82; BRN 1282794; 1-(2-hydroxy-4-methoxy-phenyl)ethanone; AI3-10581; 3R834EPI82; NSC-401442; RESACETOPHENONE 4-O-METHYL ETHER; CHEMBL1079227; CHEBI:69581; 4-08-00-01793 (Beilstein Handbook Reference); 1-(2-hydroxy-4-methoxy-phenyl)-ethanone; 1-(4-METHOXY-2-HYDROXYPHENYL)ETHANONE; 2-HYDROXY-4-METHOXYPHENYL METHYL KETONE; 2-HYDROXY-4-METHOXYACETOPHENONE (4,4,4-D3); Paeonol (Peonol); PAEONOL [INCI]; 1-[2-hydroxy-4-(methyloxy)phenyl]ethanone; Spectrum2_001981; Spectrum3_001686; PAEONOL [WHO-DD]; 2-Acetyl-5-methoxy-phenol; CBiol_000986; BSPBio_003212; MLS006011902; SPECTRUM1601021; SPBio_002161; SCHEMBL1449478; DTXSID1022059; KBio3_002432; 4-methoxy 2-hydroxy acetophenone; HMS3656E07; HMS3884J13; 2`-Hydroxy-4`-methoxyacetophenone; HY-N0159; BBL012127; BDBM50310718; CCG-39471; ICCB4_000282; NSC401442; s2339; STK078097; AKOS000119646; AC-7982; SDCCGMLS-0066845.P001; 1-(2-hydroxy-4-methoxyphenyl)-ethanone; NCGC00095977-01; NCGC00095977-02; NCGC00095977-03; 2'-Hydroxy-4'-methoxyacetophenone, 99%; AS-15489; SMR000112386; SY013508; 1-(2-Hydroxy-4-methoxyphenyl)ethanone #; 1-(4-Methoxy-2-hydroxy-phenyl)-ethanone; 1-(2-hydroxy-4-methoxyphenyl)ethane-1-one; AM20040702; FT-0602529; FT-0618875; H0789; quinuclidin-3-one oxime hydrochloride;Paeonol; SW219250-1; EN300-17920; A830551; Acetophenone, 2'-hydroxy-4'-methoxy-(7CI,8CI); SR-05000002397; Q-100626; Q7124105; SR-05000002397-1; BRD-K94239562-001-02-2; BRD-K94239562-001-03-0; Z57101020; 2 inverted exclamation mark -Hydroxy-4 inverted exclamation mark -methoxyacetophenone; 2 inverted exclamation marka-Hydroxy-4 inverted exclamation marka-methoxyacetophenone; InChI=1/C9H10O3/c1-6(10)8-4-3-7(12-2)5-9(8)11/h3-5,11H,1-2H	.	.	166.17	C9H10O3	46.5	167	2	12	1	3	2	InChI=1S/C9H10O3/c1-6(10)8-4-3-7(12-2)5-9(8)11/h3-5,11H,1-2H3	CC(=O)C1=C(C=C(C=C1)OC)O	CC(=O)C1=C(C=C(C=C1)OC)O	UILPJVPSNHJFIK-UHFFFAOYSA-N	1-(2-hydroxy-4-methoxyphenyl)ethanone
ferrodrug0105	Propranolol	Small molecular drug	propranolol; Propanolol; 525-66-6; beta-Propranolol; Betalong; Euprovasin; Proprasylyt; Reducor; Propanalol; Propanix; Avlocardyl; Dociton; propranololo; Betadren; Corpendol; Sawatal; dl-propranolol; Sumial; Anapriline; Racemic propranolol; Propranololum; D,L-Propranolol; (+-)-Propranolol; racemic-Propranolol; .beta.-Propranolol; Propranalol; CCRIS 3082; 1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol; 1-((1-Methylethyl)amino)-3-(1-naphthalenyloxy)-2-propanol; 1-(isopropylamino)-3-(1-naphthyloxy)propan-2-ol; UNII-9Y8NXQ24VQ; EINECS 208-378-0; EINECS 235-867-6; 9Y8NXQ24VQ; hemangiol; 1-Isopropylamino-3-(1-naphthyloxy)-2-propanol; Bedranol; Berkolol; Caridolol; CHEBI:8499; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-; (+/-)-propranolol; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-; CHEMBL27; AY-64043-; DTXSID6023525; 2-Propanol, 1-(isopropylamino)-3-(1-naphthyloxy)-, (+-)-; 2-Propanol, 1-[(1-methylethyl)amino]-3-(1-naphthalenyloxy)-; DL-Propranolol hydrochloride; Duranol; Efektolol; Inderex; Inderol; Migrastat; Pranolol; Propranolol (INN); (1)-1-(Isopropylamino)-3-(naphthyloxy)propan-2-ol; 1-Isopropylamino-3-(naphthalen-1-yloxy)-propan-2-ol; Beta-Tablinen; Beta-Timelets; 13013-17-7; 1-(naphthalen-1-yloxy)-3-(propan-2-ylamino)propan-2-ol; AY-20694; 1-(naphthalen-1-yloxy)-3-[(propan-2-yl)amino]propan-2-ol; PROPRANOLOL [INN]; 2-Propanol, 1-((1-methylethyl)amino)-3-(1-naphthalenyloxy)-, (+-)-; Inderal hydrochloride; Propranololo [DCIT]; 3-(naphthalen-1-yloxy)-1-(propan-2-ylamino)propan-2-ol; [2-hydroxy-3-(naphthalen-1-yloxy)propyl](propan-2-yl)amine; Propranolol [INN:BAN]; AY 20694; Propanolol [INN-Spanish]; Propranololum [INN-Latin]; etalong; Intermigran; Betachron; b-Propranolol; Kemi S; Propranolol (TN); Dociton (Salt/Mix); Inderal (Salt/Mix); Obsidan (Salt/Mix); Propanolol,(+/-); PROPRANOLOL, d; Avlocardyl (Salt/Mix); beta-Propranolol;Dociton; Propranolol Hcl Intensol; PROPANOLOL(-); PROPRANOLOL [MI]; Prestwick0_000952; Prestwick1_000952; Prestwick2_000952; Prestwick3_000952; PROPRANOLOL,(+); PROPRANOLOL,(-); Spectrum2_001301; Spectrum2_001699; Spectrum3_000883; Spectrum3_001071; Spectrum4_000974; Spectrum4_001222; Spectrum5_000751; (.+/-.)-Propranolol; PROPRANOLOL [VANDF]; SCHEMBL3955; 3-[(methylethyl)amino]-1-naphthyloxypropan-2-ol; Lopac0_000896; Oprea1_304193; BSPBio_000944; BSPBio_002682; CBDivE_006180; GTPL564; KBioGR_001347; KBioGR_001684; KBioGR_002515; KBioSS_002523; PROPRANOLOL [WHO-DD]; R,S-Propranolol Hydrochloride; DivK1c_000023; SPBio_001361; SPBio_001658; SPBio_003093; (+)-Propranolol hydrochloride; (R)-(+)-Propranolol hydrochloride; 1-(Isopropylamino)-3-(naphthalen-1-yloxy)propan-2-ol; BPBio1_001040; DTXCID903525; (S)-(-)-PROPRANOLOL; ICI 45520 (Salt/Mix); NSC 91523 (Salt/Mix); SCHEMBL12264958; BDBM25761; HY-B0573B; KBio1_000023; KBio2_002515; KBio2_005083; KBio2_007651; KBio3_001766; KBio3_001902; KBio3_002993; C07AA05; cMAP_000071; NINDS_000023; (A+/-)-Propranolol hydrochloride; Bio1_000367; Bio1_000856; Bio1_001345; HMS2090L21; HMS3428G03; BCP26001; BCP31343; BBL023437; PDSP1_000767; PDSP1_001607; PDSP1_001608; PDSP2_000755; PDSP2_001591; PDSP2_001592; STK735510; AKOS000588816; AKOS016050338; CCG-103643; DB00571; FE-0204; SDCCGSBI-0050871.P004; IDI1_000023; NCGC00015798-04; NCGC00015798-05; NCGC00015798-06; NCGC00015798-07; NCGC00015798-08; NCGC00015798-09; NCGC00015798-15; NCGC00015798-19; NCGC00024690-02; NCGC00024690-03; SBI-0050871.P003; AB00053537; CS-0069968; FT-0650563; FT-0674088; EN300-40731; C07407; D08443; AB00053537-10; AB00053537_11; AB00053537_12; 1-(Isopropylamino)-3-(1-naphthoxy)-propan-2-ol; L000679; Q423364; 1(-alpha-naphthoxy)-3-(iso-propylamino)-2-propanol; 1-(alpha-naphthoxy)-3-(iso-propylamino)-2-propanol; 1-(alpha-naphthoxy)-3-(isopropylamino)-2-propanol; 1-isopropylamino-3-(naphthalen-1-yloxy)propan-2-ol; W-109550; 1-(isopropylamino)-3-naphthalen-1-yloxy-propan-2-ol; BRD-A10070317-003-06-9; BRD-A10070317-003-17-6; 1-((1-Methylethyl)amino)-3-(1-naphthyloxy)-2-propanol; 1-(1-Naphthyloxy)-2-hydroxy-3-(isopropylamino)propane; F0001-3681; 1-[(1-methylethyl)amino]-3-(naphthalen-1-yloxy)propan-2-ol; 1H-Pyrrole-2-carboxylic acid, 4-acetyl-5-methyl-3-(trifluoromethyl)-, ethyl ester	D04JEE	DM79NTF	259.339	C16H21NO2	41.5	257	3	19	2	3	6	InChI=1S/C16H21NO2/c1-12(2)17-10-14(18)11-19-16-9-5-7-13-6-3-4-8-15(13)16/h3-9,12,14,17-18H,10-11H2,1-2H3	CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O	CC(C)NCC(COC1=CC=CC2=CC=CC=C21)O	AQHHHDLHHXJYJD-UHFFFAOYSA-N	1-naphthalen-1-yloxy-3-(propan-2-ylamino)propan-2-ol
ferrodrug0106	Penicillamine	Small molecular drug	D-Penicillamine; penicillamine; 52-67-5; Cuprimine; D-(-)-Penicillamine; 3-Mercapto-D-valine; Depen; Cuprenil; D-Penamine; (-)-Penicillamine; (2S)-2-Amino-3-methyl-3-sulfanylbutanoic acid; Artamine; D-Valine, 3-mercapto-; D-Mercaptovaline; Mercaptovaline; Cupripen; Depamine; Kuprenil; Mercaptyl; Pendramine; Penicillamin; Perdolat; Trolovol; D-3-Mercaptovaline; (S)-3,3-Dimethylcysteine; Penicilamina; Penicillaminum; Sufirtan; beta-Thiovaline; D-beta,beta-Dimethylcysteine; beta,beta-Dimethylcysteine; 3-sulfanyl-D-valine; D-Penicilamine; Penicillamina [DCIT]; Penicilamina [INN-Spanish]; Penicillaminum [INN-Latin]; Dimethylcysteine; Metalcaptase; (D)-PENICILLAMINE; (S)-2-amino-3-mercapto-3-methylbutanoic acid; Distamine; CHEBI:7959; (S)-Penicillamine; Penicillamine (Cuprimine); Reduced penicillamine; GNN1DV99GX; (2S)-2-amino-3-methyl-3-sulfanyl-butanoic acid; CHEMBL1430; Penicilllamine; Reduced D-penicillamine; D-Penicyllamine; 3,3-Dimethyl-D-cysteine; DTXSID6037069; D-(-)-2-Amino-3-mercapto-3-methylbutanoic acid; NSC-81549; (S)-Penicillamin; d,3-Mercaptovaline; NCGC00024359-04; Penicillamina; MFCD00064302; Sufortan; Cuprimine (TN); Valine, 3-mercapto-, D-; CCRIS 2904; D-beta-Mercaptovaline; Depen (TN); HSDB 3378; D(-)PENICILLAMINE HYDROCHLORIDE; SR-01000000262; EINECS 200-148-8; UNII-GNN1DV99GX; NSC 81549; alpha-Amino-beta-methyl-beta-mercaptobutyric acid; Distamine (*Hydrochloride*); d-penicillamin; Penicillamine (JAN/USP/INN); dimethyl cysteine; Metalcaptase (*Hydrochloride*); penicillamine-(d); 3-Thio-D-valine; Penicillamine,(S); NSC81549; penicillamine-(racemic); Spectrum_000283; Penicillamine [USAN:USP:INN:BAN:JAN]; Spectrum2_001029; Spectrum3_000541; Spectrum4_000470; Spectrum5_001196; PENICILLAMINE [MI]; Epitope ID:113237; P-1280; PENICILLAMINE [INN]; PENICILLAMINE [JAN]; SCHEMBL4343; PENICILLAMINE [HSDB]; PENICILLAMINE [USAN]; BSPBio_002181; KBioGR_000920; KBioSS_000763; PENICILLAMINE [VANDF]; cid_92173; DivK1c_000314; PENICILLAMINE [MART.]; SPBio_001217; D-Penicillamine, 98-101%; PENICILLAMINE [USP-RS]; PENICILLAMINE [WHO-DD]; GTPL7264; DTXCID4017069; BDBM39346; KBio1_000314; KBio2_000763; KBio2_003331; KBio2_005899; KBio3_001681; NINDS_000314; VVNCNSJFMMFHPL-VKHMYHEASA-N; PENICILLAMINE [EP IMPURITY]; PENICILLAMINE [ORANGE BOOK]; BCP17247; HY-B0300; STR02534; PENICILLAMINE [EP MONOGRAPH]; Tox21_110899; BDBM50217941; PENICILLAMINE [USP MONOGRAPH]; s1853; AKOS006237201; AM83710; CCG-266197; DB00859; CAS-52-67-5; IDI1_000314; SMP1_000042; NCGC00018283-01; NCGC00024359-05; NCGC00024359-06; P0147; EN300-52608; C07418; D00496; M06142; P15236; Q421239; SR-01000000262-3; SR-01000000262-4; Z234896485; (2S)-2-amino-3-mercapto-3-methyl-butyric acid;hydrochloride; (2S)-2-amino-3-mercapto-3-methylbutanoic acid;hydrochloride; (2S)-2-azanyl-3-methyl-3-sulfanyl-butanoic acid;hydrochloride; Penicillamine, European Pharmacopoeia (EP) Reference Standard; (2S)-2-amino-3-methyl-3-sulfanylbutanoic acid3-sulfanyl-D-valine; Penicillamine, United States Pharmacopeia (USP) Reference Standard	D08HZC	DM40EF6	149.21	C5H11NO2S	64.3	124	-1.8	9	3	4	2	InChI=1S/C5H11NO2S/c1-5(2,9)3(6)4(7)8/h3,9H,6H2,1-2H3,(H,7,8)/t3-/m0/s1	CC(C)([C@H](C(=O)O)N)S	CC(C)(C(C(=O)O)N)S	VVNCNSJFMMFHPL-VKHMYHEASA-N	(2S)-2-amino-3-methyl-3-sulfanylbutanoic acid
ferrodrug0107	Abietic acid	Small molecular drug	ABIETIC ACID; 514-10-3; Sylvic acid; Abietate; l-Abietic acid; Rosin Acid; 7,13-Abietadien-18-oic acid; Kyselina abietova; 13-Isopropylpodocarpa-7,13-dien-15-oic acid; CCRIS 3183; Abietic acid, technical; Abietinic acid; EINECS 208-178-3; NSC 25149; UNII-V3DHX33184; (-)-Abietic acid; CHEBI:28987; AI3-17273; V3DHX33184; MFCD03423567; NSC-25149; (1R,4aR,4bR,10aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,4b,5,6,10,10a-decahydrophenanthrene-1-carboxylic acid; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R,4aR,4bR,10aR)-; DTXSID7022047; 8050-09-7; NSC25149; Podocarpa-7,13-dien-15-oic acid, 13-isopropyl-; NCGC00166273-01; abieta-7,13-dien-18-oate; Kyselina abietova [Czech]; Abietic acid dimer; (1R,4aR,10aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,5,6,10,10a-decahydrophenanthrene-1-carboxylic acid; (1R,4AR,4BR,10AR)-1,2,3,4,4A,4B,5,6,10,10A-DECAHYDRO-1,4A-DIMETHYL-7-(1-METHYLETHYL)-1-PHENANTHRENECARBOXYLIC ACID; (1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid; Colophonium; Kolophonium; Highrosin; Shiragiku rosin; Yellow resin; Rondis R; WW Wood rosin; Rosin WW; Hongkong rosin WW; Levamisole resinate; AbietinsA currencyure; Rosin [USP]; Bandis G100; Abietic acid, 90%; Caswell No. 667; BALS 3A; DSSTox_CID_2047; ABIETIC ACID [MI]; D0UQ6U; ABIETIC ACID [INCI]; DSSTox_RID_82575; DSSTox_GSID_47831; SCHEMBL28888; CHEMBL71893; Podocarpa-7, 13-isopropyl-; DTXCID202047; EM 3; UNII-88S87KL877; RSWGJHLUYNHPMX-ONCXSQPRSA-; RSWGJHLUYNHPMX-ONCXSQPRSA-N; BCP14376; EINECS 232-475-7; Tox21_112386; BDBM50442901; KE 709; NSC154789; Podocarpa-7, 13-isopropyl-, dimer; s5122; AKOS016036412; 88S87KL877; Abietic acid, technical, ~75% (GC); CCG-267495; EPA Pesticide Chemical Code 067205; LMPR0104050001; NSC-154789; (5beta)-abieta-7,13-dien-18-oic acid; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl- )-; AS-35301; NCI60_002007; 13-isopropyl-podocarpa-13-dien-15-oicacid; 10248-55-2; C06087; EC 232-475-7; EN300-1699654; A871292; Q321068; WLN: L B666 EU GUTJ A1 EY1&1 KVQ K1; C32BF2BB-9F97-4AF5-8F5E-06BC0EA97E83; F8881-8980; Z1954802293; 1-PHENANTHRENECARBOXYLIC ACID, 1,2,3,4,4A,4B,5,6,10,10A-DECAHYDRO-1,4A-DIMETHYL-7-(1-METHYLETHYL)-, (1R-(1ALPHA,4ABETA,4BALPHA,10A.ALPHA)).-; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl-)-; 1-Phenanthrenecarboxylic acid,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(1-methylethyl)-, [1R-(1.alpha.,4a.beta.,4b.alpha.,10a.alpha.)]-; 15522-12-0; A9H; InChI=1/C20H30O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h7,12-13,16-17H,5-6,8-11H2,1-4H3,(H,21,22)/t16-,17+,19+,20+/m0/s1	D0UQ6U	DMW1Y2G	302.5	C20H30O2	37.3	542	4.8	22	1	2	2	InChI=1S/C20H30O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h7,12-13,16-17H,5-6,8-11H2,1-4H3,(H,21,22)/t16-,17+,19+,20+/m0/s1	CC(C)C1=CC2=CC[C@@H]3[C@@]([C@H]2CC1)(CCC[C@@]3(C)C(=O)O)C	CC(C)C1=CC2=CCC3C(C2CC1)(CCCC3(C)C(=O)O)C	RSWGJHLUYNHPMX-ONCXSQPRSA-N	(1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylic acid
ferrodrug0108	Ketamine	.	ketamine; dl-Ketamine; Ketaject; Special K; Ketalar; (+-)-Ketamine; CI 581 base; Calypsol; Ketaminum; CLSTA 20; 6740-88-1; (+/-)-Ketamine; narketan; Cetamina; Ketanest; Tekam; Ketalar base; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(Methylamino)-2-(2-chlorophenyl)cyclohexanone; Ursotamin; Vetaket; Ketamine Base; KETAMINE HCL; Anaket v; 2-(o-Chlorophenyl)-2-(methylamino)-cyclohexanone; Special K [street name]; Clorketam 1000; Ketasol 100; Imalgene 1000; ketamina; NSC 70151; EINECS 229-804-1; NSC-70151; Ketamine (INN); UNII-690G0D6V8H; BRN 2216965; CHEBI:6121; 100477-72-3; DTXSID8023187; cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-; HSDB 2180; 690G0D6V8H; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone; CHEMBL742; 2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one; (+/-)-2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; DTXCID703187; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+-)-; KETAFOL COMPONENT KETAMINE; PMI-150; EC 229-804-1; 2-(o-Chlorophenyl)-2-(methylamino)cyclohexanone; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-; DEA No. 7285; NCGC00159480-02; NCGC00159480-03; Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+/-)-; KETAMINE [INN]; Special K (street name); Ketamine [INN:BAN]; Ketaminum [INN-Latin]; Cetamina [INN-Spanish]; Ketoject; CAS-6740-88-1; Tekam (TN); Ketaminum (Latin); Ketolar (Salt/Mix); Vetalar (Salt/Mix); Kalipsol (Salt/Mix); Ketanest (Salt/Mix); KETAMINE [HSDB]; KETAMINE [MI]; KETAMINE [VANDF]; (.+/-.)-Ketamine; KETAMINE [WHO-DD]; Cyclohexanone, (.+-.)-; SCHEMBL16103; MLS001331674; DivK1c_000217; GTPL4233; (+/-)-2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone; SCHEMBL17084881; KBio1_000217; N01AX03; NINDS_000217; HMS2272G05; NSC70151; Tox21_111703; Tox21_111704; BDBM50044140; DB01221; IDI1_000217; SMR000238141; C07525; D08098; Q243547; 2-(2-Chlorophenyl)-2-(methylamino)cyclohexanone #; J-505587; (.+/-.)-2-(O-Chlorophenyl)-2-(methylamino)cyclohexanone; 2-(2-Chloro-phenyl)-2-methylamino-cyclohexanone(Ketamine); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)- (9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (+-)- (9CI); Cyclohexanone, 2-(2-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (.+/-.)-; Cyclohexanone, 2-(o-chlorophenyl)-2-(methylamino)-, (+/-)- (8CI)	.	.	237.72	C13H16ClNO	29.1	269	2.2	16	1	2	2	InChI=1S/C13H16ClNO/c1-15-13(9-5-4-8-12(13)16)10-6-2-3-7-11(10)14/h2-3,6-7,15H,4-5,8-9H2,1H3	CNC1(CCCCC1=O)C2=CC=CC=C2Cl	CNC1(CCCCC1=O)C2=CC=CC=C2Cl	YQEZLKZALYSWHR-UHFFFAOYSA-N	2-(2-chlorophenyl)-2-(methylamino)cyclohexan-1-one
ferrodrug0109	Thioctic acid	Small molecular drug	thioctic acid; dl-Thioctic acid; 1077-28-7; alpha-Lipoic acid; lipoic acid; 5-(1,2-Dithiolan-3-yl)pentanoic acid; 1,2-dithiolane-3-pentanoic acid; DL-alpha-Lipoic acid; alpha Lipoic Acid; Biletan; 62-46-4; 6,8-Thioctic acid; Thioctacid; DL-6,8-Thioctic acid; dl-Lipoic acid; 6-Thioctic acid; Lipothion; Liposan; Thioctsan; Tioctacid; Rac-lipoate; 1,2-Dithiolane-3-valeric acid; 6,8-Dithiooctanoic acid; alpha-Liponsaeure; DL-6-Thioctic acid; Thioctic acid dl-form; alpha-liponic acid; Thioktsaeure; Tioctidasi; (RS)-Lipoic acid; 5-(dithiolan-3-yl)pentanoic acid; 5-(1,2-Dithiolan-3-yl)valeric acid; espa-lipon; Acetate-replacing factor; 6,8-Thiotic acid; Thioctansaeure; 5-(Dithiolan-3-yl)valeric acid; (+-)-Lipoic acid; 6-Thiotic acid; .alpha.-Lipoic acid; DL-1,2-Dithiolane 3-valeric acid; thioctate; Thioctic acid [JAN]; Thioctsaeure; Thiocacid; Thioctan; liponic acid; Thiooctic acid; Lip(S2); a-lipoic acid; DL-.alpha.-Lipoic acid; Acidum thiocticum; (+/-)-1,2-Dithiolane-3-pentanoic acid; A-lipoicum acidum; DL-1,2-Dithiolane-3-valeric acid; lipoate; MFCD00005474; NSC 90788; Lipoic acid, alpha; Lipoic acid, dl-; NSC 628502; (+-)-1,2-Dithiolane-3-pentanoic acid; .alpha.-Liponic acid; CHEBI:16494; C8H14O2S2; DL-1,2-Dithiolan-3-valeriansaeure; (.+-.)-Lipoic acid; NSC-90788; (RS)-.alpha.-Lipoic acid; 5-[3-(1,2-dithiolanyl)]pentanoic acid; CHEMBL33864; DTXSID7025508; (.+-.)-.alpha.-Lipoic acid; 73Y7P0K73Y; 1,2-DITHIOLANE-3-VALERIC ACID, (+-)-; NSC90788; NSC-628502; Thioctic acid (JAN); NCGC00016032-06; Protogen A; (+/-)-alpha-Lipoic acid; Thiogamma; DTXCID705508; Thioktsaeure [German]; biomolipon; duralipon; Alipure; AlphaLipogamma; Thiotacid; biomo lipon; espa lipon; Alpha Lipogamma; Alpha-Lipogamma; Pyruvate oxidation factor; DL-Thiocticacid; Pleomix Alpha; Thioctacide T; Verla Lipon; AlphaLipon Stada; Alpha Lippon AL; alpha-Liponsaeure [German]; Alpha Lipon Stada; Alpha-Lipon Stada; 5-(1,2)Dithiolan-3-yl-pentanoic acid; 5-[1,2]Dithiolan-3-yl-pentanoic acid; Liponsaureratiopharm; alpha-lipon 300; SMR000058198; CAS-1077-28-7; Liponsaure-ratiopharm; (+-)-Thioctic acid; 5-(3-(1,2-DITHIOLANYL))PENTANOIC ACID; alpha Liponsaure von ct; Tioctidasi acetate replacing factor; (R)-(+)-alpha-Lipoic acid;R-(+)-Thioctic acid; SR-01000737460; DL-6,8-DITHIOOCTANOIC ACID; (RS)-alpha-Lipoic acid; EINECS 200-534-6; EINECS 214-071-2; (+-)-alpha-lipoic acid; BRN 0081853; BRN 0122410; UNII-73Y7P0K73Y; Alphalipoic-acid; DL-1,2-Dithiolan-3-valeriansaeure [German]; Thioctic acid [INN:BAN:JAN]; HSDB 7818; alpha-lipoic-acid; D,L-Lipoic acid; Thiotomin (TN); DL-a-Lipoic acid; D,L-Thioctic acid; lipoic acid (LA); alpha -Lipoic Acid; rac ?-Lipoic Acid; (RS)-thioctic acid; LIPOIC-ACID; ()-alpha-Lipoic acid; Spectrum_001618; 5-(1,2-dithiolan-3-yl)-pentanoate; Thioctic acid, dl-form; R-(+)-alpaLipoic acid; 1,2-Dithiolane-3-pentanoic acid, (+-)-; Spectrum2_001605; Spectrum3_001188; Spectrum4_000217; Spectrum5_001298; (S)-(-)-Thiocticacid; (+/-)-a-Lipoic acid; cid_864; (.+-.)-Thioctic acid; Lipoic acid, alpha [NF]; bmse000542; D0P6PQ; Epitope ID:150922; (+/-)-?-Lipoic acid; (.+/-.)-Lipoic acid; THIOCTIC ACID [MI]; SCHEMBL51065; BSPBio_002835; KBioGR_000853; KBioSS_002098; THIOCTIC ACID [HSDB]; THIOCTIC ACID [INCI]; 5-19-07-00237 (Beilstein Handbook Reference); MLS000069736; MLS001332379; MLS001332380; MLS002153365; DivK1c_000912; SPECTRUM1503941; SPBio_001609; THIOCTIC ACID [MART.]; THIOCTIC ACID [WHO-DD]; BDBM10515; HMS502N14; KBio1_000912; KBio2_002098; KBio2_004666; KBio2_007234; KBio3_002335; A-LIPOICUM ACIDUM [HPUS]; ALPHA LIPOIC ACID [VANDF]; ALPHA-LIPOIC ACID [VANDF]; NINDS_000912; thioctic acid (alpha-lipoic acid); HMS1922M22; HMS3649H08; HMS3885I16; Pharmakon1600-01503941; THIOCTIC ACID, (+/-)-; ALPHA LIPOIC ACID [USP-RS]; BCP13221; BCP14048; BCP18944; HY-N0492; THIOCTIC ACID DL-FORM [MI]; Tox21_110285; Tox21_201808; Tox21_303092; AC7875; BBL013878; CCG-39063; dl-1,2-Dithiolane-3-pentanoic acid; NSC628502; NSC758651; s3996; STK801969; THIOCTIC ACID [EP MONOGRAPH]; ()-1,2-Dithiolane-3-pentanoic acid; AKOS000121582; AKOS016339634; Tox21_110285_1; AB09328; AM84329; CS-4370; KS-1322; NSC-758651; SB49517; IDI1_000912; ALPHA LIPOIC ACID [USP IMPURITY]; NCGC00016032-02; NCGC00016032-03; NCGC00016032-04; NCGC00016032-05; NCGC00016032-07; NCGC00016032-08; NCGC00016032-09; NCGC00016032-11; NCGC00016032-14; NCGC00090872-01; NCGC00090872-02; NCGC00090872-03; NCGC00090872-04; NCGC00090872-05; NCGC00256970-01; NCGC00259357-01; (+/-)-alpha-Lipoic acid, >=98.0%; .ALPHA.-LIPOIC ACID, (+/-)-; AC-22673; BP-31070; NCI60_042014; R)-(+)-; A-Lipoic acid OOEthyAoEthAEa; SY010902; (R)-(+)-(c) paragraph sign-Lipoic acid; SBI-0051871.P002; 5-(1,2-Dithiolan-3-yl)pentanoic acid #; ( inverted exclamation markA)-a-Lipoic acid; 1,2-Dithiolane-3-valeric acid, (.+-.)-; FT-0622068; FT-0625429; FT-0670812; FT-0670813; L0058; 1,2-Dithiolane-3-pentanoic acid, (.+-.)-; 1,2-Dithiolane-3-valeric acid, (.+/-.)-; EN300-17612; 1,2-Dithiolane-3-pentanoic acid, (.+/-.)-; C00725; D00086; AB00052393_09; (+/-)?-?1,2-?Dithiolane-?3-?Pentanoic Acid; A801751; Q312229; 1,2-Dithiolane-3-pentanoic acid, (+-)- (9CI); J-002007; J-520421; SR-01000737460-2; SR-01000737460-6; 5-((3RS)-1,2-DITHIOLAN-3-YL)PENTANOIC ACID; Z56969297; F2191-0208; .DELTA.-(3-(1,2-DITHIACYCLOPENTYL))PENTANOIC ACID; Thioctic acid, European Pharmacopoeia (EP) Reference Standard; (+/-)-alpha-Lipoic acid, BioReagent, cell culture tested, >=99%; (+/-)-alpha-Lipoic acid, synthetic, >=99% (titration), powder; Alpha Lipoic Acid, United States Pharmacopeia (USP) Reference Standard; (R)-(+)-1,2-Dithiolane-3-pentanoic acid; R-(+)-Thioctic acid; R-(+)-alpha-Lipoic acid; AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade mark?-Lipoic Acid; Thioctic acid containing impurity B, European Pharmacopoeia (EP) Reference Standard; Thioctic acid for system suitability, European Pharmacopoeia (EP) Reference Standard; Thioctic Acid;1,2-Dithiolane-3-pentanoic acid;5-(1,2-Dithiolan-3-yl)valeric acid	D0P6PQ	DMNFCXW	206.3	C8H14O2S2	87.9	150	1.7	12	1	4	5	InChI=1S/C8H14O2S2/c9-8(10)4-2-1-3-7-5-6-11-12-7/h7H,1-6H2,(H,9,10)	C1CSSC1CCCCC(=O)O	C1CSSC1CCCCC(=O)O	AGBQKNBQESQNJD-UHFFFAOYSA-N	5-(dithiolan-3-yl)pentanoic acid
ferrodrug0110	Epigallocatechin Gallate	.	(-)-Epigallocatechin gallate; EGCG; 989-51-5; Epigallocatechin gallate; Epigallocatechin 3-gallate; Tea catechin; Epigallocatechin-3-gallate; Teavigo; Epigallocatechin-3-monogallate; (-)-Epigallocatechin-3-o-gallate; (-)-epigallocatechin 3-gallate; PF-EGCg 90; (-)-Epigallocatechol gallate; NVP-XAA 723; CCRIS 3729; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl 3,4,5-trihydroxybenzoate; Catechin deriv.; UNII-BQM438CTEL; BQM438CTEL; CHEBI:4806; Epigallocatechingallate; Epigallocatechin-gallate; Epigallocatechol, 3-gallate, (-)-; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl 3,4,5-trihydroxybenzoate; CHEMBL297453; DTXSID1029889; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 3,4,5-trihydroxybenzoate; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-, (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; C22H18O11; (2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-3-yl 3,4,5-trihydroxybenzoate; EGCG cpd; Gallic acid, 3-ester with epigallocatechol, (-)-; DTXCID80567; epigallo-catechin gallate; epigallocatechin-3-O-gallate; Benzoic acid, 3,4,5-trihydroxy-, 3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester, (2R-cis)-; CAS-989-51-5; SMR000449288; SR-01000759328; (-)-EPIGALLOCATECHIN-3-O-GALLATE (USP-RS); (-)-EPIGALLOCATECHIN-3-O-GALLATE [USP-RS]; L-Epigallocatechin gallate; Epigallocate; Sunphenon; EPIGALOCATECHIN GALLATE; (-)-EGCG; Epigallocic acid; Teatannin II; 2kdh; 3oob; 4awm; (-)-cis-2-(3,4,5-Trihydroxyphenyl)-3,4-dihydro-1(2H)-benzopyran-3,5,7-triol 3-gallate; (-)-epigallocatechin 3-O-gallate; KDH; Epigallocatcchin Gallate; Epigallocatechol Gallate; Spectrum_000316; SpecPlus_000277; Spectrum2_000168; Spectrum3_000244; Spectrum4_001541; Spectrum5_000102; Galloyl-L-epigallocatechol; EGCG [WHO-DD]; EGCG [MI]; 3-O-Galloylepigallocatechin; (-)-Epigallocatechin gallat; (-)-Epigallocatehin gallate; SCHEMBL35258; BSPBio_001628; epigallocatechin-gallate-(-); KBioGR_002002; KBioSS_000796; SPECTRUM210239; cid_65064; MLS000758300; MLS001424000; DivK1c_006373; SPBio_000035; Epigallocatechin monogallate, B; GTPL7002; MEGxp0_001166; (-)-Epigallocatechin-3-gallate; ACon1_001054; KBio1_001317; KBio2_000796; KBio2_003364; KBio2_005932; KBio3_001128; (-)-cis-3,3',4',5,5',7-Hexahydroxy-flavane-3-gallate; HMS2051K21; HMS3649E08; 3-O-Galloyl-(-)-epigallocatechin; EPIGALLOCATECHIN 3-O-GALLATE; Tox21_201468; Tox21_303457; BDBM50070942; CCG-38378; FR-109; LMPK12030005; s2250; AKOS015918182; CS-1258; DB12116; DS-9030; EPIGALLOCATECHIN GALLATE [INCI]; NC00078; SDCCGMLS-0066550.P001; (-)-Epigallocatechin gallate, >=95%; (-)-Epigallocatechin-3-gallate; EGCG; NCGC00164319-01; NCGC00164319-02; NCGC00164319-03; NCGC00164319-04; NCGC00164319-06; NCGC00257243-01; NCGC00259019-01; (-)-Epigallocatechin gallate (85% (-)-epigallocatechin gallate, 10% (-)-epigallocatechin, 5% (-)- epicatechin gallate); AC-34075; BP-30205; HY-13653; E0694; SW197458-3; C09731; M01719; (-)-Epigallocatechin gallate, >=97.0% (HPLC); (-)-Epigallocatechin gallate, analytical standard; A845931; Q393339; SR-01000946601; Q-100914; SR-01000759328-5; SR-01000759328-6; SR-01000946601-1; Epigallocatechin-3-gallate 1000 microg/mL in Acetonitrile; (-)-Epigallocatechin gallate, >=80% (HPLC), from green tea; Epigallocatechin gallate, primary pharmaceutical reference standard; ((2R,3R)-2-(3,4,5-trihydroxyphenyl)-5,7-dihydroxy-chroman-3-yl) 3,4,5-trihydroxybenzoate; (-)-Epigallocatechin-3-O-gallate, United States Pharmacopeia (USP) Reference Standard; (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl3,4,5-trihydroxybenzoate; [5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-3-yl] 2,3,4-trihydroxybenzoate; Epigallocatechin gallate, Pharmaceutical Secondary Standard; Certified Reference Material; (-)-cis-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-1(2H)-benzopyran-3-yl Gallate; (-)-EPIGALLOCATECHIN GALLATE (85% (-)-EPIGALLOCATECHIN GALLATE, 10% (-)-EPIGALLOCATECHIN, 5% (-)-EPICATECHIN GALLATE); (-)-EPIGALLOCATECHIN-3-O-GALLATE (EGCG) (CONSTITUENT OF POWDERED DECAFFEINATED GREEN TEA EXTRACT); (2R,3R)-5,7-Dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl-3,4,5-trihydroxybenzoate; (2R-cis)-3,4-Dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl 3,4,5-Trihydroxybenzoate; [(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl]3,4,5-trihydroxybenzoate; 3,4,5-Trihydroxybenzoic acid (2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester; 3,4-Dihydro-5,7-dihydroxy-2R-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3R-yl-3,4,5-trihydroxybenzoate; Benzoic acid, 3,4,5-trihydroxy-,(2R,3R)-3,4-dihydro-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-2H-1-benzopyran-3-yl ester	.	.	458.4	C22H18O11	197	667	1.2	33	8	11	4	InChI=1S/C22H18O11/c23-10-5-12(24)11-7-18(33-22(31)9-3-15(27)20(30)16(28)4-9)21(32-17(11)6-10)8-1-13(25)19(29)14(26)2-8/h1-6,18,21,23-30H,7H2/t18-,21-/m1/s1	C1[C@H]([C@H](OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O	C1C(C(OC2=CC(=CC(=C21)O)O)C3=CC(=C(C(=C3)O)O)O)OC(=O)C4=CC(=C(C(=C4)O)O)O	WMBWREPUVVBILR-WIYYLYMNSA-N	[(2R,3R)-5,7-dihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-chromen-3-yl] 3,4,5-trihydroxybenzoate
ferrodrug0111	Naringenin	.	naringenin; 480-41-1; Salipurol; (S)-Naringenin; (S)-5,7-Dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; pelargidanon; naringetol; (2S)-Naringenin; salipurpol; Naringenine; Asahina; NARIGENIN; NSC 11855; CCRIS 5839; (-)-(2S)-Naringenin; C15H12O5; UNII-HN5425SBF2; NSC 34875; HN5425SBF2; CHEBI:17846; AI3-23355; Flavanone, 4',5,7-trihydroxy-; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; (-)-Naringenin; YSO1; EINECS 207-550-2; NSC-11855; 2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; CHEMBL9352; NARINGENIN, (-)-; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; DTXSID1022392; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; 5,7,4'-Trihydroxyflavanone; (S)-2,3-Dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-4-benzopyrone; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4h-chroman-4-one; (-)-(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; (R,S)-Naringenin; 5,7-Dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; NSC-34875; (S)-2,3-dihydo-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (S)-; SR-01000721771; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)chroman-4-one; 4',5,7-trihydroxyflavan-4-one; Nari; BE-14348A; 2uxu; 4deu; S-Dihydrogenistein; pelargidanon 1602; Spectrum_000247; 4eh3; NARINGENIN [MI]; Spectrum2_000325; Spectrum3_000567; Spectrum4_000124; Spectrum5_001423; NARINGENIN [INCI]; 4',5,7-triOH-Flavone; 4',5,7-Trihydroxyflavanon; SCHEMBL20570; BSPBio_001954; KBioGR_000508; KBioSS_000727; MLS000574861; BIDD:ER0116; DivK1c_000118; SPECTRUM1500746; SPBio_000329; 4',5, 7-Trihydroxyflavanone; DTXCID302392; BDBM23419; HMS500F20; KBio1_000118; KBio2_000727; KBio2_003295; KBio2_005863; KBio3_001454; FTVWIRXFELQLPI-ZDUSSCGKSA-N; NINDS_000118; (2S)-5,7,4'-trihydroxyflavone; AIDS001417; HMS2202M06; (2S)-4',5,7-trihydroxyflavanone; HY-N0100; TNP00287; (2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one; CCG-38601; LMPK12140001; Phytochemistry 8: 127 (1969); s2394; AKOS016843490; CS-6421; DB03467; FS-4072; SDCCGMLS-0066570.P001; (2S)-4',5,7-trihydroxyflavan-4-one; IDI1_000118; NCGC00016457-01; NCGC00016457-02; NCGC00016457-03; NCGC00017346-01; NCGC00163598-01; AC-33954; CAS-480-41-1; Flavanone, 4',5,7-trihydroxy- (8CI); SMR000156272; FT-0617134; SW219329-1; C00509; EN300-303163; A827427; Q418374; Q-100666; SR-01000721771-3; SR-01000721771-4; BRD-K08832567-001-02-4; BRD-K08832567-001-06-5; 2,3-Dihydro-5,6-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,2,3-dihydro-5,7-dihydroxy-2-(4-hydroxyphenyl)-, (2S)-; 13308-00-4	.	.	272.25	C15H12O5	87	363	2.4	20	3	5	1	InChI=1S/C15H12O5/c16-9-3-1-8(2-4-9)13-7-12(19)15-11(18)5-10(17)6-14(15)20-13/h1-6,13,16-18H,7H2/t13-/m0/s1	C1[C@H](OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O	C1C(OC2=CC(=CC(=C2C1=O)O)O)C3=CC=C(C=C3)O	FTVWIRXFELQLPI-ZDUSSCGKSA-N	(2S)-5,7-dihydroxy-2-(4-hydroxyphenyl)-2,3-dihydrochromen-4-one
ferrodrug0112	Puerarin	Small molecular drug	Puerarin; 3681-99-0; Kakonein; Daidzein-8-C-glucoside; 7-hydroxy-3-(4-hydroxyphenyl)-8-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one; Puerarin 80 mm; CHEBI:8633; NPI 031G; Daidzein 8-c-glucoside; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; NSC-380711; Z9W8997416; Puerarin, analytical standard; AC1NQZ4N; MFCD00063399; 8-C-glucoside; 8-Glucosyldaidzein; UNII-Z9W8997416; NSC 380711; 7,4'-Dihydroxy-8-C-glucosylisoflavone; BRN 0064198; 8-Glucopyranosyldaidzein; PUERARIN [INCI]; PUERARIN [WHO-DD]; SureCN8581666; 4-19-00-03200 (Beilstein Handbook Reference); MLS002473178; BIDD:ER0101; CHEMBL486386; SCHEMBL8581666; GTPL12553; HKEAFJYKMMKDOR-VPRICQMDSA-; DTXSID30958020; HKEAFJYKMMKDOR-VPRICQMDSA-N; HMS2198M10; Puerarin, >=98.0% (HPLC); HY-N0145; BDBM50129558; 8-beta-D-Glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; AKOS007930376; AKOS015965556; CS-6158; DB12290; KS-5191; 4H-1-Benzopyran-4-one, 8-beta-D-glucopyranosyl-7-hydroxy-3-(4-hydroxyphenyl)-; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; AC-20294; SMR001397270; 4',7-DIHYDROXY-8-C-GLUCOSYLISOFLAVONE; Q63408673; Z1494829516; (1S)-1,5-Anhydro-1-[7-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-chromen-8-yl]-D-glucitol; 4H-1-BENZOPYRAN-4-ONE, 8-.BETA.-D-GLUCOPYRANOSYL-7-HYDROXY-3-(4-HYDROXYPHENYL)-; 8-(-bet.-D-Glucopyranosyl-7-hydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one; 8-(beta-D-Glucopyranosyl-7-hydroxy-3- (4-hydroxyphenyl)-4H-1-benzopyran-4-one; (1S)-1,5-anhydro-1-[7-hydroxy-3-(4-hydroxyphenyl)-4-oxo-4H-1-benzopyran-8-yl]-D-glucitol; 7-hydroxy-3-(4-hydroxyphenyl)-8-[(3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; InChI=1/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1	D0I7MT	DMJIMXH	416.4	C21H20O9	157	659	0	30	6	9	3	InChI=1S/C21H20O9/c22-7-14-17(26)18(27)19(28)21(30-14)15-13(24)6-5-11-16(25)12(8-29-20(11)15)9-1-3-10(23)4-2-9/h1-6,8,14,17-19,21-24,26-28H,7H2/t14-,17-,18+,19-,21+/m1/s1	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O	C1=CC(=CC=C1C2=COC3=C(C2=O)C=CC(=C3C4C(C(C(C(O4)CO)O)O)O)O)O	HKEAFJYKMMKDOR-VPRICQMDSA-N	7-hydroxy-3-(4-hydroxyphenyl)-8-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
ferrodrug0113	Fluvastatin	.	fluvastatin; 93957-54-1; Lescol; (3R,5S)-fluvastatin; 155229-75-7; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (+)-3R,5S-Fluvastatin sodium salt; Cranoc; (+)-(3R,5S)-fluvastatin; (3R,5S,E)-7-(3-(4-Fluorophenyl)-1-isopropyl-1H-indol-2-yl)-3,5-dihydroxyhept-6-enoic acid; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid; XU-62320; CHEBI:38565; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (3R,5S,6E)-7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; CHEMBL1078; Fluvastatin & Primycin; XU 62-320 (free acid); DTXSID2020636; NSC-758896; (-)-fluvastatin; (E,3R,5S)-7-[3-(4-fluorophenyl)-1-isopropyl-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; Prestwick2_000859; SCHEMBL2846; (3R,5S,6E)-rel-7-[3-(4-Fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid; SCHEMBL556754; GTPL2951; DTXCID0065309; BDBM86704; CHEBI:93160; FJLGEFLZQAZZCD-MCBHFWOFSA-N; DTXSID201020962; HMS2089P06; HMS3259J15; Pharmakon1600-01504911; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]- 3,5-dihydroxy-, (3R,5S,6E)-rel-; Tox21_302765; DL-108; HY-14664B; NSC758896; CCG-213323; NC00659; NCGC00256490-01; CAS-93957-54-1; CAS_93957-54-1; CS-0019897; EN300-51915; H11963; EN300-21702553; Q417942; SR-05000001489-1; BRD-K66296774-001-02-0; (3R,5S)-7-[3-(4-fluorophenyl)-1-(propan-2-yl)-1H-indol-2-yl]-3,5-dihydroxyhept-6-enoic acid; (E)-(3R,5S)-7-[3-(4-Fluoro-phenyl)-1-isopropyl-1H-indol-2-yl]-3,5-dihydroxy-hept-6-enoic acid; 6-Heptenoic acid, 7-[3-(4-fluorophenyl)-1-(1-methylethyl)-1H-indol-2-yl]-3,5-dihydroxy-, (3R,5S,6E)-	.	.	411.5	C24H26FNO4	82.7	590	3.5	30	3	5	8	InChI=1S/C24H26FNO4/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30)/b12-11+/t18-,19-/m1/s1	CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@H](C[C@H](CC(=O)O)O)O)C3=CC=C(C=C3)F	CC(C)N1C2=CC=CC=C2C(=C1C=CC(CC(CC(=O)O)O)O)C3=CC=C(C=C3)F	FJLGEFLZQAZZCD-MCBHFWOFSA-N	(E,3R,5S)-7-[3-(4-fluorophenyl)-1-propan-2-ylindol-2-yl]-3,5-dihydroxyhept-6-enoic acid
ferrodrug0114	Sodium iodate	.	SODIUM IODATE; 7681-55-2; sodium;iodate; Iodic acid, sodium salt; U558PCS5Z9; Natriumjodat; Iodic acid (HIO3), sodium salt (1:1); Natriumjodat [German]; Sodium iodate (NaIO3) pentahydrate; HSDB 749; EINECS 231-672-5; NSC 77387; UNII-U558PCS5Z9; IODIC ACID, SODIUM SALT, PENTAHYDRATE; MFCD00003533; Sodium iodate, >=99%; Na I O3; SODIUM IODATE [MI]; SODIUM IODATE [HSDB]; SODIUM IODATE [INCI]; Sodium iodate, >=99.5%; SODIUM IODATE [WHO-DD]; CHEBI:81708; DTXSID90858754; WTCBONOLBHEDIL-UHFFFAOYSA-M; AKOS015951016; 17250-90-7; Sodium iodate, BioUltra, >=99.5% (RT); C18366; Sodium iodate, puriss. p.a., >=99.5% (RT); Q411126	.	.	197.892	INaO3	57.2	49.8	.	5	0	3	0	InChI=1S/HIO3.Na/c2-1(3)4;/h(H,2,3,4);/q;+1/p-1	[O-]I(=O)=O.[Na+]	[O-]I(=O)=O.[Na+]	WTCBONOLBHEDIL-UHFFFAOYSA-M	sodium;iodate
ferrodrug0115	5-aminolevulinic acid	Small molecular drug	5-Aminolevulinic acid; Aminolevulinic acid; 106-60-5; 5-Amino-4-oxopentanoic acid; 5-Aminolevulinate; Pentanoic acid, 5-amino-4-oxo-; delta-aminolevulinic acid; Aladerm; 5-Amino-4-oxovaleric acid; Aminolevulinate; Kerastick; 5-amino-4-oxo-pentanoic acid; 5-ALA; delta-ALA; 5-amino-levulinate; 5-amino-levulinic acid; 5-Amino-4-oxopentanoate; Levulinic acid, 5-amino-; DALA; CHEMBL601; .delta.-aminolevulinic acid; 4-oxo-5-amino-pentanoic acid; CHEBI:17549; 88755TAZ87; 5-azanyl-4-oxidanylidene-pentanoic acid; delta-aminolevulinate; 5-Aminolaevulinic acid; Aminolevulinic; 5-Aminolaevulinate; SMR000857229; CCRIS 8958; D-aminolevulinic acid; EINECS 203-414-1; BF-200 ALA; UNII-88755TAZ87; FVT; Amino-levulinic acid; 5-aminolevulinic-acid; Spectrum_001582; 5-Amino-4-oxovalerate; SpecPlus_000858; Spectrum2_001662; Spectrum3_001654; Spectrum4_000618; Spectrum5_001505; 5-amino-4-oxo-Pentanoate; SCHEMBL8243; BSPBio_003407; KBioGR_001176; KBioSS_002062; MLS001333097; MLS001333098; BIDD:GT0260; DivK1c_006954; SPBio_001843; GTPL4784; DTXSID8048490; KBio1_001898; KBio2_002062; KBio2_004630; KBio2_007198; KBio3_002627; HMS2231I19; HMS3259E22; HMS3369O14; AMINOLEVULINIC ACID [VANDF]; Levulinic acid, 5-amino- (8CI); BCP23830; AC-054; AMINOLEVULINIC ACID [WHO-DD]; BDBM50240386; LMFA01100055; MFCD00044485; AKOS003587520; 5-AMINOLEVULINIC ACID [MART.]; CS-W000450; DB00855; HY-W000450; NC00601; NCGC00178086-01; NCGC00178086-06; .DELTA.-AMINOLEVULINIC ACID [MI]; AS-30950; Pentanoic acid, 5-amino-4-oxo- (9CI); SBI-0206721.P001; FT-0620021; C00430; D07567; EN300-101562; AB00053763-07; AB00053763-08; AB00053763_09; AB00053763_10; A801471; Q238474; 35BEC718-C970-426A-9859-BF58284C60B4; METHYLAMINOLEVULINATE HYDROCHLORIDE IMPURITY B [EP IMPURITY]; Aminolevulinic Acid;ALA;5-Amino-4-oxopentanoic acid;5-amino-4-oxo-pentanoic acid;5-amino-4-keto-valeric acid	D0Y7ZD	DMS4BLQ	131.13	C5H9NO3	80.4	121	-3.8	9	2	4	4	InChI=1S/C5H9NO3/c6-3-4(7)1-2-5(8)9/h1-3,6H2,(H,8,9)	C(CC(=O)O)C(=O)CN	C(CC(=O)O)C(=O)CN	ZGXJTSGNIOSYLO-UHFFFAOYSA-N	5-amino-4-oxopentanoic acid
ferrodrug0116	Artesunate	.	Artesunate; Artesunic acid; Arsumax; 88495-63-0; Plasmotrin; Qinghaozhi; Saphnate; Dihydroqinghasu hemsuccinate; Artesunatum; Zysunate; Arinate; Artesunato; Asumax; Gsunate Forte; Plasmotrim; CHEBI:63918; .alpha.-artesunic acid; Dihydroqinghaosu hemisuccinate; Succinyl dihydroartemisinin; LJPC-0118; 60W3249T9M; NSC-712571; Butanedioic acid, 1-[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-yl] ester; Arsuamoon; WR-256283; cosunate; Artesunata; Cosinate; Artesunate [USAN]; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-Decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, hydrogen succinate; 4-oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-yl)oxy)butanoic acid; 4-oxo-4-{[(3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano[4,3-j][1,2]benzodioxepin-10-yl]oxy}butanoic acid; Artesunate [INN]; Butanedioic acid, mono((3R,5aS,6R,8aS,9R,10S,12R,12aR)-decahydro-3,6,9-trimethyl-3,12-epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-yl) ester; Armax 200; Artesunatum [INN-Latin]; Artesunato [INN-Spanish]; DTXSID3042681; Artsuna; Nuartez; Artesunate [USAN:INN:BAN]; UNII-60W3249T9M; HSDB 7458; Quinghaosu reduced succinate ester; D95; Dihydroartemisinine-12alpha-succinate; ARTESUNATE [MI]; WR 256283; ARTESUNATE [HSDB]; ARTESUNATE [VANDF]; ARTESUNATE [MART.]; ARTESUNATE [USP-RS]; ARTESUNATE [WHO-DD]; ARTESUNATE [WHO-IP]; MLS006011590; CHEMBL361497; GTPL9956; ARTESUNATE [ORANGE BOOK]; SCHEMBL14552891; FIHJKUPKCHIPAT-AHIGJZGOSA-N; ARTESUNATUM [WHO-IP LATIN]; HY-N0193; STR09744; BDBM50248021; AKOS037515734; CS-8151; DB09274; NCGC00164600-10; NCGC00164600-15; SMR002499399; DIHYDROARTEMISININE-12.ALPHA.-SUCCINATE; EN300-6482026; Q707939; BRD-K54634444-001-05-9; WR-256283;ART;Armax 200;SM-804;HSDB-7458; 3R,5AS,6R,8AS,9R,10S,12R,12AR)-3,6,9-TRIMETHYLDECAHYDRO-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL HYDROGEN BUTANEDIOATE; 4-Oxo-4-(((3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3,12-epoxypyrano(4,3-j)-1,2-benzodioxepin-10-yl hydrogen butanedioate; 4-OXO-4-(3R,5AS,6R,8AS,9R,10S,12R,12AR)-3,6,9-TRIMETHYLDECAHYDRO-3,12-EPOXYPYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL HYDROGEN BUTANEDIOATE; 4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid; 4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0?,(1)(3).0?,(1)(3)]hexadecan-10-yl]oxy}butanoic acid; 4-oxo-4-{[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-yl]oxy}butanoic acid; BUTANEDIOIC ACID, MONO(DECAHYDRO-3,6,9-TRIMETHYL-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-YL) ESTER, (3R-(3.ALPHA.,5A.BETA.,6.BETA.,8A.BETA.,9.ALPHA.,10.BETA.,12.BETA.,12AR*))-	.	.	384.4	C19H28O8	101	623	2.5	27	1	8	5	InChI=1S/C19H28O8/c1-10-4-5-13-11(2)16(23-15(22)7-6-14(20)21)24-17-19(13)12(10)8-9-18(3,25-17)26-27-19/h10-13,16-17H,4-9H2,1-3H3,(H,20,21)/t10-,11-,12+,13+,16-,17-,18-,19-/m1/s1	C[C@@H]1CC[C@H]2[C@H]([C@@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)OC(=O)CCC(=O)O)C	CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)OC(=O)CCC(=O)O)C	FIHJKUPKCHIPAT-AHIGJZGOSA-N	4-oxo-4-[[(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-yl]oxy]butanoic acid
ferrodrug0117	Sodium hydrosulfide	.	SODIUM HYDROSULFIDE; Sodium bisulfide; 16721-80-5; Sodium sulfhydrate; Sodium hydrogen sulfide; Sodium sulfide (Na(SH)); Sodium mercaptan; Sodium mercaptide; NaHS; Sodium hydrosulphide; sodium sulfanide; Sodium Hydrogensulfide; sodium;sulfanide; Hydrogen sodium sulfide; Sodium sulfide (Na(HS)); Sodium hydrosulfide (Na(HS)); Sodium hydrogen sulfide (NaHS); NA2922; FWU2KQ177W; CHEMBL1644699; NSC-158264; Hidrosulfuro sodics; HNaS; Hidrosulfuro sodics [Spanish]; HSDB 5165; Hydrogenosulfure de sodium [French]; EINECS 240-778-0; Hydrogenosulfure de sodium; UN2318; UN2949; UNII-FWU2KQ177W; NSC 158264; AI3-14915; sodiumhydrogensulfide; sodium hydro-sulfide; MFCD00011124; SODIUM BISULPHIDE; EC 240-778-0; SODIUM BISULFIDE [MI]; GTPL6278; DTXSID3029738; HYHCSLBZRBJJCH-UHFFFAOYSA-M; Sodium hydrogen sulfide, anhydrous; SODIUM HYDROSULFIDE [HSDB]; NSC158264; AKOS015915184; FT-0651301; A810831; Q414203; J-013607; Sodium hydrosulfide, with <25% water of crystallization; Sodium hydrosulfide, with not <25% water of crystallization; Sodium hydrosulfide, with not <25% water of crystallization [UN2949] [Corrosive]; 115694-77-4; Sodium hydrosulfide, with <25% water of crystallization [UN2318] [Spontaneously combustible]	.	.	56.07	HNaS	1	2	.	2	1	1	0	InChI=1S/Na.H2S/h;1H2/q+1;/p-1	[Na+].[SH-]	[Na+].[SH-]	HYHCSLBZRBJJCH-UHFFFAOYSA-M	sodium;sulfanide
ferrodrug0118	Caryophyllene	.	Isocaryophyllene; Caryophyllene; 118-65-0; (-)-ISOCARYOPHYLLENE; Cis-caryophyllene; gamma-caryophyllene; NRY8I0KNIR; UNII-NRY8I0KNIR; 87-44-5; Isocaryophyllene (80per cent); (1R,4Z,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene; EINECS 204-267-6; CHEBI:5993; beta-Caryophyllen; DTXSID10881246; CARYOPHYLLENE ISOCARYOPHYLLENE; Bicyclo(7.2.0)undec-4-ene, 4,11,11-trimethyl-8-methylene-, (1R,4Z,9S)-; g-Caryophyllene; E-Caryophyllene; EINECS 201-746-1; .gamma.-Caryophyllene; (1R-(1R*,4Z,9S*))-4,11,11-Trimethyl-8-methylenebicyclo(7.2.0)undec-4-ene; (-)-E-Caryophyllene; AI3-36121; .beta.-cis-Caryophyllene; Caryophyllene (VAN); UNII-BHW853AU9H; CCRIS 8094; 2-Methylene-6,10,10-trimethylbicyclo(7.2.0)undec-5-ene; beta-Caryophyllene (natural); -Caryophyllene; ss-Caryophyllene; Bicyclo(7.2.0)undec-4-ene, 4,11,11-trimethyl-8-methylene-, (1R,4E,9S)-; 4,11,11-Trimethyl-8-methylenebicyclo(7.2.0)undec-4-ene, (1R-(1R*,4E,9S))-; Bicyclo(7.2.0)undec-4-ene, 4,11,11-trimethyl-8-methylene-, (1R-(1R*,4E,9S*))-; 4,11,11-Trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene #; CHEMBL448700; (1R,9S,E)-4,11,11-trimethyl-8-methylenebicyclo[7.2.0]undec-4-ene; DTXCID401474828; (-)-Caryophyllene sum of enantiomers; LMPR0103120002; BS-48823; CARYOPHYLLENE ISOCARYOPHYLLENE [MI]; CARYOPHYLLENE, ALPHA + BETA MIXT.; C09691; E75762; Q27106968; (-)-(E)-Caryophyllene;()--caryophyllene;()-trans-Caryophyllene	.	.	204.35	C15H24	0	293	4.4	15	0	0	0	InChI=1S/C15H24/c1-11-6-5-7-12(2)13-10-15(3,4)14(13)9-8-11/h6,13-14H,2,5,7-10H2,1,3-4H3/b11-6-/t13-,14-/m1/s1	C/C/1=C/CCC(=C)[C@H]2CC([C@@H]2CC1)(C)C	CC1=CCCC(=C)C2CC(C2CC1)(C)C	NPNUFJAVOOONJE-FLFDDASRSA-N	(1R,4Z,9S)-4,11,11-trimethyl-8-methylidenebicyclo[7.2.0]undec-4-ene
ferrodrug0119	T-2 Toxin	.	T-2 TOXIN; T2 Toxin; 21259-20-1; T2-Trichothecene; Mycotoxin T-2; Insariotoxin; Isaritoxin; T-2 mycotoxin; Fusariotoxine T2; Fusariotoxin T-2; Toxin T2; Fusariotoxin T 2; I3FL5NM3MO; T 2 Toxin; Fusariotoxin T2; Toxin T 2; 3-Hydroxy-4,15-diacetoxy-8-(3-methylbutyryloxy)-12,13-epoxy-delta-9-trichothecene; T-2 Toxin 100 microg/mL in Acetonitrile; NSC 138780; NSC-138780; T 2 mycotoxin; T-2 Lienomycin; ZBA; Scirpenol, 8-(3-methylbutyryloxy)-diacetoxy-; 12,13-Trichothecene; T(sub 2)-Trichothecene; UNII-I3FL5NM3MO; T-2 TOXIN [HSDB]; T-2 TOXIN [MI]; T-2 Toxin, reference material; CCRIS 3456; CHEBI:9381; CHEMBL152423; SCHEMBL7536392; DTXSID6021298; T2-TRICHOTHECENE [IARC]; HSDB 3544; EINECS 244-297-7; T-2 Toxin, >=98.0% (TLC); 8-(3-Methylbutyryloxy)-diacetoxyscirpenol; BT162749; Trichothec-9-ene-3,4,8,15-tetrol, 12,13-epoxy-, 4,15-diacetate 8-(3-methylbutanoate), (3alpha,4beta,8alpha)-; Q63392226; 4,15-Diacetoxy-8-(3-methylbutyryloxy)scirp-9-en-3-ol; T-2 Toxin, from Fusarium sp., powder, >=98% (HPLC); 8alpha-(3-Methylbutyryloxy)-4beta,15-diacetoxyscirp-9-en-3alpha-ol; 12,13-Epoxytrichothec-9-ene-3,4,8,15-tetrol 4,15-diacetate 8-(3-methylbutanoate); 12,13-Epoxytrichothec-9-ene-3-alpha,4-beta,8-alpha,15-tetrol 4,15-diacetate 8-isovalerate; 12,13-Epoxytrichothec-9-ene-3alpha,4beta,8alpha,15-tetrol, 4,15-diacetate 8-isovalerate; 3-Hydroxy-4,15-diacetoxy-8-(3-methylbutyryloxy)-12,13-epoxy-delta(sup 9)-trichothecene; 4,15-Diacetoxy-8-(3-methylbutyryloxy)-12,13-epoxy-delta-9-trichothecen-3-ol; 4beta,15-Diacetoxy-3alpha-hydroxy-8alpha-(3-methylbutyryloxy)-12,13-epoxytrichothec-9-ene; (3alpha,4beta,8alpha)-12,13-epoxy-4,15-diacetate 8-(3-methylbutanoate)trichothec-9-ene-3,4,8,15-tetrol; (3alpha,4beta,8alpha)-12,13-Epoxytrichothec-9-ene-3,4,8,15-tetrol 4,15-diacetate 8-(3-methylbutyrate); 3alpha-Hydroxy-4beta-15-diacetoxy-8alpha-(3-methylbutyryloxy)-12,13-epoxy-delta9-tricothecene; 4-beta,15-Diacetoxy-8-alpha-(3-methylbutyryloxy)-3-alpha-hydroxy-12,13-epoxytrichothec-9-ene; 4.BETA.,15-DIACETOXY-8.ALPHA.-(3-METHYLBUTYRYLOXY)-12,13-EPOXYTRICHOTHEC-9-EN-3.ALPHA.-OL; 4beta,15-bis(acetyloxy)-3alpha-hydroxy-12,13-epoxytrichothec-9-en-8alpha-yl 3-methylbutanoate; Butanoic acid, 3-methyl-, (3.alpha.,4.beta.,8.alpha.,12.alpha.)-4,15-bis(acetyloxy)-12,13-epoxy-3-hydroxytrichothec-9-en-8-yl ester; Trichothec-9-ene-3-alpha,4-beta,8-alpha,15-tetrol, 12,13-epoxy-, 4,15-diacetate 8-isovalerate; Trichothec-9-ene-3alpha,4beta,8alpha,15-tetrol, 12,13-epoxy-, 4,15-diacetate 8-isovalerate	.	.	466.5	C24H34O9	121	881	0.9	33	1	9	9	InChI=1S/C24H34O9/c1-12(2)7-18(27)32-16-9-23(10-29-14(4)25)17(8-13(16)3)33-21-19(28)20(31-15(5)26)22(23,6)24(21)11-30-24/h8,12,16-17,19-21,28H,7,9-11H2,1-6H3/t16-,17+,19+,20+,21+,22+,23+,24-/m0/s1	CC1=C[C@@H]2[C@](C[C@@H]1OC(=O)CC(C)C)([C@]3([C@@H]([C@H]([C@H]([C@@]34CO4)O2)O)OC(=O)C)C)COC(=O)C	CC1=CC2C(CC1OC(=O)CC(C)C)(C3(C(C(C(C34CO4)O2)O)OC(=O)C)C)COC(=O)C	BXFOFFBJRFZBQZ-QYWOHJEZSA-N	[(1S,2R,4S,7R,9R,10R,11S,12S)-11-acetyloxy-2-(acetyloxymethyl)-10-hydroxy-1,5-dimethylspiro[8-oxatricyclo[7.2.1.02,7]dodec-5-ene-12,2'-oxirane]-4-yl] 3-methylbutanoate
ferrodrug0120	D-Glucose	.	D-Glc; D-Glucopyranose; D-Glucopyranoside; D-Glucose; Glc; Glucopyranose; Glucopyranoside; Glucose; 2280-44-6; Grape sugar; D-Glcp; (3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; Glucosum, anhydrous; CHEBI:4167; 54-17-1; GLUCOSE, ALPHA-D-; rel-(3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; DTXSID901015217; Glucopyranose, D-; (3R,4S,5S,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; Glucodin; Meritose; Blood sugar; Clintose L; D-gluco-hexose; CPC hydrate; Roferose ST; Clearsweet 95; a-D-Glucopyranose; Staleydex 95M; (+)-Glucose; UNII-5J5I9EB41E; 2h-pyran-2,3,4,5-tetraol; D-Glucopyranose, anhydrous; DTXSID30197710; glc-ring; EINECS 207-757-8; Cartose Cerelose; D-glucose-ring; Glucose injection; Glucose 40; Staleydex 130; EINECS 218-914-5; Glc-OH; Meritose 200; nchembio867-comp4; Glucose (JP17); starbld0000491; 6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetraol; Anhydrous Glucose ,(S); Purified glucose (JP17); Epitope ID:142342; D-(+)-DEXTROSE; GTPL4536; CHEMBL1222250; BDBM34103; CHEBI:37661; DTXCID90120201; WQZGKKKJIJFFOK-GASJEMHNSA-N; DTXCID201473543; DTXSID501015215; 26655-34-5; AKOS025147374; NSC 287045; NCGC00166293-01; BS-48662; G0048; (3R,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-; C00031; D00009; F71542; Q37525; Q23905964; N_FULL/O_FULL_10000000000000_GS_656; D-glucose (closed ring structure, complete stereochemistry); WURCS=2.0/1,1,0/(a2122h-1a_1-5)/1/	.	.	180.16	C6H12O6	110	151	-2.6	12	5	6	1	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5-,6?/m1/s1	C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O	C(C1C(C(C(C(O1)O)O)O)O)O	WQZGKKKJIJFFOK-GASJEMHNSA-N	(3R,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
ferrodrug0121	D-Galactose	Small molecular drug	D-Gal; D-Galactopyranose; D-Galactopyranoside; D-Galactose; Gal; Galactopyranose; Galactopyranoside; Galactose; 10257-28-0; Galactose, pure; (3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; CHEBI:4139; brain sugar; (+)-Galactose; EINECS 233-595-2; cerebrose; AI3-18440; D-galacto-hexose; DTXSID001015860; NSC 8102; CHEBI:12936; NSC-8102; D Galactose; (3R,4S,5R,6R)-6-(Hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; D-Glucose-2-13C; 40825-89-6; SMR000857326; UNII-7IOF6H4H77; Galaktose; galacto-hexose; Galactose; D-Galactopyranose; D(+)-Galactose; GSK 620104E; Allopurinol related; D-Galactose (9CI); Galactose, D- (8CI); Epitope ID:141794; SCHEMBL38935; MLS001335983; MLS001335984; CHEMBL195923; DTXCID903088; CHEBI:28260; WQZGKKKJIJFFOK-SVZMEOIVSA-N; BDBM228805; DTXCID601437050; HMS2230N07; MFCD00006969; s3849; AKOS030573864; CCG-266426; NCGC00166082-01; AS-46931; CS-0204480; G0008; C00124; D-Galactose 1000 microg/mL in Methanol:Water; EN300-135967; F10950; G-1701; O_FULL_10000000000000_GS_94; Q27106307; Z1665647488; (3R,4S,5R,6R)-6-methyloltetrahydropyran-2,3,4,5-tetrol; WURCS=2.0/1,1,0/(a2112h-1x_1-5)/1/	.	DM3SZ7P	180.16	C6H12O6	110	151	-2.6	12	5	6	1	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3+,4+,5-,6?/m1/s1	C([C@@H]1[C@@H]([C@@H]([C@H](C(O1)O)O)O)O)O	C(C1C(C(C(C(O1)O)O)O)O)O	WQZGKKKJIJFFOK-SVZMEOIVSA-N	(3R,4S,5R,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
ferrodrug0122	Carboplatin	.	41575-94-4; Carboplatin; Paraplatin; Cbdca; Carboplatinum; JM-8; MFCD00070464; NSC-241240; cis-(1,1-Cyclobutanedicarboxylato)diammineplatinum(II); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II); 1,1-Cyclobutanedicarboxylate diammine platinum(II); NSC241240; cis-Diamine[1,1-cyclobutanedicarboxylato]platinum(II); cis-Diammine(1,1-cyclobutanedicarboxylato)platinum; DTXSID3046742; CHEBI:31355; NSC-201345; Platinum(II),1-cyclobutanedicarboxylato)diammine-, cis-; Platinum,1-cyclobutanedicarboxylato(2-)-O,O')-, (SP-4-2)-; Platinum,1-cyclobutanedicarboxylato(2-)-O,O']-, (SP-4-2)-; Epitope ID:194801; SCHEMBL4964; 1,1-Cyclobutanedicarboxylatodiammineplatinum(II); Paraplatin (Bristol Meyers); Lopac0_000230; DTXCID201476080; HMS3269H03; Pharmakon1600-01502106; NSC201345; NSC758182; STL451040; Tox21_112586_1; NSC-758182; NCGC00167800-01; NCGC00263858-02; BP-25385; SY075575; CAS-41575-94-4; EN300-123065; AB01273939-01; azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+); 7,7-diamino-6,8-dioxa-7-platinaspiro[3.5]nonane-5,9-dione; diamino[cyclobutane-1,1-dicarboxylato(2-)-kappa~2~O~1~,O~1~]platinum; Platinum, diammine[1,1-cyclobutanedicarboxylato(2-)-.kappa.O,.kappa.O'']-, (SP-4-2)-	.	.	371.25	C6H12N2O4Pt	76.6	177	.	13	4	6	0	InChI=1S/C6H8O4.2H2N.Pt/c7-4(8)6(5(9)10)2-1-3-6;;;/h1-3H2,(H,7,8)(H,9,10);2*1H2;/q;2*-1;+2	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]	C1CC(C1)(C(=O)O)C(=O)O.[NH2-].[NH2-].[Pt+2]	VSRXQHXAPYXROS-UHFFFAOYSA-N	azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+)
ferrodrug0123	Everolimus	.	001, RAD; 40-O-(2-hydroxyethyl)-rapamycin; 40-O-(2-Hydroxyethyl)rapamycin; Afinitor; Certican; Everolimus; RAD; RAD 001; RAD, SDZ; RAD001; SDZ RAD; SDZ-RAD; Zortress; 159351-69-6; Votubia; 42-O-(2-Hydroxyethyl)rapamycin; RAD-001; Afinitor Disperz; Everolimus [USAN]; CHEBI:68478; Rapamycin, 42-O-(2-hydroxyethyl)-; 9HW64Q8G6G; DTXSID0040599; RAD 666; RAD-666; Everolimus (INN); XIENCE V; NCGC00167512-01; Everolimus (RAD001); EVEROLIMUS [INN]; UNII-9HW64Q8G6G; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,27-dihydroxy-3-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-hexadecahydro-3H-23,27-epoxypyrido[2,1-c][1,4]oxazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; Everolimus [USAN:INN:BAN]; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.0(sup 4,9))hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-Dihydroxy-12-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo(30.3.1.04,9)hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentaone; (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,35R)-1,18-dihydroxy-12-{(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl}-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0(4,9)]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone; (3S,6R,7E,9R,10R,12R,14S,15E,17E,19E,21S,23S,26R,27R,34aS)-9,10,12,13,14,21,22,23,24,25,26,27,32,33,34,34a-Hexadecahydro-9,27-dihydroxy-3-((1R)-2-((1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl)-1-methylethyl)-10,21-dimethoxy-6,8,12,14,20,26-hexamethyl-23,27-epoxy-3H-pyrido(2,1-c)(1,4)oxaazacyclohentriacontine-1,5,11,28,29(4H,6H,31H)-pentone; NVP-RAD-001; RAD-001C; everolimusum; NSC733504; EVE - Everolimus; SDZRAD; EVEROLIMUS [MI]; Everolimus - RAD001; EVEROLIMUS [JAN]; EVEROLIMUS [VANDF]; EVEROLIMUS [MART.]; SCHEMBL4378; EVEROLIMUS [USP-RS]; EVEROLIMUS [WHO-DD]; NVP-RAD001; EVEROLIMUS [EMA EPAR]; Everolimus, analytical standard; GTPL5889; CHEMBL1908360; DTXCID8020599; EVEROLIMUS [ORANGE BOOK]; HSDB 8255; EVEROLIMUS [EP MONOGRAPH]; Everolimus; RAD001; SDZ-RAD; HKVAMNSJSFKALM-GKUWKFKPSA-N; 42-O-(2-Hydroxyethyl)-rapamycin; EX-A2057; Tox21_112510; BDBM50088378; AKOS015850977; CS-0064; DB01590; AS-16971; HY-10218; LS-143292; CAS-159351-69-6; Q421052; Q-101413; BRD-K13514097-001-01-2; BRD-K13514097-001-05-3; dihydroxy-[(1R)-2-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxy-cyclohexyl]-1-methyl-ethyl]-dimethoxy-hexamethyl-[?]pentone	.	.	958.2	C53H83NO14	205	1810	5.9	68	3	14	9	InChI=1S/C53H83NO14/c1-32-16-12-11-13-17-33(2)44(63-8)30-40-21-19-38(7)53(62,68-40)50(59)51(60)54-23-15-14-18-41(54)52(61)67-45(35(4)28-39-20-22-43(66-25-24-55)46(29-39)64-9)31-42(56)34(3)27-37(6)48(58)49(65-10)47(57)36(5)26-32/h11-13,16-17,27,32,34-36,38-41,43-46,48-49,55,58,62H,14-15,18-26,28-31H2,1-10H3/b13-11+,16-12+,33-17+,37-27+/t32-,34-,35-,36-,38-,39+,40+,41+,43-,44+,45+,46-,48-,49+,53-/m1/s1	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC	CC1CCC2CC(C(=CC=CC=CC(CC(C(=O)C(C(C(=CC(C(=O)CC(OC(=O)C3CCCCN3C(=O)C(=O)C1(O2)O)C(C)CC4CCC(C(C4)OC)OCCO)C)C)O)OC)C)C)C)OC	HKVAMNSJSFKALM-GKUWKFKPSA-N	(1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-(2-hydroxyethoxy)-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
ferrodrug0124	Chrysin	Small molecular drug	chrysin; 480-40-0; 5,7-Dihydroxyflavone; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one; Chrysine; 5,7-dihydroxy-2-phenylchromen-4-one; Crysin; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-phenyl-; NSC-407436; FLAVONE, 5,7-DIHYDROXY-; NSC 407436; Chrysinic acid; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one; EINECS 207-549-7; UNII-3CN01F5ZJ5; 5,7-Dihydroxy-2-phenyl-chromen-4-one; BRN 0233276; 3CN01F5ZJ5; DTXSID1022396; CHEBI:75095; MFCD00006834; NSC407436; 5,7-Dihydroxy-2-phenyl-4H-benzo(b)pyran-4-one; CHEMBL117; DTXCID902396; 5-18-04-00076 (Beilstein Handbook Reference); CAS-480-40-0; 5,7-dihydroxy-2-phenyl-4H-benzo[b]pyran-4-one; SMR000112318; 5,7-dihydroxy-flavone; SR-01000765660; 3ebo; 4des; 57D; Chrysin,(S); 5,7-diOH-Flavone; Flavone,7-dihydroxy-; Chrysin, 97%; Ois 3; Spectrum_000245; 5, 7-Dihydroxyflavone; CHRYSIN [INCI]; CHRYSIN [MI]; Prestwick0_000889; Prestwick1_000889; Prestwick2_000889; Prestwick3_000889; Spectrum2_000753; Spectrum3_001399; Spectrum4_000780; Spectrum5_001503; Chrysin, analytical standard; Oprea1_045160; SCHEMBL44474; BSPBio_000678; BSPBio_002514; BSPBio_003018; KBioGR_001200; KBioSS_000725; MLS000697728; MLS001074879; MLS006011841; BIDD:ER0484; DivK1c_000614; SPECTRUM1500709; SPECTRUM1505144; SPBio_000766; SPBio_002897; BDBM7461; BPBio1_000746; GTPL8789; MEGxp0_001416; ACon1_000087; cid_5281607; HMS501O16; KBio1_000614; KBio2_000725; KBio2_003293; KBio2_005861; KBio3_002238; NINDS_000614; HMS1570B20; HMS1921E20; HMS2097B20; HMS2268I23; HMS3468N08; HMS3655L20; BCP22863; Tox21_302335; BBL010449; CCG-40148; LMPK12110189; NSC818102; s2281; STK801609; AKOS000275936; BCP9000172; CS-7531; DB15581; GS-0927; NSC-818102; SDCCGMLS-0066586.P001; IDI1_000614; SMP1_000070; NCGC00016456-01; NCGC00016456-02; NCGC00016456-03; NCGC00016456-04; NCGC00016456-05; NCGC00016456-06; NCGC00016456-07; NCGC00016456-08; NCGC00016456-09; NCGC00016456-10; NCGC00016456-12; NCGC00094842-01; NCGC00094842-02; NCGC00094842-03; NCGC00094842-04; NCGC00094842-05; NCGC00168807-01; NCGC00168807-02; NCGC00168807-03; NCGC00168807-04; NCGC00255307-01; AC-10052; HY-14589; NCI60_003886; SY050125; AB00513947; C1652; FT-0619846; FT-0686390; SW197197-2; 5,7-Dihydroxy-2-phenyl-4H-chromen-4-one #; 4H-1-Benzopyran-4-one,7-dihydroxy-2-phenyl-; C-5980; EN300-303044; S00112; Chrysin 1000 microg/mL in Acetonitrile:Methanol; A827426; Q973741; SR-01000765660-3; SR-01000765660-4; 34B3B4AD-EEDD-4943-A1C6-8857D2FAA8E0; 5,7-Dihydroxy-2-phenyl-4H-1-benzopyran-4-one, 9CI; BRD-K22861715-001-07-5; BRD-K22861715-001-12-5; Z1824566175	D01UYI	DM7V2LG	254.24	C15H10O4	66.8	384	2.1	19	2	4	1	InChI=1S/C15H10O4/c16-10-6-11(17)15-12(18)8-13(19-14(15)7-10)9-4-2-1-3-5-9/h1-8,16-17H	C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O	C1=CC=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)O)O	RTIXKCRFFJGDFG-UHFFFAOYSA-N	5,7-dihydroxy-2-phenylchromen-4-one
ferrodrug0125	Baicalein	.	baicalein; 491-67-8; 5,6,7-Trihydroxyflavone; Noroxylin; 5,6,7-trihydroxy-2-phenyl-4H-chromen-4-one; Biacalein; BaiKalein; 5,6,7-trihydroxy-2-phenylchromen-4-one; Baicelein; 5,6,7-trihydroxy-2-phenyl-chromen-4-one; MFCD00017459; NSC 661431; NSC-661431; CHEBI:2979; UNII-49QAH60606; NSC661431; 49QAH60606; 5,6,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one; CHEMBL8260; 4H-1-Benzopyran-4-one, 5,6,7-trihydroxy-2-phenyl-; DTXSID2022389; 5,7-Trihydroxyflavone; BAICALEIN (USP-RS); BAICALEIN [USP-RS]; Sho-saiko-to; SMR000112462; SR-01000597499; Baicalein, 8; Baicalein,(S); 3WL; Baicalein, 14; Baicalein, 98%; Spectrum_000427; Tocris-1761; SpecPlus_000758; BAICALEIN [MI]; BAICALEIN [INCI]; Spectrum2_000466; Spectrum3_001608; Spectrum4_000537; Spectrum5_001418; BAICALEIN [WHO-DD]; Oprea1_765614; BSPBio_003215; KBioGR_001173; KBioSS_000907; MLS002473007; MLS006011756; BIDD:ER0121; DivK1c_006854; SCHEMBL139617; SPECTRUM1504002; SPBio_000572; DTXCID802389; GTPL5144; KBio1_001798; KBio2_000907; KBio2_003475; KBio2_006043; KBio3_002435; HMS1922O22; HMS2267F15; HMS3268C22; HMS3412F14; HMS3649O19; HMS3655P18; HMS3676F14; BCP14393; HY-N0196; TNP00121; BBL027840; BDBM50009001; CCG-38705; LMPK12111095; NSC729192; s2268; STL146746; AKOS005747014; AC-7991; CS-6159; NSC-729192; SDCCGMLS-0066744.P001; Baicalein, analytical reference material; SMP1_000037; NCGC00017236-01; NCGC00017236-02; NCGC00017236-03; NCGC00017236-04; NCGC00017236-05; NCGC00017236-06; NCGC00017236-07; NCGC00017236-08; NCGC00017236-10; NCGC00017236-11; NCGC00025282-01; NCGC00025282-02; NCGC00025282-03; NCGC00025282-04; NCGC00178204-01; AS-57923; PD132943; SY057137; 5,6,7-Trihydroxy-2-phenyl-chroman-4-one; FT-0622548; SW219229-1; T2721; EN300-303171; S00113; 5,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one; A827663; Q-100550; Q2879363; SR-01000597499-1; SR-01000597499-3; SR-01000597499-4; SR-01000597499-6; W-202870; 5,6,7-Trihydroxy-2-phenyl-(4H)-1-benzopyran-4-one; BRD-K72327355-001-02-2; BRD-K72327355-001-06-3; Z1824568302	.	.	270.24	C15H10O5	87	413	1.7	20	3	5	1	InChI=1S/C15H10O5/c16-9-6-11(8-4-2-1-3-5-8)20-12-7-10(17)14(18)15(19)13(9)12/h1-7,17-19H	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O	C1=CC=C(C=C1)C2=CC(=O)C3=C(O2)C=C(C(=C3O)O)O	FXNFHKRTJBSTCS-UHFFFAOYSA-N	5,6,7-trihydroxy-2-phenylchromen-4-one
ferrodrug0126	Idebenone	.	idebenone; 58186-27-9; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione; Idebenona; Idebenonum; Sovrima; hydroxydecyl ubiquinone; CV 2619; CV-2619; Oristar hdu; BRN 2001459; CHEBI:31687; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-1,4-benzoquinone; 6-(10-Hydroxydecyl)-2,3-dimethoxy-5-methyl-1,4-benzoquinone; NSC-759228; HB6PN45W4J; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-2,5-cyclohexadiene-1,4-dione; 2,5-Cyclohexadiene-1,4-dione, 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methyl-; 2-(10-Hydroxydecyl)-5,6-dimethoxy-3-methyl-p-benzoquinone; DTXSID0040678; Raxone; 5,6-DIMETHOXY-2-(10-HYDROXYDECYL)-3-METHYL-1,4-BENZOQUINONE; MFCD00274552; NCGC00160514-01; 2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylbenzo-1,4-quinone; Idebenone [INN:JAN]; Idebenonum [Latin]; Idebenona [Spanish]; DTXCID8020678; 1189907-75-2; 2,3-dimethoxy-5-methyl-6-(10'-hydroxydecyl)-1,4-benzoquinone; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4-benzoquinone; SMR000466364; CAS-58186-27-9; SR-01000759378; UNII-HB6PN45W4J; Cerestabon; Catena; Mnesis; Avan; Idebenone- Bio-X; Raxone (TN); IDEBENONE [INN]; IDEBENONE [JAN]; IDEBENONE [MI]; IDEBENONE [USAN]; IDEBENONE [MART.]; IDEBENONE [WHO-DD]; SNT-MC17; SCHEMBL28320; IDEBENONE [EMA EPAR]; Idebenone (JAN/USAN/INN); MLS000759487; MLS001032035; MLS001424002; MLS006011882; Idebenone, analytical standard; CHEMBL252556; QSA-10; Idebenone, >=98% (HPLC); FR114; HMS2051O06; HMS2089D08; HMS3393O06; HMS3656K22; HMS3713A10; HMS3884B12; Pharmakon1600-01505755; BCP09116; HY-N0303; STR09227; Tox21_111864; BBL025842; BDBM50505498; NSC759228; s2605; STK801942; HYDROXYDECYL UBIQUINONE [INCI]; 2,5-Cyclohexadiene-1,4-dione, 5,6-dimethoxy-2-(10-hydroxydecyl)-3-methyl-; AKOS005622577; Tox21_111864_1; AC-4337; CCG-100846; KS-5193; NC00096; NSC 759228; SB19130; NCGC00160514-02; NCGC00160514-03; BI164565; SY051193; SBI-0207024.P001; FT-0617205; I0848; SW219495-1; D01750; H10427; AB00639997-04; AB00639997-06; AB00639997_07; AB00639997_08; EN300-7359600; A-68500; Q4197874; SR-01000759378-4; SR-01000759378-5; SR-01000759378-6; BRD-K37516142-001-01-4; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methylbenzoquinone; Z2216898922; 2,3-Dimethoxy-6-(10-hydroxydecyl)-5-methyl-1,4benzoquinone; 2-(10-hydroxydecyl)-6-methoxy-3-methyl-5-(trideuteriomethoxy)cyclohexa-2,5-diene-1,4-dione	.	.	338.4	C19H30O5	72.8	502	4.3	24	1	5	12	InChI=1S/C19H30O5/c1-14-15(12-10-8-6-4-5-7-9-11-13-20)17(22)19(24-3)18(23-2)16(14)21/h20H,4-13H2,1-3H3	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO	CC1=C(C(=O)C(=C(C1=O)OC)OC)CCCCCCCCCCO	JGPMMRGNQUBGND-UHFFFAOYSA-N	2-(10-hydroxydecyl)-5,6-dimethoxy-3-methylcyclohexa-2,5-diene-1,4-dione
ferrodrug0127	Isoliquiritigenin	Small molecular drug	isoliquiritigenin; 961-29-5; 2',4,4'-Trihydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 4,2',4'-Trihydroxychalcone; 6'-deoxychalcone; Isoliquiritigen; GU 17; 2',4',4-Trihydroxychalcone; Chalcone, 2',4,4'-trihydroxy-; GU-17; C15H12O4; CCRIS 7676; UNII-B9CTI9GB8F; trihydroxychalcone; B9CTI9GB8F; 42'4'-trihydroxychalcone; 13745-20-5; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (2E)-; (2E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; CHEBI:310312; trans-2',4,4'-trihydroxychalcone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-, (E)-; Acrylophenone, 2',4'-dihydroxy-3-(p-hydroxyphenyl)-; CHEMBL129795; GU17; (E)-1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; (2E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-HYDROXYPHENYL)-; (E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)-2-propene-1-one; 1060-19-1; ILG; SMR000112969; GU17;ISL;Isoliquiritigen; SR-01000075499; EINECS 237-316-5; BRN 1914295; iso-Liquiritigenin; MFCD00075907; ILTG; ISLQ; Isoliquiritigenin, powder; Spectrum5_000612; Lopac0_000681; BSPBio_003411; 1-08-00-00707 (Beilstein Handbook Reference); MLS000438943; MLS002207240; MLS006010045; BIDD:ER0235; SCHEMBL161168; SPECTRUM1504200; cid_638278; MEGxp0_001326; 2',4,4'-Trihydroxy-Chalcone; DTXSID2022466; 2'',4'',4-trihydroxychalcone; 2'',4,4''-trihydroxychalcone; ACon1_000047; CHEBI:94010; TRIHYDROXYCHALCONE [INCI]; BCPP000201; HMS2233H18; HMS3262I03; 2,4''-dihydroxy-4-hydroxychalcone; BCP02312; HY-N0102; Tox21_500681; BDBM50042944; CCG-40334; CMLD3_000056; HB4213; LMPK12120096; s2404; Isoliquiritigenin, analytical standard; AKOS001590146; BCP9000795; CS-1745; DB03285; KS-5256; LP00681; SDCCGMLS-0066751.P001; SDCCGSBI-0050660.P004; NCGC00090504-01; NCGC00090504-02; NCGC00090504-03; NCGC00090504-04; NCGC00090504-05; NCGC00090504-06; NCGC00090504-07; NCGC00090504-08; NCGC00090504-24; NCGC00261366-01; AC-33981; EU-0100681; I0822; SW219658-1; C08650; I 3766; I11575; A845551; 2',4'-Dihydroxy-3-(p-hydroxyphenyl)-Acrylophenone; Q-100904; Q3155537; SR-01000075499-1; SR-01000075499-5; BRD-K33583600-001-03-9; BRD-K33583600-001-04-7; 1-(2,4-Dihydroxy-phenyl)-3-(4-hydroxy-phenyl)-propenone; 1-(2,4-Dihydroxyphenyl)-3-(4-hydroxyphenyl)-prop-2-en-1-one; (E)-1-[2,4-bis(oxidanyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; InChI=1/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3	.	DG01817	256.25	C15H12O4	77.8	331	3.2	19	3	4	3	InChI=1S/C15H12O4/c16-11-4-1-10(2-5-11)3-8-14(18)13-7-6-12(17)9-15(13)19/h1-9,16-17,19H/b8-3+	C1=CC(=CC=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O	C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O	DXDRHHKMWQZJHT-FPYGCLRLSA-N	(E)-1-(2,4-dihydroxyphenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one
ferrodrug0128	Galangin	Small molecular drug	Galangin; 548-83-4; Norizalpinin; 3,5,7-Trihydroxyflavone; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one; 3,5,7-triOH-Flavone; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; 3,5,7-Trihydroxy-2-phenyl-4-benzopyrone; 3,5,7-trihydroxy-2-phenylchromen-4-one; FLAVONE, 3,5,7-TRIHYDROXY-; NSC-407229; 4H-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl-; NSC407229; 142FWE6ECS; CHEBI:5262; CHEMBL309490; 3,5,7-trihydroxy-2-phenyl-4H-benzopyran-4-one; TNP00099; 3,5,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one; Norizalpinin;3,5,7-Trihydroxyflavone; 3,5,7-tris(oxidanyl)-2-phenyl-chromen-4-one; EINECS 208-960-4; MFCD00006833; UNII-142FWE6ECS; NSC 407229; BRN 0272179; teptochrysin; CCRIS 8471; Galangin,(S); 3,7-Trihydroxyflavone; 5,7-Dihydroxyflavonol; GALANGIN [INCI]; 3,5,7-trihydroxy-2-phenyl-chromen-4-one; GALANGIN [MI]; 3,5,7-Trihydroxy-Flavone; GTPL410; 5-18-04-00567 (Beilstein Handbook Reference); MLS002473087; SCHEMBL117225; MEGxp0_000533; ACon1_000977; cid_5281616; DTXSID70203288; HMS2268D24; EX-A4261; HY-N0382; BDBM50049391; LMPK12111653; s5529; Galangin, autophagy inducing flavonoid; AKOS003672546; AC-6383; AM85813; CCG-208629; CS-5619; NCGC00017220-01; NCGC00017220-02; NCGC00017220-03; NCGC00142457-01; NCGC00169794-01; AS-14766; SMR000112582; FT-0626589; G0370; A14607; 3,5,7-trihydroxy-2-phenyl-1-benzopyran-4-one; 3,5,7-Trihydroxy-2-phenyl-4H-chromen-4-one #; 4H-1-Benzopyran-4-one,5,7-trihydroxy-2-phenyl-; A830393; SR-05000002165; Q-100620; Q2456591; SR-05000002165-2; BRD-K16503581-001-01-5; BRD-K16503581-001-04-9; Z1980554245; 3,5,7-Trihydroxy-2-phenyl-4H-1-benzopyran-4-one, 9CI; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-phenyl- (9CI)	D0Y7HG	DM5TQ2O	270.24	C15H10O5	87	424	2.3	20	3	5	1	InChI=1S/C15H10O5/c16-9-6-10(17)12-11(7-9)20-15(14(19)13(12)18)8-4-2-1-3-5-8/h1-7,16-17,19H	C1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O	C1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O	VCCRNZQBSJXYJD-UHFFFAOYSA-N	3,5,7-trihydroxy-2-phenylchromen-4-one
ferrodrug0129	Carmustine	.	carmustine; 154-93-8; 1,3-Bis(2-chloroethyl)-1-nitrosourea; BCNU; Gliadel; Carmubris; Carmustin; Nitrumon; BiCNU; Becenun; Bischloroethyl nitrosourea; Bi CNU; Carmustinum; 1,3-Bis(2-chloroethyl)nitrosourea; Bischlorethylnitrosurea; N,N'-BIS(2-CHLOROETHYL)-N-NITROSOUREA; Bischlorethylnitrosourea; Carmustina; Urea, N,N'-bis(2-chloroethyl)-N-nitroso-; NSC-409962; Bis(2-chloroethyl)nitrosourea; Gliadel Wafer; FDA 0345; SRI 1720; BiCNU (TN); DTI 015; NCI-C04773; SK 27702; C5H9Cl2N3O2; Carmustine (98%); Bis(chloroethyl)nitrosourea; NSC 409962; bis-chloroethylnitrosourea; NSC409962; CHEMBL513; 1,3-bis(2-chloroethyl)-1-nitroso-urea; CHEBI:3423; Urea, 1,3-bis(2-chloroethyl)-1-nitroso-; Becenum; DTXSID8022743; DTI-015; U68WG3173Y; FDA-0345; SRI-1720; 1,3-bis(2-chloroethyl)-3-nitrosourea; NCGC00015204-05; SK-27702; 1,3-Bis(.beta.-chloroethyl)-1-nitrosourea; Bischloroethylnitrosourea; Carmustinum [INN-Latin]; Carmustina [INN-Spanish]; DTXCID002743; Bis(2-chloroethyl)1-nitrosourea; Bis-N,N'-(chloroethyl)nitrosourea; CAS-154-93-8; CCRIS 810; 1,3-Bis(beta-chloroethyl)-1-nitrosourea; BCNU [Chloroethyl nitrosoureas]; SR-01000075736; EINECS 205-838-2; BRN 2049744; Camustine; Carustine; UNII-U68WG3173Y; AI3-52216; HSDB 7761; BiCNU; Nitrumon; Carmustine [USAN:USP:INN:BAN]; Carmustine- Bio-X; Prestwick_997; Gliadel (TN); Bischloroethyl nitrosourea [Chloroethyl nitrosoureas]; MFCD00057706; Gliadel (MGI Pharm); Spectrum_000265; Carmustine, >=98%; CARMUSTINE [MI]; CARMUSTINE [INN]; CARMUSTINE [JAN]; Spectrum4_000888; Spectrum5_000920; CAMUSTINE [VANDF]; CARMUSTINE [HSDB]; CARMUSTINE [USAN]; Lopac-C-0400; WLN: ONN2GVM2G; C 0400; CARMUSTINE [MART.]; SCHEMBL4503; CARMUSTINE [USP-RS]; CARMUSTINE [WHO-DD]; Lopac0_000188; Carmustine (JAN/USP/INN); KBioGR_001296; KBioSS_000745; MLS001333962; DivK1c_000835; AMY382; GTPL6800; CARMUSTINE [EP IMPURITY]; CARMUSTINE [ORANGE BOOK]; HMS502J17; KBio1_000835; KBio2_000745; KBio2_003313; KBio2_005881; CARMUSTINE [EP MONOGRAPH]; NINDS_000835; CARMUSTINE [USP MONOGRAPH]; HMS2092J22; HMS2230I05; HMS3260F17; HMS3369D17; Pharmakon1600-01503110; BCP27690; Tox21_110097; Tox21_500188; BDBM50015950; CCG-39925; NSC758392; STK624770; AKOS005558013; Tox21_110097_1; BCP9000490; DB00262; LP00188; NSC-758392; SDCCGSBI-0050176.P004; IDI1_000835; Urea,3-bis(2-chloroethyl)-1-nitroso-; BISCHLOROETHYL NITROSOUREA [IARC]; NCGC00015204-01; NCGC00015204-02; NCGC00015204-03; NCGC00015204-04; NCGC00015204-06; NCGC00015204-07; NCGC00015204-08; NCGC00015204-09; NCGC00015204-18; NCGC00093665-01; NCGC00093665-02; NCGC00093665-03; NCGC00093665-04; NCGC00260873-01; Urea,N'-bis(2-chloroethyl)-N-nitroso-; AC-24196; AS-12106; BC164289; HY-13585; N,N''-Bis(2-chloroethyl)-N-nitrosourea; NCI60_003931; SMR000058426; SBI-0050176.P003; C2634; EU-0100188; FT-0602937; S3669; BCNU; 1,3-Bis(2-chloroethyl)-1-nitrosourea; C06873; D00254; EN300-123541; AB00052431-07; AB00052431_08; A809590; Q415869; SR-01000075736-1; SR-01000075736-3; W-108025; Z1269141329; Carmustine, United States Pharmacopeia (USP) Reference Standard; 1-(2-Chloroethyl)-1-([(2-chloroethyl)amino]carbonyl)-2-oxohydrazine #	.	.	214.05	C5H9Cl2N3O2	61.8	156	1.5	12	1	3	4	InChI=1S/C5H9Cl2N3O2/c6-1-3-8-5(11)10(9-12)4-2-7/h1-4H2,(H,8,11)	C(CCl)NC(=O)N(CCCl)N=O	C(CCl)NC(=O)N(CCCl)N=O	DLGOEMSEDOSKAD-UHFFFAOYSA-N	1,3-bis(2-chloroethyl)-1-nitrosourea
ferrodrug0130	Propofol	.	propofol; 2,6-DIISOPROPYLPHENOL; 2078-54-8; Diprivan; Disoprofol; Disoprivan; Fresofol; Diisopropylphenol; Ampofol; 2,6-Bis(1-methylethyl)phenol; Rapinovet; Propofolum; Ivofol; Recofol; Propofol-Lipuro; Phenol, 2,6-bis(1-methylethyl)-; Pofol; Diprifusor; Diprofol; Propovan; 2,6-di(propan-2-yl)phenol; ICI 35868; Phenol, 2,6-diisopropyl-; 2,6-Diisopropyl phenol; Diprivan 10; Propofolum [Latin]; Dipravan; Propoven; Aquafo; Diprivan Injectable emulsion; 2,6 Diisopropylphenol; NSC 5105; ICI-35868; 2,6-bis(propan-2-yl)phenol; CCRIS 9000; Lipuro; HSDB 7123; UNII-YI7VU623SF; EINECS 218-206-6; YI7VU623SF; ICI 35,868; BRN 1866484; 2,6-Di-iso-propylphenol-d18; DTXSID6023523; CHEBI:44915; AI3-26295; NSC5105; Phenol, 2,6-bis(1-methylethyl); 2,6-diisopropyl-phenol; ICI35,868; MFCD00008885; 2,6-dipropan-2-ylphenol; CHEMBL526; ICI 35-868; DTXCID103523; KETAFOL COMPONENT PROPOFOL; 4-06-00-03435 (Beilstein Handbook Reference); NSC-5105; Propofolum (Latin); NCGC00015389-08; Aquafol; CAS-2078-54-8; PROPOFOL (MART.); PROPOFOL [MART.]; PROPOFOL (USP-RS); PROPOFOL [USP-RS]; PFL; PROPOFOL (EP IMPURITY); PROPOFOL [EP IMPURITY]; PROPOFOL (EP MONOGRAPH); PROPOFOL (USP IMPURITY); PROPOFOL [EP MONOGRAPH]; PROPOFOL [USP IMPURITY]; PROPOFOL (USP MONOGRAPH); PROPOFOL [USP MONOGRAPH]; Propofol IDD-D; Diprivan (TN); SMR000059151; Propofol(2,6-Diisopropylphenol); 2, 6-Diisopropylphenol; SR-01000075468; 2,6-bis(Isopropyl)phenol; DDS-04F; ghl.PD_Mitscher_leg0.558; Propofol [USAN:USP:INN:BAN]; Propofol (Diprivan); ZD-0859; Phenol,6-diisopropyl-; PROPOFOL [HSDB]; PROPOFOL [USAN]; PROPOFOL [INN]; PROPOFOL [JAN]; PROPOFOL [MI]; PROPOFOL [VANDF]; Prestwick0_000931; Prestwick1_000931; Prestwick2_000931; Prestwick3_000931; 2,6-di isopropyl phenol; Phenol,2,6-diisopropyl-; Biomol-NT_000248; Lopac-D126608; PROPOFOL [WHO-DD]; Propofol (JAN/USP/INN); Lopac0_000437; SCHEMBL36245; BSPBio_000862; MLS001066348; MLS001335999; MLS002454360; BIDD:GT0436; PROPOFOL [GREEN BOOK]; SPECTRUM1505022; Propofol, 1mg/ml in Methanol; SPBio_003031; 2,6-Diisopropylphenol, 97%; PROPOFOL [ORANGE BOOK]; BPBio1_000950; BPBio1_000969; GTPL5464; Phenol,6-bis(1-methylethyl)-; Propofol, 10mg/ml in Methanol; Propofol, 50mg/ml in Methanol; N01AX10; Propofol 1.0 mg/ml in Methanol; Propofol, 100mg/ml in Methanol; 2,6-Diisopropylphenol, >=97%; 3f33; 3p50; HMS1570L04; HMS2089O21; HMS2094E17; HMS2097L04; HMS2231E16; HMS3259E03; HMS3261G16; HMS3369I16; HMS3714L04; Pharmakon1600-01505022; Phenol,2,6-bis(1-methylethyl)-; BCP02920; HY-B0649; Tox21_110134; Tox21_201371; Tox21_303225; Tox21_500437; AC8633; BDBM50058046; NSC758909; Phenol, 2, 6-bis(1-methylethyl)-; AKOS009159417; Tox21_110134_1; AC-2038; AM90311; CCG-204529; CS-W020057; DB00818; LP00437; NC00449; NSC-758909; SDCCGMLS-0318084.P029; SDCCGSBI-0050422.P002; 2,6-DIISOPROPYLPHENOL; PROPOFOL; MLS-0318084; NCGC00015389-01; NCGC00015389-02; NCGC00015389-03; NCGC00015389-04; NCGC00015389-05; NCGC00015389-06; NCGC00015389-07; NCGC00015389-09; NCGC00015389-10; NCGC00015389-11; NCGC00015389-14; NCGC00015389-17; NCGC00091538-01; NCGC00091538-02; NCGC00091538-03; NCGC00091538-04; NCGC00091538-05; NCGC00091538-06; NCGC00257228-01; NCGC00260670-01; NCGC00261122-01; AS-13299; SY013479; 2,6-Diisopropylphenol, analytical standard; BCP0726000298; MLS-0318084.P017; AB00513968; D0617; EU-0100437; EN300-52468; C07523; D00549; AB00513968-07; AB00513968_08; A814898; D126608; Q422740; Q-201631; SR-01000075468-1; SR-01000075468-4; SR-01000075468-6; BRD-K82255054-001-03-5; BRD-K82255054-001-08-4; Propofol, British Pharmacopoeia (BP) Reference Standard; Propofol, European Pharmacopoeia (EP) Reference Standard; Z752915492; Propofol, United States Pharmacopeia (USP) Reference Standard; Propofol, Pharmaceutical Secondary Standard; Certified Reference Material; InChI=1/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H; Propofol for peak identification, European Pharmacopoeia (EP) Reference Standard; 113981-41-2	.	.	178.27	C12H18O	20.2	135	3.8	13	1	1	2	InChI=1S/C12H18O/c1-8(2)10-6-5-7-11(9(3)4)12(10)13/h5-9,13H,1-4H3	CC(C)C1=C(C(=CC=C1)C(C)C)O	CC(C)C1=C(C(=CC=C1)C(C)C)O	OLBCVFGFOZPWHH-UHFFFAOYSA-N	2,6-di(propan-2-yl)phenol
ferrodrug0131	Flubendazole	Small molecular drug	Flubendazole; 31430-15-6; Flumoxane; Flubendazol; Fluvermal; Flubenol; Methyl (5-(4-fluorobenzoyl)-1H-benzo[d]imidazol-2-yl)carbamate; Flubendazolum; Flumoxanal; R 17,889; Methyl 5-(p-fluorobenzoyl)-2-benzimidazolecarbamate; Flubendazole D3; NSC 313680; Methyl [5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate; R 17899; NSC-313680; (5-(4-Fluorobenzoyl)-1H-benzimidazole-2-yl)carbamic acid methyl ester; Carbamic acid, (5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl)-, methyl ester; Methyl N-(5-(p-fluorobenzoyl)-2-benzimidazolyl)carbamate; CHEBI:77095; methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate; R8M46911LR; R-17889; R-17,889; NSC313680; CPD000466360; methyl N-{5-[(4-fluorophenyl)carbonyl]-1H-1,3-benzodiazol-2-yl}carbamate; Flubendazol [INN-Spanish]; Flubendazolum [INN-Latin]; SMR000466360; CCRIS 4480; SR-01000759412; EINECS 250-624-4; Flicum; UNII-R8M46911LR; Flubendazole [USAN:INN:BAN]; methyl {6-[(4-fluorophenyl)carbonyl]-1H-benzimidazol-2-yl}carbamate; MFCD00871999; Flubendazole (Flutelmium); FLUBENDAZOLE [MI]; 2-BENZIMIDAZOLECARBAMIC ACID, 5-(p-FLUOROBENZOYL)-, METHYL ESTER; Flubendazole (USAN/INN); FLUBENDAZOLE [INN]; FLUBENDAZOLE [USAN]; FLUBENDAZOLE [MART.]; MLS000759477; MLS001424042; MLS006010905; FLUBENDAZOLE [WHO-DD]; SCHEMBL167185; CHEMBL1454946; DTXSID8023058; CPEUVMUXAHMANV-UHFFFAOYSA-N; Flubendazole for system suitability; HMS2051A18; HMS2090I16; HMS3393A18; HMS3714D06; FLUBENDAZOLE [EP MONOGRAPH]; BCP34258; HY-B0294; s1837; AKOS015894917; AKOS015960439; AC-8716; CCG-100887; CCG-267614; DB08974; NC00137; NCGC00246966-01; NCGC00246966-03; NCGC00246966-12; AS-12271; F0825; FT-0626436; D04200; D70276; AB00639981-06; AB00639981-08; AB00639981_09; EN300-7361973; Flubendazol, VETRANAL(TM), analytical standard; A820846; Q241992; Flubendazole, Antibiotic for Culture Media Use Only; Q-201119; SR-01000759412-4; SR-01000759412-5; Methyl [5-(4-Fluorobenzoyl)benzimidazol-2-yl]carbamate; Z2037280409; Flubendazol, European Pharmacopoeia (EP) Reference Standard; methyl 5-(4-fluorobenzoyl)-1H-benzo[d]imidazol-2-ylcarbamate; methyl N-[5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate; [5-(4-Fluorobenzoyl)benzimidazol-2-yl]carbamic Acid Methyl Ester; Methyl (5-(4-fluorobenzoyl)-1H-benzo-[d]imidazol-2-yl)carbamate; methyl (6-(4-fluorobenzoyl)-1H-benzo[d]imidazol-2-yl)carbamate; methyl N-[5-(4-fluorobenzoyl)-1H-1,3-benzodiazol-2-yl]carbamate; Carbamicacid, [5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]-methylester; N-{5-[(4-Fluorophenyl)carbonyl]benzimidazol-2-yl}methyloxymethanamide; Carbamic acid, N-[5-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]-, methyl ester; Flubendazole for system suitability, European Pharmacopoeia (EP) Reference Standard; N-[6-[(4-fluorophenyl)-oxomethyl]-1H-benzimidazol-2-yl]carbamic acid methyl ester; NSC 313680; NSC313680; NSC-313680; R 17899; R17899; R-17899	.	DG50412	313.28	C16H12FN3O3	84.1	454	2.9	23	2	5	4	InChI=1S/C16H12FN3O3/c1-23-16(22)20-15-18-12-7-4-10(8-13(12)19-15)14(21)9-2-5-11(17)6-3-9/h2-8H,1H3,(H2,18,19,20,22)	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=C(C=C3)F	CPEUVMUXAHMANV-UHFFFAOYSA-N	methyl N-[6-(4-fluorobenzoyl)-1H-benzimidazol-2-yl]carbamate
ferrodrug0132	Camptothecin	.	camptothecin; Camptothecine; 7689-03-4; (S)-(+)-Camptothecin; Campathecin; (+)-Camptothecine; d-Camptothecin; (+)-Camptothecin; 20(S)-Camptothecine; 21,22-Secocamptothecin-21-oic acid lactone; NSC94600; Camptothecine (S,+); CHEMBL65; (S)-4-ethyl-4-hydroxy-1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NSC-94600; (4S)-4-ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; MLS000766223; XT3Z54Z28A; CHEBI:27656; MFCD00081076; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2,4(9),5,7,10,15(20)-heptaene-14,18-dione; (S)-Camptothecin; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (4S)-; 20(S)-Camptothecin; 4-ETHYL-4-HYDROXY-1,12-DIHYDRO-4H-2-OXA-6,12A-DIAZA-DIBENZO[B,H]FLUORENE-3,13-DIONE; SR-01000075798; SR-01000597379; d-camptothecine; (s)-camptothecine; Camptothecin,(S); (4S)-4-ETHYL-4-HYDROXY-1H-PYRANO(3',4':6,7)INDOLIZINO(1,2-B)QUINOLINE-3,14(4H,12H)-DIONE; (S)-4-ethyl-4-hydroxy-1H-Pyrano(3',4':6,7)indolizino(1,2-b)quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; Prestwick_102; (+)-Camptothecin;; Camptothecine (8CI); Spectrum_000299; Tocris-1100; SpecPlus_000712; Prestwick0_000200; Prestwick1_000200; Prestwick2_000200; Prestwick3_000200; Spectrum2_000903; Spectrum3_001203; Spectrum4_000738; Spectrum5_001126; CAMPTOTHECIN [MI]; Lopac-C-9911; SCHEMBL6038; UNII-XT3Z54Z28A; Lopac0_000341; BSPBio_000159; BSPBio_002586; KBioGR_001036; KBioSS_000779; KBioSS_002283; cid_24360; CAMPTOTHECIN [WHO-DD]; DivK1c_000826; DivK1c_006808; SPECTRUM1502232; SPBio_000746; SPBio_002080; BPBio1_000175; DTXSID0030956; HMS502J08; KBio1_000826; KBio1_001752; KBio2_000779; KBio2_003347; KBio2_005915; KBio3_002086; 4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; NINDS_000826; Bio1_000400; Bio1_000889; Bio1_001378; HMS1568H21; HMS1921N08; HMS2089F08; HMS2095H21; HMS3261E03; HMS3414J17; HMS3654D13; HMS3678J15; HMS3712H21; BCP02857; Tox21_500341; AC-202; BBL033963; BDBM50008923; CCG-40255; GR-301; s1288; STK801886; AKOS004119861; CS-1049; DB04690; KS-5235; LP00341; SDCCGMLS-0066688.P001; SDCCGSBI-0050329.P003; CAS-2114454; IDI1_000826; NCGC00015290-01; NCGC00016994-01; NCGC00016994-02; NCGC00016994-03; NCGC00016994-04; NCGC00016994-05; NCGC00016994-06; NCGC00016994-07; NCGC00016994-08; NCGC00016994-09; NCGC00016994-10; NCGC00016994-11; NCGC00016994-12; NCGC00016994-16; NCGC00016994-29; NCGC00024997-01; NCGC00024997-02; NCGC00024997-03; NCGC00024997-04; NCGC00024997-05; NCGC00024997-06; NCGC00178592-01; NCGC00178592-02; NCGC00261026-01; HY-16560; NCI60_042105; SMR000445686; SY010324; EU-0100341; SW196414-3; C 9911; C01897; M01564; AB00052452-08; AB00052452-09; AB00052452_10; EN300-1725804; (S)-(+)-Camptothecin, >=90% (HPLC), powder; A838882; Q419964; Q-200785; SR-01000075798-1; SR-01000075798-4; SR-01000597379-1; SR-01000597379-3; BRD-K37890730-001-09-4; BRD-K37890730-001-10-2; Z1741982070; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]florene-3,13-dione; (S)-4-ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione; 4-Ethyl-4-hydroxy-1H-pyrano-[3[,4[:6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.0^{2,11}.0^{4,9}.0^{15,20}]henicosa-1(21),2(11),3,5,7,9,15(20)-heptaene-14,18-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione; (S)-4-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione;(S)-(+)-Camptothecin; (S)-4-Ethyl-4-hydroxy-1H-pyrano[3 inverted exclamation mark ,4 inverted exclamation mark :6,7]indolizino[1,2-b]quinoline-3,14-(4H,12H)-dione; 1H-Pyrano[3',7]indolizino[1,2-b]quinoline-3,14(4H,12H)-dione, 4-ethyl-4-hydroxy-, (S)-; 4(S)-Ethyl-4-hydroxy-1H-pyrano-[3',4':6,7]indolizino[1,2-b]quinoline-3,14 (4H,12H)-dione; 4-ethyl-4-hydroxy-(4S)-3,4,12,14-tetrahydro-1H-pyrano[3'',4'':6,7]indolizino[1,2-b]quinoline-3,14-dione; 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (camptothecin or CPT); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (Camptothecin); 4-Ethyl-4-hydroxy-1,12-dihydro-4H-2-oxa-6,12a-diaza-dibenzo[b,h]fluorene-3,13-dione (CPT, Camptothecin)	.	.	348.4	C20H16N2O4	79.7	742	1	26	1	5	1	InChI=1S/C20H16N2O4/c1-2-20(25)14-8-16-17-12(7-11-5-3-4-6-15(11)21-17)9-22(16)18(23)13(14)10-26-19(20)24/h3-8,25H,2,9-10H2,1H3/t20-/m0/s1	CC[C@@]1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O	CCC1(C2=C(COC1=O)C(=O)N3CC4=CC5=CC=CC=C5N=C4C3=C2)O	VSJKWCGYPAHWDS-FQEVSTJZSA-N	(19S)-19-ethyl-19-hydroxy-17-oxa-3,13-diazapentacyclo[11.8.0.02,11.04,9.015,20]henicosa-1(21),2,4,6,8,10,15(20)-heptaene-14,18-dione
ferrodrug0133	Andrographis	Small molecular drug	Andrographolide; 5508-58-7; CHEBI:65408; HMPL004; UNII-410105JHGR; DTXSID3045980; 410105JHGR; EINECS 226-852-5; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one; NSC 383468; NSC-383468; DTXCID1025980; 3alpha,14,15,18-tetrahydroxy-5b,9bH,10a-labda-8(20),12-dien-16-oic acid gamma-Lactone; 3-(2-(Decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenenaphthyl)ethylidene)dihydro-4-hydroxyfuran-2(3H)-one; (1R-(1-alpha(E(S)),4abeta,5alpha,6alpha,8aalpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone; (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one; (3E,4S)-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-decahydronaphthalen-1-yl]ethylidene}-4-hydroxyoxolan-2-one; ANDROGRAPHOLIDE (USP-RS); ANDROGRAPHOLIDE [USP-RS]; (3E,4S)-3-(2-((1R,4AS,5R,6R,8AS)-DECAHYDRO-6-HYDROXY-5-(HYDROXYMETHYL)-5,8A-DIMETHYL-2-METHYLENE-1-NAPHTHALENYL)ETHYLIDENE)DIHYDRO-4-HYDROXY-2(3H)-FURANONE; (3E,4S)-4-hydroxy-3-{2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl]ethylidene}dihydrofuran-2(3H)-one; 2(3H)-FURANONE, 3-(2-((1R,4AS,5R,6R,8AS)-DECAHYDRO-6-HYDROXY-5-(HYDROXYMETHYL)-5,8A-DIMETHYL-2-METHYLENE-1-NAPHTHALENYL)ETHYLIDENE)DIHYDRO-4-HYDROXY-, (3E,4S)-; 2(3H)-Furanone, 3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-, (1R-(1-alpha(E(S*)),4a-beta,5-alpha,6-alpha,8a-alpha))-; 2(3H)-Furanone, 3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-, (3E,4S)-; HMPL-004; NSC383468; NCGC00095597-01; (3E,4S)-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl)ethylidene)-4-hydroxyoxolan-2-one; (3E,4S)-4-hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2(3H)-one; Andrographolide, 98%; ANDROGRAPHOLIDE [MI]; ANDROGRAPHOLIDE [INCI]; BIDD:ER0530; CHEMBL186141; GTPL9675; MEGxp0_000978; ANDROGRAPHOLIDE [WHO-DD]; SCHEMBL12056309; ACon1_002113; BOJKULTULYSRAS-OTESTREVSA-N; Andrographolide, analytical standard; HY-N0191; Tox21_111508; BDBM50084419; MFCD07778082; AKOS015920075; CCG-208428; CS-3334; DB05767; NCGC00179817-01; NCGC00179817-02; AS-13637; CAS-5508-58-7; C20214; A830479; ANDROGRAPHOLIDE (CONSTITUENT OF ANDROGRAPHIS); Q-100624; Q4759444; BRD-K89282837-001-01-0; ANDROGRAPHOLIDE (CONSTITUENT OF ANDROGRAPHIS) [DSC]; Andrographolide, United States Pharmacopeia (USP) Reference Standard; (1R-(1-alpha(E(S)),4a-beta,5alpha,6alpha,8a-alpha))-3-(2-(decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl)ethylidene)dihydro-4-hydroxy-2(3H)-furanone; (3E)-3-[2-[(1R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one;Andrographolide; (3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-decalin-1-yl]ethylidene]-4-hydroxy-tetrahydrofuran-2-one; (S,E)-4-Hydroxy-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)dihydrofuran-2; 2(3H)-Furanone,3-[2-[(1R,4aS,5R,6R,8aS)-decahydro-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylene-1-naphthalenyl]ethylidene]dihydro-4-hydroxy-,(3E,4S)-; 3.ALPHA.,14,15,18-TETRAHYDROXY-5.BETA.,9.BETA.H,10.ALPHA.-LABDA-8(20),12-DIEN-16-OIC ACID .GAMMA.-LACTONE; 3alpha,14,15,18-TETRAHYDROXY-5beta,9betaH,10alpha-LABDA-8(20),12-DIEN-16-OIC ACID gamma-LACTONE	.	DG01826	350.4	C20H30O5	87	597	2.2	25	3	5	3	InChI=1S/C20H30O5/c1-12-4-7-16-19(2,9-8-17(23)20(16,3)11-21)14(12)6-5-13-15(22)10-25-18(13)24/h5,14-17,21-23H,1,4,6-11H2,2-3H3/b13-5+/t14-,15-,16+,17-,19+,20+/m1/s1	C[C@@]12CC[C@H]([C@@]([C@H]1CCC(=C)[C@H]2C/C=C/3\[C@@H](COC3=O)O)(C)CO)O	CC12CCC(C(C1CCC(=C)C2CC=C3C(COC3=O)O)(C)CO)O	BOJKULTULYSRAS-OTESTREVSA-N	(3E,4S)-3-[2-[(1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]ethylidene]-4-hydroxyoxolan-2-one
ferrodrug0134	Indole-3-carbinol	Small molecular drug	Indole-3-carbinol; 700-06-1; INDOLE-3-METHANOL; 3-Indolemethanol; (1H-Indol-3-yl)methanol; 1H-Indole-3-methanol; 3-Hydroxymethylindole; 1H-indol-3-ylmethanol; 3-Indolylcarbinol; Indinol; (1H-Indol-3-yl)-methanol; I3C; 3-(Hydroxymethyl)indole; Indole 3-carbinol; MFCD00005632; NSC-525801; 1~{H}-indol-3-ylmethanol; DTXSID7031458; CHEBI:24814; C11E72455F; NCGC00090701-06; I0496; Indole 3 carbinol; SMR000385784; CCRIS 3261; EINECS 211-836-2; 1H-Indol-3-Yl-Methanol; NSC 525801; BRN 0121323; AI3-60090; 3-Indolecarbinol; UNII-C11E72455F; 3-Indolylmethanol; Prevention 4 (indole-3-carbinol); 3-hydroxymethyl indole; I3C;3-Indolemethanol; Spectrum2_001710; Spectrum3_001973; BSPBio_003573; MLS001333161; MLS001333162; SCHEMBL195520; SPECTRUM1505320; SPBio_001700; CHEMBL155625; 3-Phenoxybenzylaminehydrochloride; DTXCID5011458; GTPL10047; KBio3_002949; HMS1789O22; HMS2235E10; HMS3369B02; HMS3651I18; HMS3749E07; INDOLE-3-CARBINOL [VANDF]; BCP00087; HY-N0170; INDOLE-3-CARBINOL (I3C); INDOLE-3-CARBINOL [WHO-DD]; Tox21_400055; CCG-38786; HSCI1_000097; Indole-3-methanol;3-Indole methanol; NSC525801; s2313; AKOS001075120; AC-7583; CS-7780; DB12881; GS-0916; SB14958; SDCCGMLS-0065970.P001; SDCCGMLS-0065970.P002; SMP2_000172; NCGC00090701-01; NCGC00090701-02; NCGC00090701-03; NCGC00090701-04; NCGC00090701-05; NCGC00090701-07; CAS-700-06-1; SY015976; A9256; FT-0615875; SW219849-1; EN300-18594; I-2100; A836732; SR-01000838318; Q1770257; SR-01000838318-3; BRD-K01815685-001-02-3; BRD-K01815685-001-07-2; Z85923165; FXK	DN62DG	DMIGFOR	147.17	C9H9NO	36	138	1.1	11	2	1	1	InChI=1S/C9H9NO/c11-6-7-5-10-9-4-2-1-3-8(7)9/h1-5,10-11H,6H2	C1=CC=C2C(=C1)C(=CN2)CO	C1=CC=C2C(=C1)C(=CN2)CO	IVYPNXXAYMYVSP-UHFFFAOYSA-N	1H-indol-3-ylmethanol
ferrodrug0135	Decitabine	.	Decitabine; 5-Aza-2'-deoxycytidine; 2353-33-5; Dacogen; 2'-Deoxy-5-azacytidine; 5-Azadeoxycytidine; AzadC; 5-aza-CdR; 5-aza-dC; Dezocitidine; NSC 127716; Dac; 5-Aza-deoxycytidine; 4-amino-1-((2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl)-1,3,5-triazin-2(1H)-one; NSC-127716; 5A2dc; C8H12N4O4; 5-aza-2-deoxycytidine; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; MFCD00043011; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-s-triazin-2(1H)-one; 4-Amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,2-dihydro-1,3,5-triazin-2-one; MLS001332587; DTXSID7030432; CHEBI:50131; 776B62CQ27; SMR000857076; 2-Desoxy-5-azacytidine; 4-Amino-1-(2-deoxy-beta-D-ribofuranosyl)-1,3,5-triazin-2(1H)-one; 4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)tetrahydrofuran-2-yl]-1,3,5-triazin-2-one; 4-amino-1-[(2S,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one; Alpha-Decitibine; DTXCID5010432; 5-AZAdC; NSC127716; 2-deoxyazacytidine; Dacogen (TN); CAS-2353-33-5; NCGC_5ADOC; Decitabine (USAN/INN); Decitabine [USAN:INN:BAN]; CCRIS 8227; UNII-776B62CQ27; 5-Aza-2'-deoxycytidine;NSC 127716; NCGC00166088-01; Decitabine- Bio-X; deoxy-5-azacytidine; EINECS 219-089-4; BRN 0617982; Decitabine, Free Base; JNJ 30979754; JNJ-30979754; DECITABINE [MI]; DECITABINE [INN]; DECITABINE [USAN]; DECITABINE [VANDF]; MolMap_000063; E-7373; DECITABINE [MART.]; SCHEMBL4006; DECITABINE [WHO-DD]; MLS001332588; MLS006010136; ASTX-727; cid_451668; GTPL6805; CHEMBL1201129; DECITABINE [ORANGE BOOK]; BDBM96274; EX-A961; INQOVI COMPONENT DECITABINE; XAUDJQYHKZQPEU-KVQBGUIXSA-N; HMS2235O03; HMS3413L07; HMS3677L07; 105597-46-4; 22432-95-7; AMY33354; BCP02870; HY-A0004; 5-Aza-2'-deoxycytidine, >=97%; Tox21_112311; ASTX727 COMPONENT DECITABINE; HB1356; s1200; 5-aza-2'-deoxycytidine (Decitabine); DECITABINE COMPONENT OF INQOVI; 4-Amino-1-(2-deoxy-?-D-erythro-pentofuranosyl)-1,3,5-triazin-2(1H)-one; AKOS015895047; ASTX-727 COMPONENT DECITABINE; Inqovi (decitabine + cedazuridine); Tox21_112311_1; AC-1135; BCP9000593; CCG-208143; CS-0372; DB01262; 1,3,5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-.beta.-D-erythro-pentofuranosyl)-; ASTX727 (decitabine + cedazuridine); Decitabine (NSC127716; 5AZA-CdR); NCGC00166088-02; NCGC00166088-05; AS-17558; BA164359; BCP0726000271; SW218076-2; D03665; EN300-269341; AB00918337-07; AB00918337_08; SR-01000838879; J-700084; Q1181878; SR-01000838879-4; Z2467077030; decitabine (2 inverted exclamation marka-deoxy-5-azacytidine).cd; s-Triazin-2(1H)-one, 4-amino-1-(2-deoxy-beta-D-erythro-pentofuranosyl)-; 1,3, 5-Triazin-2(1H)-one, 4-amino-1-(2-deoxy--D-erythro-pentofuranosyl)-; 4-AMINO-1-(2-DEOXY-.BETA.-D-ERYTHRO-PENTOFURANOSYL)-S-TRIAZIN-2(1H)-ONE; 4-Amino-1-(2-deoxy-beta-D-erythro-pento furanosyl)-1,3,5-triazin-2(1H)-one	.	.	228.21	C8H12N4O4	121	356	-1.2	16	3	4	2	InChI=1S/C8H12N4O4/c9-7-10-3-12(8(15)11-7)6-1-4(14)5(2-13)16-6/h3-6,13-14H,1-2H2,(H2,9,11,15)/t4-,5+,6+/m0/s1	C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O	C1C(C(OC1N2C=NC(=NC2=O)N)CO)O	XAUDJQYHKZQPEU-KVQBGUIXSA-N	4-amino-1-[(2R,4S,5R)-4-hydroxy-5-(hydroxymethyl)oxolan-2-yl]-1,3,5-triazin-2-one
ferrodrug0136	Tanshinone IIA	Small molecular drug	Tanshinone IIA; 568-72-9; Tanshinone II; Dan Shen Ketone; Tanshinone B; Tanshinon II; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione; UNII-4GPC9FQG6L; 4GPC9FQG6L; C19H18O3; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione; NSC 686518; SALVIOL IIA; HSDB 8104; Phenanthro[1,2-b]furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; NSC-686519; MLS001048863; DTXSID60205352; Phenanthro(1,2-b)furan-10,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; NSC686519; NSC-686518; SMR000387068; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-dione; TANSHINONE IIA (USP-RS); TANSHINONE IIA [USP-RS]; tanshinone II A; 1,6,6-TRIMETHYL-6,7,8,9-TETRAHYDROPHENANTHRO(1,2-B)FURAN-10,11-DIONE; 6,7,8,9-TETRAHYDRO-1,6,6-TRIMETHYLPHENANTHRO(1,2-B)FURAN-10,11-DIONE; SR-01000758926; tanshinone-IIA; 6,7,8,9-Tetrahydro-1,6,6-trimethylphenanthro[1,2-b]furan-10,11-dione; Tanshinone centoA; Tanshinone 2-A; MFCD00238692; TASHINONE IIA; Tanshinone Iia ,(S); BSPBio_001597; BSPBio_002426; KBioGR_000317; KBioSS_000317; MLS006011834; SPECTRUM1505824; CHEMBL187266; cid_164676; SCHEMBL2026738; Tanshinone IIA (Tanshinone B); TANSHINONE IIA [WHO-DD]; BDBM83922; KBio2_000317; KBio2_002885; KBio2_005453; KBio3_000633; KBio3_000634; DTXCID60127843; CHEBI:108595; Bio2_000317; Bio2_000797; HMS1361P19; HMS1791P19; HMS1989P19; HMS2089H08; HMS2270D15; HMS3402P19; HMS3656C11; NP474; BCP28199; HY-N0135; Tanshinone IIA, analytical standard; BBL028449; s2365; STK801917; Tanshinone IIA, >=97% (HPLC); AKOS004120032; AC-1440; CCG-207955; CCG-208275; IDI1_034067; NCGC00095709-01; NCGC00095709-02; NCGC00095709-03; NCGC00095709-04; NCGC00095709-05; NCGC00095709-06; NCGC00095709-08; AS-16136; NCI60_031209; FT-0652880; SW220025-1; T2987; A831217; Q-100654; SR-01000758926-2; SR-01000758926-4; SR-01000758926-5; BRD-K00141480-001-03-0; Q27187517; TANSHINONE IIA (CONSTITUENT OF CHINESE SALVIA); Phenanthro[1,11-dione, 6,7,8,9-tetrahydro-1,6,6-trimethyl-; TANSHINONE IIA (CONSTITUENT OF CHINESE SALVIA) [DSC]; Tanshinone IIA, European Pharmacopoeia (EP) Reference Standard; Tanshinone IIA, United States Pharmacopeia (USP) Reference Standard; 1,6,6-Trimethyl-6,7,8,9-tetrahydrophenanthro[1,2-b]furan-10,11-dione #; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g]benzofuran-10,11-quinone; 1,6,6-trimethyl-8,9-dihydro-7H-naphtho[8,7-g]benzofuran-10,11-dione	.	DG01810	294.3	C19H18O3	47.3	509	4.3	22	0	3	0	InChI=1S/C19H18O3/c1-10-9-22-18-12-6-7-13-11(5-4-8-19(13,2)3)15(12)17(21)16(20)14(10)18/h6-7,9H,4-5,8H2,1-3H3	CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C	CC1=COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCCC4(C)C	HYXITZLLTYIPOF-UHFFFAOYSA-N	1,6,6-trimethyl-8,9-dihydro-7H-naphtho[1,2-g][1]benzofuran-10,11-dione
ferrodrug0137	Itaconic acid	.	Itaconic acid; 97-65-4; 2-Methylenesuccinic acid; METHYLENESUCCINIC ACID; 2-methylidenebutanedioic acid; Methylenebutanedioic acid; Propylenedicarboxylic acid; Butanedioic acid, methylene-; itaconate; 2-Propene-1,2-dicarboxylic acid; Succinic acid, methylene-; 2-methylenebutanedioic acid; MFCD00004260; 25119-64-6; AI3-16901; 2-Methylene-Succinic Acid; CHEMBL359159; butanedioic acid, 2-methylene-; DTXSID2026608; CHEBI:30838; NSC3357; NSC-3357; Q4516562YH; DTXCID006608; CAS-97-65-4; HSDB 5308; methylene-butanedioicaci; NSC 3357; EINECS 202-599-6; Methylenesuccinate; UNII-Q4516562YH; ITN; Methylenebutanedioate; 2-Methylenesuccinate; Propylenedicarboxylate; 2-methylenebutanedioate; Itaconic acid, >=99%; bmse000137; Probes1_000076; Probes2_000247; EC 202-599-6; 2-Methylenesuccinic acid #; ITACONIC ACID [MI]; NCIStruc1_001783; NCIStruc2_000502; 2-methylene-butanedioic acid; NCIOpen2_004822; SCHEMBL21523; ITACONIC ACID [INCI]; 2-Propene-1,2-dicarboxylate; Itaconic acid, analytical standard; Succinic acid, methylene- (8CI); HY-Y0520; Tox21_201299; Tox21_303071; BBL011584; BDBM50036216; LMFA01170063; s3095; STL163322; AKOS000118895; 2-Hydroxy-3-Naphthoyl-2-Naphthylamine; SB67306; Butanedioic acid,ethylidene-,(E)-(9ci); NCGC00249019-01; NCGC00257141-01; NCGC00258851-01; AS-11816; CS-0015302; FT-0627543; M0223; EN300-18045; C00490; E80791; Q903311; Z57127539; F2191-0234; 2-METHYLENE,1,4-BUTANEDIOIC ACID (ITACONIC ACID); 53EEC7A3-4846-4588-BBC9-CB8846377B96; InChI=1/C5H6O4/c1-3(5(8)9)2-4(6)7/h1-2H2,(H,6,7)(H,8,9	.	.	130.1	C5H6O4	74.6	158	-0.1	9	2	4	3	InChI=1S/C5H6O4/c1-3(5(8)9)2-4(6)7/h1-2H2,(H,6,7)(H,8,9)	C=C(CC(=O)O)C(=O)O	C=C(CC(=O)O)C(=O)O	LVHBHZANLOWSRM-UHFFFAOYSA-N	2-methylidenebutanedioic acid
ferrodrug0138	Betulin	.	Betulin; 473-98-3; Betulinol; Betuline; Trochol; Betulol; Lup-20(29)-ene-3b,28-diol; Betulinic alcohol; Lup-20(29)-ene-3beta,28-diol; (+)-betulin; Lup-20(30)-ene-3beta,28-diol; NSC 4644; NSC-4644; 6W70HN7X7O; CHEBI:3086; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(Hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; (3beta)-lup-20(29)-ene-3,28-diol; Lup-20(29)-ene-3,28-diol, (3.beta.)-; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol; (1R,2R,5S,8R,9R,10R,13R,14R,17S,19R)-5-(hydroxymethyl)-1,2,14,18,18-pentamethyl-8-(prop-1-en-2-yl)pentacyclo[11.8.0.0^{2,10}.0^{5,9}.0^{14,19}]henicosan-17-ol; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol; SR-05000002167; EINECS 207-475-5; lup-20(29)-ene-3 beta,28-diol; NSC4644; UNII-6W70HN7X7O; AI3-62999; NSC692218; Lup-20(29)-ene-3,28-diol, (3beta)-; Lup-20(29)-ene-3.beta.,28-diol; Lup-20(30)-ene-3.beta.,28-diol; Betulinol (obsol.); MFCD00016802; Betulin, 23; ORISTRACT BTL; CP BETULIN; BETULIN [INCI]; Betulin, >=98%; BETULIN [MI]; Prestwick3_000990; Betulinol (obsol pound(c); Betulin, analytical standard; BSPBio_001059; CHEMBL23236; SCHEMBL131739; BPBio1_001165; MEGxp0_001726; ACon1_000091; BDBM23207; FVWJYYTZTCVBKE-ROUWMTJPSA-N; DTXSID101019934; HMS2098E21; EX-A3354; HY-N0083; s4754; Lup-20(29)-ene-3 ,28-diol; AKOS005267212; Lup-20(29)-ene-3beta ,28-diol; Lup-20(30)-ene-3beta ,28-diol; CCG-208619; CS-6156; GS-3254; LMPR0106140005; NSC-692218; NCGC00168803-01; NCGC00168803-02; NCGC00168803-04; AB00513988; B0803; (3.beta.)-Lup-20(29)-ene-3,28-diol; C08618; Lup-20(29)-ene-3,28-diol, (3beta )-; A827211; Q419726; Q-100501; SR-05000002167-2; SR-05000002167-3; BRD-K64874225-001-01-3; (1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3 a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-(prop-1-en-2-yl)icosahydro-1H-cyclopenta[a]chrysen-9-ol; (3aS,5bR,9S,11aR)-3a-(hydroxymethyl)-1-isopropenyl-5a,5b,8,8,11a-pentamethyl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol;Betulin; 7372-31-8	.	.	442.7	C30H50O2	40.5	786	8.3	32	2	2	2	InChI=1S/C30H50O2/c1-19(2)20-10-15-30(18-31)17-16-28(6)21(25(20)30)8-9-23-27(5)13-12-24(32)26(3,4)22(27)11-14-29(23,28)7/h20-25,31-32H,1,8-18H2,2-7H3/t20-,21+,22-,23+,24-,25+,27-,28+,29+,30+/m0/s1	CC(=C)[C@@H]1CC[C@]2([C@H]1[C@H]3CC[C@@H]4[C@]5(CC[C@@H](C([C@@H]5CC[C@]4([C@@]3(CC2)C)C)(C)C)O)C)CO	CC(=C)C1CCC2(C1C3CCC4C5(CCC(C(C5CCC4(C3(CC2)C)C)(C)C)O)C)CO	FVWJYYTZTCVBKE-ROUWMTJPSA-N	(1R,3aS,5aR,5bR,7aR,9S,11aR,11bR,13aR,13bR)-3a-(hydroxymethyl)-5a,5b,8,8,11a-pentamethyl-1-prop-1-en-2-yl-1,2,3,4,5,6,7,7a,9,10,11,11b,12,13,13a,13b-hexadecahydrocyclopenta[a]chrysen-9-ol
ferrodrug0139	Paricalcitol	Small molecular drug	Paricalcitol; 131918-61-1; Zemplar; Compound 49510; 19-Nor-1alpha,25-dihydroxyvitamin D2; Paracalcin; Compound-49510; (1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol; CHEBI:7931; DTXSID4048640; 6702D36OG5; (1R,3R,7E)-17beta-[(2R,3E,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-9,10-secoestra-5,7-diene-1,3-diol; NCGC00182706-01; Paricalcitol [USAN]; (1R,3R)-5-(2-((1R,3aS,7aR,E)-1-((2R,5S,E)-6-hydroxy-5,6-dimethylhept-3-en-2-yl)-7a-methyloctahydro-4H-inden-4-ylidene)ethylidene)cyclohexane-1,3-diol; 19-Nor-1,25-(OH)2D2; Zemplar (TN); 19-Nor-1-alpha,25-dihydroxyvitamin D2; HSDB 7360; Paricalcitol [USAN:USP:INN]; UNII-6702D36OG5; ABT-358; (7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1alpha,3beta,25-triol; PARICALCITOL [MI]; PARICALCITOL [JAN]; (1alpha.3beta,7E,22E)-19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol; PARICALCITOL [HSDB]; SCHEMBL3655; PARICALCITOL [VANDF]; PARICALCITOL [MART.]; BIDD:GT0330; PARICALCITOL [USP-RS]; PARICALCITOL [WHO-DD]; Paricalcitol (JAN/USP/INN); GTPL2791; CHEMBL1200622; DTXCID7028566; AMY2878; BPKAHTKRCLCHEA-UBFJEZKGSA-N; BDBM233195; PARICALCITOL [ORANGE BOOK]; PARICALCITOL [USP IMPURITY]; EX-A4434; PARICALCITOL [USP MONOGRAPH]; Tox21_112987; LMST04030163; s6681; AKOS005145562; BCP9001050; CS-0705; DB00910; 19-Nor-9,10-secoergosta-5,7,22-triene-1,3,25-triol, (1alpha,3beta,7E,22E)-; HY-50919; MS-27260; CAS-131918-61-1; C08127; D00930; A937163; Q155746; (1.ALPHA.3.BETA.,7E,22E)-19-NOR-9,10-SECOERGOSTA-5,7,22-TRIENE-1,3,25-TRIOL; (7E,22E)-19-NOR-9,10-SECOERGOSTA-5,7,22-TRIENE-1.ALPHA.,3.BETA.,25-TRIOL; (1R,3R,5Z)-5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-1,3-cyclohexanediol; 1,3-Cyclohexanediol, 5-[(2E)-2-[(1R,3aS,7aR)-octahydro-1-[(1R,2E,4S)-5-hydroxy-1,4,5-trimethyl-2-hexen-1-yl]-7a-methyl-4H-inden-4-ylidene]ethylidene]-, (1R,3R,5Z)-	D0N1TP	DMYBV3G	416.6	C27H44O3	60.7	676	5	30	3	3	5	InChI=1S/C27H44O3/c1-18(8-9-19(2)26(3,4)30)24-12-13-25-21(7-6-14-27(24,25)5)11-10-20-15-22(28)17-23(29)16-20/h8-11,18-19,22-25,28-30H,6-7,12-17H2,1-5H3/b9-8+,21-11+/t18-,19+,22-,23-,24-,25+,27-/m1/s1	C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C	CC(C=CC(C)C(C)(C)O)C1CCC2C1(CCCC2=CC=C3CC(CC(C3)O)O)C	BPKAHTKRCLCHEA-UBFJEZKGSA-N	(1R,3R)-5-[(2E)-2-[(1R,3aS,7aR)-1-[(E,2R,5S)-6-hydroxy-5,6-dimethylhept-3-en-2-yl]-7a-methyl-2,3,3a,5,6,7-hexahydro-1H-inden-4-ylidene]ethylidene]cyclohexane-1,3-diol
ferrodrug0140	Lycorine	Small molecular drug	lycorine; 476-28-8; Amarylline; Galanthidine; Narcissine; Licorine; Lycorine hydrochloride; (-)-Lycorine; NSC401360; NSC683873; CHEBI:6601; CHEMBL400092; I9Q105R5BU; GNF-PF-4974; Lycoran-1-alpha,2-beta-diol, 3,3-alpha-didehydro-; NSC-401360; NSC-683873; 9,10-(methylenedioxy)-3,12-didehydrogalanthan-1alpha,2beta-diol; NSC 401360; Galanthan-1,2-diol, 3,12-didehydro-9,10-(methylenebis(oxy))-, (1-alpha,2-beta)-; (1S,2S,3a1S,12bS)-2,3a1,4,5,7,12b-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol; (1S,2S,12bS,12cS)-2,4,5,7,12b,12c-hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol; EINECS 207-503-6; UNII-I9Q105R5BU; 3,3a-Didehydrolycoran-1alpha,2beta-diol; Likorin; (1S,2S,12BS,12CS)-2,4,5,7,12B,12C-HEXAHYDRO-1H-(1,3)DIOXOLO(4,5-J)PYRROLO(3,2,1-DE)PHENANTHRIDINE-1,2-DIOL; 3,2.beta.-diol; Lycoran-1.alpha.,2.beta.-diol, 3,3a-didehydro-; LYCORINE [MI]; Lycoran-1alpha,2beta-diol, 3,3a-didehydro-; BSPBio_001302; KBioGR_000022; KBioSS_000022; SCHEMBL626071; BCBcMAP01_000100; KBio2_000022; KBio2_002590; KBio2_005158; KBio3_000043; KBio3_000044; DTXSID60197208; Bio2_000022; Bio2_000502; HMS1361B04; HMS1791B04; HMS1989B04; HMS3402B04; HMS3885I12; HY-N0288; BDBM50221066; MFCD00221746; NSC781764; s3903; Lycoran-1.alpha., 3,3a-didehydro-; AKOS000278045; CCG-208232; NSC-781764; IDI1_033772; QTL1_000052; SMP1_000184; NCGC00163413-01; NCGC00163413-02; NCGC00163413-03; NCGC00163413-07; MS-24104; NCI60_003767; CS-0008781; C08532; Q420314; BRD-K64909280-001-02-7; 3,12-[methylenebis(oxy)]-galanthan-1.alpha.,2.beta.-diol; Galanthan-1, 3,12-didehydro-9,10-[methylenebis(oxy)]-, (1.alpha.,2.beta.)-; Galanthan-1, 3,4-didehydro-11,12-[methylenebis(oxy)]-, (1.alpha.,2.beta.)-; (1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.0?,??.0?,?.0??,??]nonadeca-2,4(8),9,15-tetraene-17,18-diol; (1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol; 1H-[1,3]Dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol, 2,4,5,7,12b,12c-hexahydro-, (1S,2S,12bS,12cS)-; 2,4,5,7,12b,12c-Hexahydro-1H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol, (1S,2S,12bS, 12cS)-; 2,5,7,12b,12c-Hexahydro-1H-[1,3]-dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridine-1,2-diol; 3KD	D0MI0Q	DML9W2V	287.31	C16H17NO4	62.2	481	0	21	2	5	0	InChI=1S/C16H17NO4/c18-11-3-8-1-2-17-6-9-4-12-13(21-7-20-12)5-10(9)14(15(8)17)16(11)19/h3-5,11,14-16,18-19H,1-2,6-7H2/t11-,14-,15+,16+/m0/s1	C1CN2CC3=CC4=C(C=C3[C@H]5[C@H]2C1=C[C@@H]([C@H]5O)O)OCO4	C1CN2CC3=CC4=C(C=C3C5C2C1=CC(C5O)O)OCO4	XGVJWXAYKUHDOO-DANNLKNASA-N	(1S,17S,18S,19S)-5,7-dioxa-12-azapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-2,4(8),9,15-tetraene-17,18-diol
ferrodrug0141	Xanthohumol	.	Xanthohumol; 6754-58-1; 569-83-5; 1-(2,4-Dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; Xantho-flav; (E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; T4467YT1NT; CHEBI:66331; Xanthohumol(Random Configuration); 2',4,4'-trihydroxy-6'-methoxy-3'-prenylchalcone; 1-(2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-2-propen-1-one; (2E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one; (2E)-1-(2,4-DIHYDROXY-6-METHOXY-3-(3-METHYL-2-BUTEN-1-YL)PHENYL)-3-(4-HYDROXYPHENYL)-2-PROPEN-1-ONE; (E)-1-(2,4-Dihydroxy-6-methoxy-3-(3-methylbut-2-en-1-yl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; (E)-1-(2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl)-3-(4-hydroxyphenyl)prop-2-en-1-one; 2-Propen-1-one, 1-(2,4-hydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl)-3-(4-hydroxyphenyl)-, (E)-; UNII-T4467YT1NT; MFCD00210576; (2E)-1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one; Xanthohumol from hop (Humulus lupulus); XANTHOHUMOL [INCI]; SCHEMBL143683; CHEMBL253896; MEGxp0_000104; Xanthohumol(RandomConfiguration); ACon1_001634; CHEBI:94745; DTXSID00893171; ORXQGKIUCDPEAJ-YRNVUSSQSA-N; HMS3886H19; BCP18498; BDBM50384998; LMPK12120294; s7889; AKOS016010098; AKOS040762512; CCG-268086; DB15359; (E)-1-[2,4-Dihydroxy-6-methoxy-3-(3-methyl-2-butenyl)phenyl]-3-(4-hydroxyphenyl)propenone; SMP2_000278; NCGC00180304-01; AC-31276; BS-17392; X0068; A867246; Q408088; BRD-K77390737-001-01-6; Q27166535; Xanthohumol, primary pharmaceutical reference standard; Xanthohumol from hop (Humulus lupulus), >=96% (HPLC); 1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)-2-propen-1-one; 2-Propen-1-one, 1-[2,4-dihydroxy-6-methoxy-3-(3-methyl-2-buten-1-yl)phenyl]-3-(4-hydroxyphenyl)-, (2E)-; InChI=1/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7	.	.	354.4	C21H22O5	87	515	5.1	26	3	5	6	InChI=1S/C21H22O5/c1-13(2)4-10-16-18(24)12-19(26-3)20(21(16)25)17(23)11-7-14-5-8-15(22)9-6-14/h4-9,11-12,22,24-25H,10H2,1-3H3/b11-7+	CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)/C=C/C2=CC=C(C=C2)O)O)C	CC(=CCC1=C(C(=C(C=C1O)OC)C(=O)C=CC2=CC=C(C=C2)O)O)C	ORXQGKIUCDPEAJ-YRNVUSSQSA-N	(E)-1-[2,4-dihydroxy-6-methoxy-3-(3-methylbut-2-enyl)phenyl]-3-(4-hydroxyphenyl)prop-2-en-1-one
ferrodrug0142	Dexrazoxane	.	Dexrazoxane; 24584-09-6; Zinecard; (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione); Cardioxane; ICRF-187; Dextrorazoxane; Dexrazoxanum; Dexrazoxano; Dexrazoxanum [INN-Latin]; Dexrazoxano [INN-Spanish]; ADR-529; Desrazoxane; Eucardion; (+)-(S)-4,4'-Propylenedi-2,6-piperazinedione; 4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione; ADR 529; ICRF 187; Razoxane, d-; Razoxane, (s)-; Dexrazone; (+)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; NSC-169780; CHEBI:50223; Razoxanum [INN-Latin]; Razoxana [INN-Spanish]; dyzoxane; DTXSID3040647; 2,6-Piperazinedione, 4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; NSC 169780; (S)-(+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 048L81261F; 4-[(2S)-1-(3,5-dioxopiperazin-1-yl)propan-2-yl]piperazine-2,6-dione; (S)-1,2-Bis(3,5-dioxo-1-piperazinyl)propane; DTXCID1020647; (+)-dexrazoxane; CAS-24584-09-6; 2,6-Piperazinedione, 4,4'-(1-methyl-1,2-ethanediyl)bis-, (+)-; HSDB 7319; (+)-1,2-Bis(3,5-dioxopiperazin-1-yl)propane; 2,6-Piperazinedione, 4,4'-propylenedi-, (+)-; SR-01000883995; NSC169780; BRN 5759131; Soluble ICRF (L-isosomer); Dexrazoxane [USAN:INN:BAN]; CCRIS 9394; UNII-048L81261F; NCGC00164737-01; Dexrazoxane- Bio-X; MFCD00866449; DEXRAZOXANE [INN]; DEXRAZOXANE [JAN]; DEXRAZOXANE [HSDB]; DEXRAZOXANE [USAN]; DEXRAZOXANE [VANDF]; CHEMBL1738; DEXRAZOXANE [MART.]; SCHEMBL18400; DEXRAZOXANE [WHO-DD]; MLS006010158; BIDD:GT0068; Dexrazoxane (JAN/USAN/INN); DEXRAZOXANE [EMA EPAR]; 4,4'-(2S)-propane-1,2-diyldipiperazine-2,6-dione; GTPL7330; Dexrazoxane, >=95% (HPLC); (S)-4,4'-(Propane-1,2-diyl)-bis(piperazine-2,6-dione); RAZOXANE (+)-FORM [MI]; AMY39004; HY-B0581; Tox21_112256; 2, 4,4'-propylenedi-, (+)-; BDBM50586360; s5651; AKOS015896392; Tox21_112256_1; (+)-1,5-dioxopiperazin-1-yl)propane; CCG-267131; DB00380; DS-1394; NCGC00263544-01; NCGC00263544-02; BD164365; Dexrazoxane, analytical reference material; NCI60_001367; SMR002529680; (S)-(+)-1,5-dioxopiperazin-1-yl)propane; D4227; D03730; AB01273932-01; AB01273932-02; AB01273932_03; EN300-7356981; 2,4,4'-[(1S)-1-methyl-1,2-ethanediyl]bis-; A817380; Q524995; 2,4,4'-(1-methyl-1,2-ethanediyl)bis-, (S)-; J-015579; J-520219; SR-01000883995-1; SR-01000883995-2; SR-01000883995-5; (S)-4,4'-(propane-1,2-diyl)dipiperazine-2,6-dione; BRD-K07265709-003-01-5; 4,4'-[(2S)-1,2-Propanediyl]di(2,6-piperazinedione); 4,4'-[(1S)-1-Methyl-1,2-ethanediyl]bis-2,6-piperazinedione; 6-hydroxy-4-[(2S)-2-(5-hydroxy-3-oxo-1,2,3,6-tetrahydropyrazin-1-yl)propyl]-2,3,4,5-tetrahydropyrazin-2-one	.	.	268.27	C11H16N4O4	98.8	404	-1.4	19	2	6	3	InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1	C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2	CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2	BMKDZUISNHGIBY-ZETCQYMHSA-N	4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione
ferrodrug0143	L-Homocysteine	Small molecular drug	L-Homocysteine; homocysteine; 6027-13-0; (s)-2-amino-4-mercaptobutanoic acid; (2S)-2-amino-4-sulfanylbutanoic acid; 2-AMINO-4-MERCAPTO-BUTYRIC ACID; CHEBI:17588; L-2-Amino-4-mercaptobutyric acid; 0LVT1QZ0BA; CHEMBL469662; Hcy; homo-cys; 454-28-4; Homocysteine, L-; Butyric acid, 2-amino-4-mercapto-; MFCD00151320; HCS; Homocysteine (VAN); UNII-0LVT1QZ0BA; (S)-2-Amino-4-mercaptobutyric acid; 2-amino-4-sulfanylbutanoate; NSC-43117; NSC-118376; EINECS 227-891-0; NSC 43117; H-Hcys-OH; NSC 118376; 2-Amino-4-mercaptobutyric acid (VAN); Butyric acid, 2-amino-4-mercapto-, L-; (S)-HOMOCYSTEINE; Butanoic acid, 2-amino-4-mercapto- (VAN); HOMOCYSTEINE [MI]; Butanoic acid, 2-amino-4-mercapto-, (S)-; Epitope ID:143650; SCHEMBL35837; 2-amino-4-mercapto-Butanoate; GTPL5198; DTXSID3041039; 2-amino-4-mercapto-DL-Butyrate; 2-amino-4-mercapto-Butanoic acid; FFFHZYDWPBMWHY-VKHMYHEASA-N; (S)-2-amino-4-mercapto-Butanoate; L-2-amino-4-mercapto-Butyric acid; (s)-2-amino-4-mercaptobutanoicacid; 2-amino-4-mercapto-DL-Butyric acid; BDBM50242405; DL-2-amino-4-mercapto-Butyric acid; L-Homocysteine, >=98.0% (NT); AKOS006272166; (S)-2-amino-4-mercapto-Butanoic acid; CS-W011063; DB04422; FS-6405; HY-W010347; C00155; H-2800; I11579; A832662; Q26992833	.	DG01805	135.19	C4H9NO2S	64.3	86.1	-3.4	8	3	4	3	InChI=1S/C4H9NO2S/c5-3(1-2-8)4(6)7/h3,8H,1-2,5H2,(H,6,7)/t3-/m0/s1	C(CS)[C@@H](C(=O)O)N	C(CS)C(C(=O)O)N	FFFHZYDWPBMWHY-VKHMYHEASA-N	(2S)-2-amino-4-sulfanylbutanoic acid
ferrodrug0144	Cucurbitacin B	Small molecular drug	Cucurbitacin B; 6199-67-3; Amarine; Datisca principle B; DATISCACIN; Datiscn Principle B; (+)-Cucurbitacin B; Cucurbitacine B; 1,2-Dihydro-alpha-elaterin; UNII-0115W5MABF; 0115W5MABF; CHEBI:3941; CUCURBITACIN R - DATISCA PRINCIPLE B; HSDB 3476; NSC49451; NSC 49451; NSC-49451; NSC 144154; NSC-144154; Cucurbitacin B hydrate; (R,E)-6-((2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-17-yl)-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; [(E,6R)-6-[(2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate; C32H46O8; Cucurbitacine (B); Cucurbitacin-B; Cuc B; 25-(Acetyloxy)-2,16,20-trihydroxy-9-methyl-19-norlanosta-5,23-diene-3,11,22-trione; 19-Nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 2beta,16alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-; 19-Norlanosta-5,23-diene-3,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2beta,9beta,10alpha,16alpha,23E)-; MLS002702988; 19-nor-9.beta.,23-diene-3,11,22-trione, 9-methyl-2.beta.,16.alpha.,20,25-tetrahydroxy-, 25-acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, (2.beta.,9.beta.,10.alpha.,16.alpha.,23E)-; CUCURBITACIN B [MI]; CUCURBITACIN B [INCI]; SCHEMBL231815; CHEMBL508185; GTPL12432; DTXSID501316196; 19-Nor-9-beta,10-alpha-lanosta-5,23-diene-3,11,22-trione, 2-beta,16-alpha,20,25-tetrahydroxy-9-methyl-, 25-acetate; HY-N0416; LMST01010104; MFCD07778083; NSC144154; s8165; AKOS015897085; 1,2-DIHYDRO-.ALPHA.-ELATERIN; CCG-270043; CS-3816; AC-34283; Cucurbitacin B hydrate, >=97% (HPLC); C3442; C08794; A924078; Q-100715; Q27106259; (2.BETA.,9.BETA.,10.ALPHA.,16.ALPHA.,23E)-25-(ACETYLOXY)-2,16,20-TRIHYDROXY-9-METHYL-19-NORLANOSTA-5,23-DIENE-3,11,22-TRIONE; (2beta,9beta,10alpha,16alpha,23E)-25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-19-Norlanosta-5,23-diene-3,11,22-trione; (2S,4R,23E)-2,16beta,20-trihydroxy-9beta,10,14-trimethyl-1,11,22-trioxo-4,9-cyclo-9,10-secocholesta-5,23-dien-25-yl acetate; (3E,6R)-6-[(1R,2R,4S,10S,11S,13R,14R,15R)-4,13-dihydroxy-1,6,6,11,15-pentamethyl-5,17-dioxotetracyclo[8.7.0.0?,?.0??,??]heptadec-7-en-14-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl acetate; 19-Norlanosta-5,11,22-trione, 25-(acetyloxy)-2,16,20-trihydroxy-9-methyl-, [2.beta.,.gamma.,.beta.,10.alpha.,16.alpha.]-; 2beta,16alpha,20,25-tetrahydroxy-9-methyl-19-nor-9beta,10alpha-lanosta-5,23-diene-3,11,22-trione, 25-acetate; 2beta,16alpha,20,25-tetrahydroxy-9-methyl-3,11,22-trioxo-19-nor-9beta,10alpha-lanosta-5,23-dien-25-yl acetate	.	DG00353	558.7	C32H46O8	138	1210	2.6	40	3	8	6	InChI=1S/C32H46O8/c1-17(33)40-27(2,3)13-12-23(36)32(9,39)25-21(35)15-29(6)22-11-10-18-19(14-20(34)26(38)28(18,4)5)31(22,8)24(37)16-30(25,29)7/h10,12-13,19-22,25,34-35,39H,11,14-16H2,1-9H3/b13-12+/t19-,20+,21-,22+,25+,29+,30-,31+,32+/m1/s1	CC(=O)OC(C)(C)/C=C/C(=O)[C@@](C)([C@H]1[C@@H](C[C@@]2([C@@]1(CC(=O)[C@@]3([C@H]2CC=C4[C@H]3C[C@@H](C(=O)C4(C)C)O)C)C)C)O)O	CC(=O)OC(C)(C)C=CC(=O)C(C)(C1C(CC2(C1(CC(=O)C3(C2CC=C4C3CC(C(=O)C4(C)C)O)C)C)C)O)O	IXQKXEUSCPEQRD-DKRGWESNSA-N	[(E,6R)-6-[(2S,8S,9R,10R,13R,14S,16R,17R)-2,16-dihydroxy-4,4,9,13,14-pentamethyl-3,11-dioxo-2,7,8,10,12,15,16,17-octahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-hydroxy-2-methyl-5-oxohept-3-en-2-yl] acetate
ferrodrug0145	Ropivacaine	Small molecular drug	Ropivacaine; 84057-95-4; (S)-Ropivacaine; Naropin; Ropivacaine [INN]; Ropivacaine hydrochloride; Ropivacaina; Ropivacainum; Ropivacaina [Spanish]; S-Ropivacaine; (S)-N-(2,6-Dimethylphenyl)-1-propylpiperidine-2-carboxamide; Ropivacainum [INN-Latin]; Ropivacaina [INN-Spanish]; (2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide; Ropivicaine; Ropivacaine base; (2S)-N-(2,6-dimethylphenyl)-1-propyl-piperidine-2-carboxamide; 7IO5LYA57N; (-)-1-Propyl-2',6'-pipecoloxylidide; LEA 103; CHEBI:8890; TLC590; (2S)-N-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide; TLC-590; Ropivacaine (INN); MFCD00864425; L-N-n-propylpipecolic acid-2,6-xylidide; 2-Piperidinecarboxamide, N-(2,6-dimethylphenyl)-1-propyl-, (2S)-; (S)-(-)-1-propyl-2',6'-pipecoloxylidide; 1-propyl-2',6'-pipecoloxylidide; Noropine; Narop; LEA-103 HCl; Naropin (TN); LEA-103; NCGC00164597-01; Ropivacaine [INN:BAN]; UNII-7IO5LYA57N; AL-381; ROPIVACAINE [MI]; ROPIVACAINE [VANDF]; SCHEMBL33292; ROPIVACAINE [USP-RS]; ROPIVACAINE [WHO-DD]; BIDD:GT0203; Narop; Noropine; LEA-103; GTPL7602; (-)-1-Propyl-2',6'-dimethyl-2-piperidylcarboxyanilid; CHEMBL1077896; DTXSID4040187; ZKMNUMMKYBVTFN-HNNXBMFYSA-N; HY-B0563; BBL102321; s5504; STL556120; AKOS017343283; CCG-267197; DB00296; AS-35173; CS-0009514; R0251; C07532; D08490; AB00698466-07; AB00698466_10; EN300-7436767; A840710; Q279504; (S)-(-)-1-PROPYL-2',6'-PIPECOLOXYLIDINE; Q-201677; (-)-1-propyl-2',6'-dimethyl-2-piperidylcarboxyanilide; Z2235811359; (s)-n-(2,6-dimethylphenyl)-1-propyl-2-piperidinecarboxamide; (S)-(-)-1-PROPYLPIPERIDINE-2-CARBOXYLIC ACID (2,6-DIMETHYLPHENYL)AMIDE	D09RHQ	DMSPJG2	274.4	C17H26N2O	32.299	308	2.9	20	1	2	4	InChI=1S/C17H26N2O/c1-4-11-19-12-6-5-10-15(19)17(20)18-16-13(2)8-7-9-14(16)3/h7-9,15H,4-6,10-12H2,1-3H3,(H,18,20)/t15-/m0/s1	CCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C	CCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C	ZKMNUMMKYBVTFN-HNNXBMFYSA-N	(2S)-N-(2,6-dimethylphenyl)-1-propylpiperidine-2-carboxamide
ferrodrug0146	Fingolimod	.	Fingolimod; 162359-55-9; 2-Amino-2-(4-octylphenethyl)propane-1,3-diol; 2-Amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol; Fty-720; Fingolimod [INN]; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propanediol; 2-Amino-2-[2-(4-octylphenyl)ethyl]-1,3-propandiol; 1,3-Propanediol, 2-amino-2-[2-(4-octylphenyl)ethyl]-; Gilenya (TN); 3QN8BYN5QF; 1,3-Propanediol, 2-amino-2-(2-(4-octylphenyl)ethyl)-; CHEMBL314854; CHEBI:63115; Fingolimod (INN); 2-amino-2-(2-(4-octylphenyl)ethyl)propane-1,3-diol; FTY-720A; UNII-3QN8BYN5QF; 2-amino-2-(2-(4-octylphenyl)ethyl)-1,3-propanediol; fingolimodum; Fingolimod- Bio-X; FINGOLIMOD [MI]; FINGOLIMOD [VANDF]; FINGOLIMOD [MART.]; SCHEMBL7445; FINGOLIMOD [WHO-DD]; GTPL2407; FINGOLIMOD [ORANGE BOOK]; DTXSID40167363; KKGQTZUTZRNORY-UHFFFAOYSA-N; HMS3743O13; AMY22173; BCP05969; BDBM50158336; NSC755643; s5950; STL445699; AKOS015999594; DB05286; DB08868; NSC-755643; NCGC00188399-01; NCGC00188399-03; NCGC00188399-04; NCGC00188399-06; NCGC00188399-16; AC-25899; AS-68987; BF164460; HY-11063; FT-0660847; 2-(4-octylphenethyl)-2-aminopropane-1,3-diol; D10001; D70458; 2-amino-2-(4-octylphenyl)ethylpropane-1,3-diol; EN300-18802383; Q425137; 2-amino-2-hydroxymethyl-4-(4-(octyl)phenyl)butanol; BRD-K88025533-003-01-7; 2-Amino-2-[2-(4-octyl-phenyl)-ethyl]-propane-1,3-diol	.	.	307.5	C19H33NO2	66.5	258	4.2	22	3	3	12	InChI=1S/C19H33NO2/c1-2-3-4-5-6-7-8-17-9-11-18(12-10-17)13-14-19(20,15-21)16-22/h9-12,21-22H,2-8,13-16,20H2,1H3	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N	CCCCCCCCC1=CC=C(C=C1)CCC(CO)(CO)N	KKGQTZUTZRNORY-UHFFFAOYSA-N	2-amino-2-[2-(4-octylphenyl)ethyl]propane-1,3-diol
ferrodrug0147	Ginsenoside Rg3	.	Ginsenoside Rg3; 14197-60-5; 20(S)-Ginsenoside Rg3; (20S)-Propanaxadiol; 20s-ginsenoside rg3; 20S-propanaxadiol; (20S)-ginsenoside Rg3; S-Ginsenoside Rg3; 20(S)-Ginsenoside-Rg3; 20(S)-Propanaxidiol; CHEMBL398412; CHEBI:67991; 227D367Y57; (2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol; 11019-45-7; Rg3; ginsenoside 20-rg3; ginsenoside rg3, (s)-; ginsenoside rg3, (+)-; 20(S)-Propanaxadiol;S-ginsenoside Rg3; UNII-227D367Y57; MFCD06410950; (R)Ginsenoside-Rg3; Ginsenoside Rg3,(S); GTPL7658; GINSENOSIDE RG3 [WHO-DD]; RWXIFXNRCLMQCD-JBVRGBGGSA-N; DTXSID101316982; GLXC-19139; HMS3886B14; BDBM50317537; Ginsenoside Rg3, analytical standard; s9022; Ginsenoside Rg3, >=98% (HPLC); AKOS037514674; CCG-270472; (3beta,12beta)-12,20-dihydroxydammar-24-en-3-yl 2-O-beta-D-glucopyranosyl-beta-D-glucopyranoside; AS-56617; Dammar-24-ene-12-beta,20-diol, 3-beta-((2-O-beta-D-glucopyranosyl-beta-D-glucopyransoyl)oxy)-; C20778; Q-100154; Q27077807; .BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,12.BETA.)-12,20-DIHYDROXYDAMMAR-24-EN-3-YL 2-O-.BETA.-D-GLUCOPYRANOSYL-; 3-O-.BETA.-D-GLUCOPYRANOSYL-(1->2)-.BETA.-D-GLUCOPYRANOSYLDAMMAR-24-ENE-3.BETA.,12.BETA.,20S-TRIOL; dammar-24-ene-12beta,20-diol, 3-beta-((2-O-beta-D-glucopyranosyl-beta-D-glucopyransoyl)oxy)-	.	.	785	C42H72O13	219	1370	4	55	9	13	10	InChI=1S/C42H72O13/c1-21(2)10-9-14-42(8,51)22-11-16-41(7)29(22)23(45)18-27-39(5)15-13-28(38(3,4)26(39)12-17-40(27,41)6)54-37-35(33(49)31(47)25(20-44)53-37)55-36-34(50)32(48)30(46)24(19-43)52-36/h10,22-37,43-51H,9,11-20H2,1-8H3/t22-,23+,24+,25+,26-,27+,28-,29-,30+,31+,32-,33-,34+,35+,36-,37-,39-,40+,41+,42-/m0/s1	CC(=CCC[C@@](C)([C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)C)C)O)C)O)C	CC(=CCCC(C)(C1CCC2(C1C(CC3C2(CCC4C3(CCC(C4(C)C)OC5C(C(C(C(O5)CO)O)O)OC6C(C(C(C(O6)CO)O)O)O)C)C)O)C)O)C	RWXIFXNRCLMQCD-JBVRGBGGSA-N	(2S,3R,4S,5S,6R)-2-[(2R,3R,4S,5S,6R)-4,5-dihydroxy-2-[[(3S,5R,8R,9R,10R,12R,13R,14R,17S)-12-hydroxy-17-[(2S)-2-hydroxy-6-methylhept-5-en-2-yl]-4,4,8,10,14-pentamethyl-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-yl]oxy]-6-(hydroxymethyl)oxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol
ferrodrug0148	Sulforaphane	.	sulforaphane; 4478-93-7; DL-Sulforaphane; 1-Isothiocyanato-4-(methylsulfinyl)butane; D,L-Sulforaphane; Sulforafan; 1-Isothiocyanato-4-(methylsulfinyl)-butane; 1-isothiocyanato-4-methylsulfinylbutane; Butane, 1-isothiocyanato-4-(methylsulfinyl)-; 4-Methylsulfinylbutyl isothiocyanate; (+/-)-sulforaphane; CHEBI:47807; 41684WL1GL; 4-(Methylsulfinyl)Butyl Isothiocyanate; NSC-749790; (S)-1-Isothiocyanato-4-(methylsulfinyl)butane; R,S-Sulforaphane; Sulphoraphane; sulforaphane, (R)-; SFN; C6H11NOS2; CCRIS 7221; Sulforathane; UNII-41684WL1GL; S)-Sulforaphane; CHEMBL48802; SCHEMBL105202; GTPL6569; DTXSID8036732; SULFORAPHANE, (+/-)-; HMS3746M17; BCP31547; 4-Methylsulfinyl butyl isothiocyanate; BDBM50073654; MFCD00198068; NSC749790; s5771; 4-isothiocyanatobutyl methyl sulfoxide; AKOS006282481; CS-7809; NSC 749790; 4-(Methylsulfinyl)-butyl isothiocyanate; SULFORAPHANE (+/-)-FORM [MI]; 1-isothiocyanato-4-methylsulfinyl-butane; AC-34421; HY-13755; 1-Isothiocyanato-4-(methylsulfinyl)butane #; FT-0674748; FT-0674749; FT-0674750; FT-0674751; U0142; F17072; A912495; Q424489; DL-Sulforaphane, >=90% (HPLC), synthetic, liquid; Q-100160; BRD-A58955223-001-02-0; ISOTHIOCYANIC ACID, 4-(METHYLSULFINYL)BUTYL ESTER; Z1198151975; (R)-Sulforaphane;(-)-Sulforaphane;4-Methylsulfinylbutyl isothiocyanate	.	.	177.3	C6H11NOS2	80.7	152	1.4	10	0	4	5	InChI=1S/C6H11NOS2/c1-10(8)5-3-2-4-7-6-9/h2-5H2,1H3	CS(=O)CCCCN=C=S	CS(=O)CCCCN=C=S	SUVMJBTUFCVSAD-UHFFFAOYSA-N	1-isothiocyanato-4-methylsulfinylbutane
ferrodrug0149	Gingerol	Small molecular drug	6-Gingerol; gingerol; 23513-14-6; [6]-Gingerol; (6)-Gingerol; (S)-(+)-[6]Gingerol; (S)-(6)-Gingerol; (S)-5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one; (5S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one; 1391-73-7; (+)-[6]-Gingerol; (5S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone; 3-Decanone, 5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-, (5S)-; UNII-925QK2Z900; CHEBI:10136; (+)-5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone; 925QK2Z900; C17-H26-O4; (S)-5-Hydroxy-1-(4-hydroxy-3-methoxyphenyl)-3-decanone; CHEMBL402978; (5S)-5-Hydroxy-1-(4-hydroxy-3-methoxy-phenyl)decan-3-one; 3-Decanone, 5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-, (S)-; 3-Decanone, 5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)-, (S)-(+)-; 5-Hydroxy-1-(4'-hydroxy-3'-methoxyphenyl)-3-decanone; BDBM50317427; (S)-(+)-[6]Gingerol;6-Gingerol; MFCD00210507; CBiol_001786; SCHEMBL32102; BSPBio_001347; KBioGR_000067; KBioSS_000067; (6)-GINGEROL [MI]; CHEMBL446043; GTPL2428; DTXSID3041035; KBio2_000067; KBio2_002635; KBio2_005203; KBio3_000133; KBio3_000134; Bio1_000072; Bio1_000561; Bio1_001050; Bio2_000067; Bio2_000547; HMS1361D09; HMS1791D09; HMS1989D09; HMS3402D09; SRCG-00265; [6]-Gingerol, analytical standard; BDBM50275147; CA-422; s3836; [6]-Gingerol, >=98% (HPLC); AKOS015888215; CCG-208033; CCG-208214; CS-6333; IDI1_033817; NCGC00163131-01; NCGC00163131-02; NCGC00163131-03; AC-33934; DS-12369; HY-14615; 6-GINGEROL (CONSTITUENT OF GINGER); C10462; 6-GINGEROL (CONSTITUENT OF GINGER) [DSC]; A816759; Q421081; SR-05000002341; Q-100300; SR-05000002341-2; W-205525; BRD-K26117720-001-02-2; (S)-5-Hydroxy-1-(4-hydroxy-3-methoxy-phenyl-3-decanone; [1-(4''-hydroxy-3''-methoxyphenyl)-5-hydroxy-3-decanone]	D0Y1YR	DMNXYSM	294.4	C17H26O4	66.8	293	2.5	21	2	4	10	InChI=1S/C17H26O4/c1-3-4-5-6-14(18)12-15(19)9-7-13-8-10-16(20)17(11-13)21-2/h8,10-11,14,18,20H,3-7,9,12H2,1-2H3/t14-/m0/s1	CCCCC[C@@H](CC(=O)CCC1=CC(=C(C=C1)O)OC)O	CCCCCC(CC(=O)CCC1=CC(=C(C=C1)O)OC)O	NLDDIKRKFXEWBK-AWEZNQCLSA-N	(5S)-5-hydroxy-1-(4-hydroxy-3-methoxyphenyl)decan-3-one
ferrodrug0150	Etomidate	.	Etomidate; 33125-97-2; Hypnomidate; (+)-Etomidate; Amidate; D-Etomidate; Etomidato; Etomidatum; (R)-ETHYL 1-(1-PHENYLETHYL)-1H-IMIDAZOLE-5-CARBOXYLATE; ethyl 1-[(1R)-1-phenylethyl]-1H-imidazole-5-carboxylate; Radenarcon; R 16659; (+)-Ethyl 1-(alpha-methylbenzyl)imidazole-5-carboxylate; ethyl (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylate; R-(+)-Ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate; CHEMBL681; (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; (R)-(+)-1-(alpha-Methylbenzyl)imidazole-5-carboxylic acid ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-[(1R)-1-phenylethyl]-, ethyl ester; Amidate (pharmaceutical); Etomidic acid; CHEBI:4910; NSC-759160; 3-((R)-1-Phenyl-ethyl)-3H-imidazole-4-carboxylic acid ethyl ester; Z22628B598; 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (R)- [CAS]; (d)-Etomidate; ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate; Etomidatum [INN-Latin]; Etomidato [INN-Spanish]; (R)-(+)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylic Acid Ethyl Ester; 1H-Imidazole-5-carboxylic acid, 1-((1R)-1-phenylethyl)-, ethyl ester; 1H-Imidazole-5-carboxylic acid, 1-(1-phenylethyl)-, ethyl ester, (+)-; SMR000466277; Amidate (TN); 1-(1-Phenylethyl)-1H-imidazole-5-carboxylic acid ethyl ester; DTXSID5023033; Etomidate [USAN:USP:INN:BAN]; UNII-Z22628B598; R(+)-etomidate; V8D; EINECS 251-385-9; R-ETOMIDATE; BRN 0665833; Etomidate (USP/INN); ETOMIDATE [INN]; ETOMIDATE [MI]; ETOMIDATE [USAN]; 1-(alpha-Methylbenzyl)-1H-imidazole-5-carboxylic acid ethyl ester; ETOMIDATE [VANDF]; ETOMIDATE [MART.]; ETOMIDATE [USP-RS]; ETOMIDATE [WHO-DD]; (+)-Ethyl 1-(.alpha.-methylbenzyl)imidazole-5-carboxylate; SCHEMBL39487; MLS000758268; MLS001424163; GTPL5463; ETOMIDATE [ORANGE BOOK]; ETOMIDATE [EP MONOGRAPH]; ETOMIDATE [USP MONOGRAPH]; Etomidate 0.1 mg/ml in Methanol; Etomidate 1.0 mg/ml in Methanol; Imidazole-5-carboxylic acid, 1-(.alpha.-methylbenzyl)-, ethyl ester, (R)-(+)-; 1-(1-Phenylethyl)-imidazole-5-carboxylic acid, ethyl ester; HMS2051P18; HMS2232A08; HMS3267N06; HMS3412D11; HMS3676D11; HY-B0100; Etomidate, >98% (HPLC), powder; BDBM50125935; MFCD00869295; AKOS015920052; CCG-101054; CS-1833; DB00292; GS-3208; NC00304; NSC 759160; NCGC00025176-01; AM803710; E0897; C07522; D00548; AB00639951_06; EN300-1074318; Q418445; R-16659; SR-01000597569; Q-201102; SR-01000597569-1; BRD-K55055802-001-10-2; Z1741976844; Etomidate, European Pharmacopoeia (EP) Reference Standard; r-(+)-ethyl-1-(1-phenylethyl)-1h-imidazole-5-carboxylate; Ethyl (R)-(+)-1-(1-Phenylethyl)-1H-imidazole-5-carboxylate; Etomidate, United States Pharmacopeia (USP) Reference Standard; (R)-1-(1-phenylethyl)-1H-imidazole-5-carboxylicacid ethyl ester; Imidazole-5-carboxylic acid, 1-(alpha-methylbenzyl)-, ethyl ester, (R)-(+)-	.	.	244.29	C14H16N2O2	44.1	277	3	18	0	3	5	InChI=1S/C14H16N2O2/c1-3-18-14(17)13-9-15-10-16(13)11(2)12-7-5-4-6-8-12/h4-11H,3H2,1-2H3/t11-/m1/s1	CCOC(=O)C1=CN=CN1[C@H](C)C2=CC=CC=C2	CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2	NPUKDXXFDDZOKR-LLVKDONJSA-N	ethyl 3-[(1R)-1-phenylethyl]imidazole-4-carboxylate
ferrodrug0151	Micafungin	.	Micafungin; 235114-32-6; Mycamine; Micafungin [INN]; UNII-R10H71BSWG; R10H71BSWG; CHEBI:600520; FK-463; Micafungin (INN); Mycamine(TM); Pneumocandin A0, 1-((4R,5R)-4,5-dihydroxy-N2-(4-(5-(4-(pentyloxy)phenyl)-3-isoxazolyl)benzoyl]-L-ornithine)-4-((4S)-4-hydroxy-4-(4-hydroxy-3-(sulfooxy)phenyl)-L-threonine)-; FK463; MICAFUNGIN [MI]; MICAFUNGIN [JAN]; MICAFUNGIN [VANDF]; MICAFUNGIN [WHO-DD]; MICAFUNGIN [EMA EPAR]; CHEMBL457547; SCHEMBL11893279; PIEUQSKUWLMALL-YABMTYFHSA-N; BDBM50478216; DB01141; D08218; EN300-19634541; J-015136; Q6827850; [5-[(1S,2S)-2-[[(1R)-3-amino-1-hydroxy-3-oxo-propyl]-tetrahydroxy-[(1R)-1-hydroxyethyl]-methyl-hexaoxo-[[4-[5-(4-pentoxyphenyl)isoxazol-3-yl]benzoyl]amino][?]yl]-1,2-dihydroxy-ethyl]-2-hydroxy-phenyl] hydrogen sulfate; 5.1:6-anhydro{(4R,5R)-4,5-dihydroxy-N(2)-(4-{5-[4-(pentyloxy)phenyl]isoxazol-3-yl}benzoyl)-L-ornithyl-L-threonyl-(4R)-4-hydroxy-L-prolyl-(4S)-4-hydroxy-4-[4-hydroxy-3-(sulfooxy)phenyl]-L-threonyl-(3R)-3-hydroxy-L-glutaminyl-(3S,4S)-3-hydroxy-4-methyl-L-proline}; PNEUMOCANDIN A0, 1-((4R,5R)-4,5-DIHYDROXY-N(SUP 2)-(4-(5-(4-(PENTYLOXY)PHENYL)-3-ISOXAZOLYL)BENZOYL)-L-ORNITHINE)-4-((4S)-4-HYDROXY-4-(4-HYDROXY-3-(SULFOOXY)PHENYL)-L-THREONINE)-	.	.	1270.3	C56H71N9O23S	519	2580	-1.6	89	16	24	18	InChI=1S/C56H71N9O23S/c1-4-5-6-17-86-32-14-11-28(12-15-32)39-21-33(63-87-39)27-7-9-29(10-8-27)49(75)58-34-20-38(70)52(78)62-54(80)45-46(72)25(2)23-65(45)56(82)43(37(69)22-41(57)71)60-53(79)44(48(74)47(73)30-13-16-36(68)40(18-30)88-89(83,84)85)61-51(77)35-19-31(67)24-64(35)55(81)42(26(3)66)59-50(34)76/h7-16,18,21,25-26,31,34-35,37-38,42-48,52,66-70,72-74,78H,4-6,17,19-20,22-24H2,1-3H3,(H2,57,71)(H,58,75)(H,59,76)(H,60,79)(H,61,77)(H,62,80)(H,83,84,85)/t25-,26+,31+,34-,35-,37+,38+,42-,43-,44-,45-,46-,47-,48-,52+/m0/s1	CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)[C@@H](CC(=O)N)O)C)O)O)O	CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O	PIEUQSKUWLMALL-YABMTYFHSA-N	[5-[(1S,2S)-2-[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-3-[(1R)-3-amino-1-hydroxy-3-oxopropyl]-11,20,21,25-tetrahydroxy-15-[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[5-(4-pentoxyphenyl)-1,2-oxazol-3-yl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-6-yl]-1,2-dihydroxyethyl]-2-hydroxyphenyl] hydrogen sulfate
ferrodrug0152	Methyl vinyl ketone	Small molecular drug	METHYL VINYL KETONE; 3-Buten-2-one; but-3-en-2-one; 78-94-4; Butenone; Vinyl methyl ketone; Methylene acetone; 2-Butenone; Methylvinylketon; Acetyl ethylene; 1-Buten-3-one; 3-Butene-2-one; Methyl ethenyl ketone; Methylvinyl ketone; Methylvinylketone; 3-Butenone-2; Acetone, methylene-; Ketone, methyl vinyl; gamma-Oxo-alpha-butylene; Methyl-vinyl-cetone; 3-oxo-1-butene; but-1-en-3-one; methylvinylcetone; 3-Oxobutene; NSC 4853; UN1251; CHEBI:48058; Delta(3)-2-butenone; CH2=CHCOCH3; 25038-87-3; AR7642I1MP; CHEMBL1600824; DTXSID3025671; NSC-4853; Methgl vinyl ketone; Methylvinylketon [German]; delta(sup 3)-2-Butenone; Methyl-vinyl-cetone [French]; CCRIS 3423; HSDB 716; EINECS 201-160-6; UNII-AR7642I1MP; AI3-16048; 3-butenone; methyl vinylketone; methyl-vinylketone; methylvinyl-ketone; but-3-enone; buten-2-one; g-oxo-a-Butylene; metyl vinyl ketone; 3-oxo-l-butene; methly vinyl ketone; methyl-vinyl-ketone; 1-butene-3-one; 3-Butenen-2-one; 1-Propen-3-one; MFCD00008777; 3-oxo-but-1-ene; EC 201-160-6; .DELTA.3-2-BUTENONE; .gamma.-Oxo-.alpha.-butylene; DTXCID205671; Methyl vinyl ketone, stabilized; WLN: 1V1U1; METHYL VINYL KETONE [MI]; NSC4853; BCP24759; Tox21_200363; BDBM50245462; LMFA12000018; STL299803; .DELTA.-OXO-.ALPHA.-BUTYLENE; AKOS000120352; UN 1251; UN-1251; CAS-78-94-4; NCGC00091118-01; NCGC00091118-02; NCGC00257917-01; M0460; 3-Buten-2-one, purum, >=95.0% (GC); EN300-19794; C20701; F71092; M-6580; Q417525; InChI=1/C4H6O/c1-3-4(2)5/h3H,1H2,2H; Methyl vinyl ketone, stabilized [UN1251] [Poison]; 3-Buten-2-one, contains 0.3-1.0% hydroquinone as stabilizer, technical grade, 90%; 3-Buten-2-one, contains 0.5% hydroquinone and 0.1% acetic acid as stabilizer, 99%	.	DMUH4N7	70.09	C4H6O	17.1	54.7	0.5	5	0	1	1	InChI=1S/C4H6O/c1-3-4(2)5/h3H,1H2,2H3	CC(=O)C=C	CC(=O)C=C	FUSUHKVFWTUUBE-UHFFFAOYSA-N	but-3-en-2-one
ferrodrug0153	Dehydroabietic acid	.	DEHYDROABIETIC ACID; Dehydroabietate; 1740-19-8; Abieta-8,11,13-trien-18-oic acid; Abietic acid, dehydro-; (-)-Dehydroabietic acid; 13-Isopropylpodocarpa-8,11,13-trien-15-oic acid; NSC 2952; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R,4aS,10aR)-; CHEBI:29571; 0S5XP6S3AU; Podocarpa-8,11,13-trien-15-oic acid, 13-isopropyl-; NSC2952; Isopropyl podocarpa-8,11,13-trien-15-oic acid; NSC-2952; 6980-63-8; abieta-8(14),9(11),12-trien-18-oic acid; EINECS 217-102-8; UNII-0S5XP6S3AU; BRN 2059290; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, (1R-(1alpha,4abeta,10aalpha))-; 4-09-00-02389 (Beilstein Handbook Reference); CHEMBL12850; SCHEMBL222078; DTXSID8022163; NFWKVWVWBFBAOV-MISYRCLQSA-N; Abieta-8,13-trien-18-oic acid; AMY22483; HY-N6869; (+)-Dehydroabietic acid, tech grade; BDBM50143600; MFCD09839012; AKOS015917291; CS-W012130; LMPR0104050005; (1R-(1alpha,4Abeta,10aalpha))-1,2,3,4,4a,9,10,10a-octahydro-7-isopropyl-1,4a-dimethylphenanthren-1-carboxylic acid; AC-34629; Dehydroabietic acid, >=95% (LC/MS-ELSD); FT-0633812; S3226; 13-Isopropylpodocarpa-8,13-trien-15-oic acid; EN300-6730478; A881721; Podocarpa-8,13-trien-15-oic acid, 13-isopropyl-; W-107855; Q27110153; 5-Podocarpa-8,11,13-trien-15-oic acid, 13-isopropyl-; (1R,4aS,10aR)-1,4a-dimethyl-7-(propan-2-yl)-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid; (1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid; (1R-(1ALPHA,4ABETA,10AALPHA))-1,2,3,4,4A,9,10,10A-OCTAHYDRO- 7-ISOPROPYL-1,4A-DIMETHYLPHENANTHREN-1-CARBOXYLIC ACID; 1,2,3,4,4a,9,10,10a-Octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenecarboxylic acid; 1,3,4,4a,9,10,10a-Octahydro-1,4a-dimethyl-7-(1-methylethyl)-1-phenanthrenecarboxylic acid; 1-PHENANTHRENECARBOXYLIC ACID, 1,2,3,4,4A,9,10,10A- OCTAHYDRO-1,4A-DIMETHYL-7-(1-METHYLETHYL)-, (1R,4AS,10AR)-; 1-Phenanthrenecarboxylic acid, 1,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, [1R-(1,4a,10a)]-; 1-Phenanthrenecarboxylic acid,2,3,4,4a,9,10,10a-octahydro-1,4a-dimethyl-7-(1-methylethyl)-, [1R-(1.alpha.,4a.beta.,10a.alpha.)]-; InChI=1/C20H28O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h6,8,12-13,17H,5,7,9-11H2,1-4H3,(H,21,22)/t17-,19-,20-/m1/s; rel-(1R,4aS,10aR)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylic acid; rel-(1R,4aS,10aR)-7-Isopropyl-1,4a-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-1-carboxylicacid	.	.	300.4	C20H28O2	37.3	443	5.6	22	1	2	2	InChI=1S/C20H28O2/c1-13(2)14-6-8-16-15(12-14)7-9-17-19(16,3)10-5-11-20(17,4)18(21)22/h6,8,12-13,17H,5,7,9-11H2,1-4H3,(H,21,22)/t17-,19-,20-/m1/s1	CC(C)C1=CC2=C(C=C1)[C@]3(CCC[C@@]([C@@H]3CC2)(C)C(=O)O)C	CC(C)C1=CC2=C(C=C1)C3(CCCC(C3CC2)(C)C(=O)O)C	NFWKVWVWBFBAOV-MISYRCLQSA-N	(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-1-carboxylic acid
ferrodrug0154	Sodium Selenite	.	SODIUM SELENITE; Disodium selenite; 10102-18-8; Natriumselenit; Selenious Acid Disodium Salt; Selenious acid, disodium salt; Disodium selenium trioxide; Selenite sodium; disodium;selenite; Sodium selenite anhydrous; CCRIS 1260; HSDB 768; UNII-HIW548RQ3W; EINECS 233-267-9; HIW548RQ3W; Selenious acid, sodium salt (1:2); MFCD00003489; Selenious acid (H2SeO3), disodium salt; DTXSID0032077; CHEBI:48843; NSC-347466; DTXCID8012077; EC 233-267-9; NSC 347466; 10102-18-8(disodiumsalt)7782-82-3(monosodiumsalt); Sodium selenite (JAN); SODIUM SELENITE [JAN]; dinatriumselenit; Natriumselenit [German]; SODIUM SELENITE (EP MONOGRAPH); SODIUM SELENITE [EP MONOGRAPH]; Selenite, Sodium; Selenite, Disodium; NA2630; Selenous Acid Disodium Salt; Aselend; Selenous Acid, Disodium Salt; Sodium-selenite; H2-O3-Se.1/2Na; Aselend (TN); Sodium Selenite,(S); SODIUM SELENITE [MI]; SODIUM SELENITE [HSDB]; CHEMBL112302; SODIUM SELENITE [VANDF]; DISODIUM SELENITE [INCI]; SODIUM SELENITE [WHO-DD]; BVTBRVFYZUCAKH-UHFFFAOYSA-L; SODIUM SELENATE (NA2SEO3); Tox21_202977; SODIUM SELENITE [GREEN BOOK]; AKOS015912461; SODIUM SELENIUM OXIDE(NA2SEO3); Sodium selenite [NA2630] [Poison]; NCGC00260523-01; CAS-10102-18-8; SELENIOUS ACID(H2SEO3), DISODIUM SALT; D10530; SODIUM SELENITE HIGH PURITY GRADE 100G; Q414626	.	.	172.95	Na2O3Se	63.2	18.8	.	6	0	3	0	InChI=1S/2Na.H2O3Se/c;;1-4(2)3/h;;(H2,1,2,3)/q2*+1;/p-2	[O-][Se](=O)[O-].[Na+].[Na+]	[O-][Se](=O)[O-].[Na+].[Na+]	BVTBRVFYZUCAKH-UHFFFAOYSA-L	disodium;selenite
ferrodrug0155	Liraglutide	Small molecular drug	Liraglutide; 204656-20-2; NN2211; victoza; Liraglutida; Liraglutidum; NN-2211; NN 2211; UNII-839I73S42A; HSDB 8205; Liraglutide (rDNA origin); NNC 90-1170; CHEMBL4084119; Saxenda; CHEBI:71193; DTXSID60174433; 839I73S42A; NN-9924; NNC-90-1170; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; N26-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)glucagon-like-peptide-1-(7-37)-peptide; Arg34Lys26-(N-epsilon-(gamma-Glu(N-alpha-hexadecanoyl)))-GLP-1(7-37); Liraglutidum [INN-Latin]; N(sup 26)-(Hexadecanoyl-gamma-glutamyle)-(34-arginine)GLP-1-(7-37)-peptide; Liraglutida [INN-Spanish]; Liraglutide recombinant; Liraglutide [USAN:INN:BAN:JAN]; Liraglutidum (Latin); LIRAGLUTIDE (MART.); GTPL1133; DTXCID6096924; A10BJ02; EX-A2418; BDBM50240819; NN9924; AKOS037435224; AS-56276; A16115; XULTOPHY 100/3.6 COMPONENT LIRAGLUTIDE; LIRAGLUTIDE COMPONENT OF XULTOPHY 100/3.6; ARG(SUP 34)LYS(SUP 26)-(N-epsilon-(gamma-GLU(N-alpha-HEXADECANOYL)))-GLP-1(7-37); N(SUP epsilon26)-(N-HEXADECANOYL-L-gamma-GLUTAMYL)-(34-L-ARGININE)GLUCAGON-LIKE PEPTIDE 1-(7-37)-PEPTIDE; N26-(N-Hexadecanoyl-L-gamma-glutamyl)-(34-L-arginine)glucagon-like peptide 1-(7-37)-peptide	D03GOI	DM3FXPS	3751	C172H265N43O51	1510	8760	-3.4	266	54	55	132	InChI=1S/C172H265N43O51/c1-18-20-21-22-23-24-25-26-27-28-29-30-37-53-129(224)195-116(170(265)266)59-64-128(223)180-68-41-40-50-111(153(248)199-115(62-67-135(232)233)154(249)204-120(73-100-44-33-31-34-45-100)159(254)214-140(93(11)19-2)167(262)192-97(15)146(241)201-122(76-103-79-183-108-49-39-38-48-106(103)108)157(252)203-118(72-90(5)6)158(253)212-138(91(7)8)165(260)200-110(52-43-70-182-172(177)178)149(244)184-81-130(225)193-109(51-42-69-181-171(175)176)148(243)187-84-137(236)237)196-144(239)95(13)189-143(238)94(12)191-152(247)114(58-63-127(174)222)194-131(226)82-185-151(246)113(61-66-134(230)231)198-155(250)117(71-89(3)4)202-156(251)119(75-102-54-56-105(221)57-55-102)205-162(257)124(85-216)208-164(259)126(87-218)209-166(261)139(92(9)10)213-161(256)123(78-136(234)235)206-163(258)125(86-217)210-169(264)142(99(17)220)215-160(255)121(74-101-46-35-32-36-47-101)207-168(263)141(98(16)219)211-132(227)83-186-150(245)112(60-65-133(228)229)197-145(240)96(14)190-147(242)107(173)77-104-80-179-88-188-104/h31-36,38-39,44-49,54-57,79-80,88-99,107,109-126,138-142,183,216-221H,18-30,37,40-43,50-53,58-78,81-87,173H2,1-17H3,(H2,174,222)(H,179,188)(H,180,223)(H,184,244)(H,185,246)(H,186,245)(H,187,243)(H,189,238)(H,190,242)(H,191,247)(H,192,262)(H,193,225)(H,194,226)(H,195,224)(H,196,239)(H,197,240)(H,198,250)(H,199,248)(H,200,260)(H,201,241)(H,202,251)(H,203,252)(H,204,249)(H,205,257)(H,206,258)(H,207,263)(H,208,259)(H,209,261)(H,210,264)(H,211,227)(H,212,253)(H,213,256)(H,214,254)(H,215,255)(H,228,229)(H,230,231)(H,232,233)(H,234,235)(H,236,237)(H,265,266)(H4,175,176,181)(H4,177,178,182)/t93-,94-,95-,96-,97-,98+,99+,107-,109-,110-,111-,112-,113-,114-,115-,116-,117-,118-,119-,120-,121-,122-,123-,124-,125-,126-,138-,139-,140-,141-,142-/m0/s1	CCCCCCCCCCCCCCCC(=O)N[C@@H](CCC(=O)NCCCC[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CC2=CNC3=CC=CC=C32)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)N[C@@H](CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(=O)N)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(=O)O)NC(=O)[C@H](CO)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC5=CC=CC=C5)NC(=O)[C@H]([C@@H](C)O)NC(=O)CNC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](C)NC(=O)[C@H](CC6=CN=CN6)N)C(=O)O	CCCCCCCCCCCCCCCC(=O)NC(CCC(=O)NCCCCC(C(=O)NC(CCC(=O)O)C(=O)NC(CC1=CC=CC=C1)C(=O)NC(C(C)CC)C(=O)NC(C)C(=O)NC(CC2=CNC3=CC=CC=C32)C(=O)NC(CC(C)C)C(=O)NC(C(C)C)C(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)NC(CCCNC(=N)N)C(=O)NCC(=O)O)NC(=O)C(C)NC(=O)C(C)NC(=O)C(CCC(=O)N)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(CC(C)C)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CO)NC(=O)C(C(C)C)NC(=O)C(CC(=O)O)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C(CC5=CC=CC=C5)NC(=O)C(C(C)O)NC(=O)CNC(=O)C(CCC(=O)O)NC(=O)C(C)NC(=O)C(CC6=CN=CN6)N)C(=O)O	YSDQQAXHVYUZIW-QCIJIYAXSA-N	(2S)-5-[[(5S)-5-[[(2S)-2-[[(2S)-2-[[(2S)-5-amino-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-2-[[(2S,3R)-2-[[2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-(1H-imidazol-5-yl)propanoyl]amino]propanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-3-hydroxybutanoyl]amino]-3-phenylpropanoyl]amino]-3-hydroxybutanoyl]amino]-3-hydroxypropanoyl]amino]-3-carboxypropanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-hydroxypropanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-methylpentanoyl]amino]-4-carboxybutanoyl]amino]acetyl]amino]-5-oxopentanoyl]amino]propanoyl]amino]propanoyl]amino]-6-[[(2S)-1-[[(2S)-1-[[(2S,3S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-1-[[(2S)-5-carbamimidamido-1-[[2-[[(2S)-5-carbamimidamido-1-(carboxymethylamino)-1-oxopentan-2-yl]amino]-2-oxoethyl]amino]-1-oxopentan-2-yl]amino]-3-methyl-1-oxobutan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-3-(1H-indol-3-yl)-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-1-oxo-3-phenylpropan-2-yl]amino]-4-carboxy-1-oxobutan-2-yl]amino]-6-oxohexyl]amino]-2-(hexadecanoylamino)-5-oxopentanoic acid
ferrodrug0156	Perillaldehyde	Small molecular drug	PERILLALDEHYDE; Perillyl aldehyde; 2111-75-3; Perilla aldehyde; Perillal; Perillic aldehyde; P-Mentha-1,8-dien-7-al; Dihydrocuminyl aldehyde; 4-prop-1-en-2-ylcyclohexene-1-carbaldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-; para-Mentha-1,8-dien-7-al; 4-Isopropenyl-1-cyclohexene-1-carboxaldehyde; FEMA No. 3557; Perillylaldehyde; 1-Cyclohexene-1-carboxaldehyde, 4-isopropenyl-; (+)-Perillaaldehyde; p-Mentha-1,8-dien-7-al (natural); 1,8-p-Menthadien-7-al; NSC 138642; 4-Isopropenylcyclohex-1-enecarbaldehyde; 6EQL0XA86G; CHEMBL469537; CHEBI:15421; DL-perillaldehyde(for perfumery); 4-(prop-1-en-2-yl)cyclohex-1-enecarbaldehyde; 4-(1-Methylethenyl)-1-cyclohexene-1-carboxaldehyde; 4-(prop-1-en-2-yl)cyclohex-1-ene-1-carbaldehyde; NSC-138642; 4-Isopropenyl-1-cyclohexene-1-carbaldehyde; (S)-(-)-Perillaldehyde; (S)-(-)-Perillic aldehyde; (S)-Perillaldehyde; l-Perillaldehyde; CCRIS 9128; dl-perillaldehyde; MFCD00001543; EINECS 218-302-8; UNII-6EQL0XA86G; PERILLALDEHYDE [MI]; PERILLALDEHYDE [INCI]; 1-Cyclohexene-1-carboxaldehyde, 4-(1-methylethenyl)-, (S)-; SCHEMBL221797; (+/-)-PERILLALDEHYDE; DTXSID6051855; BDBM50276351; MFCD00062990; NSC138642; AKOS015900800; LMPR0102090010; SY057816; P-MENTHA-1,8-DIEN-7-AL [FHFI]; 2-(4-Boc-piperazinyl)-4-phenylbutanoicacid; FT-0673634; FT-0686825; FT-0737059; P0866; 4-Isopropenyl-1-cyclohexene-1-carbaldehyde #; C02576; EN300-658599; 4-ISOPROPENYL-1-CYCLOHEXENECARBOXALDEHYDE; (-)-4-Isopropenyl-1-cyclohexene-1-carboxaldehyde; 4-(1-methylethenyl)-1-cyclohexene1-carboxyaldehyde; 4-(2-PROPENYL)-1-CYCLOHEXENECARBOXALDEHYDE; Q3117895; 0659C8EF-4608-42BD-9B0A-BB8B719E80F6; 4-(1-METHYLETHENYLPRO)-1-CYCLOHEXENE-1-CARBOXALDEHYDE	D00AVT	DMZA0VD	150.22	C10H14O	17.1	201	2.6	11	0	1	2	InChI=1S/C10H14O/c1-8(2)10-5-3-9(7-11)4-6-10/h3,7,10H,1,4-6H2,2H3	CC(=C)C1CCC(=CC1)C=O	CC(=C)C1CCC(=CC1)C=O	RUMOYJJNUMEFDD-UHFFFAOYSA-N	4-prop-1-en-2-ylcyclohexene-1-carbaldehyde
ferrodrug0157	Beta-Elemene	.	BETA-ELEMENE; 515-13-9; (-)-beta-Elemene; beta-Elemen; Levo-beta-elemene; Elemene; (1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; 2,4-Diisopropenyl-1-methyl-1-vinylcyclohexane; b-elemene; beta-Elemene, (-)-; CHEBI:62855; Levo-b-elemene; UNII-2QG8CX6LXD; 2QG8CX6LXD; (-)-b-Elemene; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane; 33880-83-0; (1S,2S,4R)-2,4-diisopropenyl-1-methyl-1-vinylcyclohexane; (1S,2S,4R)-(-)-1-methyl-1-vinyl-2,4-diisopropenylcyclohexane; ELEMENE, (-)-BETA-; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S,2S,4R)-; (1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1S-(1-alpha,2-beta,4-beta))-; .beta.-Elemene; 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-cyclohexane; Cyclohexane, 2,4-diisopropenyl-1-methyl-1-vinyl-, (1S,2S,4R)-; EINECS 251-713-0; (-)-.beta.-Elemene; b-Elemen; (-)-bete-elemene; E- .beta.-Elemene; Beta elemene [WHO-DD]; Epitope ID:153551; (1S,2S,4R)-beta-elemene; Levo-b-elemene(-)-b-Elemene; CHEMBL448502; CHEBI:62854; DTXSID40865690; DTXSID60881211; SDP-111; Cyclohexane, 1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)-, (1alpha,2beta,4beta)-; OPFTUNCRGUEPRZ-QLFBSQMISA-N; ELEMENE, (-)-.BETA.-; s6957; AKOS028108977; (-)-beta-Elemene, analytical standard; AS-82909; HY-107324; CS-0028143; C17094; E79113; EN300-1709739; Q27132237; rel-(1S,2S,4R)-1-ethenyl-1-methyl-2,4-di(prop-1-en-2-yl)cyclohexane; rel-(1S,2S,4R)-1-methyl-2,4-di(prop-1-en-2-yl)-1-vinylcyclohexane; (1alpha,2beta,4beta)-1-ethenyl-1-methyl-2,4-bis(1-methylethenyl)cyclohexane	.	.	204.35	C15H24	0	284	6.1	15	0	0	3	InChI=1S/C15H24/c1-7-15(6)9-8-13(11(2)3)10-14(15)12(4)5/h7,13-14H,1-2,4,8-10H2,3,5-6H3/t13-,14+,15-/m1/s1	CC(=C)[C@@H]1CC[C@@]([C@@H](C1)C(=C)C)(C)C=C	CC(=C)C1CCC(C(C1)C(=C)C)(C)C=C	OPFTUNCRGUEPRZ-QLFBSQMISA-N	(1S,2S,4R)-1-ethenyl-1-methyl-2,4-bis(prop-1-en-2-yl)cyclohexane
ferrodrug0158	Ferric citrate	.	FERRIC CITRATE; Iron(III) citrate; Iron citrate; Zerenex; 3522-50-7; 6043-74-9; 28633-45-6; ferrum citricum; Citric acid, iron(3+) salt; FERRICCITRATE; Iron(III) citrate tribasic; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt (1:1); ferric citrate anhydrous; KRX-0502; iron(iii)citrate; Iron citrate, FeC6H5O7; Auryxia; iron(3+) citrate; 63G354M39Z; Iron, (hydrogen citrato(3-))-; 2338-05-8; Citric acid, iron(3+) salt (1:1); FERROUS CITRATE; iron(III) 2-hydroxypropane-1,2,3-tricarboxylate; 2-hydroxy-1,2,3-propanetricarboxylic acid iron salt; Ferric citrate [USAN]; Ferric citrate tetrahydrate; Iron(III) citrate; Zerenex; JTT-751; Ferric citrate (VAN); 2-hydroxypropane-1,2,3-tricarboxylate;iron(3+); NSC-112227; Fexeric; iron(3+) 2-hydroxypropane-1,2,3-tricarboxylate; UNII-63G354M39Z; JTT 751; EINECS 222-536-6; EINECS 249-117-0; Iron(III)-citrate; Iron (III) citrate; NSC 112227; Citric acid, iron salt; 1185-57-5; Citric acid,iron(3+)salt; FERRIC CITRATE [MI]; SCHEMBL42945; FERRIC CITRATE [FCC]; 2-hydroxypropane-1,2,3-tricarboxylate; iron(3+); FERRIC CITRATE [INCI]; FERRUM CITRICUM [HPUS]; CCRIS 6843; DTXSID0037657; FERRIC CITRATE [WHO-DD]; Iron(III) citrate;Iron citrate; HY-N1428C; NPFOYSMITVOQOS-UHFFFAOYSA-K; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron(3+) salt; BCP30645; FERRIC CITRATE [ORANGE BOOK]; AKOS015918266; DB09162; CS-0030977; FT-0626407; FT-0627304; FT-0652224; Iron 2-hydroxy-1,2,3-propanetricarboxylate; A832727; iron(3+); 2-oxidanylpropane-1,2,3-tricarboxylate; Q15628111; 1,2,3-Propanetricarboxylic acid, 2-hydroxy-, iron salt (1:?)	.	.	244.94	C6H5FeO7	141	211	.	14	1	7	2	InChI=1S/C6H8O7.Fe/c7-3(8)1-6(13,5(11)12)2-4(9)10;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);/q;+3/p-3	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Fe+3]	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.[Fe+3]	NPFOYSMITVOQOS-UHFFFAOYSA-K	2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)
ferrodrug0159	Buthionine sulfoximine	.	5072-26-4; BUTHIONINE SULFOXIMINE; Butionine sulfoximine; Buthionine sulphoximine; DL-Buthionine-[S,R]-sulfoximine; 2-Amino-4-(butylsulfonimidoyl)butanoic acid; Buthionine sulfoxamine; DL-Buthionine-(S,R)-sulfoximine; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-; 2-Amino-4-(S-butylsulfonimidoyl)butanoic acid; D,L-Buthionine-(S,R)-sulfoximine; DL-Buthionine-sulfoximine; Buthionine-S,R-sulfoximine; NSC 381100; dl-buthionine (s,r)-sulfoximine; 2-azaniumyl-4-(butylsulfonimidoyl)butanoate; S-butyl-DL-homocysteine (S,R)-sulfoximine; LW4108Q0BV; CHEBI:28714; DL-butathionine-(S,R)-sulfoximine; NSC326231; NSC381100; NSC-381100; S-Butyl-DL-homocysteine-[S,R]-sulfoximine; 2-amino-4-(S-butylsulfonimidoyl)butyric acid; BRN 2367136; Buthione sulfoximine; 71765-30-5; BSO; UNII-LW4108Q0BV; DL-Buthionine-S,R-sulfoximine; l-buthionine (s,r)-sulfoximine; Sulfoximine, S-(3-amino-3-carboxypropyl)-S-butyl-; MFCD00070309; Lopac0_000231; SCHEMBL62033; BSPBio_002464; SPECTRUM1505108; CHEMBL1256575; CHEMBL1627290; DTXSID6044434; CHEBI:176510; KJQFBVYMGADDTQ-UHFFFAOYSA-N; HMS3260P03; BUTHIONINE SULFOXIMINE [MI]; BCP24029; BCP27775; Tox21_500231; s2433; STL328818; AKOS022106364; DL-Buthionine-(S,R)-sulfoximine;BSO; BUTHIONINE SULFOXIMINE [WHO-DD]; CCG-204326; DB12870; LP00231; SDCCGSBI-0050219.P003; NCGC00015148-03; NCGC00015148-04; NCGC00015148-05; NCGC00015148-06; NCGC00015148-07; NCGC00015148-13; NCGC00093696-01; NCGC00093696-02; NCGC00093696-03; NCGC00260916-01; AS-67962; NCI60_002827; 2-Amino-4-(butylsulfonimidoyl)butanoicacid; HY-106376; CS-0025687; EU-0100231; FT-0624379; FT-0627738; FT-0663956; DL-Buthionine-sulfoximine, >=99.0% (TLC); 2-Amino-4-(butylsulfonimidoyl)butanoic acid #; B 2640; C04543; SR-01000075713; Q5002519; SR-01000075713-1; 2-amino-4-[butyl(imino)oxo-??-sulfanyl]butanoic acid; BRD-A04020513-001-01-9; D,L-Buthionine-(S,R)-sulfoximine (Butionine sulfoximine); dl-Buthionine(S,R)-sulfoximine (H-DL-Hcy(O,NH,Bu)-OH)	.	.	222.31	C8H18N2O3S	113	284	-0.6	14	3	5	7	InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)	CCCCS(=N)(=O)CCC(C(=O)O)N	CCCCS(=N)(=O)CCC(C(=O)O)N	KJQFBVYMGADDTQ-UHFFFAOYSA-N	2-amino-4-(butylsulfonimidoyl)butanoic acid
ferrodrug0160	Bleomycin	.	bleomycin a2; bleomycin; Bleomycins; 11116-31-7; Bleocin; Blenamax; Bleomycin Hexal; CHEBI:3139; NSC-125066; Bleo; Bleomycin hydrochloride; 11056-06-7; Bleo-kyowa; SCHEMBL134155; CHEMBL403664; DTXSID20872327; BLM; BDBM50547621; AKOS032960358; C06854; N(1)-[3-(dimethylsulfonio)propyl]bleomycinamide; Q26841044	.	.	1415.6	C55H84N17O21S3+	685	2580	-7.5	96	20	31	36	InChI=1S/C55H83N17O21S3/c1-20-33(69-46(72-44(20)58)25(12-31(57)76)64-13-24(56)45(59)82)50(86)71-35(41(26-14-61-19-65-26)91-54-43(39(80)37(78)29(15-73)90-54)92-53-40(81)42(93-55(60)88)38(79)30(16-74)89-53)51(87)66-22(3)36(77)21(2)47(83)70-34(23(4)75)49(85)63-10-8-32-67-28(18-94-32)52-68-27(17-95-52)48(84)62-9-7-11-96(5)6/h14,17-19,21-25,29-30,34-43,53-54,64,73-75,77-81H,7-13,15-16,56H2,1-6H3,(H13-,57,58,59,60,61,62,63,65,66,69,70,71,72,76,82,83,84,85,86,87,88)/p+1/t21-,22+,23+,24-,25-,29-,30+,34-,35-,36-,37+,38+,39-,40-,41-,42-,43-,53+,54-/m0/s1	CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)O[C@H]3[C@H]([C@H]([C@@H]([C@@H](O3)CO)O)O)O[C@@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O	CC1=C(N=C(N=C1N)C(CC(=O)N)NCC(C(=O)N)N)C(=O)NC(C(C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)NC(C)C(C(C)C(=O)NC(C(C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O	OYVAGSVQBOHSSS-UAPAGMARSA-O	3-[[2-[2-[2-[[(2S,3R)-2-[[(2S,3S,4R)-4-[[(2S,3R)-2-[[6-amino-2-[(1S)-3-amino-1-[[(2S)-2,3-diamino-3-oxopropyl]amino]-3-oxopropyl]-5-methylpyrimidine-4-carbonyl]amino]-3-[(2R,3S,4S,5S,6S)-3-[(2R,3S,4S,5R,6R)-4-carbamoyloxy-3,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxy-2-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]ethyl]-1,3-thiazol-4-yl]-1,3-thiazole-4-carbonyl]amino]propyl-dimethylsulfanium
ferrodrug0161	D-Mannose	Small molecular drug	D-Man; D-Mannopyranose; D-Mannopyranoside; D-Mannose; Man; Mannopyranose; Mannopyranoside; Mannose; Carubinose; Seminose; 530-26-7; D-(+)-Mannose; (+)-Mannose; CHEBI:4208; (3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol; D-Mannose 1000 microg/mL in Methanol; AI3-18442; MFCD00064122; (+-)-Mannose; SMR000857125; 2h-pyran-2,3,4,5-tetraol; manno-hexose; NSC 26247; D-Mannose,(S); alpha,beta-D-mannopyranose; bmse000018; bmse000874; bmse000882; Epitope ID:152206; SCHEMBL38300; MLS001332527; MLS001332528; CHEMBL469448; GTPL4650; DTXCID3020463; CHEBI:16024; CHEBI:37684; DTXSID501337491; HMS2236J04; BDBM50448403; s5763; AKOS025212856; D-(+)-Mannose, synthetic, >=99%; DS-3390; D-(+)-Mannose, from wood, >=99%; D-(+)-Mannose, p.a., 99.0%; NCGC00166108-01; 46032-76-2; AC-11148; D-(+)-Mannose, for microbiology, >=99%; CS-0238447; M0045; EN300-19556; (3S,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-; C00159; A829355; Q335208; D50D2EC9-C1E4-4213-AFF7-F9C678AC92C5; Z104474216; (3S,4S,5R,6R)-6-methyloltetrahydropyran-2,3,4,5-tetrol; D-(+)-Mannose, powder, BioReagent, suitable for cell culture; Mannose, United States Pharmacopeia (USP) Reference Standard; (3S,4S,5R,6R)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; (3S,4S,5S,6R)-6-(hydroxymethyl)tetrahydropyran-2,3,4,5-tetrol; D-(+)-Mannose, BioUltra, >=99.5% (sum of enantiomers, HPLC); (3S,4S,5S,6R)-6-(hydroxymethyl)tetrahydro-2H-pyran-2,3,4,5-tetraol; D-(+)-Mannose, for microbiology, >=99.0% (sum of enantiomers, HPLC)	D0GS9E	DMT6X03	180.16	C6H12O6	110	151	-2.6	12	5	6	1	InChI=1S/C6H12O6/c7-1-2-3(8)4(9)5(10)6(11)12-2/h2-11H,1H2/t2-,3-,4+,5+,6?/m1/s1	C([C@@H]1[C@H]([C@@H]([C@@H](C(O1)O)O)O)O)O	C(C1C(C(C(C(O1)O)O)O)O)O	WQZGKKKJIJFFOK-QTVWNMPRSA-N	(3S,4S,5S,6R)-6-(hydroxymethyl)oxane-2,3,4,5-tetrol
ferrodrug0162	Sodium nitroprusside	.	sodium nitroprusside; 13755-38-9; Sodium nitroferricyanide(III) dihydrate; Nitroprusside disodium dihydrate; DTXSID7041126; MFCD00149192; disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate; Sodium pentacyanonitrosylferrate(III) dihydrate; DTXCID5021126; CAS-13755-38-9; Nitropress (TN); Sodium nitroprusside (USP); CHEBI:9179; Na2[Fe(CN)5(NO)].2H2O; Tox21_110314; NITROPRUSSIDE SODIUM DIHYDRATE; AKOS040759055; Tox21_110314_1; Sodium nitroprusside dihydrate ACS grade; NCGC00166055-03; AC-37039; C07695; D00614; disodium pentacyano(nitroso)irondiuide dihydrate; F19620; sodium pentacyano(nitroso)ferrate(IV) dihydrate; sodium pentacyanidonitrosylferrate(2-) dihydrate; sodium pentacyanidonitrosylferrate(III) dihydrate; disodium pentacyanidonitrosylferrate--water (1/2); EN300-18543938; Sodium nitroferricyanide(III) dihydrate, ACS reagent, >=99%; Sodium nitroprusside dihydrate, Vetec(TM) reagent grade, 99%; Sodium nitroprusside dihydrate, p.a., ACS reagent, 99.0-102.0%; Sodium nitroferricyanide(III) dihydrate, JIS special grade, >=99.0%; Sodium nitroprusside, United States Pharmacopeia (USP) Reference Standard; Sodium nitroprusside dihydrate, puriss. p.a., ACS reagent, reag. Ph. Eur., >=99%; Sodium Nitroprusside, Pharmaceutical Secondary Standard; Certified Reference Material; Sodium nitroprusside dihydrate, puriss. p.a., ACS reagent, reag. Ph. Eur., Reag. Ph. Eur., >=99%	.	.	297.95	C5H4FeN6Na2O3	139	119	.	17	2	14	0	InChI=1S/5CN.Fe.NO.2Na.2H2O/c5*1-2;;1-2;;;;/h;;;;;;;;;2*1H2/q5*-1;+4;-1;2*+1;;	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.O.O.[Na+].[Na+].[Fe+4]	XRKMNJXYOFSTBE-UHFFFAOYSA-N	disodium;iron(4+);nitroxyl anion;pentacyanide;dihydrate
ferrodrug0163	Formononetin	.	formononetin; 485-72-3; Biochanin B; Formononetol; 7-hydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; 7-Hydroxy-4'-methoxyisoflavone; 7-hydroxy-3-(4-methoxyphenyl)chromen-4-one; Flavosil; Neochanin; Myconate; Mycotech; 4'-O-methyldaidzein; 4H-1-Benzopyran-4-one, 7-hydroxy-3-(4-methoxyphenyl)-; Isoflavone, 7-hydroxy-4'-methoxy-; NSC 93360; NSC-93360; 7-Hydroxy-3-(4-methoxyphenyl)-4-benzopyrone; CHEBI:18088; EINECS 207-623-9; UNII-295DQC67BJ; MFCD00016948; 295DQC67BJ; DTXSID4022311; 7-hydroxy-4'-methoxy-isoflavone; 7-Hydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one; DTXCID502311; NSC93360; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one; FORMONONETIN (USP-RS); FORMONONETIN [USP-RS]; SMR000470932; 7-Hydroxy-3-(4-methoxyphenyl)chromone; SR-01000765510; formononetine; Formoononetin; Formononetin,(S); Spectrum_000373; SpecPlus_000223; Daidzein 4-methyl ether; Spectrum2_000560; Spectrum3_000660; Spectrum4_001429; Spectrum5_000258; FORMONONETIN [MI]; Formononetin (Formononetol); FORMONONETIN [INCI]; NCIOpen2_005983; Oprea1_139748; Oprea1_815287; SCHEMBL62915; BSPBio_002299; KBioGR_001878; KBioSS_000853; SPECTRUM102007; MLS000697593; MLS006011897; BIDD:ER0119; DivK1c_006319; SPBio_000639; CHEMBL242341; Formononetin, analytical standard; KBio1_001263; KBio2_000853; KBio2_003421; KBio2_005989; KBio3_001519; HMS1922N18; HMS2231I04; HMS3369C07; HMS3655N22; BCP29929; Formononetin, >=99.0% (TLC); HY-N0183; TNP00176; Tox21_301848; BBL010458; BDBM50021398; CCG-38727; LMPK12050037; s2299; STK801612; AKOS000270811; AC-8001; DB15335; SDCCGMLS-0066428.P001; 7-hydroxy-4'-methoxy-Isoflavone (8CI); NCGC00017269-01; NCGC00017269-02; NCGC00017269-03; NCGC00017269-04; NCGC00017269-05; NCGC00017269-06; NCGC00017269-07; NCGC00095207-01; NCGC00095207-02; NCGC00095207-03; NCGC00178715-01; NCGC00255167-01; AS-11642; CAS-485-72-3; NCI60_042081; F0868; FT-0626540; FT-0632204; K-080; SW219915-1; C00858; EN300-116214; FORMONONETIN (CONSTITUENT OF ASTRAGALUS); AB00052676-07; FORMONONETIN (CONSTITUENT OF RED CLOVER); A827555; AE-641/01968055; Q408859; 7-hydroxy-3-(4-methoxyphenyl)-1-benzopyran-4-one; Q-100540; SR-01000765510-3; SR-01000765510-4; 7-Hydroxy-3-(4'-methoxyphenyl)-4H-benzopyran-4-one; BRD-K55567017-001-02-4; BRD-K55567017-001-06-5; FORMONONETIN (CONSTITUENT OF ASTRAGALUS) [DSC]; FORMONONETIN (CONSTITUENT OF RED CLOVER) [DSC]; F3139-1207; Z374511822; 7-hydroxy-3-(4-methoxyphenyl)-4H-benzopyran-4-one(9CI); Formononetin, United States Pharmacopeia (USP) Reference Standard; 7-Hydroxy-3-(4-methoxyphenyl)chromone, 7-Hydroxy-4'-methoxyisoflavone; Biochanin B; Flavosil; Formononetol; NSC 93360; NSC93360; NSC-93360	.	.	268.26	C16H12O4	55.8	395	2.8	20	1	4	2	InChI=1S/C16H12O4/c1-19-12-5-2-10(3-6-12)14-9-20-15-8-11(17)4-7-13(15)16(14)18/h2-9,17H,1H3	COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O	COC1=CC=C(C=C1)C2=COC3=C(C2=O)C=CC(=C3)O	HKQYGTCOTHHOMP-UHFFFAOYSA-N	7-hydroxy-3-(4-methoxyphenyl)chromen-4-one
ferrodrug0164	Nobiletin	.	Nobiletin; 478-01-3; Hexamethoxyflavone; 3',4',5,6,7,8-Hexamethoxyflavone; 5,6,7,8,3',4'-Hexamethoxyflavone; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one; NSC-76751; CCRIS 9012; UNII-D65ILJ7WLY; D65ILJ7WLY; NSC 76751; CHEBI:7602; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; NSC-618903; CHEMBL76447; Nobiletin (Hexamethoxyflavone); DTXSID30197275; NSC76751; Flavone, 5,6,7,8,3',4'-hexamethoxy; NOBILETIN (USP-RS); NOBILETIN [USP-RS]; FLAVONE, 3',4',5,6,7,8-HEXAMETHOXY-; SMR000156231; MFCD03273560; CPD000156231; Nobiletin, >=97%; NOBILETIN [INCI]; Spectrum2_001697; Spectrum3_000921; Spectrum4_001020; KBioGR_001519; MLS000574877; MLS000759462; MLS000877030; MLS001424129; Nobiletin, analytical standard; SCHEMBL244029; SPECTRUM1505268; SPBio_001654; MEGxp0_000930; ACon1_000921; GTPL12446; KBio3_001922; DTXCID40119766; 2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-chromen-4-one; HMS2051D09; HMS2234A09; HMS3373C14; HMS3393D09; HMS3651G20; HEXAMETHOXYFLAVONE [WHO-DD]; HY-N0155; 3'4'5,6,7,8-Hexamethoxyflavone; BDBM50338976; CCG-38781; LMPK12111468; NSC618903; STL565829; AKOS015965334; NOBILETIN, 20% (Technical Grade); AC-1023; CS-5518; NC00186; SDCCGMLS-0066776.P001; NCGC00095703-01; NCGC00095703-02; NCGC00095703-06; NCGC00169228-01; 5,6,7,8,3'',4''-hexamethoxyflavone; AS-17452; NCI60_041691; FT-0686667; N0871; S2333; SW197566-2; A827343; SR-01000712262; Q-100511; Q2402963; SR-01000712262-5; BRD-K06753942-001-02-0; 2-(3,4-Dimethoxy-phenyl)-5,6,7,8-tetramethoxy-chromen-4-one; 4,5,6,7,8,9,10,11,12,13-decahydrocyclododeca[d]oxazole; 4H-1-Benzopyran-4-one,4-dimethoxyphenyl)-5,6,7,8-tetramethoxy-; 2-(3,4-Dimethoxyphenyl)-5,6,7,8-tetramethoxy-4H-1-benzopyran-4-one, 9CI	.	.	402.4	C21H22O8	81.7	593	3	29	0	8	7	InChI=1S/C21H22O8/c1-23-13-8-7-11(9-15(13)24-2)14-10-12(22)16-17(25-3)19(26-4)21(28-6)20(27-5)18(16)29-14/h7-10H,1-6H3	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(O2)C(=C(C(=C3OC)OC)OC)OC)OC	MRIAQLRQZPPODS-UHFFFAOYSA-N	2-(3,4-dimethoxyphenyl)-5,6,7,8-tetramethoxychromen-4-one
ferrodrug0165	Ebselen	.	ebselen; 60940-34-3; 2-Phenyl-1,2-benzisoselenazol-3(2H)-one; 2-phenylbenzo[d][1,2]selenazol-3(2H)-one; Ebselenum; 2-phenyl-1,2-benzoselenazol-3-one; SPI-1005; Ebselene; Ebseleno; Ebselen [INN]; Ebselene [French]; Ebselenum [Latin]; Harmokisane; Ebseleno [Spanish]; C13H9NOSe; PZ 51; DR-3305; PZ-51; PZ51; MLS000028488; DR3305; CCRIS 3714; 1,2-Benzisoselenazol-3(2H)-one, 2-phenyl-; 2-Phenyl-1,2-benzisoselenazolin-3-one; SMR000058445; UNII-40X2P7DPGH; 2-phenyl-1,2-benzoisoselenazol-3(2H)-one; CHEMBL51085; NSC 639762; Prestwick_1057; SPI-3005; Prestwick0_000740; Prestwick1_000740; Prestwick2_000740; Prestwick3_000740; Spectrum2_001441; Spectrum3_000799; Spectrum4_000445; Spectrum5_001713; Lopac-E-3520; MFCD00210937; NSC639762; NSC-639762; NSC-757883; 40X2P7DPGH; Lopac0_000541; NCGC00015412-06; BSPBio_000700; BSPBio_001342; BSPBio_002538; CPD000058445; KBioGR_000062; KBioGR_000830; KBioSS_000062; DivK1c_000951; SPBio_001301; SPBio_002639; CAS-60940-34-3; MLS001148646; BPBio1_000770; DTXSID7045150; BCBcMAP01_000149; CHEBI:77543; HMS502P13; KBio1_000951; KBio2_000062; KBio2_002630; KBio2_005198; KBio3_000123; KBio3_000124; KBio3_001758; NINDS_000951; E 3520; Bio2_000062; Bio2_000542; HMS1361D04; HMS1570C22; HMS1791D04; HMS1989D04; HMS2052N09; CCG-39161; AC-1124; IDI1_000951; IDI1_033812; QTL1_000035; NCGC00015412-01; NCGC00015412-02; NCGC00015412-03; NCGC00015412-13; NCGC00024072-03; NCGC00024072-04; NCGC00024072-05; NCGC00178610-01; NCGC00178610-02; NCGC00178610-03; AB00053217; EU-0100541; MLS-0003066.0001; BRD-K29359156-001-06-1; DR 3305; RP 60931; SR-01000003081; AC1L1FDW; CID3194; SPI1005; Ebselen (C5); nchembio.109-comp1; 2-phenyl-1,2-benzoselenazol-3(2h)-one; LS-33527; SAM001247071; EBSELEN [JAN]; EBSELEN [MI]; EBSELEN [MART.]; Opera_ID_1643; EBSELEN [WHO-DD]; Ebselen, cysteine modifier; cid_3194; C042986; SCHEMBL33829; MLS001424261; MLS006010108; E3520_SIGMA; I09-1611; DTXCID5025150; BDBM34233; GTPL10583; HMS2097C22; HMS2235A11; HMS3394N09; HMS3402D04; HMS3649O05; HMS3714C22; HMS3873N13; KUC112559N; Pharmakon1600-01501188; BCP17134; EX-A1447; SPI-1005;PZ-51; Tox21_110140; 2-Phenyl-benzo[d]isoselenazol-3-one; DAP001372; HB0270; NSC757883; s6676; AKOS015898841; CS-5534; DB12610; LP00541; NC00431; SDCCGSBI-0050524.P004; KSC-325-014; NCGC00015412-04; NCGC00015412-05; NCGC00015412-07; NCGC00015412-08; NCGC00015412-09; NCGC00015412-10; NCGC00015412-11; NCGC00015412-12; NCGC00015412-21; phenyl-1,2-benzisoselenazol-3(2H)-one; 2-phenyl-1,2-benzisoselazol-3(2H)-one; HY-13750; SY052687; SBI-0050524.P003; 2-phenyl-1,2-benzisoselenazole-3(2H)-one; 2-phenyl-1,2-benzoisoselenazole-3(2H)-one; E0946; FT-0759332; 2-phenyl-1,2-benzoisoselenazole-3-(2H)-one; 2-Phenyl-benzo[d]isoselenazol-3-one(Ebselen); C75847; AB00053217_25; A868855; Q5332073; SR-01000003081-2; SR-01000003081-7; SR-01000003081-8; BRD-K29359156-001-23-6; SR-01000003081-10; SR-01000003081-14	.	.	274.19	C13H9NOSe	20.3	275	.	16	0	1	1	InChI=1S/C13H9NOSe/c15-13-11-8-4-5-9-12(11)16-14(13)10-6-2-1-3-7-10/h1-9H	C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2	C1=CC=C(C=C1)N2C(=O)C3=CC=CC=C3[Se]2	DYEFUKCXAQOFHX-UHFFFAOYSA-N	2-phenyl-1,2-benzoselenazol-3-one
ferrodrug0166	Amentoflavone	Small molecular drug	Amentoflavone; 1617-53-4; Didemethyl-ginkgetin; 3',8''-Biapigenin; Amenthoflavone; Tridemethylsciadopitysin; MLS000574827; CHEBI:2631; 9I1VC79L77; MFCD00017470; NSC-295677; 8-[5-(5,7-dihydroxy-4-oxo-chromen-2-yl)-2-hydroxy-phenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; 8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; SMR000156235; 8-(5-(5,7-Dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 4H-1-Benzopyran-4-one, 8-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-; 8-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 8-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; SR-01000721725; UNII-9I1VC79L77; 4H-1-Benzopyran-4-one, 8-[5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-; NSC 295677; AMENTOFLAVONE [INCI]; BIDD:PXR0028; I3',II8-BIAPIGENIN; GINKGETIN, DIDEMETHYL-; SCHEMBL312563; MEGxp0_000924; med.21724, Compound 138; DTXSID20167225; Amentoflavone, analytical standard; YUSWMAULDXZHPY-UHFFFAOYSA-N; BDBM429466; HMS2228B12; HMS3343J17; HMS3885A08; -hydroxyphenyl)-5,7-dihydroxy-2-; BCP13255; BEA14006; HY-N0662; Amentoflavone, >=99.0% (HPLC); LMPK12040009; NSC295677; s3833; (4-hydroxyphenyl)-4H-chromen-4-one; AKOS015896819; CCG-269950; CS-4945; 3',8-Bi[4',5,7-trihydroxyflavone]; NCGC00247542-01; NCGC00247542-02; AC-34718; BS-15502; FT-0622262; A11476; A810291; 8-(5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2; Q-100192; Q4742425; SR-01000721725-2; SR-01000721725-3; 4',5,7-Trihydroxyflavone(3'->8)-4',5,7-trihydroxyflavone; 3''',8-BIFLAVONE, 4',4''',5,5'',7,7''-HEXAHYDROXY; 4',4''',5,5'',7,7''-Hexahydroxy-3''',8-biflavone, 8CI; 4H-1-Benzopyran-4-one, 8-[5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl); 8-[5-(5,7-dihydroxy-4-oxo-chromen-2-yl)-2-hydroxy-phenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one;Amentoflavone; 8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one.	D06HRX	DMLRNV2	538.5	C30H18O10	174	1050	5	40	6	10	3	InChI=1S/C30H18O10/c31-15-4-1-13(2-5-15)24-12-23(38)29-21(36)10-20(35)27(30(29)40-24)17-7-14(3-6-18(17)33)25-11-22(37)28-19(34)8-16(32)9-26(28)39-25/h1-12,31-36H	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C(=C(C=C3O)O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O	YUSWMAULDXZHPY-UHFFFAOYSA-N	8-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
ferrodrug0167	Biochanin A	Small molecular drug	biochanin A; 491-80-5; Biochanin; 4'-Methylgenistein; 5,7-Dihydroxy-4'-methoxyisoflavone; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one; olmelin; Pratensol; Biochanine A; Genistein 4-methyl ether; 5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one; 4-Methylgenistein; 5,7-Dihydrox -4'-methoxyisoflavone; Biochanin-A; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-methoxyphenyl)-; NSC 123538; CCRIS 5449; NSC-123538; Isoflavone, 5,7-dihydroxy-4'-methoxy-; Genistein 4'-methyl ether; EINECS 207-744-7; NSC123538; UNII-U13J6U390T; 5,7-Dihydroxy-3-p-methoxyphenyl-4H-chromen-4-one; DTXSID1022394; CHEBI:17574; U13J6U390T; MFCD00006839; MLS000069443; CHEMBL131921; DTXCID102394; 4'-Methoxy-5,7-dihydroxy isoflavone; 5,7-dihydroxy-3-(4-methoxyphenyl)-4H-1-benzopyran-4-one; SMR000059116; BIOCHANIN A (USP-RS); BIOCHANIN A [USP-RS]; CAS-491-80-5; SR-01000003021; BiochaninA; QSO; Biochanin A, 9; 5,7-dihydroxy-4'-methoxy-Isoflavone; Biochanin A (BCA); Spectrum_000195; Genistein 4-Methylether; Opera_ID_621; Spectrum2_000047; Spectrum3_001098; Spectrum4_001927; Spectrum5_001624; BIOCHANIN A [MI]; Oprea1_038096; SCHEMBL61258; BSPBio_002776; KBioGR_002274; KBioSS_000675; MLS001148446; MLS006011785; BIDD:ER0123; DivK1c_001027; SPBio_000173; BDBM9461; GTPL2829; SPECTRUM10100003; Biochanin A (4-Methylgenistein); Biochanin A - 4-Methylgenistein; cid_5280373; HMS503M15; KBio1_001027; KBio2_000675; KBio2_003243; KBio2_005811; KBio3_001996; NINDS_001027; HMS2232N19; HMS3369A02; HMS3656A13; TNP00319; Isoflavone,7-dihydroxy-4'-methoxy-; Tox21_202097; Tox21_302901; BBL010523; CCG-38351; LMPK12050229; s2377; STK888295; AKOS002163860; DB15334; IDI1_001027; SMP1_000045; NCGC00017369-01; NCGC00017369-02; NCGC00017369-03; NCGC00017369-04; NCGC00017369-05; NCGC00017369-06; NCGC00017369-07; NCGC00017369-08; NCGC00017369-09; NCGC00017369-10; NCGC00022428-03; NCGC00022428-04; NCGC00022428-05; NCGC00178478-01; NCGC00256458-01; NCGC00259646-01; AC-22309; AS-17474; HY-14595; NCI60_000558; Biochanin A, analytical reference material; B4098; FT-0663120; SW219333-1; 5,7-dihydroxy-4'-methoxy-Isoflavone (8CI); BIOCHANIN A (CONSTITUENT OF RED CLOVER); C00814; Q864222; Q-100552; SR-01000003021-4; SR-01000003021-5; BIOCHANIN A (CONSTITUENT OF RED CLOVER) [DSC]; BRD-K73303757-001-02-6; BRD-K73303757-001-12-5; 5,7-Dihydroxy-3-(4-methoxyphenyl)-4H-chromen-4-one #; F1190-0491; 4H-1-Benzopyran-4-one,7-dihydroxy-3-(4-methoxyphenyl)-; 2AA2D226-B323-4AE2-B576-2D47D15F9845; Biochanin A, United States Pharmacopeia (USP) Reference Standard	D0S9YX	DM0HPWY	284.26	C16H12O5	76	424	3	21	2	5	2	InChI=1S/C16H12O5/c1-20-11-4-2-9(3-5-11)12-8-21-14-7-10(17)6-13(18)15(14)16(12)19/h2-8,17-18H,1H3	COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O	COC1=CC=C(C=C1)C2=COC3=CC(=CC(=C3C2=O)O)O	WUADCCWRTIWANL-UHFFFAOYSA-N	5,7-dihydroxy-3-(4-methoxyphenyl)chromen-4-one
ferrodrug0168	Olaparib	.	Olaparib; 763113-22-0; Lynparza; AZD2281; KU-0059436; AZD-2281; AZD 2281; 1-(Cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazinyl)methyl]-2-fluorobenzoyl]piperazine; 4-(3-(4-(Cyclopropanecarbonyl)piperazine-1-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; OLAPARIB cpd; Olaparib (AZD-2281); KU-59436; Olaparib (AZD2281, Ku-0059436); Olaparib [USAN:INN]; UNII-WOH1JD9AR8; WOH1JD9AR8; C24H23FN4O3; 4-[[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one; AZ2281; MFCD13185161; NSC-747856; CHEBI:83766; 4-(3-{[4-(Cyclopropylcarbonyl)piperazin-1-Yl]carbonyl}-4-Fluorobenzyl)phthalazin-1(2h)-One; 4-[3-(4-Cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one; AZ-2281; KEYLYNK-010 COMPONENT OLAPARIB; KU59436; OLAPARIB COMPONENT OF KEYLYNK-010; Olaparib [INN]; 4-[(3-{[4-(Cyclopropylcarbonyl)piperazin-1-yl]carbonyl}-4-fluorophenyl)methyl]phthalazin-1(2H)-one; Olaparib (AZD2281; Ku-0059436); Olaparib (AZD2281); Olaparibum; AZD221; 4-[3-[4-(Cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorobenzyl]phthalazin-1(2H)-one; Olaparib- Bio-X; Lynparza (TN); 09L; 4-((3-{(4-(cyclopropylcarbonyl)piperazin-1-yl)carbonyl}-4-fluorophenyl)methyl)phthalazin-1(2H)-one; OLAPARIB [USAN]; OLAPARIB [JAN]; KU0059436; OLAPARIB [MI]; OLAPARIB [VANDF]; Olaparib - AZD2281; OLAPARIB [MART.]; OLAPARIB [WHO-DD]; AZD-2281 (Olaparib); Olaparib (JAN/USAN/INN); MLS006010185; SCHEMBL426568; OLAPARIB [ORANGE BOOK]; CHEMBL521686; GTPL7519; BDBM27566; DTXSID60917988; EX-A002; FDLYAMZZIXQODN-UHFFFAOYSA-N; BCPP000360; HMS3295I09; HMS3426C03; HMS3654G13; HMS3746K07; HMS3870H03; AMY10295; BCP01872; 763113-22-0, Lynparza,; NSC747856; NSC753686; s1060; AKOS005145764; AC-7939; BCP9000363; CCG-264799; CS-0075; DB09074; EX-7210; NSC 747856; NSC-753686; SB14617; SS-4573; AZD2281,Olaparib, KU-0059436; NCGC00238451-01; NCGC00238451-02; NCGC00238451-08; NCGC00238451-09; NCGC00238451-11; 1(2H)-Phthalazinone, 4-[[3-[[4-(cyclopropylcarbonyl)-1-piperazinyl]carbonyl]-4-fluorophenyl]methyl]-; 4-[(3-{[4-Cyclopropylcarbonyl)piperazin-4-yl]carbonyl}-4-fluorophenyl)methyl]phtalazin-1(2H)-one; 4-{[3-(4-cyclopropanecarbonylpiperazine-1-carbonyl)-4-fluorophenyl]methyl}-1,2-dihydrophthalazin-1-one; BO164169; HY-10162; SMR004701291; SY040527; Olaparib(AZD2281,KuDOSKU-0059436); A9666; BB 0260909; FT-0651458; SW218142-2; EC-000.2324; D09730; EN300-7542225; J-503540; Q7083106; BRD-K02113016-001-08-9; BRD-K02113016-001-09-7; Z2227698469; 1-(cyclopropylcarbonyl)-4-[5-[(3,4-dihydro-4-oxo-1-phthalazine; 4-(3-(1-(cyclopropanecarbonyl)piperazine-4-carbonyl)-4-fluorobenzyl)phthalazin-1(2H)-one; (2H)-Phthalazinone, 4-((3-((4-(cyclopropylcarbonyl)-1-piperazinyl)carbonyl)-4-fluorophenyl)methyl)-; 1021843-02-6; 4-({3-[(4-cyclopropanecarbonylpiperazin-1-yl)carbonyl]-4-fluorophenyl}methyl)-1,2-dihydrophthalazin-1-one; PIPERAZINE, 1-(CYCLOPROPYLCARBONYL)-4-(5-((3,4-DIHYDRO-4-OXO-1-PHTHALAZINYL)METHYL)-2-FLUOROBENZOYL)-	.	.	434.5	C24H23FN4O3	82.1	790	1.9	32	1	5	4	InChI=1S/C24H23FN4O3/c25-20-8-5-15(14-21-17-3-1-2-4-18(17)22(30)27-26-21)13-19(20)24(32)29-11-9-28(10-12-29)23(31)16-6-7-16/h1-5,8,13,16H,6-7,9-12,14H2,(H,27,30)	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F	C1CC1C(=O)N2CCN(CC2)C(=O)C3=C(C=CC(=C3)CC4=NNC(=O)C5=CC=CC=C54)F	FDLYAMZZIXQODN-UHFFFAOYSA-N	4-[[3-[4-(cyclopropanecarbonyl)piperazine-1-carbonyl]-4-fluorophenyl]methyl]-2H-phthalazin-1-one
ferrodrug0169	Triptolide	.	triptolide; 38748-32-2; Triptolid; PG490; NSC 163062; NSC-163062; 19ALD1S53J; CHEBI:9747; CHEMBL463763; PG-490; (1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one; (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-6-hydroxy-8b-methyl-6a-(propan-2-yl)-3b,4,4a,6,6a,7a,7b,8b,9,10-decahydrotrisoxireno[6,7:8a,9:4b,5]phenanthro[1,2-c]furan-1(3H)-one; (5bS,6aS,7aS,8R,8aR,9aS,9bS,10aS,10bS)-8-Hydroxy-8a-isopropyl-10b-methyl-1,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(2H)-one; (6aS,7aS,8R,8aR,9aS,9bS,10aS,10bS)-8-hydroxy-8a-isopropyl-10b-methyl-1,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(2H)-one.; SMR000466307; UNII-19ALD1S53J; NSC163062; Triptolide, 1; (3BS,4AS,5AS,6R,6AR,7AS,7BS,8AS,8BS)-3B,4,4A,6,6A,7A,7B,8B,9,10-DECAHYDRO-6-HYDROXY-8B-METHYL-6A-(1-METHYLETHYL)TRISOXIRENO(4B,5:6,7:8A,9)PHENANTHRO(1,2-C)FURAN-1(3H)-ONE; (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-3b,4,4a,6,6a,7a,7b,8b,9,10-Decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)trisoxireno[4b,5:6,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one; Trisoxireno[6,7:8a,9:4b,5]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; MFCD00210565; CPD000466307; TRIPTOLIDE [MI]; TRIPTOLIDE [WHO-DD]; BSPBio_001595; KBioGR_000315; KBioSS_000315; MLS000759410; MLS001424107; MLS006010844; SCHEMBL413634; DTXSID5041144; EX-A7744A; KBio2_000315; KBio2_002883; KBio2_005451; KBio3_000629; KBio3_000630; DFBIRQPKNDILPW-CIVMWXNOSA-N; Bio2_000315; Bio2_000795; HMS1361P17; HMS1791P17; HMS1989P17; HMS2051N13; HMS3402P17; 144539-79-7; TPL; BDBM50241049; NSC839303; s3604; AKOS022168197; AM84923; CCG-100957; CS-0286; DB12025; NC00207; NSC-839303; IDI1_034065; NCGC00163411-01; NCGC00163411-02; NCGC00163411-03; NCGC00163411-07; BP-25386; BS-16697; HY-32735; NCI60_001223; Trisoxireno(4b,5:6,7:8a,9)phenanthro(1,2-c)furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, (3bS,4aS,5aS,6R,6aR,7aS,7bS,8aS,8bS)-; T2899; C09204; AB00639938-06; AB00639938-08; Q906351; Q-100450; BRD-K39484304-001-02-5; BRD-K39484304-001-06-6; BRD-K39484304-001-16-5; Triptolide, Tripterygium wilfordii - CAS 38748-32-2; (1S,2S,4S,5S,7R,8R,9S,11S)-8-Hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one; (3BS,4AS,5AS,6R,6AR,7AS,7BS,8AS,8BS)-3B,4,4A,6,6A,7A,7B,8B,9,10-DECAHYDRO-6-HYDROXY-6A-ISOPROPYL-8B-METHYLTRISOXIRENO(6,7:8A,9:4B,5)PHENANTHRO(1,2-C)FURAN-1(3H)-ONE; (5bS,6aS,7aS,8R,8aR,9aS,9bS,10aS,10bS)-8-hydroxy-8a-isopropyl-10b-methyl-2,5,5b,6,6a,8,8a,9a,9b,10b-decahydrotris(oxireno)[2',3':4b,5;2'',3'':6,7;2''',3''':8a,9]phenanthro[1,2-c]furan-3(1H)-one; Trisoxireno[4b,7:8a,9]phenanthro[1,2-c]furan-(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS*,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS*,8b.beta.)]-; Trisoxireno[4b,7:8a,9]phenanthro[1,2-c]furan-1(3H)-one, 3b,4,4a,6,6a,7a,7b,8b,9,10-decahydro-6-hydroxy-8b-methyl-6a-(1-methylethyl)-, [3bR-(3b.alpha.,4a.alpha.,5aS*,6.beta.,6a.beta.,7a.beta.,7b.alpha.,8aS*,8b.beta.)]-	.	.	360.4	C20H24O6	84.1	819	0.2	26	1	6	1	InChI=1S/C20H24O6/c1-8(2)18-13(25-18)14-20(26-14)17(3)5-4-9-10(7-23-15(9)21)11(17)6-12-19(20,24-12)16(18)22/h8,11-14,16,22H,4-7H2,1-3H3/t11-,12-,13-,14-,16+,17-,18-,19+,20+/m0/s1	CC(C)[C@@]12[C@@H](O1)[C@H]3[C@@]4(O3)[C@]5(CCC6=C([C@@H]5C[C@H]7[C@]4([C@@H]2O)O7)COC6=O)C	CC(C)C12C(O1)C3C4(O3)C5(CCC6=C(C5CC7C4(C2O)O7)COC6=O)C	DFBIRQPKNDILPW-CIVMWXNOSA-N	(1S,2S,4S,5S,7R,8R,9S,11S,13S)-8-hydroxy-1-methyl-7-propan-2-yl-3,6,10,16-tetraoxaheptacyclo[11.7.0.02,4.02,9.05,7.09,11.014,18]icos-14(18)-en-17-one
ferrodrug0170	Canagliflozin	.	Canagliflozin; 842133-18-0; Invokana; Canagliflozin anhydrous; TA-7284; JNJ-28431754; JNJ 24831754ZAE; canagliflozin hemihydrate; Canagliflozin [INN]; Canagliflozin hydrate; (2S,3R,4R,5S,6R)-2-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-6-(HYDROXYMETHYL)TETRAHYDRO-2H-PYRAN-3,4,5-TRIOL; TA 7284; 1-(Glucopyranosyl)-4-methyl-3-(5-(4-fluorophenyl)-2-thienylmethyl)benzene; JNJ 28431754; CHEBI:73274; 6S49DGR869; (2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (1S)-1,5-Anhydro-1-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-D-glucitol; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methylphenyl)-D-glucitol; (1S)-1,5-Anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-D-glucitol; D-Glucitol,1,5-anhydro-1-C-[3-[[5-(4-fluorophenyl)-2-thienyl]methyl]-4-methylphenyl]-, (1S)-; (1s)-1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4-methylphenyl)-d-glucitol; (2S,3R,4R,5S,6R)-2-(3-{[5-(4-fluorophenyl)thiophen-2-yl]methyl}-4-methylphenyl)-6-(hydroxymethyl)oxane-3,4,5-triol; UNII-6S49DGR869; JNJ 24831754AAA; JNJ 24831754; CANAGLIFLOZIN [MI]; MLS006011126; SCHEMBL157162; CANAGLIFLOZIN [WHO-DD]; GTPL4582; CHEMBL2048484; HSDB 8284; AMY3291; XTNGUQKDFGDXSJ-ZXGKGEBGSA-N; BCPP000303; DTXSID601004469; JNJ 28431754AAA; BDBM50386885; MFCD18251436; s2760; AKOS025401827; BCP9000477; CCG-229581; CS-0522; DB08907; KS-1443; NCGC00346691-02; (1S)-1,5-Anhydro-1-c-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-D-glucitol; AC-26303; HY-10451; SMR004702906; SW219119-1; A25050; EN300-6733492; J-500391; Q5030940; Z2235801995; (1S)-1,5-anhydro-1-(3-{[5-(4-fluorophenyl)-2-thienyl]methyl}-4-methyl-phenyl)-D-glucitol; (1S)-1,5-ANHYDRO-1-C-(3-((5-(4-FLUOROPHENYL)THIOPHEN-2-YL)METHYL)-4-METHYLPHENYL)-D- GLUCITOL; D-Glucitol, 1,5-anhydro-1-C-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1S)-; D-glucitol, 1,5-anhydro-1-c-(3-((5-(4-fluorophenyl)-2-thienyl)methyl)-4- methylphenyl)-, (1s)-; D-GLUCITOL, 1,5-ANHYDRO-1-C-(3-((5-(4-FLUOROPHENYL)-2-THIENYL)METHYL)-4-METHYLPHENYL)-; JNJ24831754ZAE; TA 7284;(2S,3R,4R,5S,6R)-2-(3-((5-(4-fluorophenyl)thiophen-2-yl)methyl)-4-methylphenyl)-6-(hydroxymethyl)-tetrahydro-2H-pyran-3,4,5-triol	.	.	444.5	C24H25FO5S	118	574	3.2	31	4	7	5	InChI=1S/C24H25FO5S/c1-13-2-3-15(24-23(29)22(28)21(27)19(12-26)30-24)10-16(13)11-18-8-9-20(31-18)14-4-6-17(25)7-5-14/h2-10,19,21-24,26-29H,11-12H2,1H3/t19-,21-,22+,23-,24+/m1/s1	CC1=C(C=C(C=C1)[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F	CC1=C(C=C(C=C1)C2C(C(C(C(O2)CO)O)O)O)CC3=CC=C(S3)C4=CC=C(C=C4)F	XTNGUQKDFGDXSJ-ZXGKGEBGSA-N	(2S,3R,4R,5S,6R)-2-[3-[[5-(4-fluorophenyl)thiophen-2-yl]methyl]-4-methylphenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
ferrodrug0171	Empagliflozin	Small molecular drug	Empagliflozin; 864070-44-0; JARDIANCE; BI 10773; BI10773; BI-10773; Empagliflozin (BI 10773); UNII-HDC1R2M35U; HDC1R2M35U; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-(((S)-tetrahydrofuran-3-yl)oxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; CHEBI:82720; 1-chloro-4-(glucopyranos-1-yl)-2-(4-(tetrahydrofuran-3-yloxy)benzyl)benzene; (2S,3R,4R,5S,6R)-2-[4-chloro-3-({4-[(3S)-oxolan-3-yloxy]phenyl}methyl)phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; (1S)-1,5-anhydro-1-(4-chloro-3-{4-[(3S)-tetrahydrofuran-3-yloxy]benzyl}phenyl)-D-glucitol; GLYXAMBI COMPONENT EMPAGLIFLOZIN; EMPAGLIFLOZIN COMPONENT OF GLYXAMBI; EMPAGLIFLOZIN COMPONENT OF SYNJARDY; TRIJARDY XR COMPONENT EMPAGLIFLOZIN; EMPAGLIFLOZIN COMPONENT OF TRIJARDY XR; (2S,3R,4R,5S,6R)-2-[4-CHLORO-3-[[4-[(3S)-OXOLAN-3-YL]OXYPHENYL]METHYL]PHENYL]-6-(HYDROXYMETHYL)OXANE-3,4,5-TRIOL; D-Glucitol, 1,5-anhydro-1-C-(4-chloro-3-((4-(((3S)-tetrahydro-3-furanyl)oxy)phenyl)methyl)phenyl)-, (1S)-; Empagliflozin (BI-10773;BI 10773;BI10773); (1S)-1,5-ANHYDRO-1-C-(4-CHLORO-3-((4-(((3S)-OXAN-3-YL)OXY)PHENYL)METHYL)PHENYL)-D-GLUCITOL; (1S)-1,5-anhydro-1-C-{4-chloro-3-((4-{((3S)-oxolan-3-yl)oxy}phenyl)methyl)phenyl}-D-glucitol; (2S,3R,4R,5S,6R)-2-[4-chloranyl-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol; Empagliflozin [INN]; Empagliflozin [USAN:INN]; Empagliflozina; Empagliflozine; Empagliflozinum; C23H27ClO7; MFCD22566222; Jardiance (TN); (1S)-1,5-anhydro-1-(4-chloro-3-(4-((3S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-D-glucitol; (1S)-1,5-Anhydro-1-C-(4-chloro-3-((4-(((3S)-oxolan-3-yl)oxy)phenyl)methyl)phenyl)-D-glucitol; 7R3; EMPAGLIFLOZIN [MI]; BI-10773;Empagliflozin; EMPAGLIFLOZIN [JAN]; EMPAGLIFLOZIN [USAN]; Empagliflozin (BI10773); EMPAGLIFLOZIN [VANDF]; SCHEMBL899986; EMPAGLIFLOZIN [WHO-DD]; GTPL4754; CHEMBL2107830; Empagliflozin (JAN/USAN/INN); A10BK03; AMY1858; EX-A414; BDBM150162; DTXSID601026093; EMPAGLIFLOZIN [ORANGE BOOK]; BBL104150; HB4638; s8022; STL557964; US8980829, EMPAGLIFLOZIN; AKOS024464680; CCG-269242; CS-0940; DB09038; DS-9824; PB23119; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; AC-27643; HY-15409; SW219120-1; C22194; D10459; EN300-7422890; A852380; AU-004/43508285; Q5373824; Z2235802079; 1,5-anhydro-1-{4-chloro-3-[4-(tetrahydro-3-furanyloxy)benzyl]phenyl}hexitol; (2S,3R,4R,5S,6R)-2-(4-chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxyMethyl)-tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-(4-Chloro-3-(4-((S)-tetrahydrofuran-3-yloxy)benzyl)phenyl)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; (2S,3R,4R,5S,6R)-2-[4-Chloro-3-[[4-[(3S)-tetrahydrofuran-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; D-Glucitol, 1,5-anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-, (1S)-; (1S)-1,5-Anhydro-1-C-[4-chloro-3-[[4-[[(3S)-tetrahydro-3-furanyl]oxy]phenyl]methyl]phenyl]-D-glucitol; BI 10773; Empagliflozin; Jardiance	D06ALD	DMRF9YK	450.9	C23H27ClO7	109	558	2	31	4	7	6	InChI=1S/C23H27ClO7/c24-18-6-3-14(23-22(28)21(27)20(26)19(11-25)31-23)10-15(18)9-13-1-4-16(5-2-13)30-17-7-8-29-12-17/h1-6,10,17,19-23,25-28H,7-9,11-12H2/t17-,19+,20+,21-,22+,23-/m0/s1	C1COC[C@H]1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)Cl	C1COCC1OC2=CC=C(C=C2)CC3=C(C=CC(=C3)C4C(C(C(C(O4)CO)O)O)O)Cl	OBWASQILIWPZMG-QZMOQZSNSA-N	(2S,3R,4R,5S,6R)-2-[4-chloro-3-[[4-[(3S)-oxolan-3-yl]oxyphenyl]methyl]phenyl]-6-(hydroxymethyl)oxane-3,4,5-triol
ferrodrug0172	Allicin	Small molecular drug	Allicin; 539-86-6; Diallyl thiosulfinate; S-allyl prop-2-ene-1-sulfinothioate; Diallyldisulfid-S-oxid; Thio-2-propene-1-sulfinic acid S-allyl ester; Allylthiosulphinic acid allyl ester; DADSO; S-Allyl acrylo-1-sulphinothioate; 2-Propene-1-sulfinothioic acid, S-2-propenyl ester; C6H10OS2; CCRIS 9053; S-allyl 2-propene-1-sulfinothioate; EINECS 208-727-7; UNII-3C39BY17Y6; BRN 1752823; 3-prop-2-enylsulfinylsulfanylprop-1-ene; 2-Propene-1-sulfinothioic acid S-2-propenyl ester; CHEBI:28411; 3C39BY17Y6; 2-Propene-1-sulfinic acid, thio-, S-allyl ester; CHEMBL359965; DTXSID6043707; 3-[(prop-2-ene-1-sulfinyl)sulfanyl]prop-1-ene; 4-04-00-00007 (Beilstein Handbook Reference); S-prop-2-en-1-yl prop-2-ene-1-sulfinothioate; S-2-PROPEN-1-YL 2-PROPENE-1-SULFINOTHIOATE; allimin; diallyl disulfide-oxide; allylthiosulfinate; Allicin kit; 3-allylsulfinylsulfanylprop-1-ene; Allicin, tech. grade; Diallyldisulfid-S-oxide; Allicin (not validated); Dianyctrsnlgide;Allisatin; ALLICIN [MI]; ALLICIN [WHO-DD]; ALLICIN(TECH GRADE); SCHEMBL2920; GTPL2419; 2-Propene-1-sulfinothioic Acid S-2-Propen-1-yl Ester; DTXCID4023707; JDLKFOPOAOFWQN-UHFFFAOYSA-N; 3-allylsulfinylsulfanyl-prop-1-ene; BCP08391; HY-N0315; BDBM50240948; MFCD00468100; NSC707388; s3860; AKOS006282482; ALLICIN (CONSTITUENT OF GARLIC); CCG-266298; DB11780; FD10435; NSC-707388; 3-(prop-2-enylsulfinylthio)-1-propene; AC-34150; XA162045; XA176305; CS-0008813; FT-0621982; ALLICIN (CONSTITUENT OF GARLIC) [DSC]; C07600; EN300-217463; S-2-Propenyl 2-propene-1-sulfinothioate, 9CI; A829889; Q409641; Q-200609; 2-Propene-1-sulfinothioic acid, S-2-propenyl ester (9CI); Diallyl thiosulfinate and Allylthiosulphinic acid allyl ester; Diallyldisulfid-S-oxid, 3-prop-2-enylsulfinylsulfanylprop-1-ene	D0X9YD	DMSOJ6H	162.3	C6H10OS2	61.6	120	1.3	9	0	3	5	InChI=1S/C6H10OS2/c1-3-5-8-9(7)6-4-2/h3-4H,1-2,5-6H2	C=CCSS(=O)CC=C	C=CCSS(=O)CC=C	JDLKFOPOAOFWQN-UHFFFAOYSA-N	3-prop-2-enylsulfinylsulfanylprop-1-ene
ferrodrug0173	Butein	.	butein; 487-52-5; 2',3,4,4'-Tetrahydroxychalcone; 2',4',3,4-Tetrahydroxychalcone; 3,4,2',4'-Tetrahydroxychalcone; (E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; AC1NQY7L; UNII-4WVS5M0LGF; 4WVS5M0LGF; EINECS 207-659-5; CHEBI:3237; NSC-652892; (2E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one; CHEMBL128000; 21849-70-7; 1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-; ISOLIQUIRITIGENIN METABOLITE M4; (E)-2',3,4,4'-terahydroxychalcone; Chalcone, 2',3,4,4'-tetrahydroxy-; Acrylophenone, 2',4'-dihydroxy-3-(3,4-dihydroxyphenyl)-; TETRAHYDROXYCHALCONE, 3,4,2',4'-; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-; MFCD00017300; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(3,4-DIHYDROXYPHENYL)-, (E)-; Butein, solid; LAVENDUSTINC; 2-Propen-1-one,1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-, (2E)-; Butein, analytical standard; SCHEMBL139243; 2,3,4,4-tetrahydroxy Chalcone; CHEBI:92312; 3,4,2',4'-Tetrahydroxychalone; DTXSID101025569; 2',3,4,4'-Tetrahydroxy-chalcone; 3,4,2'',4''-tetrahydroxychalone; BDBM50042949; HSCI1_000162; LMPK12120111; NSC652892; s8036; (2E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one; AKOS032948361; CCG-208298; CS-5675; 2 inverted exclamation mark ,3,4,4 inverted exclamation mark -tetrahydroxy Chalcone; NCGC00163519-01; AS-35311; HY-16558; 2',3,4,4'-Tetrahydroxychalcone; Butein; B3803; SW219249-1; C08578; A871883; Chalcone, 2',3,4,4'-tetrahydroxy-(7CI,8CI); SR-05000002316; Q5002498; SR-05000002316-2; BRD-K17497770-001-01-0; Z2312273638; 3-(3,4-Dihydroxy-phenyl)-1-(2,4-dihydroxy-phenyl)-propenone; (E)-3-(3,4-Dihydroxy-phenyl)-1-(2,4-dihydroxy-phenyl)-propenone; 2-Propen-1-one,1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-; (E)-1-(2,4-Dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)-2-propen-1-one	.	.	272.25	C15H12O5	98	367	2.8	20	4	5	3	InChI=1S/C15H12O5/c16-10-3-4-11(14(19)8-10)12(17)5-1-9-2-6-13(18)15(20)7-9/h1-8,16,18-20H/b5-1+	C1=CC(=C(C=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O)O	C1=CC(=C(C=C1C=CC(=O)C2=C(C=C(C=C2)O)O)O)O	AYMYWHCQALZEGT-ORCRQEGFSA-N	(E)-1-(2,4-dihydroxyphenyl)-3-(3,4-dihydroxyphenyl)prop-2-en-1-one
ferrodrug0174	Cabergoline	.	cabergoline; 81409-90-7; Dostinex; Cabaser; Cabergolinum [Latin]; Cabergolina [Spanish]; Cabergolinum; Cabergolina; FCE-21336; FCE 21336; Velactis; C26H37N5O2; 1-((6-Allylergolin-8beta-yl)carbonyl)-1-(3-(dimethylamino)propyl)-3-ethylurea; Cabaseril; CHEBI:3286; LL60K9J05T; DTXSID6022719; 1-[(6-allylergoline-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; 1-ethyl-3-(3'-dimethylamionpropyl)-2-(6'-allylergoline-8'beta-carbonyl)urea; (8R)-6-allyl-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)ergoline-8-carboxamide; (6aR,9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-(2-propenyl)-ergoline-8-carboxamide; DTXCID502719; Sogilen; Dostinex (TN); 1-[3-(dimethylamino)propyl]-3-ethyl-1-{[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(16),9,12,14-tetraen-4-yl]carbonyl}urea; Cabaser (TN); CAS-81409-90-7; SR-05000001493; BRN 6020775; UNII-LL60K9J05T; Caberlin; 1-[(6-allylergolin-8beta-yl)carbonyl]-1-[3-(dimethylamino)propyl]-3-ethylurea; NCGC00167821-01; Cabergoline [USAN:USP:INN:BAN]; CG-101; MFCD00867887; CABERGOLINE [MI]; CABERGOLINE [INN]; CABERGOLINE [JAN]; CABERGOLINE [USAN]; GTPL37; CABERGOLINE [VANDF]; CABERGOLINE [MART.]; SCHEMBL42292; CABERGOLINE [USP-RS]; CABERGOLINE [WHO-DD]; BIDD:GT0775; Cabergoline (JAN/USP/INN); CHEMBL1201087; Cabergoline, >=98% (HPLC); CABERGOLINE [ORANGE BOOK]; KORNTPPJEAJQIU-KJXAQDMKSA-N; CABERGOLINE [EP MONOGRAPH]; HMS2090A09; HMS3886H05; CABERGOLINE [USP MONOGRAPH]; Tox21_112589; BDBM50426497; s5842; 1-Ethyl-3-(3'-dimethylaminopropyl)-3-(6'-allylergoline-8'beta-carbonyl)urea; AKOS015961587; Tox21_112589_1; DB00248; FCE-21336FCE-21336; CABERGOLINE [EMA EPAR VETERINARY]; NCGC00344544-01; (8beta)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-(prop-2-en-1-yl)ergoline-8-carboxamide; (8beta)-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-6-prop-2-en-1-ylergoline-8-carboxamide; AC-26126; Ergoline-8-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-, (8-beta)-; Ergoline-8beta-carboxamide, N-(3-(dimethylamino)propyl)-N-((ethylamino)carbonyl)-6-(2-propenyl)-; HY-15296; MS-28208; Cabergoline 1000 microg/mL in Acetonitrile; C08187; D00987; F17353; AB01275484-01; EN300-19767804; Q423308; SR-05000001493-1; SR-05000001493-2; BRD-K86882815-001-01-6; Cabergoline, European Pharmacopoeia (EP) Reference Standard; Cabergoline, United States Pharmacopeia (USP) Reference Standard; ETHYL4-METHYL-2-PYRIDIN-3-YL-1,3-THIAZOLE-5-CARBOXYLATE; 6-allyl-N-[3-(dimethylamino)propyl]-N-[(ethylamino)carbonyl]-ergoline-8beta-carboxamide; N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-6-allyl-ergoline-8beta-carboxamide; (6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide; (9R,10aR)-7-allyl-N-(3-(dimethylamino)propyl)-N-(ethylcarbamoyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinoline-9-carboxamide; 1-[3-(dimethylamino)propyl]-3-ethyl-1-[(2R,4R,7R)-6-(prop-2-en-1-yl)-6,11-diazatetracyclo[7.6.1.0^{2,7}.0^{12,16}]hexadeca-1(15),9,12(16),13-tetraene-4-carbonyl]urea; Cabergoline; 1-Ethyl-3-[3-(dimethylamino)propyl]-3-[[(6aR,9R,10aR)-7-(prop-2-enyl)-4,6,6a,7,8,9,10,10a-octahydroindolo[4,3-fg]quinolin-9-yl]carbonyl]urea; ERGOLINE-8.BETA.-CARBOXAMIDE, N-(3-(DIMETHYLAMINO)PROPYL)-N-((ETHYLAMINO)CARBONYL)-6-(2-PROPENYL)-	.	.	451.6	C26H37N5O2	71.7	713	3.4	33	2	4	8	InChI=1S/C26H37N5O2/c1-5-11-30-17-19(25(32)31(26(33)27-6-2)13-8-12-29(3)4)14-21-20-9-7-10-22-24(20)18(16-28-22)15-23(21)30/h5,7,9-10,16,19,21,23,28H,1,6,8,11-15,17H2,2-4H3,(H,27,33)/t19-,21-,23-/m1/s1	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C	CCNC(=O)N(CCCN(C)C)C(=O)C1CC2C(CC3=CNC4=CC=CC2=C34)N(C1)CC=C	KORNTPPJEAJQIU-KJXAQDMKSA-N	(6aR,9R,10aR)-N-[3-(dimethylamino)propyl]-N-(ethylcarbamoyl)-7-prop-2-enyl-6,6a,8,9,10,10a-hexahydro-4H-indolo[4,3-fg]quinoline-9-carboxamide
ferrodrug0175	Juglone	.	juglone; 481-39-0; 5-Hydroxy-1,4-naphthoquinone; 5-Hydroxy-1,4-naphthalenedione; 5-Hydroxynaphthalene-1,4-dione; Regianin; Nucin; Juglon; Akhnot; Yuglon; C.I. Natural Brown 7; 8-Hydroxy-1,4-naphthoquinone; 5-Hydroxynaphthoquinone; 1,4-NAPHTHALENEDIONE, 5-HYDROXY-; 5-Hydroxy-p-naphthoquinone; C.I. 75500; 1,4-Naphthoquinone, 5-hydroxy-; Juglane; Jugnlon; Iuglon; 1,4-Naphthoquinone, 8-hydroxy-; 5-Hydroxy-1,4-naphthosemiquinone; 5-Hydroxy-1,4-naftochinon; NSC 153189; NSC 622948; 5-hydroxy-1,4-dihydronaphthalene-1,4-dione; JUGLONE CRYSTALLIZED; CHEMBL43612; W6Q80SK9L6; 5-Hydroxy-[1,4]Naphthoquinone; 8-Hydroxy-1,4-naphthalenedione; CHEBI:15794; NCI 2323; NSC34266; NSC153189; NSC622948; NSC-153189; NSC-622948; 481-13-0; 1, 8-hydroxy-; WLN: L66 BV EVJ GQ; Caswell No. 515AA; CCRIS 5423; EINECS 207-567-5; 5-Hydroxy-1,4-naftochinon [Czech]; BRN 1909764; UNII-W6Q80SK9L6; Antibiotic PD7; MFCD00001684; Spectrum_000415; 3b7j; JUGLONE [MI]; Spectrum2_000778; Spectrum3_001228; Spectrum4_001769; Spectrum5_000357; 5-HNQ; SCHEMBL34185; BSPBio_001157; BSPBio_002676; KBioGR_000497; KBioGR_002257; KBioGR_002470; KBioSS_000497; KBioSS_000895; KBioSS_002477; SPECTRUM300038; 4-08-00-02368 (Beilstein Handbook Reference); DivK1c_001026; SPBio_000856; -Hydroxy-1,4-naphthalenedione; DTXSID0031504; BDBM24777; HMS503M13; KBio1_001026; KBio2_000497; KBio2_000895; KBio2_002470; KBio2_003065; KBio2_003463; KBio2_005038; KBio2_005633; KBio2_006031; KBio2_007606; KBio3_000913; KBio3_000914; KBio3_002176; KBio3_002948; 5-hydroxy-naphthalene-1,4-dione; cMAP_000058; NINDS_001026; Bio1_000441; Bio1_000930; Bio1_001419; Bio2_000409; Bio2_000889; HMS1362I19; HMS1792I19; HMS1923G07; HMS1990I19; HMS3403I19; Juglone - CAS 481-39-0; 5-hydroxy-1,4-naphthoquinone, 4; HY-N6949; CCG-40256; NSC-34266; s5512; ZB1862; 5-Hydroxy-1,4-naphthoquinone, 97%; AKOS001576598; 5-Hydroxy-1,4-naphthalenedione, 9CI; CS-W017516; SDCCGMLS-0066542.P001; IDI1_001026; IDI1_002164; SMP1_000168; NCGC00095247-01; NCGC00095247-02; NCGC00095247-03; NCGC00095247-04; NCGC00095247-05; CI 75500; CI-75500; 1,4-dihydro-1,4-dioxo-5-hydroxynaphthalene; AM20040546; FT-0627559; H0286; C03840; EN300-160375; F17689; A827478; A936425; Q900912; SR-05000002406; J-650071; Q-100522; SR-05000002406-1; F0451-0746; InChI=1/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12	.	.	174.15	C10H6O3	54.4	280	1.9	13	1	3	0	InChI=1S/C10H6O3/c11-7-4-5-9(13)10-6(7)2-1-3-8(10)12/h1-5,12H	C1=CC2=C(C(=O)C=CC2=O)C(=C1)O	C1=CC2=C(C(=O)C=CC2=O)C(=C1)O	KQPYUDDGWXQXHS-UHFFFAOYSA-N	5-hydroxynaphthalene-1,4-dione
ferrodrug0176	Baicalin	Small molecular drug	Baicalin; 21967-41-9; Baicalein 7-O-glucuronide; 7-D-Glucuronic acid-5,6-dihydroxyflavone; CHEBI:2981; Baicalein 7-glucuronide; MFCD00134418; 347Q89U4M5; 5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl beta-D-glucopyranosiduronic acid; CHEMBL485818; UNII-347Q89U4M5; 5,6,7-trihydroxyflavone 7-O-beta-D-glucuronide; Baicalein 7-O-.beta.-D-glucuronide; (2S,3S,4S,5R,6S)-6-[(5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy]-3,4,5-trihydroxyoxane-2-carboxylic acid; beta-D-Glucopyranosiduronic acid, 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl; 5,6-dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl beta-D-glucopyranosiduronic acid; 5,6-Dihydroxy-4-oxo-2-phenyl-4H-1-benzopyran-7-yl ; A-D-Glucopyranosiduronic Acid; BAICALEIN 7-O-GLUCURONIDE (USP-RS); BAICALEIN 7-O-GLUCURONIDE [USP-RS]; BAICALEIN 7-O-BETA-D-GLUCURONIDE; baikalin; Baicaloside; 31564-28-0; Baicalin,(S); (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; 0XE; Baicalin, 95%; (2S,3S,4S,5R,6S)-6-((5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid; BAICALIN [INCI]; 7-D-glucuronic acid-5,6-dihydroxy-flavone; BAICALIN [VANDF]; Baicalein-7-D-glucuronide; BAICALIN [WHO-DD]; SCHEMBL285082; Baicalein 7-beta-D-glucuronide; Baicalein 7-O-b-D-glucuronide; TJN-151; IKIIZLYTISPENI-ZFORQUDYSA-N; DTXSID701346569; Baicalin, >=99.0% (HPLC); HY-N0197; BDBM50242173; AKOS007930529; AKOS015955933; Baicalin 1000 microg/mL in Methanol; AC-7990; AM84780; CCG-214128; CS-5302; Baicalein 7-beta-D-glucopyranosiduronate; NCGC00386028-03; (2S,3S,4S,5R,6S)-6-(5,6-DIHYDROXY-4-OXO-2-PHENYL-CHROMEN-7-YL)OXY-3,4,5-TRIHYDROXY-OXANE-2-CARBOXYLIC ACID; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenyl-chromen-7-yl)oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; AS-13226; PD132941; A815791; J-013512; Q-100275; Q2879368; BRD-K49962337-001-01-1; Baicalin, European Pharmacopoeia (EP) Reference Standard; 5,6,7-Trihydroxyflavone-7-O-.beta.-D-glucopyranosideuronic acid; (2S,3S,4S,5R,6R)-6-(5,6-dihydroxy-4-oxo-2-phenyl-chromen-7-yl)oxy-3,4,5-trihydroxy-tetrahydropyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenyl-4H-chromen-7-yloxy)-3,4,5-trihydroxy-tetrahydro-2H-pyran-2-carboxylic acid; (2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylicacid; .BETA.-D-GLUCOPYRANOSIDURONIC ACID, 5,6-DIHYDROXY-4-OXO-2-PHENYL-4H-1-BENZOPYRAN-7-YL	D08PUW	DMY1TLZ	446.4	C21H18O11	183	748	1.1	32	6	11	4	InChI=1S/C21H18O11/c22-9-6-10(8-4-2-1-3-5-8)30-11-7-12(14(23)15(24)13(9)11)31-21-18(27)16(25)17(26)19(32-21)20(28)29/h1-7,16-19,21,23-27H,(H,28,29)/t16-,17-,18+,19-,21+/m0/s1	C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)O)O)O)O)O)O	C1=CC=C(C=C1)C2=CC(=O)C3=C(C(=C(C=C3O2)OC4C(C(C(C(O4)C(=O)O)O)O)O)O)O	IKIIZLYTISPENI-ZFORQUDYSA-N	(2S,3S,4S,5R,6S)-6-(5,6-dihydroxy-4-oxo-2-phenylchromen-7-yl)oxy-3,4,5-trihydroxyoxane-2-carboxylic acid
ferrodrug0177	Levosimendan	Small molecular drug	LEVOSIMENDAN; 141505-33-1; Simdax; (R)-Simendan; Levosimedan; (-)-OR-1259; OR-1259; Simendan, (r)-; CHEBI:50567; NSC-759644; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile; DTXSID9046445; C6T4514L4E; OR1259; (R)-((4-(1,4,5,6-Tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono) propanedintrile; (R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide; Levosimendan [INN]; Mesoxalonitrile (p-((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-pyridazinyl)phenyl)hydrazone; DTXCID7026445; levosimendanum; ((4-(1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazono)propanedinitrile; Simsndan;OR-1259; 1-cyano-N-{4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}methanecarbohydrazonoyl cyanide; SMR002529692; Simdax (TN); CAS-141505-33-1; Levosimendan (USAN/INN); Levosimendan [USAN:INN]; OR 1259; UNII-C6T4514L4E; Levosimendan- Bio-X; LEVOSIMENDAN [MI]; LEVOSIMENDAN [USAN]; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6-oxo-3-pyridazinyl)phenyl)hydrazone; SCHEMBL83243; LEVOSIMENDAN [MART.]; MLS003899227; MLS006010741; LEVOSIMENDAN [WHO-DD]; CHEMBL2051955; Levosimendan, >=98% (HPLC); WHXMKTBCFHIYNQ-SECBINFHSA-N; HMS3264G03; HMS3884N17; KUC109648N; Pharmakon1600-01502356; BCP07048; Tox21_112191; Tox21_113768; BDBM50469700; MFCD00867135; NSC759644; s2446; AKOS015895214; Tox21_112191_1; AC-1752; AM84381; CCG-213048; DB00922; DS-8918; NSC 759644; ({4-[(4R)-4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl]phenyl}hydrazono)propanedintrile; 2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazono]propanedinitrile; KSC-210-010; NCGC00253641-01; NCGC00263564-01; NCGC00263564-02; BM164625; HY-14286; L0320; SW219172-1; A11874; D04720; N12889; AB01562970_01; AB01562970_02; A807767; EN300-18567987; Q162541; SR-01000931342; SR-01000931342-2; 1-beta-D-Ribofuranose-1H-1,2,4-triazole-3-methylcarbonate; (R)-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyl dicyanide; (R)-N-(4-(4-methyl-6-oxo-1,4,5,6-tetrahydropyridazin-3-yl)phenyl)carbonohydrazonoyldicyanide; 2-(2-(4-((4R)-1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)HYDRAZINYLIDENE)PROPANEDINITRILE; Mesoxalonitrile (-)-(p((R)-1,4,5,6-tetrahydro-4-methyl-6- oxo-3-pyridazinyl)phenyl)hydrazone; PROPANEDINITRILE, ((4-(1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)HYDRAZONO)-, (R)-; PROPANEDINITRILE, 2-(2-(4-((4R)-1,4,5,6-TETRAHYDRO-4-METHYL-6-OXO-3-PYRIDAZINYL)PHENYL)HYDRAZINYLIDENE)-	D0C4HG	DMKBOS2	280.28	C14H12N6O	113	549	2.3	21	2	6	3	InChI=1S/C14H12N6O/c1-9-6-13(21)19-20-14(9)10-2-4-11(5-3-10)17-18-12(7-15)8-16/h2-5,9,17H,6H2,1H3,(H,19,21)/t9-/m1/s1	C[C@@H]1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N	CC1CC(=O)NN=C1C2=CC=C(C=C2)NN=C(C#N)C#N	WHXMKTBCFHIYNQ-SECBINFHSA-N	2-[[4-[(4R)-4-methyl-6-oxo-4,5-dihydro-1H-pyridazin-3-yl]phenyl]hydrazinylidene]propanedinitrile
ferrodrug0178	Tectorigenin	.	Tectorigenin; 548-77-6; Tectorigenine; 4',5,7-Trihydroxy-6-methoxyisoflavone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-chromen-4-one; K 251T; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxychromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-; 5,7,4'-Trihydroxy-6-methoxyisoflavone; 5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one; CHEBI:9429; CHEMBL242740; 855130H9CO; 3-(4-hydroxyphenyl)-6-methoxy-5,7-bis(oxidanyl)chromen-4-one; BRN 0305601; 4',5',7-trihydroxy-6-methoxyisoflavone; UNII-855130H9CO; Spectrum_000761; SpecPlus_000145; TECTORIGENIN [MI]; KBioSS_001241; 5-18-05-00311 (Beilstein Handbook Reference); ISOFLAVONE, 4',5,7-TRIHYDROXY-6-METHOXY-; DivK1c_006241; SCHEMBL351641; GTPL9738; KBio1_001185; KBio2_001241; KBio2_003809; KBio2_006377; Tectorigenin, analytical standard; DTXSID50203286; EX-A6676; HY-N0792; BDBM50241222; LMPK12050385; MFCD00597094; s9122; AKOS015897084; CCG-267463; AS-56397; CS-0009804; FT-0688353; T3729; A870334; Q-100619; Q3517006; 5,7-Dihydroxy-3-(4-hydroxy-phenyl)-6-methoxy-chromen-4-one; R0U	.	.	300.26	C16H12O6	96.2	454	2.6	22	3	6	2	InChI=1S/C16H12O6/c1-21-16-11(18)6-12-13(15(16)20)14(19)10(7-22-12)8-2-4-9(17)5-3-8/h2-7,17-18,20H,1H3	COC1=C(C2=C(C=C1O)OC=C(C2=O)C3=CC=C(C=C3)O)O	COC1=C(C2=C(C=C1O)OC=C(C2=O)C3=CC=C(C=C3)O)O	OBBCRPUNCUPUOS-UHFFFAOYSA-N	5,7-dihydroxy-3-(4-hydroxyphenyl)-6-methoxychromen-4-one
ferrodrug0179	Ibrutinib	.	Ibrutinib; 936563-96-1; PCI-32765; IMBRUVICA; PCI 32765; Ibrutinib (PCI-32765); PCI-32765 (Ibrutinib); CRA-032765; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; Pc-32765; 1X70OSD4VX; PCI-32765-00; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; CHEBI:76612; PCI32765; 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one; 1-{(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl}prop-2-en-1-one; 2-Propen-1-one, 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)-1-piperidinyl)-; C25H24N6O2; (R)-1-(3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one.; 1-((3R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo(3,4-d)pyrimidin-1-yl)piperidin-1- yl)prop-2-en-1-one; Ibrutinib [USAN]; Ibrutinib [USAN:INN]; UNII-1X70OSD4VX; ibrutinibum; JNJ 02; Imbruvica (TN); Ibrutinib- Bio-X; 1-{(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1- yl}prop-2-en-1-one; 2-Propen-1-one, 1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-; CRA 032765; Ibrutinib, Free Base; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl]-1-piperidinyl]-2-propen-1-one; IBRUTINIB [INN]; IBRUTINIB [JAN]; IBRUTINIB [MI]; Ibrutinib (JAN/USAN); IBRUTINIB [VANDF]; IBRUTINIB [WHO-DD]; Imbruvica; PCI-32765; MLS006010041; SCHEMBL201859; GTPL6912; IBRUTINIB [ORANGE BOOK]; CHEMBL1873475; HSDB 8260; DTXSID60893450; EX-A066; XYFPWWZEPKGCCK-GOSISDBHSA-N; AMY27873; BDBM50357312; MFCD20261150; NSC800769; AKOS022185476; DB09053; EX-5960; NSC-800769; NCGC00187912-01; NCGC00187912-02; NCGC00187912-03; NCGC00187912-12; (R)-1-(3-(4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo-[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; AC-26942; BI164531; HY-10997; SMR004701213; SW218096-2; EN300-97039; D10223; A1-01649; J-523872; Q5984881; Z1302446275; (R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-ylprop-2-en-1-one; 1-((R)-3-(4-amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-1-yl)piperidin-1-yl)prop-2-en-1-one; 1-[(3R)-3-[4-Amino-3-(4-phenoxyphenyl)pyrazolo[3, 4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one	.	.	440.5	C25H24N6O2	99.2	678	3.6	33	1	6	5	InChI=1S/C25H24N6O2/c1-2-21(32)30-14-6-7-18(15-30)31-25-22(24(26)27-16-28-25)23(29-31)17-10-12-20(13-11-17)33-19-8-4-3-5-9-19/h2-5,8-13,16,18H,1,6-7,14-15H2,(H2,26,27,28)/t18-/m1/s1	C=CC(=O)N1CCC[C@H](C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N	C=CC(=O)N1CCCC(C1)N2C3=NC=NC(=C3C(=N2)C4=CC=C(C=C4)OC5=CC=CC=C5)N	XYFPWWZEPKGCCK-GOSISDBHSA-N	1-[(3R)-3-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]piperidin-1-yl]prop-2-en-1-one
ferrodrug0180	Sesamin	.	sesamin; 607-80-7; Fagarol; Sezamin; (+)-Sesamin; D-(+)-Sesamin; d-Sesamin; Asarinin; Episesamin; (+/-)-Sesamin; Sesamin dl-form [MI]; CHEBI:66470; Sesamin, (+/-)-; pseudocubebin; NSC 36403; (+)-Segamin; UNII-S7946O4P76; AI3-00811; S7946O4P76; FY3S29JVC9; NSC-36403; 1H,3H-Furo(3,4-c)furan, tetrahydro-1,4-bis(3,4-(methylenedioxy)phenyl)-, (1S,3aR,4S,6aR)-; 81602-22-4; PSEUDO CUBEBIN; Sesamin, (+)-; 1,3-Benzodioxole, 5,5'-((1R,3as,4R,6as)-tetrahydro-1H,3h-furo(3,4-c)furan-1,4-diyl)bis-, rel-; 1,3-Benzodioxole, 5,5'-(tetrahydro-1H,3H-furo(3,4-c)furan-1,4-diyl)bis-, (1S-(1alpha,3a alpha,4alpha,6a alpha))-; 5-[(3S,3aR,6S,6aR)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-1,3-benzodioxole; l-sesamin; (1S,3aR,4S,6aR)-1,4-Bis(benzo[d][1,3]dioxol-5-yl)hexahydrofuro[3,4-c]furan; 5,5'-(TETRAHYDRO-1H,3H-FURO(3,4-C)FURAN-1,4-DIYL)BIS-1,3-BENZODIOXOLE; TETRAHYDRO-1,4-BIS(3,4-(METHYLENEDIOXY)PHENYL)-1H,3H-FURO(3,4-C)FURAN; SMR000445559; SR-01000777562; UNII-FY3S29JVC9; Fsesamin; 5,5'-(1S,3aR,4S,6aR)-tetrahydro-1H,3H-furo(3,4-c)furan-1,4-diylbis(1,3-benzodioxole); 5,5'-(1S,3aR,4S,6aR)-tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diylbis(1,3-benzodioxole); Sesamin (Fagarol); Sesamin - Fagarol; 5-[(3S,3aR,6S,6aR)-6-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-3-yl]-1,3-benzodioxole; Sesamin,(S); Rel-(7S,7'S8R,8'R)-Sesamin; MFCD00216134; SESAMIN D-FORM; SESAMIN [MI]; SESAMIN [WHO-DD]; Sesamin, analytical standard; SCHEMBL94517; SESAMIN D-FORM [MI]; MLS000728578; MLS002473316; CHEMBL252915; Sesamin, >=95%, crystalline; Sesamin, >=98% (HPLC); ACon0_000323; ACon1_002421; GTPL11372; DTXSID301030528; HMS2232F11; HY-N0121; BDBM50542904; s2392; AKOS022168195; CCG-268081; (1S,3aR,4S,6aR)-1,4-bis(benzo[d][1,3]dioxol-5-yl)tetrahydro-1H,3H-furo[3,4-c]furan; dioxol-5-yl)hexahydrofuro[3,4-c]furan; NCGC00169864-01; NCGC00169864-02; 1,3-Benzodioxole, 5,5'-(tetrahydro-1H,3h-furo(3,4-c)furan-1,4-diyl)bis-, (1alpha,3aalpha,4alpha,6aalpha)-; 1,3-Benzodioxole, 5,5'-(tetrahydro-1H,3h-furo(3,4-c)furan-1,4-diyl)bis-, (1alpha,3aalpha,4alpha,6aalpha)-(+/-)-; 1,3-Benzodioxole, 5,5'-(tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diyl)bis-, (1S,3aR,4S,6aR)-; AS-13527; REL-(7S,7'S,8R,8'R)-SESAMIN; CS-0007831; (1S,3aR,4S,6aR)-1,4-di(benzo[d][1,3]; A832882; Q-100697; Q3511416; SR-01000777562-3; SR-01000777562-4; (1S,3aR,4S,6aR)-1,4-di(benzo[d][1,3]dioxol-5-yl)hexahydrofuro[3,4-c]furan; 5,5'-(1S,3aR,4S,6aR)-Tetrahydro-1H,3H-furo[3,4-c]furan-1,4-diylbis(1,3-benzodioxol); 1,3-BENZODIOXOLE, 5,5'-(TETRAHYDRO-1H,3H-FURO(3,4-C)FURAN-1,4-DIYL)BIS-, (1.ALPHA.,3A.ALPHA.,4.ALPHA.,6A.ALPHA.)-; 1,3-BENZODIOXOLE, 5,5'-(TETRAHYDRO-1H,3H-FURO(3,4-C)FURAN-1,4-DIYL)BIS-, (1.ALPHA.,3A.ALPHA.,4.ALPHA.,6A.ALPHA.)-(+/-)-; 1,3-BENZODIOXOLE, 5,5'-(TETRAHYDRO-1H,3H-FURO(3,4-C)FURAN-1,4-DIYL)BIS-, (1S-(1.ALPHA.,3A .ALPHA.,4.ALPHA.,6A .ALPHA.))-	.	.	354.4	C20H18O6	55.4	482	2.7	26	0	6	2	InChI=1S/C20H18O6/c1-3-15-17(25-9-23-15)5-11(1)19-13-7-22-20(14(13)8-21-19)12-2-4-16-18(6-12)26-10-24-16/h1-6,13-14,19-20H,7-10H2/t13-,14-,19+,20+/m0/s1	C1[C@H]2[C@H](CO[C@@H]2C3=CC4=C(C=C3)OCO4)[C@H](O1)C5=CC6=C(C=C5)OCO6	C1C2C(COC2C3=CC4=C(C=C3)OCO4)C(O1)C5=CC6=C(C=C5)OCO6	PEYUIKBAABKQKQ-AFHBHXEDSA-N	5-[(3S,3aR,6S,6aR)-3-(1,3-benzodioxol-5-yl)-1,3,3a,4,6,6a-hexahydrofuro[3,4-c]furan-6-yl]-1,3-benzodioxole
ferrodrug0181	Ruxolitinib	.	Ruxolitinib; 941678-49-5; INCB018424; Ruxolitinib (INCB018424); INCB-018424; (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile; INCB 018424; R-Ruxolitinib; INC424; UNII-82S8X8XX8H; 82S8X8XX8H; CHEBI:66919; (R)-ruxolitinib; INCB18424; INC 424; INC-424; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; INCB-18424; HSDB 8259; DTXSID10240930; (3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; (betaR)-beta-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; (3R)-3-cyclopentyl-3-(4-{7H-pyrrolo[2,3-d]pyrimidin-4-yl}-1H-pyrazol-1-yl)propanenitrile; (3R)-3-CYCLOPENTYL-3-(4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)PYRAZOL-1-YL)PROPANENITRILE; 1H-Pyrazole-1-propanenitrile, beta-cyclopentyl-4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-,(betaR)-; Ruxolitinib [INN]; Ruxolitinib [USAN:INN]; ruxolitinibum; INCB 18424; (3R)-3-cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)-1H-pyrazol-1-yl)propanenitrile; RXT; RUXOLITINIB [MI]; 1092939-15-5; Ruxolitinib (USAN/INN); INCB18424,Ruxolitinib; RUXOLITINIB [USAN]; RUXOLITINIB [VANDF]; RUXOLITINIB [WHO-DD]; SCHEMBL171319; GTPL5688; INCB018424 - Ruxolitinib; CHEMBL1789941; SCHEMBL16546708; DTXCID40163421; L01XE18; HFNKQEVNSGCOJV-OAHLLOKOSA-N; Oral JAK Inhibitor INCB18424; AMY24152; EX-A1670; BDBM50355501; MFCD12031592; NSC763371; NSC800874; s1378; AKOS016842401; BCP9000784; CCG-264889; CS-0864; DB08877; NSC-763371; NSC-800874; NCGC00244253-01; NCGC00244253-02; NCGC00244253-11; NCGC00244253-12; AC-24280; AS-18619; HY-50856; A14955; A23578; D09959; AB01565782_02; EN300-18772174; Q7383611; BRD-K53972329-001-02-1; BRD-K53972329-001-03-9; (3R)-3-cyclopentyl-3-[4-(1H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile; (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H -pyrazol-1-yl)-3-cyclopentylpropanenitrile; 3-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(beta-R)-1H-pyrazole-1-propanenitrile; 3R)-3-cyclopentyl-3-(4-(7H-pyrrolo(2,3-d)pyrimidin-4-yl)pyrazol-1-yl)propanenitrile; A-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-(AR)-1H-pyrazole-1-propanenitrile; (?R)-?-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; (3R)-3-Cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl]propanenitrile; (?R)-?-Cyclopentyl-4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazole-1-propanenitrile; INC 424; INCB 018424; Ruxolitinib; (3R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile;Ruxolitinib; 1H-PYRAZOLE-1-PROPANENITRILE, .BETA.-CYCLOPENTYL-4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (.BETA.R)-; 1H-PYRAZOLE-1-PROPANENITRILE, beta-CYCLOPENTYL-4-(7H-PYRROLO(2,3-D)PYRIMIDIN-4-YL)-, (betaR)-	.	.	306.4	C17H18N6	83.2	453	2.1	23	1	4	4	InChI=1S/C17H18N6/c18-7-5-15(12-3-1-2-4-12)23-10-13(9-22-23)16-14-6-8-19-17(14)21-11-20-16/h6,8-12,15H,1-5H2,(H,19,20,21)/t15-/m1/s1	C1CCC(C1)[C@@H](CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3	C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3	HFNKQEVNSGCOJV-OAHLLOKOSA-N	(3R)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
ferrodrug0182	Trolox	.	trolox; 53188-07-1; 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; TROLOX C; 6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; 56305-04-5; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-; CHEBI:82625; S18UL9710X; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-chromene-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-chromane-2-carboxylic acid; (+/-)-6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; 6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydro-2H-1-benzopyran-2-carboxylic acid; EINECS 258-422-8; MFCD00006846; BRN 5052542; UNII-S18UL9710X; Trolox(TM); Prestwick_855; TROLOX [INCI]; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid; Prestwick0_000530; Prestwick1_000530; Prestwick2_000530; Prestwick3_000530; TROLOX [MI]; CHEMBL153; SCHEMBL3226; 2H-1-Benzopyran-2-carboxylic acid, 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-, (+-)-; Oprea1_727377; BSPBio_000519; MLS002153860; SPBio_002440; (+/-)-TROLOX; BPBio1_000571; 6-Hydroxy-2,5,7,8-tetramethyl-chroman-2-carboxylic acid; DTXSID60866306; HMS1569J21; HMS2096J21; HMS2230A15; HMS3369E20; HMS3713J21; HMS3885K19; (R,S)-6-hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid; BCP16474; BBL103047; BDBM50359629; GEO-03688; s3665; STL556856; AKOS015856256; CCG-207912; CS-8035; 3,4-dihydro-6-hydroxy-2,5,7,8-tetramethyl-2h-1-benzopyran-2- carboxylic acid; NCGC00179534-01; AS-30121; SMR001233218; HY-101445; FT-0621156; FT-0770514; H0726; EN300-370592; Q245489; SR-01000841227; SR-01000841227-2; BRD-A17846016-001-03-0; BRD-A17846016-001-07-1; 6-hydroxy-2,5,7,8-tetramethychroman-2-carboxylic acid; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromancarboxylic acid; Z3013814504; 6-Hydroxy-2,5,7,8-tetramethyl-2-chromanecarboxylic acid #; (6-hydroxy-2,5,7,8-tetramethylchroman-2-yl)carboxylic acid; (+/-)- 6-hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid; (+/-)-6-Hydroxy-2,5,7,8-tetramethylchromane-2-carboxylic acid, 97%; (S)-(-)-6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLICACID; 6-HYDROXY-2,5,7,8-TETRAMETHYLCHROMAN-2-CARBOXYLIC ACID, (+/-)-; 3,4-Dihydro-6-hydroxy-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic Acid;; 6-hydroxy-3,4-dihydro-2,5,7,8-tetramethyl-2H-1-benzopyran-2-carboxylic acid; Trolox is also know as 6-Hydroxy-2,5,7,8-tetramethylchroman-2-carboxylic acid.; 2H-1-BENZOPYRAN-2-CARBOXYLIC ACID, 3,4-DIHYDRO-6-HYDROXY-2,5,7,8-TETRAMETHYL-, (+/-)-	.	.	250.29	C14H18O4	66.8	343	2.8	18	2	4	1	InChI=1S/C14H18O4/c1-7-8(2)12-10(9(3)11(7)15)5-6-14(4,18-12)13(16)17/h15H,5-6H2,1-4H3,(H,16,17)	CC1=C(C2=C(CCC(O2)(C)C(=O)O)C(=C1O)C)C	CC1=C(C2=C(CCC(O2)(C)C(=O)O)C(=C1O)C)C	GLEVLJDDWXEYCO-UHFFFAOYSA-N	6-hydroxy-2,5,7,8-tetramethyl-3,4-dihydrochromene-2-carboxylic acid
ferrodrug0183	Dimethyl trisulfide	.	Dimethyl trisulfide; 3658-80-8; Trisulfide, dimethyl; Methyl trisulfide; DIMETHYLTRISULFIDE; 2,3,4-Trithiapentane; (methyltrisulfanyl)methane; Dimethyl trisulphide; dimethyltrisulfane; DMTS; FEMA No. 3275; CH3SSSCH3; 3E691T3NL1; NSC-97324; UNII-3E691T3NL1; Dimethyl trisufide; EINECS 222-910-9; 2,4-Trithiapentane; NSC 97324; trisulfane, dimethyl-; 1,3-Dimethyltrisulfane; AI3-26172; 1,3-Dimethyltrisulfane #; SCHEMBL446658; methylsulfanyldisulfanyl-methane; CHEBI:4614; DTXSID9063118; YWHLKYXPLRWGSE-UHFFFAOYSA-N; DIMETHYL TRISULFIDE [FHFI]; Dimethyl trisulfide, >=98%, FG; NSC97324; MFCD00039808; NSC801680; s6311; AKOS015897465; NSC-801680; 2,3,4-Trithiapentane; NSC 97324; Dimethyl trisulfide, analytical standard; BS-43830; 1,3-Dimethyltrisulfane (ACD/Name 4.0); HY-128454; CS-0099182; D3418; FT-0625104; FT-0667568; C08372; D90187; InChI=1/C2H6S3/c1-3-5-4-2/h1-2H; A823301; Q-100435; Q5277321; FLAMMABLE LIQUID, N.O.S. (DIMETHYL TRISULPHIDE)	.	.	126.3	C2H6S3	75.9	12.4	1.3	5	0	3	2	InChI=1S/C2H6S3/c1-3-5-4-2/h1-2H3	CSSSC	CSSSC	YWHLKYXPLRWGSE-UHFFFAOYSA-N	(methyltrisulfanyl)methane
ferrodrug0184	Dexmedetomidine	Small molecular drug	DEXMEDETOMIDINE; 113775-47-6; Dexmedetomidinum; MPV 1440; Precedex; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole; MPV-1440; Dexmedetomidina; (+)-4-((S)-alpha,2,3-Trimethylbenzyl)imidazole; Medetomidine, (s)-; (S)-5-(1-(2,3-Dimethylphenyl)ethyl)-1H-imidazole; Precedex (TN); CHEMBL778; 67VB76HONO; CHEBI:4466; 113775-47-6 (free base); 1H-Imidazole, 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-; 4-[(1~{S})-1-(2,3-dimethylphenyl)ethyl]-1~{H}-imidazole; (S)-4-[1-(2,3-Dimethylphenyl)ethyl]-1H-imidazole; UNII-67VB76HONO; Dexmedetomidine (USAN/INN); Dexmedetomidinum [INN-Latin]; Dexmedetomidina [INN-Spanish]; MFCD00880557; Dexmedetomidine [USAN:INN:BAN]; Dexdor (TN); Tocris-2023; NCGC00025347-01; (S)-4-(1-(2,3-dimethylphenyl)ethyl)-1H-imidazole; DEXMEDETOMIDINE [MI]; SCHEMBL26433; DEXMEDETOMIDINE [INN]; GTPL521; DEXMEDETOMIDINE [USAN]; DEXMEDETOMIDINE [VANDF]; (+)-(S)-4-[1-(2,3-dimethylphenyl) ethyl]-1H -imidazole monohydrochloride; DEXMEDETOMIDINE [WHO-DD]; DexmedetomidineHclC13H16N2.Hcl; DTXSID10873388; TPU 006; CUHVIMMYOGQXCV-NSHDSACASA-N; HMS3885M07; DEXMEDETOMIDINE [GREEN BOOK]; BDBM50085683; s3075; AKOS025149503; AKOS026750524; CCG-266586; DB00633; Igalmi (dexmedetomidine sublingual film); NCGC00371080-02; NCGC00371080-09; AS-68685; HY-12719; CS-0012295; SW219607-1; C07450; D00514; EN300-127736; AB01566872_01; AB01566872_02; Q412133; 4-[(1S)-1-(2,3-Dimethylphenyl)ethyl]-1H-imidazol; 4-[(1S)-1-(2,3-dimethylphenyl)ethyl]-3H-imidazole; 1H-Imidazole, 5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-; 4-[(s)-1-(2,3-dimethyl-phenyl)-ethyl]-1h-imidazole; (+)-4-((S)-.ALPHA.,2,3-TRIMETHYLBENZYL)IMIDAZOLE	D0U3DU	DM93L4X	200.28	C13H16N2	28.7	205	3.1	15	1	1	2	InChI=1S/C13H16N2/c1-9-5-4-6-12(10(9)2)11(3)13-7-14-8-15-13/h4-8,11H,1-3H3,(H,14,15)/t11-/m0/s1	CC1=C(C(=CC=C1)[C@H](C)C2=CN=CN2)C	CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C	CUHVIMMYOGQXCV-NSHDSACASA-N	5-[(1S)-1-(2,3-dimethylphenyl)ethyl]-1H-imidazole
ferrodrug0185	Dihydromyricetin	.	Dihydromyricetin; Ampelopsin; 27200-12-0; Ampeloptin; (+)-Dihydromyricetin; (+)-Ampelopsin; (2r,3r)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)chroman-4-one; Telocapil; Myriceline spe; C15H12O8; Flavanone, 3,3',4',5,5',7-hexahydroxy-; 4H-1-Benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, (2R-trans)-; (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydrochromen-4-one; KD8QND6427; CHEBI:28429; 4H-1-Benzopyran-4-one, 2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-, (2R,3R)-; (2R,3R)-2,3-dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; (2R,3R)-3,5,7,3',4',5'-hexahydroxyflavanone; Ampelopsin (flavanol); (2R,3R)-3,3',4',5,5',7-hexahydroxy-2,3-dihydroflavanonol; dihydro-myricetin; Ampelopsin;Ampeloptin; (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydro-4H-chromen-4-one; UNII-KD8QND6427; 3,3',4',5,5',7-Hexahydroxy-2,3-dihydroflavanonol; AMPELOPSIN [MI]; (2r,3r)-dihydromyricetin; Dihydromyricetin (diH-Myr); (2R-trans)-2,3-Dihydro-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-4H-1-benzopyran-4-one; Dihydromyricetin (Ampeloptin); Dihydromyricetin - Ampeloptin; SCHEMBL723736; DIHYDROMYRICETIN [INCI]; CHEMBL3348861; DTXSID50181676; BDBM212434; HMS3884B17; Dihydromyricetin, >=98% (HPLC); HY-N0112; Dihydromyricetin, analytical standard; MFCD00189451; s2399; AKOS022168215; AC-8004; CCG-267699; CS-3809; NCGC00346604-01; AS-71702; D5464; SW219328-1; C02906; A818952; Q422305; 2B89FBAC-4DD1-44C9-BE2A-9D0C173BDFD8; Q-100341; (2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-3,4-dihydro-2H-1-benzopyran-4-one	.	.	320.25	C15H12O8	148	445	1.1	23	6	8	1	InChI=1S/C15H12O8/c16-6-3-7(17)11-10(4-6)23-15(14(22)13(11)21)5-1-8(18)12(20)9(19)2-5/h1-4,14-20,22H/t14-,15+/m0/s1	C1=C(C=C(C(=C1O)O)O)[C@@H]2[C@H](C(=O)C3=C(C=C(C=C3O2)O)O)O	C1=C(C=C(C(=C1O)O)O)C2C(C(=O)C3=C(C=C(C=C3O2)O)O)O	KJXSIXMJHKAJOD-LSDHHAIUSA-N	(2R,3R)-3,5,7-trihydroxy-2-(3,4,5-trihydroxyphenyl)-2,3-dihydrochromen-4-one
ferrodrug0186	Levobupivacaine	Small molecular drug	Levobupivacaine; 27262-47-1; (S)-bupivacaine; (-)-bupivacaine; L(-)-Bupivacaine; Levobupivacaine hydrochloride; Novabupi; (S)-1-Butyl-2',6'-pipecoloxylidide; L-(-)-bupivacaine; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; L-bupivacaine; Levobupivacaine free base; (S)-1-Butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide; Bupivacaine, (s)-; L-(-)-1-Butyl-2',6'-pipecoloxylidide; Bupivacaine, (-)-; Bupivacaine (-)-form; Levobupivacaine (INN); A5H73K9U3W; CHEBI:6149; (2S)-1-butyl-N-(2,6-dimethylphenyl)-2-piperidinecarboxamide; 2-Piperidinecarboxamide, 1-butyl-N-(2,6-dimethylphenyl)-, (2S)-; 27262-47-1 (free base); LEVOBUPIVACAINE [INN]; Levobupivacaine [INN:BAN]; Levobupivacaina; (2~{S})-1-butyl-~{N}-(2,6-dimethylphenyl)piperidine-2-carboxamide; Novabupi (TN); NCGC00159482-02; (S)-(-)-Bupivacaine; UNII-A5H73K9U3W; 2',6'-Pipecoloxylidide, 1-butyl-, L-(-)-; SCHEMBL34537; BIDD:GT0471; LEVOBUPIVACAINE [VANDF]; GTPL7211; LEVOBUPIVACAINE [MART.]; CHEMBL1201193; DTXSID8048496; LEVOBUPIVACAINE [WHO-DD]; LEBVLXFERQHONN-INIZCTEOSA-N; (s)-1-butyl-n-(2,6-dimethylphenyl)-2-piperidinecarboxamide; HY-B0653; BUPIVACAINE (-)-FORM [MI]; BDBM50350791; BDBM50417951; MFCD00936851; s5181; AKOS016340525; DB01002; KS-5195; NCGC00016733-01; NCGC00159482-03; CAS-18010-40-7; CS-0009570; C07887; D08116; D87861; A818983; Q-100344; Q3272027; Z2242128693; (2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboximidic acid; ROPIVACAINE HYDROCHLORIDE MONOHYDRATE IMPURITY A [EP IMPURITY]; OJ0	D09QUQ	DM783CH	288.4	C18H28N2O	32.299	321	3.4	21	1	2	5	InChI=1S/C18H28N2O/c1-4-5-12-20-13-7-6-11-16(20)18(21)19-17-14(2)9-8-10-15(17)3/h8-10,16H,4-7,11-13H2,1-3H3,(H,19,21)/t16-/m0/s1	CCCCN1CCCC[C@H]1C(=O)NC2=C(C=CC=C2C)C	CCCCN1CCCCC1C(=O)NC2=C(C=CC=C2C)C	LEBVLXFERQHONN-INIZCTEOSA-N	(2S)-1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide
ferrodrug0187	Cannabinol	Small molecular drug	cannabinol; 521-35-7; Cannabinolo [DCIT]; Cannabinolum [INN-Latin]; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo(b,d)pyran-1-ol; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo(b,d)pyran; 6H-Dibenzo(b,d)pyran-1-ol, 6,6,9-trimethyl-3-pentyl-; 6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol; NSC 134455; 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol; 7UYP6MC9GH; NSC-134455; CHEMBL74415; CHEBI:3360; DTXSID3048996; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl-; NCGC00168261-01; Cannabinolo; Cannabinolum; Cannabinol [INN:BAN]; Cannabinol (CBN); UNII-7UYP6MC9GH; BRN 0237145; Cannabinol; 3-Amyl-1-hydroxy-6,6,9-trimethyl-6H-dibenzo[b,d]pyran; 6,6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; CBN; NSC 134455; Cannabinoids; Cannabinol (6CI); CANNABINOL [MI]; CANNABINOL [INN]; CANNABINOL [WHO-DD]; GTPL740; 5-17-04-00567 (Beilstein Handbook Reference); DivK1c_000972; SCHEMBL121085; Cannabinol, analytical standard; Cannabinol, 1mg/ml in Methanol; DTXCID3028922; HMS503C05; KBio1_000972; NINDS_000972; Cannabinol 1.0 mg/ml in Methanol; Tox21_113486; BDBM50061117; LMPK13120002; NSC134455; AKOS024457448; DB14737; IDI1_000972; CAS-521-35-7; 6H-Dibenzo[b, 6,6,9-trimethyl-3-pentyl-; Cannabinol (CBN) 100 microg/mL in Methanol; C07580; Cannabinol (CBN) 1000 microg/mL in Methanol; Cannabinol (CBN) 250 microg/mL in Acetonitrile; EN300-7456337; A934070; L000158; Q265831; WLN: T B666 HO IHJ CQ E5 I1 I1 M1; 6,9-Trimethyl-3-pentyl-6H-dibenzo[b,d]pyran-1-ol; 3-Amyl-1-hydroxy-6,9-trimethyl-6H-dibenzo[b,d]pyran; 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol #; Cannabinoids Mixture 187 100 microg/mL in Acetonitrile; Cannabinoids Mixture 188 500 microg/mL in Acetonitrile; Z2680631269; Cannabinoids Mixture 189 1000 microg/mL in Acetonitrile; Cannabinoids Mixture 201 1000 microg/mL in Acetonitrile; 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol(Cannabinol); 6,6,9-Trimethyl-3-pentyl-6H-benzo[c]chromen-1-ol (Cannabinol); 6H-Dibenzo[b,d]pyran-1-ol, 6,6,9-trimethyl-3-pentyl- (7CI,8CI,9CI)	D0U5LL	DMM6A7P	310.4	C21H26O2	29.5	391	6.1	23	1	2	4	InChI=1S/C21H26O2/c1-5-6-7-8-15-12-18(22)20-16-11-14(2)9-10-17(16)21(3,4)23-19(20)13-15/h9-13,22H,5-8H2,1-4H3	CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O	CCCCCC1=CC(=C2C(=C1)OC(C3=C2C=C(C=C3)C)(C)C)O	VBGLYOIFKLUMQG-UHFFFAOYSA-N	6,6,9-trimethyl-3-pentylbenzo[c]chromen-1-ol
ferrodrug0188	Sertaconazole	Small molecular drug	Sertaconazole; 99592-32-2; Sertaconazol [Spanish]; Sertaconazolum [Latin]; Sertaconazol; Sertaconazolum; FI-7045; Sertaconazole [INN]; Demofix; 1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; 1-(2-((7-Chlorobenzo[b]thiophen-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; Sertaconazole (INN); CHEBI:83682; 1-(2-((7-Chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-1H-imidazole; 72W71I16EG; 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}-1H-imidazole; 7-Chloro-3-(1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl)benzo(b)thiophene; 1H-Imidazole, 1-(2-((7-chlorobenzo(b)thien-3-yl)methoxy)-2-(2,4-dichlorophenyl)ethyl)-; 7-Chloro-3-[1-(2,4-dichlorophenyl)-2-(1H-imidazol-1-yl)ethoxy-methyl]benzo[b]thiophene; Sertaconazole [INN:BAN]; BRN 5385663; UNII-72W71I16EG; SR-05000001439; 1-{2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole; 1H-Imidazole, 1-[2-[(7-chlorobenzo[b]thien-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]-; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno [Spanish]; Prestwick0_001045; Prestwick1_001045; Prestwick2_001045; Prestwick3_001045; SERTACONAZOLE [MI]; (+-)-1-(2,4-Dichloro-beta-((7-chlorobenzo(b)thien-3-yl)methoxy)phenethyl)imidazole; 7-Cloro-3-(1-(2,4-diclorofenil)-2-(1H-imidazol-1-il)etoxi-metil)benzo(b)tiofeno; SCHEMBL66043; BSPBio_000970; SERTACONAZOLE [VANDF]; SPBio_002905; SERTACONAZOLE [WHO-DD]; BPBio1_001068; CHEMBL1201196; DTXSID0048551; JLGKQTAYUIMGRK-UHFFFAOYSA-N; HMS2089M16; BCP12180; HY-B0736; BDBM50051842; DL-208; STL452922; AKOS015850283; AC-6939; DB01153; 1-[2-[(7-chlorobenzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; NCGC00179356-01; NCGC00179356-09; AB00514018; CS-0009631; FT-0631003; FT-0674559; FT-0674560; FT-0674561; D06883; AB00514018-07; AB00514018_08; EN300-6481081; Q3479994; SR-05000001439-1; BRD-A95939040-008-03-3; Z2194031487; 1-[2-[(7-chlorobenzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole; nitric acid; SZ	D0O6UZ	DM1A9XO	437.8	C20H15Cl3N2OS	55.3	488	6.3	27	0	3	6	InChI=1S/C20H15Cl3N2OS/c21-14-4-5-16(18(23)8-14)19(9-25-7-6-24-12-25)26-10-13-11-27-20-15(13)2-1-3-17(20)22/h1-8,11-12,19H,9-10H2	C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl	C1=CC2=C(C(=C1)Cl)SC=C2COC(CN3C=CN=C3)C4=C(C=C(C=C4)Cl)Cl	JLGKQTAYUIMGRK-UHFFFAOYSA-N	1-[2-[(7-chloro-1-benzothiophen-3-yl)methoxy]-2-(2,4-dichlorophenyl)ethyl]imidazole
ferrodrug0189	Dyclonine	Small molecular drug	dyclonine; Dyclocaine; 586-60-7; Dyclonin; Dyclocainum; Diclonina; Dycloninum; 1-(4-butoxyphenyl)-3-(piperidin-1-yl)propan-1-one; Dycloninum [INN-Latin]; Diclonina [INN-Spanish]; 4'-Butoxy-3-piperidinopropiophenone; 1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one; 3-Piperidino-4'-butoxypropiophenone; 1-Propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl)-; Dyclonine (INN); Diclonia; 2-(1-piperidyl)ethyl p-butoxyphenyl ketone; 4-butoxy-beta-piperidinopropiophenone; 1-(4-Butoxyphenyl)-3-(1-piperidinyl)-1-propanone; 4-n-butoxy-beta-(1-piperidyl)propiophenone; CHEBI:4724; PROPIOPHENONE, 4'-BUTOXY-3-PIPERIDINO-; 078A24Q30O; DYCLONINE [INN]; Dyclonine [INN:BAN]; NCGC00016498-01; CAS-536-43-6; BRN 0224037; UNII-078A24Q30O; Dyclone (Salt/Mix); Tanaclone (Salt/Mix); Spectrum_001016; DYCLONINE [MI]; Prestwick0_000264; Prestwick1_000264; Prestwick2_000264; Prestwick3_000264; Spectrum2_001013; Spectrum3_000410; Spectrum4_000529; Spectrum5_000951; DYCLONINE [VANDF]; DYCLONINE [WHO-DD]; SCHEMBL25773; BSPBio_000108; BSPBio_001940; KBioGR_001137; KBioSS_001496; DivK1c_000632; 1-propanone, 1-(4-butoxyphenyl)-3-(1-piperidinyl); SPBio_001165; SPBio_002327; 1-(4-Butoxy-phenyl)-3-piperidin-1-yl-propan-1-one; BPBio1_000120; GTPL7173; CHEMBL1201217; DTXSID6047864; KBio1_000632; KBio2_001496; KBio2_004064; KBio2_006632; KBio3_001160; BZEWSEKUUPWQDQ-UHFFFAOYSA-N; NINDS_000632; EX-A5489; AM9638; STK524544; AKOS000505031; DB00645; IDI1_000632; NCGC00016498-02; NCGC00016498-03; NCGC00016498-04; NCGC00016498-05; AC-12286; SBI-0051358.P003; AB00053467; FT-0660914; C07881; D07881; AB00053467_13; AB00053467_14; EN300-25300221; Q425386; BRD-K72259270-003-05-8; BRD-K72259270-003-15-7; N8R	D04QLR	DMU6OFP	289.4	C18H27NO2	29.5	292	3.6	21	0	3	8	InChI=1S/C18H27NO2/c1-2-3-15-21-17-9-7-16(8-10-17)18(20)11-14-19-12-5-4-6-13-19/h7-10H,2-6,11-15H2,1H3	CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2	CCCCOC1=CC=C(C=C1)C(=O)CCN2CCCCC2	BZEWSEKUUPWQDQ-UHFFFAOYSA-N	1-(4-butoxyphenyl)-3-piperidin-1-ylpropan-1-one
ferrodrug0190	Niraparib	.	Niraparib; 1038915-60-4; MK-4827; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide; MK4827; Niraparib [USAN]; 2-{4-[(3s)-piperidin-3-yl]phenyl}-2h-indazole-7-carboxamide; MK 4827; HMC2H89N35; 2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide; CHEMBL1094636; Niraparib (USAN); ZL-2306; JNJ-64091742; (S)-2-(4-(piperidin-3-yl)phenyl)-2H-indazole-7-carboxamide;MK-4827; Niraparib [USAN:INN]; 2-{4-[(3S)-piperidin-3-yl]phenyl}indazole-7-carboxamide; UNII-HMC2H89N35; MK 4827 (Base); 3JD; Zejula (TN); NIRAPARIB [INN]; NIRAPARIB [MI]; MK-4827(Niraparib); NIRAPARIB [WHO-DD]; GTPL8275; SCHEMBL1421875; AMY4192; DTXSID50146129; EX-A290; CHEBI:176844; MK-4827 (PARP-1); BDBM50316226; MFCD17779309; NSC754355; NSC800020; s2741; AKOS016004869; BCP9000940; CCG-267709; compound 56 [PMID 19873981]; CS-0780; DB11793; MK-4827/MK4827; NSC-754355; NSC-800020; NCGC00346435-01; NCGC00346435-04; AC-28447; AS-35248; HY-10619; BCP0726000077; D10140; EN300-7364833; A857972; Q25326660; 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide; 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]; 2H-INDAZOLE-7-CARBOXAMIDE, 2-(4-(3S)-3-PIPERIDINYLPHENYL)-; 2H-Indazole-7-carboxamide, 2-[4-(3S)-3-piperidinylphenyl]-; 2-[4-(3S)-3-Piperidinylphenyl]-2H-indazole-7-carboxamide; Niraparib; Zejula; MK-4827	.	.	320.4	C19H20N4O	72.9	449	2.2	24	2	3	3	InChI=1S/C19H20N4O/c20-19(24)17-5-1-3-15-12-23(22-18(15)17)16-8-6-13(7-9-16)14-4-2-10-21-11-14/h1,3,5-9,12,14,21H,2,4,10-11H2,(H2,20,24)/t14-/m1/s1	C1C[C@H](CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N	C1CC(CNC1)C2=CC=C(C=C2)N3C=C4C=CC=C(C4=N3)C(=O)N	PCHKPVIQAHNQLW-CQSZACIVSA-N	2-[4-[(3S)-piperidin-3-yl]phenyl]indazole-7-carboxamide
ferrodrug0191	Peoniflorin	Small molecular drug	Paeoniflorin; 23180-57-6; Peoniflorin; Paeonia moutan; NSC 178886; UNII-21AIQ4EV64; 21AIQ4EV64; CCRIS 6494; EINECS 245-476-2; PAEONIFLORIN (USP-RS); PAEONIFLORIN [USP-RS]; C23H28O11; NSC-178886; ((2S,2aR,2a1S,3aR,4R,5aR)-4-Hydroxy-2-methyl-2a-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-1,5-dioxa-2,4-methanocyclobuta[cd]pentalen-2a1-yl)methyl benzoate; NSC178886; .BETA.-D-GLUCOPYRANOSIDE, (1AR,2S,3AR,5R,5AR,5BS)-5B-((BENZOYLOXY)METHYL)TETRAHYDRO-5-HYDROXY-2-METHYL-2,5-METHANO-1H-3,4-DIOXACYCLOBUTA(CD)PENTALEN-1A(2H)-YL; .beta.-D-Glucopyranoside, (1aR,2S,3aR,5R,5aR,5bS)-5b-[(benzoyloxy)methyl]tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl; PEONIFLORIN [INCI]; SCHEMBL549033; CHEBI:7889; CHEMBL4303209; DTXSID2042648; Paeoniflorin, analytical standard; Paeoniflorin, >=98% (HPLC); HMS3884D17; HY-N0293; s2410; AKOS025311455; CCG-269549; AS-12193; beta-D-Glucopyranoside, (1aS,2R,3aR,5R,5aR,5bS)-5b-((benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl; C09959; AB01566855_01; Q-100296; Q7124104; ((2S,2aR,2a1S,3aR,4R,5aR)-4-Hydroxy-2-methyl-2a-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)hexahydro-2H-1,5-dioxa-2,4-methanocyclobuta[cd]pentalen-2a1-yl)methylbenzoate; .BETA.-D-GLUCOPYRANOSIDE, 5B-((BENZOYLOXY)METHYL)TETRAHYDRO-5-HYDROXY-2-METHYL-2,5-METHANO-1H-3,4-DIOXACYCLOBUTA(CD)PENTALEN-1A(2H)-YL, (1AR-(1A.ALPHA.,2.BETA.,3A.ALPHA.,5.ALPHA.,5A.ALPHA.,5B.ALPHA.))-; [(1R,2S,3R,5R,6R,8S)-6-hydroxy-8-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-2-yl]methyl benzoate; [hydroxy-methyl-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-[?]yl]methyl benzoate; 5b-((Benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-lH-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl-beta-D-glucopyranoside; b-D-Glucopyranoside,(1aR,2S,3aR,5R,5aR,5bS)-5b-[(benzoyloxy)methyl]tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta[cd]pentalen-1a(2H)-yl; beta-D-GLUCOPYRANOSIDE, (1AR,2S,3AR,5R,5AR,5BS)-5B-((BENZOYLOXY)METHYL)TETRAHYDRO-5-HYDROXY-2-METHYL-2,5-METHANO-1H-3,4-DIOXACYCLOBUTA(CD)PENTALEN-1A(2H)-YL; beta-D-Glucopyranoside, 5b-((benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl, (1aR-(1a-alpha,2-beta,3a-alpha,5-alpha,5a-alpha,5b-alpha))-; beta-d-Glucopyranoside, 5b-((benzoyloxy)methyl)tetrahydro-5-hydroxy-2-methyl-2,5-methano-1H-3,4-dioxacyclobuta(cd)pentalen-1a(2H)-yl, (1aR-(1aalpha,2beta,3aalpha,5alpha,5aalpha,5balpha))-	D0PD0F	DMJ5TAU	480.5	C23H28O11	164	849	-1	34	5	11	7	InChI=1S/C23H28O11/c1-20-9-22(29)13-7-23(20,32-18-16(27)15(26)14(25)12(8-24)31-18)21(13,19(33-20)34-22)10-30-17(28)11-5-3-2-4-6-11/h2-6,12-16,18-19,24-27,29H,7-10H2,1H3/t12-,13-,14-,15+,16-,18+,19-,20+,21+,22-,23+/m1/s1	C[C@]12C[C@@]3([C@@H]4C[C@]1([C@@]4([C@H](O2)O3)COC(=O)C5=CC=CC=C5)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O)O	CC12CC3(C4CC1(C4(C(O2)O3)COC(=O)C5=CC=CC=C5)OC6C(C(C(C(O6)CO)O)O)O)O	YKRGDOXKVOZESV-WRJNSLSBSA-N	[(1R,2S,3R,5R,6R,8S)-6-hydroxy-8-methyl-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-9,10-dioxatetracyclo[4.3.1.02,5.03,8]decan-2-yl]methyl benzoate
ferrodrug0192	Roxadustat	Small molecular drug	Roxadustat; FG-4592; 808118-40-3; FG4592; Roxadustat (FG-4592); ASP1517; ASP 1517; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]glycine; Roxadustat [USAN:INN]; UNII-X3O30D9YMX; X3O30D9YMX; 2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid; Glycine, N-[(4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-; ASP-1517; FG 4592; CHEMBL2338329; (((4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl)amino)acetic acid; (4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)glycine; N-[(4-hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]glycine; Evrenzo; 2-(4-hydroxy-1-Methyl-7-phenoxyisoquinoline-3-carboxaMido)acetic acid; n-((4-hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl)glycine; [[(4-Hydroxy-1-methyl-7-phenoxyisoquinolin-3-yl)carbonyl]amino]acetic Acid; 2-[(1-methyl-4-oxidanyl-7-phenoxy-isoquinolin-3-yl)carbonylamino]ethanoic acid; roxadustatum; FG-4592 (ASP1517); GLYCINE, N-((4-HYDROXY-1-METHYL-7-PHENOXY-3-ISOQUINOLINYL)CARBONYL)-; 8HO; Evrenzo (TN); Fg-4592[roxadustat]; ROXADUSTAT [INN]; ROXADUSTAT [JAN]; ROXADUSTAT [USAN]; Roxadustat(FG-4592); ROXADUSTAT [WHO-DD]; MLS006010023; Roxadustat (JAN/USAN/INN); SCHEMBL523705; GTPL8454; DTXSID60230644; EX-A390; CHEBI:132774; YOZBGTLTNGAVFU-UHFFFAOYSA-N; BCPP000230; HMS3654M03; AMY16514; BCP02523; BDBM50431015; FG-4592,ASP1517; MFCD20040519; s1007; AKOS026674331; BCP9000684; CCG-268052; CS-1094; DB04847; SB16615; NCGC00346527-01; NCGC00346527-07; AC-31003; AS-17052; HY-13426; SMR004701207; SW219900-1; D10593; J-522733; Q27088611; 2-[[4-hydroxy-1-methyl-7-(phenoxy)isoquinoline-3-carbonyl]amino]acetic acid; N-[(4-Hydroxy-1-methyl-7-phenoxy-3-isoquinolinyl)carbonyl]-glycine, Roxadustat	D03YKE	DM4XSQ2	352.3	C19H16N2O5	109	508	3.4	26	3	6	5	InChI=1S/C19H16N2O5/c1-11-15-9-13(26-12-5-3-2-4-6-12)7-8-14(15)18(24)17(21-11)19(25)20-10-16(22)23/h2-9,24H,10H2,1H3,(H,20,25)(H,22,23)	CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3	CC1=C2C=C(C=CC2=C(C(=N1)C(=O)NCC(=O)O)O)OC3=CC=CC=C3	YOZBGTLTNGAVFU-UHFFFAOYSA-N	2-[(4-hydroxy-1-methyl-7-phenoxyisoquinoline-3-carbonyl)amino]acetic acid
ferrodrug0193	Dihydrotanshinone I	.	Dihydrotanshinone I; 87205-99-0; 15,16-dihydrotanshinone I; DihydrotanshinoneI; (-)-Dihydrotanshinone I; Dihydrotanshinone-I; Tanshinone I, dihydro-; HSDB 8105; UNII-562G9360V6; 562G9360V6; DTXSID20236187; (1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione; DIHYDROTANSHINONE I, (-)-; DIHYDROTANSHINONE; (1R)-1,6-Dimethyl-1,2-dihydrophenanthro(1,2-b)furan-10,11-dione; (R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione; PHENANTHRO(1,2-B)FURAN-10,11-DIONE, 1,2-DIHYDRO-1,6-DIMETHYL-, (1R)-; SR-05000002191; 15,16-dihydrotanshinone-I; (1R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione; DHTS; 4m0e; CHEMBL227075; SCHEMBL13049977; DTXCID20158678; CHEBI:149872; HARGZZNYNSYSGJ-JTQLQIEISA-N; HY-N0360; BDBM50423877; MFCD28016070; s9020; AKOS032962078; CCG-208567; Dihydrotanshinone I, >=98% (HPLC); NCGC00163651-01; NCGC00163651-06; D5379; A862726; SR-05000002191-2; SR-05000002191-3; Q21099654; DIHYDROTANSHINONE (CONSTITUENT OF CHINESE SALVIA); DIHYDROTANSHINONE (CONSTITUENT OF CHINESE SALVIA) [DSC]; '(1R)-1,6-dimethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione'; (-)-1,2-Dihydro-1,6-dimethylphenanthro[1,2-b]furan-10,11-dione;1,6-Dimethyl-1,2,10,11-tetrahydrophenanthro[1,2-b]furan-10,11-dione;4,17-Dimethyl-15-oxagona-1,3,5(10),6,8,13-hexene-11,12-dione;15,16-Dihydrotanshine I;1,6-DiMethyl-1,2-dihydrophenanthro[1,2-b]furan-10,11-dione	.	.	278.3	C18H14O3	43.4	533	3.2	21	0	3	0	InChI=1S/C18H14O3/c1-9-4-3-5-12-11(9)6-7-13-15(12)17(20)16(19)14-10(2)8-21-18(13)14/h3-7,10H,8H2,1-2H3/t10-/m0/s1	C[C@H]1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C	CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C(C=CC=C43)C	HARGZZNYNSYSGJ-JTQLQIEISA-N	(1R)-1,6-dimethyl-1,2-dihydronaphtho[1,2-g][1]benzofuran-10,11-dione
ferrodrug0194	Fedratinib	.	Fedratinib; 936091-26-8; Tg-101348; TG101348; SAR302503; SAR-302503; N-(tert-butyl)-3-((5-methyl-2-((4-(2-(pyrrolidin-1-yl)ethoxy)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide; Inrebic; SAR 302503; TG 101348; Fedratinib (SAR302503, TG101348); N-(1,1-Dimethylethyl)-3-[[5-methyl-2-[[4-[2-(1-pyrrolidinyl)ethoxy]phenyl]amino]-4-pyrimidinyl]amino]benzenesulfonamide; TG101348 (SAR302503); CHEMBL1287853; 6L1XP550I6; 936091-26-8 (free base); N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide; Benzenesulfonamide, N-(1,1-dimethylethyl)-3-((5-methyl-2-((4-(2-(1-pyrrolidinyl)ethoxy)phenyl)amino)-4-pyrimidinyl)amino)-; N-Tert-butyl-3-(5-methyl-2-(4-(2-pyrrolidin-1-yl-ethoxy)-phenylamino)-pyrimidin-4-ylamino)-benzenesulfonamide; N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzenesulfonamide; Fedratinib [USAN]; Fedratinib [USAN:INN]; UNII-6L1XP550I6; 2TA; FEDRATINIB [MI]; FEDRATINIB [INN]; Fedratinib (USAN/INN); TG101348(Fedratinib); FEDRATINIB [WHO-DD]; Fedratinib (TG101348); MLS006011155; N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide; SCHEMBL263741; GTPL5716; CHEBI:91408; DTXSID90239483; EX-A170; HMS3295I03; HMS3656L19; HMS3744G17; HMS3868L03; BCP02300; BDBM50332294; MFCD12922515; NSC767600; NSC800099; s2736; AKOS015842621; CCG-264990; CS-0052; DB12500; EX-5961; NSC-767600; NSC-800099; SB14604; NCGC00244252-01; NCGC00244252-07; AC-30260; AS-16248; HY-10409; SMR004702929; FT-0705969; FT-0763396; FT-0766818; SW218187-2; A25534; D10630; F17372; J-523769; Q7670147; BRD-K12502280-001-01-5; Z2037280076; N-TERT-BUTYL-3-((5-METHYL-2-(4-(2-(PYRROLIDIN-1-YL)ETHOXY)ANILINO(PYRIMIDIN-4-YL)AMINO)BENZENESULFONAMIDE; N-tert-butyl-3-{[5-methyl-2-({4-[2-(pyrrolidin-1-yl)ethoxy]phenyl}amino)pyrimidin-4-yl]amino}benzene-1-sulfonamide; SAR302503, N-tert-butyl-3-(5-methyl-2-(4-(2-(pyrrolidin-1-yl)ethoxy)phenylamino)pyrimidin-4-ylamino)benzenesulfonamide	.	.	524.7	C27H36N6O3S	117	787	4.8	37	3	9	11	InChI=1S/C27H36N6O3S/c1-20-19-28-26(30-21-10-12-23(13-11-21)36-17-16-33-14-5-6-15-33)31-25(20)29-22-8-7-9-24(18-22)37(34,35)32-27(2,3)4/h7-13,18-19,32H,5-6,14-17H2,1-4H3,(H2,28,29,30,31)	CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4	CC1=CN=C(N=C1NC2=CC(=CC=C2)S(=O)(=O)NC(C)(C)C)NC3=CC=C(C=C3)OCCN4CCCC4	JOOXLOJCABQBSG-UHFFFAOYSA-N	N-tert-butyl-3-[[5-methyl-2-[4-(2-pyrrolidin-1-ylethoxy)anilino]pyrimidin-4-yl]amino]benzenesulfonamide
ferrodrug0195	lipoxin A4	Small molecular drug	lipoxin A4; LXA4; 89663-86-5; 5S,6R-LipoxinA4; CHEBI:6498; 5S,6R,15S-trihydroxy-7E,9E,11Z,13E-Eicosatetraenoic acid; F7C6J3D79J; LIPOXINA4; (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid; (7E,9E,11Z,13E)-(5S,6R,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-tetraenoic acid; Lipoxin A; 5,6,15-triHETE; 7,9,11,13-Eicosatetraenoicacid, 5,6,15-trihydroxy-, (5S,6R,7E,9E,11Z,13E,15S)-; 5S,6S-Lipoxin A4; LXA4-[19,19,20,20,20-d5]; UNII-F7C6J3D79J; 6R-LXA4; BSPBio_001378; BML1-E11; CHEMBL392438; GTPL1034; DTXSID6040535; HMS1361E20; HMS1791E20; HMS1989E20; HMS3402E20; BDBM50520816; LMFA03040001; AKOS040755014; IDI1_033848; NCGC00161280-01; NCGC00161280-02; NCGC00161280-03; HY-113509; CS-0062443; C06314; SR-01000946984; SR-01000946984-1; Q27082450; 5S,6R,15S-Trihydroxy-7E,9E,11Z,13E-eicosatetraenoate; (5S,6R,15S)-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid; 5(S),6(R),15(S)-trihydroxyeicosa-7E,9E,11Z,13E-tetraenoic acid; 5S,6R,15S-trihydroxy-7,9,13-trans-11-cis-eicosatetraenoic acid; (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxy-7,9,11,13-eicosatetraenoic acid; (5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyeicosa-7,9,11,13-tetraenoic acid; (7E,9E,11Z,13E)-(5S,6R,15S)-5,6,15-Trihydroxyicosa-7,9,11,13-tetraenoate; 7,9,11,13-Eicosatetraenoic acid, 5,6,15-trihydroxy-, (5S,6R,7E,9E,11Z,13E,15S)-	D0R1FZ	DMGSVL0	352.5	C20H32O5	98	451	3.1	25	4	5	14	InChI=1S/C20H32O5/c1-2-3-8-12-17(21)13-9-6-4-5-7-10-14-18(22)19(23)15-11-16-20(24)25/h4-7,9-10,13-14,17-19,21-23H,2-3,8,11-12,15-16H2,1H3,(H,24,25)/b6-4-,7-5+,13-9+,14-10+/t17-,18+,19-/m0/s1	CCCCC[C@@H](/C=C/C=C\C=C\C=C\[C@H]([C@H](CCCC(=O)O)O)O)O	CCCCCC(C=CC=CC=CC=CC(C(CCCC(=O)O)O)O)O	IXAQOQZEOGMIQS-SSQFXEBMSA-N	(5S,6R,7E,9E,11Z,13E,15S)-5,6,15-trihydroxyicosa-7,9,11,13-tetraenoic acid
ferrodrug0196	Polydatin	.	Piceid; 27208-80-6; 65914-17-2; Trans-Piceid; 3,4,5-Trihydroxystilbene-3-beta-monoglucoside; 3,4,5-Tsg; (2S,3R,4S,5S,6R)-2-(3-Hydroxy-5-(4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; Resveratrol 3-beta-mono-D-glucoside; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol; Resveratrol 3-O-beta-glucopyranoside; (E/Z)-Piceid; MLS001424114; CHEBI:8198; XM261C37CQ; (2S,3R,4S,5S,6R)-2-(3-hydroxy-5-((E)-4-hydroxystyryl)phenoxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; trans-resveratrol 3-beta-glucoside; trans-resveratrol 3-beta-D-glucoside; 3,4'-5-Trihydroxystilbene-3-beta-D-glucopyranoside; trans-resveratrol 3-O-beta-D-glucoside; 3,5,4'-Trihydroxystilbene 3-glucoside; SMR000466371; 3,4',5-trihydroxystilbene-3-beta-D-glucoside; b-D-Glucopyranoside,3-hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl; C20H22O8; Resveratrol 3-Glucoside; 5-Tsg; resveratrol 3-O-beta-D-glucoside; UNII-XM261C37CQ; MFCD00210592; E/Z-Polydatin; E/Z-Piceid; (E)-Piceid; 5-Trihydroxystilbene-3-beta-monoglucoside; 3-Hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl-beta-D-glucoside; Resveratrol 3-O-glucoside; Resveratrol 5-O-glucoside; SCHEMBL41411; MLS000759499; trans-Resveratrol 3-glucoside; CHEMBL142652; Resveratrol 3-beta-D-glucoside; trans-Resveratrol 3-O-glucoside; BDBM60919; CHEBI:94610; cid_5281718; HSTZMXCBWJGKHG-CUYWLFDKSA-N; DTXSID001030555; HMS2051A20; HY-N0120; resveratrol-3-O-b-mono-D-glucoside; LMPK13090012; s2390; AKOS015961013; CCG-100895; DB11263; KS-5384; NC00145; Resveratrol 3-.beta.-mono-d-glucoside; NCGC00246971-01; NCGC00246971-04; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]phenoxy]-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol; AS-13910; trans-resveratrol 3-beta-d-glucopyranoside; CS-0007830; AB00639953-07; EN300-7416763; 3,4',5-Trihydroxystilbene-3-b-D-glucopyranoside; A818955; 5,4'-dihydroxystilbene-3-O-beta-D-glucopyranoside; Q-100342; Q3902665; RESVERATROL 3-.BETA.-MONO-D-GLUCOSIDE [MI]; W-203441; 3,4',5-TRIHYDROXYSTILBENE-3-BETA-MONOGLUCOSIDE; 3,4'-5-Trihydroxystilbene-3-beta-D-glucopyranoside, 97%; 3,4'-5-TRIHYDROXYSTILBENE-3-.BETA.-D-GLUCOPYRANOSIDE; 3-Hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl-beta-D-glucopyranoside; 3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenyl beta-D-glucopyranoside; 3-Hydroxy-5-[2-(4-hydroxyphenyl)ethenyl]phenyl beta-D-glucopyranoside; b-D-Glucopyranoside, 3-hydroxy-5-[2-(4-hydroxyphenyl)ethenyl]phenyl; beta-D-Glucopyranoside, 3-hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl; GLUCOPYRANOSIDE, 3-HYDROXY-5-(P-HYDROXYSTYRYL)PHENYL, .BETA.-D-; .BETA.-D-GLUCOPYRANOSIDE, 3-HYDROXY-5-((1E)-2-(4-HYDROXYPHENYL)ETHENYL)PHENYL; .BETA.-D-GLUCOPYRANOSIDE, 3-HYDROXY-5-(2-(4-HYDROXYPHENYL)ETHENYL)PHENYL; 5-((1E)-2-(4-HYDROXYPHENYL)ETHENYL)-1,3-BENZENEDIOL-3-.BETA.-MONO-D-GLUCOSIDE; beta-D-Glucopyranoside, 3-hydroxy-5-(2-(4-hydroxyphenyl)ethenyl)phenyl-, (E)-; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[3-[(E)-2-(4-hydroxyphenyl)ethenyl]-5-oxidanyl-phenoxy]oxane-3,4,5-triol; (2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)vinyl]phenoxy]-6-methylol-tetrahydropyran-3,4,5-triol; (2S,3R,4S,5S,6R)-2-{3-hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenoxy}-6-(hydroxymethyl)oxane-3,4,5-triol; .beta.-D-Glucopyranoside, 3-hydroxy-5-[(1E)-2-(4-hydroxyphenyl)ethenyl]phenyl3,5,4'-Trihydroxystilbene 3-glucoside	.	.	390.4	C20H22O8	140	506	1.7	28	6	8	5	InChI=1S/C20H22O8/c21-10-16-17(24)18(25)19(26)20(28-16)27-15-8-12(7-14(23)9-15)2-1-11-3-5-13(22)6-4-11/h1-9,16-26H,10H2/b2-1+/t16-,17-,18+,19-,20-/m1/s1	C1=CC(=CC=C1/C=C/C2=CC(=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)O	C1=CC(=CC=C1C=CC2=CC(=CC(=C2)OC3C(C(C(C(O3)CO)O)O)O)O)O	HSTZMXCBWJGKHG-CUYWLFDKSA-N	(2S,3R,4S,5S,6R)-2-[3-hydroxy-5-[(E)-2-(4-hydroxyphenyl)ethenyl]phenoxy]-6-(hydroxymethyl)oxane-3,4,5-triol
ferrodrug0197	Romidepsin	.	Romidepsin; Depsipeptide; FK228; Chromadax; 128517-07-7; Istodax; Antibiotic FR 901228; FR901228; FK 228; FK-228; FR 901228; FR-901228; NSC-630176; C24H36N4O6S2; NSC 630176; CHEMBL343448; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; CHEBI:61080; NSC630176; NSC754143; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Istodax (TN); Romidepsin [USAN]; CX3T89XQBK; HDInhib_000006; romidepsina; romidepsine; romidepsinum; OXA-12,8,20,23-TETRAZABICYCLO[8.7.6]TRICOSANE, CYCLIC PEPTIDE DERIV.; Romidepsin (FK228); Romidepsin; FK-228; ROMIDEPSIN [MI]; FK-901228; ROMIDEPSIN [INN]; ROMIDEPSIN [JAN]; ROMIDEPSIN [VANDF]; Probes1_000153; Probes2_000337; ROMIDEPSIN [MART.]; ROMIDEPSIN [WHO-DD]; DEPSIPEPTIDE [WHO-DD]; Romidepsin (JAN/USAN/INN); SCHEMBL677497; GTPL7006; ROMIDEPSIN [ORANGE BOOK]; Romidepsin, >=98% (HPLC); BDBM19151; Romidepsin (FK228 ,depsipeptide); (1S,4S,7Z,10S,16E,21R)-7-Ethylidene-4,21-bis(1-methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; Cyclo((2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl), cyclic (3->5)-disulfide; HB1386; MFCD18433404; s3020; API0005301; CS-0985; DB06176; NSC-754143; HY-15149; D06637; AB01273968-01; EN300-22844947; SR-01000941579; Q7363205; SR-01000941579-1; L-Valine,3-didehydro-2- aminobutanoyl-,.xi.-lactone, cyclic (1.fwdarw.2)-disulfide; L-Valine,3-didehydro-2-aminobutanoyl-,.xi.-lactone, cyclic (1.fwdarw.2)-disulfide; (1S,4S,7Z,10S,16E,21R)-7- ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23- tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-bis(1methylethyl)-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16ene-3,6,9,19,22-pentone; (E)-(1S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2- oxa-12,13-dithia-5,8,20,23- tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; (E)-(1S,10S,21R)-7-[(Z)-Ethylidene]-4,21-diisopropyl-2- oxa-12,13-dithia-5,8,20,23-tetraazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone; CYCLO((2Z)-2-AMINO-2-BUTENOYL-L-VALYL-(3S,4E)-3-HYDROXY-7-MERCAPTO-4-HEPTENOYL-D-VALYL-D-CYSTEINYL), CYCLIC (3->5)-DISULPHIDE; Cyclo[(2Z)-2-amino-2-butenoyl-L-val yl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valy l-D-cysteinyl], cyclic (3-5) disulfide; Cyclo[(2Z)-2-amino-2-butenoyl-L-valyl-(3S,4E)-3-hydroxy-7-mercapto-4-heptenoyl-D-valyl-D-cysteinyl], cyclic (3-5) disulfide	.	.	540.7	C24H36N4O6S2	193	905	2.2	36	4	8	2	InChI=1S/C24H36N4O6S2/c1-6-16-21(30)28-20(14(4)5)24(33)34-15-9-7-8-10-35-36-12-17(22(31)25-16)26-23(32)19(13(2)3)27-18(29)11-15/h6-7,9,13-15,17,19-20H,8,10-12H2,1-5H3,(H,25,31)(H,26,32)(H,27,29)(H,28,30)/b9-7+,16-6-/t15-,17-,19-,20+/m1/s1	C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C	CC=C1C(=O)NC(C(=O)OC2CC(=O)NC(C(=O)NC(CSSCCC=C2)C(=O)N1)C(C)C)C(C)C	OHRURASPPZQGQM-GCCNXGTGSA-N	(1S,4S,7Z,10S,16E,21R)-7-ethylidene-4,21-di(propan-2-yl)-2-oxa-12,13-dithia-5,8,20,23-tetrazabicyclo[8.7.6]tricos-16-ene-3,6,9,19,22-pentone
ferrodrug0198	20-Hydroxyeicosatetraenoic acid	Small molecular drug	20-Hete; 79551-86-3; 20-Hydroxyeicosatetraenoic acid; 20-Hydroxy arachidonic acid; 20-Hydroxyarachidonic acid; (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoic acid; 20-hydroxy-5,8,11,14-eicosatetraenoic acid; 20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid; 20-Hydroxyicosatetraenoic acid; 20-Hydroxyeicosatetraeonic acid; 20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoic acid; 5,8,11,14-Eicosatetraenoicacid, 20-hydroxy-, (5Z,8Z,11Z,14Z)-; 20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoate; (5Z,8Z,11Z,14Z)-20-Hydroxyicosa-5,8,11,14-tetraenoate; 20-Hydroxyicosatetraenoate; SCHEMBL505713; GTPL4103; CHEMBL4085458; CHEBI:34306; 5,8,11,14-Eicosatetraenoic acid, 20-hydroxy-, (all-Z)-; DTXSID601009895; LMFA03060009; CS-1451; HY-15598; 20-hydroxy-5,8,11,14-eicosatetraenoate; 20-hydroxy-5Z,8Z,11Z,14Z-eicosatetraenoate; SR-01000946981; (all-Z)-20-hydroxy-5,8,11,14-Eicosatetraenoate; SR-01000946981-1; Q21099666; (all-Z)-20-hydroxy-5,8,11,14-Eicosatetraenoic acid; 20-hydroxy-5(Z),8(Z),11(Z),14(Z)-eicosatetraenoic acid; 20-Hydroxy-(5Z,8Z,11Z,14Z)-eicosatetraenoic acid, ~100 mug/mL in ethanol, >=90% (HPLC)	D07UFO	DM5BAJ9	320.5	C20H32O3	57.5	378	4.7	23	2	3	15	InChI=1S/C20H32O3/c21-19-17-15-13-11-9-7-5-3-1-2-4-6-8-10-12-14-16-18-20(22)23/h1,3-4,6-7,9-10,12,21H,2,5,8,11,13-19H2,(H,22,23)/b3-1-,6-4-,9-7-,12-10-	C(CC/C=C\C/C=C\C/C=C\C/C=C\CCCC(=O)O)CCO	C(CCC=CCC=CCC=CCC=CCCCC(=O)O)CCO	NNDIXBJHNLFJJP-DTLRTWKJSA-N	(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoic acid
ferrodrug0199	D-(-)-Fructose	.	D-(-)-Fructose; 57-48-7; D(-)-Fructose; (3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-one; D-Levulose; DL-Fructose; 30237-26-4; Methose; arabino-2-Hexulose; keto-D-fructose; 6YSS42VSEV; DTXSID5023081; CHEBI:48095; 02T79V874P; Sugar, fruit; Fructose, D-; Fructose [JAN]; rel-(3S,4R,5R)-1,3,4,5,6-Pentahydroxyhexan-2-one; D-(-)-Fructose, >=99%; Fructose, pure; CAS-57-48-7; D-(-)fructose; (+-)-Fructose; CCRIS 3335; Fructose [USP:JAN]; EINECS 200-333-3; UNII-6YSS42VSEV; MFCD00148910; AI3-23514; D-fructose-ring; UNII-02T79V874P; NCGC00160604-01; Fructose (VAN); Fructose,(S); FUD; Fructon (TN); D(-)-ructose; D-Fructose,(S); pentahydroxyhexan-2-one; FRUCTOSE [INCI]; .ALPHA.-ACROSE; FRUCTOSE [FCC]; FRUCTOSE [MI]; FRUCTOSE, DL-; D-(-)-Fructose, LR; Fructose (JP17/USP); DL-FRUCTOSE [MI]; Topiramate impurity E CRS; FRUCTOSE [WHO-DD]; SCHEMBL3965; D-(-)-Fructose, BioXtra; D-(-)-Fructose, puriss.; D-fructose (open structure); (+/-)-FRUCTOSE; GTPL4654; CHEMBL1232863; FRUCTOSE, (+/-)-; BJHIKXHVCXFQLS-UYFOZJQFSA-N; HY-N7092; Tox21_113557; Tox21_200762; s5176; AKOS015901521; NSC 760385; GLUCOSE IMPURITY D [EP IMPURITY]; NCGC00258316-01; LACTULOSE IMPURITY D [EP IMPURITY]; CS-0008532; D-(-)-Fructose, for microbiology, >=99.0%; D-(-)-Fructose, tested according to Ph.Eur.; D00114; EN300-218371; A870797; D-(-)-Fructose, BioUltra, >=99.0% (HPLC); D-(-)-Fructose, meets USP testing specifications; D-(-)-Fructose, SAJ special grade, >=98.0%; Q122043; TOPIRAMATE IMPURITY, FRUCTOSE- [USP IMPURITY]; (3S,4R,5R)-1,3,4,5,6-; DFA8C62B-E34B-4603-A548-F6A8D25645DD; Fructose, European Pharmacopoeia (EP) Reference Standard; Z1255372738; (3S,4R,5R)-1,3,4,5,6-pentakis(oxidanyl)hexan-2-one; Fructose, United States Pharmacopeia (USP) Reference Standard; D-(-)-Fructose, meets analytical specification of Ph.??Eur., BP; FRUCTOSE (CONSTITUENT OF CRANBERRY LIQUID PREPARATION) [DSC]; Fructose, Pharmaceutical Secondary Standard; Certified Reference Material; D-(-)-Fructose, BioReagent, suitable for cell culture, suitable for insect cell culture; 25702-76-5; D-(-)-Fructose, analytical standard, analytical standard for fructose assay kit, for use with enzymatic assay kit FA20	.	.	180.16	C6H12O6	118	147	-3.2	12	5	6	5	InChI=1S/C6H12O6/c7-1-3(9)5(11)6(12)4(10)2-8/h3,5-9,11-12H,1-2H2/t3-,5-,6-/m1/s1	C([C@H]([C@H]([C@@H](C(=O)CO)O)O)O)O	C(C(C(C(C(=O)CO)O)O)O)O	BJHIKXHVCXFQLS-UYFOZJQFSA-N	(3S,4R,5R)-1,3,4,5,6-pentahydroxyhexan-2-one
ferrodrug0200	Alumina	.	Alumina; Emery; Corundum; 1302-74-5; oxo(oxoalumanyloxy)alumane; Corundum (Al2O3); Sapphire (Al2O3); 12415-34-8; Aluminum oxide, alpha-phase; Electrocorundum; Aluminum oxide, alpha; Aluminum oxide, gamma; Korund; alpha-Corundum; Aluminum oxide, gamma-alpha; Abramant F 36; Abramax F 46; Abramax F 54; Aluminum oxide, catalyst support; MP 1 (Refractory); Dural F 30; MFCD00003424; Aluminum oxide, fused, insulating powder; KO 7; Aluminum oxide, neutral, HPLC Flash Grade; EKF 100; KER 710; KU 10; NK 63; FN 237; KU 5-3; Aluminum oxide, Drysphere desiccant, without indicator; Aluminumoxide; Aluminum oxide, CP; Anti-bumping granules; Aluminum oxide, cement; Aluminum oxide, puriss.; gamma-Alumina, low soda; Aluminum oxide 90 acidic; Aluminum oxide, Type A-5; Aluminum oxide, Puratronic?; Aluminum oxide, 1-5 micron; Aluminum oxide, Type CG-20; Aluminum oxide, pellets, 3 mm; Aluminum oxide 90 active basic; CHEMBL4594252; gamma-Alumina, 1/16' spheres; Aluminum Oxide Powder, 99.5%; Aluminum oxide desiccant, regular; TWNQGVIAIRXVLR-UHFFFAOYSA-N; Aluminum oxide, for chromatography; Aluminum oxide, powder, ultra dry; Aluminum oxide, Type WA-4: Acid; Aluminum oxide, Type WA-7: Acid; Aluminum oxide, Type WB-5: Basic; MFCD00211795; MFCD07370730; Aluminum oxide, Type WN-9: Neutral; AKOS015903822; Aluminum oxide, -100, +325 mesh; Aluminum oxide, 5 mum mean particle size; Aluminum oxide, basic, HPLC Flash Grade; BP-31011; Aluminum oxide, acidic, HPLC Flash Grade; Aluminum oxide, Grade H-152, 1/8 in.; Aluminum oxide, calcined, insulating powder; Aluminum oxide, catalyst support, low silica; Aluminum oxide (alpha) powder, 99.97% Nano; Aluminum oxide Corundum, a-phase, -100 mesh; Aluminum Oxide Powder (alpha), 99.9% Nano; Aluminum oxide, 99.997% trace metals basis; Aluminum oxide (gamma) Powder, 99.97% Nano; Aluminum oxide, polishing compound, 2oz (57g); Aluminum oxide, puriss., >=98% Al2O3 basis; Aluminum oxide, SAJ special grade, >=98.0%; Aluminum oxide, pore size 58 ??, ~150 mesh; Alumina, NIST(R) SRM(R) 699, reduction grade; Alumina, NIST(R) SRM(R) 742, reference point; Aluminum oxide, 20% in H2O, colloidal dispersion; Aluminum oxide, Aerosol Refractory Brushable Paint; Aluminum oxide, catalyst support, low surface area; Aluminum oxide, Corundum, alpha-phase, -100 mesh; Aluminum oxide, powder, 99.99% trace metals basis; Aluminum oxide, Drysphere desiccant, with 20% indicator; Aluminum oxide, nanopowder, <50 nm particle size (TEM); Aluminum oxide, basic, for TLC, 5-15 Micron APS Powder; Aluminum oxide, nanofiber, diam. x L <20 nm x 100 mum; Aluminum oxide, nanofiber, diam. x L <20 nm x 500 mum; Aluminum oxide, 99.3%, < 325 mesh, d 50 5 - 7 micron; Aluminum oxide, nanowires, diam. x L 2-6 nm x 200-400 nm; Aluminum oxide, single crystal substrate, <0001>; Aluminum oxide, Type WN-6, Neutral, Activity Grade Super I; Aluminum oxide substrate, 10x10x0.5mm, polished one side, A plane; Aluminum oxide substrate, 10x10x1mm, polished one side, C plane; Aluminum oxide, alpha, catalyst support, low surface area, trimodal; Aluminum oxide, fused, powder, primarily alpha-phase, -325 mesh; Aluminum oxide, fused, powder, primarily alpha-phase, 100-200 mesh; Aluminum oxide, gamma, catalyst support, high surface area, bimodal; Inhibitor removers, Prepacked column, for removing tert-butylcatechol; Aluminum oxide, calcined, powder, primarily alpha-phase, 100-325 mesh; Aluminum oxide, catalyst support, intermediate surface area (low SiO2); Aluminum oxide, mesoporous, MSU-X (wormhole), average pore size 3.8 nm; Aluminum oxide, primarily alpha-phase, fused, 200-325 mesh, >=99%; Inhibitor removers, replacement packing, for removing tert-butylcatechol; Aluminum oxide, nanopowder, 13 nm primary particle size (TEM), 99.8% trace metals basis; Sapphire substrate, 10x10x0.432mm, EPI polished two sides, C-axis, LED grade; 12174-49-1; Aluminum oxide 90 active neutral, (activity stage I) for column chromatography 0.063-0.200 mm (70 - 230 mesh ASTM); Aluminum oxide, powder, primarily alpha phase, <=10 mum avg. part. size, 99.5% trace metals basis; Inhibitor removers, Prepacked column for removing hydroquinone and monomethyl ether hydroquinone; Inhibitor removers, replacement packing for removing hydroquinone and monomethyl ether hydroquinone; Sapphire substrate, 50.8mm dia x 0.332mm thick, EPI polished one side, C-axis, HEMCOR single crystal; Sapphire substrate, 50.8mm dia x 0.332mm thick, EPI polished two sides, C-axis, HEMCOR single crystal; Sapphire substrate, 50.8mm dia x 0.432mm thick, EPI polished one side, C-axis, HEMCOR single crystal	.	.	101.961	Al2O3	43.4	34.2	.	5	0	3	0	InChI=1S/2Al.3O	O=[Al]O[Al]=O	O=[Al]O[Al]=O	TWNQGVIAIRXVLR-UHFFFAOYSA-N	oxo(oxoalumanyloxy)alumane
ferrodrug0201	D-2-hydroxyglutarate	.	(R)-2-Hydroxypentanedioic acid; 13095-47-1; (2R)-2-hydroxypentanedioic acid; D-2-Hydroxyglutaric acid; (R)-2-hydroxyglutaric acid; (R)-Hydroxyglutarate; (R)-2-hydroxyglutarate; Pentanedioic acid, 2-hydroxy-, (2R)-; d-alpha-hydroxyglutaric acid; R9UK2G8Y79; 2-Hydroxyglutaric acid, (R)-; CHEMBL1614745; CHEBI:32796; Glutaric acid, 2-hydroxy-, D-; (R)-(-)-2-Hydroxyglutaric acid; Pentanedioic acid, 2-hydroxy-, (R)-; D-2-Hydroxyglutarate; D-Hydroxyglutarate; 2HG; D-a-Hydroxyglutarate; 2-hydroxy-D-Glutarate; (R)-a-Hydroxyglutarate; delta-2-Hydroxyglutarate; D-a-Hydroxyglutaric acid; 2-hydroxy-delta-Glutarate; D-?-Hydroxyglutaric Acid; D-; A-Hydroxyglutaric acid; 2-hydroxy-D-Glutaric acid; (R)-alpha-Hydroxyglutarate; delta-alpha-Hydroxyglutarate; SCHEMBL8032; (R)-a-Hydroxyglutaric acid; UNII-R9UK2G8Y79; delta-2-Hydroxyglutaric acid; (R)-2-hydroxy-Pentanedioate; 2-hydroxy-delta-Glutaric acid; (R)-2-Hydroxypentanedioicacid; (R)-alpha-Hydroxyglutaric acid; delta-alpha-Hydroxyglutaric acid; (R)-alpha-Hydroxyglutaric acid-; (R)-2-hydroxy-Pentanedioic acid; DTXSID80897218; BDBM50361471; AKOS027325193; FD21404; BS-50252; (R)-.ALPHA.-HYDROXYGLUTARIC ACID-; HY-113038; CS-0059411; C01087; EN300-209542; 93397C3E-3CE9-4FEA-A2ED-8F6FA59A1FEA; Q27104222; Z1205493868; 636-67-9	.	.	148.11	C5H8O5	94.8	141	-1	10	3	5	4	InChI=1S/C5H8O5/c6-3(5(9)10)1-2-4(7)8/h3,6H,1-2H2,(H,7,8)(H,9,10)/t3-/m1/s1	C(CC(=O)O)[C@H](C(=O)O)O	C(CC(=O)O)C(C(=O)O)O	HWXBTNAVRSUOJR-GSVOUGTGSA-N	(2R)-2-hydroxypentanedioic acid
ferrodrug0202	Auranofin	.	AURANOFIN; 34031-32-8; (1-Thio-beta-D-glucopyranosato)(triethylphosphine)gold 2,3,4,6-tetraacetate; BCP08217; MFCD00080759; MMV688978; SKF 39162; AKOS026750078; FT-0662343; D78135; A937040; 1-Thio-; A-D-glucopyranosatotriethylphosphine gold-2,3,4,6-tetraacetate; 1-Thio-beta-D-glucopyranosatotriethyl phosphine gold-2,3,4,6-tetraacetate; 3,4,5-Triacetyloxy-6-(acetyloxymethyl) oxane-2-thiolate triethylphosphanium; gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane; SKF-39162; SKF-D-39162; SKF 39162; SKF D 39162; SKFD-39162; SKFD39162	.	.	678.5	C20H34AuO9PS	115	532	.	32	0	10	12	InChI=1S/C14H20O9S.C6H15P.Au/c1-6(15)19-5-10-11(20-7(2)16)12(21-8(3)17)13(14(24)23-10)22-9(4)18;1-4-7(5-2)6-3;/h10-14,24H,5H2,1-4H3;4-6H2,1-3H3;/q;;+1/p-1	CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]	CCP(CC)CC.CC(=O)OCC1C(C(C(C(O1)[S-])OC(=O)C)OC(=O)C)OC(=O)C.[Au+]	AUJRCFUBUPVWSZ-UHFFFAOYSA-M	gold(1+);3,4,5-triacetyloxy-6-(acetyloxymethyl)oxane-2-thiolate;triethylphosphane
ferrodrug0203	Ferric ammonium citrate	.	FERRIC AMMONIUM CITRATE; 1185-57-5; Ammonium iron(III) citrate; Ferric Ammonium Citrate, Brown; iron(3+) 2-hydroxypropane-1,2,3-tricarboxylate ammoniate; Ferriseltz (TN); 7050-19-3; Ammonium iron III citrate; Ammonium ferric citrate;FAC; SCHEMBL1920826; Ferric ammonium citrate (JAN/USP); AKOS015918211; D01644; E75831; J-003847; azane;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)	.	.	261.98	C6H8FeNO7	142	211	.	15	2	8	2	InChI=1S/C6H8O7.Fe.H3N/c7-3(8)1-6(13,5(11)12)2-4(9)10;;/h13H,1-2H2,(H,7,8)(H,9,10)(H,11,12);;1H3/q;+3;/p-3	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.N.[Fe+3]	C(C(=O)[O-])C(CC(=O)[O-])(C(=O)[O-])O.N.[Fe+3]	FRHBOQMZUOWXQL-UHFFFAOYSA-K	azane;2-hydroxypropane-1,2,3-tricarboxylate;iron(3+)
ferrodrug0204	Oxaliplatin	.	oxaliplatin; DTXSID0036760; Oxalato(trans-l-1,2-cyclohexanediamine)platinum(II); cis-oxalato-trans-l-1,2-diaminocyclohexaneplatinum(II); DTXCID8016760; CAS-61825-94-3; NCGC00167798-01; SCHEMBL19511; HMS3269F19; Tox21_112585; Tox21_112629; AKOS005766023; AKOS015855804; CS-0992; BP-25383; HY-17371; [(1S,2S)-2-azanidylcyclohexyl]azanide; oxalate; platinum(4+)	.	.	397.29	C8H14N2O4Pt	76.6	191	.	15	4	6	0	InChI=1S/C6H12N2.C2H2O4.Pt/c7-5-3-1-2-4-6(5)8;3-1(4)2(5)6;/h5-8H,1-4H2;(H,3,4)(H,5,6);/q-2;;+2/t5-,6-;;/m1../s1	C1CC[C@H]([C@@H](C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]	C1CCC(C(C1)[NH-])[NH-].C(=O)(C(=O)O)O.[Pt+2]	DRMCATBEKSVAPL-BNTLRKBRSA-N	[(1R,2R)-2-azanidylcyclohexyl]azanide;oxalic acid;platinum(2+)
ferrodrug0205	Honokiol	.	Honokiol; 35354-74-6; 5,3'-Diallyl-2,4'-dihydroxybiphenyl; NSC 293100; 3,5'-Diallyl-4,2'-dihydroxybiphenyl; C18H18O2; 3',5-diallyl-2,4'-biphenyldiol; 3',5-Diallylbiphenyl-2,4'-diol; CPD000387107; CHEMBL16901; 2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol; CHEBI:5759; 4-allyl-2-(3-allyl-4-hydroxy-phenyl)phenol; 11513CCO0N; 2-[4-hydroxy-3-(prop-2-en-1-yl)phenyl]-4-(prop-2-en-1-yl)phenol; 5,3'-Diallyl-biphenyl-2,4'-diol; MFCD00016674; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propenyl-; NSC-293100; 2-(4-hydroxy-3-prop-2-enyl-phenyl)- 4-prop-2-enyl-phenol; 3',5-(5,5'-)Diallyl-[1,1'-biphenyl]-2,4'-(2,2'-)diol; Honokiol,(S); SMR000387107; 3',5-di(prop-2-en-1-yl)biphenyl-2,4'-diol; (1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPENYL-; UNII-11513CCO0N; -dihydroxydiphenyl; 3',5-diallyl-[1,1'-biphenyl]-2,4'-diol; Honokiol, HO; 5,3&prime; Honokiol - 95%; -Diallyl-2,4&prime; FMLT BSASM H; HONOKIOL [INCI]; HONOKIOL [MI]; HONOKIOL [WHO-DD]; Honokiol, analytical standard; cid_72303; MLS000759481; MLS001048916; MLS001423980; MLS006011755; SCHEMBL133034; REGID_for_CID_72303; GTPL11610; DTXSID30188845; 3',1'-biphenyl)-2,4'-diol; FVYXIJYOAGAUQK-UHFFFAOYSA-N; HMS2051C12; HMS2271J07; HMS3393C12; HMS3656G03; (1,1'-BIPHENYL)-2,4'-DIOL, 3',5-DI-2-PROPEN-1-YL-; AMY40657; BCP28282; HY-N0003; AC-486; BBL027819; BDBM50157304; HB0328; NSC293100; s2310; STK801954; 3'',5-diallylbiphenyl-2,4''-diol; Honokiol, >=98% (HPLC), powder; 3,5'-diallyl-2',4-dihydroxybiphenyl; AKOS005622639; 3',5-Diallyl-2,4'-dihydroxybiphenyl; CCG-100864; CS-1696; NC00114; 5,3''-Diallyl-biphenyl-2,4''-diol; SMP2_000040; NCGC00163567-01; NCGC00163567-02; NCGC00163567-03; NCGC00163567-08; AS-15333; XH163752; 5,3''''-Diallyl-biphenyl-2,4''''-diol; FT-0601638; H1309; SW197494-3; EN300-7399522; A822747; SR-01000758208; Q-100425; Q5896650; SR-01000758208-5; {1,1'-Biphenyl]-2,4'-diol, 3,5-di-2-propenyl-; 3'',5-di-2-propenyl-1,1''-biphenyl-2,4''-diol; BRD-K98493452-001-01-6; 3',5-Di-2-propen-1-yl[1,1'-biphenyl]-2,4'-diol; Honokiol, European Pharmacopoeia (EP) Reference Standard; Z2065671480; [1,1'-Biphenyl]-2,4'-diol, 3',5-di-2-propen-1-yl; 4-[2-hydroxy-5-(prop-2-en-1-yl)phenyl]-2-(prop-2-en-1-yl)phenol; 947686-05-7; InChI=1/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H	.	.	266.3	C18H18O2	40.5	325	5	20	2	2	5	InChI=1S/C18H18O2/c1-3-5-13-7-9-18(20)16(11-13)14-8-10-17(19)15(12-14)6-4-2/h3-4,7-12,19-20H,1-2,5-6H2	C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C	C=CCC1=CC(=C(C=C1)O)C2=CC(=C(C=C2)O)CC=C	FVYXIJYOAGAUQK-UHFFFAOYSA-N	2-(4-hydroxy-3-prop-2-enylphenyl)-4-prop-2-enylphenol
ferrodrug0206	Salidroside	.	Salidroside; 10338-51-9; Rhodioloside; Rhodosin; sallidroside; salidroside, (-)-; Glucopyranoside, p-hydroxyphenethyl; Tyrosol glucoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-(4-hydroxyphenethoxy)tetrahydro-2H-pyran-3,4,5-triol; UNII-M983H6N1S9; 2-(4-Hydroxyphenyl)ethyl beta-D-glucopyranoside; DTXSID4049034; M983H6N1S9; NSC-741643; 8-O-b-D-glucoside of tyrosol; CHEBI:9009; CHEMBL465208; DTXCID9028960; beta-D-Glucopyranoside, 2-(4-hydroxyphenyl)ethyl; NSC 741643; MFCD00210553; p-Hydroxyphenethyl alcohol 1-O-beta-D-glucoside; SALIDROSIDE (USP-RS); SALIDROSIDE [USP-RS]; CAS-10338-51-9; p-Hydroxyphenethyl glucopyranoside; Salidroside,(S); NCGC00169145-02; pyran-3,4,5-triol; 2-(4-hydroxyphenyl)ethyl-beta-d-glucopyranoside; salidroside (rhodioloside); Salidroside - Rhodioloside; beta-D-glucopyranoside, 2-(4-hydroxyphenyl)ethyl-; MLS006010734; SCHEMBL148079; MEGxp0_000478; Salidroside, analytical standard; ACon1_000366; 2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]tetrahydropyran-3,4,5-triol; HMS3884N15; AMY22501; HY-N0109; Tox21_113565; (4-hydroxyphenethoxy)tetrahydro-2H-; BDBM50269651; NSC741643; s2396; 4-hydroxyphenyl-2-ethylglucopyranoside; AKOS015895134; Tox21_113565_1; AC-6071; CCG-267467; CS-5300; Salidroside, >=95% (LC/MS-ELSD); NCGC00169145-01; NCGC00169145-03; SMR001294679; TYROSOL alpha-(beta-D-GLUCOPYRANOSIDE); SW219124-1; 2-(4-Hydroxyphenyl)ethyl ?-D-glucopyranoside; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-; C06046; 2-(4-Hydroxyphenyl)ethyl bet.-D-glucopyranoside; A800725; SALIDROSIDE (CONSTITUENT OF RHODIOLA ROSEA); Q-100031; Q7404463; TYROSOL .ALPHA.-(.BETA.-D-GLUCOPYRANOSIDE); BRD-K66030860-001-01-0; Salidroside, primary pharmaceutical reference standard; 2-(4-HYDROXYPHENYL)ETHYL-.BETA.-D-GLUCOPYRANOSIDE; SALIDROSIDE (CONSTITUENT OF RHODIOLA ROSEA) [DSC]; .BETA.-D-GLUCOPYRANOSIDE, 2-(4-HYDROXYPHENYL)ETHYL-; Salidroside, United States Pharmacopeia (USP) Reference Standard; (2R,3R,4S,5S,6R)-2-[2-(4-hydroxyphenyl)ethoxy]-6-methylol-tetrahydropyran-3,4,5-triol; (2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]tetrahydropyran-3,4,5-triol	.	.	300.3	C14H20O7	120	306	-0.6	21	5	7	5	InChI=1S/C14H20O7/c15-7-10-11(17)12(18)13(19)14(21-10)20-6-5-8-1-3-9(16)4-2-8/h1-4,10-19H,5-7H2/t10-,11-,12+,13-,14-/m1/s1	C1=CC(=CC=C1CCO[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O)O	C1=CC(=CC=C1CCOC2C(C(C(C(O2)CO)O)O)O)O	ILRCGYURZSFMEG-RKQHYHRCSA-N	(2R,3S,4S,5R,6R)-2-(hydroxymethyl)-6-[2-(4-hydroxyphenyl)ethoxy]oxane-3,4,5-triol
ferrodrug0207	Icariin	Small molecular drug	Icariin; 489-32-7; Ieariline; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; CHEBI:78420; MFCD00210516; VNM47R2QSQ; Icariine; 3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4H-chromen-7-yl beta-D-glucopyranoside; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one; SMR000466309; UNII-VNM47R2QSQ; -Anhydroicaritin; 3-((6-Deoxymannopyranosyl)oxy)-7-(glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-4H-1-benzopyran-4-one; Epimedii herba icariin; Spectrum2_001695; Spectrum3_001130; Spectrum4_001975; Spectrum5_000933; Icariin, analytical standard; BSPBio_002599; KBioGR_002475; MLS000759413; MLS001424083; MLS006011789; SCHEMBL312615; SPECTRUM1505257; SPBio_001650; CHEMBL553204; Icariin, >=94% (HPLC); KBio3_002099; DTXSID00964133; TZJALUIVHRYQQB-XLRXWWTNSA-N; HMS2051J13; HMS2235I20; BCP18807; EPIMEDII HERBA ICARIIN [MI]; EX-A6783; HY-N0014; BBL010487; BDBM50027363; CCG-38780; STK801622; AKOS005614005; AM85785; CCG-100955; CS-3675; DB12052; NC00205; SDCCGMLS-0066754.P001; NCGC00178583-01; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-7-(beta-D-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-; VS-02526; C17555; AB00639912-06; A827628; SR-01000759346; Q-100549; Q5985057; SR-01000759346-4; BRD-K65639003-001-02-5; BRD-K65639003-001-05-8; BRD-K65639003-001-09-0; 3-[(6-Deoxy-alpha-L-mannopyranosyl)oxy]-7-(beta-D-glucopyranosyloxy)-5-hydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-4H-1-benzopyran-4-one; 4H-1-BENZOPYRAN-4-ONE, 3-((6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)OXY)-7-(.BETA.-D-GLUCOPYRANOSYLOXY)-5-HYDROXY-2-(4-METHOXYPHENYL)-8-(3-METHYL-2-BUTEN-1-YL)-; 5-Hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-(((2S,4S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-3-(((3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-3-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4H-chromen-4-one; 5-HYDROXY-2-(4-METHOXYPHENYL)-8-(3-METHYLBUT-2-EN-1-YL)-7-{[3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL]OXY}-3-[(3,4,5-TRIHYDROXY-6-METHYLOXAN-2-YL)OXY]-4H-CHROMEN-4-ONE; 5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-3-((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-4H-chromen-4-one	D05OQG	DMOJQGT	676.7	C33H40O15	234	1170	1.7	48	8	15	9	InChI=1S/C33H40O15/c1-13(2)5-10-17-19(45-33-28(42)26(40)23(37)20(12-34)46-33)11-18(35)21-24(38)31(48-32-27(41)25(39)22(36)14(3)44-32)29(47-30(17)21)15-6-8-16(43-4)9-7-15/h5-9,11,14,20,22-23,25-28,32-37,39-42H,10,12H2,1-4H3/t14-,20+,22-,23+,25+,26-,27+,28+,32-,33+/m0/s1	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O	CC1C(C(C(C(O1)OC2=C(OC3=C(C2=O)C(=CC(=C3CC=C(C)C)OC4C(C(C(C(O4)CO)O)O)O)O)C5=CC=C(C=C5)OC)O)O)O	TZJALUIVHRYQQB-XLRXWWTNSA-N	5-hydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
ferrodrug0208	Loganin	.	Loganin; 18524-94-2; Loganoside; 7-Hydroxy-6-desoxyverbenalin; CHEBI:15771; UNII-H7WJ16Q93C; H7WJ16Q93C; EINECS 242-398-0; C17H26O10; NSC 606403; LOGANIN, (-)-; NSC-606403; (1S,4aS,6S,7R,7aS)-Methyl 6-hydroxy-7-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-1H,4aH,5H,6H,7H,7aH-cyclopenta[c]pyran-4-carboxylate; (-)-Loganin; Meliatin; 1-(beta-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta(c)pyran-4-carboxylic acid methyl ester; 1-(beta-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta[c]pyran-4-carboxylic acid methyl ester; methyl (1S,4aS,6S,7R,7aS)-1-(beta-D-glucopyranosyloxy)-6-hydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta(c)pyran-4-carboxylate; methyl (1S,4aS,6S,7R,7aS)-1-(beta-D-glucopyranosyloxy)-6-hydroxy-7-methyl-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; Spectrum_001503; SpecPlus_000563; LOGANIN [MI]; Spectrum2_001637; Spectrum3_001875; Spectrum4_001914; Spectrum5_000628; Loganin, analytical standard; BSPBio_003350; KBioGR_002535; KBioSS_001983; DivK1c_006659; SCHEMBL307017; SPECTRUM1504066; SPBio_001733; MEGxp0_000723; CHEMBL1081584; ACon1_001749; KBio1_001603; KBio2_001983; KBio2_004551; KBio2_007119; KBio3_002852; AMBQHHVBBHTQBF-UOUCRYGSSA-N; CYCLOPENTA(C)PYRAN-4-CARBOXYLIC ACID, 1-(.BETA.-D-GLUCOPYRANOSYLOXY)-1,4A,5,6,7,7A-HEXAHYDRO-6-HYDROXY-7-METHYL-, METHYL ESTER; CYCLOPENTA(C)PYRAN-4-CARBOXYLIC ACID, 1-(.BETA.-D-GLUCOPYRANOSYLOXY)-1,4A,5,6,7,7A-HEXAHYDRO-6-HYDROXY-7-METHYL-, METHYL ESTER, (1S-(1.ALPHA.,4A.ALPHA.,6.ALPHA.,7.ALPHA.,7A.ALPHA.))-; HY-N0512; BDBM50279529; CCG-38757; MFCD00075645; s3835; AKOS022190418; CS-5019; LMPR0102070001; SDCCGMLS-0066747.P001; NCGC00178124-01; NCGC00178124-02; NCGC00178124-04; AC-34479; AS-75232; cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1S, 4aS, 6S, 7R, 7aS)-; Cyclopenta(c)pyran-4-carboxylic acid, 1-(beta-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1S-(1alpha,4aalpha,6alpha,7alpha,7aalpha))-; methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; C01433; A812937; Q-100220; 5A5AFFBA-93AB-4635-A071-FC87B9DC023D; Q15426222; (1S)-1.ALPHA.-(.BETA.-D-GLUCOPYRANOSYLOXY)-1,4A.ALPHA.,5,6,7,7A.ALPHA.-HEXAHYDRO-6.ALPHA.-HYDROXY-7.ALPHA.-METHYLCYCLOPENTA(C)PYRAN-4-CARBOXYLIC ACID METHYL ESTER; (1S)-1alpha-(beta-D-GLUCOPYRANOSYLOXY)-1,4Aalpha,5,6,7,7Aalpha-HEXAHYDRO-6alpha-HYDROXY-7alpha-METHYLCYCLOPENTA(C)PYRAN-4-CARBOXYLIC ACID METHYL ESTER; (1S,4aS,6S,7R,7aS)-methyl 6-hydroxy-7-methyl-1-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; (1S,4aS,6S,7R,7aS)-Methyl6-hydroxy-7-methyl-1-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; 6-hydroxy-7-methyl-1-[[3,4,5-trihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylic acid methyl ester; CYCLOPENTA(C)PYRAN-4-CARBOXYLIC ACID, 1-(.BETA.-D-GLUCOPYRANOSYLOXY)-1,4A,5,6,7,7A-HEXAHYDRO-6-HYDROXY-7-METHYL-, METHYL ESTER, (1S,4AS,6S,7R,7AS)-; CYCLOPENTA(C)PYRAN-4-CARBOXYLIC ACID, 1-(beta-D-GLUCOPYRANOSYLOXY)-1,4A,5,6,7,7A-HEXAHYDRO-6-HYDROXY-7-METHYL-, METHYL ESTER; CYCLOPENTA(C)PYRAN-4-CARBOXYLIC ACID, 1-(beta-D-GLUCOPYRANOSYLOXY)-1,4A,5,6,7,7A-HEXAHYDRO-6-HYDROXY-7-METHYL-, METHYL ESTER, (1S,4AS,6S,7R,7AS)-; Cyclopenta[c]pyran-4-carboxylic acid,1-(b-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methyl-, methyl ester, (1S,4aS,6S,7R,7aS)-; methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate; METHYL (1S-(1.ALPHA.,4A.ALPHA.,6.ALPHA.,7.ALPHA.,7A.ALPHA.))-1-(.BETA.-D-GLUCOPYRANOSYLOXY)-1,4A,5,6,7,7A-HEXAHYDRO-6-HYDROXY-7-METHYLCYCLOPENTA(C)PYRAN-4-CARBOXYLATE; Methyl (1S-(1alpha,4aalpha,6alpha,7alpha,7aalpha))-1-(beta-D-glucopyranosyloxy)-1,4a,5,6,7,7a-hexahydro-6-hydroxy-7-methylcyclopenta(c)pyran-4-carboxylate; Methyl 6-hydroxy-7-methyl-1-((3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-1,4a,5	.	.	390.4	C17H26O10	155	580	-1.4	27	5	10	5	InChI=1S/C17H26O10/c1-6-9(19)3-7-8(15(23)24-2)5-25-16(11(6)7)27-17-14(22)13(21)12(20)10(4-18)26-17/h5-7,9-14,16-22H,3-4H2,1-2H3/t6-,7+,9-,10+,11+,12+,13-,14+,16-,17-/m0/s1	C[C@H]1[C@H](C[C@H]2[C@@H]1[C@@H](OC=C2C(=O)OC)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O	CC1C(CC2C1C(OC=C2C(=O)OC)OC3C(C(C(C(O3)CO)O)O)O)O	AMBQHHVBBHTQBF-UOUCRYGSSA-N	methyl (1S,4aS,6S,7R,7aS)-6-hydroxy-7-methyl-1-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,4a,5,6,7,7a-hexahydrocyclopenta[c]pyran-4-carboxylate
ferrodrug0209	Neratinib	.	Neratinib; 698387-09-6; HKI-272; Neratinib (HKI-272); Nerlynx; HKI 272; PB-272; JJH94R3PWB; (2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; (E)-N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; CHEMBL180022; CDP-820; 698387-09-6 (free base); HKI272; WAY-179272; (2E)-N-(4-{[3-chloro-4-(pyridin-2-ylmethoxy)phenyl]amino}-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; (E)-N-(4-((3-Chloro-4-(pyridin-2-ylmethoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; 876310-02-0; (E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; N-(4-(3-Chloro-4-(2-pyridinylmethoxy)anilino)-3-cyano-7-ethoxy-6-quinolyl)-4-(dimethylamino)-2-butenamide; (2e)-n-(4-((3-chloro-4-((pyridin-2-yl)methoxy)phenyl)amino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; 2-Butenamide, N-(4-((3-chloro-4-(2-pyridinylmethoxy)phenyl)amino)-3-cyano-7-ethoxy-6-quinolinyl)-4-(dimethylamino)-, (2E)-; Neratinib [USAN]; Neratinib(HKI-272); Neratinib [USAN:INN]; UNII-JJH94R3PWB; Neratinib- Bio-X; (2E)-N-[4-({3-chloro-4-[(pyridin-2-yl)methoxy]phenyl}amino)-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide; PB 272; NERATINIB [INN]; NERATINIB [MI]; Neratinib (USAN/INN); Neratinib - HKI-272; NERATINIB [MART.]; NERATINIB [WHO-DD]; SCHEMBL571762; SCHEMBL571763; GTPL5686; CHEBI:61397; AMY9255; DTXSID70220132; EX-A062; BCPP000151; BDBM50161957; MFCD09752958; NSC757439; NSC800803; s2150; WAY-179272-B; AKOS005146340; AKOS025149637; BCP9000984; CCG-270036; DB11828; NSC-757439; NSC-800803; NCGC00241101-01; NCGC00241101-03; NCGC00241101-09; AC-25073; AS-16279; BN164645; HY-32721; N1062; EC-000.2260; A25338; D08950; EN300-7386009; Q-101402; Q6995920; BRD-K85606544-001-01-8; (2E)-N-[4-[[3-Chloro-4-(2-pyridinylmethoxy)phenyl]amino]-3-cyano-7-ethoxy-6-quinolinyl]-4-(dimethylamino)-2-butenamide; (E)-4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide; 4-Dimethylamino-but-2-enoic acid {4-[3-chloro-4-(pyridin-2-ylmethoxy)-phenylamino]-3-cyano-7-ethoxy-quinolin-6-yl}-amide; HKI-272; PB272;;(2E)-N-[4-[[3-chloro-4-[(pyridin-2-yl)methoxy]phenyl]amino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide;HKI-272; N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)but-2-enamide; N-(4-(3-chloro-4-(pyridin-2-ylmethoxy)phenylamino)-3-cyano-7-ethoxyquinolin-6-yl)-4-(dimethylamino)butanamide	.	.	557	C30H29ClN6O3	112	881	4.9	40	2	8	11	InChI=1S/C30H29ClN6O3/c1-4-39-28-16-25-23(15-26(28)36-29(38)9-7-13-37(2)3)30(20(17-32)18-34-25)35-21-10-11-27(24(31)14-21)40-19-22-8-5-6-12-33-22/h5-12,14-16,18H,4,13,19H2,1-3H3,(H,34,35)(H,36,38)/b9-7+	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)/C=C/CN(C)C	CCOC1=C(C=C2C(=C1)N=CC(=C2NC3=CC(=C(C=C3)OCC4=CC=CC=N4)Cl)C#N)NC(=O)C=CCN(C)C	JWNPDZNEKVCWMY-VQHVLOKHSA-N	(E)-N-[4-[3-chloro-4-(pyridin-2-ylmethoxy)anilino]-3-cyano-7-ethoxyquinolin-6-yl]-4-(dimethylamino)but-2-enamide
ferrodrug0210	Ginkgetin	.	Ginkgetin; 481-46-9; 7,4'-Dimethylamentoflavone; Amentoflavone 7,4'-dimethyl ether; CHEBI:5353; HY5EZW8269; 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxochromen-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)chromen-4-one; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-(5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl)-2-(4-hydroxyphenyl)-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)-; 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 5,7-dihydroxy-8-(5-(5-hydroxy-7-methoxy-4-oxo-4H-1-benzopyran-2-yl)-2-methoxyphenyl)-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; Spectrum_001932; Spectrum2_000054; Spectrum3_001727; Spectrum4_001610; Spectrum5_000339; UNII-HY5EZW8269; BSPBio_003374; KBioGR_001959; KBioSS_002476; SCHEMBL888410; SPBio_000207; jm5b01461, Compound 89; KBio2_002469; KBio2_005037; KBio2_007605; KBio3_002594; DTXSID70197416; BDBM429271; HY-N0889; LMPK12040003; MFCD09970948; AKOS015896770; CS-3727; Ginkgetin 7''-O-beta-D-glucopyranoside; 5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxo-chromen-2-yl)-2-methoxy-phenyl]-2-(4-hydroxyphenyl)chromen-4-one; AC-35029; MS-30254; FT-0686623; Q-100523; BRD-K92123432-237-02-8; Q27089352; 3''',8-Biflavone, 4',5,5'',7-tetrahydroxy-4''',7''-dimethoxy-; 4''',5,5'',7''-tetrahydroxy-4',7-dimethoxy-(3'->8'')-biflavone	.	.	566.5	C32H22O10	152	1080	5.7	42	4	10	5	InChI=1S/C32H22O10/c1-39-18-10-20(34)30-23(37)13-27(41-28(30)11-18)16-5-8-25(40-2)19(9-16)29-21(35)12-22(36)31-24(38)14-26(42-32(29)31)15-3-6-17(33)7-4-15/h3-14,33-36H,1-2H3	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)OC)O)C4=C(C=C(C5=C4OC(=CC5=O)C6=CC=C(C=C6)O)O)O	COC1=C(C=C(C=C1)C2=CC(=O)C3=C(C=C(C=C3O2)OC)O)C4=C(C=C(C5=C4OC(=CC5=O)C6=CC=C(C=C6)O)O)O	AIFCFBUSLAEIBR-UHFFFAOYSA-N	5,7-dihydroxy-8-[5-(5-hydroxy-7-methoxy-4-oxochromen-2-yl)-2-methoxyphenyl]-2-(4-hydroxyphenyl)chromen-4-one
ferrodrug0211	Dioscin	Small molecular drug	Dioscin; 19057-60-4; Collettiside III; Dioscine; CCRIS 4123; CHEBI:74023; UNII-3B95U4OLWV; 3B95U4OLWV; PARIS III; (+)-DIOSCIN; (2S,3R,4R,5R,6S)-2-[(2R,3S,4S,5R,6R)-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol; 3-O-(Rhaalpha1-4(Rhaalpha1-2)Glcbeta)-(25R)-spirost-5-en-3beta-ol; Diosgenin bis-alpha-L-rhamnopyranosyl)-(1-2 and 1-4)-beta-D-glucopyranoside; 3-O-[alpha-L-Rha-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Glc]-diosgenin; 3-O-[alpha-L-Rhap-(1->4)-[alpha-L-Rhap-(1->2)]-beta-D-Glcp]-diosgenin; (25R)-spirost-5-en-3beta-yl alpha-L-rhamnopyranosyl-(1->2)-[alpha-L-mannopyranosyl-(1->4)]-beta-D-glucopyranoside; beta-D-Glucopyranoside, (3beta,25R)-spirost-5-en-3-yl O-6-deoxy-alpha-L-mannopyranosyl-(1-2)-O-(6-deoxy-alpha-L-mannopyranosyl-(1-4))-; Collettiside III;CCRIS 4123; DTXSID50903916; 3-O-(alpha-L-Rha-(1->4)-(alpha-L-Rha-(1->2))-beta-D-Glc)-diosgenin; 3-O-(alpha-L-Rha-(1->4)-(alpha-L-Rha-(1->2))-beta-D-Glc)diosgenin; 3-O-(alpha-L-Rhap-(1->4)-(alpha-L-Rhap-(1->2))-beta-D-Glcp)-diosgenin; 3-O-[alpha-L-Rha-(1->4)-[alpha-L-Rha-(1->2)]-beta-D-Glc]diosgenin; Collettinside III; (25R)-spirost-5-en-3beta-yl alpha-L-rhamnopyranosyl-(1->2)-(alpha-L-mannopyranosyl-(1->4))-beta-D-glucopyranoside; DIOSCIN [MI]; DIOSCIN [WHO-DD]; Dioscin (Collettiside III); GTPL840; SCHEMBL526528; CHEMBL507001; Dioscin, >=95% (HPLC); DTXCID101331877; GLXC-13125; HY-N0124; BDBM50088500; MFCD02094174; s2379; AKOS022168201; CCG-270544; C08897; A880409; Q-100228; Q63395447; (25r)-3beta-[2-O,4-O-bis(alpha-l-rhamnopyranosyl)-beta-d-glucopyranosyloxy]spirosta-5-ene; (3.BETA.,25R)-SPIROST-5-EN-3-YL O-6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL-(1->2)-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL-(1->4))-.BETA.-D-GLUCOPYRANOSIDE; (3beta,25R)-SPIROST-5-EN-3-YL O-6-DEOXY-alpha-L-MANNOPYRANOSYL-(1->2)-O-(6-DEOXY-alpha-L-MANNOPYRANOSYL-(1->4))-beta-D-GLUCOPYRANOSIDE; .BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,25R)-SPIROST-5-EN-3-YL O-6- DEOXY-ALPHA-L-MANNOPYRANOSYL-(1->2)-O-(6-DEOXY-.ALPHA.-L- MANNOPYRANOSYL-(1->4))-; [(25R)-Spirost-5-en-3beta-yl]2-O-(6-deoxy-alpha-L-mannopyranosyl)-4-O-(6-deoxy-alpha-L-mannopyranosyl)-beta-D-glucopyranoside; 3-O-beta-D-alpha-L-Rhamnopyranosyl(1->4)-[alpha-L-rhamnopyranosyl(1->2)]-beta-D-glucopyranoside-diosgenin; beta-D-GLUCOPYRANOSIDE, (3beta,25R)-SPIROST-5-EN-3-YL O-6-DEOXY-ALPHA-L-MANNOPYRANOSYL-(1->2)-O-(6-DEOXY-alpha-L-MANNOPYRANOSYL-(1->4))-; DIOSGENIN 3-O-.ALPHA.-L-RHAMNOPYRANOSYL-(1->2)-(.ALPHA.-L-RHAMNOPYRANOSYL-(1->4))-.BETA.-D-GLUCOPYRANOSIDE; DIOSGENIN 3-O-alpha-L-RHAMNOPYRANOSYL-(1->2)-(alpha-L-RHAMNOPYRANOSYL-(1->4))-beta-D-GLUCOPYRANOSIDE	D0F2AD	DM5H2W9	869	C45H72O16	236	1600	1.3	61	8	16	7	InChI=1S/C45H72O16/c1-19-9-14-45(54-18-19)20(2)30-28(61-45)16-27-25-8-7-23-15-24(10-12-43(23,5)26(25)11-13-44(27,30)6)57-42-39(60-41-36(52)34(50)32(48)22(4)56-41)37(53)38(29(17-46)58-42)59-40-35(51)33(49)31(47)21(3)55-40/h7,19-22,24-42,46-53H,8-18H2,1-6H3/t19-,20+,21+,22+,24+,25-,26+,27+,28+,29-,30+,31+,32+,33-,34-,35-,36-,37+,38-,39-,40+,41+,42-,43+,44+,45-/m1/s1	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)OC1	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)O)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)OC1	VNONINPVFQTJOC-ZGXDEBHDSA-N	(2S,3R,4R,5R,6S)-2-[(2R,3S,4S,5R,6R)-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
ferrodrug0212	Piperlongumine	.	Piperlongumine; Piplartine; 20069-09-4; UNII-SGD66V4SVJ; (E)-1-(3-(3,4,5-trimethoxyphenyl)acryloyl)-5,6-dihydropyridin-2(1H)-one; SGD66V4SVJ; PPLGM; CHEBI:8241; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-1,2,5,6-tetrahydropyridin-2-one; 1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one; 2(1H)-Pyridinone, 5,6-dihydro-1-(1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl)-, (E)-; 2(1H)-Pyridinone, 5,6-dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-; BRD2293; BRD-2293; (E)-1-[3-(3,4,5-Trimethoxyphenyl)acryloyl]-5,6-dihydropyridin-2(1H)-one; Piplartine;PPLGM; Prestwick_399; MFCD00075706; FERROUSFLUOBORATE; ST079382; Prestwick2_000604; Prestwick3_000604; Piperlongumine; Piplartine; PIPERLONGUMINE [MI]; 5,6-Dihydro-1-[(2E)-1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propen-1-yl]-2(1H)-pyridinone; BSPBio_000508; PIPERLONGUMINE [INCI]; MLS002153903; SCHEMBL173092; SPECTRUM1505135; BPBio1_000560; CHEMBL465843; SCHEMBL2465593; 1-[3-(3,4,5-Trimethoxy-phenyl)-acryloyl]-5,6-dihydro-1H-pyridin-2-one; ACon1_001541; CHEBI:92424; DTXSID801029762; HMS1569J10; HMS2096J10; HMS2234K24; Piperlongumine, >=97% (HPLC); BCP13030; EX-A2925; HY-N2329; BDBM50462013; NSC794671; s7551; AKOS024284776; CCG-214375; NSC-794671; NCGC00096028-01; NCGC00096028-02; NCGC00096028-03; NCGC00096028-04; NCGC00096028-14; AC-32683; AS-74140; BP-25401; SMR001233252; CS-0021113; P2361; A14124; EN300-7424497; A920539; SR-01000841248; A1-00162; J-012992; N-(3,4,5-Trimethoxycinnamoyl)-D3-piperidin-2-one; Q7197361; SR-01000841248-2; BRD-K24132293-001-05-3; BRD-K24132293-001-09-5; BRD-K24132293-001-16-0; 5,6-Dihydro-1-(3,4,5-trimethoxycinnamoyl)-2(1H)-pyridinone; 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)-2-propenoyl]-5,6-dihydro-2(1H)-pyridinone; 1-[(2E)-3-(3,4,5-Trimethoxyphenyl)-2-propenoyl]-5,6-dihydro-2(1H)-pyridinone #; 1-[(2E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-5,6-dihydropyridin-2(1H)-one; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-2-propenyl]-2(1H)-pyridinone, 9CI; 5,6-dihydro-1-[1-oxo-3-(3,4,5-triMethoxyphenyl)-allyl]-2(1H)-pyridinone; 5,6-Dihydro-1-[1-oxo-3-(3,4,5-trimethoxyphenyl)-trans-2-propenyl]-2(1H)-pyridinone; Prop-2-en-1-one, 3-(3,4,5-trimethoxyphenyl)-1-(2,3-dihydropyridin-6(1H)-one-1-yl)-; 2(1H)-PYRIDINONE, 5,6-DIHYDRO-1-(1-OXO-3-(3,4,5-TRIMETHOXYPHENYL)-2- PROPENYL)-, (E)-	.	.	317.34	C17H19NO5	65.099	473	2.1	23	0	5	5	InChI=1S/C17H19NO5/c1-21-13-10-12(11-14(22-2)17(13)23-3)7-8-16(20)18-9-5-4-6-15(18)19/h4,6-8,10-11H,5,9H2,1-3H3/b8-7+	COC1=CC(=CC(=C1OC)OC)/C=C/C(=O)N2CCC=CC2=O	COC1=CC(=CC(=C1OC)OC)C=CC(=O)N2CCC=CC2=O	VABYUUZNAVQNPG-BQYQJAHWSA-N	1-[(E)-3-(3,4,5-trimethoxyphenyl)prop-2-enoyl]-2,3-dihydropyridin-6-one
ferrodrug0213	Bazedoxifene	Small molecular drug	Bazedoxifene; 198481-32-2; Bazedoxifene [INN]; TSE-424; Bazedoxifene free base; 1H-Indol-5-ol, 1-[[4-[2-(hexahydro-1H-azepin-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methyl-; Q16TT9C5BK; 1-(4-(2-(azepan-1-yl)ethoxy)benzyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; CHEMBL46740; 198481-32-2 (free base); 1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol; WAY 140424; Bazedoxifeno; C30H34N2O3; 1-[4-(2-Azepan-1-yl-ethoxy)-benzyl]-2-(4-hydroxy-phenyl)-3-methyl-1H-indol-5-ol; 1H-Indol-5-ol, 1-((4-(2-(hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-; UNII-Q16TT9C5BK; Bazedoxifeno [INN-Spanish]; 1-{4-[2-(azepan-1-yl)ethoxy]benzyl}-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; BAZEDOXIFENE [MI]; BAZEDOXIFENE [VANDF]; SCHEMBL41935; BAZEDOXIFENE [WHO-DD]; GTPL7355; BAZEDOXIFENE [EMA EPAR]; DTXSID70173593; CHEBI:135947; UCJGJABZCDBEDK-UHFFFAOYSA-N; EX-A5409; HY-A0031; BDBM50099585; NSC823462; AKOS030255808; AK R215 COMPONENT BAZEDOXIFENE; AK-R215 COMPONENT BAZEDOXIFENE; CS-0932; DB06401; NSC-823462; SB19326; 1-[[4-[2-(AZEPAN-1-YL)ETHOXY]PHENYL]METHYL]-2-(4-HYDROXYPHENYL)-3-METHYL-INDOL-5-OL; 1-((4-(2-Hexahydro-1H-azepin-1-yl)ethoxy)phenyl)methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; AS-78494; US8815934, No. 98; A15019; D94589; AB01566901_01; A879977; EN300-20600169; J-012822; Q4875166; 1-({4-[2-(azepan-1-yl)ethoxy]phenyl}methyl)-2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol; 1-(P-(2-(HEXAHYDRO-1H-AZEPIN-1-YL)ETHOXY)BENZYL)-2-(P-HYDROXYPHENYL)-3-METHYLINDOL-5-OL	D0JY8T	DMY85QW	470.6	C30H34N2O3	57.9	623	6.1	35	2	4	7	InChI=1S/C30H34N2O3/c1-22-28-20-26(34)12-15-29(28)32(30(22)24-8-10-25(33)11-9-24)21-23-6-13-27(14-7-23)35-19-18-31-16-4-2-3-5-17-31/h6-15,20,33-34H,2-5,16-19,21H2,1H3	CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O	CC1=C(N(C2=C1C=C(C=C2)O)CC3=CC=C(C=C3)OCCN4CCCCCC4)C5=CC=C(C=C5)O	UCJGJABZCDBEDK-UHFFFAOYSA-N	1-[[4-[2-(azepan-1-yl)ethoxy]phenyl]methyl]-2-(4-hydroxyphenyl)-3-methylindol-5-ol
ferrodrug0214	Kainic acid	Small molecular drug	kainic acid; 487-79-6; Digenin; Digenic acid; Helminal; Kainate; L-alpha-Kainic acid; alpha-Kainic acid; Digensaeure; Kainsaeure; Acidum kainicum; Acide kainique; Acido kainico; C10H15NO4; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S,3S,4S)-; alpha- Kainic acid; (2S,3S,4S)-3-(Carboxymethyl)-4-(prop-1-en-2-yl)pyrrolidine-2-carboxylic acid; rac Kainic Acid; CHEMBL275040; SIV03811UC; DTXSID7040526; CHEBI:31746; 2-Carboxy-4-isopropenyl-3-pyrrolidineacetic acid; 3-Pyrrolidineacetic acid, 2-carboxy-4-isopropenyl-; NSC136038; NSC-759587; NCGC00024504-05; (3S,4R)-3-(carboxymethyl)-4-(prop-1-en-2-yl)-L-proline; 2-Carboxy-3-carboxymethyl-4-isopropenylpyrrolidine; NSC 136038; (2S-(2alpha,3beta,4beta))-2-carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; DTXCID5020526; (3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-yl-L-proline; (2S,3S,4S)-Carboxy-4-(1-methylethenyl)-3-pyrrolidineacetic acid; Kainic acid [INN:JAN]; (2S,3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylic acid; 3-(Carboxymethyl)-4-isopropenylproline; 4071-38-9; CAS-487-79-6; Acide kainique [INN-French]; Acido kainico [INN-Spanish]; Acidum kainicum [INN-Latin]; SR-01000075454; BRN 0086660; UNII-SIV03811UC; kainic-acid; NSC-136038; KAI; 1p1n; Kainic acid (synthetic); KAINIC ACID [MI]; Biomol-NT_000217; KAINIC ACID [INN]; UPCMLD-DP146; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2alpha,3beta,4beta))-; Lopac0_000656; SCHEMBL15777; 4-22-00-01523 (Beilstein Handbook Reference); MLS001074661; KAINIC ACID [WHO-DD]; BPBio1_001306; (-)-(.alpha.)-Kainic Acid; UPCMLD-DP146:001; UPCMLD-DP146:002; HMS2233K05; HMS3262C13; HMS3266C11; HMS3411A21; HMS3675A21; HY-N2309; Tox21_110905; Tox21_500656; BDBM50002369; HB0355; Kainic Acid - CAS 487-79-6; AKOS024456995; Tox21_110905_1; CCG-204742; LP00656; SDCCGSBI-0050635.P002; 3-Pyrrolidineacetic acid, 2-carboxy-4-(1-methylethenyl)-, (2S-(2-alpha,3-beta,4-beta))-; NCGC00024504-02; NCGC00024504-03; NCGC00024504-04; NCGC00024504-06; NCGC00024504-07; NCGC00024504-08; NCGC00024504-09; NCGC00024504-15; NCGC00261341-01; SMR000471885; CS-0020451; EU-0100656; K 0250; Q390239; SR-01000597728; SR-01000075454-1; SR-01000075454-5; SR-01000075454-6; SR-01000075454-7; SR-01000597728-1; rel-(3R,4R)-3-(carboxymethyl)-4-isopropenyl-D-proline; 2S-CARBOXY-4S-(1-METHYLETHENYL)-3S-PYRROLDINEACETIC ACID; L-proline, 3-(carboxymethyl)-4-(1-methylethenyl)-, (3S,4S)-; (2S,3S,4S)-3-(Carboxymethyl)-4-Prop-1-En-2-yl-Pyrrolidine-2-Carboxylicacid; (2S-(2.ALPHA.,3.BETA.,4.BETA.))-2-CARBOXY-4-(1-METHYLETHENYL)-3-PYRROLIDINEACETIC ACID; InChI=1/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s	.	DG01793	213.23	C10H15NO4	86.6	300	-1.8	15	3	5	4	InChI=1S/C10H15NO4/c1-5(2)7-4-11-9(10(14)15)6(7)3-8(12)13/h6-7,9,11H,1,3-4H2,2H3,(H,12,13)(H,14,15)/t6-,7+,9-/m0/s1	CC(=C)[C@H]1CN[C@@H]([C@H]1CC(=O)O)C(=O)O	CC(=C)C1CNC(C1CC(=O)O)C(=O)O	VLSMHEGGTFMBBZ-OOZYFLPDSA-N	(2S,3S,4S)-3-(carboxymethyl)-4-prop-1-en-2-ylpyrrolidine-2-carboxylic acid
ferrodrug0215	Norcantharidin	.	Norcantharidin; 5442-12-6; Endothall anhydride; 29745-04-8; Norcantharadine; Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; 4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-; 3,6-Endoxohexahydrophthalic anhydride; 4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione; 7-Oxabicyclo(2.2.1)heptane-2,3-dicarboxylic anhydride; (+/-)-Norcantharidin; Isocantharidin; (+/-)-NCTD; NCTD; exo-7-oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; DEMETHYL-CANTHARIDIN; NSC-14003; NSC-59023; 3, hexahydro-; NSC 14003; Norcantharidin, solid; Spectrum_001667; 3,6-Endooxyphthalic anhydride, hexahydro-; SpecPlus_000904; Phthalic anhydride, hexahydro-3,6-endoxo-; 4,3-dione, hexahydro-; Spectrum2_001683; Spectrum3_001634; Spectrum4_000601; Spectrum5_001514; CHEMBL8327; Lopac0_000830; BSPBio_003327; KBioGR_001122; KBioSS_002147; Phthalic anhydride,6-endoxo-; MLS002153470; DivK1c_007000; SCHEMBL177729; SPECTRUM1504153; SPBio_001606; YSCH0101; 4,10-dioxatricyclo[5.2.1.0<2,6>]decane-3,5-dione; KBio1_001944; KBio2_002147; KBio2_004715; KBio2_007283; KBio3_002547; DTXSID30884158; JAABVEXCGCXWRR-UHFFFAOYSA-N; HMS3262F21; HMS3370H07; BCP09826; BCP25426; HY-N0585; NSC14003; NSC59023; Tox21_500830; WLN: T C555 A AO DVOVTJ; CCG-39454; MFCD00213361; NSC148536; s3759; STK424286; AKOS003267901; FS-4623; LP00830; NSC-148536; SDCCGSBI-0050807.P003; NCGC00015756-03; NCGC00015756-04; NCGC00015756-05; NCGC00015756-06; NCGC00015756-07; NCGC00015756-08; NCGC00015756-09; NCGC00015756-14; NCGC00094161-01; NCGC00094161-02; NCGC00094161-03; NCGC00094161-04; NCGC00094161-05; NCGC00094161-06; NCGC00261515-01; NCI60_001019; SMR000326693; CS-0009119; EU-0100830; FT-0614776; FT-0621477; FT-0626378; hexahydro-4,7-epoxy-2-benzofuran-1,3-dione; N 8784; 3,6-Endoxohexahydrophthalic anhydride, exo isomer; SR-01000076037; SR-01000076037-1; BRD-A66914119-001-04-0; Q15425762; 4,10-Dioxa-tricyclo[5.2.1.02,6]decane-3,5-dione; 3-(5'-(4-(diphenylamino)phenyl)-[2,2'-bithiophen]-5-yl)cyclohex-2-enone; EXO-7-OXA-BICYCLO(2.2.1)-HEPTANE-2,3-DICARBOXYLIC ANHYDRIDE; Exo-cis-Hexahydro-4,7-epoxyisobenzofuran-1,3-dione; Endothall anhydride; 4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione; 7-Oxabicyclo[2.2.1]heptane-2,3-dicarboxylic anhydride; 51154-98-4; TIMTEC-BB SBB005955;4,7-Epoxyisobenzofuran-1,3-dione, hexahydro-;4,10-Dioxatricyclo[5.2.1.0(2,6)]decane-3,5-dione	.	.	168.15	C8H8O4	52.6	246	-0.1	12	0	4	0	InChI=1S/C8H8O4/c9-7-5-3-1-2-4(11-3)6(5)8(10)12-7/h3-6H,1-2H2	C1CC2C3C(C1O2)C(=O)OC3=O	C1CC2C3C(C1O2)C(=O)OC3=O	JAABVEXCGCXWRR-UHFFFAOYSA-N	4,10-dioxatricyclo[5.2.1.02,6]decane-3,5-dione
ferrodrug0216	Tectoridin	.	Tectoridin; 611-40-5; Shekanin; 4',5-Dihydro-6-methoxy-7-(o-glucoside)isoflavone; BRN 0068384; CHEBI:9428; 968X515NZH; 5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; 5-Hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 7-(beta-D-Glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one, 7-(.beta.-D-glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-; Tectoridin (7CI,8CI); UNII-968X515NZH; 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-; TECTORIDIN [MI]; 4-18-00-03312 (Beilstein Handbook Reference); SCHEMBL241734; CHEMBL520214; TECTORIGENIN-7-GLUCOSIDE; DTXSID70209982; CNOURESJATUGPN-UDEBZQQRSA-N; HY-N0791; BDBM50540975; MFCD01662715; AKOS015897164; CCG-269367; Tectorigenin 7-O-beta-D-glucopyranoside; 5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; BS-17204; CS-0009803; S3818; T3724; A868796; TECTORIGENIN 7-O-.BETA.-D-GLUCOPYRANOSIDE; Q-100704; Q10860610; 5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-4-oxo-4H-1-benzopyran-7-yl beta-D-glucopyranoside	.	.	462.4	C22H22O11	175	721	0.8	33	6	11	5	InChI=1S/C22H22O11/c1-30-21-13(32-22-20(29)19(28)17(26)14(7-23)33-22)6-12-15(18(21)27)16(25)11(8-31-12)9-2-4-10(24)5-3-9/h2-6,8,14,17,19-20,22-24,26-29H,7H2,1H3/t14-,17-,19+,20-,22-/m1/s1	COC1=C(C=C2C(=C1O)C(=O)C(=CO2)C3=CC=C(C=C3)O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O	COC1=C(C=C2C(=C1O)C(=O)C(=CO2)C3=CC=C(C=C3)O)OC4C(C(C(C(O4)CO)O)O)O	CNOURESJATUGPN-UDEBZQQRSA-N	5-hydroxy-3-(4-hydroxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
ferrodrug0217	Withaferin A	Small molecular drug	Withaferin A; 5119-48-2; Withaferine A; NSC 273757; WITHAFERIN DERIV JPR, IOWA U. COMPOUND; CHEBI:69120; NSC-101088; NSC101088; L6DO3QW4K5; CHEMBL517080; Ashwagandha; NSC-273757; 4beta,27-dihydroxy-1-oxo-5beta,6beta-epoxywitha-2,24-dienolide; (1S,2R,6S,7R,9R,11S,12S,15R,16S)-6-hydroxy-15-[(1S)-1-[(2R)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-4-en-3-one; (6S,7R,9R)-6-Hydroxy-15-[(2R,3R)-3-hydroxy-4-(4-methyl-5-oxo-2H-furan-3-yl)butan-2-yl]-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-4-en-3-one; UNII-L6DO3QW4K5; BRN 1335150; 5.beta.-Ergosta-2, 5,6.beta.-epoxy-4.beta.,22,27-trihydroxy-1-oxo-, .delta.-lactone, (20S,22R)-; Ergosta-2, 5,6-epoxy-4,22,27-trihydroxy-1-oxo-, .delta.-lactone, (4.beta.,5.beta.,6.beta.,22R)-; NSC 101088; WITHAFERIN A [MI]; 5-19-06-00604 (Beilstein Handbook Reference); MLS006010687; SCHEMBL157208; Withaferin A, analytical standard; Withaferin A, >=95% (HPLC); HY-N2065; BDBM50599323; MFCD10687098; NSC273757; s8587; AKOS040758787; (4beta,5beta,6beta,22R)-4,27-dihydroxy-5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione; NCGC00180796-02; (4beta,5beta,6beta,22R)-5,6-Epoxy-4,22,27-trihydroxy-1-oxoergosta-2,24-dien-26-oic acid, delta-lactone; 5-beta-Ergosta-2,24-dien-26-oic acid, 5,6-beta-epoxy-4-beta,22,27-trihydroxy-1-oxo-, delta-lactone, (20S,22R)-; 5beta-Ergosta-2,24-dien-26-oic acid, 5,6beta-epoxy-4beta,22,27-trihydroxy-1-oxo-, delta-lactone, (20S,22R)-; AS-77575; Ergosta-2,24-dien-26-oic acid, 5,6-epoxy-4,22,27-trihydroxy-1-oxo-, gamma-lactone, (4bta,5beta,6beta,22R)-; NCI60_000031; SMR004701668; CS-0018562; Withaferin A 100 microg/mL in Acetonitrile; C08841; A871350; A1-06845; Q6606395; BRD-K88378636-001-01-0; WLN: T3 F5 E666 1A R AXO OV PU CH&TTTTJ J1 N1 RQ IY1&- FT6OV CUTJ C1Q D1; (4.BETA.,5.BETA.,6.BETA.,22R)-4,27-DIHYDROXY-5,6:22,26-DIEPOXYERGOSTA-2,24-DIENE-1,26-DIONE; (4S,4aR,5aR,6aS,6bS,9R,9aS,11aS,11bR)-4-hydroxy-9-((S)-1-((R)-5-(hydroxymethyl)-4-methyl-6-oxo-3,6-dihydro-2H-pyran-2-yl)ethyl)-9a,11b-dimethyl-5a,6,6a,6b,7,8,9,9a,10,11,11a,11b-dodecahydrocyclopenta[1,2]phenanthro[8a,9-b]oxiren-1(4H)-one; Ergosta-2,24-dien-26-oicacid, 5,6-epoxy-4,22,27-trihydroxy-1-oxo-, d-lactone, (4b,5b,6b,22R)-; NCGC00180796-02_C28H38O6_(4beta,5beta,6beta,22R)-4,27-Dihydroxy-5,6:22,26-diepoxyergosta-2,24-diene-1,26-dione	.	DG51650	470.6	C28H38O6	96.4	999	3.8	34	2	6	3	InChI=1S/C28H38O6/c1-14-11-21(33-25(32)17(14)13-29)15(2)18-5-6-19-16-12-24-28(34-24)23(31)8-7-22(30)27(28,4)20(16)9-10-26(18,19)3/h7-8,15-16,18-21,23-24,29,31H,5-6,9-13H2,1-4H3/t15-,16-,18+,19-,20-,21+,23-,24+,26+,27-,28+/m0/s1	CC1=C(C(=O)O[C@H](C1)[C@@H](C)[C@H]2CC[C@@H]3[C@@]2(CC[C@H]4[C@H]3C[C@@H]5[C@]6([C@@]4(C(=O)C=C[C@@H]6O)C)O5)C)CO	CC1=C(C(=O)OC(C1)C(C)C2CCC3C2(CCC4C3CC5C6(C4(C(=O)C=CC6O)C)O5)C)CO	DBRXOUCRJQVYJQ-CKNDUULBSA-N	(1S,2R,6S,7R,9R,11S,12S,15R,16S)-6-hydroxy-15-[(1S)-1-[(2R)-5-(hydroxymethyl)-4-methyl-6-oxo-2,3-dihydropyran-2-yl]ethyl]-2,16-dimethyl-8-oxapentacyclo[9.7.0.02,7.07,9.012,16]octadec-4-en-3-one
ferrodrug0218	Tirapazamine	Small molecular drug	TIRAPAZAMINE; 27314-97-2; 3-Aminobenzo[e][1,2,4]triazine 1,4-dioxide; 1,2,4-Benzotriazin-3-amine, 1,4-dioxide; Tirazone; 3-Amino-1,2,4-benzotriazine 1,4-dioxide; Win-59075; WIN 59075; SR 4233; SR-4233; 3-Amino-1,2,4-benzotriazine-1,4-dioxide; CHEBI:78887; SR-259075; NSC-130181; SR259075; 1,2,4-Benzotriazin-3-amine 1,4-Dioxide; 1UD32YR59G; SR259075;SR4233;Win59075; Tirapazamine [USAN:INN]; 1,2,4-benzotriazin-3-amine,1,4-dioxide; NSC 130181; BRN 0179322; UNII-1UD32YR59G; Win59075; SR4233; 4-hydroxy-1-oxido-1,2,4-benzotriazin-1-ium-3-imine; TIRAPAZAMINE [MI]; Tirapazamine (USAN/INN); TIRAPAZAMINE [INN]; TIRAPAZAMINE [USAN]; SCHEMBL4048; SCHEMBL4049; 1,2,4-Benzotriazine, 3-amino-, 1,4-dioxide; TIRAPAZAMINE [MART.]; 4-26-00-01120 (Beilstein Handbook Reference); CHEMBL50882; SCHEMBL872285; TIRAPAZAMINE [WHO-DD]; Tirapazamine, >=98% (HPLC); ORYDPOVDJJZGHQ-UHFFFAOYSA-N; AMY38675; BCP03663; EX-A2967; BDBM50226806; MFCD00132954; AKOS006271584; AKOS037645846; DB04858; NCGC00390788-04; AC-31305; AS-64112; HY-13767; BCP0726000167; FT-0661586; T3823; 3-Aminobenzo[e][1,2,4]triazine1,4-dioxide; D06167; T72208; J-016728; Q3529346; 1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine; 4-hydroxy-3-imino-3,4-dihydro-1,2,4-benzotriazin-1-ium-1-olate	D09XQU	DMBFE4K	178.15	C7H6N4O2	89.8	191	-0.3	13	1	4	0	InChI=1S/C7H6N4O2/c8-7-9-11(13)6-4-2-1-3-5(6)10(7)12/h1-4H,(H2,8,9)	C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-]	C1=CC=C2C(=C1)[N+](=C(N=[N+]2[O-])N)[O-]	ORYDPOVDJJZGHQ-UHFFFAOYSA-N	1,4-dioxido-1,2,4-benzotriazine-1,4-diium-3-amine
ferrodrug0219	Nortriptyline hydrochloride	.	Nortriptyline hydrochloride; 894-71-3; Nortriptyline Hcl; Pamelor; Desmethylamitriptyline hydrochloride; Allegron; Acetexa; Altilev; Nortriptyline (hydrochloride); Nortrilen; Aventyl hydrochloride; Sensival; Aventyl allegron; Ateben hydrochloride; Nortab hydrochloride; Vividyl; Nortriptylin hydrochloride; Lilly 38489; Noramitriptyline hydrochloride; Nortriptyline monohydrochloride; Norzepine; NSC-169453; 3-(10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-1-propanamine Hydrochloride; MLS000069673; 00FN6IH15D; DTXSID2045109; Nortriptyline.HCl; N 7048; SMR000058486; Pamelor hydrochloride; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo(a,d)cyclohepten-5-ylidene)-N-methyl-, hydrochloride; Nortriptylene hydrochloride; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-amine hydrochloride; WLN: L C676 BY&T&J BU3M1 &GH; NSC78248; NORTRIPTYLINEHYDROCHLORIDE; NSC169453; SR-01000000223; CAS-894-71-3; MFCD00058024; UNII-00FN6IH15D; 5-[3-(Methylamino)propylidene]dibenzo[a,5]diene hydrochloride; (2)10,d]cycloheptene-.delta.5.gamma.-propylamine, hydrochloride; 5-[(3-(Methylamino)propylidene]-10,d]cycloheptene hydrochloride; 5H-Dibenzo[a,.gamma.-propylamine, 10,11-dihydro-N-methyl-, hydrochloride; 5H-Dibenzo[a,.gamma.-propylamine, 10-11-dihydro-N-methyl-, hydrochloride; 1-Propanamine,11-dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene)-N-methyl-, hydrochloride; Desitriptyline HCl; Prestwick_366; EINECS 212-973-0; Pamelor (TN); NSC 78248; NSC 169453; CPD000058486; ELF-101 hydrochloride; EN-7048 hydrochloride; Nortriptyline hydrochloride [USAN:USP:JAN]; Opera_ID_1915; SCHEMBL41329; MLS001077267; MLS002222206; MLS006010656; CHEBI:7641; CHEMBL1201156; DTXCID0025109; REGID_for_CID_441358; SHAYBENGXDALFF-UHFFFAOYSA-N; HMS1568D10; Nortriptyline hydrochloride- Bio-X; HY-B1417; Nortriptyline for system suitability; Tox21_110048; Tox21_500868; NSC-78248; s3698; 5-(3-(Methylamino)propylidene)dibenzo(a,e)cyclohepta(1,5)diene hydrochloride; AKOS015889095; CCG-212718; CS-4913; KS-1306; LP00868; NC00522; Nortriptyline.HCl, 1mg/ml in Methanol; 10,11-Dihydro-5-(N-methyl-3-aminopropylidene)-5H-dibenzo[a,d]cycloheptene Hydrochloride; 5-(3-Methylaminopropylidene)-10,11-dihydro-5H-dibenzo(a,d)cycloheptene hydrochloride; NORTRIPTYLINE HYDROCHLORIDE [MI]; NCGC00014483-01; NCGC00094192-01; NCGC00094192-02; NCGC00261553-01; NORTRIPTYLINE HYDROCHLORIDE [JAN]; 1-Propanamine, 3-(10,11-dihydro-5H-dibenzo[ a,d]cyclohepten-5-ylidene)-N-methyl-, hydrochloride; 10,11-Dihydro-N-methyl-5H-dibenzo(a,d)cycloheptene-delta(sup 5,gamma)-propylamine hydrochloride; BN164160; NORTRIPTYLINE HYDROCHLORIDE [HSDB]; NORTRIPTYLINE HYDROCHLORIDE [USAN]; NORTRIPTYLINE HYDROCHLORIDE [MART.]; NORTRIPTYLINE HYDROCHLORIDE [VANDF]; NORTRIPTYLINE HYDROCHLORIDE [USP-RS]; NORTRIPTYLINE HYDROCHLORIDE [WHO-DD]; EU-0100868; FT-0673146; FT-0673147; N0957; Nortriptyline hydrochloride (JP17/USP/INN); EN300-26665; D00816; F19641; N 7261; NORTRIPTYLINE HYDROCHLORIDE [ORANGE BOOK]; NORTRIPTYLINE HYDROCHLORIDE [EP MONOGRAPH]; NORTRIPTYLINE HYDROCHLORIDE [USP MONOGRAPH]; Nortriptyline hydrochloride, >=98% (TLC), powder; SR-01000000223-2; SR-01000000223-7; W-109609; Q27231345; Z227834786; Nortriptyline Hydrochloride 1.0 mg/ml in Methanol (as free base); Nortriptyline hydrochloride, British Pharmacopoeia (BP) Reference Standard; Nortriptyline hydrochloride, European Pharmacopoeia (EP) Reference Standard; 3-(10,11-2H-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methyl-1-propanaminium chloride; 3-(10,11-dihydro-5H-dibenzo[a,d][7]annulen-5-ylidene)-N-methylpropan-1-aminehydrochloride; Nortriptyline for system suitability, European Pharmacopoeia (EP) Reference Standard; Nortriptyline hydrochloride, United States Pharmacopeia (USP) Reference Standard; 10,11-DIHYDRO-N-METHYL-5H-DIBENZO(A,D)CYCLOHEPTENE-D(SUP5,.GAMMA.)-PROPYLAMINE HYDROCHLORIDE; 1001637-77-9; 5H-Dibenzo(a,d)cycloheptene-delta(sup 5),gamma-propylamine, 10-11-dihydro-N-methyl-, hydrochloride; methyl(3-{tricyclo[9.4.0.0,3,8]pentadeca-1(15),3,5,7,11,13-hexaen-2-ylidene}propyl)amine hydrochloride	.	.	299.8	C19H22ClN	12	307	.	21	2	1	3	InChI=1S/C19H21N.ClH/c1-20-14-6-11-19-17-9-4-2-7-15(17)12-13-16-8-3-5-10-18(16)19;/h2-5,7-11,20H,6,12-14H2,1H3;1H	CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl	CNCCC=C1C2=CC=CC=C2CCC3=CC=CC=C31.Cl	SHAYBENGXDALFF-UHFFFAOYSA-N	N-methyl-3-(2-tricyclo[9.4.0.03,8]pentadeca-1(15),3,5,7,11,13-hexaenylidene)propan-1-amine;hydrochloride
ferrodrug0220	Misonidazole	Small molecular drug	Misonidazole; 13551-87-6; Ro 7-0582; 1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol; 1-methoxy-3-(2-nitro-1H-imidazol-1-yl)propan-2-ol; SRI 1354; NSC-261,037; NSC-261037; 8FE7LTN8XE; 1-(2-Hydroxy-3-methoxypropyl)-2-nitroimidazole; alpha-(Methoxymethyl)-2-nitroimidazole-1-ethanol; Ro-7-0582; 1-(2-NITRO-1-IMIDAZOLYL)-3-METHOXY-2-PROPANOL; MLS003115361; 1H-Imidazole-1-ethanol, .alpha.-(methoxymethyl)-2-nitro-; NSC261037; Ro-70582; Ro-07-0582; Ro 7-0582; SR 1354; Misonidazol; Misonidazolum; Misonidazol [INN-Spanish]; Misonidazolum [INN-Latin]; (+-)-Misonidazole; CCRIS 1160; EINECS 236-931-6; UNII-8FE7LTN8XE; SR 1354; BRN 0613655; alpha-(Methoxymethyl)-2-nitro-1H-imidazole-1-ethanol; Misonidazole [USAN:INN:BAN]; 1-(2'-hydroxy-3'-methoxypropyl)-2-nitroimidazole; 1H-Imidazole-1-ethanol, alpha-(methoxymethyl)-2-nitro-; Misonidazole (USAN/INN); MISONIDAZOLE [INN]; MISONIDAZOLE [USAN]; SCHEMBL51943; MISONIDAZOLE [MART.]; CHEMBL42161; MISONIDAZOLE [WHO-DD]; DTXSID80864420; OBBCSXFCDPPXOL-UHFFFAOYSA-N; DB11716; NCGC00241115-01; 95120-44-8; NCI60_002086; SMR001830939; HY-105061; CS-0024849; D05052; EN300-180393; .alpha.-(Methoxymethyl)-2-nitroimidazole-1-ethanol; Q6875874; 1-methoxy-3-(2-nitro-1H-imidazol-1-yl)-2-propanol; Imidazole-1-ethanol, .alpha.-(methoxymethyl)-2-nitro-	.	DMYB0HK	201.18	C7H11N3O4	93.1	196	-0.4	14	1	5	4	InChI=1S/C7H11N3O4/c1-14-5-6(11)4-9-3-2-8-7(9)10(12)13/h2-3,6,11H,4-5H2,1H3	COCC(CN1C=CN=C1[N+](=O)[O-])O	COCC(CN1C=CN=C1[N+](=O)[O-])O	OBBCSXFCDPPXOL-UHFFFAOYSA-N	1-methoxy-3-(2-nitroimidazol-1-yl)propan-2-ol
ferrodrug0221	SP600125	.	129-56-6; 1,9-Pyrazoloanthrone; SP600125; Pyrazolanthrone; Dibenzo[cd,g]indazol-6(2H)-one; Pyrazoleanthrone; SP 600125; Anthra[1,9-cd]pyrazol-6(2H)-one; SP-600125; JNK Inhibitor II; Anthra-1,9-pyrazol-6-none; ANTHRA(1,9-cd)PYRAZOL-6(2H)-ONE; C.I. 70300; 2H-Dibenzo[cd,g]indazol-6-one; NSC 75890; 1pmv; NSC75890; NSC-75890; 2h-dibenzo(cd,g)indazol-6-one; CHEMBL7064; MLS002693964; DTXSID2040525; CHEBI:90695; 2,6-DIHYDROANTHRA/1,9-CD/PYRAZOL-6-ONE; Anthra[1-9-cd]pyrazol-6(2H)-one; 1TW30Y2766; NCGC00015958-03; 14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one; SMR000015440; SR-01000075840; EINECS 204-955-6; BRN 0746890; UNII-1TW30Y2766; 2zmd; Kinome_3844; Tocris-1496; CI 70300; BiomolKI_000068; Lopac-S-5567; BiomolKI2_000072; cid_8515; CBiol_002049; Lopac0_000473; BMK1-G8; BSPBio_001066; ChemBiol10705 Compound 4; KBioGR_000406; KBioSS_000406; JMC517015 Compound 2; MLS002153267; MLS006011577; SCHEMBL170980; anthra[1,9-cd]pyrazol-6-one; GTPL5273; Pyrazolanthrone (SP600125); CHEMBL1725279; DTXCID0020525; SCHEMBL15583517; BCBcMAP01_000053; BDBM16018; KBio2_000406; KBio2_002974; KBio2_005542; KBio3_000771; KBio3_000772; Bio1_000335; Bio1_000824; Bio1_001313; Bio2_000373; Bio2_000853; HMS1362F07; HMS1667K13; HMS1792F07; HMS1990F07; HMS2250C03; HMS3229I16; HMS3261O08; HMS3267P06; HMS3295M01; HMS3403F07; HMS3412F05; HMS3654P10; HMS3676F05; HMS3747M19; AMY31086; Anthra[1,9cd]pyrazol-6(2H)-one; BCP05457; EX-A1998; Tox21_110267; Tox21_500473; BDBM50024294; BDBM50433916; CCG-47500; Dibenzo[cd,g]indazol-6(2H)-one #; HB2234; HSCI1_000136; MFCD00022289; NSC755773; s1460; AKOS000115584; AKOS040751313; Anthrapyrazolone; 1,9-Pyrazoloanthrone; CCG-100672; CS-0196; DB01782; LP00473; NSC-755773; SDCCGSBI-0050458.P003; WLN: T C66651A P IV OMNJ; 1,6-dihydrodibenzo[cd,g]indazol-6-one; 2,6-dihydrodibenzo[cd,g]indazol-6-one; IDI1_002128; QTL1_000077; s10332; SMP2_000240; NCGC00015958-01; NCGC00015958-02; NCGC00015958-04; NCGC00015958-05; NCGC00015958-06; NCGC00015958-07; NCGC00015958-08; NCGC00015958-22; NCGC00025186-01; NCGC00025186-02; NCGC00025186-03; NCGC00025186-04; NCGC00025186-05; NCGC00261158-01; WLN: T C6665 1A P IV OMNJ; AC-32051; AS-14374; CAS-129-56-6; HY-12041; JNK Inhibitor II - CAS 129-56-6; SMR002530644; EU-0100473; FT-0607068; SW218106-2; EN300-02083; Anthra[1,9-cd]pyrazol-6(2H)-one & Z-100; K00068; S 5567; SP600125, >=98% (HPLC); AB00075935-01; SP 600125 & Z-100; A888840; Anthra[1,9-cd]pyrazol-6(2H)-one;SP-600125; Q4545713; SR-01000075840-1; SR-01000075840-2; SR-01000075840-4; SR-01000075840-6; SR-01000637108-1; W-108360; BRD-K01567962-001-04-0; BRD-K01567962-001-06-5; BRD-K01567962-001-08-1; BRD-K01567962-001-22-2; Z56785477; F1414-1245; 14,15-diazatetracyclo[7.6.1.0;{2,7}.0;{13,16}]hexadeca-1(15),2(7),3,5,9(16),10,12-heptaen-8-one; 14,15-diazatetracyclo[7.6.1.0^{2,7}.0^{13,16}]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one	.	.	220.23	C14H8N2O	45.8	343	2.7	17	1	2	0	InChI=1S/C14H8N2O/c17-14-9-5-2-1-4-8(9)13-12-10(14)6-3-7-11(12)15-16-13/h1-7H,(H,15,16)	C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O	C1=CC=C2C(=C1)C3=NNC4=CC=CC(=C43)C2=O	ACPOUJIDANTYHO-UHFFFAOYSA-N	14,15-diazatetracyclo[7.6.1.02,7.013,16]hexadeca-1(15),2,4,6,9(16),10,12-heptaen-8-one
ferrodrug0222	Lorlatinib	.	Lorlatinib; 1454846-35-5; PF-06463922; Loratinib; Lorbrena; Lorviqua; PF06463922; PF 06463922; OSP71S83EU; PF06463922(Lorlatinib); CHEMBL3286830; PF-6463922; (10R)-7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile; (16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile; (R)-26-Amino-55-fluoro-11,4,7-trimethyl-6-oxo-11H-3-oxa-7-aza-2(3,5)-pyridina-1(4,3)-pyrazola-5(1,2)-benzenacyclooctaphane-15-carbonitrile; 2H-4,8-Methenopyrazolo(4,3-H)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-; (10r)-7-Amino-12-Fluoro-2,10,16-Trimethyl-15-Oxo-10,15,16,17-Tetrahydro-2h-8,4-(Metheno)pyrazolo[4,3-H][2,5,11]benzoxadiazacyclotetradecine-3-Carbonitrile; UNII-OSP71S83EU; lorlatinibum; Lorlatinib (PF-06463922); C21H19FN6O2; 4cli; 4clj; Lorbrena (TN); 2H-4,8-Methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, 7-amino-12-fluoro-10,15,16,17-tetrahydro-2,10,16-trimethyl-15-oxo-, (10R)-; LORLATINIB [MI]; LORLATINIB [INN]; LORLATINIB [JAN]; Lorlatinib [USAN:INN]; LORLATINIB [USAN]; PFE-PKIS 10; LORLATINIB [WHO-DD]; 7-Amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo(4,3-h)(2,5,11)benzoxadiazacyclotetradecine-3-carbonitrile; Lorlatinib (JAN/USAN/INN); GTPL7476; LORLATINIB [ORANGE BOOK]; PF-06463922 Lorlatinib; SCHEMBL15261807; AMY3295; EX-A828; CHEBI:143117; DTXSID201027944; BCP10287; BDBM50018830; MFCD28144520; NSC780108; NSC800990; s7536; AKOS027250753; CCG-268718; CS-3983; DB12130; NSC-780108; NSC-800990; NCGC00386417-02; NCGC00386417-13; AC-30881; HY-12215; A14207; D11012; A857523; J-690185; Q27285820; (10R)-7-AMINO-12-FLUORO-2,10,16-TRIMETHYL-15-OXO-10,15,16,17-TETRAHYDRO-2H-4,8- METHENOPYRAZOLO(4,3-H)(2,5,11)BENZOXADIAZACYCLOTETRADECINE-3-CARBONITRILE; (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-4,8-methenopyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile	.	.	406.4	C21H19FN6O2	110	700	1.5	30	1	7	0	InChI=1S/C21H19FN6O2/c1-11-15-7-13(22)4-5-14(15)21(29)27(2)10-16-19(17(8-23)28(3)26-16)12-6-18(30-11)20(24)25-9-12/h4-7,9,11H,10H2,1-3H3,(H2,24,25)/t11-/m1/s1	C[C@@H]1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C	CC1C2=C(C=CC(=C2)F)C(=O)N(CC3=NN(C(=C3C4=CC(=C(N=C4)N)O1)C#N)C)C	IIXWYSCJSQVBQM-LLVKDONJSA-N	(16R)-19-amino-13-fluoro-4,8,16-trimethyl-9-oxo-17-oxa-4,5,8,20-tetrazatetracyclo[16.3.1.02,6.010,15]docosa-1(22),2,5,10(15),11,13,18,20-octaene-3-carbonitrile
ferrodrug0223	Dauricine	.	Dauricine; 524-17-4; NSC 36413; 8QTO90G5W5; CHEBI:4331; 4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-[4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]phenoxy]phenol; 4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}-2-(4-{[(1R)-6,7-dimethoxy-2-methyl-1,2,3,4-tetrahydroisoquinolin-1-yl]methyl}phenoxy)phenol; UNII-8QTO90G5W5; NSC-36413; DAURICINE [MI]; 6,6'-Di-O-methyldauricoline; CHEMBL442717; SCHEMBL2233953; DTXSID90966808; 4-(((1R)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-ISOQUINOLINYL)METHYL)-2-(4-(((1R)-1,2,3,4-TETRAHYDRO-6,7-DIMETHOXY-2-METHYL-1-ISOQUINOLINYL)METHYL)PHENOXY)PHENOL; HY-N0220; BDBM50370415; s9295; AKOS037514611; CCG-270271; Phenol, 4-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)-2-(4-((1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl)methyl)phenoxy)-, (R-(R*,R*))-; CS-0008258; FT-0624458; A14718; C09419; Q5228100; Phenol, 4-[[(1R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]-2-[4-[[(1R)-1,2,3,4-tetrahydro-6,7-dimethoxy-2-methyl-1-isoquinolinyl]methyl]phenoxy]-	.	.	624.8	C38H44N2O6	72.9	933	6.7	46	1	8	10	InChI=1S/C38H44N2O6/c1-39-15-13-26-20-35(42-3)37(44-5)22-29(26)31(39)17-24-7-10-28(11-8-24)46-34-19-25(9-12-33(34)41)18-32-30-23-38(45-6)36(43-4)21-27(30)14-16-40(32)2/h7-12,19-23,31-32,41H,13-18H2,1-6H3/t31-,32-/m1/s1	CN1CCC2=CC(=C(C=C2[C@H]1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)C[C@@H]5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC)OC	CN1CCC2=CC(=C(C=C2C1CC3=CC=C(C=C3)OC4=C(C=CC(=C4)CC5C6=CC(=C(C=C6CCN5C)OC)OC)O)OC)OC	AQASRZOCERRGBL-ROJLCIKYSA-N	4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]-2-[4-[[(1R)-6,7-dimethoxy-2-methyl-3,4-dihydro-1H-isoquinolin-1-yl]methyl]phenoxy]phenol
ferrodrug0224	27-Hydroxycholesterol	Small molecular drug	27-hydroxycholesterol; 20380-11-4; (25R)-26-Hydroxycholesterol; (25R)-Cholest-5-ene-3beta,26-diol; Cholest-5-ene-3beta,27-diol; cholest-(25R)-5-en-3beta,26-diol; 6T2NA6P5SQ; 27-hydroxy-cholesterol(25R); 25(R)-27-hydroxy Cholesterol; CHEBI:76591; (3S,8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol; (3S,8S,9S,10R,13R,14S,17R)-17-((2R,6R)-7-Hydroxy-6-methylheptan-2-yl)-10,13-dimethyl-2,3,4,7,8,9,10,11,12,13,14,15,16,17-tetradecahydro-1H-cyclopenta[a]phenanthren-3-ol; 5-cholestene-3 beta,27-diol; UNII-6T2NA6P5SQ; Cholest-5-ene-3-beta,26-diol; 27HC; NSC-226105; (3beta,25R)-cholest-5-ene-3,26-diol; Cholest-5-ene-3beta,26-diol, (25R)-; 26-hydroxycholesterol(25R); 5-cholestene-3beta,27-diol; SCHEMBL288494; 27 OHC; CHEMBL353882; Cholest-5-ene-3-b,27-diol; GTPL2752; BDBM20183; Cholest-5-ene-3-beta,27-diol; DTXSID40864941; FYHRJWMENCALJY-YSQMORBQSA-N; 27 HC; 13095-61-9; HY-N2371; 5-,25r-Cholesten-3beta,26-diol; LMST01010088; (25R)-Cholest-5-ene-3b,26-diol; (3-beta)-cholest-5-ene-3,26-diol; AKOS027381276; CS-6949; (3b,25R)-Cholest-5-ene-3,26-diol; 26-HYDROXYCHOLESTEROL, (25R)-; MS-26874; PD018880; (3?,25R)-Cholest-5-ene-3,26-diol; (3beta,25R)-Cholest-5-ene-3,26,diol; (-)-(25R)-26-HYDROXYCHOLESTEROL; cholest-5-ene-3,26-diol, (3beta,25R)-; Cholest-5-ene-3,26,diol, (3beta,25R)-; (25R)-CHOLEST-5-ENE-3.BETA.,26-DIOL; (3.BETA.,25R)-CHOLEST-5-ENE-3,26-DIOL; CHOLEST-5-ENE-3.BETA.,26-DIOL, (25R)-; J-013261; Q15634124; CHOLEST-5-ENE-3,26-DIOL, (3.BETA.,25R)-; (1S,2R,5S,10S,11S,14R,15R)-14-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-2,15-dimethyltetracyclo[8.7.0.0;{2,7}.0;{11,15}]heptadec-7-en-5-ol; (3S,8S,9S,10R,13R,14S,17R)-17-[(1R,5R)-6-hydroxy-1,5-dimethyl-hexyl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol	D0H2YM	DM2L6OZ	402.7	C27H46O2	40.5	612	7.1	29	2	2	6	InChI=1S/C27H46O2/c1-18(17-28)6-5-7-19(2)23-10-11-24-22-9-8-20-16-21(29)12-14-26(20,3)25(22)13-15-27(23,24)4/h8,18-19,21-25,28-29H,5-7,9-17H2,1-4H3/t18-,19-,21+,22+,23-,24+,25+,26+,27-/m1/s1	C[C@H](CCC[C@@H](C)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC=C4[C@@]3(CC[C@@H](C4)O)C)C)CO	CC(CCCC(C)C1CCC2C1(CCC3C2CC=C4C3(CCC(C4)O)C)C)CO	FYHRJWMENCALJY-YSQMORBQSA-N	(3S,8S,9S,10R,13R,14S,17R)-17-[(2R,6R)-7-hydroxy-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-ol
ferrodrug0225	Nickel Chloride	Small molecular drug	NICKEL CHLORIDE; 7718-54-9; Nickel dichloride; dichloronickel; Nickelous chloride; NiCl2; Nickel(2+) chloride; Nickel(II) chloride anhydrous; Nichel(II) chloride; 37211-05-5; Nickel chloride (NiCl2); Nickel dichloride (nicl2); Nickel(II) chloride (1:2); CCRIS 1788; HSDB 860; Nickel (II) chloride; EINECS 231-743-0; EINECS 253-399-0; NSC 254532; UNII-696BNE976J; CHEBI:34887; 696BNE976J; MFCD00011142; NSC254532; NSC-254532; (NiCl2); [NiCl2]; EC 231-743-0; Nickel(II) chloride, anhydrous; dichloro nickel; dichloronickel(II); NI(II) chloride; dichloronickel (II); nickel-(II)-chloride; nickel (11) chloride; WLN: NI G2; Nickel(II) chloride, 98%; Nickel(II) chloride, ultra dry; QMMRZOWCJAIUJA-UHFFFAOYSA-L; FT-0689065; FT-0689074; Q29397; Nickel(II) chloride, LR, 44.6-46% Ni basis; Nickel(II) chloride, anhydrous, powder, 99.99% trace metals basis	D08MKF	DMI12Y8	129.6	Cl2Ni	0	2.8	.	3	0	0	0	InChI=1S/2ClH.Ni/h2*1H;/q;;+2/p-2	Cl[Ni]Cl	Cl[Ni]Cl	QMMRZOWCJAIUJA-UHFFFAOYSA-L	dichloronickel
ferrodrug0226	Dihydroartemisinin	.	Dihydroartemisinin; 71939-50-9; Artenimol; Cotexin; Dihydroqinghaosu; Alaxin; Cotecxin; Dihydroartemisinine; 81496-82-4; Dynamax; Salaxin; Santecxin; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-3H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol; Di-hydroqinghaosu; GNF-PF-5634; Artenimol [INN]; Dihydro Artemisinin; (3r,5as,6r,8as,9r,10s,12r,12ar)-decahydro-3,6,9-trimethyl-3,12-epoxy-12h-pyrano[4,3-j][1,2]benzodioxepin-10-ol; .beta.-dihydroartemisinin; Dihydroartemisinin, .beta.-; 6A9O50735X; 3,12-Epoxy-12H-pyrano(4,3-j)-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-; 3,12-Epoxy-12H-pyrano[4,3-j]-1,2-benzodioxepin-10-ol, decahydro-3,6,9-trimethyl-, (3R,5aS,6R,8aS,9R,10S,12R,12aR)-; b-Dihydroartemisinin; ARTENIMOL [MART.]; ARTENIMOL [WHO-DD]; ARTENIMOL [WHO-IP]; DIHYDROARTEMISININ [MI]; GTPL9957; SCHEMBL17156483; CHEBI:135921; DTXSID501021652; ARTENIMOLUM [WHO-IP LATIN]; DIHYDROARTEMISININ [USP-RS]; DIHYDROARTEMISININ [WHO-DD]; HY-N0176; AKOS032949625; CS-5595; FT-0649320; EURARTESIM COMPONENT DIHYDROARTEMISININ; EN300-7419972; BRD-K62213621-001-01-6; (1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.0^{4,13}.0^{8,13}]hexadecan-10-ol; (3R,5aS,6R,8aS,9R,10S,12R,12aR)-3,6,9-trimethyldecahydro-12H-3,12-epoxy[1,2]dioxepino[4,3-i]isochromen-10-ol; (3R,5AS,6R,8AS,9R,10S,12R,12AR)-3,6,9-TRIMETHYLDECAHYDRO-3,12-EPOXY-12H-PYRANO(4,3-J)-1,2-BENZODIOXEPIN-10-OL	.	.	284.35	C15H24O5	57.2	415	2.5	20	1	5	0	InChI=1S/C15H24O5/c1-8-4-5-11-9(2)12(16)17-13-15(11)10(8)6-7-14(3,18-13)19-20-15/h8-13,16H,4-7H2,1-3H3/t8-,9-,10+,11+,12+,13-,14-,15-/m1/s1	C[C@@H]1CC[C@H]2[C@H]([C@H](O[C@H]3[C@@]24[C@H]1CC[C@](O3)(OO4)C)O)C	CC1CCC2C(C(OC3C24C1CCC(O3)(OO4)C)O)C	BJDCWCLMFKKGEE-ISOSDAIHSA-N	(1R,4S,5R,8S,9R,10S,12R,13R)-1,5,9-trimethyl-11,14,15,16-tetraoxatetracyclo[10.3.1.04,13.08,13]hexadecan-10-ol
ferrodrug0227	Oxidopamine	.	oxidopamine; 6-HYDROXYDOPAMINE; 1199-18-4; 5-(2-aminoethyl)benzene-1,2,4-triol; 2,4,5-Trihydroxyphenethylamine; 6-OHDA; Hydroxydopamine; Oxidopamina; Oxidopaminum; Topamine; 1,2,4-Benzenetriol, 5-(2-aminoethyl)-; 5-(2-Aminoethyl)-1,2,4-benzenetriol; 8HW4YBZ748; CHEMBL337702; CHEBI:78741; 6-Hydroxy Dopamine hydrobromide; MLS002207128; Oxidopamine [USAN:INN]; Oxidopaminum [INN-Latin]; Oxidopamina [INN-Spanish]; 6-HD; CCRIS 4342; SMR001306725; EINECS 214-842-3; BRN 2211011; UNII-8HW4YBZ748; 5-(2-aminoethyl)benzene-1,2,4-triol;hydrobromide; 6-hydroxy-dopamine; Spectrum_000309; Spectrum2_001018; Spectrum3_001753; Spectrum4_000462; OXIDOPAMINE [INN]; Oxidopamine (USAN/INN); OXIDOPAMINE [USAN]; SCHEMBL37507; BSPBio_003486; KBioGR_000904; KBioSS_000789; 4-13-00-02916 (Beilstein Handbook Reference); DivK1c_000362; SPBio_001175; cid_176170; DTXSID0036768; BDBM81264; KBio1_000362; KBio2_000789; KBio2_003357; KBio2_005925; KBio3_002706; NINDS_000362; KUC106765N; AKOS006230272; IDI1_000362; NCGC00167769-01; NCGC00167769-02; KSC-11-228-9; NCI60_001890; SBI-0051469.P003; D05294; AB00053512_09; Q780181; 5-(2-azanylethyl)benzene-1,2,4-triol;hydrobromide	.	.	169.18	C8H11NO3	86.7	142	0.2	12	4	4	2	InChI=1S/C8H11NO3/c9-2-1-5-3-7(11)8(12)4-6(5)10/h3-4,10-12H,1-2,9H2	C1=C(C(=CC(=C1O)O)O)CCN	C1=C(C(=CC(=C1O)O)O)CCN	DIVDFFZHCJEHGG-UHFFFAOYSA-N	5-(2-aminoethyl)benzene-1,2,4-triol
ferrodrug0228	Ginkgolide B	Small molecular drug	Ginkgolide B; 15291-77-7; Ginkolide B; Gingko lactone; BN 52021; SR-01000597598; bn52021; Ginklide B; 7-Deoxyginkgolide C; CHEMBL266625; SCHEMBL14279903; 1-Hydroxy-(1beta)-Ginkgolide A; BCP25992; NSC110257; PDSP1_000734; PDSP2_000724; AKOS015895882; NSC-110257; tert-butyl-trihydroxy-methyl-[?]trione; NCGC00025245-01; 99796-69-7; AS-56165; L000993; SR-01000597598-1; SR-01000597598-3; 8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione	D04ZCZ	DMLIM7B	424.4	C20H24O10	149	925	-0.4	30	3	10	1	InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3	CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O	CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O	SQOJOAFXDQDRGF-UHFFFAOYSA-N	8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
ferrodrug0229	Nicotinamide mononucleotide	Small molecular drug	1094-61-7; beta-Nicotinamide mononucleotide; nicotinamide mononucleotide; Nicotinamide ribotide; NMN zwitterion; beta-NMN; nicotinamide nucleotide; NMN; beta-nicotinamide D-ribonucleotide; nicotinamide ribonucleotide; nicotinamide D-ribonucleotide; beta-Nicotinamide ribonucleotide; 2KG6QX4W0V; CHEBI:16171; 3-(Aminocarbonyl)-1-(5-O-phosphonato-beta-D-ribofuranosyl)pyridinium; Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)-, inner salt; ((2R,3S,4R,5R)-5-(3-Carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate; beta-nicotinamide ribose monophosphate; ((2R,3S,4R,5R)-5-(3-carbamoylpyridinium-1-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl hydrogen phosphate; Nicotinamide ribonucleoside 5'-phosphate; UNII-2KG6QX4W0V; -Nicotinamide mononucleotide; MFCD00038748; EINECS 214-136-5; ss-NMN; BETANMN; b-NM; Nicotinamidmononucleotid; -NM;NMN; .BETA.-NMN; .BETA.-D-NMN; bmse000260; ?-Nicotinamidemononucleotide; NMN [MI]; ss-Nicotinamide mononucleotide; fA-Nicotinamide Mononucleotide; SCHEMBL105618; CHEMBL610238; beta -Nicotinamide mononucleotide; DTXSID50911152; DAYLJWODMCOQEW-TURQNECASA-N; Pyridinium, 3-(aminocarbonyl)-1-(5-O-phosphono-.beta.-D-ribofuranosyl)-, inner salt; B-NICOTINAMIDE MONONUCLEOTIDE; EX-A3534; HY-F0004; BDBM50366763; 3-(Aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium inner salt; AKOS015896881; CCG-267847; CS-4996; 3-carbamoyl-1-beta-D-ribofuranosylpyridinium hydroxide 5'-(dihydrogen phosphate) inner salt; AC-35057; AS-59655; N1123; C00455; H11919; J-002287; Q21547155; 3-carbamoyl-1-[5-O-(hydroxyphosphinato)-beta-D-ribofuranosyl]pyridinium; 3-(AMINOCARBONYL)-1-(5-O-PHOSPHONO-.BETA.-D-RIBOFURANOSYL)PYRIDINIUM INNER SALT; 3-(aminocarbonyl)-1-(5-O-phosphono-beta-D-ribofuranosyl)pyridinium, inner salt; [(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methylhydrogenphosphate; 3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1$l^{5}-pyridin-1-ylium; 3-carbamoyl-1-[(2R,3R,4S,5R)-5-[(hydrogen phosphonatooxy)methyl]-3,4-dihydroxyoxolan-2-yl]-1??-pyridin-1-ylium; AfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade markAfA centA centasA notA em leaderA inverted exclamation mark-Nicotinamide mononucleotide	.	DMW1LKP	334.22	C11H15N2O8P	166	455	-3.5	22	4	8	5	InChI=1S/C11H15N2O8P/c12-10(16)6-2-1-3-13(4-6)11-9(15)8(14)7(21-11)5-20-22(17,18)19/h1-4,7-9,11,14-15H,5H2,(H3-,12,16,17,18,19)/t7-,8-,9-,11-/m1/s1	C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)(O)[O-])O)O)C(=O)N	C1=CC(=C[N+](=C1)C2C(C(C(O2)COP(=O)(O)[O-])O)O)C(=O)N	DAYLJWODMCOQEW-TURQNECASA-N	[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl hydrogen phosphate
ferrodrug0230	Wogonin	.	Wogonin; 632-85-9; 5,7-Dihydroxy-8-methoxyflavone; Vogonin; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; Norwogonin 8-methyl ether; 5,7-dihydroxy-8-methoxy-2-phenyl-4H-chromen-4-one; 5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one; FLAVONE, 5,7-DIHYDROXY-8-METHOXY-; POK93PO28W; CHEMBL16171; CHEBI:10043; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one; UNII-POK93PO28W; BRN 0287152; wagonin; Wogonin hydrate; Wogonin,(S); 5,7-dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one; ST077088; WOGONIN [INCI]; Wogonin, S. baicalensis; MLS002473006; SCHEMBL139083; DTXSID70212557; HMS2270G08; AMY25744; HY-N0400; BDBM50140257; HB4126; LMPK12111330; MFCD00017736; NSC717845; s4743; AKOS015917860; CCG-208499; CS-3959; NSC-717845; NCGC00247464-01; AC-20338; AC-32550; AS-70103; NCI60_040649; SMR001397111; FT-0603499; W0010; Q409606; SR-05000002216; Q-100730; SR-05000002216-2; 5,7-Dihydroxy-8-methoxy-2-phenyl-chromen-4-one(Wogonin); 4H-1-Benzopyran-4-one, 5,7-dihydroxy-8-methoxy-2-phenyl-; Flavone, 5,7-dihydroxy-8-methoxy- (7CI,8CI); Wogonin (6CI); 5,7-Dihydroxy-8-methoxy-2-phenyl-4H-1-benzopyran-4-one; 5,7-Dihydroxy-8-methoxyflavone	.	.	284.26	C16H12O5	76	426	3	21	2	5	2	InChI=1S/C16H12O5/c1-20-15-12(19)7-10(17)14-11(18)8-13(21-16(14)15)9-5-3-2-4-6-9/h2-8,17,19H,1H3	COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)O	COC1=C(C=C(C2=C1OC(=CC2=O)C3=CC=CC=C3)O)O	XLTFNNCXVBYBSX-UHFFFAOYSA-N	5,7-dihydroxy-8-methoxy-2-phenylchromen-4-one
ferrodrug0231	Kaempferide	Small molecular drug	Kaempferide; 491-54-3; Kaempferid; 4'-Methylkaempferol; 4'-O-Methylkaempferol; Kaempferol 4'-methyl ether; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one; 3,5,7-trihydroxy-2-(4-methoxyphenyl)chromen-4-one; Campheride; Kaempferol 4'-O-methyl ether; Kaemperide; Kampheride; 5,7-Dihydroxy-4'-methoxyflavonol; 4H-1-Benzopyran-4-one, 3,5,7-trihydroxy-2-(4-methoxyphenyl)-; 4'-Methoxy-3,5,7-trihydroxyflavone; NSC 407294; KAMPFERIDE; NSC-407294; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; CHEMBL40919; 508XL61MPD; CHEBI:6099; FLAVANONE, 4'-METHOXY-3,5,7-TRIHYDROXY-; NSC407294; Kempferide; 4'-Methoxykaempferol; EINECS 207-738-4; BRN 0305378; UNII-508XL61MPD; Kaemferide; Flavone, 3,5,7-trihydroxy-4'-methoxy-; Kaempferide (AS); 3 5 7-trihydroxy-4'-methoxyflavone; 3,5,7-Trihydroxy-4'-methoxyflavone; 4'-Methoxy-3',5,7-trihydroxyflavone; Kaempferol 4''-methyl ether; 5-18-05-00253 (Beilstein Handbook Reference); SCHEMBL426774; Kaempferide, analytical standard; DTXSID9034155; AMY5862; SQFSKOYWJBQGKQ-UHFFFAOYSA-N; HMS3746E09; BCP20573; BDBM50084978; LMPK12110563; MFCD00016771; s3879; Flavone,5,7-trihydroxy-4'-methoxy-; AKOS015903441; 3,5,7-Trihydroxy-4'-methoxy-Flavone; CCG-267464; CS-0957; 4'-Methoxy-3,5,7-trihydroxy-Flavanone; NCGC00379085-03; AC-30805; BS-16895; HY-15449; FT-0625213; K0057; WLN: T66 BO EVJ CR DO1& DQ GQ IQ; A827662; Q3116775; 1.3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4-benzopyrone; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-chromen-4-one #; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one; 4H-1-Benzopyran-4-one,5,7-trihydroxy-2-(4-methoxyphenyl)-; 3,5,7-Trihydroxy-2-(4-methoxyphenyl)-4H-1-benzopyran-4-one, 9CI	D04DYO	DMUWA2G	300.26	C16H12O6	96.2	465	2.2	22	3	6	2	InChI=1S/C16H12O6/c1-21-10-4-2-8(3-5-10)16-15(20)14(19)13-11(18)6-9(17)7-12(13)22-16/h2-7,17-18,20H,1H3	COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O	COC1=CC=C(C=C1)C2=C(C(=O)C3=C(C=C(C=C3O2)O)O)O	SQFSKOYWJBQGKQ-UHFFFAOYSA-N	3,5,7-trihydroxy-2-(4-methoxyphenyl)chromen-4-one
ferrodrug0232	Seratrodast	Small molecular drug	SERATRODAST; 112665-43-7; Bronica; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid; Abbott 73001; ABT-001; AA-2414; Abbott-73001; AA 2414; (+-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; 103185-78-0; A-73001; NSC-759640; DTXSID4021397; 4U58JM421N; MFCD00875701; NCGC00181296-01; Seratrodast [USAN:INN]; DTXCID201397; ABT 001; Bronica (TN); CCRIS 8939; CAS-112665-43-7; A 73001; UNII-4U58JM421N; Seratrodast (JAN/USAN/INN); (+/-)-2,4,5-Trimethyl-3,6-dioxo-zeta-phenyl-1,4-cyclohexadiene-1-heptanoic acid; 7-(3,5,6-trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic acid; Seratrodast- Bio-X; SERATRODAST [MI]; SERATRODAST [INN]; SERATRODAST [JAN]; SERATRODAST [USAN]; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxo-cyclohexa-1,4-dien-1-yl)heptanoic acid; (+-)-2,4,5-Trimethyl-3,6-dioxo-zeta-phenyl-1,4-cyclohexadiene-1-heptanoic acid; Benzeneheptanoic acid, zeta-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-, (+-)-; SERATRODAST [MART.]; SCHEMBL98402; SERATRODAST [WHO-DD]; MLS006012011; CHEBI:32126; Seratrodast, >=98% (HPLC); ZBVKEHDGYSLCCC-UHFFFAOYSA-N; HMS3264K16; HMS3748I13; Pharmakon1600-01502336; BCP08860; HY-B0774; Tox21_112774; NSC759640; s2072; STL556121; (+/-)-7-(3,5,6-Trimethyl-1,4-benzoquinon-2-yl)-7-phenylheptanoic Acid; AKOS015911825; Seratrodast(AA-2414, ABT-001); Tox21_112774_1; CCG-207903; DB06739; NSC 759640; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxo-1-cyclohexa-1,4-dienyl)heptanoic acid; NCGC00181296-02; AS-12945; BS164397; SMR002530529; FT-0631064; D01123; AB01563274_01; A802627; L001973; SR-01000944172; J-002813; Q7452735; SR-01000944172-1; 6-(6-Carboxy-1-phenylhexyl)-2,3,5-trimethylbenzoquinone; 7-(3,5,6-trimethyl-1,4-benzoquinone-2-yl)-7-phenylheptanoic acid; 7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dienyl)heptanoic acid; (+/-)-2,4,5-TRIMETHYL-3,6-DIOXO-.ZETA.-PHENYL-1,4-CYCLOHEXADIENE-1-HEPTANOIC ACID; 7-phenyl-7-[2,4,5-trimethyl-3,6-bis(oxidanylidene)cyclohexa-1,4-dien-1-yl]heptanoic acid; Benzeneoctanoic acid,H-(2,4,5-trimethyl-3,6-dioxo-1,4-cyclohexadien-1-yl)-; 103186-19-2; BENZENEHEPTANOIC ACID, .ZETA.-(2,4,5-TRIMETHYL-3,6-DIOXO-1,4-CYCLOHEXADIEN-1-YL)-, (+/-)-	D04SPK	DMPNTDL	354.4	C22H26O4	71.4	633	4.4	26	1	4	8	InChI=1S/C22H26O4/c1-14-15(2)22(26)20(16(3)21(14)25)18(17-10-6-4-7-11-17)12-8-5-9-13-19(23)24/h4,6-7,10-11,18H,5,8-9,12-13H2,1-3H3,(H,23,24)	CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C	CC1=C(C(=O)C(=C(C1=O)C)C(CCCCCC(=O)O)C2=CC=CC=C2)C	ZBVKEHDGYSLCCC-UHFFFAOYSA-N	7-phenyl-7-(2,4,5-trimethyl-3,6-dioxocyclohexa-1,4-dien-1-yl)heptanoic acid
ferrodrug0233	Carnosic acid	.	Carnosic acid; 3650-09-7; Salvin; Carnosicacid; LI791SXT24; CHEBI:65585; 139236-75-2; UNII-LI791SXT24; 11,12-dihydroxyabieta-8,11,13-trien-20-oic acid; NSC694080; (4aR,10aS)-5,6-Dihydroxy-7-isopropyl-1,1-dimethyl-1,2,3,4,4a,9,10,10a-octahydrophenanthrene-4a-carboxylic Acid; 11,12-dihydroxy-13-isopropylpodocarpa-8,11,13-trien-17-oic acid; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-(propan-2-yl)-1,3,4,9,10,10a-hexahydrophenanthrene-4a(2H)-carboxylic acid; 4a(2H)-Phenanthrenecarboxylic acid, 1,3,4,9,10,10a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1-methylethyl)-, (4aR,10aS)-rel-; 4a(2H)-Phenanthrenecarboxylic acid, 1,3,4,9,10,10a-hexahydro-5,6-dihydroxy-1,1-dimethyl-7-(1-methylethyl)-, (4aR-trans)-; RoseOx; CARNOSIC ACID (USP-RS); CARNOSIC ACID [USP-RS]; Podocarpa-8,11,13-trien-17-oic acid, 11,12-dihydroxy-13-isopropyl-; (4AR,10AS)-1,3,4,9,10,10A-HEXAHYDRO-5,6-DIHYDROXY-1,1-DIMETHYL-7-(1-METHYLETHYL)-4A(2H)-PHENANTHRENECARBOXYLIC ACID; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid; Rosamox; Carnosic-acid; Carsonic acid; Carnosic acid; MFCD02259459; Deoxypicrosalvinic acid; UPCMLD-DP056; CARNOSIC ACID [MI]; CARNOSIC ACID [INCI]; CHEMBL484853; SCHEMBL9923661; UPCMLD-DP056:001; DTXSID20904450; QRYRORQUOLYVBU-VBKZILBWSA-N; BCPP000299; Carnosic acid, analytical standard; HY-N0644; BDBM50371232; s3838; AKOS015901362; AC-6030; BCP9000491; CCG-207954; NSC-694080; SMP2_000204; NCGC00161623-01; AS-31052; NCI60_033653; BCP0726000155; C2488; C3477; CS-0009671; C21818; CARNOSIC ACID (CONSTITUENT OF ROSEMARY); A918580; Q412827; SR-05000002202; SR-05000002202-2; CARNOSIC ACID (CONSTITUENT OF ROSEMARY) [DSC]; Carnosic acid, primary pharmaceutical reference standard; Carnosic acid from Rosmarinus officinalis, >=91%, powder; Carnosic acid, United States Pharmacopeia (USP) Reference Standard; (4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylicacid	.	.	332.4	C20H28O4	77.8	500	4.9	24	3	4	2	InChI=1S/C20H28O4/c1-11(2)13-10-12-6-7-14-19(3,4)8-5-9-20(14,18(23)24)15(12)17(22)16(13)21/h10-11,14,21-22H,5-9H2,1-4H3,(H,23,24)/t14-,20+/m0/s1	CC(C)C1=C(C(=C2C(=C1)CC[C@@H]3[C@@]2(CCCC3(C)C)C(=O)O)O)O	CC(C)C1=C(C(=C2C(=C1)CCC3C2(CCCC3(C)C)C(=O)O)O)O	QRYRORQUOLYVBU-VBKZILBWSA-N	(4aR,10aS)-5,6-dihydroxy-1,1-dimethyl-7-propan-2-yl-2,3,4,9,10,10a-hexahydrophenanthrene-4a-carboxylic acid
ferrodrug0234	Gastrodin	.	Gastrodin; 62499-27-8; Gastrodine; Gastrodin Hemihydrate; UNII-5YS9U2W3RQ; 5YS9U2W3RQ; 4-(Hydroxymethyl)phenyl beta-D-Glucopyranoside; beta-D-Glucopyranoside, 4-(hydroxymethyl)phenyl; (-)-GASTRODIN; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(hydroxymethyl)phenoxy)tetrahydro-2H-pyran-3,4,5-triol; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[4-(hydroxymethyl)phenoxy]oxane-3,4,5-triol; CHEMBL274739; CHEBI:80828; 4-(Hydroxymethyl)phenyl-beta-D-glucopyranoside; Gastrodin,(S); Gastrodin (Gastrodine); GASTRODIN [MI]; 4-(beta-D-glucopyranosyloxy)benzyl alcohol; GASTRODIN [INCI]; 2H-pyran-3,4,5-triol; GASTRODIN [WHO-DD]; SCHEMBL1076037; Gastrodin, >=98% (HPLC); DTXSID30978086; HMS3884L15; HY-N0115; BDBM50177403; MFCD00272169; s2383; (4-(hydroxymethyl)phenoxy)tetrahydro-; AKOS015951256; 4-; A-D-Glucopyranosyloxybenzyl alcohol; AC-8028; BCP9000710; CCG-267336; CS-7969; NCGC00346601-02; AS-17473; Gastrodin, from Gastrodia alata, >=98%; 4-[beta-d-glucopyranosyloxy] benzyl alcohol; 4-(beta-D-GLUCOPYRANOSYL)-BENZYLALCOHOL; 4-(Hydroxymethyl)phenylbeta-D-Glucopyranoside; b-D-Glucopyranoside, 4-(hydroxymethyl)phenyl; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-; C16964; 4-(.BETA.-D-GLUCOPYRANOSYL)-BENZYLALCOHOL; A833810; Q-100720; Q5526833; 4-(.BETA.-D-GLUCOPYRANOSYLOXY)BENZYL ALCOHOL; beta-D-GLUCOPYRANOSIDE, 4-(HYDROXYMETHYL)PHENYL-; .BETA.-D-GLUCOPYRANOSIDE, 4-(HYDROXYMETHYL)PHENYL; .BETA.-D-GLUCOPYRANOSIDE, 4-(HYDROXYMETHYL)PHENYL-; 4-HYDROXYBENZYL ALCOHOL 4-O-beta-D-GLUCOPYRANOSIDE; 4-HYDROXYBENZYL ALCOHOL 4-O-.BETA.-D-GLUCOPYRANOSIDE; NCGC00346601-02_C13H18O7_beta-D-Glucopyranoside, 4-(hydroxymethyl)phenyl; (2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-(4-(hydroxymethyl)phenoxy)-tetrahydro-2H-pyran-3,4,5-triol	.	.	286.28	C13H18O7	120	292	-0.8	20	5	7	4	InChI=1S/C13H18O7/c14-5-7-1-3-8(4-2-7)19-13-12(18)11(17)10(16)9(6-15)20-13/h1-4,9-18H,5-6H2/t9-,10-,11+,12-,13-/m1/s1	C1=CC(=CC=C1CO)O[C@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)O)O	C1=CC(=CC=C1CO)OC2C(C(C(C(O2)CO)O)O)O	PUQSUZTXKPLAPR-UJPOAAIJSA-N	(2R,3S,4S,5R,6S)-2-(hydroxymethyl)-6-[4-(hydroxymethyl)phenoxy]oxane-3,4,5-triol
ferrodrug0235	Tiliroside	Small molecular drug	Tiliroside; 20316-62-5; Tribuloside; Trans-Tiliroside; 15M04TXR9M; CHEMBL266564; [(2R,3S,4S,5R,6S)-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(4-hydroxyphenyl)prop-2-enoate; CHEBI:80944; 22153-44-2; 2-Propenoic acid, 3-(4-hydroxyphenyl)-, 6'-ester with 3-(beta-D-glucopyranosyloxy)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; ((2R,3S,4S,5R,6S)-6-((5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl (E)-3-(4-hydroxyphenyl)acrylate; [(2R,3S,4S,5R,6S)-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-chromen-3-yl]oxy-3,4,5-trihydroxy-tetrahydropyran-2-yl]methyl (E)-3-(4-hydroxyphenyl)prop-2-enoate; UNII-15M04TXR9M; Potengriffioside A; RONACARE TILIROSIDE; TILIROSIDE [INCI]; SCHEMBL23597; Tiliroside, analytical standard; MEGxp0_000169; DTXSID601021936; GLXC-13144; 6''-O-trans-p-Coumaroylastragalin; Kaempferol-3-(p-coumaryl)glucoside; HY-N2443; BDBM50241244; MFCD00017454; AKOS015896718; NCGC00163634-01; ASTRAGALIN-6''-TRANS-P-COUMARATE; MS-30569; CS-0022668; kaempferol 3-O-(6'-O-p-coumaroyl)-glucoside; C17140; A814433; Q-100248; KAEMPFEROL 3-O-(6''-O-P-COUMAROYL)GLUCOSIDE; Q23418844; kaempferol-3-beta-D-(6-O-trans-p-coumaroyl)glucopyranoside; Kaempferol-3-O-(6-O-trans-p-coumaroyl)-.beta.-glucopyranoside; kaempferol-3-O-beta-D-(6''-(E)-p-coumaroyl)-glucopyranoside; 3-O-KAEMPFEROL 6-O-(TRANS-P-COUMAROYL)-.BETA.-D-GLUCOPYRANOSIDE; kaempferol 3-O-(6'''' ''''-O-E-p-coumaroyl)-beta-D-glucopyranoside; KAEMPFEROL 3-O-(6''-O-(E)-P-COUMAROYL)-.BETA.-D-GLUCOPYRANOSIDE; KAEMPFEROL 3-O-.BETA.-D-(6-O-TRANS-P-COUMAROYL)GLUCOPYRANOSIDE; KAEMPFEROL-3-O(-6-O-TRANS-P-COUMAROYL-.BETA.-GLUCOPYRANOSIDE; KAEMPFEROL 3-O-(6''-O-(TRANS-P-COUMAROYL))-.BETA.-D-GLUCOPYRANOSIDE; ((2R,3S,4S,5R,6S)-6-((5,7-Dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yl)oxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 3-(4-hydroxyphenyl)acrylate; (E)-((2R,3S,4S,5R,6S)-6-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yloxy)-3,4,5-trihydroxy-tetrahydro-2H-pyran-2-yl)methyl 3-(4-hydroxyphenyl)acrylate; (E)-((2R,3S,4S,5R,6S)-6-(5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4H-chromen-3-yloxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)methyl 3-(4-hydroxyphenyl)acrylate; 2-PROPENOIC ACID, 3-(4-HYDROXYPHENYL)-, 6'-ESTER WITH 3-(.BETA.-D-GLUCOPYRANOSYLOXY)-5,7-DIHYDROXY-2-(4-HYDROXYPHENYL)-4H-1-BENZOPYRAN-4-ONE, (E)-; 4H-1-BENZOPYRAN-4-ONE, 5,7-DIHYDROXY-2-(4-HYDROXYPHENYL)-3-((6-O-((2E)-3-(4-HYDROXYPHENYL)-1-OXO-2-PROPEN-1-YL)-.BETA.-D-GLUCOPYRANOSYL)OXY)-; 4H-1-Benzopyran-4-one, 5,7-dihydroxy-2-(4-hydroxyphenyl)-3-[[6-O-[(2E)-3-(4-hydroxyphenyl)-1-oxo-2-propenyl]-.beta.-D-glucopyranosyl]oxy]-; 5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxo-4E-1-benzopyran-3-yl 6-O-[(2E)-3-(4-hydroxyphenyl)prop-2-enoyl]-beta-D-glucopyranoside	D0IB3K	DMLNTB5	594.5	C30H26O13	213	1040	2.5	43	7	13	8	InChI=1S/C30H26O13/c31-16-6-1-14(2-7-16)3-10-22(35)40-13-21-24(36)26(38)27(39)30(42-21)43-29-25(37)23-19(34)11-18(33)12-20(23)41-28(29)15-4-8-17(32)9-5-15/h1-12,21,24,26-27,30-34,36,38-39H,13H2/b10-3+/t21-,24-,26+,27-,30+/m1/s1	C1=CC(=CC=C1/C=C/C(=O)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O	C1=CC(=CC=C1C=CC(=O)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC=C(C=C5)O)O)O)O)O	DVGGLGXQSFURLP-VWMSDXGPSA-N	[(2R,3S,4S,5R,6S)-6-[5,7-dihydroxy-2-(4-hydroxyphenyl)-4-oxochromen-3-yl]oxy-3,4,5-trihydroxyoxan-2-yl]methyl (E)-3-(4-hydroxyphenyl)prop-2-enoate
ferrodrug0236	Indole-3-pyruvic acid	.	Indole-3-pyruvic acid; 392-12-1; 3-(1H-Indol-3-yl)-2-oxopropanoic acid; Indole-3-pyruvate; indolepyruvate; 3-Indolylpyruvic acid; Indolepyruvic acid; Indolyl-3-pyruvate; 3-Indolepyruvic acid; 3-(indol-3-yl)pyruvic acid; 3-Indolylpyroracemic acid; 3-(3-Indolyl)-2-oxopropanoic acid; NSC 88874; 1H-Indole-3-propanoic acid, alpha-oxo-; (Indol-3-yl)pyruvate; (indol-3-yl)pyruvic acid; 4QM0LT13A8; 1H-Indole-3-propanoic acid, .alpha.-oxo-; DTXSID3042053; CHEBI:29750; NSC-88874; indol-3-yl pyruvic acid; 3IO; beta-Indolepyruvic acid; beta-Indolylpyruvic acid; Indole-3-pyruvic acid monohydrate; Indole pyruvic acid; EINECS 206-874-1; BRN 0172966; UNII-4QM0LT13A8; 3-indol-3-yl-2-oxopropanoic acid; 3-Indolpyruvic acid; indol-3-pyruvic acid; KETO TRYPTOPHAN; 3-indole-pyruvic acid; .beta.-Indolepyruvic acid; .beta.-Indolylpyruvic acid; bmse000646; bmse000685; 1H-Indole-3-pyruvic acid; Indole-3-Acetylformic Acid; 5-22-06-00324 (Beilstein Handbook Reference); MLS000515792; SCHEMBL125249; CHEMBL485012; DTXCID1022053; HMS2270A21; NSC88874; Tox21_301365; MFCD00005640; STL286879; AKOS005267243; HY-W028393; NCGC00247042-01; NCGC00255790-01; AC-10208; AS-63461; CAS-392-12-1; SMR000112266; 3-(1H-indol-3-yl)-2-keto-propionic acid; Indole-3-pyruvic acid, >=98.0% (TLC); CS-0072417; FT-0627222; C00331; EN300-218335; I-4200; 1H-INDOLE-3-PROPANOIC ACID, .ALPHA.-OXO; A824463; 3-(1H-indol-3-yl)-2-oxidanylidene-propanoic acid; AC17FD8D-94BC-4C87-B5E6-D2B60F03B45D; Q23905803; F9995-2651	.	.	203.19	C11H9NO3	70.2	277	1.3	15	2	3	3	InChI=1S/C11H9NO3/c13-10(11(14)15)5-7-6-12-9-4-2-1-3-8(7)9/h1-4,6,12H,5H2,(H,14,15)	C1=CC=C2C(=C1)C(=CN2)CC(=O)C(=O)O	C1=CC=C2C(=C1)C(=CN2)CC(=O)C(=O)O	RSTKLPZEZYGQPY-UHFFFAOYSA-N	3-(1H-indol-3-yl)-2-oxopropanoic acid
ferrodrug0237	Isoorientin	.	Isoorientin; Homoorientin; 4261-42-1; iso-orientin; Lespecapitioside; Luteolin-6-C-glucoside; Luteolin 6-C-glucoside; CHEBI:17965; 2-(3,4-Dihydroxyphenyl)-6-beta-D-glucopyranosyl-5,7-dihydroxy-4H-1-benzopyran-4-one; UNII-A37342TIX1; LUTONARETIN; Luteolin-6-C-beta-D-glucoside; A37342TIX1; 6C-hexosyl luteolin; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-4H-chromen-4-one; 6-Glc-luteolin; (1S)-1,5-anhydro-1-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-6-yl]-D-glucitol; 2-[3,4-bis(oxidanyl)phenyl]-6-[(2S,3R,4R,5S,6R)-6-(hydroxymethyl)-3,4,5-tris(oxidanyl)oxan-2-yl]-5,7-bis(oxidanyl)chromen-4-one; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one; Homoori-entin; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-6-beta-D-glucopyranosyl-5,7-dihydroxy-; (1S)-1,5-anhydro-1-(2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-4-oxo-4H-chromen-6-yl)-D-glucitol; MFCD00017433; Homoorientin; Isoorientin; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl)chromen-4-one; SCHEMBL23761; MLS002473101; CHEMBL239559; Isoorientin, analytical standard; Luteolin 6-C-bet.-D-glucoside; Isoorientin, >=98% (HPLC); DTXSID50962609; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-6-.beta.-D-glucopyranosyl-5,7-dihydroxy-; luteolin-6-C-B-D-glucopyranoside; ODBRNZZJSYPIDI-VJXVFPJBSA-N; HMS2225D20; HY-N0767; Isoorientin, >=98.0% (HPLC); BDBM50487756; s9248; AKOS015896766; CCG-208392; CS-7515; NCGC00163566-01; AC-34983; AS-56302; SMR001397203; I1087; C01821; Q-100474; Q3155592; Isoorientin, primary pharmaceutical reference standard; 2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]chromen-4-one; 61383-35-5; H9R	.	.	448.4	C21H20O11	197	729	-0.2	32	8	11	3	InChI=1S/C21H20O11/c22-6-14-17(27)19(29)20(30)21(32-14)16-11(26)5-13-15(18(16)28)10(25)4-12(31-13)7-1-2-8(23)9(24)3-7/h1-5,14,17,19-24,26-30H,6H2/t14-,17-,19+,20-,21+/m1/s1	C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O)O	C1=CC(=C(C=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)C4C(C(C(C(O4)CO)O)O)O)O)O)O	ODBRNZZJSYPIDI-VJXVFPJBSA-N	2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-6-[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]chromen-4-one
ferrodrug0238	Germacrone	Small molecular drug	Germacrone; 6902-91-6; (3E,7E)-3,7-Dimethyl-10-(propan-2-ylidene)cyclodeca-3,7-dienone; Germacron; E2WQ6N4FBP; (3E,7E)-3,7-dimethyl-10-propan-2-ylidenecyclodeca-3,7-dien-1-one; (E,E)-Germacrone; Germacrone,(S); Germacrol (obsol;); UNII-E2WQ6N4FBP; Germacrone, analytical standard; SCHEMBL2551615; SCHEMBL14215872; CHEBI:80830; CAULGCQHVOVVRN-UPAULDTKSA-N; HY-N0440; MFCD00210050; s9311; AKOS016009673; CCG-266711; NCGC00482596-01; AC-34324; CS-0008961; G0519; (E,E)-Germacra-3,7(11),9-trien-6-one; C16966; Q-100776; Q15410959; trans,trans-3,7-dimethyl-10-isopropylidene-3,7-cyclodecadien-1-one; (3E,7E)-3,7-DIMETHYL-10-(1-METHYLETHYLIDENE)-3,7-CYCLODECADIEN-1-ONE	.	DG00616	218.33	C15H22O	17.1	363	3.5	16	0	1	0	InChI=1S/C15H22O/c1-11(2)14-9-8-12(3)6-5-7-13(4)10-15(14)16/h7-8H,5-6,9-10H2,1-4H3/b12-8+,13-7+	C/C/1=C\CC(=C(C)C)C(=O)C/C(=C/CC1)/C	CC1=CCC(=C(C)C)C(=O)CC(=CCC1)C	CAULGCQHVOVVRN-SWZPTJTJSA-N	(3E,7E)-3,7-dimethyl-10-propan-2-ylidenecyclodeca-3,7-dien-1-one
ferrodrug0239	Dichloroacetate	.	Dichloroacetate; 2,2-dichloroacetate; Dichloracetate; 13425-80-4; Dichloroacetate ion; Dichloroacetic acid ion(1-); DCA; BRN 3903873; Ion Chromatography Standard: Dichloroacetate @ 500 microg/mL in H2O; Acetic acid, 2,?2-?dichloro-?, ion(1-?); Acetic acid, dichloro-, ion(1-) (8CI,9CI); 2,2-Dichloroacetate; Dichloroacetate anion; Dichloroacetate ion; Dichloroacetate ion(1-); 2q8h; ACETIC ACID, DICHLORO-, ION(1-); 2,2-bis(chloranyl)ethanoate; GTPL4518; CHEBI:28240; DTXSID40158610; STL483470; NCGC00241105-01; A839686; Q27077050	.	.	127.93	C2HCl2O2-	40.1	55.1	1.8	6	0	2	0	InChI=1S/C2H2Cl2O2/c3-1(4)2(5)6/h1H,(H,5,6)/p-1	C(C(=O)[O-])(Cl)Cl	C(C(=O)[O-])(Cl)Cl	JXTHNDFMNIQAHM-UHFFFAOYSA-M	2,2-dichloroacetate
ferrodrug0240	Butyrate	.	butyrate; butanoate; N-Butyrate; n-butanoate; Butanoic acid, ion(1-); 461-55-2; butanate; 1-butanoate; propanecarboxylate; 1-butyrate; 1-propanecarboxylate; CHEMBL62381; NCGC00167555-01; ethyl,acetate; Sodium; butyrate; C11H23NOS; DTXSID8040432; CHEBI:17968; FERIUCNNQQJTOY-UHFFFAOYSA-M; CH3-[CH2]2-COO(-); BDBM50079401; c0035; PD121533; AB01566831_01; Q55582441	.	.	87.1	C4H7O2-	40.1	44	1.4	6	0	2	1	InChI=1S/C4H8O2/c1-2-3-4(5)6/h2-3H2,1H3,(H,5,6)/p-1	CCCC(=O)[O-]	CCCC(=O)[O-]	FERIUCNNQQJTOY-UHFFFAOYSA-M	butanoate
ferrodrug0241	Lactate	.	lactate; 2-hydroxypropanoate; 113-21-3; 2-Hydroxypropionate; Lactate ion, DL-; MeCH(OH)CO2 anion; Propanoic acid, 2-hydroxy-, ion(1-); 13GMT0VU0O; L-LACTIC ACID, 40% SOLN; CHEMBL1357; UNII-13GMT0VU0O; Lithium L(+)-lactate; Lithium; dl-lactate; DL lactate; DL lactic acid; DL-lactate ion; (RS)-lactate; (RS)-lactic acid; Lactate ion(1-); LACTATE ANION; LACTATE ION; Sodium; 2-hydroxy-propionate; LACTIC ACID, ION(1-); CHEBI:24996; DTXSID10873500; 2-Hydroxypropanoic acid ion(1-); JVTAAEKCZFNVCJ-UHFFFAOYSA-M; 2-hydroxypropanoic acid, ion(1-); BDBM50159794; AKOS015995352; NCGC00249038-01; AB01563159_01; Q27895931; 859046-34-7	.	.	89.07	C3H5O3-	60.4	53.5	0.2	6	1	3	0	InChI=1S/C3H6O3/c1-2(4)3(5)6/h2,4H,1H3,(H,5,6)/p-1	CC(C(=O)[O-])O	CC(C(=O)[O-])O	JVTAAEKCZFNVCJ-UHFFFAOYSA-M	2-hydroxypropanoate
ferrodrug0242	Tetraarsenic tetrasulfide	.	Tetraarsenic tetrasulfide; 12279-90-2; ZIK02R2PSD; As4S4 cpd; XIONGHUANG; ARSENIC DISULPHIDE; REALGAR [CHP]; UNII-ZIK02R2PSD; REALGAR [WHO-DD]; ARSENIC MONOSULPHIDE; ARSENIC SULPHIDE RED; ARSENIC SULFIDE [MI]; TETRAARSENIC TETRASULPHIDE; DTXSID50153717; TETRA-ARSENIC TETRA-SULFIDE; ARSENICUM SULPHURATUM RUBRUM; TETRA-ARSENIC TETRA-SULPHIDE; 2,4,6,8-Tetrathia-1,3,5,7-tetraarsatricyclo[3.3.0.03,7]octane; TETRAARSENIC TETRASULFIDE [WHO-DD]; ARSENICUM SULPHURATUM RUBRUM [HPUS]; Q27295581; 2,4,6,8-tetrathia-1,3,5,7-tetrarsatricyclo[3.3.0.03,7]octane	.	.	428	As4S4	101	88	.	8	0	4	0	InChI=1S/As4S4/c5-1-2-7-3(5)4(6-1)8-2	S1[As]2S[As]3[As]1S[As]2S3	S1[As]2S[As]3[As]1S[As]2S3	XPDICGYEJXYUDW-UHFFFAOYSA-N	2,4,6,8-tetrathia-1,3,5,7-tetrarsatricyclo[3.3.0.03,7]octane
ferrodrug0243	Pseudolaric acid B	.	Pseudolaric acid B; 82508-31-4; Pseudolaric-Acid-B; Pseudolaric acid b(pba); CHEBI:189471; BCP07962; PD087135; Q-100841; (2E,4E)-5-[(1S,7S,8S,9R)-7-Acetyloxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoic acid	.	.	432.5	C23H28O8	116	913	2.3	31	1	8	7	InChI=1S/C23H28O8/c1-14(18(25)26)6-5-10-21(3)17-9-12-22(20(28)31-21)11-7-16(19(27)29-4)8-13-23(17,22)30-15(2)24/h5-7,10,17H,8-9,11-13H2,1-4H3,(H,25,26)/b10-5+,14-6+/t17-,21+,22-,23-/m0/s1	C/C(=C\C=C\[C@@]1([C@@H]2CC[C@]3([C@@]2(CCC(=CC3)C(=O)OC)OC(=O)C)C(=O)O1)C)/C(=O)O	CC(=CC=CC1(C2CCC3(C2(CCC(=CC3)C(=O)OC)OC(=O)C)C(=O)O1)C)C(=O)O	VDGOFNMYZYBUDT-YCONPBHISA-N	(2E,4E)-5-[(1S,7S,8S,9R)-7-acetyloxy-4-methoxycarbonyl-9-methyl-11-oxo-10-oxatricyclo[6.3.2.01,7]tridec-3-en-9-yl]-2-methylpenta-2,4-dienoic acid
ferrodrug0244	Cisplatin	.	cisplatin; 14913-33-8; trans-Dichlorodiamineplatinum(II); azane;dichloroplatinum; Platinum, diamminedichloro-, (SP-4-1)-; trans-Diamminedichloro platinum(II); trans-Platinum(II)diammine dichloride; MFCD00011623; trans-Dichlorodiamineplatinum(II);Transplatin; SR-05000001586; IA call; Trans-Platinum diammine dichloride; Cisplatin in water; Cisplatin,(S); Cisplatin in DMSO; DDP-H; PLATINOL (TN); SPECTRUM1502107; Cisplatin (JP17/USP/INN); cis-Diaminodichloroplatinum(II); HMS502M12; HMS1921J18; HMS2092D04; BCP01792; BCP18182; CCG-39901; AKOS005137969; NCGC00094962-01; NCGC00094962-02; NCGC00094962-03; FT-0777996; C06911; D00275; cis-Diammineplatinum(II) dichloride, crystalline; Q412415; SR-01000076254; SR-01000076254-1; SR-05000001586-1; SR-05000001586-3; Z3182781436; Cisplatin, European Pharmacopoeia (EP) Reference Standard; Cisplatin, United States Pharmacopeia (USP) Reference Standard; cis-Diamineplatinum(II) dichloride, >=99.9% trace metals basis; Cisplatin impurity A, European Pharmacopoeia (EP) Reference Standard; Transplatin, United States Pharmacopeia (USP) Reference Standard; Cisplatin, Pharmaceutical Secondary Standard; Certified Reference Material	.	.	300.05	Cl2H6N2Pt	2	2.8	.	5	2	2	0	InChI=1S/2ClH.2H3N.Pt/h2*1H;2*1H3;/q;;;;+2/p-2	N.N.Cl[Pt]Cl	N.N.Cl[Pt]Cl	LXZZYRPGZAFOLE-UHFFFAOYSA-L	azane;dichloroplatinum
ferrodrug0245	Fraxetin	.	Fraxetin; 574-84-5; 7,8-Dihydroxy-6-methoxycoumarin; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one; 7,8-dihydroxy-6-methoxychromen-2-one; 2H-1-Benzopyran-2-one, 7,8-dihydroxy-6-methoxy-; UNII-CD3GD44O3K; 7,8-Dihydroxy-6-methoxy-2-benzopyrone; CD3GD44O3K; 7,8-Dihydroxy-6-methoxy-chromen-2-one; CHEMBL54909; CHEBI:5169; EINECS 209-376-2; 7,8-Dihydroxy-6-methoxy-2H-1-benzopyran-2-one; Fraxetol; 8-hydroxyscopoletin; Spectrum_001507; SpecPlus_000477; FRAXETIN [MI]; Spectrum2_001639; Spectrum3_001842; Spectrum4_001686; Spectrum5_000332; Oprea1_735469; SCHEMBL43472; BSPBio_003224; Fraxetin, analytical standard; KBioGR_001952; KBioSS_001987; MLS002207123; DivK1c_006573; SPECTRUM1504069; SPBio_001737; MEGxp0_000506; ACon0_001071; ACon1_000442; KBio1_001517; KBio2_001987; KBio2_004555; KBio2_007123; KBio3_002724; DTXSID00205992; HAVWRBANWNTOJX-UHFFFAOYSA-N; 7,8-dihydroxy-6-methoxy coumarin; KUC106681N; HY-N0580; TNP00177; Coumarin, 7,8-dihydroxy-6-methoxy; BDBM50206215; CCG-38759; MFCD00006873; s9503; STL564671; Coumarin, 7,8-dihydroxy-6-methoxy-; AKOS000277991; 7,8-Dihydroxy-6-methoxycoumarin, 98%; NCGC00017270-01; NCGC00017270-02; NCGC00017270-03; NCGC00017270-04; NCGC00017270-05; NCGC00096046-01; NCGC00096046-02; NCGC00169075-01; NCGC00169075-02; AC-34572; AS-67313; SMR000112323; KSC-11-207-12; CS-0009115; FT-0632418; 7,8-Dihydroxy-6-methoxy-2H-chromen-2-one #; A14554; C09265; SR-05000002449; Q-100662; SR-05000002449-1; BRD-K76587808-001-03-8; Q15410973; InChI=1/C10H8O5/c1-14-6-4-5-2-3-7(11)15-10(5)9(13)8(6)12/h2-4,12-13H,1H	.	.	208.17	C10H8O5	76	288	1.2	15	2	5	1	InChI=1S/C10H8O5/c1-14-6-4-5-2-3-7(11)15-10(5)9(13)8(6)12/h2-4,12-13H,1H3	COC1=C(C(=C2C(=C1)C=CC(=O)O2)O)O	COC1=C(C(=C2C(=C1)C=CC(=O)O2)O)O	HAVWRBANWNTOJX-UHFFFAOYSA-N	7,8-dihydroxy-6-methoxychromen-2-one
ferrodrug0246	Wedelolactone	Small molecular drug	Wedelolactone; 524-12-9; 7-Methoxy-5,11,12-trihydroxycoumestan; 7-Methoxy-5,11,12-trihydroxy-coumestan; IKK Inhibitor II; 1,8,9-Trihydroxy-3-methoxycoumestan; CHEMBL97453; 0K6L725GNS; CHEBI:10037; 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c]chromen-6-one; 5,11,12-Trihydroxy-7-methoxycoumestan; 1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one; 6H-Benzofuro(3,2-c)(1)benzopyran-6-one, 1,8,9-trihydroxy-3-methoxy-; 1,8,9-Trihydroxy-3-methoxy-6H-[1]benzofuro[3,2-c]chromen-6-one; UNII-0K6L725GNS; 1,8,9-TRIHYDROXY-3-METHOXY-6H-(1)BENZOFURO(3,2-C)CHROMEN-6-ONE; MFCD07778564; 1,8,9-Trihydroxy-3-methoxy-6H-benzofuro[3,2-c][1]benzopyran-6-one; SCHEMBL601220; GTPL5551; DTXSID60200408; Wedelolactone, analytical standard; 1,8,9-trihydroxy-3-methoxy-benzofuro[3,2-c]chromen-6-one; HMS2043P19; BCP19859; HY-N0551; BDBM50096619; HB4124; LMPK12090046; s9042; AKOS015897173; CCG-208289; SMP2_000112; NCGC00163667-01; NCGC00163667-02; NCGC00163667-03; Wedelolactone, >=98% (HPLC), powder; AC-34562; CS-0009079; FT-0698529; W0015; A14804; K00058; A936784; SR-05000002318; Q6586709; SR-05000002318-2; BRD-K53635676-001-01-5; BRD-K53635676-001-02-3; Wedelolactone; 7-Methoxy-5,11,12-trihydroxy-coumestan; B0005-464576; 1,8,9-trihydroxy-3-methoxy-[1]benzoxolo[3,2-c]chromen-6-one; Wedelolactone, European Pharmacopoeia (EP) Reference Standard; 1,8,9-Trihydroxy-3-methoxy-benzo[4,5]furo[3,2-c]chromen-6-one	D0F8QJ	DMHL3YV	314.25	C16H10O7	109	483	2.4	23	3	7	1	InChI=1S/C16H10O7/c1-21-6-2-10(19)14-12(3-6)23-16(20)13-7-4-8(17)9(18)5-11(7)22-15(13)14/h2-5,17-19H,1H3	COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O	COC1=CC(=C2C(=C1)OC(=O)C3=C2OC4=CC(=C(C=C43)O)O)O	XQDCKJKKMFWXGB-UHFFFAOYSA-N	1,8,9-trihydroxy-3-methoxy-[1]benzofuro[3,2-c]chromen-6-one
ferrodrug0247	Nuciferine	.	Nuciferine; 475-83-2; Nuciferin; Sanjoinine E; l-Nuciferine; (-)-nuciferine; (-)-Nucipherine; (R)-1,2-Dimethoxyaporphine; (R)-1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline; W26UEB90B7; (6ar)-1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4h-dibenzo[de,g]quinoline; 4H-Dibenzo(de,g)quinoline, 5,6,6a,7-tetrahydro-1,2-dimethoxy-6-methyl-, (R)-; l-5,6-Dimethoxyaporphine; 1,2-Dimethoxy-6abeta-aporphine; 1-5, 6-Dimethoxyaporphine; UNII-W26UEB90B7; 6a-.beta.-Aporphine, 1,2-dimethoxy-; 6a-beta-APORPHINE, 1,2-DIMETHOXY-; (R)-NUCIFERINE; D-(-)-NUCIFERINE; CHEMBL464529; SCHEMBL20544868; DTXSID40963862; VLT 049; ORJVQPIHKOARKV-OAHLLOKOSA-N; HMS3887A19; HY-N0049; MFCD01664592; NSC785145; s3821; AKOS015903258; AC-7998; CCG-267422; CS-4270; NSC-785145; BS-42200; 1,2-DIMETHOXY-6A.BETA.-APORPHINE; N1170; A872116; Q-100504; Q7067904; 4H-DIBENZO(DE,G)QUINOLINE, 5,6,6A,7-TETRAHYDRO-1,2-DIMETHOXY-6-METHYL-, (6AR)-	.	.	295.4	C19H21NO2	21.7	401	3.4	22	0	3	2	InChI=1S/C19H21NO2/c1-20-9-8-13-11-16(21-2)19(22-3)18-14-7-5-4-6-12(14)10-15(20)17(13)18/h4-7,11,15H,8-10H2,1-3H3/t15-/m1/s1	CN1CCC2=CC(=C(C3=C2[C@H]1CC4=CC=CC=C43)OC)OC	CN1CCC2=CC(=C(C3=C2C1CC4=CC=CC=C43)OC)OC	ORJVQPIHKOARKV-OAHLLOKOSA-N	(6aR)-1,2-dimethoxy-6-methyl-5,6,6a,7-tetrahydro-4H-dibenzo[de,g]quinoline
ferrodrug0248	Ruscogenin	.	Ruscogenin; 472-11-7; UNII-BXI92R2VUJ; BXI92R2VUJ; CHEBI:8913; Spirost-5-ene-1,3-diol, (1b,3b,25R)-; (1beta,3beta,25R)-Spirost-5-ene-1,3-diol; EINECS 207-447-2; (25R)-spirost-5-en-1beta,3beta-diol; (25R)-Spirost-5-ene-1beta,3beta-diol; Spirost-5-ene-1,3-diol, (1.beta.,3.beta.,25R)-; Ruscogenins; Ruscorectal (TN); RUSCOGENIN [INCI]; RUSCOGENIN [MART.]; RUSCOGENIN [WHO-DD]; SCHEMBL147884; CHEMBL1169820; Ruscogenin, >=98% (HPLC); DTXSID401019319; HY-N0496; LMST01080038; MFCD00210550; CCG-269015; AC-34398; CS-0009017; S9183; C08909; D08498; Q-201689; (25R)-SPIROST-5-ENE-1.BETA.,3.BETA.-DIOL; Q27108184; SPIROST-5-ENE-1.BETA.,3.BETA.-DIOL, (25R)-; Z2037319104; (1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,14R,16R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14,16-diol	.	.	430.6	C27H42O4	58.9	779	4.7	31	2	4	0	InChI=1S/C27H42O4/c1-15-7-10-27(30-14-15)16(2)24-22(31-27)13-21-19-6-5-17-11-18(28)12-23(29)26(17,4)20(19)8-9-25(21,24)3/h5,15-16,18-24,28-29H,6-14H2,1-4H3/t15-,16+,18-,19-,20+,21+,22+,23-,24+,25+,26+,27-/m1/s1	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5([C@@H](C[C@@H](C6)O)O)C)C)C)OC1	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(C(CC(C6)O)O)C)C)C)OC1	QMQIQBOGXYYATH-IDABPMKMSA-N	(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,14R,16R)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-14,16-diol
ferrodrug0249	Atranorin	.	Atranorin; 479-20-9; Atranoric acid; Atranorine; Parmelin; Usnarin; Antranoric acid; Parmelin acid; Usnarin acid; 3-Hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl 3-formyl-2,4-dihydroxy-6-methylbenzoate; NSC 249980; NSC 685591; NSC-685591; 450U2VJ2VG; CHEMBL173395; Benzoic acid,3-formyl-2,4-dihydroxy-6-methyl-,3-hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl ester; NSC685591; NSC-249980; 3-formyl-2,4-dihydroxy-6-methylbenzoic acid 3-hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl ester; Benzoic acid, 3-formyl-2,4-dihydroxy-6-methyl-, 3-hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl ester; EINECS 207-527-7; UNII-450U2VJ2VG; Benzoic acid,4-dihydroxy-6-methyl-, 3-hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl ester; Isophthalaldehydic acid,4-dihydroxy-6-methyl-, 4-ester with methyl 3,6-dimethyl-.beta.-resorcylate; Spectrum_000143; SpecPlus_000239; ATRANORIN [MI]; Spectrum2_001749; Spectrum3_001716; Spectrum4_001700; Spectrum5_000380; (3-hydroxy-4-methoxycarbonyl-2,5-dimethylphenyl) 3-formyl-2,4-dihydroxy-6-methylbenzoate; BSPBio_003332; KBioGR_002000; KBioSS_000623; SPECTRUM200034; DivK1c_006335; SPBio_001858; SCHEMBL1370191; KBio1_001279; KBio2_000623; KBio2_003191; KBio2_005759; KBio3_002552; DTXSID10197319; CHEBI:144119; YLOYKYXNDHOHHT-UHFFFAOYSA-N; HY-N2907; NSC87512; BDBM50056919; CCG-38801; MFCD00016597; NSC-87512; NSC249980; AKOS024319117; SDCCGMLS-0066426.P001; NCGC00095465-01; NCGC00095465-02; Isophthalaldehydic acid, 2,4-dihydroxy-6-methyl-, 4-ester with methyl 3,6-dimethyl-beta-resorcylate; MS-26044; CS-0023502; FT-0769622; SR-05000002629; SR-05000002629-1; Q27258788; (3-hydroxy-4-methoxycarbonyl-2,5-dimethyl-phenyl) 3-formyl-2,4-dihydroxy-6-methyl-benzoate; 3-Hydroxy-4-(methoxycarbonyl)-2,5-dimethylphenyl 3-formyl-2,4-dihydroxy-6-methylbenzoate #; Methyl 4-(3-formyl-2,4-dihydroxy-6-methyl-benzoyloxy)-2-hydroxy- 3,6-dimethyl-benzoate; Isophthalaldehydic acid, 2,4-dihydroxy-6-methyl-, 4-ester with methyl 3,6-dimethyl-.beta.-resorcylate; methyl 1-(3-formyl-2,4-dihydroxy-6-methylphenylcarbonyloxy)-3-hydroxy-2,5-dimethyl-4-benzenecarboxylate	.	.	374.3	C19H18O8	130	564	4.3	27	3	8	6	InChI=1S/C19H18O8/c1-8-5-12(21)11(7-20)17(23)15(8)19(25)27-13-6-9(2)14(18(24)26-4)16(22)10(13)3/h5-7,21-23H,1-4H3	CC1=CC(=C(C(=C1C(=O)OC2=C(C(=C(C(=C2)C)C(=O)OC)O)C)O)C=O)O	CC1=CC(=C(C(=C1C(=O)OC2=C(C(=C(C(=C2)C)C(=O)OC)O)C)O)C=O)O	YLOYKYXNDHOHHT-UHFFFAOYSA-N	(3-hydroxy-4-methoxycarbonyl-2,5-dimethylphenyl) 3-formyl-2,4-dihydroxy-6-methylbenzoate
ferrodrug0250	Bicyclol	.	bicyclol; 118159-48-1; Methyl 5'-(hydroxymethyl)-7,7'-dimethoxy-[4,4'-bibenzo[d][1,3]dioxole]-5-carboxylate; Bicyclol [WHO-DD]; SY801; 9734122TH2; 4,4'-Bi-1,3-benzodioxole)-5-carboxylic acid, 5'-(hydroxymethyl)-7,7'-dimethoxy-, methyl ester; 5'-(hydroxymethyl)-7,7'-dimethoxy-[4,4'-bi-1,3-benzodioxole]-5-carboxylic acid, methyl ester; UNII-9734122TH2; SY 801; methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate; CHEMBL482035; SCHEMBL9600725; Bicyclol, >=98% (HPLC); DTXSID30152026; BCP25554; HY-B0766; s6453; 6-methoxycarbonyl-6'-hydroxymethyl-2,3,2',3'-bis(methylenedioxy)-4,4'-dimethoxybiphenyl; NCGC00408803-01; 4,4'-bi-(1,3-benzodioxole)-5-carboxylic acid, 5'-(hydroxymethyl)-7,7'-dimethoxy-, methyl ester; AS-16866; F85022; J-003718; Q27271958	.	.	390.3	C19H18O9	102	558	2.1	28	1	9	6	InChI=1S/C19H18O9/c1-22-11-4-9(6-20)13(17-15(11)25-7-27-17)14-10(19(21)24-3)5-12(23-2)16-18(14)28-8-26-16/h4-5,20H,6-8H2,1-3H3	COC1=C2C(=C(C(=C1)CO)C3=C4C(=C(C=C3C(=O)OC)OC)OCO4)OCO2	COC1=C2C(=C(C(=C1)CO)C3=C4C(=C(C=C3C(=O)OC)OC)OCO4)OCO2	KXMTXZACPVCDMH-UHFFFAOYSA-N	methyl 4-[5-(hydroxymethyl)-7-methoxy-1,3-benzodioxol-4-yl]-7-methoxy-1,3-benzodioxole-5-carboxylate
ferrodrug0251	Echinatin	.	Echinatin; 34221-41-5; Retrochalcone; 4,4'-DIHYDROXY-2-METHOXYCHALCONE; 3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one; (E)-3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one; UNII-3816S4UA9R; CHEMBL141530; 3816S4UA9R; 2-Propen-1-one, 3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)-, (2E)-; (E)-3-(4-Hydroxy-2-methoxy-phenyl)-1-(4-hydroxy-phenyl)-propenone; Echinantin; SCHEMBL618086; 4'-Dihydroxy-2-methoxychalcone; 4',4-dihydroxy-2-methoxychalcone; DTXSID301019928; HY-N0269; BDBM50068267; LMPK12120431; MFCD00075719; s9437; AKOS016010242; CCG-267154; AC-34080; AS-77068; CS-0008288; A14853; A875066; Q27256724; (E)-3-(4-hydroxy-2-methoxy-phenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one	.	.	270.28	C16H14O4	66.8	344	3	20	2	4	4	InChI=1S/C16H14O4/c1-20-16-10-14(18)8-4-12(16)5-9-15(19)11-2-6-13(17)7-3-11/h2-10,17-18H,1H3/b9-5+	COC1=C(C=CC(=C1)O)/C=C/C(=O)C2=CC=C(C=C2)O	COC1=C(C=CC(=C1)O)C=CC(=O)C2=CC=C(C=C2)O	QJKMIJNRNRLQSS-WEVVVXLNSA-N	(E)-3-(4-hydroxy-2-methoxyphenyl)-1-(4-hydroxyphenyl)prop-2-en-1-one
ferrodrug0252	Pachymic acid	.	Pachymic acid; 29070-92-6; 3-O-Acetyltumulosic acid; UNII-X2FCK16QAH; X2FCK16QAH; CCRIS 7792; Lanost-8-en-21-oic acid, 3-(acetyloxy)-16-hydroxy-24-methylene-, (3beta,16alpha)-; CHEMBL468034; CHEBI:80885; NSC 244427; NSC-244427; Pachymic-acid; HY-N0371; BDBM50292363; MFCD00238657; (3b,16a)-3-(Acetyloxy)-16-hydroxy-24-methylenelanost-8-en-21-oic acid; AKOS030526129; CS-5368; AC-33955; BS-42182; C17044; A912692; Q-100369; EBURICA-8,24(28)-DIEN-21-OIC ACID, 3.BETA.,16.ALPHA.-DIHYDROXY-, 3-ACETATE; LANOST-8-EN-21-OIC ACID, 3.BETA.,16.ALPHA.-DIHYDROXY-24-METHYLENE-, 3-ACETATE; LANOST-8-EN-21-OIC ACID, 3-(ACETYLOXY)-16-HYDROXY-24-METHYLENE-, (3.BETA.,16.ALPHA.)-	.	.	528.8	C33H52O5	83.8	1020	7.2	38	2	5	8	InChI=1S/C33H52O5/c1-19(2)20(3)10-11-22(29(36)37)28-25(35)18-33(9)24-12-13-26-30(5,6)27(38-21(4)34)15-16-31(26,7)23(24)14-17-32(28,33)8/h19,22,25-28,35H,3,10-18H2,1-2,4-9H3,(H,36,37)/t22-,25-,26+,27+,28+,31-,32-,33+/m1/s1	CC(C)C(=C)CC[C@H]([C@H]1[C@@H](C[C@@]2([C@@]1(CCC3=C2CC[C@@H]4[C@@]3(CC[C@@H](C4(C)C)OC(=O)C)C)C)C)O)C(=O)O	CC(C)C(=C)CCC(C1C(CC2(C1(CCC3=C2CCC4C3(CCC(C4(C)C)OC(=O)C)C)C)C)O)C(=O)O	VDYCLYGKCGVBHN-DRCQUEPLSA-N	(2R)-2-[(3S,5R,10S,13R,14R,16R,17R)-3-acetyloxy-16-hydroxy-4,4,10,13,14-pentamethyl-2,3,5,6,7,11,12,15,16,17-decahydro-1H-cyclopenta[a]phenanthren-17-yl]-6-methyl-5-methylideneheptanoic acid
ferrodrug0253	Bisindolylmaleimide i	Small molecular drug	bisindolylmaleimide i; 133052-90-1; GF 109203X; GF109203X; GF-109203X; Go 6850; Go-6850; 3-(1-(3-(Dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-1H-pyrrole-2,5-dione; 3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione; Bisindolylmaleimide I (GF 109203X); 2-[1-(3-dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl)maleimide; CHEMBL7463; 3-{1-[3-(DIMETHYLAMINO)PROPYL]-1H-INDOL-3-YL}-4-(1H-INDOL-3-YL)-1H-PYRROLE-2,5-DIONE; L79H6N0V6C; 2-(1-(3-Dimethylaminopropyl)indol-3-yl)-3-(indol-3-yl)maleimide; 1H-Pyrrole-2,5-dione, 3-(1-(3-(dimethylamino)propyl)-1H-indol-3-yl)-4-(1H-indol-3-yl)-; Bisindolylmaleimide I (GF109203X); 3-{1-[3-(dimethylamino)propyl]-1H-indol-3-yl}-4-(1H-indol-3-yl)-2,5-dihydro-1H-pyrrole-2,5-dione; 3-[1-[3-(dimethylamino)propyl]-1h-indol-3-yl]-4-(1h-indol-3-yl)-1h-pyrrole-2,5-dione; BI1; UNII-L79H6N0V6C; 1zrz; 1H-Pyrrole-2,5-dione, 3-[1-[3-(dimethylamino)propyl]-1H-indol-3-yl]-4-(1H-indol-3-yl)-; bisin-dolylmaleimide; BisindolylmaleimideI; Bisindolylmaleimide 1; Gouml6850; Tocris-0741; 1uu8; BIM I; GF-109203; BiomolKI_000031; BiomolKI2_000039; BIM-1; SCHEMBL78990; BMK1-D7; BSPBio_001160; KBioGR_000500; KBioSS_000500; JMC526193 Compound 2; SCHEMBL338086; BDBM2683; GTPL5193; KBio2_000500; KBio2_003068; KBio2_005636; KBio3_000919; KBio3_000920; DTXSID50157932; Bio2_000420; Bio2_000900; HMS1362J21; HMS1792J21; HMS1990J21; HMS3229A21; HMS3266P07; HMS3403J21; HMS3411F13; HMS3653O17; HMS3675F13; BCP08311; EX-A1223; EI-246; HSCI1_000290; MFCD00236428; s7208; AKOS024458625; CCG-100635; CS-6154; DB03777; SB19439; IDI1_002175; NCGC00024760-01; NCGC00024760-02; NCGC00024760-03; NCGC00024760-04; NCGC00024760-07; AC-32872; AS-74139; HY-13867; B5781; FT-0623120; SW219715-1; EC-000.2373; A13197; C72321; GF 109203X, synthetic, >=90% (HPLC); A888223; Q866357; SR-01000597689; J-006293; SR-01000597689-1; BRD-K31342827-001-05-4; 2-[1-(3-dimethylaminopropyl)-indol-3-yl]-3-(indol-3-yl)maleimide; 2-[1-(3-Dimethylaminopropyl)indol-3-yl]-3-(indol-3-yl) maleimide; 2-(1H-Indol-3-yl)-3-[1-(3-dimethylaminopropyl)-1H-indol-3-yl]-maleinimide	D0TO6S	DMOQJZC	412.5	C25H24N4O2	70.1	748	3.1	31	2	3	6	InChI=1S/C25H24N4O2/c1-28(2)12-7-13-29-15-19(17-9-4-6-11-21(17)29)23-22(24(30)27-25(23)31)18-14-26-20-10-5-3-8-16(18)20/h3-6,8-11,14-15,26H,7,12-13H2,1-2H3,(H,27,30,31)	CN(C)CCCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54	CN(C)CCCN1C=C(C2=CC=CC=C21)C3=C(C(=O)NC3=O)C4=CNC5=CC=CC=C54	QMGUOJYZJKLOLH-UHFFFAOYSA-N	3-[1-[3-(dimethylamino)propyl]indol-3-yl]-4-(1H-indol-3-yl)pyrrole-2,5-dione
ferrodrug0254	Icariside II	Small molecular drug	Baohuoside I; 113558-15-9; Icariside II; Icarlin II; BAOHUOSIDEI; CHEBI:82619; 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one; CHEMBL560116; 3,5,7-Trihydroxy-4'-methoxyl-8-prenylflavone-3-O-rhamnopyranoside; Icariin-II;Icariside-II; Baohuoside-I; Icariside-II; Icariin-II; AMY496; SCHEMBL4229321; GTPL10686; DTXSID40150457; 2h44; EX-A6795; HY-N0011; BDBM50503751; AKOS037514560; CS-3673; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-; AC-33977; AS-75062; anhydroicaritin-3-O-alpha-L-rhamnopyranoside; Baohuoside I; Anhydroicaritin; Icariside II; A894345; Q-100071; Q27156136; 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone-3-O-rhamnopyranoside; 3,5,7-trihydroxy-4'-methoxy-8-prenylflavone-3-O-alpha-L-rhamnopyranoside; 3,5,7-Trihydroxy-4'-methoxyl-8-prenylflavone-3-O-rhamnopyranoside; 4H-1-Benzopyran-4-one, 3-((6-deoxy-alpha-L-mannopyranosyl)oxy)-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-butenyl)-; 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4H-chromen-3-yl 6-deoxy-alpha-L-mannopyranosideohuside I; Icariin II; Icariside II; 4H-1-Benzopyran-4-one, 3-[(6-deoxy-alpha-L-mannopyranosyl)oxy]-5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methyl-2-buten-1-yl)-; 5,7-Dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-3-(((2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-3-{[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}-4H-chromen-4-one; 5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-en-1-yl)-4-oxo-4H-chromen-3-yl 6-deoxy-alpha-L-mannopyranoside	D06TLQ	DM3DB8X	514.5	C27H30O10	155	874	3.5	37	5	10	6	InChI=1S/C27H30O10/c1-12(2)5-10-16-17(28)11-18(29)19-21(31)26(37-27-23(33)22(32)20(30)13(3)35-27)24(36-25(16)19)14-6-8-15(34-4)9-7-14/h5-9,11,13,20,22-23,27-30,32-33H,10H2,1-4H3/t13-,20-,22+,23+,27-/m0/s1	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O)O)O	CC1C(C(C(C(O1)OC2=C(OC3=C(C(=CC(=C3C2=O)O)O)CC=C(C)C)C4=CC=C(C=C4)OC)O)O)O	NGMYNFJANBHLKA-LVKFHIPRSA-N	5,7-dihydroxy-2-(4-methoxyphenyl)-8-(3-methylbut-2-enyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxychromen-4-one
ferrodrug0255	Butin	.	Butin; (-)-Butin; 492-14-8; 7,3',4'-Trihydroxyflavanone; CHEBI:27725; (2S)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrochromen-4-one; S23T8BI9DD; 4H-1-Benzopyran-4-one, 2-(3,4-dihydroxyphenyl)-2,3-dihydro-7-hydroxy-, (S)-; UNII-S23T8BI9DD; SCHEMBL68554; CHEMBL451168; DTXSID60197708; HY-N6020; BDBM50009647; LMPK12140075; AKOS026674267; MS-23850; FLAVANONE, 3',4',7-TRIHYDROXY-; (S)-7,3',4'-TRIHYDROXYFLAVANONE; CS-0032187; C09614; E80807; Q5002528; (2S)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydro-4H-chromen-4-one; (2S)-2-(3,4-DIHYDROXYPHENYL)-2,3-DIHYDRO-7-HYDROXY-4H-1-BENZOPYRAN-4-ONE; 4H-1-BENZOPYRAN-4-ONE, 2-(3,4-DIHYDROXYPHENYL)-2,3-DIHYDRO-7-HYDROXY-, (2S)-	.	.	272.25	C15H12O5	87	371	1.8	20	3	5	1	InChI=1S/C15H12O5/c16-9-2-3-10-12(18)7-14(20-15(10)6-9)8-1-4-11(17)13(19)5-8/h1-6,14,16-17,19H,7H2/t14-/m0/s1	C1[C@H](OC2=C(C1=O)C=CC(=C2)O)C3=CC(=C(C=C3)O)O	C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC(=C(C=C3)O)O	MJBPUQUGJNAPAZ-AWEZNQCLSA-N	(2S)-2-(3,4-dihydroxyphenyl)-7-hydroxy-2,3-dihydrochromen-4-one
ferrodrug0256	Nitidine chloride	Small molecular drug	Nitidine chloride; 13063-04-2; Nitidine (chloride); 2,3-Dimethoxy-12-methyl-[1,3]dioxolo[4',5':4,5]benzo[1,2-c]phenanthridin-12-ium chloride; Nitidine, chloride; NSC146397; NSC-146397; XO8WQL69T8; 13063-04-2 (CHLORIDE); (1,3)-BENZODIOXOLO(5,6-c)PHENANTHRIDINIUM, 2,3-DIMETHOXY-12-METHYL-, CHLORIDE; NSC 146397; 2,3-Dimethoxy-12-methyl-(1,3)-benzodioxolo(5,6-c)phenanthridinium chloride; Nitidinechloride; 2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride; angolinine; Nitidine-Chloride; UNII-XO8WQL69T8; CHEMBL8443; SCHEMBL420918; DTXSID50926842; HY-N0498; MFCD01659688; AKOS016003480; CCG-268448; 2,3-Dimethoxy-12-methyl-[1,3]dioxolo[4',5':4,5]-benzo[1,2-c]phenanthridin-12-ium chloride; AS-73875; CS-0009022; FT-0689357; A14701; A909300; Q-100120; Q-100770; WLN: T G6 D6 C665 EK SO UO THJ E1 IO1 JO1 &G; [1,6-c]phenanthridinium, 2,3-dimethoxy-12-methyl-, chloride; [1,3]Benzodioxolo[5,6-c]phenanthridinium, 2,3-dimethoxy-12-methyl-, chloride (1:1); 1,3)BENZODIOXOLO(5,6-C)PHENANTHRIDINIUM, 2,3-DIMETHOXY-12-METHYL-, CHLORIDE (1:1); 2,3-Dimethoxy-12-methyl-9H-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium chloride; 16,17-DIMETHOXY-21-METHYL-5,7-DIOXA-21-AZAPENTACYCLO[11.8.0.0(2),(1)?.0?,?.0(1)?,(1)?]HENICOSA-1(13),2(10),3,8,11,14(19),15,17,20-NONAEN-21-IUM CHLORIDE	.	DG50368	383.8	C21H18ClNO4	40.8	516	.	27	0	5	2	InChI=1S/C21H18NO4.ClH/c1-22-10-13-7-17(23-2)18(24-3)8-15(13)14-5-4-12-6-19-20(26-11-25-19)9-16(12)21(14)22;/h4-10H,11H2,1-3H3;1H/q+1;/p-1	C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.[Cl-]	C[N+]1=CC2=CC(=C(C=C2C3=C1C4=CC5=C(C=C4C=C3)OCO5)OC)OC.[Cl-]	QLDAACVSUMUMOR-UHFFFAOYSA-M	2,3-dimethoxy-12-methyl-[1,3]benzodioxolo[5,6-c]phenanthridin-12-ium;chloride
ferrodrug0257	Aristololactam	Small molecular drug	Aristololactam; Aristolactam I; 13395-02-3; Aristololactam I; Aristolactam; Aristololactum; NSC 87406; Aristololactam; Aristolactam; 3G8CFM4T9A; CHEMBL479127; NSC-87406; 8-Methoxybenzo[f]-1,3-benzodioxolo[6,5,4-cd]indol-5(6H)-one; Benzo(f)-1,3-benzodioxolo(6,5,4-cd)indol-5(6H)-one, 8-methoxy-; 14-methoxy-3,5-dioxa-10-azapentacyclo[9.7.1.02,6.08,19.013,18]nonadeca-1(18),2(6),7,11(19),12,14,16-heptaen-9-one; Benzo[f]-1,3-benzodioxolo[6,5,4-cd]indol-5(6H)-one, 8-methoxy-; CCRIS 1545; BRN 0307971; Aristolactam-I; UNII-3G8CFM4T9A; 4-27-00-06628 (Beilstein Handbook Reference); DTXSID60158430; HY-N2013; NSC87406; BDBM50306869; MFCD00797313; AKOS028111118; AC-34507; MS-24190; CS-0018333; FT-0697578; Q-100130; 8-methoxy-[1,3]dioxolo[4',5':4,5]benzo[1,2,3-cd]benzo[f]indol-5(6H)-one; 8-Methoxy-6H-benzo[f][1,3]dioxolo[4'',5'':4,5]benzo[1,2,3-cd]indol-5-one	.	DG50763	293.27	C17H11NO4	56.8	483	3.1	22	1	4	1	InChI=1S/C17H11NO4/c1-20-12-4-2-3-8-9(12)5-11-14-10(17(19)18-11)6-13-16(15(8)14)22-7-21-13/h2-6H,7H2,1H3,(H,18,19)	COC1=CC=CC2=C3C4=C(C=C21)NC(=O)C4=CC5=C3OCO5	COC1=CC=CC2=C3C4=C(C=C21)NC(=O)C4=CC5=C3OCO5	MXOKGWUJNGEKBH-UHFFFAOYSA-N	14-methoxy-3,5-dioxa-10-azapentacyclo[9.7.1.02,6.08,19.013,18]nonadeca-1(18),2(6),7,11(19),12,14,16-heptaen-9-one
ferrodrug0258	EX-527	Small molecular drug	49843-98-3; Selisistat; 6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; EX-527; EX 527; SEN0014196; SIRT1 Inhibitor III; Selisistat [INN]; EX527; EX 527 (Selisistat); Selisistat (EX 527); CHEMBL420311; CHEBI:90369; rac-6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; L19ECD5014; 1H-Carbazole-1-carboxamide, 6-chloro-2,3,4,9-tetrahydro-; UNII-L19ECD5014; SEN-0014196; EX-527(Selisistat); EX 527 (SEN0014196); Cambridge id 6859180; SELISISTAT [WHO-DD]; Oprea1_353257; Oprea1_367943; MLS006011757; GTPL8100; SCHEMBL1275557; EX-527 (SELISISTAT); DTXSID10964442; FUZYTVDVLBBXDL-UHFFFAOYSA-N; HMS3426E09; HMS3654P22; HMS3743I17; HMS3747M05; HMS3884K19; BCP02889; EX-A1064; BDBM50178769; MFCD03009471; s1541; STK522511; AKOS002364303; AB88646; AB89313; BCP9000673; CCG-208710; CS-0960; DB13978; SB16664; EX 527,SEN0014196; NCGC00242458-01; AC-32746; HY-15452; SMR004703473; BCP0726000108; EX-527, >=98% (HPLC); C2739; FT-0698480; SW218147-2; A21392; AB00121519-01; SR-01000501008; SR-01000501008-1; BRD-A73908300-001-04-2; Q27088776; (+/-)-6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide; 6-Chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxylic acid, amide	D0E3LP	DMLDBQ5	248.71	C13H13ClN2O	58.9	323	2.5	17	2	1	1	InChI=1S/C13H13ClN2O/c14-7-4-5-11-10(6-7)8-2-1-3-9(13(15)17)12(8)16-11/h4-6,9,16H,1-3H2,(H2,15,17)	C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N	C1CC(C2=C(C1)C3=C(N2)C=CC(=C3)Cl)C(=O)N	FUZYTVDVLBBXDL-UHFFFAOYSA-N	6-chloro-2,3,4,9-tetrahydro-1H-carbazole-1-carboxamide
ferrodrug0259	GW501516	Small molecular drug	317318-70-0; Endurobol; GW501516; GW 501516; GW-501516; Cardarine; GSK-516; GW1516; GW 1516; UNII-7I2HA1NU22; GW-1516; 2-(4-((2-(4-(Trifluoromethyl)phenyl)-4-methylthiazol-5-yl)methylthio)-2-methylphenoxy)acetic acid; 2-(2-Methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-5-yl)methyl)thio)phenoxy)acetic acid; 2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid; GW-516; CHEMBL38943; 7I2HA1NU22; {2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid; 2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetic acid; CHEBI:73726; GW501516(GSK-516); GW501,516; GW 501,516; GW-501,516; GSK 516; GW501516 (Endurobol); SCHEMBL68714; 2-[2-Methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]acetic Acid; MLS006010753; ENDUROBOL;GW501516; GTPL2687; DTXSID3041037; BDBM28661; EX-A723; HMS3674C03; HMS3744O09; BCP21491; MFCD09033000; PDSP1_000255; PDSP2_000254; s5615; AKOS015965103; CCG-269268; CS-0438; DB05416; EX-3881; SB19569; GW501516(G); NCGC00241455-01; NCGC00241455-02; NCGC00241455-08; AC-23001; HY-10838; SMR004701706; AM20040157; A26949; GW501516, >=98% (HPLC); 6T-0058; Benzenesulfonylchloride,4-(2-methylpropyl)-(9CI); J-018519; Q5515069; BRD-K14880289-001-01-4; (2-METHYL-4-(((4-METHYL-2-(4-(TRIFLUOROMETHYL)PHENYL)-1,3-THIAZOL-5-YL)METHYL)THIO)PHENOXY)ACETIC ACID; {2-Methyl-4-{{4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl}methylthio}phenoxy}acetic acid, analytical standard; {4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]-2-methylphenoxy}acetic acid; 2-(2-methyl-4-((5-methyl-2-(4-(trifluoromethyl)phenyl)thiazol-4-yl)methylthio)phenoxy)acetic acid;GW 501516; 2-{2-methyl-4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-yl}methyl)sulfanyl]phenoxy}acetic acid; 7T1; Acetic acid, (2-methyl-4-(((4-methyl-2-(4-(trifluoromethyl)phenyl)-5-thiazolyl)methyl)thio)phenoxy)-; Acetic acid, 2-[2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]-5-thiazolyl]methyl]thio]phenoxy]-	D05HDX	DMPL2KM	453.5	C21H18F3NO3S2	113	572	5.9	30	1	9	7	InChI=1S/C21H18F3NO3S2/c1-12-9-16(7-8-17(12)28-10-19(26)27)29-11-18-13(2)25-20(30-18)14-3-5-15(6-4-14)21(22,23)24/h3-9H,10-11H2,1-2H3,(H,26,27)	CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O	CC1=C(C=CC(=C1)SCC2=C(N=C(S2)C3=CC=C(C=C3)C(F)(F)F)C)OCC(=O)O	YDBLKRPLXZNVNB-UHFFFAOYSA-N	2-[2-methyl-4-[[4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl]methylsulfanyl]phenoxy]acetic acid
ferrodrug0260	Oridonin	.	Oridonin; 28957-04-2; Oridonine; ISODONOL; Rubescensin A; 0APJ98UCLQ; CHEMBL1164920; Kaur-16-en-15-one, 7,20-epoxy-1,6,7,14-tetrahydroxy-, (1alpha,6beta,7alpha,14R)-; Rubescensin; NSC-250682; PURE ORIDONIN; NSC-250682; Isodonol; UNII-0APJ98UCLQ; Rubescenin; NSC 250682; ORIDONIN [INCI]; Curator_000006; SCHEMBL19217133; CHEBI:138236; DTXSID201021760; HY-N0004; BDBM50605174; (14R)-7-alpha,20-Epoxy-1-alpha,6-beta,7,14-tetrahydroxykaur-16-en-15-one; AKOS025310967; CCG-208386; (1-alpha,6-beta,7-alpha,14R)-7,20-Epoxy-1,6,7,14-tetrahydroxykaur-16-en-15-one; AS-15421; CS-0007086; O0387; H10339; Q27236543; Z2037317501; 7?,20-Epoxy-1?,6?,7,14-tetrahydroxykaur-16-en-15-one; (1alpha,6beta,7alpha,14R)-7,20-epoxy-1,6,7,14-tetrahydroxykaur-16-en-15-one; KAUR-16-EN-15-ONE, 7-alpha,20-EPOXY-1-alpha,6-beta,7,14-TETRAHYDROXY-, (14R)-; (1; A,6; A,7; A,14R)-1,5,6,14-Tetrahydroxy-4,4-dimethyl-8-methylenedecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-7(8H)-one; (1alpha,5beta,6beta,7alpha,8alpha,9beta,10alpha,13alpha,14R)-1,6,7,14-tetrahydroxy-7,20-epoxykaur-16-en-15-one; KAUR-16-EN-15-ONE, 7,20-EPOXY-1,6,7,14-TETRAHYDROXY-, (1.ALPHA.,6.BETA.,7.ALPHA.,14R)-; KAUR-16-EN-15-ONE, 7.ALPHA.,20-EPOXY-1.ALPHA.,6.BETA.,7,14-TETRAHYDROXY-, (14R)-	.	.	364.4	C20H28O6	107	717	0.1	26	4	6	0	InChI=1S/C20H28O6/c1-9-10-4-5-11-18-8-26-20(25,19(11,14(9)22)15(10)23)16(24)13(18)17(2,3)7-6-12(18)21/h10-13,15-16,21,23-25H,1,4-8H2,2-3H3/t10-,11-,12-,13+,15+,16-,18+,19-,20+/m0/s1	CC1(CC[C@@H]([C@]23[C@@H]1[C@@H]([C@]([C@]45[C@H]2CC[C@H]([C@H]4O)C(=C)C5=O)(OC3)O)O)O)C	CC1(CCC(C23C1C(C(C45C2CCC(C4O)C(=C)C5=O)(OC3)O)O)O)C	SDHTXBWLVGWJFT-XKCURVIJSA-N	(1S,2S,5S,8R,9S,10S,11R,15S,18R)-9,10,15,18-tetrahydroxy-12,12-dimethyl-6-methylidene-17-oxapentacyclo[7.6.2.15,8.01,11.02,8]octadecan-7-one
ferrodrug0261	Diphenyleneiodonium	.	Diphenyleneiodonium; Dibenziodolium; 244-54-2; 2,2'-Biphenylyleneiodonium; dibenzo[b,d]iodolium; (1,1'-Biphenyl)-2,2'-diyliodonium; Dibenzo[b,d]iodol-5-ium; diphenyl-iodonium hydrochloride; Diphenylene iodonium; CHEBI:77986; 6HJ411TU98; 8-iodoniatricyclo[7.4.0.02,7]trideca-1(13),2,4,6,9,11-hexaene; CHEMBL397686; UNII-6HJ411TU98; Tocris-0504; 1010-76-0; Lopac-D-2926; Lopac0_000367; BSPBio_001027; KBioGR_000367; KBioSS_000367; SCHEMBL219548; CHEMBL365739; KBio2_000367; KBio2_002935; KBio2_005503; KBio3_000713; KBio3_000714; QFXKXRXFBRLLPQ-UHFFFAOYSA-; DTXSID00924595; Bio1_000428; Bio1_000917; Bio1_001406; Bio2_000344; Bio2_000824; HMS1362C09; HMS1792C09; HMS1990C09; HMS3403C09; BDBM50206334; CCG-204462; IDI1_002099; QTL1_000031; NCGC00015334-01; NCGC00015334-02; NCGC00015334-03; NCGC00015334-04; NCGC00015334-05; NCGC00015334-06; NCGC00015334-07; NCGC00015334-13; NCGC00024620-01; NCGC00024620-02; NCGC00024620-03; NCGC00024620-04; BRD-K65814004-001-02-3; BRD-K65814004-003-01-1; Q27147567; 5-METHYL-1-(2-METHYLPHENYL)-1H-PYRAZOLE-4-CARBONYLCHLORIDE; InChI=1/C12H8I/c1-3-7-11-9(5-1)10-6-2-4-8-12(10)13-11/h1-8H/q+1	.	.	279.1	C12H8I+	0	170	4.1	13	0	0	0	InChI=1S/C12H8I/c1-3-7-11-9(5-1)10-6-2-4-8-12(10)13-11/h1-8H/q+1	C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2	C1=CC=C2C(=C1)C3=CC=CC=C3[I+]2	QFXKXRXFBRLLPQ-UHFFFAOYSA-N	8-iodoniatricyclo[7.4.0.02,7]trideca-1(13),2,4,6,9,11-hexaene
ferrodrug0262	Liquiritin	.	Liquiritin; 551-15-5; Liquiritoside; Likviritin; 7-Hydroxyflavanone 4'-O-glucoside; CHEBI:80845; UNII-T0O79T74CD; T0O79T74CD; 4',7-Dihydroxyflavanone 4'-(beta-D-glucopyranoside); Liquiritigenin-4'-O-glucoside; Liquiritigenin-4'-beta-glucoside; DTXSID40203619; 4',7-Dihydroxyflavanone 4'-(beta-D-glucoside); liquiritigenin-4'-beta-D-glucoside; 4'-O-beta-D-glucopyranosyl-7-hydroxyflavan-4-one; 7-hydroxyflavanone 4'-O-beta-D-glucoside; liquiritigenin 4'-O-beta-D-glucopyranoside; (S)-2-(4-(beta-D-Glucopyranosyloxy)phenyl)-2,3-dihydro-7-hydroxy-4H-1-benzopyran-4-one; (2S)-7-hydroxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]chroman-4-one; Likviriton; 4H-1-Benzopyran-4-one, 2-(4-(beta-D-glucopyranosyloxy)phenyl)-2,3-dihydro-7-hydroxy-, (S)-; 4-((2S)-7-hydroxy-4-oxo-3,4-dihydro-2H-1-benzopyran-2-yl)phenyl beta-D-glucopyranoside; 4-[(2S)-7-hydroxy-4-oxo-3,4-dihydro-2H-1-benzopyran-2-yl]phenyl beta-D-glucopyranoside; MLS000575018; CHEMBL511995; DTXCID20126110; DEMKZLAVQYISIA-ZRWXNEIDSA-N; GLXC-13392; HMS2214B11; HY-N0376; BDBM50479044; MFCD00210526; s3930; AKOS015897117; CCG-268869; 4H-1-benzopyran-4-one, 2-(4-(beta-D-glucopyranosyloxy)phenyl)-2,3-dihydro-7-hydroxy-, (2S)-; AC-34230; AS-74201; SMR000232362; CS-0008920; L0269; C16989; LIQUIRITIGENIN 4'-beta-D-GLUCOPYRANOSIDE; A870271; LIQUIRITIGENIN 4'-.BETA.-D-GLUCOPYRANOSIDE; Q-100625; Q3242316; 4H-1-Benzopyran-4-one,2-[4-(b-D-glucopyranosyloxy)phenyl]-2,3-dihydro-7-hydroxy-, (2S)-; (2S)-7-hydroxy-2-(4-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)-3,4-dihydro-2H-1-benzopyran-4-one; (S)-7-hydroxy-2-(4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yloxy)phenyl)chroman-4-one; (S)-7-Hydroxy-2-[4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyl-tetrahydro-pyran-2-yloxy)-phenyl]-chroman-4-one; (S)-7-Hydroxy-2-[4-((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-hydroxymethyltetrahydropyran-2-yloxy)phenyl]chroman-4-one; 4H-1-BENZOPYRAN-4-ONE, 2-(4-(.BETA.-D-GLUCOPYRANOSYLOXY)PHENYL)-2,3-DIHYDRO-7-HYDROXY-, (2S)-; 4H-1-Benzopyran-4-one, 2-[4-(?-D-glucopyranosyloxy)phenyl]-2,3-dihydro-7-hydroxy-, (2S)-	.	.	418.4	C21H22O9	146	593	0.4	30	5	9	4	InChI=1S/C21H22O9/c22-9-17-18(25)19(26)20(27)21(30-17)28-12-4-1-10(2-5-12)15-8-14(24)13-6-3-11(23)7-16(13)29-15/h1-7,15,17-23,25-27H,8-9H2/t15-,17+,18+,19-,20+,21+/m0/s1	C1[C@H](OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O	C1C(OC2=C(C1=O)C=CC(=C2)O)C3=CC=C(C=C3)OC4C(C(C(C(O4)CO)O)O)O	DEMKZLAVQYISIA-ZRWXNEIDSA-N	(2S)-7-hydroxy-2-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]-2,3-dihydrochromen-4-one
ferrodrug0263	Atractylodin	.	Atractylodin; 55290-63-6; Atractydin; 2-[(1E,7E)-nona-1,7-dien-3,5-diynyl]furan; V73E8B6UAC; (E,E)-2-(1,7-Nonadiene-3,5-diynyl)furan; 2-(NONA-1,7-DIEN-3,5-DIYN-1-YL)FURAN; Furan, 2-(1,7-nonadiene-3,5-diynyl)-, (E,E)-; 2-((1E,7E)-Nona-1,7-dien-3,5-diyn-1-yl)furan-1-yl)furan; 97235-99-9; UNII-V73E8B6UAC; CHEBI:80795; GRBKWAXRYIITKG-QFMFQGICSA-N; DTXSID901019940; BCP28324; HY-N0238; MFCD01075143; AKOS006281381; CS-3672; AC-34063; AS-82932; A14776; C16918; Q-100629; Q27149839; 3,5-BIS(TRIFLUOROMETHYL)-4-CHLORO-NITROBENZENE; Furan, 2-[(1E,7E)-1,7-nonadiene-3,5-diyn-1-yl]-	.	.	182.22	C13H10O	13.1	348	3.5	14	0	1	2	InChI=1S/C13H10O/c1-2-3-4-5-6-7-8-10-13-11-9-12-14-13/h2-3,8-12H,1H3/b3-2+,10-8+	C/C=C/C#CC#C/C=C/C1=CC=CO1	CC=CC#CC#CC=CC1=CC=CO1	GRBKWAXRYIITKG-QFMFQGICSA-N	2-[(1E,7E)-nona-1,7-dien-3,5-diynyl]furan
ferrodrug0264	Platycodin D	.	Platycodin D; 58479-68-8; PlatycodinD; CWJ06TA2GI; CHEBI:70436; Platycodin-D; UNII-CWJ06TA2GI; C57H92O28; PLATYCODIN D [INCI]; CHEMBL1641859; SCHEMBL23500390; SINGLEEX PLATYCODIN D 98; DTXSID901021773; HMS3887G11; HY-N1411; MFCD09952590; s9304; AKOS037514784; CCG-270661; AC-34319; BS-14123; CS-0016836; C17410; Q-100670; Q15425261; Olean-12-en-28-oic acid, 3-(beta-D-glucopyranosyloxy)-2,16,23,24-tetrahydroxy-, O-D-apio-beta-D-furanosyl-(1-3)-O-beta-D-xylopyranosyl-(1-4)-O-6-deoxy-alpha-L-mannopyranosyl-(1-2)-L-arabinopyranosyl ester, (2beta,3beta,16alpha)-	.	.	1225.3	C57H92O28	453	2380	-3.7	85	17	28	15	InChI=1S/C57H92O28/c1-23-40(81-45-39(72)41(28(64)18-76-45)82-49-43(73)56(75,21-61)22-78-49)36(69)38(71)46(79-23)83-42-33(66)27(63)17-77-48(42)85-50(74)57-12-11-51(2,3)13-25(57)24-7-8-30-52(4)14-26(62)44(84-47-37(70)35(68)34(67)29(16-58)80-47)55(19-59,20-60)31(52)9-10-53(30,5)54(24,6)15-32(57)65/h7,23,25-49,58-73,75H,8-22H2,1-6H3/t23-,25-,26-,27-,28+,29+,30+,31+,32+,33-,34+,35-,36-,37+,38+,39+,40-,41-,42+,43-,44-,45-,46-,47-,48-,49-,52+,53+,54+,56+,57+/m0/s1	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@H](CO[C@H]2OC(=O)[C@]34CCC(C[C@H]3C5=CC[C@H]6[C@]([C@@]5(C[C@H]4O)C)(CC[C@@H]7[C@@]6(C[C@@H]([C@@H](C7(CO)CO)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O)C)C)(C)C)O)O)O)O)O[C@H]9[C@@H]([C@H]([C@@H](CO9)O)O[C@H]1[C@@H]([C@](CO1)(CO)O)O)O	CC1C(C(C(C(O1)OC2C(C(COC2OC(=O)C34CCC(CC3C5=CCC6C(C5(CC4O)C)(CCC7C6(CC(C(C7(CO)CO)OC8C(C(C(C(O8)CO)O)O)O)O)C)C)(C)C)O)O)O)O)OC9C(C(C(CO9)O)OC1C(C(CO1)(CO)O)O)O	CYBWUNOAQPMRBA-NDTOZIJESA-N	[(2S,3R,4S,5S)-3-[(2S,3R,4S,5R,6S)-5-[(2S,3R,4S,5R)-4-[(2S,3R,4R)-3,4-dihydroxy-4-(hydroxymethyl)oxolan-2-yl]oxy-3,5-dihydroxyoxan-2-yl]oxy-3,4-dihydroxy-6-methyloxan-2-yl]oxy-4,5-dihydroxyoxan-2-yl] (4aR,5R,6aR,6aS,6bR,8aR,10R,11S,12aR,14bS)-5,11-dihydroxy-9,9-bis(hydroxymethyl)-2,2,6a,6b,12a-pentamethyl-10-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylate
ferrodrug0265	Iridin	.	Iridin; 491-74-7; UNII-6NTS007OHQ; 6NTS007OHQ; CHEBI:5963; Spectrum_000619; SpecPlus_000143; Spectrum2_000198; Spectrum3_000192; DTXSID80197689; irigenin 7-O-beta-D-glucopyranoside; 5-hydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one; Irigenin 7-O-glucoside; Lridin; 4H-1-Benzopyran-4-one, 7-(beta-D-glucopyranosyloxy)-5-hydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-; 5-hydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-4-oxo-4H-1-benzopyran-7-yl beta-D-glucopyranoside; 5-HYDROXY-3-(3-HYDROXY-4,5-DIMETHOXYPHENYL)-6-METHOXY-7-((2S,3R,4S,5S,6R)-3,4,5-TRIHYDROXY-6-(HYDROXYMETHYL)OXAN-2-YL)OXYCHROMEN-4-ONE; Irisin; C24H26O13; Spectrum4_001510; Spectrum5_000279; BSPBio_001743; KBioGR_002179; KBioSS_001099; SPECTRUM200793; DivK1c_006239; SCHEMBL243567; SPBio_000155; CHEMBL487014; KBio1_001183; KBio2_001099; KBio2_003667; KBio2_006235; KBio3_001243; DTXCID90120180; HY-N3011; CCG-38404; MFCD28166495; SDCCGMLS-0066463.P001; NCGC00179041-01; AC-34954; MS-29677; CS-0022925; Q419014; SR-05000002736; SR-05000002736-1; BRD-K22550622-001-02-7; BRD-K22550622-001-03-5; 5-hydroxy-3-(3-hydroxy-4,5-dimethoxy-phenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-chromen-4-one; 5-hydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one; 5-hydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-7-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-4H-chromen-4-one	.	.	522.5	C24H26O13	194	823	0.8	37	6	13	7	InChI=1S/C24H26O13/c1-32-13-5-9(4-11(26)22(13)33-2)10-8-35-12-6-14(23(34-3)19(29)16(12)17(10)27)36-24-21(31)20(30)18(28)15(7-25)37-24/h4-6,8,15,18,20-21,24-26,28-31H,7H2,1-3H3/t15-,18-,20+,21-,24-/m1/s1	COC1=CC(=CC(=C1OC)O)C2=COC3=CC(=C(C(=C3C2=O)O)OC)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O	COC1=CC(=CC(=C1OC)O)C2=COC3=CC(=C(C(=C3C2=O)O)OC)OC4C(C(C(C(O4)CO)O)O)O	LNQCUTNLHUQZLR-OZJWLQQPSA-N	5-hydroxy-3-(3-hydroxy-4,5-dimethoxyphenyl)-6-methoxy-7-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxychromen-4-one
ferrodrug0266	Erianin	.	Erianin; 95041-90-0; 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol; 2-methoxy-5-(3,4,5-trimethoxyphenethyl)phenol; Phenol, 2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]-; CHEMBL10557; 2-Methoxy-5-[2-(3,4,5-trimethoxy-phenyl)-ethyl]-phenol; NSC613744; Dendrobium chrysotoxum; SCHEMBL1535646; DTXSID40326751; UXDFUVFNIAJEGM-UHFFFAOYSA-N; B817373-K388, same as; BCP07974; EX-A7098; HY-N0517; BDBM50005478; MFCD06795132; s9137; AKOS025401669; CCG-267683; NSC-613744; AC-24234; AS-78334; 3'-Hydroxy-3,4,4',5-tetramethoxybibenzyl; CS-0009056; FT-0686606; B817373-K346; 5-(3,4,5-trimethoxyphenethyl)-2-methoxyphenol; A851725; Q-100898; 7BA	.	.	318.4	C18H22O5	57.2	323	3.7	23	1	5	7	InChI=1S/C18H22O5/c1-20-15-8-7-12(9-14(15)19)5-6-13-10-16(21-2)18(23-4)17(11-13)22-3/h7-11,19H,5-6H2,1-4H3	COC1=C(C=C(C=C1)CCC2=CC(=C(C(=C2)OC)OC)OC)O	COC1=C(C=C(C=C1)CCC2=CC(=C(C(=C2)OC)OC)OC)O	UXDFUVFNIAJEGM-UHFFFAOYSA-N	2-methoxy-5-[2-(3,4,5-trimethoxyphenyl)ethyl]phenol
ferrodrug0267	Isorhynchophylline	.	Isorhynchophylline; 6859-01-4; Isorhyncophylline; 7-Isorhyncophylline; Isorhychophylline; 7F4P99KHLJ; CHEBI:70071; UNII-7F4P99KHLJ; methyl (E)-2-[(3S,6'R,7'S,8'aS)-6'-ethyl-2-oxospiro[1H-indole-3,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate; (16E,20-alpha)-16,17-Didehydro-17-methoxy-2-oxo-corynoxan-16-carboxylic acid; Corynoxan-16-carboxylic acid, 16,17-didehydro-17-methoxy-2-oxo-, methyl ester, (16E,20-alpha)-; Rel-methyl (E)-2-((3S,6'R,7'S,8a'S)-6'-ethyl-2-oxo-2',3',6',7',8',8a'-hexahydro-5'H-spiro[indoline-3,1'-indolizin]-7'-yl)-3-methoxyacrylate; 39032-62-7; IsoRhy; MLS000728608; CHEMBL480521; SCHEMBL23259272; HMS2267O23; HMS3886F22; HY-N0766; BDBM50531282; BP0799; s9310; AKOS025402306; AC-7996; CCG-268459; CS-3805; AS-75287; SMR000470794; C16980; Q-100013; ISORHYNCHOPHYLLINE (CONSTITUENT OF CAT'S CLAW); Q27138409; ISORHYNCHOPHYLLINE (CONSTITUENT OF CAT'S CLAW) [DSC]; CORYNOXAN-16-CARBOXYLIC ACID, 16,17-DIDEHYDRO-17-METHOXY-2-OXO-, METHYL ESTER, (16E,20.ALPHA.)-; CORYNOXAN-16-CARBOXYLIC ACID, 16,17-DIDEHYDRO-17-METHOXY-2-OXO-, METHYL ESTER, (16E,20alpha)-; methyl (2E)-2-[(3S,6'R,7'S,8'aS)-6'-ethyl-2-oxo-1,2,3',5',6',7',8',8'a-octahydro-2'H-spiro[indole-3,1'-indolizin]-7'-yl]-3-methoxyprop-2-enoate; SPIRO(3H-INDOLE-3,1'(5'H)-INDOLIZINE)-7'-ACETIC ACID, 6'-ETHYL-1,2,2',3',6',7',8',8'A-OCTAHYDRO-.ALPHA.-(METHOXYMETHYLENE)-2-OXO-, METHYL ESTER, (.ALPHA.E,1'S,6'R,7'S,8'AS)-; SPIRO(3H-INDOLE-3,1'(5'H)-INDOLIZINE)-7'-ACETIC ACID, 6'-ETHYL-1,2,2',3',6',7',8',8'A-OCTAHYDRO-alpha-(METHOXYMETHYLENE)-2-OXO-, METHYL ESTER, (alphaE,1'S,6'R,7'S,8'AS)-; Spiro[3H-indole-3,1'(5'H)-indolizine]-7'-acetic acid,6'-ethyl-1,2,2',3',6',7',8',8'a-octahydro-a-(methoxymethylene)-2-oxo-,methyl ester, (aE,1'S,6'R,7'S,8'aS)-	.	.	384.5	C22H28N2O4	67.9	663	2.3	28	1	5	5	InChI=1S/C22H28N2O4/c1-4-14-12-24-10-9-22(17-7-5-6-8-18(17)23-21(22)26)19(24)11-15(14)16(13-27-2)20(25)28-3/h5-8,13-15,19H,4,9-12H2,1-3H3,(H,23,26)/b16-13+/t14-,15-,19-,22-/m0/s1	CC[C@H]1CN2CC[C@@]3([C@@H]2C[C@@H]1/C(=C\OC)/C(=O)OC)C4=CC=CC=C4NC3=O	CCC1CN2CCC3(C2CC1C(=COC)C(=O)OC)C4=CC=CC=C4NC3=O	DAXYUDFNWXHGBE-VKCGGMIFSA-N	methyl (E)-2-[(3S,6'R,7'S,8'aS)-6'-ethyl-2-oxospiro[1H-indole-3,1'-3,5,6,7,8,8a-hexahydro-2H-indolizine]-7'-yl]-3-methoxyprop-2-enoate
ferrodrug0268	Robustaflavone	.	Robustaflavone; 49620-13-5; 3',6''-Biapigenin; CHEBI:8881; 6-(5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; 6-[5-(5,7-dihydroxy-4-oxo-4H-chromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-chromen-4-one; SCHEMBL561807; DTXSID30197937; BORWSEZUWHQTOK-UHFFFAOYSA-N; LMPK12040005; AKOS040747412; 6-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one; FT-0776777; Q27089374; 4H-1-Benzopyran-4-one, 6-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl); 4H-1-Benzopyran-4-one, 6-[5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl-; 6-(5-(5,7-dihydroxy-4-oxo-4H-1-benzopyran-2-yl)-2-hydroxyphenyl)-5,7-dihydroxy-2-(4-hydroxyphenyl)-4H-1-benzopyran-4-one; 6-[5-(5,7-Dihydroxy-4-oxo-chromen-2-yl)-2-hydroxy-phenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one	.	.	538.5	C30H18O10	174	1050	5	40	6	10	3	InChI=1S/C30H18O10/c31-15-4-1-13(2-5-15)23-11-22(37)29-26(39-23)12-20(35)27(30(29)38)17-7-14(3-6-18(17)33)24-10-21(36)28-19(34)8-16(32)9-25(28)40-24/h1-12,31-35,38H	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O)O	C1=CC(=CC=C1C2=CC(=O)C3=C(O2)C=C(C(=C3O)C4=C(C=CC(=C4)C5=CC(=O)C6=C(C=C(C=C6O5)O)O)O)O)O	BORWSEZUWHQTOK-UHFFFAOYSA-N	6-[5-(5,7-dihydroxy-4-oxochromen-2-yl)-2-hydroxyphenyl]-5,7-dihydroxy-2-(4-hydroxyphenyl)chromen-4-one
ferrodrug0269	Astragaloside IV	Small molecular drug	Astragaloside IV; 84687-43-4; Astragaloside A; Cyclosiversioside F; Astrasieversianin XIV; 1J6XA9YCFV; CHEBI:65457; 83207-58-3; (2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; AS-IV; (2R,3R,4S,5S,6R)-2-[[(1S,3R,8R,9S,11S,12S,14S,15R,16R)-14-Hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; AstragalosideIV; 3-O-beta-D-xylopyranosyl-6-O-beta-D-glucopyranosylcycloastragenol; C41H68O14; AST-IV; Astramembrannin I;Astragalin A; UNII-1J6XA9YCFV; beta-D-Glucopyranoside, (3beta,6alpha,16beta,20R,24S)-20,24-epoxy-16,25-dihydroxy-3-(beta-D-xylopyranosyloxy)-9,19-cyclolanostan-6-yl; Cyclosieversioside F; Astragaloside IV 95%; ASTRAVERSIANIN XIV; Astragaloside IV, >98.0%; CHEMBL3121562; SCHEMBL21888259; ASTRAGALOSIDE IV [USP-RS]; DTXSID801026063; HMS3885E12; HY-N0431; MFCD16036240; s3901; AKOS025311424; CCG-270470; AS-19402; C17799; Q27133900; ASTRAGALOSIDE IV (CONSTITUENT OF ASTRAGALUS) [DSC]; Astragaloside IV, European Pharmacopoeia (EP) Reference Standard; Astragaloside IV, United States Pharmacopeia (USP) Reference Standard; (2R,3R,4S,5S,6R)-2-(((2aR,3R,4S,5aS,5bS,7S,7aR,9S,11aR,12aS)-4-hydroxy-3-((2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyltetrahydrofuran-2-yl)-2a,5a,8,8-tetramethyl-9-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)tetradecahydro-1H,12H-cyclopenta[a]cyclopropa[e]phenanthren-7-yl)oxy)-6-(hydroxymethyl)tetrahydro-2H-pyran-3,4,5-triol; .BETA.-D-GLUCOPYRANOSIDE, (3.BETA.,6.ALPHA.,16.BETA.,20R,24S)-20,24-EPOXY-16,25-DIHYDROXY-3-(.BETA.-D-XYLOPYRANOSYLOXY)-9,19-CYCLOLANOSTAN-6-YL	.	DG01839	785	C41H68O14	228	1460	1.3	55	9	14	7	InChI=1S/C41H68O14/c1-35(2)24(54-33-29(48)26(45)20(44)17-51-33)9-11-41-18-40(41)13-12-37(5)31(39(7)10-8-25(55-39)36(3,4)50)19(43)15-38(37,6)23(40)14-21(32(35)41)52-34-30(49)28(47)27(46)22(16-42)53-34/h19-34,42-50H,8-18H2,1-7H3/t19-,20+,21-,22+,23-,24-,25-,26-,27+,28-,29+,30+,31-,32-,33-,34+,37+,38-,39+,40-,41+/m0/s1	C[C@]12CC[C@@]34C[C@@]35CC[C@@H](C([C@@H]5[C@H](C[C@H]4[C@@]1(C[C@@H]([C@@H]2[C@]6(CC[C@H](O6)C(C)(C)O)C)O)C)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)(C)C)O[C@H]8[C@@H]([C@H]([C@@H](CO8)O)O)O	CC1(C(CCC23C1C(CC4C2(C3)CCC5(C4(CC(C5C6(CCC(O6)C(C)(C)O)C)O)C)C)OC7C(C(C(C(O7)CO)O)O)O)OC8C(C(C(CO8)O)O)O)C	QMNWISYXSJWHRY-YLNUDOOFSA-N	(2R,3R,4S,5S,6R)-2-[[(1S,3R,6S,8R,9S,11S,12S,14S,15R,16R)-14-hydroxy-15-[(2R,5S)-5-(2-hydroxypropan-2-yl)-2-methyloxolan-2-yl]-7,7,12,16-tetramethyl-6-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy-9-pentacyclo[9.7.0.01,3.03,8.012,16]octadecanyl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
ferrodrug0270	Auriculasin	.	AURICULASIN; 60297-37-2; Cudraisoflavone A; 7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one; NSC285656; CHEMBL459129; DTXSID50418510; CHEBI:178564; HY-N2911; BDBM50442400; LMPK12050247; AKOS040761390; FS-8648; NSC 285656; NSC-285656; CS-0023510; 7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methyl-2-buten-1-yl)-2h,6h-pyrano[3,2-g]chromen-6-one; NCGC00384963-01!7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one	.	.	420.5	C25H24O6	96.2	792	5.5	31	3	6	3	InChI=1S/C25H24O6/c1-13(2)5-7-16-23-15(9-10-25(3,4)31-23)21(28)20-22(29)17(12-30-24(16)20)14-6-8-18(26)19(27)11-14/h5-6,8-12,26-28H,7H2,1-4H3	CC(=CCC1=C2C(=C(C3=C1OC=C(C3=O)C4=CC(=C(C=C4)O)O)O)C=CC(O2)(C)C)C	CC(=CCC1=C2C(=C(C3=C1OC=C(C3=O)C4=CC(=C(C=C4)O)O)O)C=CC(O2)(C)C)C	PSEBCAMYGWGJMH-UHFFFAOYSA-N	7-(3,4-dihydroxyphenyl)-5-hydroxy-2,2-dimethyl-10-(3-methylbut-2-enyl)pyrano[3,2-g]chromen-6-one
ferrodrug0271	Oxyfedrine	.	OXYFEDRINE; 15687-41-9; Oxifedrinum; Oxyfedrinum; Oxifedrina; Dl-Oxyphedrinum; Oxyfedrinum [INN-Latin]; Oxifedrina [INN-Spanish]; UNII-DWL616XF1K; (-)-oxyfedrine; DWL616XF1K; Oxyfedrine [INN:BAN:DCF]; Oxyfedrine (INN); 3-[[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-(3-methoxyphenyl)propan-1-one; OXYFEDRINE [INN]; DL-Oxyfedrin; DL-Oxyfedrine; NCGC00182060-02; OXYFEDRINE [MI]; OXYFEDRINE [WHO-DD]; SCHEMBL152553; CHEMBL1651913; DTXSID0023408; CHEBI:135343; AC-904; AKOS025402433; DL-3-((beta-Hydroxy-alpha-methylphenethyl)amino)-3'-methoxy-propiophenone; DB13398; Propiophenone, 3-((beta-hydroxy-alpha-methylphenethyl)amino)-3'-methoxy-, stereoisomer; 1-Propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, (R*,S*)-(+-)-; 1-Propanone, 3-((2-hydroxy-1-methyl-2-phenylethyl)amino)-1-(3-methoxyphenyl)-, (R-(R*,S*))-; HY-112070; CS-0043279; D08321; 3-(((alphaS,betaR)-beta-Hydroxy-alpha-methylphenethyl)amino)-3'-methoxypropiophenone; 3-[[(1S,2R)-2-Hydroxy-1-methyl-2-phenylethyl]amino]-1-(3-methoxyphenyl)-1-propanone;; 3-{[(1S,2R)-2-hydroxy-1-methyl-2-phenylethyl]amino}-1-[3-(methyloxy)phenyl]propan-1-one; 1-PROPANONE, 3-(((1S,2R)-2-HYDROXY-1-METHYL-2-PHENYLETHYL)AMINO)-1-(3-METHOXYPHENYL)-; 21071-51-2; 3-(((.ALPHA.S,.BETA.R)-.BETA.-HYDROXY-.ALPHA.-METHYLPHENETHYL)AMINO)-3'-METHOXYPROPIOPHENONE	.	.	313.4	C19H23NO3	58.6	355	2.4	23	2	4	8	InChI=1S/C19H23NO3/c1-14(19(22)15-7-4-3-5-8-15)20-12-11-18(21)16-9-6-10-17(13-16)23-2/h3-10,13-14,19-20,22H,11-12H2,1-2H3/t14-,19-/m0/s1	C[C@@H]([C@@H](C1=CC=CC=C1)O)NCCC(=O)C2=CC(=CC=C2)OC	CC(C(C1=CC=CC=C1)O)NCCC(=O)C2=CC(=CC=C2)OC	GDYUVHBMFVMBAF-LIRRHRJNSA-N	3-[[(1R,2S)-1-hydroxy-1-phenylpropan-2-yl]amino]-1-(3-methoxyphenyl)propan-1-one
ferrodrug0272	Punicic Acid	.	Punicic acid; Trichosanic acid; 544-72-9; Trichosanoic acid; (9Z,11E,13Z)-octadeca-9,11,13-trienoic acid; 9-cis,11-trans,13-cis-octadecatrienoic acid; cis-9,trans-11,cis-13-Octadecatrienoic acid; UNII-VFQ03H211O; VFQ03H211O; 9,11,13-Octadecatrienoic acid, (9Z,11E,13Z)-; 9,11,13-Octadecatrienoic acid, (Z,Z,E)-; cis,trans,cis-9,11,13-Octadecatrienoic acid; 9Z,11E,13Z-octadeca-9,11,13-trienoic acid; 9(Z),11(E),13(Z)-OCTADECATRIENOIC ACID; 9c,11t,13c-linolenic acid; CHEBI:8638; DTXSID10897463; Octadeca-9c,11t,13c-triensaeure; 9Z,11E,13Z-octadecatrienoic acid; octadeca-9c,11t,13c-trienoic acid; (9Z,11E,13Z)-octadecatrienoic acid; 9cis,11trans,13cis-octadecatrienoic acid; (Z,E,Z)-octadeca-9,11,13-trienoic acid; cis-9, trans-11, cis-13-octadecatrienoic acid; Punicinic acid; C18:3n-5,7,9; 9c,11t,13c-18:3; C18:3 n-5 cis, 7 trans, 9 cis; Fatty Acid 18:3 n-5; SCHEMBL158967; CHEMBL5205249; CUXYLFPMQMFGPL-BGDVVUGTSA-N; DTXCID801326803; LMFA01030146; PD088520; HY-139066; CS-0179308; C08364; Cis,trans,cis-octadeca-9,11,13-trienoic acid; Q201502	.	.	278.4	C18H30O2	37.3	301	6.4	20	1	2	13	InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h5-10H,2-4,11-17H2,1H3,(H,19,20)/b6-5-,8-7+,10-9-	CCCC/C=C\C=C\C=C/CCCCCCCC(=O)O	CCCCC=CC=CC=CCCCCCCCC(=O)O	CUXYLFPMQMFGPL-BGDVVUGTSA-N	(9Z,11E,13Z)-octadeca-9,11,13-trienoic acid
ferrodrug0273	Gossypol acetic acid	Small molecular drug	Gossypol acetic acid; 12542-36-8; gossypol-Acetic acid; Gossypol acetate; 866541-93-7; Acetate gossypol; AT101; Gossypol (acetic acid); 5453-04-3; (-)-Gossypol acetic acid; (S)-Gossypol (acetic acid); 1189561-66-7; (R)-Gossypol acetic acid; (R)-(-)-Gossypol acetic acid; (S)-Gossypol acetic acid; Gossypol acetate, (R)-; Gossypol acetic acid, R-; AT-101 (acetic acid); Gossypol acetic acid, (R)-; R-(-)-gossypol acetic acid; Gossypol acetic acid clathrate; GOSSYPOLACETATE; NSC 19048; U9GNI6VT5N; (+/-)-Gossypol acetic acid; MLS000028630; MLS002702979; NSC19048; acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; SMR000058743; 12542-36-8 (ACETIC ACID); NSC-19048; acetic acid compound with (S)-1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1:1); 115038-46-5; (+/-)-Gossypol-acetic acid;BL 193 (acetic acid); UNII-U9GNI6VT5N; Acetate-gossypol; GossypolAcOHSalt; Aceticacidgossypol; Gossypol xAcetate; AT101 acetate; AT 101 acetic acid; Opera_ID_1014; Gossypol acetic acid [MI]; SCHEMBL352576; (R)-Gossypol acetic acid salt; (S)-Gossypol acetic acid salt; CHEMBL1516388; Gossypol acetic acid [WHO-DD]; HMS500I15; DTXSID90921593; NIOHNDKHQHVLKA-UHFFFAOYSA-N; HMS3651H13; BCP09006; BCP24040; CCG-39212; HY-15464A; MFCD00058385; NSC727858; s2303; s2812; AKOS022188380; AT-101 (AT101); CS-3859; NSC-727858; NCGC00178279-01; AC-34098; AS-15487; HY-17510; FT-0686636; FT-0768953; G0543; SW197103-3; A13578; A14795; A16323; F85115; F85296; ()-Gossypol-acetic acid;BL 193 (acetic acid); ( inverted exclamation markA)-Gossypol-acetic acid; A900030; A920161; J-005228; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde acetate salt; 1,1',6,6',7,7'-Hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthalene-8,8'-dicarbaldehyde - acetic acid (1:1); 732279-26-4; Acetic acid compound with 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1:1); acetic acid compound with 1,1',6,6',7,7'-hexahydroxy-5,5'-diisopropyl-3,3'-dimethyl-2,2'-binaphthyl-8,8'-dicarbaldehyde (1:1); Acetic acid--1,1',6,6',7,7'-hexahydroxy-3,3'-dimethyl-5,5'-di(propan-2-yl)[2,2'-binaphthalene]-8,8'-dicarbaldehyde (1/1); aceticacid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde; AT 101 acetic acid; AT101 acetic acid;AT-101 acetic acid; (-)-Gossypol acetic acid; (R)-Gossypol acetic acid; Gossypol acetic acid	.	DG51210	578.6	C32H34O10	193	811	.	42	7	10	5	InChI=1S/C30H30O8.C2H4O2/c1-11(2)19-15-7-13(5)21(27(35)23(15)17(9-31)25(33)29(19)37)22-14(6)8-16-20(12(3)4)30(38)26(34)18(10-32)24(16)28(22)36;1-2(3)4/h7-12,33-38H,1-6H3;1H3,(H,3,4)	CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O.CC(=O)O	CC1=CC2=C(C(=C(C(=C2C(C)C)O)O)C=O)C(=C1C3=C(C4=C(C=C3C)C(=C(C(=C4C=O)O)O)C(C)C)O)O.CC(=O)O	NIOHNDKHQHVLKA-UHFFFAOYSA-N	acetic acid;7-(8-formyl-1,6,7-trihydroxy-3-methyl-5-propan-2-ylnaphthalen-2-yl)-2,3,8-trihydroxy-6-methyl-4-propan-2-ylnaphthalene-1-carbaldehyde
ferrodrug0274	GKT137831	Small molecular drug	1218942-37-0; GKT137831; Setanaxib; GKT-137831; 2-(2-Chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione; GKT-831; GKT831; 2-(2-Chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1H-pyrazolo(4,3-c)pyridine-3,6(2H,5H)-dione; 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione; 45II35329V; 2-(2-chlorophenyl)-4-(3-(dimethylamino)phenyl)-5-methyl-1,2-dihydro-3H-pyrazolo[4,3-c]pyridine-3,6(5H)-dione; 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H,2H,3H,5H,6H-pyrazolo[4,3-c]pyridine-3,6-dione; UNII-45II35329V; 1H-PYRAZOLO(4,3-C)PYRIDINE-3,6(2H,5H)-DIONE, 2-(2-CHLOROPHENYL)-4-(3-(DIMETHYLAMINO)PHENYL)-5-METHYL-; 1H-Pyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione, 2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-; GKT 137831; SETANAXIB [INN]; GTPL9932; SCHEMBL1302603; CHEMBL4303187; DTXSID30153432; EX-A577; BCP14159; MFCD27923122; s7171; AKOS022176138; CCG-268595; CS-3290; SB19230; NCGC00378460-05; NCGC00378460-08; NCGC00378460-09; AC-33132; AS-74753; HY-12298; FT-0700121; A14433; EN300-20043919; J-690070; Q27258840; 2-(2-Chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methylpyrazolo[4,3-c]pyridine-3,6(2H,5H)-dione	D04XVU	DMOVB3Y	394.9	C21H19ClN4O2	55.9	732	3.2	28	1	4	3	InChI=1S/C21H19ClN4O2/c1-24(2)14-8-6-7-13(11-14)20-19-16(12-18(27)25(20)3)23-26(21(19)28)17-10-5-4-9-15(17)22/h4-12,23H,1-3H3	CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl	CN1C(=O)C=C2C(=C1C3=CC(=CC=C3)N(C)C)C(=O)N(N2)C4=CC=CC=C4Cl	RGYQPQARIQKJKH-UHFFFAOYSA-N	2-(2-chlorophenyl)-4-[3-(dimethylamino)phenyl]-5-methyl-1H-pyrazolo[4,3-c]pyridine-3,6-dione
ferrodrug0275	Manoalide	Small molecular drug	manoalide; 75088-80-1; CHEMBL463914; CHEBI:66666; E1DK0157K9; (2R)-2-hydroxy-3-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one; UNII-E1DK0157K9; SCHEMBL20551728; DTXSID401028174; HY-N7487; BDBM50250399; AT25841; 2(5H)-Furanone, 4-((2R,6R)-3,6-dihydro-6-hydroxy-5-((3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-, (5R)-; 2(5H)-Furanone, 4-(3,6-dihydro-6-hydroxy-5-(4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexenyl)-2H-pyran-2-yl)-5-hydroxy-; CS-0129960; C17156; HMP Linker?4-(Hydroxymethyl) Phenoxyacetic Acid; A838321; Q10853851; (2R)-2-hydroxy-3-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexenyl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one; (2R)-3-[(2R,6R)-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-6-oxidanyl-3,6-dihydro-2H-pyran-2-yl]-2-oxidanyl-2H-furan-5-one; (5R)-5-HYDROXY-4-((2R,6R)-6-HYDROXY-5-((E)-4-METHYL-6-(2,6,6-TRIMETHYL-1-CYCLOHEXENYL)HEX-3-ENYL)-3,6-DIHYDRO-2H-PYRAN-2-YL)-5H-FURAN-2-ONE; (5R)-5-hydroxy-4-{(2R,6R)-6-hydroxy-5-[(3E)-4-methyl-6-(2,6,6-trimethylcyclohex-1-en-1-yl)hex-3-en-1-yl]-3,6-dihydro-2H-pyran-2-yl}furan-2(5H)-one; 2(5H)-Furanone, 4-[(2R,6R)-3,6-dihydro-6-hydroxy-5-[(3E)-4-methyl-6-(2,6,6-trimethyl-1-cyclohexen-1-yl)-3-hexen-1-yl]-2H-pyran-2-yl]-5-hydroxy-, (5R)-; 5-Hydroxy-4-{(R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethyl-cyclohex-1-enyl)-hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl}-5H-furan-2-one	D00XQO	DMB4A8I	416.5	C25H36O5	76	783	3.5	30	2	5	7	InChI=1S/C25H36O5/c1-16(10-12-20-17(2)8-6-14-25(20,3)4)7-5-9-18-11-13-21(29-23(18)27)19-15-22(26)30-24(19)28/h7,11,15,21,23-24,27-28H,5-6,8-10,12-14H2,1-4H3/b16-7+/t21-,23-,24-/m1/s1	CC1=C(C(CCC1)(C)C)CC/C(=C/CCC2=CC[C@@H](O[C@H]2O)C3=CC(=O)O[C@H]3O)/C	CC1=C(C(CCC1)(C)C)CCC(=CCCC2=CCC(OC2O)C3=CC(=O)OC3O)C	FGJIDQWRRLDGDB-CPIXEKRISA-N	(2R)-2-hydroxy-3-[(2R,6R)-6-hydroxy-5-[(E)-4-methyl-6-(2,6,6-trimethylcyclohexen-1-yl)hex-3-enyl]-3,6-dihydro-2H-pyran-2-yl]-2H-furan-5-one
ferrodrug0276	Cyperquat	Small molecular drug	Cyperquat; MPP+; 1-METHYL-4-PHENYLPYRIDINIUM; N-Methyl-4-phenylpyridine; 48134-75-4; N-Methyl-4-phenylpyridinium ion; 1-methyl-4-phenylpyridin-1-ium; N-Methyl-4-phenylpyridinium; Pyridinium, 1-methyl-4-phenyl-; CHEBI:641; R865A5OY8J; Pyridinium,1-methyl-4-phenyl-; Cyperquat [ANSI]; 1 Methyl 4 Phenylpyridinium; CCRIS 2187; 1-Methyl-4-phenylpyridinium Ion; CYPERQUAT ION; BRN 1618932; CYPERQUAT CATION; CYPERQUAT [ISO]; Cyperquat [ANSI:ISO]; UNII-R865A5OY8J; SCHEMBL37321; CHEMBL311617; GTPL4568; DTXSID4058106; BDBM81945; CAS_39484; NSC_39484; 5-20-07-00550 (Beilstein Handbook Reference); Q161645; WRF	.	DG01798	170.23	C12H12N+	3.9	141	2.7	13	0	0	1	InChI=1S/C12H12N/c1-13-9-7-12(8-10-13)11-5-3-2-4-6-11/h2-10H,1H3/q+1	C[N+]1=CC=C(C=C1)C2=CC=CC=C2	C[N+]1=CC=C(C=C1)C2=CC=CC=C2	FMGYKKMPNATWHP-UHFFFAOYSA-N	1-methyl-4-phenylpyridin-1-ium
ferrodrug0277	l-Buthionine sulfoximine	.	l-buthionine sulfoximine; 83730-53-4; L-Buthionine-(S,R)-sulfoximine; L-Buthionine-sulfoximine; (2S)-2-Amino-4-(butylsulfonimidoyl)butanoic acid; Butanoic acid, 2-amino-4-(S-butylsulfonimidoyl)-, (2S)-; Buthionine sulfoximine, L-; (2S)-2-Amino-4-(S-butylsulfonimidoyl)butanoic Acid; BUTHIONINE SULFOXIME; NSC 326231; EEY8DZS103; NSC-326231; L-BSO; BRN 2367136; l-buthionine(s,r)-sulfoximine; 2-amino-4-(S-butylsulfonimidoyl)butanoate; UNII-EEY8DZS103; L-Buthionine (SR)-sulfoximine; Buthionine-S,R-sulfoximine, L-; L-Buthionine-(S,R)-sulphoximine; MFCD00067000; L-Butionine sulfoximine; NCIMech_000342; BUTHIONINE-SULFOXIMINE; Lopac0_000221; SCHEMBL62034; CHEMBL261642; l-buthionine-(r,s)-sulfoximine; CHEBI:94288; DTXSID70894150; HMS3260N03; BSO; Tox21_500221; BDBM50487312; NSC801426; s9728; AKOS027320570; CS-W020947; HY-106376A; LP00221; NSC-801426; SDCCGSBI-0050209.P002; BSO (L-Buthionine-(S,R)-sulfoximine); NCGC00093690-01; NCGC00093690-02; NCGC00093690-03; NCGC00093690-11; NCGC00260906-01; AS-69850; L-Buthionine-sulfoximine, >=97% (TLC); EU-0100221; B 2515; A857917; L-Buthionine-sulfoximine (H-L-Hcy(O,NH,Bu)-OH); SR-01000075712; SR-01000075712-1; BRD-A47706533-001-01-8; Q27166100; (2S)-2-AMINO-4-[BUTYL(IMINO)OXO-??-SULFANYL]BUTANOIC ACID; Butanoic acid, 2-amino-4-((R)-S-butylsulfonimidoyl)-, (2S)-rel-	.	.	222.31	C8H18N2O3S	113	284	-0.6	14	3	5	7	InChI=1S/C8H18N2O3S/c1-2-3-5-14(10,13)6-4-7(9)8(11)12/h7,10H,2-6,9H2,1H3,(H,11,12)/t7-,14?/m0/s1	CCCCS(=N)(=O)CC[C@@H](C(=O)O)N	CCCCS(=N)(=O)CCC(C(=O)O)N	KJQFBVYMGADDTQ-CVSPRKDYSA-N	(2S)-2-amino-4-(butylsulfonimidoyl)butanoic acid
ferrodrug0278	ginkgolide-B	.	Ginkgolide B; ginkgolide-B; 15291-77-7; Ginkolide B; CHEMBL514432; BN 52021; BN-52021; SMR000544403; Gingkolide B; Ginkgolide B,(S); Ginkgolide B from Ginkgo biloba leaves; MLS001216216; MLS006011991; 18 - Potency of Gingko biloba; SCHEMBL12714280; Ginkgolide B, analytical standard; SQOJOAFXDQDRGF-MMQTXUMRSA-N; HMS2864N19; BDBM50251276; AKOS025311549; DB06744; G-170; Q-100180; Q27095719; Ginkgolide B from Ginkgo biloba leaves, >=90% (HPLC); ((1R,3R,6R,7S,8S,10R,11R,12R,13S,16S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0^{1,11}.0^{3,7}.0^{7,11}.0^{13,17}]nonadecane-5,15,18-trione.	.	.	424.4	C20H24O10	149	925	-0.4	30	3	10	1	InChI=1S/C20H24O10/c1-6-12(23)28-11-9(21)18-8-5-7(16(2,3)4)17(18)10(22)13(24)29-15(17)30-20(18,14(25)27-8)19(6,11)26/h6-11,15,21-22,26H,5H2,1-4H3/t6-,7+,8-,9+,10+,11+,15+,17+,18+,19-,20-/m1/s1	C[C@@H]1C(=O)O[C@@H]2[C@]1([C@@]34C(=O)O[C@H]5[C@]3([C@H]2O)[C@@]6([C@@H](C5)C(C)(C)C)[C@H](C(=O)O[C@H]6O4)O)O	CC1C(=O)OC2C1(C34C(=O)OC5C3(C2O)C6(C(C5)C(C)(C)C)C(C(=O)OC6O4)O)O	SQOJOAFXDQDRGF-MMQTXUMRSA-N	(1R,3R,6R,7S,8S,10R,11R,12R,13S,16S,17R)-8-tert-butyl-6,12,17-trihydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.01,11.03,7.07,11.013,17]nonadecane-5,15,18-trione
ferrodrug0279	Oxalate	Small molecular drug	oxalate; Oxalate Ion; ethanedioate; oxalate(2-); Oxalic acid, ion(2-); Ethanedioic acid, ion(2-); 338-70-5; PQ7QG47K6T; oxalate2-; oxalate dianion; 3mof; 2rk7; OXL; OXALATE ION(2-); UNII-PQ7QG47K6T; OXALATE (C2O42-); GTPL4538; BDBM92964; CHEBI:30623; OXALATE ION (C2O42-); MUBZPKHOEPUJKR-UHFFFAOYSA-L; DTXSID901047254; A808245; Q27088221	D01FAR	DM40SEU	88.02	C2O4-2	80.3	60.5	1	6	0	4	0	InChI=1S/C2H2O4/c3-1(4)2(5)6/h(H,3,4)(H,5,6)/p-2	C(=O)(C(=O)[O-])[O-]	C(=O)(C(=O)[O-])[O-]	MUBZPKHOEPUJKR-UHFFFAOYSA-L	oxalate
ferrodrug0280	moracin N	.	moracin N; CHEMBL465881; 5-[6-hydroxy-5-(3-methylbut-2-enyl)-1-benzofuran-2-yl]benzene-1,3-diol; 135248-05-4; 5-[6-hydroxy-5-(3-methylbut-2-en-1-yl)-1-benzofuran-2-yl]benzene-1,3-diol; SCHEMBL6822289; CHEBI:174237; WBSCSIABHGPAMC-UHFFFAOYSA-N; DTXSID501318704; BDBM50251014; HY-N11849; 1,3-benzenediol, 5-[6-hydroxy-5-(3-methyl-2-butenyl)-2-benzofuranyl]-; CS-0880943; 2-(3,5-Dihydroxyphenyl)-6-hydroxy-5-prenylbenzofuran; 5-[6-hydroxy-5-(3-methylbut-2-enyl)-1-benzouran-2-yl]benzene-1,3-diol; InChI=1/C19H18O4/c1-11(2)3-4-12-5-13-8-18(23-19(13)10-17(12)22)14-6-15(20)9-16(21)7-14/h3,5-10,20-22H,4H2,1-2H	.	.	310.3	C19H18O4	73.8	421	4.8	23	3	4	3	InChI=1S/C19H18O4/c1-11(2)3-4-12-5-13-8-18(23-19(13)10-17(12)22)14-6-15(20)9-16(21)7-14/h3,5-10,20-22H,4H2,1-2H3	CC(=CCC1=C(C=C2C(=C1)C=C(O2)C3=CC(=CC(=C3)O)O)O)C	CC(=CCC1=C(C=C2C(=C1)C=C(O2)C3=CC(=CC(=C3)O)O)O)C	WBSCSIABHGPAMC-UHFFFAOYSA-N	5-[6-hydroxy-5-(3-methylbut-2-enyl)-1-benzofuran-2-yl]benzene-1,3-diol
ferrodrug0281	Proanthocyanidin	.	Proanthocyanidin; Proanthocyanidin A; 18206-61-6; Ouratea proanthocyanidin A; (3R)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2R,3R,4R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]-3,4-dihydro-2H-chromene-3,5,7-triol; 274678-42-1; Zangrado; CCRIS 9188; SCHEMBL4747623; AKOS015967674; (4,8'-Bi-2H-1-benzopyran)-3,3',5,5',7,7'-hexol, 2'-(3,5-dihydroxy-4-methoxyphenyl)-3,3',4,4'-tetrahydro-2-(4-hydroxyphenyl)-, (2R-(2alpha,3alpha,4beta(2'R*,3'R*)))-; J-011651; (2R,3R,4R)-4-[(3R)-2-(3,5-dihydroxy-4-methoxyphenyl)-3,5,7-trihydroxychroman-8-yl]-2-(4-hydroxyphenyl)chroman-3,5,7-triol; 2-(3,5-Dihydroxy-4-methoxyphenyl)-8-[3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]-3,4-dihydro-2H-chromene-3,5,7-triol	.	.	592.5	C31H28O12	210	920	2.7	43	9	12	4	InChI=1S/C31H28O12/c1-41-31-20(37)6-13(7-21(31)38)28-22(39)10-16-17(34)11-19(36)25(30(16)43-28)26-24-18(35)8-15(33)9-23(24)42-29(27(26)40)12-2-4-14(32)5-3-12/h2-9,11,22,26-29,32-40H,10H2,1H3/t22-,26-,27-,28?,29-/m1/s1	COC1=C(C=C(C=C1O)C2[C@@H](CC3=C(O2)C(=C(C=C3O)O)[C@@H]4[C@H]([C@H](OC5=CC(=CC(=C45)O)O)C6=CC=C(C=C6)O)O)O)O	COC1=C(C=C(C=C1O)C2C(CC3=C(O2)C(=C(C=C3O)O)C4C(C(OC5=CC(=CC(=C45)O)O)C6=CC=C(C=C6)O)O)O)O	JPFCOVZKLAXXOE-XBNSMERZSA-N	(3R)-2-(3,5-dihydroxy-4-methoxyphenyl)-8-[(2R,3R,4R)-3,5,7-trihydroxy-2-(4-hydroxyphenyl)-3,4-dihydro-2H-chromen-4-yl]-3,4-dihydro-2H-chromene-3,5,7-triol
ferrodrug0282	Panaxydol	.	Panaxydol; (-)-Panaxydol; 114718-63-7; 8-(3-heptyloxiran-2-yl)oct-1-en-4,6-diyn-3-ol; 9,10-epoxy-heptadeca-1-en-4,6-diyn-3-ol; 9,10-epoxy-1-heptadecen-4,6-diyn-3-ol; SCHEMBL2266131; DTXSID10415267; GVLDSGIQZAFIAN-UHFFFAOYSA-N; LMFA05000028; 9,10-Epoxy-1-heptadecene-4,6-diyn-3-ol; 8-(3-Heptyloxiranyl)-1-Octene-4,6-diyn-3-ol; 8-(3-Heptyloxiranyl)-1-octene-4,6-diyn-3-ol, 9CI; (3R,9R,10S)-9,10-Epoxy-1-heptadecene-4,6-diyn-3-ol; (R)-8-((2R,3S)-3-Heptyloxiran-2-yl)octa-1-en-4,6-diyn-3-ol; 1-Octene-4,6-diyn-3-ol, 8-[(2R,3S)-3-heptyl-2-oxiranyl]-, (3R)-; 1-Octene-4,6-diyn-3-ol, 8-[(2R,3S)-3-heptyloxiranyl]-, (3R)-; 1-Octene-4,6-diyn-3-ol, 8-(3-heptyloxiranyl)-, [2R-[2.alpha.(R*),3.alpha.]]-	.	.	260.399	C17H24O2	32.8	398	4.5	19	1	2	9	InChI=1S/C17H24O2/c1-3-5-6-7-10-13-16-17(19-16)14-11-8-9-12-15(18)4-2/h4,15-18H,2-3,5-7,10,13-14H2,1H3	CCCCCCCC1C(O1)CC#CC#CC(C=C)O	CCCCCCCC1C(O1)CC#CC#CC(C=C)O	GVLDSGIQZAFIAN-UHFFFAOYSA-N	8-(3-heptyloxiran-2-yl)oct-1-en-4,6-diyn-3-ol
ferrodrug0283	Cephalosporin	Small molecular drug	CEPHALOSPORIN; CHEMBL1235646; Q27465008; (2R)-2-[(R)-{[(6R)-6-amino-6-carboxyhexanoyl]amino}(carboxy)methyl]-5-methylidene-5,6-dihydro-2H-1,3-thiazine-4-carboxylic acid; REC	D07JVS	DM79XDW	387.4	C15H21N3O7S	205	635	-3.1	26	5	10	10	InChI=1S/C15H21N3O7S/c1-7-6-26-12(18-10(7)14(22)23)11(15(24)25)17-9(19)5-3-2-4-8(16)13(20)21/h8,11-12H,1-6,16H2,(H,17,19)(H,20,21)(H,22,23)(H,24,25)/t8-,11+,12-/m1/s1	C=C1CS[C@@H](N=C1C(=O)O)[C@@H](C(=O)O)NC(=O)CCCC[C@H](C(=O)O)N	C=C1CSC(N=C1C(=O)O)C(C(=O)O)NC(=O)CCCCC(C(=O)O)N	JGKXEMYIHDYWCZ-JFUSQASVSA-N	(2R)-2-[(R)-[[(6R)-6-amino-6-carboxyhexanoyl]amino]-carboxymethyl]-5-methylidene-2H-1,3-thiazine-4-carboxylic acid
ferrodrug0284	Heteronemin	.	Heteronemin; 62008-04-2; CHEMBL514498; SCHEMBL2321982; BDBM50398322; CCG-257553; [(1S,4S,5aS,5bR,7aS,11aS,11bR,13R,13aS,13bR)-1-acetyloxy-13-hydroxy-5b,8,8,11a,13a-pentamethyl-1,4,5,5a,6,7,7a,9,10,11,11b,12,13,13b-tetradecahydrophenanthro[2,1-e][2]benzofuran-4-yl] acetate	.	.	488.7	C29H44O6	82.1	940	5.7	35	1	6	4	InChI=1S/C29H44O6/c1-16(30)34-19-13-22-28(6)12-9-20-26(3,4)10-8-11-27(20,5)21(28)14-23(32)29(22,7)24-18(19)15-33-25(24)35-17(2)31/h15,19-25,32H,8-14H2,1-7H3/t19-,20-,21+,22-,23+,24+,25-,27-,28+,29+/m0/s1	CC(=O)O[C@H]1C[C@H]2[C@@]3(CC[C@@H]4[C@@]([C@H]3C[C@H]([C@@]2([C@@H]5C1=CO[C@H]5OC(=O)C)C)O)(CCCC4(C)C)C)C	CC(=O)OC1CC2C3(CCC4C(CCCC4(C3CC(C2(C5C1=COC5OC(=O)C)C)O)C)(C)C)C	VYIQDOVNWPEWRJ-JVQIYTTCSA-N	[(1S,4S,5aS,5bR,7aS,11aS,11bR,13R,13aS,13bR)-1-acetyloxy-13-hydroxy-5b,8,8,11a,13a-pentamethyl-1,4,5,5a,6,7,7a,9,10,11,11b,12,13,13b-tetradecahydrophenanthro[2,1-e][2]benzofuran-4-yl] acetate
ferrodrug0285	Erastin	.	ERASTIN; 571203-78-6; 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4(3H)-Quinazolinone; 2-(1-(4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4(3H)-one; 2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one; 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)-1-piperazinyl)ethyl)-3-(2-ethoxyphenyl)-4(3H)-quinazolinone; 2-(1-(4-(2-(4-Chlorophenoxy)acetyl)piperazin-1-yl)ethyl)-3-(2-ethoxyphenyl)quinazolin-4-one; MFCD09837984; ZJA3NS42T9; CHEMBL401989; SCHEMBL4457820; Erastin, >=98% (HPLC); CHEBI:94287; DTXSID80458949; EX-A295; HMS3653K21; HMS3868M03; BCP27907; WXA20378; BDBM50376126; s7242; AKOS025147365; CCG-269987; CS-1675; Erastin - CAS 571203-78-6; SB19588; NCGC00351608-10; NCGC00351608-14; AC-35446; AS-55898; HY-15763; E7781; FT-0700333; SW208651-2; C21478; E-7781; A869751; BRD-A25004090-001-01-9; BRD-A25004090-001-02-7; BRD-A25004090-001-06-8; Q27166099; 2-[1-[4-[2-(4-chlorophenoxy)-1-oxoethyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-4-quinazolinone; 4(3H)-Quinazolinone, 2-[1-[4-[2-(4-chlorophenoxy)acetyl]-1-piperazinyl]ethyl]-3-(2-ethoxyphenyl)-; Piperazine, 1-((4-chlorophenoxy)acetyl)-4-(1-(3-(2-ethoxyphenyl)-3,4-dihydro-4-oxo-2-quinazolinyl)ethyl)-	.	.	547	C30H31ClN4O4	74.7	871	4.8	39	0	6	8	InChI=1S/C30H31ClN4O4/c1-3-38-27-11-7-6-10-26(27)35-29(32-25-9-5-4-8-24(25)30(35)37)21(2)33-16-18-34(19-17-33)28(36)20-39-23-14-12-22(31)13-15-23/h4-15,21H,3,16-20H2,1-2H3	CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl	CCOC1=CC=CC=C1N2C(=O)C3=CC=CC=C3N=C2C(C)N4CCN(CC4)C(=O)COC5=CC=C(C=C5)Cl	BKQFRNYHFIQEKN-UHFFFAOYSA-N	2-[1-[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]ethyl]-3-(2-ethoxyphenyl)quinazolin-4-one
ferrodrug0286	Isoliquiritin	.	Isoliquiritin; 5041-81-6; Isoliquiritoside; 7014-39-3; UNII-2Y348H1V4W; CHEBI:80839; 2Y348H1V4W; (E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one; 4-beta-D-glucopyranosyloxy-2',4'-dihydroxy-trans-chalcone; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-(4-(beta-D-glucopyranosyloxy)phenyl)-, (2E)-; 4-[(1E)-3-(2,4-dihydroxyphenyl)-3-oxoprop-1-en-1-yl]phenyl beta-D-glucopyranoside; 4-((1E)-3-(2,4-dihydroxyphenyl)-3-oxoprop-1-en-1-yl)phenyl beta-D-glucopyranoside; 2-PROPEN-1-ONE, 1-(2,4-DIHYDROXYPHENYL)-3-(4-(.BETA.-D-GLUCOPYRANOSYLOXY)PHENYL)-, (2E)-; 2-Propen-1-one, 1-(2,4-dihydroxyphenyl)-3-[4-(.beta.-D-glucopyranosyloxy)phenyl]-, (2E)-; SCHEMBL676338; CHEMBL599763; MEGxp0_001945; YNWXJFQOCHMPCK-LXGDFETPSA-N; DTXSID901317746; HY-N0765; BDBM50362885; LMPK12120021; MFCD00272145; s9293; AKOS015897131; CCG-268868; AC-34973; AS-56442; CS-0009792; I1144; C16978; A918375; Q-100563; Q27151336; (E)-1-(2,4-Dihydroxyphenyl)-3-(4-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)phenyl)prop-2-en-1-one; (E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxyphenyl]prop-2-en-1-one	.	.	418.4	C21H22O9	157	589	1.7	30	6	9	6	InChI=1S/C21H22O9/c22-10-17-18(26)19(27)20(28)21(30-17)29-13-5-1-11(2-6-13)3-8-15(24)14-7-4-12(23)9-16(14)25/h1-9,17-23,25-28H,10H2/b8-3+/t17-,18-,19+,20-,21-/m1/s1	C1=CC(=CC=C1/C=C/C(=O)C2=C(C=C(C=C2)O)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O	C1=CC(=CC=C1C=CC(=O)C2=C(C=C(C=C2)O)O)OC3C(C(C(C(O3)CO)O)O)O	YNWXJFQOCHMPCK-LXGDFETPSA-N	(E)-1-(2,4-dihydroxyphenyl)-3-[4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]prop-2-en-1-one
ferrodrug0287	Siramesine	Small molecular drug	Siramesine; 147817-50-3; Siramesine [INN]; 1'-(4-(1-(4-fluorophenyl)-1H-indol-3-yl)butyl)-3H-spiro[isobenzofuran-1,4'-piperidine]; Lu 28-179; Lu-28-179; 3IX8CWR24V; CHEMBL61479; 1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine]; UNII-3IX8CWR24V; Siramesine(Lu 28-179); SCHEMBL2090079; DTXSID90163810; EX-A355; XWAONOGAGZNUSF-UHFFFAOYSA-N; BCP08745; BDBM50035105; AKOS027251054; CS-1920; DB06555; Spiro[isobenzofuran-1(3H),4'-piperidine], 1'-[4-[1-(4-fluorophenyl)-1H-indol-3-yl]butyl]-; NCGC00370727-06; HY-14221; A13036; A857438; Q7529961; 1'-(4-(1-(p-Fluorophenyl)indol-3-yl)butyl)spiro(phthalan-1,4'-piperidine); Lu-28-179; Lu 28-179; Lu28-179; Lu-28179; Lu 28179; Lu28179; 1''-{4-[1-(4-fluorophenyl)-1H-3-indolyl]butyl}spiro[1,3-dihydroisobenzofuran-1,4''-(hexahydropyridine)]; 1''-{4-[1-(4-fluorophenyl)-1H-3-indolyl]butyl}spiro[1,3-dihydroisobenzofuran-1,4''-(hexahydropyridine)](Lu 28-179); 1'-[4-[1-(4-fluorophenyl)-1H-indole-3-yl]-1-butyl]-spiro[isobenzofuran-1(3H),4'-piperidine]	D0XK2K	DMB6T7K	454.6	C30H31FN2O	17.4	656	6	34	0	3	6	InChI=1S/C30H31FN2O/c31-25-12-14-26(15-13-25)33-21-23(27-9-2-4-11-29(27)33)7-5-6-18-32-19-16-30(17-20-32)28-10-3-1-8-24(28)22-34-30/h1-4,8-15,21H,5-7,16-20,22H2	C1CN(CCC12C3=CC=CC=C3CO2)CCCCC4=CN(C5=CC=CC=C54)C6=CC=C(C=C6)F	C1CN(CCC12C3=CC=CC=C3CO2)CCCCC4=CN(C5=CC=CC=C54)C6=CC=C(C=C6)F	XWAONOGAGZNUSF-UHFFFAOYSA-N	1'-[4-[1-(4-fluorophenyl)indol-3-yl]butyl]spiro[1H-2-benzofuran-3,4'-piperidine]
ferrodrug0288	Tubastatin A	.	Tubastatin A; 1252003-15-8; Tubastatin-A; Tubastatin A BASE; Tubastatin A (free base); 2XTSOX1NF8; N-hydroxy-4-((2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5(2H)-yl)methyl)benzamide; Tubastatin A(free base); UNII-2XTSOX1NF8; N-hydroxy-4-[(2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl)methyl]benzamide; Tubastatin A (trifluoroacetate); CHEMBL2018302; 1252003-15-8 (free base); Benzamide, N-hydroxy-4-((1,2,3,4-tetrahydro-2-methyl-5H-pyrido(4,3-b)indol-5-yl)methyl)-; N-Hydroxy-4-((1,2,3,4-tetrahydro-2-methyl-5H-pyrido(4,3-b)indol-5-yl)methyl)benzamide; Tubastatin A Trifluoroacetate; 4-[(2-methyl-3,4-dihydro-1~{H}-pyrido[4,3-b]indol-5-yl)methyl]-~{N}-oxidanyl-benzamide; TubaststinA HCl; N-Hydroxy-4-((2-methyl-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)methyl)benzamide; N-hydroxy-4-[(2-methyl-1,2,3,4-tetrahydro-5H-pyrido[4,3-b]indol-5-yl)methyl]benzamide; Benzamide, N-hydroxy-4-[(1,2,3,4-tetrahydro-2-methyl-5H-pyrido[4,3-b]indol-5-yl)methyl]-; N9W; MLS006011088; GTPL9702; SCHEMBL1057119; CHEBI:94186; EX-A685; GOVYBPLHWIEHEJ-UHFFFAOYSA-N; DTXSID701318079; HMS3656P20; HMS3744E15; BCP09011; CAC00315; BDBM50380399; HY-13271A; MFCD18071463; s8049; AKOS027422742; CCG-267860; CS-5376; SB19289; NCGC00263606-03; NCGC00263606-15; AS-16945; SMR004702876; FT-0700144; SW219287-2; EC-000.2473; US8748451, 6; J-690100; BRD-K00627859-001-01-5; Q27165946; 4-[(2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl)methyl]benzenecarbohydroxamic acid; N-hydroxy-4-(2-methyl-1,2,3,4-tetrahydro-pyrido[4,3-b]indol-5-ylmethyl)benzamide; 1-(4-{[2-(1H-Indazol-4-yl)-4-(4-morpholinyl)thieno[3,2-d]pyrimidin-6-yl]methyl}-1-piperazinyl)-6-methyl-5-heptene-1,4-dione	.	.	335.4	C20H21N3O2	57.5	478	2.3	25	2	3	3	InChI=1S/C20H21N3O2/c1-22-11-10-19-17(13-22)16-4-2-3-5-18(16)23(19)12-14-6-8-15(9-7-14)20(24)21-25/h2-9,25H,10-13H2,1H3,(H,21,24)	CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO	CN1CCC2=C(C1)C3=CC=CC=C3N2CC4=CC=C(C=C4)C(=O)NO	GOVYBPLHWIEHEJ-UHFFFAOYSA-N	N-hydroxy-4-[(2-methyl-3,4-dihydro-1H-pyrido[4,3-b]indol-5-yl)methyl]benzamide
ferrodrug0289	Forsythoside A	Small molecular drug	Forsythoside A; Forsythiaside; 79916-77-1; Forsythiaside A; CHEMBL504363; OUH5BQ893P; CHEBI:5160; MEGxp0_001187; NSC-729638; [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; (E)-(2R,3S,4R,5R,6R)-6-(3,4-Dihydroxyphenethoxy)-4,5-dihydroxy-2-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl 3-(3,4-dihydroxyphenyl)acrylate; AC1NQZ1W; UNII-OUH5BQ893P; Forsythoside-A; SureCN3318896; SCHEMBL3318896; ACon1_001402; DTXSID801317212; HY-N0028; BDBM50269517; MFCD08460220; NSC729638; s9317; AKOS015897128; CCG-270267; NSC 729638; NCGC00180544-01; [(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyl-tetrahydropyran-2-yl]oxymethyl]tetrahydropyran-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate; beta-D-Glucopyranoside, 2-(3,4-dihydroxyphenyl)ethyl 6-O-(6-deoxy-alpha-L-mannopyranosyl)-, 4-(3-(3,4-dihydroxyphenyl)-2-propenoate), (E)-; CS-0007097; A854587; Q-100834; BRD-K62073009-001-01-6; Q27106670; (2R,3S,4R,5R,6R)-6-(3,4-dihydroxyphenethoxy)-4,5-dihydroxy-2-((((2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-3-yl (E)-3-(3,4-dihydroxyphenyl)acrylate; .BETA.-D-GLUCOPYRANOSIDE, 2-(3,4-DIHYDROXYPHENYL)ETHYL 6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-, 4-((2E)-3-(3,4-DIHYDROXYPHENYL)-2-PROPENOATE); .BETA.-D-GLUCOPYRANOSIDE, 2-(3,4-DIHYDROXYPHENYL)ETHYL 6-O-(6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL)-, 4-(3-(3,4-DIHYDROXYPHENYL)-2-PROPENOATE), (E)-	D0P4JO	DMPC568	624.6	C29H36O15	245	936	-0.5	44	9	15	11	InChI=1S/C29H36O15/c1-13-22(35)23(36)25(38)29(42-13)41-12-20-27(44-21(34)7-4-14-2-5-16(30)18(32)10-14)24(37)26(39)28(43-20)40-9-8-15-3-6-17(31)19(33)11-15/h2-7,10-11,13,20,22-33,35-39H,8-9,12H2,1H3/b7-4+/t13-,20+,22-,23+,24+,25+,26+,27+,28+,29+/m0/s1	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OCCC3=CC(=C(C=C3)O)O)O)O)OC(=O)/C=C/C4=CC(=C(C=C4)O)O)O)O)O	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OCCC3=CC(=C(C=C3)O)O)O)O)OC(=O)C=CC4=CC(=C(C=C4)O)O)O)O)O	DTOUWTJYUCZJQD-UJERWXFOSA-N	[(2R,3S,4R,5R,6R)-6-[2-(3,4-dihydroxyphenyl)ethoxy]-4,5-dihydroxy-2-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-3-yl] (E)-3-(3,4-dihydroxyphenyl)prop-2-enoate
ferrodrug0290	Bavachin	.	Bavachin; 19879-32-4; Corylifolin; (S)-7-Hydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-en-1-yl)chroman-4-one; 4H-1-Benzopyran-4-one, 2,3-dihydro-7-hydroxy-2-(4-hydroxyphenyl)-6-(3-methyl-2-butenyl)-, (2S)-; CORYFOLIN; CHEMBL469444; SCHEMBL4223610; HY-N0233; MFCD11617359; NSC808860; s5469; AKOS032962062; CCG-267746; CS-6113; NSC-808860; AC-34020; AS-75959; A879959; 7-Hydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-en-1-yl)chroman-4-one	.	.	324.4	C20H20O4	66.8	474	4.1	24	2	4	3	InChI=1S/C20H20O4/c1-12(2)3-4-14-9-16-18(23)11-19(24-20(16)10-17(14)22)13-5-7-15(21)8-6-13/h3,5-10,19,21-22H,4,11H2,1-2H3/t19-/m0/s1	CC(=CCC1=CC2=C(C=C1O)O[C@@H](CC2=O)C3=CC=C(C=C3)O)C	CC(=CCC1=CC2=C(C=C1O)OC(CC2=O)C3=CC=C(C=C3)O)C	OAUREGNZECGNQS-IBGZPJMESA-N	(2S)-7-hydroxy-2-(4-hydroxyphenyl)-6-(3-methylbut-2-enyl)-2,3-dihydrochromen-4-one
ferrodrug0291	Schisandrin B	.	Schisandrin B; Schizandrin B; 61281-37-6; gamma-Schisandrin; CHEMBL479488; Schizandrin-B;Wuweizisu-B;gamma-Schisandrin; 3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaene; S(-) Schisandrin B; Schizandrin-B; 1,2,3,13-tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydrobenzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxole; ; A-Schisandrin; S(-) Wuweizisu B; Gamma-Schisandrin ,(S); SCHEMBL3380716; DTXSID60976772; GLXC-19128; HMS3652I13; BCP30085; HY-N0089; BDBM50341711; AKOS015897166; CCG-208607; CS-3659; NCGC00163663-01; FT-0775855; Schisandrin B; Wuweizisu-B; gamma-Schisandrin; SR-05000002175; Q-100707; SR-05000002175-2; (5S,6S,7S,13aS)-5,6,7,8-Tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethylbenzo[3,4]cycloocta[1,2-f][1,3] benzodioxole-5,6-diol 5-Benzoate; 1,2,3,13-Tetramethoxy-6,7-dimethyl-5,6,7,8-tetrahydro-11H-benzo[3',4']cycloocta[1',2':4,5]benzo[1,2-d][1,3]dioxole; Benzo[3,4]cycloocta[1,2-f][1,3]benzodioxole,5,6,7,8-tetrahydro-1,2,3,13-tetramethoxy-6,7-dimethyl-, stereoisomer	.	.	400.5	C23H28O6	55.4	544	5.1	29	0	6	4	InChI=1S/C23H28O6/c1-12-7-14-9-16(24-3)20(25-4)22(26-5)18(14)19-15(8-13(12)2)10-17-21(23(19)27-6)29-11-28-17/h9-10,12-13H,7-8,11H2,1-6H3	CC1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4CC1C)OC)OC)OC)OC)OCO3	CC1CC2=CC3=C(C(=C2C4=C(C(=C(C=C4CC1C)OC)OC)OC)OC)OCO3	RTZKSTLPRTWFEV-UHFFFAOYSA-N	3,4,5,19-tetramethoxy-9,10-dimethyl-15,17-dioxatetracyclo[10.7.0.02,7.014,18]nonadeca-1(19),2,4,6,12,14(18)-hexaene
ferrodrug0292	Apatinib	.	Apatinib; 811803-05-1; rivoceranib; Apatinib free base; N-(4-(1-Cyanocyclopentyl)phenyl)-2-((pyridin-4-ylmethyl)amino)nicotinamide; YN968D1; N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide; 5S371K6132; N-(4-(1-cyanocyclopentyl)phenyl)-2-(pyridin-4-ylmethylamino)nicotinamide; 3-Pyridinecarboxamide, N-(4-(1-cyanocyclopentyl)phenyl)-2-((4-pyridinylmethyl)amino)-; UNII-5S371K6132; apatinib (in China); RIVOCERANIB [INN]; Rivoceranib (USAN/INN); RIVOCERANIB [USAN]; RIVOCERANIB [WHO-DD]; GTPL7648; SCHEMBL1814966; CHEMBL3186534; Apatinib free base; YN-968D1; DTXSID601024366; AMY21302; BCP02840; EX-A1794; HY-13342A; MFCD21648511; NSC772886; NSC799333; s5248; AKOS024464453; CCG-268625; DB14765; DS-7455; NSC-772886; NSC-799333; SB16590; N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]-3-pyridinecarboxamide; NCGC00249393-01; NCGC00249393-08; AC-27461; BA175030; CS-0003200; C76598; D11288; AB01274807-01; AB01274807_02; Q27262801; N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(4-pyridinylmethyl)amino]nicotinamide; N-[4-(1-Cyanocyclopentyl)phenyl]-2-[(pyridin-4-ylmethyl)amino]pyridine-3-carboxamide	.	.	397.5	C24H23N5O	90.7	608	4.1	30	2	5	6	InChI=1S/C24H23N5O/c25-17-24(11-1-2-12-24)19-5-7-20(8-6-19)29-23(30)21-4-3-13-27-22(21)28-16-18-9-14-26-15-10-18/h3-10,13-15H,1-2,11-12,16H2,(H,27,28)(H,29,30)	C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4	C1CCC(C1)(C#N)C2=CC=C(C=C2)NC(=O)C3=C(N=CC=C3)NCC4=CC=NC=C4	WPEWQEMJFLWMLV-UHFFFAOYSA-N	N-[4-(1-cyanocyclopentyl)phenyl]-2-(pyridin-4-ylmethylamino)pyridine-3-carboxamide
ferrodrug0293	Quisinostat	.	QUISINOSTAT; 875320-29-9; JNJ-26481585; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; JNJ26481585; JNJ 26481585; N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide; 9BJ85K1J8S; Quisinostat (JNJ-26481585); 5-Pyrimidinecarboxamide, N-hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)-1-piperidinyl)-; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)-methyl)piperidin-1-yl)pyrimidine-5-carboxamide; 2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]-~{N}-oxidanyl-pyrimidine-5-carboxamide; Quisinostat [USAN]; Quisinostat [USAN:INN]; UNII-9BJ85K1J8S; GOK; N-Hydroxy-2-[4-({[(1-methyl-1H-indol-3-yl)methyl]amino}methyl)piperidin-1-yl]pyrimidine-5-carboxamide; QUISINOSTAT [INN]; Quisinostat (USAN/INN); QUISINOSTAT [WHO-DD]; MLS006011096; GTPL7503; SCHEMBL2360460; CHEMBL2105763; CHEBI:94771; DTXSID90236376; JNJ 26481585 dihydrochloride; HMS3654M19; HMS3747E21; BCP01811; BDBM50105327; MFCD17010272; NSC759657; AKOS016004011; BCP9000803; CS-5065; DB12985; NSC-759657; SB16528; NCGC00346487-01; NCGC00346487-04; AC-27415; AS-16361; HY-15433; N-Hydroxy-2-(4-((((1-methyl-1H-indol-3-yl)methyl)amino)methyl)piperidin-1-yl)pyrimidine-5-carboxamid; N-hydroxy-2-(4-(((1-methyl-1H-indol-3-yl)methylamino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide; SMR004702884; FT-0700499; SW219796-1; EC-000.2337; D10321; A862539; Q7272620; BRD-K83837640-001-01-4; N-hydroxy-2-(4-(((1-methyl-1H-indol-3-yl)methylamino)methyl)piperidin-1-yl)pyrimidine-5-carboxamide dihydrochloride; N-Hydroxy-2-[4-[[[(1-methyl-1H-indol-3-yl)methyl]amino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide	.	.	394.5	C21H26N6O2	95.3	533	1.3	29	3	6	6	InChI=1S/C21H26N6O2/c1-26-14-17(18-4-2-3-5-19(18)26)11-22-10-15-6-8-27(9-7-15)21-23-12-16(13-24-21)20(28)25-29/h2-5,12-15,22,29H,6-11H2,1H3,(H,25,28)	CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO	CN1C=C(C2=CC=CC=C21)CNCC3CCN(CC3)C4=NC=C(C=N4)C(=O)NO	PAWIYAYFNXQGAP-UHFFFAOYSA-N	N-hydroxy-2-[4-[[(1-methylindol-3-yl)methylamino]methyl]piperidin-1-yl]pyrimidine-5-carboxamide
ferrodrug0294	Ginsenoside Rh4	.	Ginsenoside Rh4; 174721-08-5; Ginsenoside Rh(4); (2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2E)-6-methylhepta-2,5-dien-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol; CHEMBL504029; CHEBI:176255; DTXSID001317113; HY-N0905; MFCD22125012; AKOS030526659; CS-3843; FS-7833; NCGC00485965-01; AC-34672	.	.	620.9	C36H60O8	140	1120	5.6	44	6	8	6	InChI=1S/C36H60O8/c1-19(2)10-9-11-20(3)21-12-15-35(7)27(21)22(38)16-25-34(6)14-13-26(39)33(4,5)31(34)23(17-36(25,35)8)43-32-30(42)29(41)28(40)24(18-37)44-32/h10-11,21-32,37-42H,9,12-18H2,1-8H3/b20-11+/t21-,22-,23+,24-,25-,26+,27+,28-,29+,30-,31+,32-,34-,35-,36-/m1/s1	CC(=CC/C=C(\C)/[C@H]1CC[C@@]2([C@@H]1[C@@H](C[C@H]3[C@]2(C[C@@H]([C@@H]4[C@@]3(CC[C@@H](C4(C)C)O)C)O[C@H]5[C@@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)C)O)C)C	CC(=CCC=C(C)C1CCC2(C1C(CC3C2(CC(C4C3(CCC(C4(C)C)O)C)OC5C(C(C(C(O5)CO)O)O)O)C)O)C)C	OZTXYFOXQFKYRP-TXRYYSRHSA-N	(2R,3R,4S,5S,6R)-2-[[(3S,5R,6S,8R,9R,10R,12R,13R,14R,17S)-3,12-dihydroxy-4,4,8,10,14-pentamethyl-17-[(2E)-6-methylhepta-2,5-dien-2-yl]-2,3,5,6,7,9,11,12,13,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-6-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol
ferrodrug0295	Artepillin C	Small molecular drug	Artepillin C; 72944-19-5; artepillin; (E)-3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-enoic acid; ArtepillinC; CCRIS 8746; CHEMBL456309; GTPL6302; SCHEMBL1229229; DTXSID201317933; 3-(4-Hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-2-propenoic acid; BDBM50362836; HY-N10319; NSC718732; AT37734; FS-6839; NSC-718732; CS-0379815; Q27074514; (2E)-3-[4-HYDROXY-3,5-BIS(3-METHYLBUT-2-EN-1-YL)PHENYL]PROP-2-ENOIC ACID; 2-Propenoic acid, 3-(4-hydroxy-3,5-bis(3-methyl-2-butenyl)phenyl)-, (E)-	D0U4VL	DMWCDM8	300.4	C19H24O3	57.5	421	5.4	22	2	3	6	InChI=1S/C19H24O3/c1-13(2)5-8-16-11-15(7-10-18(20)21)12-17(19(16)22)9-6-14(3)4/h5-7,10-12,22H,8-9H2,1-4H3,(H,20,21)/b10-7+	CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)/C=C/C(=O)O)C	CC(=CCC1=CC(=CC(=C1O)CC=C(C)C)C=CC(=O)O)C	KABCFARPAMSXCC-JXMROGBWSA-N	(E)-3-[4-hydroxy-3,5-bis(3-methylbut-2-enyl)phenyl]prop-2-enoic acid
ferrodrug0296	Ferrostatin-1	.	Ferrostatin-1; 347174-05-4; Ethyl 3-amino-4-(cyclohexylamino)benzoate; Ferrostatin-1 (Fer-1); Ferrostatin 1; Fer-1; Benzoic acid, 3-amino-4-(cyclohexylamino)-, ethyl ester; 3-amino-4-cyclohexylaminobenzoic acid ethyl ester; MFCD08072959; 3-amino-4-(cyclohexylamino)-benzoic acid, ethyl ester; ferrrostatin 1; SCHEMBL2032512; CHEMBL3633556; SCHEMBL18137149; CHEBI:173086; UJHBVMHOBZBWMX-UHFFFAOYSA-N; HMS3653M21; BCP17366; EX-A4243; s7243; AKOS003388952; CCG-267075; SB19587; ethyl 3-amino-4-cyclohexylaminobenzoate; Ethyl3-amino-4-(cyclohexylamino)benzoate; NCGC00370951-06; AC-36537; AS-57497; SY270013; HY-100579; CS-0019733; F1302; SW219400-1; C74788; 3-Amino-4-cyclohexylaminobenzoic acid, ethyl ester; A903830; 3-Amino-4-cyclohexylamino-benzoic Acid Ethyl Ester; J-019728	.	.	262.35	C15H22N2O2	64.4	290	3.3	19	2	4	5	InChI=1S/C15H22N2O2/c1-2-19-15(18)11-8-9-14(13(16)10-11)17-12-6-4-3-5-7-12/h8-10,12,17H,2-7,16H2,1H3	CCOC(=O)C1=CC(=C(C=C1)NC2CCCCC2)N	CCOC(=O)C1=CC(=C(C=C1)NC2CCCCC2)N	UJHBVMHOBZBWMX-UHFFFAOYSA-N	ethyl 3-amino-4-(cyclohexylamino)benzoate
ferrodrug0297	Ungeremine	.	Ungeremine; Lycobetaine; 72510-04-4; 2121-12-2; 9EVC5B2RPS; Lycoranium, 1,2,3,3a,6,7,12b,12c-octadehydro-2-hydroxy-; 5,7-dioxa-12-azoniapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-1(18),2,4(8),9,11,15(19),16-heptaen-17-ol; 1,2,3,3a,6,7,12b,12c-Octadehydro-2-hydroxylycoranium; 4,5-Dihydro-2-hydroxy-(1,3)dioxolo(4,5-j)pyrrolo(3,2,1-de)phenanthridinium; (1,3)Dioxolo(4,5-j)pyrrolo(3,2,1-de)phenanthridinium, 4,5-dihydro-2-hydroxy-; Ungerimine; [1,3]Dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridinium, 4,5-dihydro-2-hydroxy-; LycobetaineUngeremine; UNII-9EVC5B2RPS; NCIMech_000324; CHEMBL253553; SCHEMBL20741474; DTXSID50175439; HY-N1971; CCG-35585; 4,5-Dihydro-2-hydroxy-(1,3)dioxolo(4,5-j)pyrrolo(3.2.1-de)phenanthridinium; AKOS037515332; NCI60_002978; CS-0018291; FT-0698899; FT-0701446; Q15633984; 2121-12-2 (Cl: 2121-16-6); 2-hydroxy-4H,5H-[1,3]dioxolo[4,5-j]pyrrolo[3,2,1-de]phenanthridin-6-ium; 17-hydroxy-5,7-dioxa-12; E?-azapentacyclo[10.6.1.0?,??.0?,?.0??,??]nonadeca-1(18),2,4(8),9,11,15(19),16-heptaen-12-ylium	.	.	266.27	C16H12NO3+	42.6	403	3	20	1	3	0	InChI=1S/C16H11NO3/c18-11-3-9-1-2-17-7-10-4-14-15(20-8-19-14)6-12(10)13(5-11)16(9)17/h3-7H,1-2,8H2/p+1	C1C[N+]2=CC3=CC4=C(C=C3C5=CC(=CC1=C52)O)OCO4	C1C[N+]2=CC3=CC4=C(C=C3C5=CC(=CC1=C52)O)OCO4	DFQOXFIPAAMFAU-UHFFFAOYSA-O	5,7-dioxa-12-azoniapentacyclo[10.6.1.02,10.04,8.015,19]nonadeca-1(18),2,4(8),9,11,15(19),16-heptaen-17-ol
ferrodrug0298	Capsiate	.	capsiate; 205687-01-0; (E)-4-Hydroxy-3-methoxybenzyl 8-methylnon-6-enoate; (4-hydroxy-3-methoxyphenyl)methyl (E)-8-methylnon-6-enoate; PX8I7HG5I3; (4-hydroxy-3-methoxyphenyl)methyl (6E)-8-methylnon-6-enoate; Capsiate Natura; (6E)-8-METHYL-6-NONENOIC ACID (4-HYDROXY-3-METHOXYPHENYL)METHYL ESTER; UNII-PX8I7HG5I3; SCHEMBL1585964; DTXSID20174575; CHEBI:134190; ZICNYIDDNJYKCP-SOFGYWHQSA-N; HY-N8377; vanillyl (6E)-8-methylnon-6-enoate; vanillyl trans-8-methyl-non-6-enoate; C-255; CS-0143769; C20203; E88102; 4-Hydroxy-3-methoxybenzyl 8-methyl-6-nonenoate; (E)-4-Hydroxy-3-methoxybenzyl8-methylnon-6-enoate; Q27286800; (4-hydroxy-3-methoxyphenyl)methyl (E)-8-methylnon-6-enoate.; 6-Nonenoic acid, 8-methyl-, (4-hydroxy-3-methoxyphenyl)methyl ester, (E)-; 6-nonenoic acid, 8-methyl-, (4-hydroxy-3-methoxyphenyl)methyl ester, (6E)-	.	.	306.4	C18H26O4	55.8	338	4.2	22	1	4	10	InChI=1S/C18H26O4/c1-14(2)8-6-4-5-7-9-18(20)22-13-15-10-11-16(19)17(12-15)21-3/h6,8,10-12,14,19H,4-5,7,9,13H2,1-3H3/b8-6+	CC(C)/C=C/CCCCC(=O)OCC1=CC(=C(C=C1)O)OC	CC(C)C=CCCCCC(=O)OCC1=CC(=C(C=C1)O)OC	ZICNYIDDNJYKCP-SOFGYWHQSA-N	(4-hydroxy-3-methoxyphenyl)methyl (E)-8-methylnon-6-enoate
ferrodrug0299	JQ1	.	1268524-70-4; (+)-JQ1; (+)-JQ-1; JQ1 compound; JQ1; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; JQ-1; (S)-JQ1; 1MRH0IMX0W; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; CHEMBL1957266; (S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; 6H-Thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, 1,1-dimethylethyl ester, (6S)-; tert-butyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; tert-Butyl 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno(3,2-f)(1,2,4)triazolo(4,3-a)(1,4)diazepin-6-yl)acetate; (S)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno-[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; 6H-Thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid, 4-(4-chlorophenyl)-2,3,9-trimethyl-, 1,1-dimethylethyl ester, (6S)-; Bromodomain Inhibitor, (+)-JQ1; UNII-1MRH0IMX0W; C23H25ClN4O2S; 3mxf; 4flp; 4qzs; (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepine-6-acetic acid 1,1-dimethylethyl ester; tert-butyl 2-((6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; MLS006011158; SCHEMBL881227; GTPL7511; CHEBI:95080; DTXSID20155309; EX-A457; CHEBI:137113; DNVXATUJJDPFDM-KRWDZBQOSA-N; BDBM50365262; HB1448; NSC760183; NSC764043; s7110; AKOS016344680; (+)JQ-1; CCG-269306; CS-0581; JQ1 (+); JQ1-(+); NSC-760183; NSC-764043; NCGC00250412-01; NCGC00250412-15; NCGC00250412-21; (S)-tert-butyl 2-(4-(4-chlorophenyl)-2,3,9-triMethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diaz; AC-32617; AS-16352; BP-21590; HY-13030; SMR004702930; BB 0262647; (+)-JQ1, >=98% (HPLC); EN300-7404173; A854208; Q3156953; Z2235802082; (6S)-4-(4-Chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]di azepine-6-acetic acid 1,1-dimethylethyl ester; tert-butyl (S)-2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate;(S)-(+)-tert-Butyl 2-(4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)acetate; tert-butyl [(6S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate; tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3.0.0,2,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate; tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate; tert-butyl[(S)-4-(4-chlorophenyl)-2,3,9-trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl]acetate	.	.	457	C23H25ClN4O2S	97.6	706	4.9	31	0	6	5	InChI=1S/C23H25ClN4O2S/c1-12-13(2)31-22-19(12)20(15-7-9-16(24)10-8-15)25-17(11-18(29)30-23(4,5)6)21-27-26-14(3)28(21)22/h7-10,17H,11H2,1-6H3/t17-/m0/s1	CC1=C(SC2=C1C(=N[C@H](C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C	CC1=C(SC2=C1C(=NC(C3=NN=C(N32)C)CC(=O)OC(C)(C)C)C4=CC=C(C=C4)Cl)C	DNVXATUJJDPFDM-KRWDZBQOSA-N	tert-butyl 2-[(9S)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetrazatricyclo[8.3.0.02,6]trideca-2(6),4,7,10,12-pentaen-9-yl]acetate
ferrodrug0300	XAV939	Small molecular drug	284028-89-3; XAV-939; XAV939; 3,5,7,8-Tetrahydro-2-[4-(trifluoromethyl)phenyl]-4H-thiopyrano[4,3-d]pyrimidin-4-one; XAV 939; 2-[4-(trifluoromethyl)phenyl]-1,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one; CHEBI:62878; CHEMBL1086580; XAV-939 (GMP); CID 2726824; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano[4,3-d]pyrimidin-4-ol; 2-[4-(trifluoromethyl)phenyl]-7,8-dihydro-5H-thiino[4,3-d]pyrimidin-4-ol; 2-[4-(Trifluoromethyl)phenyl]-7,8-Dihydro-5h-Thiopyrano[4,3-D]pyrimidin-4-Ol; NVP-XAV-939; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-3H-thiopyrano[4,3-d]pyrimidin-4(5H)-one; C14H11F3N2OS; XAV; MFCD16879017; 3kr8; 3uh4; Maybridge3_005018; NVP-XAV939; MLS006012021; SCHEMBL7783488; TB3748-GMP; SCHEMBL15315468; DTXSID60369423; XAV939,XAV-939; BCPP000009; HMS1445E02; HMS3414D07; HMS3648B17; HMS3654O16; HMS3678D07; HMS3743E05; BCP02128; EX-A1760; BDBM50188594; BDBM50318567; HB0660; HY-15147G; NSC755761; s1180; 2-[4-(trifluoromethyl)phenyl]-5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-ol; AKOS015954858; AKOS024457786; AKOS026750243; CCG-208105; CS-0494; NSC-755761; SB19432; IDI1_016405; NCGC00250397-01; NCGC00484998-01; AC-28393; CS-10386; HY-15147; SMR003874205; XAV939, >=98% (HPLC); CS-0615627; FT-0675873; SW218311-2; X0077; A25698; EN300-6732792; SR-01000946403; J-511234; SR-01000946403-1; BRD-K12762134-001-01-3; BRD-K12762134-001-05-4; Q27132250; Z2235801832; 2-(4-(Trifluoromethyl)phenyl)-3,5,7,8-tetrahydro-4H-thiopyrano[4,3-d]pyrimidin-4-one; 2-(4-(trifluoromethyl)phenyl)-7,8-dihydro-1H-thiopyrano[4,3-d]pyrimidin-4(5H)-one; 2-(4-(Trifluoromethyl)phenyl)-7,8-dihydro-5H-thiopyrano-[4,3-d]pyrimidin-4-ol; 2-[4-(trifluoromethyl)phenyl]-1H,4H,5H,7H,8H-thiopyrano[4,3-d]pyrimidin-4-one; 4H-Thiopyrano[4,3-d]pyrimidin-4-one, 3,5,7,8-tetrahydro-2-[4-(trifluoromethyl)phenyl]-?	.	DG01666	312.31	C14H11F3N2OS	66.8	505	2.3	21	1	6	1	InChI=1S/C14H11F3N2OS/c15-14(16,17)9-3-1-8(2-4-9)12-18-11-5-6-21-7-10(11)13(20)19-12/h1-4H,5-7H2,(H,18,19,20)	C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F	C1CSCC2=C1N=C(NC2=O)C3=CC=C(C=C3)C(F)(F)F	KLGQSVMIPOVQAX-UHFFFAOYSA-N	2-[4-(trifluoromethyl)phenyl]-3,5,7,8-tetrahydrothiopyrano[4,3-d]pyrimidin-4-one
ferrodrug0301	Solasonine	.	Solasonine; 19121-58-5; Tomatine solaradixine; Solasonin; alpha-Solasonine; CHEBI:9191; TR60638HXL; C45H73NO16; .alpha.-Solasonine; EINECS 242-826-6; beta-D-Galactopyranoside, (3beta,22alpha,25R)-spirosol-5-en-3-yl O-6-deoxy-alpha-L-mannopyranosyl-(1-2)-O-(beta-D-glucopyranosyl-(1-3))- (9CI); UNII-TR60638HXL; NSC-82149; NSC 82149; PURAPURINE; SOLASONINE [MI]; CHEMBL438956; SCHEMBL2683980; QCTMYNGDIBTNSK-XEAAVONHSA-N; DTXSID801028790; AKOS030528257; CCG-270555; AC-33986; BS-16392; S9144; Q7557107; (2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-2-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-piperidine]-16-yl]oxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol; .BETA.-D-GALACTOPYRANOSIDE, (3.BETA.,22.ALPHA.,25R)-SPIROSOL-5-EN-3-YL O-6- DEOXY-.ALPHA.-L-MANNOPYRANOSYL-(1-2)-O-(.BETA.-D-GLUCOPYRANOSYL-(1-3))-; .BETA.-D-GALACTOPYRANOSIDE, (3.BETA.,22.ALPHA.,25R)-SPIROSOL-5-EN-3-YL O-6-DEOXY-.ALPHA.-L-MANNOPYRANOSYL-(1->2)-O-(.BETA.-D-GLUCOPYRANOSYL-(1->3))-; beta-D-Galactopyranoside, (3beta,22alpha,25R)-spirosol-5-en-3-yl O-6-deoxy-alpha-L-mannopyranosyl-(1-->2)-O-[beta-D-glucopyranosyl-(1-->3)]-; beta-D-Galactopyranoside, (3beta,22alpha,25R)-spirosol-5-en-3-yl O-6-deoxy-alpha-L-mannopyranosyl-(1-2)-O-(beta-D-glucopyranosyl-(1-3))-	.	.	884.1	C45H73NO16	259	1630	1.1	62	10	17	8	InChI=1S/C45H73NO16/c1-19-8-13-45(46-16-19)20(2)30-27(62-45)15-26-24-7-6-22-14-23(9-11-43(22,4)25(24)10-12-44(26,30)5)57-42-39(61-40-36(54)34(52)31(49)21(3)56-40)38(33(51)29(18-48)59-42)60-41-37(55)35(53)32(50)28(17-47)58-41/h6,19-21,23-42,46-55H,7-18H2,1-5H3/t19-,20+,21+,23+,24-,25+,26+,27+,28-,29-,30+,31+,32-,33+,34-,35+,36-,37-,38+,39-,40+,41+,42-,43+,44+,45-/m1/s1	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@H]([C@H](O7)CO)O)O[C@H]8[C@@H]([C@H]([C@@H]([C@H](O8)CO)O)O)O)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)C)C)C)NC1	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)O)OC8C(C(C(C(O8)CO)O)O)O)OC9C(C(C(C(O9)C)O)O)O)C)C)C)NC1	QCTMYNGDIBTNSK-XEAAVONHSA-N	(2S,3R,4R,5R,6S)-2-[(2R,3R,4S,5S,6R)-5-hydroxy-6-(hydroxymethyl)-2-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-piperidine]-16-yl]oxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-3-yl]oxy-6-methyloxane-3,4,5-triol
ferrodrug0302	APR-246	.	APR-246; 5291-32-7; PRIMA-1MET; Eprenetapopt; 2-(Hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one; 2-(Hydroxymethyl)-2-(methoxymethyl)quinuclidin-3-one; APR 246; Eprenetapopt [USAN]; Z41TGB4080; 3-Quinuclidinone, 2-(hydroxymethyl)-2-(methoxymethyl)-; 1-Azabicyclo(2.2.2)octan-3-one, 2-(hydroxymethyl)-2-(methoxymethyl)-; Prima 1MET; UNII-Z41TGB4080; EPRENETAPOPT [INN]; MLS006010767; EPRENETAPOPT [WHO-DD]; APR246; SCHEMBL2228161; CHEMBL3186011; SCHEMBL21636035; PRIMA-1MET(APR-246); APR-246 (PRIMA-1MET); DTXSID401164013; BCP20294; EX-A2772; MFCD20620963; NSC791496; s7724; WHO 11387; AKOS024457764; CCG-266578; CS-7614; DB11684; NSC-791496; SB19737; NCGC00346881-01; AC-32964; AS-72033; BA176962; HY-19980; SMR004701457; A901731; Q27294965; 2-hydroxymethyl-2-methoxymethyl-1-azabicyclo[2.2.2]octan-3-one	.	.	199.25	C10H17NO3	49.8	236	-0.1	14	1	4	3	InChI=1S/C10H17NO3/c1-14-7-10(6-12)9(13)8-2-4-11(10)5-3-8/h8,12H,2-7H2,1H3	COCC1(C(=O)C2CCN1CC2)CO	COCC1(C(=O)C2CCN1CC2)CO	BGBNULCRKBVAKL-UHFFFAOYSA-N	2-(hydroxymethyl)-2-(methoxymethyl)-1-azabicyclo[2.2.2]octan-3-one
ferrodrug0303	Go-6976	.	136194-77-9; Go 6976; GO6976; Go-6976; Goe 6976; 3-(13-Methyl-5-oxo-6,7-dihydro-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12(13H)-yl)propanenitrile; 5,6,7,13-Tetrahydro-13-Methyl-5-oxo-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile; B9IQO7JZ16; 12-(2-Cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrrolo[3,4-c]carbazole; CHEMBL302449; CHEBI:51913; 12H-Indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; 12H-indolo[2,3-a]pyrrolo[3,4-c]carbazole-12-propanenitrile, 5,6,7,13-tetrahydro-13-methyl-5-oxo-; 12-(2-cyanoethyl)-6,7,12,13-tetrahydro-13-methyl-5-oxo-5H-indolo[2,3-a]pyrolo[3,4-c]carbazole; 3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propanenitrile; UNII-B9IQO7JZ16; Goe-6976; Kinome_3630; Gouml 6976; G ouml 6976; CBiol_001871; G? 6976; BSPBio_001101; KBioGR_000441; KBioSS_000441; 13-Methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo(2,3-a)pyrrolo(3,4-c)carbazole-12-propanenitrile; BDBM3033; GTPL5973; SCHEMBL2175239; BCBcMAP01_000156; KBio2_000441; KBio2_003009; KBio2_005577; KBio3_000821; KBio3_000822; DTXSID70159731; Bio1_000157; Bio1_000646; Bio1_001135; Bio2_000381; Bio2_000861; HMS1362G03; HMS1792G03; HMS1990G03; HMS3229E13; HMS3403G03; BCP06797; 3-[methyl(oxo)[?]yl]propanenitrile; EI-269; HB0302; s7119; AKOS024457007; AT23580; CCG-206755; IDI1_002136; NCGC00163451-01; NCGC00163451-02; NCGC00163451-03; NCGC00163451-04; AS-16804; BG168444; HY-10183; CS-0002498; FT-0697606; EC-000.2399; G?? 6976, >=98% (HPLC), powder; A924795; Go 6976 - CAS 136194-77-9; J-006821; BRD-K59304176-001-02-5; BRD-K59304176-001-03-3; Q27077832; 3-(13-methyl-5-oxo-5,6,7,13-tetrahydro-12H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-12-yl)propionitrile; 3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10.0^{4,9.0^{11,15.0^{17,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile; 3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile; 3-(9-methyl-1-oxo-2,3-dihydro-1H-indolo[2,3-a]pyrrolo[3,4-c]carbazol-8(9H)-yl)propanenitrile; 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4(9),5,7,11(15),17,19,21-nonaen-3-yl}propanenitrile; 3-{23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.0^{2,10}.0^{4,9}.0^{11,15}.0^{17,22}]tricosa-1(16),2(10),4,6,8,11(15),17,19,21-nonaen-3-yl}propanenitrile	.	.	378.4	C24H18N4O	62.8	730	3.2	29	1	2	2	InChI=1S/C24H18N4O/c1-27-17-9-4-2-7-14(17)20-21-16(13-26-24(21)29)19-15-8-3-5-10-18(15)28(12-6-11-25)23(19)22(20)27/h2-5,7-10H,6,12-13H2,1H3,(H,26,29)	CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O	CN1C2=CC=CC=C2C3=C4C(=C5C6=CC=CC=C6N(C5=C31)CCC#N)CNC4=O	VWVYILCFSYNJHF-UHFFFAOYSA-N	3-(23-methyl-14-oxo-3,13,23-triazahexacyclo[14.7.0.02,10.04,9.011,15.017,22]tricosa-1,4,6,8,10,15,17,19,21-nonaen-3-yl)propanenitrile
ferrodrug0304	Geraniin	Small molecular drug	Geraniin; 60976-49-0; Geraniiin; CHEBI:5328; CHEMBL506069; C10230; JQQBXPCJFAKSPG-SVYIMCMUSA-N; BDBM50242278; AKOS015965424; AC-8425; Q-100702; Q5549854; [undecahydroxy(pentaoxo)[?]yl] 3,4,5-trihydroxybenzoate; N-(4-CARBETHOXYPHENYL)-N-4-(6-BENZOTHIAZOLE)AMINE; .beta.-D-Glucopyranose, cyclic 2.fwdarw.7:4.fwdarw.5-(3,6-dihydro-2,9,10,11,11-pentahydroxy-3-oxo-2,6-methano-2H-1-benzoxocin-5,7-dicarboxylate)cyclic 3,6-(4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate) 1-(3,4,5-trihydroxybenzoate), stereoisomer	D0C6QS	DMB5I03	952.6	C41H28O27	450	2080	-0.6	68	14	27	3	InChI=1S/C41H28O27/c42-13-1-8(2-14(43)24(13)48)34(54)67-39-33-32-30(64-38(58)12-6-19(47)41(61)40(59,60)23(12)22-11(37(57)66-33)5-17(46)27(51)31(22)68-41)18(63-39)7-62-35(55)9-3-15(44)25(49)28(52)20(9)21-10(36(56)65-32)4-16(45)26(50)29(21)53/h1-6,18,23,30,32-33,39,42-46,48-53,59-61H,7H2/t18-,23+,30-,32+,33-,39+,41+/m1/s1	C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@@H]7C(=CC(=O)[C@@](C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)O	C1C2C3C(C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5C7C(=CC(=O)C(C7(O)O)(O6)O)C(=O)O3)O)O)OC(=O)C8=CC(=C(C(=C8C9=C(C(=C(C=C9C(=O)O1)O)O)O)O)O)O	JQQBXPCJFAKSPG-SVYIMCMUSA-N	[(1R,7R,8S,26R,28S,29R,38R)-1,13,14,15,18,19,20,34,35,39,39-undecahydroxy-2,5,10,23,31-pentaoxo-6,9,24,27,30,40-hexaoxaoctacyclo[34.3.1.04,38.07,26.08,29.011,16.017,22.032,37]tetraconta-3,11,13,15,17,19,21,32,34,36-decaen-28-yl] 3,4,5-trihydroxybenzoate
ferrodrug0305	U0126	.	U0126; 109511-58-2; U-0126; 1,4-Diamino-2,3-dicyano-1,4-bis(o-aminophenylmercapto)butadiene; U 0126; 218601-62-8; (2Z,3Z)-2,3-bis(amino((2-aminophenyl)thio)methylene)succinonitrile; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylidene}butanedinitrile; FT-1069-1; CHEBI:64208; 8027P94HLL; 109511-58-2 (free); 2,3-Bis(amino((2-aminophenyl)thio)methylene)succinonitrile; (2z)-Bis{amino[(2-Aminophenyl)sulfanyl]methylidene}butanedinitrile; (2Z,3Z)-2,3-Bis[amino[(2-aminophenyl)thio]methylene]butanedinitrile; (2Z,3Z)-bis{amino[(2-aminophenyl)sulfanyl]methylene}succinonitrile; Butanedinitrile, bis(amino((2-aminophenyl)thio)methylene)-, (2Z,3Z)-; 1,4-Diamino-2,3-dicyano-1,4-bis[2-aminophenylthio]butadiene; (2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile; 1,4-Diamino-2,3-dicyano-1,4-bis(2-aminophenylthio)butadiene; BiomolKI_000002; BiomolKI2_000012; BMK1-B2; BSPBio_001224; CHEMBL34704; UNII-8027P94HLL; GTPL5282; Succinonitrile, bis(amino(o-aminophenylthio)methylene)-; CHEBI:90693; CHEBI:91463; Butanedinitrile, bis(amino((2-aminophenyl)thio)methylene)-; DTXSID10892034; HMS1362N05; HMS1792N05; HMS1990N05; HMS3403N05; HMS3414K05; HMS3678K05; AMY31125; BCP01851; EX-A1754; HB2246; HY-12031A; (2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanyl-methylene]butanedinitrile; (2Z,3Z)-bis({amino[(2-aminophenyl)sulfanyl]methylidene})butanedinitrile; AKOS024456414; AKOS040744815; CCG-100606; IDI1_002207; SMP2_000197; NCGC00025029-02; NCGC00025029-03; NCGC00025029-04; CS-0003351; U 126; A846574; A906530; SR-01000597365; J-002297; Q7863562; SR-01000597365-1; BRD-K18787491-001-04-5; BRD-K46419649-001-01-8; U-0126 is known as an MEK inhibitor and AMPK activator.; Butanedinitrile,2,3-bis[amino[(2-aminophenyl)thio]methylene]-; 5BM	.	.	380.5	C18H16N6S2	202	610	2	26	4	8	5	InChI=1S/C18H16N6S2/c19-9-11(17(23)25-15-7-3-1-5-13(15)21)12(10-20)18(24)26-16-8-4-2-6-14(16)22/h1-8H,21-24H2/b17-11+,18-12+	C1=CC=C(C(=C1)N)S/C(=C(/C(=C(/SC2=CC=CC=C2N)\N)/C#N)\C#N)/N	C1=CC=C(C(=C1)N)SC(=C(C#N)C(=C(N)SC2=CC=CC=C2N)C#N)N	DVEXZJFMOKTQEZ-JYFOCSDGSA-N	(2Z,3Z)-2,3-bis[amino-(2-aminophenyl)sulfanylmethylidene]butanedinitrile
ferrodrug0306	Fatostatin	.	FATOSTATIN; Fatostatin A; 125256-00-0; 4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole; 2-(2-propylpyridin-4-yl)-4-(p-tolyl)thiazole; CHEMBL1621019; 4-[4-(4-methylphenyl)-1,3-thiazol-2-yl]-2-propylpyridine; MLS000332366; SMR000221636; 2-Propyl-4-(4-p-tolyl-thiazol-2-yl)-pyridine; 4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole;hydrobromide; Fatostatin;125B11; Oprea1_120708; SCHEMBL2742732; BDBM78179; CHEBI:95052; cid_2850562; ZROSUBKIGBSZCG-UHFFFAOYSA-N; AMY41632; BCP20994; s9785; STK326446; AKOS005434229; CS-5810; AC-35652; BS-15072; HY-14452; 2-(2-propyl-4-pyridyl)-4-(p-tolyl)thiazole; D84076; 4-(4-methylphenyl)-2-(2-propyl-4-pyridinyl)thiazole; Q27166821; 2-(2-propyl-4-pyridyl)-4-(p-tolyl)thiazole;hydrobromide; 4-(4-methylphenyl)-2-(2-propyl-4-pyridinyl)thiazole;hydrobromide; 4-(4-METHYLPHENYL)-2-(2-PROPYL-4-PYRIDYL)-1,3-THIAZOLE	.	.	294.4	C18H18N2S	54	314	4.8	21	0	3	4	InChI=1S/C18H18N2S/c1-3-4-16-11-15(9-10-19-16)18-20-17(12-21-18)14-7-5-13(2)6-8-14/h5-12H,3-4H2,1-2H3	CCCC1=NC=CC(=C1)C2=NC(=CS2)C3=CC=C(C=C3)C	CCCC1=NC=CC(=C1)C2=NC(=CS2)C3=CC=C(C=C3)C	ZROSUBKIGBSZCG-UHFFFAOYSA-N	4-(4-methylphenyl)-2-(2-propylpyridin-4-yl)-1,3-thiazole
ferrodrug0307	alpha-Eleostearic acid	.	alpha-Eleostearic acid; 506-23-0; UNII-934U1Q8QHG; cis-eleostearic acid; 934U1Q8QHG; 9,11,13-Octadecatrienoic acid, (E,Z,E)-; 9Z,11E,13E-octadecatrienoic acid; EINECS 208-029-2; (9Z,11E,13E)-octadeca-9,11,13-trienoic acid; AI3-22367; (9E,11Z,13E)-9,11,13-Octadecatrienoic acid; (9Z,11E,13E)-Octadecatrienoic acid; alpha-ELA; (9Z,11E,13E)-9,11,13-Octadecatrienoic acid; cis-9, trans-11, trans-13-octadecatrienoic acid; 9(Z),11(E),13(E)-Octadecatrienoic acid; 9c,11t,13t-CLnA; c9,t11,t13-CLnA; c9,t11,t13-linolenic acid; 9c11t13t-18:3; C18:3n-5,7,9; 9cis,11trans,13trans-octadecatrienoic acid; (Z,E,E)-octadeca-9,11,13-trienoic acid; 9-cis,11-trans,13-trans-octadecatrienoic acid; Margarolic acid; elaeostearic acid; alpha-ESA; alpha-eleostearinic acid; 9(E),11(Z),13(E)-Octadecatrienoic acid; SCHEMBL38279; .ALPHA.-ELEOSTEARIC ACID; CHEBI:10275; DTXSID00897457; HMS3650A22; LMFA01030147; AKOS040755421; C08315; cis,trans,trans-octadeca-9,11,13-trienoic acid; octadeca-9-Cis,11-trans,13-trans-trienoic acid; SR-01000946262; 9,11,13-Octadecatrienoic acid, (9Z,11E,13E)-; Q2712733; SR-01000946262-1; CIS,TRANS,TRANS-9,11,13-OCTADECATRIENOIC ACID	.	.	278.4	C18H30O2	37.3	301	6.4	20	1	2	13	InChI=1S/C18H30O2/c1-2-3-4-5-6-7-8-9-10-11-12-13-14-15-16-17-18(19)20/h5-10H,2-4,11-17H2,1H3,(H,19,20)/b6-5+,8-7+,10-9-	CCCC/C=C/C=C/C=C\CCCCCCCC(=O)O	CCCCC=CC=CC=CCCCCCCCC(=O)O	CUXYLFPMQMFGPL-WPOADVJFSA-N	(9Z,11E,13E)-octadeca-9,11,13-trienoic acid
ferrodrug0308	Chebulagic Acid	Small molecular drug	Chebulagic acid; CHEBI:3583; 23094-71-5; 2-[(4R,5S,7R,25S,26R,29S,30S,31S)-13,14,15,18,19,20,31,35,36-Nonahydroxy-2,10,23,28,32-pentaoxo-5-(3,4,5-trihydroxybenzoyl)oxy-3,6,9,24,27,33-hexaoxaheptacyclo[28.7.1.04,25.07,26.011,16.017,22.034,38]octatriaconta-1(37),11,13,15,17,19,21,34(38),35-nonaen-29-yl]acetic acid; CHEMBL525240; NSC636590; 2-[nonahydroxy-pentaoxo-(3,4,5-trihydroxybenzoyl)oxy-[?]yl]acetic acid; C41-H30-O27; GN-29; BDBM50366290; E80601; Q5089009; .beta.-D-Glucopyranose, cyclic 3,6-[(1R)-4,4',5,5',6,6'-hexahydroxy[1,1'-biphenyl]-2,2'-dicarboxylate] 1-(3,4,5-trihydroxybenzoate), cyclic	D0J5OV	DM0H7AV	954.7	C41H30O27	447	1970	0.4	68	13	27	5	InChI=1S/C41H30O27/c42-13-1-8(2-14(43)24(13)49)35(56)68-41-34-33-31(64-39(60)12(6-19(47)48)22-23-11(38(59)67-34)5-17(46)27(52)32(23)65-40(61)30(22)55)18(63-41)7-62-36(57)9-3-15(44)25(50)28(53)20(9)21-10(37(58)66-33)4-16(45)26(51)29(21)54/h1-5,12,18,22,30-31,33-34,41-46,49-55H,6-7H2,(H,47,48)/t12-,18+,22-,30-,31+,33-,34+,41-/m0/s1	C1[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O	C1C2C3C(C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5C(C(C(=O)O3)CC(=O)O)C(C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7C8=C(C(=C(C=C8C(=O)O1)O)O)O)O)O)O	HGJXAVROWQLCTP-YABCKIEDSA-N	2-[(4R,5S,7R,25S,26R,29S,30S,31S)-13,14,15,18,19,20,31,35,36-nonahydroxy-2,10,23,28,32-pentaoxo-5-(3,4,5-trihydroxybenzoyl)oxy-3,6,9,24,27,33-hexaoxaheptacyclo[28.7.1.04,25.07,26.011,16.017,22.034,38]octatriaconta-1(37),11,13,15,17,19,21,34(38),35-nonaen-29-yl]acetic acid
ferrodrug0309	Necrostatin-1	.	Necrostatin-1; 4311-88-0; MTH-DL-Tryptophan; Necrostatin 1; Nec-1; 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone; 5-((1H-indol-3-yl)methyl)-3-methyl-2-thioxoimidazolidin-4-one; MTH-trp; methyl-thiohydantoin-tryptophan; 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one; Necrostatin-1 inactive control; 4-imidazolidinone, 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-; Methylthiohydantoin-DL-tryptophan;MTH-DL-tryptophan; 5-(1H-Indol-3-ylmethyl)-3-methyl-2-thioxoimidazolidin-4-one; MFCD00056916; NECROSTATIN; CID2828334; Oprea1_645908; CBDivE_006695; MLS006011643; SCHEMBL856922; CHEMBL195008; GTPL9750; methylthiohydantoin-DL-tryptophan; BDBM36371; CHEBI:91658; DTXSID40385186; HMS3229H21; HMS3268N04; HMS3413G04; HMS3653J04; HMS3673K15; HMS3677G04; BCP06760; EX-A2108; Necrostatin-1, >=98% (HPLC); s8037; STL452869; STL511330; AKOS001662677; AKOS016050497; AKOS023092523; CCG-265032; CS-1666; NCGC00092372-01; NCGC00092372-02; NCGC00092372-03; NCGC00092372-15; AC-32084; AS-10165; HY-15760; SMR001375661; FT-0635218; N1174; SW219795-1; EC-000.2418; AB00073999-01; A826160; BRD-A36318220-001-01-3; Q27163481; Hydantoin, 5-(indol-3-ylmethyl)-3-methyl-2-thio- (7CI,8CI); 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylidene-4-imidazolidinone; 4-Imidazolidinone, 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo- (9CI); 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-4-Imidazolidinone, Nec-1; 5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanyl-3,5-dihydro-4H-imidazol-4-one; 5-(1H-indol-3-ylmethyl)-3-methyl-2-thioxo-imidazolidin-4-one;Necrostatin 1	.	.	259.329	C13H13N3OS	80.2	373	1.9	18	2	2	2	InChI=1S/C13H13N3OS/c1-16-12(17)11(15-13(16)18)6-8-7-14-10-5-3-2-4-9(8)10/h2-5,7,11,14H,6H2,1H3,(H,15,18)	CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32	CN1C(=O)C(NC1=S)CC2=CNC3=CC=CC=C32	TXUWMXQFNYDOEZ-UHFFFAOYSA-N	5-(1H-indol-3-ylmethyl)-3-methyl-2-sulfanylideneimidazolidin-4-one
ferrodrug0310	Nutlin-3	.	Nutlin-3; 548472-68-0; 890090-75-2; nutlin 3; 4-(4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one; (Rac)-Nutlin-3; (+/-)-Nutlin3; 4-[[4,5-Bis(4-chlorophenyl)-4,5-dihydro-2-[4-methoxy-2-(1-methylethoxy)phenyl]-1H-imidazol-1-yl]carbonyl]-2-piperazinone; 4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one; CHEMBL211045; (+)-Nutlin-3; (?)-Nutlin-3; MFCD14636430; Nutlin 3(Random Configuration); Nutlin3; NSC-732664; Rac-Nutlin-3; Nutln 3A; MFCD07784509; 4-({4,5-bis(4-chlorophenyl)-2-[4-methoxy-2-(propan-2-yloxy)phenyl]-4,5-dihydro-1H-imidazol-1-yl}carbonyl)piperazin-2-one; the p53/MDM2 Agonist; SCHEMBL2458627; BDBM31197; CHEBI:93777; EX-A851; HMS3651G03; HMS3653F08; HMS3653J08; HMS3750A11; AMY39899; BCP02265; BCP05161; BCP29278; MFCD11977784; NSC732664; s1061; AKOS005146527; CCG-264800; SB19406; SB19407; NCGC00165848-01; NCGC00165848-02; AC-35939; AS-10121; SY283510; SY289992; FT-0700329; FT-0713388; FT-0771774; FT-0773561; SW220144-1; H10266; A861337; J-514247; J-523776; BRD-A12230535-001-01-8; Q27165473; Z2159890360; (+-)-4-[4,5-dihydro-imidazole-1-carbonyl]piperazin-2-one; (-)-4-(4,5-bis-(4-Chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydroimidazole-1-carbonyl)piperazine-2-one; (??)-4-[4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxy-phenyl)-4,5-dihydro-imidazole-1-carbonyl]-piperazin-2-one; 4-{[(4S,5R)-4,5-Bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazol-1-yl]carbonyl}-2-piperazinone; RG7112;R7112;rel-4-((4R,5S)-4,5-bis(4-chlorophenyl)-2-(2-isopropoxy-4-methoxyphenyl)-4,5-dihydro-1H-imidazole-1-carbonyl)piperazin-2-one	.	.	581.5	C30H30Cl2N4O4	83.5	919	5.2	40	1	5	6	InChI=1S/C30H30Cl2N4O4/c1-18(2)40-25-16-23(39-3)12-13-24(25)29-34-27(19-4-8-21(31)9-5-19)28(20-6-10-22(32)11-7-20)36(29)30(38)35-15-14-33-26(37)17-35/h4-13,16,18,27-28H,14-15,17H2,1-3H3,(H,33,37)	CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl	CC(C)OC1=C(C=CC(=C1)OC)C2=NC(C(N2C(=O)N3CCNC(=O)C3)C4=CC=C(C=C4)Cl)C5=CC=C(C=C5)Cl	BDUHCSBCVGXTJM-UHFFFAOYSA-N	4-[4,5-bis(4-chlorophenyl)-2-(4-methoxy-2-propan-2-yloxyphenyl)-4,5-dihydroimidazole-1-carbonyl]piperazin-2-one
ferrodrug0311	Cryptochlorogenic acid	.	Cryptochlorogenic acid; 905-99-7; 4-Caffeoylquinic acid; 4-O-Caffeoylquinic acid; 4-Cqa; 4-o-Caffeoyl quinic acid; Quinic acid 4-O-caffeate; 4-O-(3,4-Dihydroxycinnamoyl)-D-quinic acid; F23DJ84IZ9; (3R,5R)-4-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,3,5-trihydroxycyclohexane-1-carboxylic acid; CHEMBL4203706; 4-(3,4-Dihydroxycinnamoyl)quinic acid; (1alpha,3R,4alpha,5R)-4-[[3-(3,4-Dihydroxyphenyl)-1-oxo-2-propen-1-yl]oxy]-1,3,5-trihydroxycyclohexanecarboxylic acid; 82638-23-1; 87099-73-8; rel-(1S,3R,4S,5R)-4-(((E)-3-(3,4-Dihydroxyphenyl)acryloyl)oxy)-1,3,5-trihydroxycyclohexanecarboxylic acid; 4-O-trans-caffeoylquinic acid; MFCD10566638; Cryptochlorogenic-acid; 4-Caffeoylquinic acid;4-O-Caffeoylquinic acid; Quinic acid, 4-caffeoyl-; UNII-F23DJ84IZ9; 4-O-(E)-caffeoylquinic acid; CHEMBL3092676; Cinnamic acid, 3,4-dihydroxy-, 4-carboxy-2,4,6-trihydroxycyclohexyl ester; Quinic acid, 4-caffeoyl-, E-; SCHEMBL18180782; SCHEMBL20883249; ACon1_000120; CHEBI:75491; HY-N0787; BDBM50455380; s9319; 4-O-Caffeoylquinic acid, >=98.0%; AKOS037514601; CCG-268076; CS-3767; NCGC00180861-01; (1alpha,3alpha,4alpha,5beta)-4-(3-(3,4-(Dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-1,3,5-trihydroxycyclohexanecarboxylic acid; (3R,5R)-4-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,3,5-trihydroxy-cyclohexanecarboxylic acid; BS-17821; PD118874; Cryptochlorogenic acid, analytical standard; 4-Caffeoylquinic acid/ Cryptochlorogenic acid; Q-100886; B0B55D52-5101-4E6D-AA67-72D1CECBAA5A; Q27145347; 49B68A4C-6EC9-4441-B7D7-E3B740A8CDEC; (1S,3R,4S,5R)-4-{[(2E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy}-1,3,5-trihydroxycyclohexanecarboxylic acid; CYCLOHEXANECARBOXYLIC ACID, 4-(((2E)-3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPEN-1-YL)OXY)-1,3,5-TRIHYDROXY-, (1.ALPHA.,3R,4.ALPHA.,5R)-; Cyclohexanecarboxylic acid, 4-(((2E)-3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)-1,3,5-trihydroxy-, (1alpha,3R,4alpha,5R)-; Cyclohexanecarboxylic acid, 4-((3-(3,4-dihydroxyphenyl)-1-oxo-2-1R-propenyl)oxy)-1,3,5-trihydroxy-, (1R-(1alpha,3alpha,4alpha,5beta))-; CYCLOHEXANECARBOXYLIC ACID, 4-((3-(3,4-DIHYDROXYPHENYL)-1-OXO-2-PROPEN-1-YL)OXY)-1,3,5-TRIHYDROXY-, (1.ALPHA.,3R,4.ALPHA.,5R)-; Cyclohexanecarboxylic acid, 4-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propen-1-yl)oxy)-1,3,5-trihydroxy-, (1alpha,3R,4alpha,5R)-; Cyclohexanecarboxylic acid, 4-((3-(3,4-dihydroxyphenyl)-1-oxo-2-propenyl)oxy)-1,3,5-trihydroxy-, (1alpha,3R,4alpha,5R)-	.	.	354.31	C16H18O9	165	520	-0.4	25	6	9	5	InChI=1S/C16H18O9/c17-9-3-1-8(5-10(9)18)2-4-13(21)25-14-11(19)6-16(24,15(22)23)7-12(14)20/h1-5,11-12,14,17-20,24H,6-7H2,(H,22,23)/b4-2+/t11-,12-,14?,16?/m1/s1	C1[C@H](C([C@@H](CC1(C(=O)O)O)O)OC(=O)/C=C/C2=CC(=C(C=C2)O)O)O	C1C(C(C(CC1(C(=O)O)O)O)OC(=O)C=CC2=CC(=C(C=C2)O)O)O	GYFFKZTYYAFCTR-AVXJPILUSA-N	(3R,5R)-4-[(E)-3-(3,4-dihydroxyphenyl)prop-2-enoyl]oxy-1,3,5-trihydroxycyclohexane-1-carboxylic acid
ferrodrug0312	Dynasore	.	Dynasore; 304448-55-3; Dynamin Inhibitor I, Dynasore; CHEMBL1209885; N'-(3,4-Dihydroxybenzylidene)-3-hydroxy-2-naphthohydrazide; N'-[(3,4-dihydroxyphenyl)methylidene]-3-hydroxynaphthalene-2-carbohydrazide; N-[(E)-(3,4-dihydroxyphenyl)methylideneamino]-3-hydroxynaphthalene-2-carboxamide; Dynamin Inhibitor I; 3-Hydroxynaphthalene-2-carboxylic acid (3,4-dihydroxybenzylidene)hydrazide; DTXSID60420841; CHEBI:132754; BDBM50323460; HB1245; MFCD00292551; s8047; STK028329; 3-Hydroxy-naphthalene-2-carboxylic acid (3,4-dihydroxy-benzylidene)-hydrazide; AKOS000486035; AKOS026750233; CCG-267726; CS-1340; UPCMLD0ENAT5920180:001; NCGC00386289-03; AC-32834; AS-74080; HY-15304; EC-000.2052; EN300-97658; J-017955; Z49628777; N''-(3,4-dihydroxybenzylidene)-3-hydroxy-2-naphthohydrazide; N'-[(E)-(3,4-dihydroxyphenyl)methylene]-3-hydroxy-2-naphthohydrazide; 2-Naphthalenecarboxylic acid, 3-hydroxy-, 2-[(3,4-dihydroxyphenyl)methylene]hydrazide; Dynamin Inhibitor I, Dynasore is known as a Dynamin I and Dynamin II inhibitor.; N'-[(E)-(3,4-dihydroxyphenyl)methylidene]-3-hydroxynaphthalene-2-carbohydrazide	.	.	322.3	C18H14N2O4	102	470	3.6	24	4	5	3	InChI=1S/C18H14N2O4/c21-15-6-5-11(7-17(15)23)10-19-20-18(24)14-8-12-3-1-2-4-13(12)9-16(14)22/h1-10,21-23H,(H,20,24)/b19-10+	C1=CC=C2C=C(C(=CC2=C1)C(=O)N/N=C/C3=CC(=C(C=C3)O)O)O	C1=CC=C2C=C(C(=CC2=C1)C(=O)NN=CC3=CC(=C(C=C3)O)O)O	SYNDQCRDGGCQRZ-VXLYETTFSA-N	N-[(E)-(3,4-dihydroxyphenyl)methylideneamino]-3-hydroxynaphthalene-2-carboxamide
ferrodrug0313	Carabrone	.	Carabrone; 1748-81-8; Carabron; (3aR,4aS,5S,5aR,6aR)-5a-methyl-3-methylidene-5-(3-oxobutyl)-3a,4,4a,5,6,6a-hexahydrocyclopropa[f][1]benzofuran-2-one; CCRIS 1880; grandicin; 2H-Cyclopropa(f)benzofuran-2-one, octahydro-5a-methyl-3-methylene-5-(3-oxobutyl)-; MEGxp0_001642; CHEMBL3315226; ACon0_000363; DTXSID90938585; HY-N5020; AKOS015998610; NCGC00385841-01; AC-34820; MS-23515; CS-0032087; A881657; 5a-Methyl-3-methylidene-5-(3-oxobutyl)octahydro-2H-cyclopropa[f][1]benzofuran-2-one; (1R,3S,4S,5R,7R)-5-methyl-10-methylidene-4-(3-oxobutyl)-8-oxatricyclo[5.3.0.0?,?]decan-9-one; (3aR,4aS,5S,5aR,6aR)-5a-Methyl-3-methylene-5-(3-oxobutyl)octahydro-2H-cyclopropa[f]benzofuran-2-one; NCGC00385841-01_C15H20O3_2H-Cyclopropa[f]benzofuran-2-one, octahydro-5a-methyl-3-methylene-5-(3-oxobutyl)-, (3aR,4aS,5S,5aR,6aR)-	.	.	248.32	C15H20O3	43.4	439	2	18	0	3	3	InChI=1S/C15H20O3/c1-8(16)4-5-11-12-6-10-9(2)14(17)18-13(10)7-15(11,12)3/h10-13H,2,4-7H2,1,3H3/t10-,11+,12+,13-,15-/m1/s1	CC(=O)CC[C@H]1[C@H]2[C@@]1(C[C@@H]3[C@H](C2)C(=C)C(=O)O3)C	CC(=O)CCC1C2C1(CC3C(C2)C(=C)C(=O)O3)C	AGIQIKMGJVLKMA-NLRWUALESA-N	(3aR,4aS,5S,5aR,6aR)-5a-methyl-3-methylidene-5-(3-oxobutyl)-3a,4,4a,5,6,6a-hexahydrocyclopropa[f][1]benzofuran-2-one
ferrodrug0314	CyPPA	Small molecular drug	CyPPA; 73029-73-9; N-cyclohexyl-2-(3,5-dimethyl-1H-pyrazol-1-yl)-6-methylpyrimidin-4-amine; cyclohexyl-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-pyrimidin-4-yl]-amine; CHEMBL453730; N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine; N-Cyclohexyl-N-[2-(3,5-dimethyl-pyrazol-1-yl)-6-methyl-4-pyrimidinamine; C16H23N5; GTPL2323; SCHEMBL3233745; DTXSID20358676; USEMRPYUFJNFQN-UHFFFAOYSA-N; HMS3262M15; HMS3742C19; AMY18135; EX-A5595; Tox21_500707; BDBM50275157; CyPPA, >=98% (HPLC), solid; HB1044; STK052676; AKOS015999173; CCG-222011; CS-W012225; HY-W011509; LP00707; SDCCGSBI-0633746.P001; NCGC00186022-01; NCGC00186022-05; NCGC00261392-01; MS-24068; F85618; Q27076959	D00DIF	DM64L9I	285.39	C16H23N5	55.6	331	3.8	21	1	4	3	InChI=1S/C16H23N5/c1-11-10-15(18-14-7-5-4-6-8-14)19-16(17-11)21-13(3)9-12(2)20-21/h9-10,14H,4-8H2,1-3H3,(H,17,18,19)	CC1=CC(=NC(=N1)N2C(=CC(=N2)C)C)NC3CCCCC3	CC1=CC(=NC(=N1)N2C(=CC(=N2)C)C)NC3CCCCC3	USEMRPYUFJNFQN-UHFFFAOYSA-N	N-cyclohexyl-2-(3,5-dimethylpyrazol-1-yl)-6-methylpyrimidin-4-amine
ferrodrug0315	Poricoic acid A	.	Poricoic acid A; 137551-38-3; Poricoic acid A(F); CHEBI:68353; (2R)-2-[(2R,3R,3aR,6S,7S,9bR)-6-(2-carboxyethyl)-2-hydroxy-3a,6,9b-trimethyl-7-prop-1-en-2-yl-1,2,3,4,7,8-hexahydrocyclopenta[a]naphthalen-3-yl]-6-methyl-5-methylideneheptanoic acid; PoricoicacidA; CHEMBL461483; SCHEMBL22200216; DTXSID401346653; HY-N2995; NSC715080; AKOS027326667; NSC-715080; AC-34216; MS-29260; NCI60_039753; CS-0023654; A903857; Q27136850; 16.alpha.-Hydroxy-3,7,9(11),24(24(sup 1))-tetraene-3,21-dioic acid; (2R)-2-[(2R,3R,3aR,6S,7S,9bR)-6-(2-carboxyethyl)-2-hydroxy-3a,6,9b-trimethyl-7-(prop-1-en-2-yl)-2,3,3a,4,6,7,8,9b-octahydro-1H-cyclopenta[a]naphthalen-3-yl]-6-methyl-5-methylideneheptanoic acid; (2R)-2-[(2R,3R,3aR,6S,7S,9bR)-6-(2-carboxyethyl)-2-hydroxy-7-isopropenyl-3a,6,9b-trimethyl-1,2,3,4,7,8-hexahydrocyclopenta[a]naphthalen-3-yl]-6-methyl-5-methylene-heptanoic acid; (2R,3R,3aR,6S,7S,9bR)-3-[(1R)-1-Carboxy-5-methyl-4-methylenehexyl]-2,3,3a,4,6,7,8,9b-octahydro-2-hydroxy-3a,6,9b-trimethyl-7-(1-methylethenyl)-1H-benz[e]indene-6-propanoic acid; (R)-2-[(2R,3R,3aR,6S,7S,9bR)-6-(2-Carboxy-ethyl)-2-hydroxy-7-isopropenyl-3a,6,9b-trimethyl-2,3,3a,4,6,7,8,9b-octahydro-1H-benz[e]inden-3-yl]-6-methyl-5-methylene-heptanoic acid	.	.	498.7	C31H46O5	94.8	1000	6.4	36	3	5	10	InChI=1S/C31H46O5/c1-18(2)20(5)9-10-21(28(35)36)27-25(32)17-31(8)24-12-11-22(19(3)4)29(6,15-14-26(33)34)23(24)13-16-30(27,31)7/h12-13,18,21-22,25,27,32H,3,5,9-11,14-17H2,1-2,4,6-8H3,(H,33,34)(H,35,36)/t21-,22+,25-,27+,29+,30-,31+/m1/s1	CC(C)C(=C)CC[C@H]([C@H]1[C@@H](C[C@@]2([C@@]1(CC=C3C2=CC[C@H]([C@]3(C)CCC(=O)O)C(=C)C)C)C)O)C(=O)O	CC(C)C(=C)CCC(C1C(CC2(C1(CC=C3C2=CCC(C3(C)CCC(=O)O)C(=C)C)C)C)O)C(=O)O	KVAQLXUMUVEKGR-SMFZDKLCSA-N	(2R)-2-[(2R,3R,3aR,6S,7S,9bR)-6-(2-carboxyethyl)-2-hydroxy-3a,6,9b-trimethyl-7-prop-1-en-2-yl-1,2,3,4,7,8-hexahydrocyclopenta[a]naphthalen-3-yl]-6-methyl-5-methylideneheptanoic acid
ferrodrug0316	Curcumenol	.	Curcumenol; 19431-84-6; (+)-Curcumenol; 6H-3a,6-Epoxyazulen-6-ol, 1,2,3,4,5,8a-hexahydro-3,8-dimethyl-5-(1-methylethylidene)-, (3S-(3-alpha,3a-alpha,6-alpha,8a-beta))-; 6H-3a,6-Epoxyazulen-6-ol,1,2,3,4,5,8a-hexahydro-3,8-dimethyl-5-(1-methylethylidene)-, (3S,3aS,6R,8aS)-; (1S,2S,5S,8R)-2,6-Dimethyl-9-propan-2-ylidene-11-oxatricyclo[6.2.1.01,5]undec-6-en-8-ol; BRN 3094585; 5-beta-Guiaia-7(11),9-dien-8-alpha-ol, 5,8-epoxy-; DTXSID0058011; HMS3885G10; HY-N2259; s3874; AKOS030529143; CCG-266822; AC-34181; AS-76068; CS-0019588; Q-100237	.	.	234.33	C15H22O2	29.5	430	2.2	17	1	2	0	InChI=1S/C15H22O2/c1-9(2)13-8-14-11(4)5-6-12(14)10(3)7-15(13,16)17-14/h7,11-12,16H,5-6,8H2,1-4H3/t11-,12-,14-,15+/m0/s1	C[C@H]1CC[C@@H]2[C@]13CC(=C(C)C)[C@](O3)(C=C2C)O	CC1CCC2C13CC(=C(C)C)C(O3)(C=C2C)O	ISFMXVMWEWLJGJ-NZBPQXDJSA-N	(1S,2S,5S,8R)-2,6-dimethyl-9-propan-2-ylidene-11-oxatricyclo[6.2.1.01,5]undec-6-en-8-ol
ferrodrug0317	Otssp167	.	OTSSP167; 1431697-89-0; OTS-167; OTSSP-167; OTS167; OTSSP167 free base; MELK inhibitor; AMX10201; Melk inhibitor OTS167; VY778IXU5T; 1431697-89-0 (free base); 1-(6-(3,5-dichloro-4-hydroxyphenyl)-4-(((1r,4r)-4-((dimethylamino)methyl)cyclohexyl)amino)-1,5-naphthyridin-3-yl)ethanone; 1-[6-(3,5-Dichloro-4-Hydroxyphenyl)-4-({trans-4-[(Dimethylamino)methyl]cyclohexyl}amino)-1,5-Naphthyridin-3-Yl]ethanone; 4-[7-acetyl-8-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1H-1,5-naphthyridin-2-ylidene]-2,6-dichlorocyclohexa-2,5-dien-1-one; Ethanone, 1-(6-(3,5-dichloro-4-hydroxyphenyl)-4-((trans-4-((dimethylamino)methyl)cyclohexyl)amino)-1,5-naphthyridin-3-yl)-; 1-(6-(3,5-Dichloro-4-hydroxyphenyl)-4-((trans-4-((dimethylamino)methyl)cyclohexyl)amino)-1,5-naphthyridin-3-yl)ethanone; UNII-VY778IXU5T; GTPL8046; CHEMBL3688339; CHEMBL3692820; SCHEMBL16337704; SCHEMBL16337706; SCHEMBL16337987; SCHEMBL23867214; BDBM60438; CHEBI:95088; DTXSID90856134; OTS 167; BDBM166063; BDBM166150; BCP09935; EX-A2119; NSC801013; AKOS025117446; CS-1147; NSC-801013; SB17231; NCGC00386398-02; NCGC00386398-03; NCGC00389259-02; BO170790; BS-15570; HY-15512; FT-0702382; S7159; C72690; US9067937, 6; US9067937, 28; US9067937, 94; Q27088220; Q27292088; 1-(6-(3,5-Dichloro-4-hydroxyphenyl)-4-(((1r,4r)-4-((dimethylamino)methyl)cyclohexyl)amino)-1,5-naphthyridin-3-yl)ethan-1-one; 1-(6-(3,5-Dichloro-4-hydroxyphenyl)-4-((trans-4-((dimethylamino)methyl)cyclohexyl)amino)-1,5-naphthyridin-3-yl)-ethanone; 1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone; OT5	.	.	487.4	C25H28Cl2N4O2	78.4	648	5.6	33	2	6	6	InChI=1S/C25H28Cl2N4O2/c1-14(32)18-12-28-22-9-8-21(16-10-19(26)25(33)20(27)11-16)30-24(22)23(18)29-17-6-4-15(5-7-17)13-31(2)3/h8-12,15,17,33H,4-7,13H2,1-3H3,(H,28,29)	CC(=O)C1=CN=C2C=CC(=NC2=C1NC3CCC(CC3)CN(C)C)C4=CC(=C(C(=C4)Cl)O)Cl	CC(=O)C1=CN=C2C=CC(=NC2=C1NC3CCC(CC3)CN(C)C)C4=CC(=C(C(=C4)Cl)O)Cl	DKZYXHCYPUVGAF-UHFFFAOYSA-N	1-[6-(3,5-dichloro-4-hydroxyphenyl)-4-[[4-[(dimethylamino)methyl]cyclohexyl]amino]-1,5-naphthyridin-3-yl]ethanone
ferrodrug0318	I-BET151	.	1300031-49-5; I-BET151; GSK1210151A; I-BET151 (GSK1210151A); 7-(3,5-Dimethylisoxazol-4-yl)-8-methoxy-1-((R)-1-(pyridin-2-yl)ethyl)-1H-imidazo[4,5-c]quinolin-2(3H)-one; 7-(3,5-Dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]quinolin-2-one; GSK1210151A (I-BET151); CHEMBL2017291; (R)-7-(3,5-dimethylisoxazol-4-yl)-8-methoxy-1-(1-(pyridin-2-yl)ethyl)-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 7-(3,5-Dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-(pyridin-2-yl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; 7-(3,5-Dimethyl-1,2-Oxazol-4-Yl)-8-Methoxy-1-[(1r)-1-(Pyridin-2-Yl)ethyl]-1h,2h,3h-Imidazo[4,5-C]quinolin-2-One; 7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-pyridin-2-ylethyl]-3H-imidazo[4,5-c]quinolin-2-one; I-BET 151; 3zyu; 4alg; 1GH; MLS006011182; GTPL7518; SCHEMBL1906755; CHEBI:95083; I-BET-151; DTXSID10680599; BCP03612; EX-A1561; BDBM50380682; MFCD22124472; NSC767599; s2780; AKOS016004407; BCP9000734; CS-0930; NSC-767599; GSK1210151A/I-BET 151; NCGC00344588-01; NCGC00344588-04; NCGC00344588-08; NCGC00344588-15; 7-(3,5-Dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-2H-imidazo[4,5-c]q; 7-(3,5-Dimethyl-4-isoxazolyl)-8-(methyloxy)-1-[(1R)-1-(2-pyridinyl)ethyl]-1,3-dihydro-2H-imidazo[4,5-c]quinolin-2-one; AC-27406; HY-13235; SMR004702951; BCP0726000180; SW219264-1; C72196; J-519026; Q27078015; (r)-7-(3,5-dimethyl isoxazol-4-yl)-8-methoxy-1-(1-(pyridin-2-yl)ethyl)-1,3-dihydro-2h-imidazo[4,5-c]quinolin-2-one; 2H-Imidazo[4,5-c]quinolin-2-one, 7-(3,5-dimethyl-4-isoxazolyl)-1,3-dihydro-8-methoxy-1-[(1R)-1-(2-pyridinyl)ethyl]-; 7-(dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-(pyridin-2-yl)ethyl]-1H,2H,3H-imidazo[4,5-c]quinolin-2-one	.	.	415.4	C23H21N5O3	93.4	665	2.7	31	1	6	4	InChI=1S/C23H21N5O3/c1-12-21(14(3)31-27-12)16-9-18-15(10-20(16)30-4)22-19(11-25-18)26-23(29)28(22)13(2)17-7-5-6-8-24-17/h5-11,13H,1-4H3,(H,26,29)/t13-/m1/s1	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)[C@H](C)C5=CC=CC=N5)OC	CC1=C(C(=NO1)C)C2=C(C=C3C(=C2)N=CC4=C3N(C(=O)N4)C(C)C5=CC=CC=N5)OC	VUVUVNZRUGEAHB-CYBMUJFWSA-N	7-(3,5-dimethyl-1,2-oxazol-4-yl)-8-methoxy-1-[(1R)-1-pyridin-2-ylethyl]-3H-imidazo[4,5-c]quinolin-2-one
ferrodrug0319	Doranidazole	.	Doranidazole; 161903-10-2; Doranidazole [INN]; PR-69; 149838-23-3; PR-350; 4BLU68P76A; DTXSID3048817; 911XR034RX; NCGC00183013-01; RP 343; RP-343; 1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)-, (2R,3S)-; 1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)-, (S-(R*,S*))-; (2R,3S)-3-[(2-nitroimidazol-1-yl)methoxy]butane-1,2,4-triol; (2R,3S)-3-((2-nitro-1H-imidazol-1-yl)methoxy)butane-1,2,4-triol; (2RS,3SR)-3-{(2-Nitroimidazol-1-yl)methoxy}butane-1,2,4-triol; 1,2,4-Butanetriol, 3-[(2-nitro-1H-imidazol-1-yl)methoxy]-, (2R,3S)-; PR 350; UNII-4BLU68P76A; UNII-911XR034RX; (2RS,3SR)-3-((2-NITROIMIDAZOL-1-YL)METHOXY)BUTANE-1,2,4-TRIOL; 1-((2',3'-Dihydroxy-1'-hydroxymethyl)propoxy)methyl-2-nitroimidazole; 3-((2-Nitro-1H-imidazol-1-yl)methoxy)-1,2,4-butanetriol (R*,S*)-; DORANIDAZOLE [JAN]; SCHEMBL8279381; CHEMBL2107741; DTXCID0028743; Tox21_113294; 1,2,4-Butanetriol, 3-((2-nitro-1H-imidazol-1-yl)methoxy)-, (R*,S*)-; AKOS040751633; CAS-149838-23-3; 1-(1',3',4'-Trihydroxy-2'-butoxy)methyl-2-nitroimidazole; (2RSs,3SR)-3-((2-nitroimidazol-1-yl)methoxy)butane-1,2,4-triol; (2R,3S)-3-((2-NITRO-1H-IMIDAZOL-1-YL)METHOXY)-1,2,4-BUTANETRIOL; 1,2,4-BUTANETRIOL, 3-((2-NITRO-1H-IMIDAZOL-1-YL)METHOXY)-, (2R,3S)-REL-	.	.	247.21	C8H13N3O6	134	248	-1.8	17	3	7	6	InChI=1S/C8H13N3O6/c12-3-6(14)7(4-13)17-5-10-2-1-9-8(10)11(15)16/h1-2,6-7,12-14H,3-5H2/t6-,7+/m1/s1	C1=CN(C(=N1)[N+](=O)[O-])CO[C@@H](CO)[C@@H](CO)O	C1=CN(C(=N1)[N+](=O)[O-])COC(CO)C(CO)O	FIITXXIVUIXYMI-RQJHMYQMSA-N	(2R,3S)-3-[(2-nitroimidazol-1-yl)methoxy]butane-1,2,4-triol
ferrodrug0320	SRT1720	Small molecular drug	1001645-58-4; SRT1720; SRT 1720 Hydrochloride; SRT1720 HCl; SRT 1720 (Hydrochloride); SRT1720 xHydrochloride; N-(2-(3-(piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide hydrochloride; N-[2-[3-(1-Piperazinylmethyl)imidazo[2,1-b]thiazol-6-yl]phenyl]-2-quinoxalinecarboxamide hydrochloride; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;hydrochloride; SRT1720 Hydrochloride; SRT1720xHydrochloride; SRT1720 xHCl; MLS006011149; CHEMBL4639328; SCHEMBL16372055; DTXSID80649411; SRT-1720, SRT 1720, 1001645-58-4; BCP01774; s1129; AKOS025401934; SRT-1720, SRT1720; CCG-264830; CS-0509; AC-27409; AS-35151; HY-15145; N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide,hydrochloride; SMR004702924; FT-0761472; SW218151-2; A24478; J-000057; J-523315; N-(2-(3-(Piperazin-1-ylmethyl)imidazo[2,1-b]thiazol-6-yl)phenyl)quinoxaline-2-carboxamide xhydrochloride; N-(2-{3-[(Piperazin-1-yl)methyl]imidazo[2,1-b][1,3]thiazol-6-yl}phenyl)quinoxaline-2-carboxamide--hydrogen chloride (1/1)	D03EGA	DMUKVHQ	506	C25H24ClN7OS	116	707	.	35	3	7	5	InChI=1S/C25H23N7OS.ClH/c33-24(22-13-27-20-7-3-4-8-21(20)28-22)29-19-6-2-1-5-18(19)23-15-32-17(16-34-25(32)30-23)14-31-11-9-26-10-12-31;/h1-8,13,15-16,26H,9-12,14H2,(H,29,33);1H	C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl	C1CN(CCN1)CC2=CSC3=NC(=CN23)C4=CC=CC=C4NC(=O)C5=NC6=CC=CC=C6N=C5.Cl	DTGRRMPPXCRRIM-UHFFFAOYSA-N	N-[2-[3-(piperazin-1-ylmethyl)imidazo[2,1-b][1,3]thiazol-6-yl]phenyl]quinoxaline-2-carboxamide;hydrochloride
ferrodrug0321	Hydroxysafflor Yellow A	.	Hydroxysafflor Yellow A; Safflomin A; 78281-02-4; HSYA; HI7O919OYZ; 146087-19-6; (6E)-2,5-dihydroxy-6-[(E)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione; Hydroxy safflor yellow A; 2,5-Cyclohexadien-1-one, 2,4-di-beta-D-glucopyranosyl-3,4,5-trihydroxy-6-((2E)-3-(4-hydroxyphenyl)-1-oxo-2-propenyl)-; C27H32O16; UNII-HI7O919OYZ; SCHEMBL21315816; CHEBI:139030; DTXSID801031226; HY-N0567; s9061; AKOS037514823; CCG-270235; CCG-270236; CS-4544; PD087332; W-201291; 2,4-Di-b-D-glucopyranosyl-3,4,5-trihydroxy-6-[(2E)-3-(4-hydroxyphenyl-1-oxo-2-propen-1-yl)-2,5-cyclohexadien-1-one; 2,4-di-beta-D-glucopyranosyl-3,4,5-trihydroxy-6-[(2E)-3-(4-hydroxyphenyl-1-oxo-2-propen-1-yl)]-2,5-cyclohexadien-1-one; 2,4-di-beta-D-glucopyranosyl-3,4,5-trihydroxy-6-[(2E)-3-(4-hydroxyphenyl-1-oxo-prop-2-en-1-yl)]cyclohexa-2,5-dien-1-one; 2,5-CYCLOHEXADIEN-1-ONE, 2,4-DI-.BETA.-D-GLUCOPYRANOSYL-3,4,5-TRIHYDROXY-6-((2E)-3-(4-HYDROXYPHENYL)-1-OXO-2-PROPEN-1-YL)-; 2-Hydroxy-4-(?3-(4-hydroxyphenyl)acryloyl)-2-((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)-6-((2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethy, AldrichCPR; 855782-18-2	.	.	612.5	C27H32O16	295	1160	-3.5	43	12	16	6	InChI=1S/C27H32O16/c28-7-12-16(32)19(35)21(37)23(42-12)15-18(34)14(11(31)6-3-9-1-4-10(30)5-2-9)24(39)27(41,25(15)40)26-22(38)20(36)17(33)13(8-29)43-26/h1-6,12-13,16-17,19-23,26,28-38,41H,7-8H2/b6-3+,14-11+/t12-,13-,16-,17-,19+,20+,21-,22-,23+,26-,27?/m1/s1	C1=CC(=CC=C1/C=C/C(=C\2/C(=C(C(=O)C(C2=O)([C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O)O)[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)/O)O	C1=CC(=CC=C1C=CC(=C2C(=C(C(=O)C(C2=O)(C3C(C(C(C(O3)CO)O)O)O)O)C4C(C(C(C(O4)CO)O)O)O)O)O)O	IAVUBSCVWHLRGE-UXEKTNMQSA-N	(6E)-2,5-dihydroxy-6-[(E)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2,4-bis[(2S,3R,4R,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione
ferrodrug0322	Chebulinic Acid	Small molecular drug	Chebulinic acid; 18942-26-2; NSC69862; CHEBI:3584; AC-31408; FT-0697896; Q-100932	D0Z9YK	DMR8HKC	956.7	C41H32O27	447	1880	0.7	68	13	27	12	InChI=1S/C41H32O27/c42-15-1-10(2-16(43)26(15)51)35(56)62-9-22-31-33(66-36(57)11-3-17(44)27(52)18(45)4-11)34(41(63-22)68-37(58)12-5-19(46)28(53)20(47)6-12)67-38(59)13-7-21(48)29(54)32-25(13)24(30(55)40(61)65-32)14(8-23(49)50)39(60)64-31/h1-7,14,22,24,30-31,33-34,41-48,51-55H,8-9H2,(H,49,50)/t14-,22+,24-,30-,31+,33-,34+,41-/m0/s1	C1=C(C=C(C(=C1O)O)O)C(=O)OC[C@@H]2[C@@H]3[C@@H]([C@H]([C@@H](O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5[C@H]([C@@H](C(=O)O3)CC(=O)O)[C@@H](C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O	C1=C(C=C(C(=C1O)O)O)C(=O)OCC2C3C(C(C(O2)OC(=O)C4=CC(=C(C(=C4)O)O)O)OC(=O)C5=CC(=C(C6=C5C(C(C(=O)O3)CC(=O)O)C(C(=O)O6)O)O)O)OC(=O)C7=CC(=C(C(=C7)O)O)O	YGVHOSGNOYKRIH-FJPMMHPYSA-N	2-[(4R,5S,7R,8R,11S,12S,13S,21S)-13,17,18-trihydroxy-2,10,14-trioxo-5,21-bis[(3,4,5-trihydroxybenzoyl)oxy]-7-[(3,4,5-trihydroxybenzoyl)oxymethyl]-3,6,9,15-tetraoxatetracyclo[10.7.1.14,8.016,20]henicosa-1(19),16(20),17-trien-11-yl]acetic acid
ferrodrug0323	SR8278	Small molecular drug	SR8278; 1254944-66-5; SR 8278; SR-8278; ethyl 2-{[5-(methylsulfanyl)thiophen-2-yl]carbonyl}-1,2,3,4-tetrahydroisoquinoline-3-carboxylate; CHEMBL4754504; ethyl 2-(5-(methylthio)thiophene-2-carbonyl)-1,2,3,4-tetrahydroisoquinoline-3-carboxylate; ethyl 2-(5-methylsulfanylthiophene-2-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate; 1,2,3,4-Tetrahydro-2-[[5-(methylthio)-2-thienyl]carbonyl]-3-isoquinolinecarboxylic acid ethyl ester; GTPL2904; SCHEMBL20488638; DTXSID80693813; SR8278, >=98%, semisolid; EX-A4711; BDBM50560413; AKOS024458171; AC-36621; AS-16390; HY-14415; CS-0003348; D80535; A899051; J-005234; Q27088866; ethyl2-(5-methylsulfanylthiophene-2-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate	D0K1VV	DMSK5N3	361.5	C18H19NO3S2	100	473	4.1	24	0	5	5	InChI=1S/C18H19NO3S2/c1-3-22-18(21)14-10-12-6-4-5-7-13(12)11-19(14)17(20)15-8-9-16(23-2)24-15/h4-9,14H,3,10-11H2,1-2H3	CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C3=CC=C(S3)SC	CCOC(=O)C1CC2=CC=CC=C2CN1C(=O)C3=CC=C(S3)SC	UIEBLUZPSFAFOC-UHFFFAOYSA-N	ethyl 2-(5-methylsulfanylthiophene-2-carbonyl)-3,4-dihydro-1H-isoquinoline-3-carboxylate
ferrodrug0324	Gambogenic Acid	.	Gambogenic Acid; 173932-75-7; (Z)-4-((1S,3aR,5S,12aS)-9-((E)-3,7-dimethylocta-2,6-dien-1-yl)-8,10-dihydroxy-2,2-dimethyl-11-(3-methylbut-2-en-1-yl)-4,7-dioxo-1,2,5,7-tetrahydro-1,5-methanofuro[2,3-d]xanthen-3a(4H)-yl)-2-methylbut-2-enoic acid; CHEMBL2205166; (Z)-4-[(1S,2S,13S,15R)-7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-enyl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.02,11.02,15.04,9]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid; HY-N5024; BDBM50256792; s9031; AKOS040759332; CCG-270288; AC-34876; CS-0032096	.	.	630.8	C38H46O8	130	1440	7.9	46	3	8	10	InChI=1S/C38H46O8/c1-20(2)10-9-11-22(5)13-15-25-30(39)26(14-12-21(3)4)33-29(31(25)40)32(41)27-18-24-19-28-36(7,8)46-37(34(24)42,38(27,28)45-33)17-16-23(6)35(43)44/h10,12-13,16,18,24,28,39-40H,9,11,14-15,17,19H2,1-8H3,(H,43,44)/b22-13+,23-16-/t24-,28+,37+,38-/m1/s1	CC(=CCC/C(=C/CC1=C(C(=C2C(=C1O)C(=O)C3=C[C@@H]4C[C@@H]5[C@@]3(O2)[C@](C4=O)(OC5(C)C)C/C=C(/C)\C(=O)O)CC=C(C)C)O)/C)C	CC(=CCCC(=CCC1=C(C(=C2C(=C1O)C(=O)C3=CC4CC5C3(O2)C(C4=O)(OC5(C)C)CC=C(C)C(=O)O)CC=C(C)C)O)C)C	RCWNBHCZYXWDOV-VSFMGBBVSA-N	(Z)-4-[(1S,2S,13S,15R)-7-[(2E)-3,7-dimethylocta-2,6-dienyl]-6,8-dihydroxy-17,17-dimethyl-5-(3-methylbut-2-enyl)-10,14-dioxo-3,16-dioxapentacyclo[11.4.1.02,11.02,15.04,9]octadeca-4,6,8,11-tetraen-15-yl]-2-methylbut-2-enoic acid
ferrodrug0325	Ardisiacrispin B	.	Ardisiacrispin B; 112766-96-8; CHEMBL220982; HY-N8198; AKOS040760274; MS-31927; CS-0140295	.	.	1075.2	C53H86O22	343	2060	-0.6	75	12	22	11	InChI=1S/C53H86O22/c1-23-32(58)36(62)39(65)43(69-23)75-42-38(64)34(60)25(19-55)71-46(42)72-26-20-67-45(41(35(26)61)74-44-40(66)37(63)33(59)24(18-54)70-44)73-31-10-11-49(5)27(47(31,2)3)8-12-50(6)28(49)9-13-53-29-16-48(4,21-56)14-15-52(29,22-68-53)30(57)17-51(50,53)7/h21,23-46,54-55,57-66H,8-20,22H2,1-7H3/t23-,24+,25+,26-,27-,28+,29+,30+,31-,32-,33+,34+,35-,36+,37-,38-,39+,40+,41+,42+,43-,44-,45-,46-,48-,49-,50+,51-,52+,53-/m0/s1	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2O[C@H]3CO[C@H]([C@@H]([C@H]3O)O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O[C@H]5CC[C@@]6([C@H]7CC[C@@]89[C@@H]1C[C@@](CC[C@]1(CO8)[C@@H](C[C@]9([C@@]7(CC[C@H]6C5(C)C)C)C)O)(C)C=O)C)CO)O)O)O)O)O	CC1C(C(C(C(O1)OC2C(C(C(OC2OC3COC(C(C3O)OC4C(C(C(C(O4)CO)O)O)O)OC5CCC6(C(C5(C)C)CCC7(C6CCC89C7(CC(C1(C8CC(CC1)(C)C=O)CO9)O)C)C)C)CO)O)O)O)O)O	ZDIHSHLFPFGAGP-LLEYBADXSA-N	(1S,2R,4S,5R,8R,10S,13R,14R,17S,18R,20S)-10-[(2S,3R,4S,5S)-5-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-6-(hydroxymethyl)-3-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-3-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyoxan-2-yl]oxy-2-hydroxy-4,5,9,9,13,20-hexamethyl-24-oxahexacyclo[15.5.2.01,18.04,17.05,14.08,13]tetracosane-20-carbaldehyde
ferrodrug0326	Talaroconvolutin A	.	Talaroconvolutin A; TalaA; (-)-talaroconvolutin A; CHEMBL495874; CHEBI:173105; (5Z)-3-[(1R,2S,4aS,6S,8aR)-3,4a,6-trimethyl-2-[(E)-4-methylhex-2-en-2-yl]-2,5,6,7,8,8a-hexahydro-1H-naphthalene-1-carbonyl]-5-[(4-hydroxyphenyl)methylidene]pyrrol-2-one; (5Z)-5-(4-hydroxybenzylidene)-3-({(1R,2S,4aS,6S,8aR)-3,4a,6-trimethyl-2-[(2E)-4-methylhex-2-en-2-yl]-1,2,4a,5,6,7,8,8a-octahydronaphthalen-1-yl}carbonyl)-1,5-dihydro-2H-pyrrol-2-one; 273199-42-1	.	.	487.7	C32H41NO3	66.4	993	7.9	36	2	3	6	InChI=1S/C32H41NO3/c1-7-19(2)14-21(4)28-22(5)18-32(6)17-20(3)8-13-27(32)29(28)30(35)26-16-24(33-31(26)36)15-23-9-11-25(34)12-10-23/h9-12,14-16,18-20,27-29,34H,7-8,13,17H2,1-6H3,(H,33,36)/b21-14+,24-15-/t19?,20-,27+,28-,29+,32+/m0/s1	CCC(C)/C=C(\C)/[C@@H]1[C@@H]([C@H]2CC[C@@H](C[C@@]2(C=C1C)C)C)C(=O)C3=C/C(=C/C4=CC=C(C=C4)O)/NC3=O	CCC(C)C=C(C)C1C(C2CCC(CC2(C=C1C)C)C)C(=O)C3=CC(=CC4=CC=C(C=C4)O)NC3=O	QCTUYJGFLVZOTL-NKPJVERHSA-N	(5Z)-3-[(1R,2S,4aS,6S,8aR)-3,4a,6-trimethyl-2-[(E)-4-methylhex-2-en-2-yl]-2,5,6,7,8,8a-hexahydro-1H-naphthalene-1-carbonyl]-5-[(4-hydroxyphenyl)methylidene]pyrrol-2-one
ferrodrug0327	Formosanin C	.	Formosanin C; 50773-42-7; CHEMBL503436; Pennogenin rahamnosyl chacotrioside; HY-N2389; s3279; AKOS040754473; CS-0022592	.	.	1015.2	C51H82O20	295	1900	0.2	71	10	20	9	InChI=1S/C51H82O20/c1-20-10-15-51(62-19-20)21(2)32-30(71-51)17-29-27-9-8-25-16-26(11-13-49(25,6)28(27)12-14-50(29,32)7)66-48-44(70-46-39(59)36(56)34(54)23(4)64-46)41(61)43(31(18-52)67-48)69-47-40(60)37(57)42(24(5)65-47)68-45-38(58)35(55)33(53)22(3)63-45/h8,20-24,26-48,52-61H,9-19H2,1-7H3/t20-,21+,22+,23+,24+,26+,27-,28+,29+,30+,31-,32+,33+,34+,35-,36-,37+,38-,39-,40-,41+,42+,43-,44-,45+,46+,47+,48-,49+,50+,51-/m1/s1	C[C@@H]1CC[C@@]2([C@H]([C@H]3[C@@H](O2)C[C@@H]4[C@@]3(CC[C@H]5[C@H]4CC=C6[C@@]5(CC[C@@H](C6)O[C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O[C@H]8[C@@H]([C@@H]([C@H]([C@@H](O8)C)O[C@H]9[C@@H]([C@@H]([C@H]([C@@H](O9)C)O)O)O)O)O)O)O[C@H]2[C@@H]([C@@H]([C@H]([C@@H](O2)C)O)O)O)C)C)C)OC1	CC1CCC2(C(C3C(O2)CC4C3(CCC5C4CC=C6C5(CCC(C6)OC7C(C(C(C(O7)CO)OC8C(C(C(C(O8)C)OC9C(C(C(C(O9)C)O)O)O)O)O)O)OC2C(C(C(C(O2)C)O)O)O)C)C)C)OC1	OZIHYFWYFUSXIS-HDDFSWBLSA-N	(2S,3R,4R,5R,6S)-2-[(2S,3R,4S,5R,6S)-4,5-dihydroxy-6-[(2R,3S,4S,5R,6R)-4-hydroxy-2-(hydroxymethyl)-6-[(1S,2S,4S,5'R,6R,7S,8R,9S,12S,13R,16S)-5',7,9,13-tetramethylspiro[5-oxapentacyclo[10.8.0.02,9.04,8.013,18]icos-18-ene-6,2'-oxane]-16-yl]oxy-5-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-2-methyloxan-3-yl]oxy-6-methyloxane-3,4,5-triol
ferrodrug0328	GSK3368715	Small molecular drug	1629013-22-4; GSK3368715; EPZ019997; N~1~-({5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)-N~1~,N~2~-dimethylethane-1,2-diamine; N'-[[5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N,N'-dimethylethane-1,2-diamine; N1-((3-(4,4-Bis(ethoxymethyl)cyclohexyl)-1H-pyrazol-4-yl)methyl)-N1,N2-dimethylethane-1,2-diamine; SCHEMBL16121956; EX-A4367; MFCD32174310; NSC823806; AKOS040733328; EPZ-019997; NSC-823806; GSK-3368715; N'-[[3-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N,N'-dimethyl-ethane-1,2-diamine; PS-18471; SY311406; HY-128717; CS-0099584; F88777; EN300-7443094; {2-[({3-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl}methyl)(methyl)amino]ethyl}(methyl)amine; KZS; N1-[[3-[4,4-Bis(ethoxymethyl)cyclohexyl]-4-pyrazolyl]methyl]-N1,N2-dimethylethane-1,2-diamine	DHYZ53	DMVEGND	366.5	C20H38N4O2	62.4	365	1.5	26	2	5	12	InChI=1S/C20H38N4O2/c1-5-25-15-20(16-26-6-2)9-7-17(8-10-20)19-18(13-22-23-19)14-24(4)12-11-21-3/h13,17,21H,5-12,14-16H2,1-4H3,(H,22,23)	CCOCC1(CCC(CC1)C2=C(C=NN2)CN(C)CCNC)COCC	CCOCC1(CCC(CC1)C2=C(C=NN2)CN(C)CCNC)COCC	SPEGERVLTUWZPA-UHFFFAOYSA-N	N'-[[5-[4,4-bis(ethoxymethyl)cyclohexyl]-1H-pyrazol-4-yl]methyl]-N,N'-dimethylethane-1,2-diamine
ferrodrug0329	Ulinastatin	Small molecular drug	80499-32-7; 2,4-Dioxaspiro[5.5]undec-8-ene, 3-(2-furanyl)-; 80449-32-7; 3-(FURAN-2-YL)-2,4-DIOXASPIRO[5.5]UNDEC-8-ENE; Trypsin inhibitor (human urine urinastatin protein moiety); 3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene; 2,4-Dioxaspiro(5.5)undec-8-ene, 3-(2-furanyl)-; Trypsin inhibitor (human urine urinastatin protein moiety)80499-32-7; Trypsin inhibitor MR-20; MR-20 (Magnetic powder); Uti(68); Acid-stable protease inhibitor; Urinary trypsin inhibitor (68); MR 20; UNII-OR3S9IF86U; Uristatin; Mingin; Urinary trypsin inhibitor-like inhibitor (43); Trypsin inhibitor UTI; Ulinastatin [INN:JAN]; Trypsin inhibitor, mingin; Trypsin inhibitor, bikunin; Urinary trypsin inhibitor 1; 3-(2-Furanyl)-2,4-dioxaspiro(5.5)undec-8-ene; DTXSID801001247; BCP08067; AKOS025401879; AC-26827; HY-21646; D77201; 9-(2-furyl)-8,10-dioxaspiro[5.5]undec-3-ene; UTI	D0DF1R	DMIQCFG	220.26	C13H16O3	31.6	266	2.1	16	0	3	1	InChI=1S/C13H16O3/c1-2-6-13(7-3-1)9-15-12(16-10-13)11-5-4-8-14-11/h1-2,4-5,8,12H,3,6-7,9-10H2	C1CC2(CC=C1)COC(OC2)C3=CC=CO3	C1CC2(CC=C1)COC(OC2)C3=CC=CO3	ODVKSTFPQDVPJZ-UHFFFAOYSA-N	3-(furan-2-yl)-2,4-dioxaspiro[5.5]undec-9-ene
ferrodrug0330	tagitinin C	.	tagitinin C; CHEMBL463060; MEGxp0_000077; BDBM50433428; [(3aR,4R,6R,7E,10Z,11aR)-6-hydroxy-6,10-dimethyl-3-methylidene-2,9-dioxo-3a,4,5,11a-tetrahydrocyclodeca[b]furan-4-yl] 2-methylpropanoate	.	.	348.4	C19H24O6	89.9	671	2.1	25	1	6	3	InChI=1S/C19H24O6/c1-10(2)17(21)25-15-9-19(5,23)7-6-13(20)11(3)8-14-16(15)12(4)18(22)24-14/h6-8,10,14-16,23H,4,9H2,1-3,5H3/b7-6+,11-8-/t14-,15-,16+,19+/m1/s1	C/C/1=C/[C@@H]2[C@@H]([C@@H](C[C@@](/C=C/C1=O)(C)O)OC(=O)C(C)C)C(=C)C(=O)O2	CC1=CC2C(C(CC(C=CC1=O)(C)O)OC(=O)C(C)C)C(=C)C(=O)O2	DUQSSEQKLJQACA-FESGBCJUSA-N	[(3aR,4R,6R,7E,10Z,11aR)-6-hydroxy-6,10-dimethyl-3-methylidene-2,9-dioxo-3a,4,5,11a-tetrahydrocyclodeca[b]furan-4-yl] 2-methylpropanoate
ferrodrug0331	Salicylaldehyde isonicotinoyl hydrazone	.	salicylaldehyde isonicotinoyl hydrazone; N-[(2-hydroxyphenyl)methylideneamino]pyridine-4-carboxamide; N'-[(2-HYDROXYPHENYL)METHYLIDENE]PYRIDINE-4-CARBOHYDRAZIDE; DTXSID0046272; Salinazid 100 microg/mL in Acetonitrile; CBDivE_001657; VBIZUNYMJSPHBH-UHFFFAOYSA-N; HMS2231I23; HMS3371L08; FT-0632228	.	.	241.24	C13H11N3O2	74.6	301	1.4	18	2	4	3	InChI=1S/C13H11N3O2/c17-12-4-2-1-3-11(12)9-15-16-13(18)10-5-7-14-8-6-10/h1-9,17H,(H,16,18)	C1=CC=C(C(=C1)C=NNC(=O)C2=CC=NC=C2)O	C1=CC=C(C(=C1)C=NNC(=O)C2=CC=NC=C2)O	VBIZUNYMJSPHBH-UHFFFAOYSA-N	N-[(2-hydroxyphenyl)methylideneamino]pyridine-4-carboxamide
ferrodrug0332	Tyrosylalanine	.	tyrosylalanine; YA dipeptide; Y-A Dipeptide; Tyrosine Alanine dipeptide; Tyrosine-Alanine dipeptide; SCHEMBL238987; NLKUJNGEGZDXGO-UHFFFAOYSA-N; YA; AKOS024319161	.	.	252.27	C12H16N2O4	113	301	-3.1	18	4	5	5	InChI=1S/C12H16N2O4/c1-7(12(17)18)14-11(16)10(13)6-8-2-4-9(15)5-3-8/h2-5,7,10,15H,6,13H2,1H3,(H,14,16)(H,17,18)	CC(C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)N	CC(C(=O)O)NC(=O)C(CC1=CC=C(C=C1)O)N	NLKUJNGEGZDXGO-UHFFFAOYSA-N	2-[[2-amino-3-(4-hydroxyphenyl)propanoyl]amino]propanoic acid
ferrodrug0333	Curculigoside	.	Curculigoside; 85643-19-2; curculigoside A; A6S7X76UM5; [5-hydroxy-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl 2,6-dimethoxybenzoate; beta-D-Glucopyranoside, 2-(((2,6-dimethoxybenzoyl)oxy)methyl)-4-hydroxyphenyl; beta-D-Glucopyranoside, 2-[[(2,6-dimethoxybenzoyl)oxy]methyl]-4-hydroxyphenyl; Curculigoside,(S); UNII-A6S7X76UM5; CHEMBL258048; DTXSID30234896; HMS3886E06; HY-N0705; MFCD00800689; s5457; AKOS015897151; trihydroxy-6-(hydroxymethyl)tetrahydro; CCG-269418; AC-33958; AS-56484; C3504; CS-0009721; -2H-pyran-2-yloxy)benzyl 2,6-dimethoxybenzoate; Q-100862; Q5194662; 5-hydroxy-2-((2S,3R,4S,5S,6R)-3,4,5-; 2-(((2,6-DIMETHOXYBENZOYL)OXY)METHYL)-4-HYDROXYPHENYL .BETA.-D-GLUCOPYRANOSIDE; (5-Hydroxy-2-{[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}phenyl)methyl 2,6-dimethoxybenzoate; [5-hydroxy-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl2,6-dimethoxybenzoate	.	.	466.4	C22H26O11	164	607	0.7	33	5	11	9	InChI=1S/C22H26O11/c1-29-14-4-3-5-15(30-2)17(14)21(28)31-10-11-8-12(24)6-7-13(11)32-22-20(27)19(26)18(25)16(9-23)33-22/h3-8,16,18-20,22-27H,9-10H2,1-2H3/t16-,18-,19+,20-,22-/m1/s1	COC1=C(C(=CC=C1)OC)C(=O)OCC2=C(C=CC(=C2)O)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O)O)O	COC1=C(C(=CC=C1)OC)C(=O)OCC2=C(C=CC(=C2)O)OC3C(C(C(C(O3)CO)O)O)O	SJJRKHVKAXVFJQ-QKYBYQKWSA-N	[5-hydroxy-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxyphenyl]methyl 2,6-dimethoxybenzoate
ferrodrug0334	BMS536924	.	BMS-536924; 468740-43-4; BMS536924; BMS 536924; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-[7-methyl-5-(4-morpholinyl)-1H-benzimidazol-2-yl]-2(1H)-pyridinone; 40E3AZG1MX; CHEMBL401930; (S)-4-((2-(3-chlorophenyl)-2-hydroxyethyl)amino)-3-(4-methyl-6-morpholino-1H-benzo[d]imidazol-2-yl)pyridin-2(1H)-one; CS-0117; HY-10262; KIN001-126; (3M)-4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-benzimidazol-2-yl]pyridin-2(1H)-one; 4-[[(2S)-2-(3-Chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one; UNII-40E3AZG1MX; (S)-4-((2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(4-METHYL-6-MORPHOLINO-1H-BENZO(D)IMIDAZOL-2-YL)PYRIDIN-2(1H)-ONE; 4-(((2S)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(7-METHYL-5-(4-MORPHOLINYL)-1H-BENZIMIDAZOL-2-YL)-2(1H)-PYRIDINONE; N6I; MLS006011171; SCHEMBL4132577; SCHEMBL15974144; BDBM27879; CHEBI:91454; BCP02116; EX-A4566; NSC761760; s1012; BMS 536924 [WHO-DD]; AKOS024458339; AKOS025149514; CCG-269544; NSC-761760; NCGC00346460-02; NCGC00346460-04; NCGC00346460-05; NCGC00346460-06; AC-32997; AS-78828; SMR004702940; SW218124-2; D94990; BMS-536924, >=98% (HPLC); J-514217; BRD-K34581968-001-01-2; Q27163296; Q27258319; 2(1H)-PYRIDINONE, 4-(((2S)-2-(3-CHLOROPHENYL)-2-HYDROXYETHYL)AMINO)-3-(7-METHYL-5-(4-MORPHOLINYL)-1H-BENZIMIDAZOL-2-YL)-; 4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-[4-methyl-6-(4-morpholinyl)-1,3-dihydrobenzimidazol-2-ylidene]-2-pyridinone; 4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[4-methyl-6-(morpholin-4-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydropyridin-2-one; 4-{[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino}-3-[7-methyl-5-(morpholin-4-yl)-1H-1,3-benzodiazol-2-yl]-1,2-dihydropyridin-2-one	.	.	480	C25H26ClN5O3	103	801	2.7	34	4	6	6	InChI=1S/C25H26ClN5O3/c1-15-11-18(31-7-9-34-10-8-31)13-20-23(15)30-24(29-20)22-19(5-6-27-25(22)33)28-14-21(32)16-3-2-4-17(26)12-16/h2-6,11-13,21,32H,7-10,14H2,1H3,(H,29,30)(H2,27,28,33)/t21-/m1/s1	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NC[C@H](C4=CC(=CC=C4)Cl)O)N5CCOCC5	CC1=CC(=CC2=C1N=C(N2)C3=C(C=CNC3=O)NCC(C4=CC(=CC=C4)Cl)O)N5CCOCC5	ZWVZORIKUNOTCS-OAQYLSRUSA-N	4-[[(2S)-2-(3-chlorophenyl)-2-hydroxyethyl]amino]-3-(4-methyl-6-morpholin-4-yl-1H-benzimidazol-2-yl)-1H-pyridin-2-one
ferrodrug0335	RSL3	Small molecular drug	RSL3; 1219810-16-8; 1S,3R-RSL3; RSL3 1S,3R-; (1S,3R)-RSL3; RSL3 (1S,3R-); CHEMBL4747331; (1S,3R)-Methyl 2-(2-chloroacetyl)-1-(4-(methoxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate; methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-(methoxycarbonyl)phenyl)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indole-3-carboxylate; methyl (1S,3R)-2-(2-chloroacetyl)-1-[4-(methoxycarbonyl)phenyl]-1H,2H,3H,4H,9H-pyrido[3,4-b]indole-3-carboxylate; methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate; RSL3 1S; SCHEMBL13402744; EX-A1392; BDBM50547192; NSC833292; s8155; AKOS030632788; CCG-269132; CS-5650; HY-100218A; NSC-833292; CID 1750826; AC-35345; AS-55795; K601; C21479; C71823; EN300-7365470; Q55879537; (1S,3R)-Methyl 2-(2-chloroacetyl)-2,3,4,9-tetrahydro-1-[4-(methoxycarbonyl)phenyl]-1H-pyrido[3,4-b]indole-3-carboxylate	.	DG60885	440.9	C23H21ClN2O5	88.7	696	3.5	31	1	5	6	InChI=1S/C23H21ClN2O5/c1-30-22(28)14-9-7-13(8-10-14)21-20-16(15-5-3-4-6-17(15)25-20)11-18(23(29)31-2)26(21)19(27)12-24/h3-10,18,21,25H,11-12H2,1-2H3/t18-,21+/m1/s1	COC(=O)[C@H]1CC2=C([C@@H](N1C(=O)CCl)C3=CC=C(C=C3)C(=O)OC)NC4=CC=CC=C24	COC(=O)C1CC2=C(C(N1C(=O)CCl)C3=CC=C(C=C3)C(=O)OC)NC4=CC=CC=C24	TXJZRSRTYPUYRW-NQIIRXRSSA-N	methyl (1S,3R)-2-(2-chloroacetyl)-1-(4-methoxycarbonylphenyl)-1,3,4,9-tetrahydropyrido[3,4-b]indole-3-carboxylate
ferrodrug0336	4-Methylumbelliferyl beta-D-xylopyranoside	.	6734-33-4; 4-Methylumbelliferyl beta-D-xylopyranoside; 4-Methylumbelliferyl-beta-D-xylopyranoside; 4-Methylumbelliferyl b-D-xylopyranoside; 4-Methylumbelliferyl beta-D-xyloside; Methylumbelliferyl-beta-D-xyloside; CHEMBL1938471; 4-Methylumbelliferyl beta-xyloside; 4-methyl-7-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxychromen-2-one; EINECS 229-784-4; MFCD00037607; 766N8850JA; 4-Methylumbelliferyl-; A-D-xylopyranoside; 4-Methyl-7-(beta-D-xylopyranosyloxy)-2H-1-benzopyran-2-one; 2H-1-Benzopyran-2-one, 4-methyl-7-(.beta.-D-xylopyranosyloxy)-; 4'-Methylumbelliferyl-b-D-xylose; 4-Methylumbelliferyl-beta-D-xyloside; 4-Methylumbelliferylb-D-xylopyranoside; SCHEMBL197177; UNII-766N8850JA; DTXSID10217687; 4-methylumbelliferyl-beta-xyloside; 2H-1-Benzopyran-2-one, 4-methyl-7-(b-D-xylopyranosyloxy)-; 2H-1-Benzopyran-2-one,4-methyl-7-(b-D-xylopyranosyloxy)-; 2H-1-Benzopyran-2-one, 4-methyl-7-(beta-D-xylopyranosyloxy)-; AMY41722; BDBM50361734; AKOS005257904; AKOS015899834; s12045; AS-70369; PD171160; 4-Methylumbelliferyl I(2)-D-xylopyranoside; HY-137824; 4-Methylumbelliferyl- beta -D-xylopyranoside; (4-Methylumbelliferone)-beta-D-xylopyranoside; Boc-(S)-3-Amino-4-(2-thienyl)butanoicacid; 4-METHYLUMBELLIFERONE-.BETA.-D-XYLOSIDE; 4-METHYLUMBELLIFERYL .BETA.-D-XYLOPYRANOSIDE; Q27894530; 4-METHYLUMBELLIFERYL .BETA.-D-XYLOPYRANOSIDE, (-)-; COUMARIN, 4-METHYL-7-(.BETA.-D-XYLOPYRANOSYLOXY)-; 7-(beta-D-Xylopyranosyloxy)-4-methyl-2H-1-benzopyran-2-one; 4-Methylumbelliferyl-beta-D-xylopyranoside, beta-xylosidase substrate; 4-METHYL-7-(.BETA.-D-XYLOPYRANOSYLOXY)-2H-1-BENZOPYRAN-2-ONE; 4-methyl-7-((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yloxy)-2H-chromen-2-one; 4-methyl-7-{[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxy}-2H-chromen-2-one; 4-methyl-7-(((2S,3R,4S,5R)-3,4,5-trihydroxytetrahydro-2H-pyran-2-yl)oxy)-2H-chromen-2-one	.	.	308.28	C15H16O7	105	463	-0.7	22	3	7	2	InChI=1S/C15H16O7/c1-7-4-12(17)22-11-5-8(2-3-9(7)11)21-15-14(19)13(18)10(16)6-20-15/h2-5,10,13-16,18-19H,6H2,1H3/t10-,13+,14-,15+/m1/s1	CC1=CC(=O)OC2=C1C=CC(=C2)O[C@H]3[C@@H]([C@H]([C@@H](CO3)O)O)O	CC1=CC(=O)OC2=C1C=CC(=C2)OC3C(C(C(CO3)O)O)O	JWIYLOHVJDJZOQ-KAOXEZKKSA-N	4-methyl-7-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxychromen-2-one
ferrodrug0337	Clausenamide	.	Clausenamide; 103541-15-7; (+)-Clausenamide; 109905-95-5; (-)-Clausenamide; (3R,4S,5S)-3-hydroxy-5-[(R)-hydroxy(phenyl)methyl]-1-methyl-4-phenylpyrrolidin-2-one; 3-hydroxy-5-[hydroxy(phenyl)methyl]-1-methyl-4-phenylpyrrolidin-2-one; ( )-Clausenamide; (3R,4S,5S)-3-Hydroxy-5-((R)-hydroxyphenylmethyl)-1-methyl-4-phenylpyrrolidin-2-one; (3R,4S,5S)-3-HYDROXY-5-[(R)-HYDROXY-PHENYL-METHYL]-1-METHYL-4-PHENYL-P YRROLIDIN-2-ONE; Zetaclausenamide; CHEMBL508970; SCHEMBL6369855; DTXSID10908462; 2-Pyrrolidinone,3-hydroxy-5-((R)-hydroxyphenylmethyl)-1-methyl-4-phenyl-, (3R,4S,5S)-rel; DL-Xylonic acid, 3,4-dideoxy-4-(methylamino)-3-phenyl-5-C-phenyl-, gamma-lactam, (S*)-	.	.	297.3	C18H19NO3	60.8	388	1.5	22	2	3	3	InChI=1S/C18H19NO3/c1-19-15(16(20)13-10-6-3-7-11-13)14(17(21)18(19)22)12-8-4-2-5-9-12/h2-11,14-17,20-21H,1H3/t14-,15-,16+,17+/m0/s1	CN1[C@@H]([C@@H]([C@H](C1=O)O)C2=CC=CC=C2)[C@@H](C3=CC=CC=C3)O	CN1C(C(C(C1=O)O)C2=CC=CC=C2)C(C3=CC=CC=C3)O	WGYGSZOQGYRGIP-MWDXBVQZSA-N	(3R,4S,5S)-3-hydroxy-5-[(R)-hydroxy(phenyl)methyl]-1-methyl-4-phenylpyrrolidin-2-one
ferrodrug0338	Typhaneoside	.	Typhaneoside; 104472-68-6; CHEMBL450526; CHEBI:191968; HY-N0712; s9076; AKOS037514873; CCG-270457; CS-0009730; 3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one	.	.	770.7	C34H42O20	313	1320	-2.1	54	11	20	9	InChI=1S/C34H42O20/c1-10-20(38)24(42)27(45)32(49-10)48-9-18-22(40)26(44)31(54-33-28(46)25(43)21(39)11(2)50-33)34(52-18)53-30-23(41)19-15(37)7-13(35)8-17(19)51-29(30)12-4-5-14(36)16(6-12)47-3/h4-8,10-11,18,20-22,24-28,31-40,42-46H,9H2,1-3H3/t10-,11-,18+,20-,21-,22+,24+,25+,26-,27+,28+,31+,32+,33-,34-/m0/s1	C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)OC[C@@H]2[C@H]([C@@H]([C@H]([C@@H](O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)OC)O[C@H]6[C@@H]([C@@H]([C@H]([C@@H](O6)C)O)O)O)O)O)O)O)O	CC1C(C(C(C(O1)OCC2C(C(C(C(O2)OC3=C(OC4=CC(=CC(=C4C3=O)O)O)C5=CC(=C(C=C5)O)OC)OC6C(C(C(C(O6)C)O)O)O)O)O)O)O)O	POMAQDQEVHXLGT-QDYYQVSOSA-N	3-[(2S,3R,4S,5S,6R)-4,5-dihydroxy-3-[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy-6-[[(2R,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxymethyl]oxan-2-yl]oxy-5,7-dihydroxy-2-(4-hydroxy-3-methoxyphenyl)chromen-4-one
ferrodrug0339	[4-[Bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone	.	1360705-96-9; ML-210; [4-[bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone; ML 210; (4-(bis(4-chlorophenyl)methyl)piperazin-1-yl)(5-methyl-4-nitroisoxazol-3-yl)methanone; ML210; CHEMBL1951048; CID 49766530; BRD7528; BRD-7528; TL_HRAS26; MLS003265661; SCHEMBL21965947; CHEBI:92034; HMS3874L03; BCP29439; EX-A3516; BDBM50547193; MFCD22666407; NCGC00386679-01; NCGC00386679-02; AC-36416; BM170835; BS-51618; SMR001941104; HY-100003; ML 210, >=98% (HPLC); CS-0017911; S0788; D83838; BRD-K01877528-001-01-6; BRD-K01877528-001-02-4; BRD-K01877528-001-03-2; BRD-K01877528-001-04-0; BRD-K01877528-001-07-3; BRD-K01877528-001-08-1; BRD-K01877528-001-09-9; BRD-K01877528-001-11-5; Q27163827; [4-[Bis(4-chlorophenyl)methyl]-1-piperazinyl](5-methyl-4-nitro-3-isoxazolyl)methanone; [4-[bis(4-chlorophenyl)methyl]-1-piperazinyl]-(5-methyl-4-nitro-3-isoxazolyl)methanone; CID 49766530; CID-49766530; CID49766530; ML-210; ML 210	.	.	475.3	C22H20Cl2N4O4	95.4	635	4.6	32	0	6	4	InChI=1S/C22H20Cl2N4O4/c1-14-20(28(30)31)19(25-32-14)22(29)27-12-10-26(11-13-27)21(15-2-6-17(23)7-3-15)16-4-8-18(24)9-5-16/h2-9,21H,10-13H2,1H3	CC1=C(C(=NO1)C(=O)N2CCN(CC2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)[N+](=O)[O-]	CC1=C(C(=NO1)C(=O)N2CCN(CC2)C(C3=CC=C(C=C3)Cl)C4=CC=C(C=C4)Cl)[N+](=O)[O-]	VIBHJPDPEVVDTB-UHFFFAOYSA-N	[4-[bis(4-chlorophenyl)methyl]piperazin-1-yl]-(5-methyl-4-nitro-1,2-oxazol-3-yl)methanone
ferrodrug0340	1,2-Dioxolane	.	1,2-Dioxolane; 4362-13-4; 3H-1,2-Dioxole, dihydro-; DTXSID10195890	.	.	74.08	C3H6O2	18.5	24.1	0.3	5	0	2	0	InChI=1S/C3H6O2/c1-2-4-5-3-1/h1-3H2	C1COOC1	C1COOC1	SNQXJPARXFUULZ-UHFFFAOYSA-N	dioxolane
ferrodrug0341	GW4869	.	GW4869; 6823-69-4; GW69A; GW 4869; GW-4869 HCl; GW4869 dihydrochloride; 6823-69-4 (HCl); GW-4869; (2E,2'E)-3,3'-(1,4-phenylene)bis(N-(4-(4,5-dihydro-1H-imidazol-2-yl)phenyl)acrylamide) dihydrochloride; p-Benzenediacrylanilide, 4 inverted exclamation marka,4 inverted exclamation marka inverted exclamation marka-di-2-imidazolin-2-yl-, dihydrochloride; GW554869A; N-SMase Inhibitor; (E)-3-[4-[(E)-3-[4-(4,5-dihydro-1H-imidazol-2-yl)anilino]-3-oxoprop-1-enyl]phenyl]-N-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]prop-2-enamide; EX-A1154; MFCD06411564; CS-6865; BS-17430; HY-19363; SR-01000946355; SR-01000946355-1; (E)-3-[4-[(E)-3-[4-(4,5-dihydro-1H-imidazol-2-yl)anilino]-3-oxoprop-1-enyl]phenyl]-N-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]prop-2-enamide;dihydrochloride; 2-Propenamide, 3,3'-(1,4-phenylene)bis[N-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]-, dihydrochloride; p-Benzenediacrylanilide,4invertedexclamationmarka,4invertedexclamationmarkainvertedexclamationmarka-di-2-imidazolin-2-yl-,dihydrochloride	.	.	577.5	C30H30Cl2N6O2	107	856	.	40	6	4	8	InChI=1S/C30H28N6O2.2ClH/c37-27(35-25-11-7-23(8-12-25)29-31-17-18-32-29)15-5-21-1-2-22(4-3-21)6-16-28(38)36-26-13-9-24(10-14-26)30-33-19-20-34-30;;/h1-16H,17-20H2,(H,31,32)(H,33,34)(H,35,37)(H,36,38);2*1H/b15-5+,16-6+;;	C1NC(=NC1)C2=CC=C(C=C2)NC(=O)/C=C/C3=CC=C(C=C3)/C=C/C(=O)NC4=CC=C(C=C4)C5=NCCN5.Cl.Cl	C1CN=C(N1)C2=CC=C(C=C2)NC(=O)C=CC3=CC=C(C=C3)C=CC(=O)NC4=CC=C(C=C4)C5=NCCN5.Cl.Cl	NSFKAZDTKIKLKT-CLEIDKRQSA-N	(E)-3-[4-[(E)-3-[4-(4,5-dihydro-1H-imidazol-2-yl)anilino]-3-oxoprop-1-enyl]phenyl]-N-[4-(4,5-dihydro-1H-imidazol-2-yl)phenyl]prop-2-enamide;dihydrochloride
ferrodrug0342	Aridanin	.	Aridanin; 81053-26-1; CHEBI:2822; CHEMBL505516; (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid; (4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)tetrahydropyran-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid; AC1L2JCT; KST-1A8590; DTXSID101001739; Olean-12-en-28-oic acid, 3-[[2-(acetylamino)-2-deoxy-.beta.-D-glucopyranosyl]oxy]-, (3.beta.)-; BDBM50591797; C08922; Q27105836; 3-({2-Deoxy-2-[(1-hydroxyethylidene)amino]hexopyranosyl}oxy)olean-12-en-28-oic acid; Olean-12-en-28-oic acid, 3-((2-(acetylamino)-2-deoxy-beta-D-glucopyranosyl)oxy)-, (3beta)-	.	.	659.9	C38H61NO8	146	1300	5.9	47	5	8	5	InChI=1S/C38H61NO8/c1-21(41)39-28-30(43)29(42)24(20-40)46-31(28)47-27-12-13-35(6)25(34(27,4)5)11-14-37(8)26(35)10-9-22-23-19-33(2,3)15-17-38(23,32(44)45)18-16-36(22,37)7/h9,23-31,40,42-43H,10-20H2,1-8H3,(H,39,41)(H,44,45)/t23-,24+,25-,26+,27-,28+,29+,30+,31-,35-,36+,37+,38-/m0/s1	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2CC[C@]3([C@H](C2(C)C)CC[C@@]4([C@@H]3CC=C5[C@]4(CC[C@@]6([C@H]5CC(CC6)(C)C)C(=O)O)C)C)C)CO)O)O	CC(=O)NC1C(C(C(OC1OC2CCC3(C(C2(C)C)CCC4(C3CC=C5C4(CCC6(C5CC(CC6)(C)C)C(=O)O)C)C)C)CO)O)O	VRFWJSCLROXBBW-FUHHSGJXSA-N	(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
ferrodrug0343	DO264	.	DO-264; 2301866-59-9; DO264; 1-[1-[3-chloro-4-[2-chloro-4-(trifluoromethoxy)phenoxy]pyridin-2-yl]piperidin-4-yl]-3-pyridin-3-ylthiourea; CHEMBL4444498; 1-(1-(3-Chloro-4-(2-chloro-4-(trifluoromethoxy)phenoxy)pyridin-2-yl)piperidin-4-yl)-3-(pyridin-3-yl)thiourea; SCHEMBL23111592; GTPL10250; PIEQDBPBBQPLPL-UHFFFAOYSA-N; DO-26; BCP31625; BSD86659; EX-A3811; BDBM50526084; DO 264; DO264;DO 264; AKOS037648996; BS-16210; HY-114157; CS-0077182; D80833	.	.	558.4	C23H20Cl2F3N5O2S	104	720	6.1	36	2	9	6	InChI=1S/C23H20Cl2F3N5O2S/c24-17-12-16(35-23(26,27)28)3-4-18(17)34-19-5-9-30-21(20(19)25)33-10-6-14(7-11-33)31-22(36)32-15-2-1-8-29-13-15/h1-5,8-9,12-14H,6-7,10-11H2,(H2,31,32,36)	C1CN(CCC1NC(=S)NC2=CN=CC=C2)C3=NC=CC(=C3Cl)OC4=C(C=C(C=C4)OC(F)(F)F)Cl	C1CN(CCC1NC(=S)NC2=CN=CC=C2)C3=NC=CC(=C3Cl)OC4=C(C=C(C=C4)OC(F)(F)F)Cl	PIEQDBPBBQPLPL-UHFFFAOYSA-N	1-[1-[3-chloro-4-[2-chloro-4-(trifluoromethoxy)phenoxy]pyridin-2-yl]piperidin-4-yl]-3-pyridin-3-ylthiourea
ferrodrug0344	Eupalinolide B	.	Eupalinolide A; Eupalinolide B; 877822-41-8; C24H30O9; Eupalinolide-A; 877822-40-7; DTXSID50855825; HY-N0753; AC-35004; CS-0009781; (3aR,4R,6Z,9S,10E,11aR)-9-(Acetyloxy)-6-[(acetyloxy)methyl]-10-methyl-3-methylidene-2-oxo-2,3,3a,4,5,8,9,11a-octahydrocyclodeca[b]furan-4-yl (2E)-4-hydroxy-2-methylbut-2-enoate	.	.	462.5	C24H30O9	125	909	1.2	33	1	9	9	InChI=1S/C24H30O9/c1-13(8-9-25)23(28)32-21-11-18(12-30-16(4)26)6-7-19(31-17(5)27)14(2)10-20-22(21)15(3)24(29)33-20/h6,8,10,19-22,25H,3,7,9,11-12H2,1-2,4-5H3/b13-8+,14-10+,18-6-/t19-,20+,21+,22-/m0/s1	C/C/1=C\[C@@H]2[C@@H]([C@@H](C/C(=C/C[C@@H]1OC(=O)C)/COC(=O)C)OC(=O)/C(=C/CO)/C)C(=C)C(=O)O2	CC1=CC2C(C(CC(=CCC1OC(=O)C)COC(=O)C)OC(=O)C(=CCO)C)C(=C)C(=O)O2	HPWMABTYJYZFLK-FHEQDPKSSA-N	[(3aR,4R,6Z,9S,10E,11aR)-9-acetyloxy-6-(acetyloxymethyl)-10-methyl-3-methylidene-2-oxo-3a,4,5,8,9,11a-hexahydrocyclodeca[b]furan-4-yl] (E)-4-hydroxy-2-methylbut-2-enoate
ferrodrug0345	MCTR1	.	MCTR1; 1784701-61-6; (4Z,7Z,9E,11E,13R,14S,16Z,19Z)-13-[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-14-hydroxydocosa-4,7,9,11,16,19-hexaenoic acid; L-gamma-glutamyl-S-[(1R,2E,4E,6Z,9Z)-12-carboxy-1-[(1S,3Z,6Z)-1-hydroxy-3,6-nonadien-1-yl]-2,4,6,9-dodecatetraen-1-yl]-L-cysteinyl-glycine; CHEBI:138202; AKOS040755873; Q60998626; (13R)-S-glutathionyl-(14S)-hydroxy-(4Z,7Z,9E,11E,16Z,19Z)-docosahexaenoic acid; L-gamma-glutamyl-S-[(3Z,6Z,9S,10R,11E,13E,15Z,18Z)-21-carboxy-9-hydroxyhenicosa-3,6,11,13,15,18-hexaen-10-yl]-L-cysteinylglycine	.	.	649.8	C32H47N3O9S	242	1100	0.5	45	7	11	25	InChI=1S/C32H47N3O9S/c1-2-3-4-5-11-14-17-26(36)27(18-15-12-9-7-6-8-10-13-16-19-29(38)39)45-23-25(31(42)34-22-30(40)41)35-28(37)21-20-24(33)32(43)44/h3-4,6-7,9-15,18,24-27,36H,2,5,8,16-17,19-23,33H2,1H3,(H,34,42)(H,35,37)(H,38,39)(H,40,41)(H,43,44)/b4-3-,7-6-,12-9+,13-10-,14-11-,18-15+/t24-,25-,26-,27+/m0/s1	CC/C=C\C/C=C\C[C@@H]([C@@H](/C=C/C=C/C=C\C/C=C\CCC(=O)O)SC[C@@H](C(=O)NCC(=O)O)NC(=O)CC[C@@H](C(=O)O)N)O	CCC=CCC=CCC(C(C=CC=CC=CCC=CCCC(=O)O)SCC(C(=O)NCC(=O)O)NC(=O)CCC(C(=O)O)N)O	NWYKIASJHFGEAN-CPMAONNBSA-N	(4Z,7Z,9E,11E,13R,14S,16Z,19Z)-13-[(2R)-2-[[(4S)-4-amino-4-carboxybutanoyl]amino]-3-(carboxymethylamino)-3-oxopropyl]sulfanyl-14-hydroxydocosa-4,7,9,11,16,19-hexaenoic acid
ferrodrug0346	Hydnocarpin D	.	Hydnocarpin D; CHEMBL89401	.	.	464.4	C25H20O9	135	772	3.3	34	4	9	4	InChI=1S/C25H20O9/c1-31-20-7-13(2-4-15(20)28)25-23(11-26)32-18-5-3-12(6-21(18)34-25)19-10-17(30)24-16(29)8-14(27)9-22(24)33-19/h2-10,23,25-29H,11H2,1H3/t23-,25-/m1/s1	COC1=C(C=CC(=C1)[C@@H]2[C@H](OC3=C(O2)C=C(C=C3)C4=CC(=O)C5=C(C=C(C=C5O4)O)O)CO)O	COC1=C(C=CC(=C1)C2C(OC3=C(O2)C=C(C=C3)C4=CC(=O)C5=C(C=C(C=C5O4)O)O)CO)O	ZYWKQKQEAVWKHD-ILBGXUMGSA-N	5,7-dihydroxy-2-[(2R,3R)-3-(4-hydroxy-3-methoxyphenyl)-2-(hydroxymethyl)-2,3-dihydro-1,4-benzodioxin-6-yl]chromen-4-one
ferrodrug0347	Diethylhexylphthalate	.	Diethylhexylphthalate; Di-(2-ethylhexyl) phthalate; CHEMBL402794; BDBM50371947; 1-O-[(2S)-2-ethylhexyl] 2-O-[(2R)-2-ethylhexyl] benzene-1,2-dicarboxylate	.	.	390.6	C24H38O4	52.6	394	7.4	28	0	4	16	InChI=1S/C24H38O4/c1-5-9-13-19(7-3)17-27-23(25)21-15-11-12-16-22(21)24(26)28-18-20(8-4)14-10-6-2/h11-12,15-16,19-20H,5-10,13-14,17-18H2,1-4H3/t19-,20+	CCCC[C@@H](CC)COC(=O)C1=CC=CC=C1C(=O)OC[C@@H](CC)CCCC	CCCCC(CC)COC(=O)C1=CC=CC=C1C(=O)OCC(CC)CCCC	BJQHLKABXJIVAM-BGYRXZFFSA-N	1-O-[(2R)-2-ethylhexyl] 2-O-[(2S)-2-ethylhexyl] benzene-1,2-dicarboxylate
ferrodrug0348	1,6-O,O-diacetylbritannilactone	.	1,6-O,O-diacetylbritannilactone; CHEMBL480459; [(4S)-4-[(3aR,4R,7aR)-4-acetyloxy-6-methyl-3-methylidene-2-oxo-3a,4,7,7a-tetrahydro-1-benzofuran-5-yl]pentyl] acetate	.	.	350.4	C19H26O6	78.9	617	1.9	25	0	6	8	InChI=1S/C19H26O6/c1-10(7-6-8-23-13(4)20)16-11(2)9-15-17(12(3)19(22)25-15)18(16)24-14(5)21/h10,15,17-18H,3,6-9H2,1-2,4-5H3/t10-,15+,17+,18-/m0/s1	CC1=C([C@@H]([C@H]2[C@@H](C1)OC(=O)C2=C)OC(=O)C)[C@@H](C)CCCOC(=O)C	CC1=C(C(C2C(C1)OC(=O)C2=C)OC(=O)C)C(C)CCCOC(=O)C	MVCCWTMPDBIKCJ-IMKJFWDFSA-N	[(4S)-4-[(3aR,4R,7aR)-4-acetyloxy-6-methyl-3-methylidene-2-oxo-3a,4,7,7a-tetrahydro-1-benzofuran-5-yl]pentyl] acetate
ferrodrug0349	Liproxstatin-1	.	Liproxstatin-1; 950455-15-9; Liproxstatin 1; N-(3-Chlorobenzyl)-1'H-spiro[piperidine-4,2'-quinoxalin]-3'-amine; N-[(3-chlorophenyl)methyl]spiro[4H-quinoxaline-3,4'-piperidine]-2-amine; N-[(3-CHLOROPHENYL)METHYL]-1'H-SPIRO[PIPERIDINE-4,2'-QUINOXALIN]-3'-AMINE; liproxstatin1; Lip-1; CHEMBL2094750; SCHEMBL17757281; EX-A558; CHEBI:173097; Liproxstatin-1, >98% (HPLC); BCP15985; DNDI1417503; MFCD14948691; s7699; AKOS001973583; CCG-175950; CS-3994; N-[(3-chlorophenyl)methyl]spiro[1,4-dihydroquinoxaline-3,4'-piperidine]-2-imine; AC-33023; BS-18273; HY-12726; EN300-202271; F17363; N-[(3-chlorophenyl)methyl]-1'H-spiro[piperidine-4,2'-quinoxaline]-3'-amine	.	.	340.8	C19H21ClN4	48.4	460	3.2	24	3	3	2	InChI=1S/C19H21ClN4/c20-15-5-3-4-14(12-15)13-22-18-19(8-10-21-11-9-19)24-17-7-2-1-6-16(17)23-18/h1-7,12,21,24H,8-11,13H2,(H,22,23)	C1CNCCC12C(=NCC3=CC(=CC=C3)Cl)NC4=CC=CC=C4N2	C1CNCCC12C(=NCC3=CC(=CC=C3)Cl)NC4=CC=CC=C4N2	YAFQFNOUYXZVPZ-UHFFFAOYSA-N	N-[(3-chlorophenyl)methyl]spiro[1,4-dihydroquinoxaline-3,4'-piperidine]-2-imine
ferrodrug0350	FIN56	.	FIN56; 1083162-61-1; N2,N7-dicyclohexyl-9-(hydroxyimino)-9H-fluorene-2,7-disulfonamide; FIN 56; FIN-56; 2-N,7-N-Dicyclohexyl-9-hydroxyiminofluorene-2,7-disulfonamide; FIN56;FIN 56; SCHEMBL21460308; CHEBI:176419; BCP29145; s8254; AKOS034831611; CCG-269836; CS-7632; BS-14396; HY-103087; C71305; A920909; N,N'-dicyclohexyl-9-(hydroxyimino)-9H-fluorene-2,7-disulfonamide; N(2),N(7)-dicyclohexyl-9-(hydroxyimino)-9H-fluorene-2,7-disulfonamide	.	.	517.7	C25H31N3O5S2	142	900	4.9	35	3	8	6	InChI=1S/C25H31N3O5S2/c29-26-25-23-15-19(34(30,31)27-17-7-3-1-4-8-17)11-13-21(23)22-14-12-20(16-24(22)25)35(32,33)28-18-9-5-2-6-10-18/h11-18,27-29H,1-10H2	C1CCC(CC1)NS(=O)(=O)C2=CC3=C(C=C2)C4=C(C3=NO)C=C(C=C4)S(=O)(=O)NC5CCCCC5	C1CCC(CC1)NS(=O)(=O)C2=CC3=C(C=C2)C4=C(C3=NO)C=C(C=C4)S(=O)(=O)NC5CCCCC5	JLCFMMIWBSZOIS-UHFFFAOYSA-N	2-N,7-N-dicyclohexyl-9-hydroxyiminofluorene-2,7-disulfonamide
ferrodrug0351	MI463	.	MI-463; 1628317-18-9; 4-methyl-5-((4-((6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl)amino)piperidin-1-yl)methyl)-1H-indole-2-carbonitrile; CHEMBL3780895; MI463; 4-methyl-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1H-indole-2-carbonitrile; SCHEMBL16092792; DZACSLYTXLZAAF-UHFFFAOYSA-N; BCP23982; EX-A1849; BDBM50455859; s7816; CCG-269582; CS-6219; AC-36210; BS-15946; HY-19809; A857526; 4-Methyl-5-[(4-{[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino}-1-piperidinyl)methyl]-1H-indole-2-carbonitrile; 4-methyl-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1H	.	.	484.5	C24H23F3N6S	109	751	5.9	34	2	9	5	InChI=1S/C24H23F3N6S/c1-14-15(2-3-21-19(14)8-17(11-28)31-21)12-33-6-4-16(5-7-33)32-22-20-9-18(10-24(25,26)27)34-23(20)30-13-29-22/h2-3,8-9,13,16,31H,4-7,10,12H2,1H3,(H,29,30,32)	CC1=C(C=CC2=C1C=C(N2)C#N)CN3CCC(CC3)NC4=C5C=C(SC5=NC=N4)CC(F)(F)F	CC1=C(C=CC2=C1C=C(N2)C#N)CN3CCC(CC3)NC4=C5C=C(SC5=NC=N4)CC(F)(F)F	DZACSLYTXLZAAF-UHFFFAOYSA-N	4-methyl-5-[[4-[[6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1H-indole-2-carbonitrile
ferrodrug0352	GAP 27	.	GAP 27; 198284-64-9; Gap27; Connexin mimetic peptide; Connexin43 mimetic peptide; DTXSID80432769; MFCD03456920; AKOS024456622; H-Ser-Arg-Pro-Thr-Glu-Lys-Thr-Ile-Phe-Ile-Ile-OH	.	.	1304.5	C60H101N15O17	534	2480	-6.2	92	18	20	42	InChI=1S/C60H101N15O17/c1-9-31(4)44(54(86)69-41(29-36-19-13-12-14-20-36)52(84)70-45(32(5)10-2)55(87)72-46(59(91)92)33(6)11-3)71-57(89)48(35(8)78)73-51(83)38(21-15-16-26-61)66-50(82)39(24-25-43(79)80)67-56(88)47(34(7)77)74-53(85)42-23-18-28-75(42)58(90)40(22-17-27-65-60(63)64)68-49(81)37(62)30-76/h12-14,19-20,31-35,37-42,44-48,76-78H,9-11,15-18,21-30,61-62H2,1-8H3,(H,66,82)(H,67,88)(H,68,81)(H,69,86)(H,70,84)(H,71,89)(H,72,87)(H,73,83)(H,74,85)(H,79,80)(H,91,92)(H4,63,64,65)/t31-,32-,33-,34+,35+,37-,38-,39-,40-,41-,42-,44-,45-,46-,47-,48-/m0/s1	CC[C@H](C)[C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)O)NC(=O)[C@H](CC1=CC=CC=C1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@@H]2CCCN2C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CO)N	CCC(C)C(C(=O)NC(C(C)CC)C(=O)O)NC(=O)C(CC1=CC=CC=C1)NC(=O)C(C(C)CC)NC(=O)C(C(C)O)NC(=O)C(CCCCN)NC(=O)C(CCC(=O)O)NC(=O)C(C(C)O)NC(=O)C2CCCN2C(=O)C(CCCN=C(N)N)NC(=O)C(CO)N	SXRAPDIXXYFGJG-MDAHIHQXSA-N	(2S,3S)-2-[[(2S,3S)-2-[[(2S)-2-[[(2S,3S)-2-[[(2S,3R)-2-[[(2S)-6-amino-2-[[(2S)-2-[[(2S,3R)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-amino-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxybutanoyl]amino]-4-carboxybutanoyl]amino]hexanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylpentanoyl]amino]-3-phenylpropanoyl]amino]-3-methylpentanoyl]amino]-3-methylpentanoic acid
ferrodrug0353	Imidazole ketone erastin	Small molecular drug	Imidazole ketone erastin; 1801530-11-9; IKE; PUN30119; Imidazole ketone erastinIKE; CHEMBL3629671; 3-(5-(2-(1H-imidazol-1-yl)acetyl)-2-isopropoxyphenyl)-2-((4-(2-(4-chlorophenoxy)acetyl)piperazin-1-yl)methyl)quinazolin-4(3H)-one; SCHEMBL16924899; BCP31858; BXC53011; EX-A3112; BDBM50126162; NSC819610; s8877; ZB1594; AKOS037648788; Ferroptosis inducer IKE; PUN-30119; NSC-819610; AC-35771; BS-15620; HY-114481; CS-0086985; D70076; IKE; Ferroptosis inducer IKE; PUN30119; PUN-30119; PUN 30119; 2-[[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]methyl]-3-[5-(2-imidazol-1-ylacetyl)-2-propan-2-yloxyphenyl]quinazolin-4-one	.	DG68267	655.1	C35H35ClN6O5	110	1120	4.5	47	0	8	11	InChI=1S/C35H35ClN6O5/c1-24(2)47-32-12-7-25(31(43)20-40-14-13-37-23-40)19-30(32)42-33(38-29-6-4-3-5-28(29)35(42)45)21-39-15-17-41(18-16-39)34(44)22-46-27-10-8-26(36)9-11-27/h3-14,19,23-24H,15-18,20-22H2,1-2H3	CC(C)OC1=C(C=C(C=C1)C(=O)CN2C=CN=C2)N3C(=NC4=CC=CC=C4C3=O)CN5CCN(CC5)C(=O)COC6=CC=C(C=C6)Cl	CC(C)OC1=C(C=C(C=C1)C(=O)CN2C=CN=C2)N3C(=NC4=CC=CC=C4C3=O)CN5CCN(CC5)C(=O)COC6=CC=C(C=C6)Cl	PSPXJPWGVFNGQI-UHFFFAOYSA-N	2-[[4-[2-(4-chlorophenoxy)acetyl]piperazin-1-yl]methyl]-3-[5-(2-imidazol-1-ylacetyl)-2-propan-2-yloxyphenyl]quinazolin-4-one
ferrodrug0354	SRS 16-86	.	SRS16-86; 1793052-96-6; tert-butyl 4-(1-adamantylamino)-3-(pyrimidin-5-ylmethylideneamino)benzoate; 3-[(Z)-(5-pyrimidinylmethylene)amino]-4-(tricyclo[3.3.1.13,7]dec-1-ylamino)-benzoic acid, 1,1-dimethylethyl ester; CHEMBL3781699; SCHEMBL16799435; SCHEMBL16801340; SCHEMBL21394329; CHEBI:173096; s9840; SRS 16-86; AKOS040759650; MS-27720; HY-135430; CS-0112778; (Z)-tert-Butyl 4-(adamantan-1-ylamino)-3-((pyrimidin-5-ylmethylene)amino)benzoate; tert-butyl 4-[(adamantan-1-yl)amino]-3-{(Z)-[(pyrimidin-5-yl)methylidene]amino}benzoate; 3-[(Z)-(5-pyrimidinylmethylene)amino]-4-(tricyclo[3.3.1.1(3,7)]dec-1-ylamino)-benzoic acid 1,1-dimethylethyl ester; tert-butyl 3-[(Z)-(pyrimidin-5-ylmethylidene)amino]-4-(tricyclo[3.3.1.1(3,7)]decan-1-ylamino)benzoate	.	.	432.6	C26H32N4O2	76.5	668	5	32	1	6	7	InChI=1S/C26H32N4O2/c1-25(2,3)32-24(31)21-4-5-22(23(9-21)29-15-20-13-27-16-28-14-20)30-26-10-17-6-18(11-26)8-19(7-17)12-26/h4-5,9,13-19,30H,6-8,10-12H2,1-3H3	CC(C)(C)OC(=O)C1=CC(=C(C=C1)NC23CC4CC(C2)CC(C4)C3)N=CC5=CN=CN=C5	CC(C)(C)OC(=O)C1=CC(=C(C=C1)NC23CC4CC(C2)CC(C4)C3)N=CC5=CN=CN=C5	DFENTOUMMDWZAF-UHFFFAOYSA-N	tert-butyl 4-(1-adamantylamino)-3-(pyrimidin-5-ylmethylideneamino)benzoate
ferrodrug0355	Hepcidin	.	Hepcidin; Hepcidin-25 (human); UNII-XUH21YGS7O; Hepcidin [USAN]; 1356390-47-0; hepcidin-25; XUH21YGS7O; WHO 11354; Asp-thr-his-phe-pro-ile-cys-ile-phe-cys-cys-gly-cys-cys-his-arg-ser-lys-cys-gly-met-cys-cys-lys-thr (7->23),(10->13),(11->19),(14->22)-tetrakis(disulfide)	.	.	2789.4	C113H170N34O31S9	1250	5940	-10.9	187	36	46	49	InChI=1S/C113H170N34O31S9/c1-8-56(3)86-108(173)132-69(36-60-22-12-10-13-23-60)97(162)139-80-52-183-182-48-76-101(166)140-78-50-185-186-51-79(138-95(160)68(30-35-179-7)126-83(151)43-122-91(156)74(46-180-181-47-75(137-104(80)169)92(157)123-44-84(152)127-76)136-94(159)65(26-16-18-31-114)129-100(165)73(45-148)135-93(158)67(28-20-33-121-113(117)118)128-98(163)70(131-103(78)168)38-62-41-119-54-124-62)105(170)141-77(102(167)130-66(27-17-19-32-115)96(161)146-89(59(6)150)112(177)178)49-184-187-53-81(106(171)143-86)142-109(174)87(57(4)9-2)144-107(172)82-29-21-34-147(82)111(176)72(37-61-24-14-11-15-25-61)134-99(164)71(39-63-42-120-55-125-63)133-110(175)88(58(5)149)145-90(155)64(116)40-85(153)154/h10-15,22-25,41-42,54-59,64-82,86-89,148-150H,8-9,16-21,26-40,43-53,114-116H2,1-7H3,(H,119,124)(H,120,125)(H,122,156)(H,123,157)(H,126,151)(H,127,152)(H,128,163)(H,129,165)(H,130,167)(H,131,168)(H,132,173)(H,133,175)(H,134,164)(H,135,158)(H,136,159)(H,137,169)(H,138,160)(H,139,162)(H,140,166)(H,141,170)(H,142,174)(H,143,171)(H,144,172)(H,145,155)(H,146,161)(H,153,154)(H,177,178)(H4,117,118,121)/t56-,57-,58+,59+,64-,65-,66-,67-,68-,69-,70-,71-,72-,73-,74-,75-,76-,77-,78-,79-,80-,81-,82-,86-,87-,88-,89-/m0/s1	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H]4CSSC[C@@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H]([C@@H](C)CC)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CC6=CC=CC=C6)NC(=O)[C@H](CC7=CNC=N7)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(=O)O)N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(=O)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CSSC[C@@H](C(=O)NCC(=O)N3)NC2=O)NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H](NC4=O)CC8=CNC=N8)CCCNC(=N)N)CO)CCCCN)CCSC)CC9=CC=CC=C9	CCC(C)C1C(=O)NC(C(=O)NC2CSSCC3C(=O)NC4CSSCC(C(=O)NC(CSSCC(C(=O)N1)NC(=O)C(C(C)CC)NC(=O)C5CCCN5C(=O)C(CC6=CC=CC=C6)NC(=O)C(CC7=CNC=N7)NC(=O)C(C(C)O)NC(=O)C(CC(=O)O)N)C(=O)NC(CCCCN)C(=O)NC(C(C)O)C(=O)O)NC(=O)C(NC(=O)CNC(=O)C(CSSCC(C(=O)NCC(=O)N3)NC2=O)NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC4=O)CC8=CNC=N8)CCCNC(=N)N)CO)CCCCN)CCSC)CC9=CC=CC=C9	XJOTXKZIRSHZQV-RXHOOSIZSA-N	(3S)-3-amino-4-[[(2S,3R)-1-[[(2S)-1-[[(2S)-1-[(2S)-2-[[(2S,3S)-1-[[(1R,6R,12R,17R,20S,23S,26R,31R,34R,39R,42S,45S,48S,51S,59S)-51-(4-aminobutyl)-31-[[(2S)-6-amino-1-[[(1S,2R)-1-carboxy-2-hydroxypropyl]amino]-1-oxohexan-2-yl]carbamoyl]-20-benzyl-23-[(2S)-butan-2-yl]-45-(3-carbamimidamidopropyl)-48-(hydroxymethyl)-42-(1H-imidazol-4-ylmethyl)-59-(2-methylsulfanylethyl)-7,10,19,22,25,33,40,43,46,49,52,54,57,60,63,64-hexadecaoxo-3,4,14,15,28,29,36,37-octathia-8,11,18,21,24,32,41,44,47,50,53,55,58,61,62,65-hexadecazatetracyclo[32.19.8.26,17.212,39]pentahexacontan-26-yl]amino]-3-methyl-1-oxopentan-2-yl]carbamoyl]pyrrolidin-1-yl]-1-oxo-3-phenylpropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-3-hydroxy-1-oxobutan-2-yl]amino]-4-oxobutanoic acid
ferrodrug0356	2-Imino-6-methoxy-2H-chromene-3-carbothioamide	.	2-Imino-6-methoxy-2H-chromene-3-carbothioamide; 2-imino-6-methoxychromene-3-carbothioamide; NSC684971; 71796-75-3; CHEMBL2004669; DTXSID20356657; STL171476; AKOS003794097; NSC-684971; NCI60_030552; 2-imino-6-methoxy-chromene-3-carbothioamide; 2-imino-6-methoxychromene-3-carboximidothioic acid; AH-034/06206012	.	.	234.28	C11H10N2O2S	100	354	1.7	16	2	4	2	InChI=1S/C11H10N2O2S/c1-14-7-2-3-9-6(4-7)5-8(11(13)16)10(12)15-9/h2-5,12H,1H3,(H2,13,16)	COC1=CC2=C(C=C1)OC(=N)C(=C2)C(=S)N	COC1=CC2=C(C=C1)OC(=N)C(=C2)C(=S)N	LUCOUNTXDLWPQS-UHFFFAOYSA-N	2-imino-6-methoxychromene-3-carbothioamide
ferrodrug0357	3,5-bis((E)-2-fluorobenzylidene)piperidin-4-one hydrochloride	.	EF24; 342808-40-6; 3,5-Bis[(2-fluorophenyl)methylene]-4-piperidinone; 3,5-bis((E)-2-fluorobenzylidene)piperidin-4-one hydrochloride; (3E,5E)-3,5-bis[(2-fluorophenyl)methylidene]piperidin-4-one;hydrochloride	.	.	347.8	C19H16ClF2NO	29.1	458	.	24	2	4	2	InChI=1S/C19H15F2NO.ClH/c20-17-7-3-1-5-13(17)9-15-11-22-12-16(19(15)23)10-14-6-2-4-8-18(14)21;/h1-10,22H,11-12H2;1H/b15-9+,16-10+;	C\1NC/C(=C\C2=CC=CC=C2F)/C(=O)/C1=C/C3=CC=CC=C3F.Cl	C1C(=CC2=CC=CC=C2F)C(=O)C(=CC3=CC=CC=C3F)CN1.Cl	ILMJCEBAMHGBAA-XETSTSIRSA-N	(3E,5E)-3,5-bis[(2-fluorophenyl)methylidene]piperidin-4-one;hydrochloride
ferrodrug0358	Cyanidin-3-glucoside	.	Cyanidin 3-glucoside; 7084-24-4; Cyanidin 3-O-glucoside; cyanidin-3-o-glucoside chloride; 2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride; 27214-71-7; Chrysanthemin; (2S,3R,4S,5S,6R)-2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride; C21-H21-O11.Cl; Chrysontemin;Cyanidin 3-O-glucoside chloride; Cyanidin galactoside; Cyanindin-3-Gal; Idaein; Ideain; Ideanin; CHEBI:189578; BCP28559; AKOS015968430; FT-0638681; Chrysontemin; Cyanidin 3-O-glucoside chloride; A818960; 2-[[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-1-benzopyrylium-3-yl]oxy]-6-(hydroxymethyl)oxane-3,4,5-triol chloride; 2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxy-chromenylium-3-yl]oxy-6-(hydroxymethyl)tetrahydropyran-3,4,5-triol chloride	.	.	484.8	C21H21ClO11	181	623	.	33	8	11	4	InChI=1S/C21H20O11.ClH/c22-7-16-17(27)18(28)19(29)21(32-16)31-15-6-10-12(25)4-9(23)5-14(10)30-20(15)8-1-2-11(24)13(26)3-8;/h1-6,16-19,21-22,27-29H,7H2,(H3-,23,24,25,26);1H	C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2OC4C(C(C(C(O4)CO)O)O)O)O)O)O)O.[Cl-]	C1=CC(=C(C=C1C2=[O+]C3=CC(=CC(=C3C=C2OC4C(C(C(C(O4)CO)O)O)O)O)O)O)O.[Cl-]	YTMNONATNXDQJF-UHFFFAOYSA-N	2-[2-(3,4-dihydroxyphenyl)-5,7-dihydroxychromenylium-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol;chloride
ferrodrug0359	Kayadiol	.	KAYADIOL; CHEMBL1277840; BDBM50483054	.	.	306.5	C20H34O2	40.5	439	4.7	22	2	2	5	InChI=1S/C20H34O2/c1-15(10-13-21)6-8-17-16(2)7-9-18-19(3,14-22)11-5-12-20(17,18)4/h10,17-18,21-22H,2,5-9,11-14H2,1,3-4H3/b15-10-/t17-,18-,19-,20+/m0/s1	C/C(=C/CO)/CC[C@H]1C(=C)CC[C@@H]2[C@@]1(CCC[C@@]2(C)CO)C	CC(=CCO)CCC1C(=C)CCC2C1(CCCC2(C)CO)C	MJHWZTRFACWHTA-COPBVACWSA-N	(Z)-5-[(1S,4aR,5R,8aR)-5-(hydroxymethyl)-5,8a-dimethyl-2-methylidene-3,4,4a,6,7,8-hexahydro-1H-naphthalen-1-yl]-3-methylpent-2-en-1-ol
ferrodrug0360	LCZ696	Small molecular drug	LCZ-696; LCZ696 (Valsarta + sacubitril); sodium (S)-5-(4'-((N-(1-carboxylato-2-methylpropyl)pentanamido)methyl)-[1,1'-biphenyl]-2-yl)tetrazol-1-ide 4-(((2S,4R)-1-([1,1'-biphenyl]-4-yl)-5-ethoxy-4-methyl-5-oxopentan-2-yl)amino)-4-oxobutanoate hydrate; LCZ-696A; BCP10630; Q6457467; Trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;hydrate	.	DG01295	931	C48H57N6Na3O9	197	1140	.	66	2	13	20	InChI=1S/C24H29N5O3.C24H29NO5.3Na.H2O/c1-4-5-10-21(30)29(22(16(2)3)24(31)32)15-17-11-13-18(14-12-17)19-8-6-7-9-20(19)23-25-27-28-26-23;1-3-30-24(29)17(2)15-21(25-22(26)13-14-23(27)28)16-18-9-11-20(12-10-18)19-7-5-4-6-8-19;;;;/h6-9,11-14,16,22H,4-5,10,15H2,1-3H3,(H2,25,26,27,28,31,32);4-12,17,21H,3,13-16H2,1-2H3,(H,25,26)(H,27,28);;;;1H2/q;;3*+1;/p-3/t22-;17-,21+;;;;/m01..../s1	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)[C@@H](C(C)C)C(=O)[O-].CCOC(=O)[C@H](C)C[C@@H](CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.[Na+].[Na+].[Na+]	CCCCC(=O)N(CC1=CC=C(C=C1)C2=CC=CC=C2C3=NN=N[N-]3)C(C(C)C)C(=O)[O-].CCOC(=O)C(C)CC(CC1=CC=C(C=C1)C2=CC=CC=C2)NC(=O)CCC(=O)[O-].O.[Na+].[Na+].[Na+]	UOLUPHRXIRFONO-JOYYXRJNSA-K	trisodium;4-[[(2S,4R)-5-ethoxy-4-methyl-5-oxo-1-(4-phenylphenyl)pentan-2-yl]amino]-4-oxobutanoate;(2S)-3-methyl-2-[pentanoyl-[[4-[2-(1,2,3-triaza-4-azanidacyclopenta-2,5-dien-5-yl)phenyl]phenyl]methyl]amino]butanoate;hydrate
ferrodrug0361	JP4-039	.	JP4-039; CHEMBL3326504	.	.	424.6	C23H42N3O4	71.7	602	3.7	30	2	4	9	InChI=1S/C23H42N3O4/c1-16(2)13-17(25-20(28)30-21(3,4)5)11-10-12-19(27)24-18-14-22(6,7)26(29)23(8,9)15-18/h10-11,16-18H,12-15H2,1-9H3,(H,24,27)(H,25,28)/b11-10+/t17-/m1/s1	CC(C)C[C@@H](/C=C/CC(=O)NC1CC(N(C(C1)(C)C)[O])(C)C)NC(=O)OC(C)(C)C	CC(C)CC(C=CCC(=O)NC1CC(N(C(C1)(C)C)[O])(C)C)NC(=O)OC(C)(C)C	AJHRJWQXDNEJAG-SXSDINLZSA-N	.
ferrodrug0362	1-Methylnaphthalene-4-propionate endoperoxide	.	1-Methylnaphthalene-4-propionate endoperoxide; SCHEMBL86110; 3-(1,4-epidioxy-4-methyl-1,4-dihydro-1-naphthyl)propionic acid; 3-(8-Methyl-9,10-dioxatricyclo[6.2.2.02,7]dodeca-2,4,6,11-tetraen-1-yl)propanoic acid	.	.	246.26	C14H14O4	55.8	391	1.7	18	1	4	3	InChI=1S/C14H14O4/c1-13-8-9-14(18-17-13,7-6-12(15)16)11-5-3-2-4-10(11)13/h2-5,8-9H,6-7H2,1H3,(H,15,16)	CC12C=CC(C3=CC=CC=C31)(OO2)CCC(=O)O	CC12C=CC(C3=CC=CC=C31)(OO2)CCC(=O)O	ANJQRGGBEZTGOB-UHFFFAOYSA-N	3-(8-methyl-9,10-dioxatricyclo[6.2.2.02,7]dodeca-2,4,6,11-tetraen-1-yl)propanoic acid
ferrodrug0363	Fucoidan	.	(2S,3S,4S,5S,6R)-4,5-Dihydroxy-2,6-dimethyltetrahydro-2H-pyran-3-yl hydrogen sulfate; Fucoidan - Ascophyllum nodosum; Fucoidan - Alaria; Fucoidan - Ecklonia; Fucoidan - Durvillea; Fucoidan - Sargassum; Fucoidan - Cladosiphon; Fucoidan - Fucus serratus; Fucoidan - Fucus vesiculosus; Fucoidan - Laminaria digitata; Fucoidan - Laminaria japonicia; Fucoidan - Lessonia nigrescens; Fucoidan - Macrocystis pyrifera; Fucoidan - Pelvetia canaliculata; YF01606; YF09360; YF09361; YF09362; YF09363; YF57714; YF145109; YF146833; YF146834; YF153483; YF157138; YF157165; YF157166; YF157167; Fucoidan - Ascophyllum nodosum, analytical grade	.	.	242.25	C7H14O7S	122	308	-1.5	15	3	7	2	InChI=1S/C7H14O7S/c1-3-5(8)6(9)7(4(2)13-3)14-15(10,11)12/h3-9H,1-2H3,(H,10,11,12)/t3-,4+,5-,6+,7-/m1/s1	C[C@@H]1[C@H]([C@@H]([C@@H]([C@@H](O1)C)OS(=O)(=O)O)O)O	CC1C(C(C(C(O1)C)OS(=O)(=O)O)O)O	NLMDZXKCTWKRSQ-IBISWUOJSA-N	[(2S,3S,4S,5S,6R)-4,5-dihydroxy-2,6-dimethyloxan-3-yl] hydrogen sulfate
ferrodrug0364	Ferroptocide	.	Ferroptocide; CHEMBL5075911; CHEBI:173106; (2S,3aS,4S,5R,7R,8S,8aS,9R)-5-(1,3-dioxo-2-phenyl-2,3,5,8-tetrahydro-1H-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-2,8a-dihydroxy-4,8,9-trimethyl-1-oxooctahydro-1H-3a,8-propanoazulen-7-yl chloroacetate	.	.	586.1	C30H36ClN3O7	128	1190	3.2	41	2	7	5	InChI=1S/C30H36ClN3O7/c1-17-9-11-29-14-22(35)25(37)30(29,40)28(17,3)23(41-24(36)15-31)13-21(18(29)2)19-10-12-32-26(38)34(27(39)33(32)16-19)20-7-5-4-6-8-20/h4-8,10,17-18,21-23,35,40H,9,11-16H2,1-3H3/t17-,18+,21-,22+,23-,28+,29+,30-/m1/s1	C[C@@H]1CC[C@@]23C[C@@H](C(=O)[C@]2([C@@]1([C@@H](C[C@H]([C@@H]3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O	CC1CCC23CC(C(=O)C2(C1(C(CC(C3C)C4=CCN5C(=O)N(C(=O)N5C4)C6=CC=CC=C6)OC(=O)CCl)C)O)O	LLYJISDUHFXOHK-GOCONZMPSA-N	[(1S,3S,5S,6S,7R,9R,10S,13R)-9-(1,3-dioxo-2-phenyl-5,8-dihydro-[1,2,4]triazolo[1,2-a]pyridazin-6-yl)-3,5-dihydroxy-6,10,13-trimethyl-4-oxo-7-tricyclo[4.4.3.01,5]tridecanyl] 2-chloroacetate
ferrodrug0365	Punicalin	.	Punicalin; 65995-64-4; CHEBI:167696; DTXSID301030154; AKOS037514809; Q-100755	.	.	782.5	C34H22O22	377	1580	-0.3	56	13	22	0	InChI=1S/C34H22O22/c35-6-1-4-9(19(39)17(6)37)11-15-13-14-16(33(50)56-28(13)23(43)21(11)41)12(22(42)24(44)29(14)55-32(15)49)10-5(2-7(36)18(38)20(10)40)31(48)54-27-8(3-52-30(4)47)53-34(51)26(46)25(27)45/h1-2,8,25-27,34-46,51H,3H2/t8-,25-,26-,27-,34?/m1/s1	C1[C@@H]2[C@H]([C@@H]([C@H](C(O2)O)O)O)OC(=O)C3=CC(=C(C(=C3C4=C(C(=C5C6=C4C(=O)OC7=C(C(=C(C8=C(C(=C(C=C8C(=O)O1)O)O)O)C(=C67)C(=O)O5)O)O)O)O)O)O)O	C1C2C(C(C(C(O2)O)O)O)OC(=O)C3=CC(=C(C(=C3C4=C(C(=C5C6=C4C(=O)OC7=C(C(=C(C8=C(C(=C(C=C8C(=O)O1)O)O)O)C(=C67)C(=O)O5)O)O)O)O)O)O)O	IQHIEHIKNWLKFB-OBOTWMKHSA-N	(10S,11R,12R,15R)-3,4,5,11,12,13,21,22,23,26,27,38,39-tridecahydroxy-9,14,17,29,36-pentaoxaoctacyclo[29.8.0.02,7.010,15.019,24.025,34.028,33.032,37]nonatriaconta-1(39),2,4,6,19,21,23,25,27,31,33,37-dodecaene-8,18,30,35-tetrone
ferrodrug0366	BEBT-908	.	BEBT-908; 1235449-52-1; CUDC-908; DQ7TD3X4ZJ; N-hydroxy-2-[methyl-[[2-[6-(methylamino)pyridin-3-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide; BEBT-908CUDC-908; 5-Pyrimidinecarboxamide, N-hydroxy-2-(methyl((2-(6-(methylamino)-3-pyridinyl)-4-(4-morpholinyl)thieno(3,2-d)pyrimidin-6-yl)methyl)amino)-; N-Hydroxy-2-(methyl((2-(6-(methylamino)-3-pyridinyl)-4-(4-morpholinyl)thieno(3,2-d)pyrimidin-6-yl)methyl)amino)-5-pyrimidinecarboxamide; PI3Ka inhibitor 1; UNII-DQ7TD3X4ZJ; BEBT908 FREE BASE; BEBT-908 FREE BASE; CUDC 908; SCHEMBL1284514; BCP17145; EX-A1176; CS-5445; AC-36829; HY-19763; MS-29429; F85359; A906906; PI3KAfAE'A centa' notA inverted exclamation markAfasA'A; AfAE'Adaggeratrade mark? inhibitor 1	.	.	507.6	C23H25N9O3S	170	725	1.4	36	3	12	7	InChI=1S/C23H25N9O3S/c1-24-18-4-3-14(10-25-18)20-28-17-9-16(36-19(17)21(29-20)32-5-7-35-8-6-32)13-31(2)23-26-11-15(12-27-23)22(33)30-34/h3-4,9-12,34H,5-8,13H2,1-2H3,(H,24,25)(H,30,33)	CNC1=NC=C(C=C1)C2=NC3=C(C(=N2)N4CCOCC4)SC(=C3)CN(C)C5=NC=C(C=N5)C(=O)NO	CNC1=NC=C(C=C1)C2=NC3=C(C(=N2)N4CCOCC4)SC(=C3)CN(C)C5=NC=C(C=N5)C(=O)NO	TWJZFXHSPBBPNI-UHFFFAOYSA-N	N-hydroxy-2-[methyl-[[2-[6-(methylamino)pyridin-3-yl]-4-morpholin-4-ylthieno[3,2-d]pyrimidin-6-yl]methyl]amino]pyrimidine-5-carboxamide
ferrodrug0367	Ringer's lactate	.	Ringer's lactate; 8022-63-7; Ringer-lactate; Ringer's injection, lactated; Propanoic acid, 2-hydroxy-, monosodium salt, mixt. with calcium chloride (CaCl2), potassium chloride (KCl) and sodium chloride (NaCl)	.	.	357	C3H6CaCl4KNa2O3	57.5	65.8	.	14	2	7	1	InChI=1S/C3H6O3.Ca.4ClH.K.2Na/c1-2(4)3(5)6;;;;;;;;/h2,4H,1H3,(H,5,6);;4*1H;;;/q;+2;;;;;+1;;+1/p-4	CC(C(=O)O)O.[Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2]	CC(C(=O)O)O.[Na].[Na+].[Cl-].[Cl-].[Cl-].[Cl-].[K+].[Ca+2]	ZEWYCNBZMPELPF-UHFFFAOYSA-J	.
ferrodrug0368	ZZW-115	.	ZZW-115; 801991-87-7; ZZW-115 trihydrochloride; CHEMBL524240; ICI738; SCHEMBL10168901; HUDONDPCYIGAMQ-UHFFFAOYSA-O; EX-A5834; HY-111838; CS-0093153; N,N-Dimethyl-2-(4-(3-(2-(trifluoromethyl)-10H-phenothiazin-10-yl)propyl)piperazin-1-yl)ethanamine trihydrochloride; N,N-dimethyl-2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanamine	.	.	464.6	C24H31F3N4S	38.3	582	5.1	32	0	8	7	InChI=1S/C24H31F3N4S/c1-28(2)12-13-30-16-14-29(15-17-30)10-5-11-31-20-6-3-4-7-22(20)32-23-9-8-19(18-21(23)31)24(25,26)27/h3-4,6-9,18H,5,10-17H2,1-2H3	CN(C)CCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F	CN(C)CCN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F	HUDONDPCYIGAMQ-UHFFFAOYSA-N	N,N-dimethyl-2-[4-[3-[2-(trifluoromethyl)phenothiazin-10-yl]propyl]piperazin-1-yl]ethanamine
ferrodrug0369	Bromelain	.	MUXF; carbohydrate moiety of bromelain; M0XF(3); Bromelain, Technical Grade; CHEBI:53469; Fuc-alpha-(1->3)-[Man-alpha-(1->6)-[Xyl-beta-(1->2)]-Man-beta-(1->4)-GlcNAc-beta-(1->4)]-GlcNAc; alpha-L-Fuc-(1->3)-[alpha-D-Man-(1->6)-[beta-D-Xyl-(1->2)]-beta-D-Man-(1->4)-beta-D-GlcNAc-(1->4)]-D-GlcNAc; alpha-L-fucopyranosyl-(1->3)-[alpha-D-mannopyranosyl-(1->6)-[beta-D-xylopyranosyl-(1->2)]-beta-D-mannopyranosyl-(1->4)-2-acetamido-2-deoxy-beta-D-glucopyranosyl-(1->4)]-2-acetamido-2-deoxy-D-glucopyranose; alpha-L-fucosyl-(1->3)-[alpha-D-mannosyl-(1->6)-[beta-D-xylosyl-(1->2)]-beta-D-mannosyl-(1->4)-N-acetyl-beta-D-glucosaminyl-(1->4)]-N-acetyl-D-glucosamine; alpha-L-Fucp-(1->3)-[alpha-D-Manp-(1->6)-[beta-D-Xylp-(1->2)]-beta-D-Manp-(1->4)-beta-D-GlcpNAc-(1->4)]-D-GlcpNAc; bromelaine; Epitope ID:115005; GLXC-19140; Q27124066; N_FULL_22100100000000_GS_1023_c1; Man(a1-6)[Xyl(b1-2)]Man(b1-4)GlcNAc(b1-4)[Fuc(a1-3)]GlcNAc	.	.	1026.9	C39H66N2O29	483	1680	-11.6	70	18	29	16	InChI=1S/C39H66N2O29/c1-9-19(48)24(53)29(58)38(62-9)69-32-18(41-11(3)46)34(59)63-15(6-44)31(32)68-35-17(40-10(2)45)23(52)30(14(5-43)65-35)67-39-33(70-37-27(56)20(49)12(47)7-60-37)26(55)22(51)16(66-39)8-61-36-28(57)25(54)21(50)13(4-42)64-36/h9,12-39,42-44,47-59H,4-8H2,1-3H3,(H,40,45)(H,41,46)/t9-,12+,13+,14+,15+,16+,17+,18+,19+,20-,21+,22+,23+,24+,25-,26-,27+,28-,29-,30+,31+,32+,33-,34?,35-,36-,37-,38-,39-/m0/s1	C[C@H]1[C@H]([C@H]([C@@H]([C@@H](O1)O[C@H]2[C@@H]([C@H](OC([C@@H]2NC(=O)C)O)CO)O[C@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CO)O[C@H]4[C@H]([C@H]([C@@H]([C@H](O4)CO[C@@H]5[C@H]([C@H]([C@@H]([C@H](O5)CO)O)O)O)O)O)O[C@H]6[C@@H]([C@H]([C@@H](CO6)O)O)O)O)NC(=O)C)O)O)O	CC1C(C(C(C(O1)OC2C(C(OC(C2OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)COC5C(C(C(C(O5)CO)O)O)O)O)O)OC6C(C(C(CO6)O)O)O)O)NC(=O)C)CO)O)NC(=O)C)O)O)O	UNMLVGNWZDHBRA-UFAVQCRNSA-N	N-[(2S,3R,4R,5S,6R)-2-[(2R,3S,4R,5R)-5-acetamido-6-hydroxy-2-(hydroxymethyl)-4-[(2S,3S,4R,5S,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl]oxy-5-[(2S,3S,4S,5S,6R)-4,5-dihydroxy-6-[[(2S,3S,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3-[(2S,3R,4S,5R)-3,4,5-trihydroxyoxan-2-yl]oxyoxan-2-yl]oxy-4-hydroxy-6-(hydroxymethyl)oxan-3-yl]acetamide
ferrodrug0370	Elabela	.	Elabela/Toddler-11; 1784687-32-6; ELA-11; GTPL8526; CHEMBL3809035; BDBM50172365	.	.	1283.6	C58H90N16O13S2	468	2470	-2.7	89	14	18	34	InChI=1S/C58H90N16O13S2/c1-32(2)25-39(68-52(81)43-16-10-21-72(43)54(83)38(19-24-89-5)66-47(76)36(59)30-88)49(78)67-40(27-35-28-62-31-64-35)50(79)70-42(29-75)51(80)65-37(15-9-20-63-58(60)61)48(77)71-46(33(3)4)56(85)73-22-11-17-44(73)53(82)69-41(26-34-13-7-6-8-14-34)55(84)74-23-12-18-45(74)57(86)87/h6-8,13-14,28,31-33,36-46,75,88H,9-12,15-27,29-30,59H2,1-5H3,(H,62,64)(H,65,80)(H,66,76)(H,67,78)(H,68,81)(H,69,82)(H,70,79)(H,71,77)(H,86,87)(H4,60,61,63)/t36-,37-,38-,39-,40-,41-,42-,43-,44-,45-,46-/m0/s1	CC(C)C[C@@H](C(=O)N[C@@H](CC1=CN=CN1)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCN=C(N)N)C(=O)N[C@@H](C(C)C)C(=O)N2CCC[C@H]2C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N4CCC[C@H]4C(=O)O)NC(=O)[C@@H]5CCCN5C(=O)[C@H](CCSC)NC(=O)[C@H](CS)N	CC(C)CC(C(=O)NC(CC1=CN=CN1)C(=O)NC(CO)C(=O)NC(CCCN=C(N)N)C(=O)NC(C(C)C)C(=O)N2CCCC2C(=O)NC(CC3=CC=CC=C3)C(=O)N4CCCC4C(=O)O)NC(=O)C5CCCN5C(=O)C(CCSC)NC(=O)C(CS)N	XXKPNJFJXZBRMX-HDKAIKTRSA-N	(2S)-1-[(2S)-2-[[(2S)-1-[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-1-[(2S)-2-[[(2R)-2-amino-3-sulfanylpropanoyl]amino]-4-methylsulfanylbutanoyl]pyrrolidine-2-carbonyl]amino]-4-methylpentanoyl]amino]-3-(1H-imidazol-5-yl)propanoyl]amino]-3-hydroxypropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-methylbutanoyl]pyrrolidine-2-carbonyl]amino]-3-phenylpropanoyl]pyrrolidine-2-carboxylic acid
ferrodrug0371	Cotylenin A	.	COTYLENIN A; (2E)-10-[[5-Hydroxy-2-(methoxymethyl)-9-methyl-9-(oxiran-2-yl)-3,7,10,11-tetraoxatricyclo[6.2.1.01,6]undecan-4-yl]oxy]-4-(methoxymethyl)-1,8-dimethyl-12-propan-2-yltricyclo[9.3.0.03,7]tetradeca-2,11-diene-4,9-diol; NSC319518; NSC-319518; CHEMBL1997435	.	.	622.7	C33H50O11	138	1200	0.2	44	3	11	8	InChI=1S/C33H50O11/c1-16(2)18-8-10-30(4)12-20-19(9-11-32(20,36)15-38-7)17(3)24(34)26(23(18)30)41-28-25(35)27-33(22(40-28)13-37-6)43-29(42-27)31(5,44-33)21-14-39-21/h12,16-17,19,21-22,24-29,34-36H,8-11,13-15H2,1-7H3/b20-12+	CC1C\2CCC(/C2=C/C3(CCC(=C3C(C1O)OC4C(C5C6(C(O4)COC)OC(O5)C(O6)(C)C7CO7)O)C(C)C)C)(COC)O	CC1C2CCC(C2=CC3(CCC(=C3C(C1O)OC4C(C5C6(C(O4)COC)OC(O5)C(O6)(C)C7CO7)O)C(C)C)C)(COC)O	SMQRKTIIIYTOTN-UDWIEESQSA-N	(2E)-10-[[5-hydroxy-2-(methoxymethyl)-9-methyl-9-(oxiran-2-yl)-3,7,10,11-tetraoxatricyclo[6.2.1.01,6]undecan-4-yl]oxy]-4-(methoxymethyl)-1,8-dimethyl-12-propan-2-yltricyclo[9.3.0.03,7]tetradeca-2,11-diene-4,9-diol
ferrodrug0372	Anhydrosafflor yellow B	.	.	.	.	1044.9	C48H52O26	480	2360	-5.1	74	19	26	14	InChI=1S/C48H52O26/c49-13-22(56)30(57)37(64)40-27(28-33(60)25(20(54)11-5-16-1-7-18(52)8-2-16)41(67)47(70,43(28)69)45-38(65)35(62)31(58)23(14-50)72-45)29-34(61)26(21(55)12-6-17-3-9-19(53)10-4-17)42(68)48(71,44(29)74-40)46-39(66)36(63)32(59)24(15-51)73-46/h1-12,22-24,27,30-32,35-40,45-46,49-54,56-66,70-71H,13-15H2/b11-5+,12-6+,25-20?/t22-,23-,24-,27?,30-,31-,32-,35+,36+,37+,38-,39-,40+,45-,46-,47?,48?/m1/s1	C1=CC(=CC=C1/C=C/C(=O)C2=C(C3=C(C(C2=O)([C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)CO)O)O)O)O)O[C@@H](C3C5=C(C(=C(/C=C/C6=CC=C(C=C6)O)O)C(=O)C(C5=O)([C@H]7[C@@H]([C@H]([C@@H]([C@H](O7)CO)O)O)O)O)O)[C@H]([C@@H]([C@@H](CO)O)O)O)O)O	C1=CC(=CC=C1C=CC(=O)C2=C(C3=C(C(C2=O)(C4C(C(C(C(O4)CO)O)O)O)O)OC(C3C5=C(C(=C(C=CC6=CC=C(C=C6)O)O)C(=O)C(C5=O)(C7C(C(C(C(O7)CO)O)O)O)O)O)C(C(C(CO)O)O)O)O)O	NOXZTJVQKYBYAV-SOPRAFLBSA-N	4-[(2S)-4,7-dihydroxy-5-[(E)-3-(4-hydroxyphenyl)prop-2-enoyl]-6-oxo-2-[(1S,2R,3R)-1,2,3,4-tetrahydroxybutyl]-7-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]-2,3-dihydro-1-benzofuran-3-yl]-2,5-dihydroxy-6-[(E)-1-hydroxy-3-(4-hydroxyphenyl)prop-2-enylidene]-2-[(2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]cyclohex-4-ene-1,3-dione
ferrodrug0373	XN4	.	(5S)-5-butyl-4-({1-[(4-chlorophenyl)methyl]-1H-imidazol-5-yl}methyl)-1-[3-(trifluoromethoxy)phenyl]piperazin-2-one; CHEMBL5171383; XN4	.	.	521	C26H28ClF3N4O2	50.6	707	6	36	0	7	9	InChI=1S/C26H28ClF3N4O2/c1-2-3-5-22-16-34(21-6-4-7-24(12-21)36-26(28,29)30)25(35)17-32(22)15-23-13-31-18-33(23)14-19-8-10-20(27)11-9-19/h4,6-13,18,22H,2-3,5,14-17H2,1H3/t22-/m0/s1	CCCC[C@H]1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)Cl)C4=CC(=CC=C4)OC(F)(F)F	CCCCC1CN(C(=O)CN1CC2=CN=CN2CC3=CC=C(C=C3)Cl)C4=CC(=CC=C4)OC(F)(F)F	POBHWQSJZMJUAH-QFIPXVFZSA-N	(5S)-5-butyl-4-[[3-[(4-chlorophenyl)methyl]imidazol-4-yl]methyl]-1-[3-(trifluoromethoxy)phenyl]piperazin-2-one
ferrodrug0374	VBIT-12	.	VBIT-12; 2089227-65-4; N-[[1-(1-naphthalenylmethyl)-4-(phenylamino)-4-piperidinyl]carbonyl]-glycine; 2-[[4-anilino-1-(naphthalen-1-ylmethyl)piperidine-4-carbonyl]amino]acetic acid; VBIT12; VBIT 12; SCHEMBL19972411; BCP32721; EX-A3741; s8936; AKOS040759338; AC-36876; HY-135885; CS-0115969; (1-(Naphthalen-1-ylmethyl)-4-(phenylamino)piperidine-4-carbonyl)glycine	.	.	417.5	C25H27N3O3	81.7	611	1.7	31	3	5	7	InChI=1S/C25H27N3O3/c29-23(30)17-26-24(31)25(27-21-10-2-1-3-11-21)13-15-28(16-14-25)18-20-9-6-8-19-7-4-5-12-22(19)20/h1-12,27H,13-18H2,(H,26,31)(H,29,30)	C1CN(CCC1(C(=O)NCC(=O)O)NC2=CC=CC=C2)CC3=CC=CC4=CC=CC=C43	C1CN(CCC1(C(=O)NCC(=O)O)NC2=CC=CC=C2)CC3=CC=CC4=CC=CC=C43	JZDHWOWCHGYSGA-UHFFFAOYSA-N	2-[[4-anilino-1-(naphthalen-1-ylmethyl)piperidine-4-carbonyl]amino]acetic acid
ferrodrug0375	4-(cyclohexylamino)-3-[(phenylmethyl)amino]-N-[2-(1-piperazinyl)ethyl]-benzenesulfonamide	.	UAMC-3203; 2271358-64-4; UAMC3203; UAMC-3203 free base; 4-(cyclohexylamino)-3-[(phenylmethyl)amino]-N-[2-(1-piperazinyl)ethyl]-benzenesulfonamide; 3-(benzylamino)-4-(cyclohexylamino)-N-(2-piperazin-1-ylethyl)benzenesulfonamide; CHEMBL4301351; SCHEMBL21245912; UAMC 3203; BCP30684; EX-A4549; UAMC 3203;UAMC3203; WQD35864; s8792; AKOS037515666; HY-112909; CS-0067929	.	.	471.7	C25H37N5O2S	93.9	652	3.5	33	4	7	10	InChI=1S/C25H37N5O2S/c31-33(32,28-15-18-30-16-13-26-14-17-30)23-11-12-24(29-22-9-5-2-6-10-22)25(19-23)27-20-21-7-3-1-4-8-21/h1,3-4,7-8,11-12,19,22,26-29H,2,5-6,9-10,13-18,20H2	C1CCC(CC1)NC2=C(C=C(C=C2)S(=O)(=O)NCCN3CCNCC3)NCC4=CC=CC=C4	C1CCC(CC1)NC2=C(C=C(C=C2)S(=O)(=O)NCCN3CCNCC3)NCC4=CC=CC=C4	HSYSVXKJIVUNBR-UHFFFAOYSA-N	3-(benzylamino)-4-(cyclohexylamino)-N-(2-piperazin-1-ylethyl)benzenesulfonamide
ferrodrug0376	Furosine dihydrochloride	.	furosine; 19746-33-9; (2S)-2-amino-6-[[2-(furan-2-yl)-2-oxoethyl]amino]hexanoic acid; Epsilon-N-(2-furoyl-methyl)-L-lysine 2hcl; Furosine 2HCl; N6-[2-(2-furanyl)-2-oxoethyl]-L-Lysine; N6-(2-(2-Furanyl-2-oxoethyl))-L-lysine; C9XU89FM3X; Nepsilon-(2-Furoylmethyl)-L-lysine; Epsilon-N-(2-furoyl-methyl)-L-lysine; Epsilon-n-(2-furoyl-methyl)-l-lysine2hcl; W-201729; (2S)-2-AZANYL-6-((2-(FURAN-2-YL)-2-OXIDANYLIDENE-ETHYL)AMINO)HEXANOIC ACID	.	.	254.28	C12H18N2O4	106	283	-1.9	18	3	6	9	InChI=1S/C12H18N2O4/c13-9(12(16)17)4-1-2-6-14-8-10(15)11-5-3-7-18-11/h3,5,7,9,14H,1-2,4,6,8,13H2,(H,16,17)/t9-/m0/s1	C1=COC(=C1)C(=O)CNCCCC[C@@H](C(=O)O)N	C1=COC(=C1)C(=O)CNCCCCC(C(=O)O)N	YQHPCDPFXQXCMV-VIFPVBQESA-N	(2S)-2-amino-6-[[2-(furan-2-yl)-2-oxoethyl]amino]hexanoic acid
ferrodrug0377	Albiziabioside A	.	Albiziabioside A	.	.	792	C43H69NO12	205	1550	3.8	56	7	12	7	InChI=1S/C43H69NO12/c1-22(45)44-30-33(49)32(48)26(21-54-36-34(50)31(47)25(46)20-53-36)55-35(30)56-29-12-13-40(6)27(39(29,4)5)11-14-42(8)28(40)10-9-23-24-19-38(2,3)15-17-43(24,37(51)52)18-16-41(23,42)7/h9,24-36,46-50H,10-21H2,1-8H3,(H,44,45)(H,51,52)/t24-,25+,26+,27-,28+,29-,30+,31+,32+,33+,34-,35-,36-,40-,41+,42+,43-/m0/s1	CC(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@H]1O[C@H]2CC[C@]3([C@H](C2(C)C)CC[C@@]4([C@@H]3CC=C5[C@]4(CC[C@@]6([C@H]5CC(CC6)(C)C)C(=O)O)C)C)C)CO[C@H]7[C@H]([C@@H]([C@@H](CO7)O)O)O)O)O	CC(=O)NC1C(C(C(OC1OC2CCC3(C(C2(C)C)CCC4(C3CC=C5C4(CCC6(C5CC(CC6)(C)C)C(=O)O)C)C)C)COC7C(C(C(CO7)O)O)O)O)O	MBMJMOODCJFAET-FTLPUPRYSA-N	(4aS,6aR,6aS,6bR,8aR,10S,12aR,14bS)-10-[(2R,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-[[(2S,3S,4R,5R)-3,4,5-trihydroxyoxan-2-yl]oxymethyl]oxan-2-yl]oxy-2,2,6a,6b,9,9,12a-heptamethyl-1,3,4,5,6,6a,7,8,8a,10,11,12,13,14b-tetradecahydropicene-4a-carboxylic acid
ferrodrug0378	RR-11a	.	RR-11a; (5S,8S,E)-2,5-Dioxopyrrolidin-1-yl 11-(2-amino-2-oxoethyl)-5,8-dimethyl-3,6,9,12-tetraoxo-1-phenyl-2-oxa-4,7,10,11-tetraazapentadec-13-en-15-oate; 1361390-56-8; SCHEMBL10044438; AKOS040736812; HY-112205; CS-0044123	.	.	560.5	C24H28N6O10	224	1040	-1.2	40	4	10	13	InChI=1S/C24H28N6O10/c1-14(27-24(38)39-13-16-6-4-3-5-7-16)22(36)26-15(2)23(37)28-29(12-17(25)31)18(32)10-11-21(35)40-30-19(33)8-9-20(30)34/h3-7,10-11,14-15H,8-9,12-13H2,1-2H3,(H2,25,31)(H,26,36)(H,27,38)(H,28,37)/b11-10+/t14-,15-/m0/s1	C[C@@H](C(=O)NN(CC(=O)N)C(=O)/C=C/C(=O)ON1C(=O)CCC1=O)NC(=O)[C@H](C)NC(=O)OCC2=CC=CC=C2	CC(C(=O)NN(CC(=O)N)C(=O)C=CC(=O)ON1C(=O)CCC1=O)NC(=O)C(C)NC(=O)OCC2=CC=CC=C2	OBTLSXIZYGMZRE-BWLFODOESA-N	(2,5-dioxopyrrolidin-1-yl) (E)-4-[(2-amino-2-oxoethyl)-[[(2S)-2-[[(2S)-2-(phenylmethoxycarbonylamino)propanoyl]amino]propanoyl]amino]amino]-4-oxobut-2-enoate
ferrodrug0379	XJB-5-131	.	866404-31-1; CHEBI:173099; DTXSID401030557; XJB-5131; XJB-5 131; AKOS040758407; [4-[[1-[(2S,5S)-2-Benzyl-5-(tert-butyloxycarbonylamino)-7-methyl-3-octenoyl]-L-Pro-L-Val-N5-Cbz-L-Orn-]amino]-2,2,6,6-tetramethyl-1-piperidinyloxy]radical; (4-{[(2S)-2-{[(2S)-2-({[(2S)-1-{(2S,3E,5S)-2-benzyl-5-[(tert-butoxycarbonyl)amino]-7-methyloct-3-enoyl}pyrrolidin-2-yl]carbonyl}amino)-3-methylbutanoyl]amino}-5-{[(benzyloxy)carbonyl]amino}pentanoyl]amino}-2,2,6,6-tetramethylpiperidin-1-yl)oxidanyl; {4-[(1-{(2S,3E,5S)-2-benzyl-5-[(tert-butoxycarbonyl)amino]-7-methyloct-3-enoyl}-L-prolyl-L-valyl-N(5)-[(benzyloxy)carbonyl]-L-ornithyl)amino]-2,2,6,6-tetramethylpiperidin-1-yl}oxidanyl	.	.	959.2	C53H80N7O9	189	1700	7.8	69	5	9	24	InChI=1S/C53H80N7O9/c1-35(2)30-40(56-50(66)69-51(5,6)7)27-26-39(31-37-20-14-12-15-21-37)48(64)59-29-19-25-43(59)46(62)58-44(36(3)4)47(63)57-42(24-18-28-54-49(65)68-34-38-22-16-13-17-23-38)45(61)55-41-32-52(8,9)60(67)53(10,11)33-41/h12-17,20-23,26-27,35-36,39-44H,18-19,24-25,28-34H2,1-11H3,(H,54,65)(H,55,61)(H,56,66)(H,57,63)(H,58,62)/b27-26+/t39-,40-,42+,43+,44+/m1/s1	CC(C)C[C@@H](/C=C/[C@H](CC1=CC=CC=C1)C(=O)N2CCC[C@H]2C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(=O)OCC3=CC=CC=C3)C(=O)NC4CC(N(C(C4)(C)C)[O])(C)C)NC(=O)OC(C)(C)C	CC(C)CC(C=CC(CC1=CC=CC=C1)C(=O)N2CCCC2C(=O)NC(C(C)C)C(=O)NC(CCCNC(=O)OCC3=CC=CC=C3)C(=O)NC4CC(N(C(C4)(C)C)[O])(C)C)NC(=O)OC(C)(C)C	VDQKIDYOPUMJGQ-VQPCLXHQSA-N	.
ferrodrug0380	Epunctanone	.	Epunctanone	.	.	604.8	C38H52O6	101	1260	9.4	44	2	6	9	InChI=1S/C38H52O6/c1-22(2)11-14-26-20-37-21-27(15-12-23(3)4)36(9,10)44-33(37)30(31(41)25-13-16-28(39)29(40)19-25)32(42)38(34(37)43,35(26,7)8)18-17-24(5)6/h12-13,16-17,19,22,26-27,39-40H,11,14-15,18,20-21H2,1-10H3/t26-,27-,37-,38-/m0/s1	CC(C)CC[C@H]1C[C@]23C[C@@H](C(OC2=C(C(=O)[C@@](C3=O)(C1(C)C)CC=C(C)C)C(=O)C4=CC(=C(C=C4)O)O)(C)C)CC=C(C)C	CC(C)CCC1CC23CC(C(OC2=C(C(=O)C(C3=O)(C1(C)C)CC=C(C)C)C(=O)C4=CC(=C(C=C4)O)O)(C)C)CC=C(C)C	ZNQJJVUWTVVSJR-PFACJMQPSA-N	(1S,3S,9R,11S)-7-(3,4-dihydroxybenzoyl)-4,4,10,10-tetramethyl-3,9-bis(3-methylbut-2-enyl)-11-(3-methylbutyl)-5-oxatricyclo[7.3.1.01,6]tridec-6-ene-8,13-dione
ferrodrug0381	Carbonyl cyanide-m-chlorophenyl-hydrazine	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0382	Astragalus polysaccharide	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0383	1,1-(Decane-1,10-diyl)bis(5-fluoroindoline-2,3-dione)	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0384	Indolylmaleimide derivative IM-93	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0385	Polyphyllin III	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0386	Lycium barbarumpolysaccharide	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0387	Polyphyllin I	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0388	Isothiocyanate-containing hybrid AR antagonist 13	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0389	Eucommia ulmoides Oliver-Tribulus terrestrisL	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0390	Robustaflavone 7,5'-dimethyl ether	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0391	R46A2	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0392	Lipopolysaccharide	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0393	Panax notoginseng saponins	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0394	Compound Tongluo Decoction	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0395	Guizhi Fuling Capsule	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0396	Huaiqihuang	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0397	Naotaifang Extract	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0398	Shuganning injection	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0399	Soyauxinium chloride	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0400	Tetrahydroxy stilbene glycoside	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0401	Tongxinluo	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0402	Xiaojianzhong	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0403	Xiaoyaosan	Traditional Chinese Medicin	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0404	All-trans retinoic acid derivative	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0405	ALZ003	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0406	DETD-35	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0407	Fer-1 analogue 37	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0408	Fer-1 analogue 38	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0409	Fer-1 analogue 39	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0410	GIF-2114	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0411	GIF-2197-r	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0412	QD394-Me	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0413	Quinazolinyl-arylurea derivatives 7J	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0414	Seco-Lupane Triterpene Derivatives	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0415	Ze 450	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0416	(6R,6aR,9S,11bS,14R)-4,4-Dimethyl-8-methylene-7,11,12-trioxododecahydro-1H-6,11b-(epoxymethano)-6a,9-methanocyclohepta[a]naphthalen-14-yl valinate	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0417	2-pyridylhydrazone dithiocarbamate s-acetic acid	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0418	ADA-409-052	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0419	Ajudecunoid C	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0420	N2L	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0421	Pt3R5G	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0422	11-hydroxy-ent-16-kaurene-15-one	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0423	Antagomir	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0424	DET	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0425	FIPC-1	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0426	Ginkgo biflavones	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0427	Herceptin	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0428	Histochrome	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0429	NCS207895	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0430	NL01	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0431	Polygonatum cyrtonemaHua Polysaccharides	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0432	Polyphyllin B	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0433	QD394	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0434	S-3'-hydroxy-7', 2', 4'-trimethoxyisoxane	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0435	SN38	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0436	zero-valent-iron nanoparticle	Small molecule	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0437	DNA (cytosine-5)-methyltransferase 1	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0438	Klotho	Protein	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0439	L. lactis MG1363-pMG36e-GLP-1	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0440	Carthamin yellow	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0441	Actinidia chinensis Planch	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0442	L-F001	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0443	T. vulgaris and A. lappa	Others	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0444	Cetuximab	Antibody	.	D0N5OV	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
ferrodrug0445	Tocilizumab mimotope	Antibody	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
